

0000950170-24-09332910-Q Vital Farms, Inc. 202408082024080807303001073031 0 0000950170-24-093329 10-Q 103 20240630 20240808 Vital Farms, Inc. 0001579733 2000 270496985 DE 1231 10-Q 04 001-39411 241186065 3601 SOUTH CONGRESS AVENUE SUITE C100 AUSTIN TX 78704 (877) 455-3063 3601 SOUTH CONGRESS AVENUE SUITE C100 AUSTIN TX 78704 10-Q 1 vitl-20240630.htm 10-Q 10-Q false--12-310001579733366Q2276 00015797332022-12-262023-06-2500015797333vitl.jpMorganCreditFacilityMember2024-04-0900015797333us-gaap:SalesRevenueNetMembervitl:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-3000015797333us-gaap:PerformanceSharesMember2024-01-012024-06-3000015797333us-gaap:CommonStockMember2023-03-2600015797332023-03-2600015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2022-12-262023-06-2500015797333us-gaap:RevolvingCreditFacilityMembervitl:JPMorganChaseBankNAMember2024-04-0900015797333vitl:EggsAndEggRelatedProductsMember2023-12-3100015797333us-gaap:VehiclesMember2023-12-3100015797333vitl:PackagingMember2024-06-3000015797333us-gaap:SalesRevenueNetMembervitl:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-3000015797333vitl:SoybeanMealMember2024-06-3000015797333us-gaap:AdditionalPaidInCapitalMember2023-12-3100015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-2600015797333us-gaap:FurnitureAndFixturesMember2023-12-3100015797333us-gaap:RestrictedStockUnitsRSUMember2024-06-3000015797333us-gaap:EmployeeStockOptionMember2022-12-262023-06-2500015797333us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-06-3000015797333vitl:ButterAndButterRelatedProductsMember2023-12-3100015797333us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100015797333us-gaap:LeaseholdImprovementsMember2023-12-3100015797333us-gaap:EmployeeStockOptionMember2024-01-012024-06-3000015797333us-gaap:EmployeeStockOptionMember2023-03-272023-06-2500015797332024-01-012024-03-3100015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2024-04-012024-06-3000015797333us-gaap:TradeAccountsReceivableMember2024-03-3100015797333us-gaap:CommonStockMembervitl:TwentyTwentyEmployeeStockPurchasePlanMember2024-04-012024-06-3000015797333vitl:ButterAndButterRelatedProductsMember2024-01-012024-06-3000015797333vitl:EggsAndEggRelatedProductsMember2024-01-012024-06-3000015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2023-03-272023-06-2500015797333us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-262023-06-2500015797333us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2024-04-012024-06-3000015797333vitl:KathrynMckeenMember2024-04-012024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEquityIncentivePlanMember2020-07-3100015797333us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEquityIncentivePlanMember2020-07-3100015797333us-gaap:10015797333vitl:CustomerDMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-262023-12-3100015797332022-12-262023-03-2600015797333us-gaap:RestrictedStockUnitsRSUMember2022-12-262023-06-2500015797333us-gaap:TradeAccountsReceivableMember2024-04-012024-06-3000015797332023-06-2500015797333us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:EmployeeStockOptionMember2024-04-012024-06-3000015797333us-gaap:RevolvingCreditFacilityMember2023-03-272023-06-2500015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEmployeeStockPurchasePlanMember2024-01-012024-06-3000015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-2500015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100015797333us-gaap:CommonStockMember2022-12-262023-03-2600015797333us-gaap:BuildingAndBuildingImprovementsMember2024-06-3000015797333us-gaap:RetainedEarningsMember2024-06-3000015797333vitl:EmployeeStockPurchasePlanMember2022-12-262023-06-2500015797333vitl:CustomerCMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-262023-12-3100015797333us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEmployeeStockPurchasePlanMember2020-07-012020-07-3100015797333us-gaap:ConstructionInProgressMember2023-12-3100015797333us-gaap:CommonStockMember2024-06-3000015797333us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2022-12-262023-06-2500015797333us-gaap:PerformanceSharesMember2024-04-012024-06-3000015797332024-01-012024-06-3000015797333us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-3000015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100015797333vitl:ButterAndButterRelatedProductsMember2024-06-3000015797333us-gaap:EmployeeStockOptionMember2024-01-012024-06-3000015797333vitl:EggsAndEggRelatedProductsMember2023-03-272023-06-2500015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797332023-03-2600015797333us-gaap:10015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:CreditFacilityMembervitl:PNCBankNationalAssociationMember2024-01-012024-06-3000015797333us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-01-012024-03-3100015797333us-gaap:CommonStockMember2024-04-012024-06-3000015797333us-gaap:LandMember2023-12-3100015797333us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333vitl.jpMorganCreditFacilityMember2024-04-092024-04-0900015797333us-gaap:CostOfSalesMember2023-03-272023-06-2500015797333us-gaap:RevolvingCreditFacilityMember2024-01-012024-06-3000015797333us-gaap:CommonStockMember2023-12-3100015797333us-gaap:CostOfSalesMember2022-12-262023-06-2500015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2024-06-3000015797333us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-272023-06-2500015797333us-gaap:BuildingAndBuildingImprovementsMember2023-12-3100015797333us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-06-3000015797333us-gaap:RetainedEarningsMember2024-03-3100015797333us-gaap:EmployeeStockOptionMember2024-06-3000015797333srt:MaximumMember2024-06-3000015797333vitl:OtherMember2023-12-3100015797333vitl:CustomerBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-3000015797333us-gaap:RetainedEarningsMember2022-12-262023-03-2600015797333us-gaap:AdditionalPaidInCapitalMember2024-03-3100015797333us-gaap:PerformanceSharesMember2022-12-262023-06-2500015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMember2024-06-3000015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEquityIncentivePlanMember2024-01-012024-01-0100015797333us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-3100015797333us-gaap:EmployeeStockOptionMember2023-12-3100015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-262023-03-2600015797333us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2024-01-012024-06-3000015797333us-gaap:EmployeeStockOptionMember2024-04-012024-06-3000015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2024-01-012024-06-3000015797333vitl:OtherMember2024-06-3000015797333us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:AdditionalPaidInCapitalMember2023-06-2500015797333us-gaap:SalesRevenueNetMembervitl:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2022-12-262023-06-2500015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:10015797333vitl:PeterPappasMember2024-04-012024-06-3000015797333us-gaap:RetainedEarningsMember2022-12-2500015797333us-gaap:RetainedEarningsMember2023-03-2600015797333vitl.jpMorganCreditFacilityMember2024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEmployeeStockPurchasePlanMember2024-01-012024-01-0100015797333vitl:SandpebbleBuildersPreconstructionIncorporationMember2023-06-2500015797333us-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembervitl.jpMorganCreditFacilityMember2024-04-092024-04-0900015797332024-03-3100015797333us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:RestrictedStockUnitsRSUMember2023-03-272023-06-2500015797333vitl:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-262023-12-3100015797333us-gaap:AdditionalPaidInCapitalMember2023-06-2500015797333vitl:CornMember2024-06-3000015797333us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-3000015797333vitl:PNCBankNationalAssociationMemberus-gaap:RevolvingCreditFacilityMembervitl:SixthAmendmentMember2024-03-3100015797333vitl:ButterAndButterRelatedProductsMember2024-04-012024-06-3000015797333us-gaap:PerformanceSharesMember2024-04-012024-06-3000015797333us-gaap:CommonStockMember2022-12-2500015797333us-gaap:CommonStockMembervitl:TwentyTwentyEquityIncentivePlanMember2024-01-012024-06-3000015797333us-gaap:PerformanceSharesMember2024-01-012024-06-3000015797333vitl:ButterAndButterRelatedProductsMember2023-03-272023-06-2500015797333vitl:PulletsMember2023-12-3100015797333vitl:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEmployeeStockPurchasePlanMember2020-07-3100015797333us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-03-3100015797333vitl:EggsAndEggRelatedProductsMember2022-12-262023-06-2500015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-272023-06-2500015797333us-gaap:RestrictedStockUnitsRSUMember2023-12-3100015797333us-gaap:RevolvingCreditFacilityMember2024-04-012024-06-3000015797333vitl:EggsAndEggRelatedProductsMember2024-04-012024-06-3000015797333vitl:EmployeeStockPurchasePlanMember2024-04-012024-06-3000015797333us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333vitl:PNCBankNationalAssociationMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMembervitl:TenthAmendmentMember2024-01-012024-03-3100015797333vitl:ButterAndButterRelatedProductsMember2022-12-262023-06-2500015797333us-gaap:EmployeeStockOptionMember2023-03-272023-06-2500015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMember2023-12-3100015797333us-gaap:LeaseholdImprovementsMember2024-06-3000015797333us-gaap:RestrictedStockUnitsRSUMember2022-12-262023-06-2500015797333vitl:EmployeeStockPurchasePlanMember2023-03-272023-06-2500015797333us-gaap:CommonStockMember2024-01-012024-03-3100015797333us-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333us-gaap:TradeAccountsReceivableMember2023-12-3100015797333us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:RetainedEarningsMember2023-03-272023-06-2500015797333vitl:TwentyTwentyEquityIncentivePlanAndTwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2024-06-3000015797333us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-3000015797333us-gaap:EmployeeStockOptionMember2022-12-262023-06-2500015797333us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-04-012024-06-3000015797333vitl:PNCBankNationalAssociationMemberus-gaap:RevolvingCreditFacilityMembervitl:TenthAmendmentMembervitl:AlternateBaseRateMember2024-01-012024-03-3100015797333us-gaap:MachineryAndEquipmentMember2023-12-3100015797332024-08-0500015797333us-gaap:ConstructionInProgressMember2024-06-3000015797333us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-03-272023-06-2500015797333us-gaap:AdditionalPaidInCapitalMember2023-03-2600015797333us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-06-3000015797333us-gaap:FurnitureAndFixturesMember2024-06-3000015797333vitl:SoybeanMealMember2023-12-3100015797333us-gaap:LandImprovementsMember2023-12-3100015797333us-gaap:TradeAccountsReceivableMember2024-01-012024-03-3100015797333vitl:KathrynMckeenMember2024-06-3000015797333us-gaap:CommonStockMember2024-03-3100015797333vitl:PackagingMember2023-12-3100015797333us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2023-03-272023-06-2500015797333us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-3000015797333us-gaap:AdditionalPaidInCapitalMember2023-03-272023-06-2500015797333us-gaap:RevolvingCreditFacilityMember2022-12-262023-06-2500015797333us-gaap:CostOfSalesMember2024-04-012024-06-3000015797333us-gaap:CostOfSalesMember2024-01-012024-06-3000015797333us-gaap:CommonStockMembervitl:TwentyTwentyEquityIncentivePlanMember2024-06-3000015797333us-gaap:PerformanceSharesMember2023-12-3100015797333us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100015797333us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-12-262023-06-2500015797332023-12-3100015797333us-gaap:10015797333vitl:TwentyTwentyEquityIncentivePlanAndTwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2023-12-3100015797333us-gaap:RetainedEarningsMember2023-12-3100015797333vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000015797333vitl:EmployeeStockPurchasePlanMember2024-01-012024-06-3000015797333us-gaap:MachineryAndEquipmentMember2024-06-3000015797333us-gaap:TradeAccountsReceivableMember2024-06-3000015797333us-gaap:RetainedEarningsMember2024-04-012024-06-3000015797333us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-06-3000015797332024-06-3000015797332022-12-2500015797333us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-2500015797333vitl:EggsAndEggRelatedProductsMember2024-06-3000015797333us-gaap:AdditionalPaidInCapitalMember2022-12-2500015797333us-gaap:SalesRevenueNetMembervitl:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2023-03-272023-06-25xbrli:purevitl:Securityxbrli:sharesvitl:Positionutr:Tiso4217:USDxbrli:sharesutr:buiso4217:USD Å UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Å Å FORM 10-Q Å Å (Mark One) Å Å " QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR Å Å TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39411 Å Å Vital Farms, Inc. (Exact name of registrant as specified in its charter) Å Å Delaware 27-0496985 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer identification No.) Å Å 3601 South Congress Avenue Suite C100 Austin, Texas 78704 (Address of principal executive offices) (Zip Code) (877) 455-3063 (Registrant's telephone number, including area code) Å Å Securities registered pursuant to Section 12(b) of the Act: Å Title of each class Å Trading Symbol(s) Å Name of each exchange on which registered Common Stock, par value \$0.0001 per share Å VITL Å The Nasdaq Stock Market LLC Å Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes Å No Å Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Å§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

a." No "a" Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. A "Large accelerated filer" "Accelerated filer" "A" "A" "A" Non-accelerated filer "A" "A" "A" "A" Emerging Growth Company "A" "A" "A" If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. "I" Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "A" No "A" As of August 5, 2024 the registrant had 43,098,946 shares of common stock, \$0.0001 par value per share, outstanding. "A" "A" Table of Contents "A" Page "A" Special Note Regarding Forward-Looking Statements ii "A" PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) "A" Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Income 2 "A" Condensed Consolidated Statements of Comprehensive Income 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3. Quantitative and Qualitative Disclosures About Market Risk 35 Item 4. Controls and Procedures 35 PART II. OTHER INFORMATION 36 Item 1. Legal Proceedings 36 Item 1A. Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 66 Item 3. Defaults Upon Senior Securities 66 Item 4. Mine Safety Disclosures 66 Item 5. Other Information 66 Item 6. Exhibits 67 "A" Signatures 68 "A" "A" "A" SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report") contains forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: our expectations regarding our revenue, expenses and other operating results; our ability to acquire new customers and successfully retain existing customers; our ability to attract and retain our suppliers, distributors and co-manufacturers; our ability to maintain relationships with our existing farm networks or further expand our farm networks and our plans for future farm development; our ability to sustain or increase our profitability; our expectations regarding our future growth in the foodservice channel, including commercial and non-commercial foodservice business; our ability to procure sufficient high-quality eggs, cream for our butter and other raw materials; real or perceived quality or food safety issues with our products or other issues that adversely affect our brand and reputation; changes in the tastes and preferences of our consumers; the financial condition of, and our relationships with, our farmers, suppliers, co-manufacturers, distributors, retailers and foodservice customers, as well as the health of the foodservice industry generally; the effects of outbreaks of agricultural diseases, such as avian influenza, or the perception that outbreaks may occur or regulatory or market responses to such outbreaks generally; the ability of our farmers, suppliers and co-manufacturers to comply with food safety, environmental or other laws or regulations; the effects of a public health pandemic or contagious disease, or fear of such outbreaks, on our supply chain, the demand for our products, and overall economic conditions, consumer confidence and spending levels; specifications and timing of our next planned egg washing and packing facility in Seymour, Indiana, and the impacts of completed or future expansions of our egg washing and packing facilities on our revenue; future investments in our business, our anticipated capital expenditures and our estimates regarding our capital requirements; anticipated changes in our product offerings and our ability to innovate to offer new products; our ability to successfully enter new product categories; the costs and success of our marketing efforts and our ability to promote our brand; our reliance on key personnel and our ability to identify, recruit and retain personnel; our ability to effectively manage our growth; the potential influence of our focus on a specific public benefit purpose and producing a positive effect for society; our environmental, sustainability and governance goals, opportunities and initiatives, as well as the standards and expectations of third parties regarding these matters; our ability to compete effectively with existing competitors and new market entrants; the impact of adverse economic conditions, including as a result of unfavorable global economic and political conditions, elevated interest rates and inflation; ii "A" our estimates of future capital expenditures and the sufficiency of our cash, cash equivalents, marketable securities and availability of credit under our credit facility to meet our liquidity needs; our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012; seasonality; and the growth rates of the markets in which we compete. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled "Risk Factors" and elsewhere in this Quarterly Report. A summary of selected risks associated with our business is set forth at the beginning of the section titled "Risk Factors." Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report to reflect events or circumstances after the date of this Quarterly Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. iii "A" PART I "A" FINANCIAL INFORMATION VITAL FARMS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share amounts) "A" June 30, 2024 "A" December 31, 2023 "A" "A" (Unaudited) "A" "A" Assets "A" "A" "A" Current assets: "A" "A" "A" Cash and cash equivalents "A" \$ 133,173 "A" \$ 84,149 "A" Investment securities, available-for-sale "A" \$ 19,533 "A" \$ 32,667 "A" Accounts receivable, net of allowance for credit losses of \$514 and \$550 as of June 30, 2024 and December 31, 2023, respectively "A" \$ 42,863 "A" \$ 39,699 "A" Inventories "A" \$ 31,448 "A" \$ 32,895 "A" Prepaid expenses and other current assets, net of allowance for credit losses of \$117 and \$227 as of June 30, 2024 and December 31, 2023, respectively "A" \$ 4,530 "A" \$ 6,114 "A" Income taxes receivable "A" \$ 2,663 "A" "A" Total current assets "A" \$ 234,210 "A" \$ 195,524 "A" Property, plant and equipment, net "A" \$ 68,327 "A" \$ 66,839 "A" Operating lease right-of-use assets "A" \$ 12,478 "A" \$ 8,911 "A" Goodwill and other assets "A" \$ 5,474 "A" \$ 3,904 "A" Total assets "A" \$ 320,489 "A" \$ 275,178 "A" Liabilities and Stockholders' Equity "A" "A" "A" Current liabilities: "A" "A" "A" Accounts payable "A" \$ 33,358 "A" \$ 33,485 "A" Accrued liabilities "A" \$ 25,928 "A" \$ 24,218 "A" Operating lease liabilities, current "A" \$ 4,085 "A" \$ 4,085 "A" Finance lease liabilities, current "A" \$ 3,620 "A" \$ 3,255 "A" Income taxes payable "A" \$ 1,206 "A" "A" Total current liabilities "A" \$ 66,991 "A" \$ 65,221 "A" Operating lease liabilities, non-current "A" \$ 4,387 "A" \$ 5,771 "A" Finance lease liabilities, non-current "A" \$ 9,593 "A" \$ 10,481 "A" Other liabilities "A" \$ 1,097 "A" \$ 1,028 "A" Total liabilities "A" \$ 82,068 "A" \$ 82,501 "A" Commitments and contingencies (Note 20) "A" "A" "A" Stockholders' equity: "A" "A" "A" Preferred stock, \$0.0001 par value per share, 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 "A" "A" "A" Common stock, \$0.0001 par value per share, 310,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 42,971,988 and 41,684,649 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively "A" \$ 4 "A" \$ 4 "A" Additional paid-in capital "A" \$ 173,498 "A" \$ 163,325 "A" Retained earnings "A" \$ 65,087 "A" \$ 29,725 "A" Accumulated other comprehensive loss "A" \$ (168) "A" \$ (377) "A" Total stockholders' equity "A" \$ 238,421 "A" \$ 192,677 "A" Total liabilities and stockholders' equity "A" \$ 320,489 "A" \$ 275,178 "A" See accompanying notes to the unaudited condensed consolidated financial statements. 1 "A" VITAL FARMS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts in thousands, except share and per share data) (Unaudited) "A" 13-Weeks Ended "A" 26-Weeks Ended "A" "A" June 30, 2024 "A" June 25, 2023 "A" June 30, 2024 "A" June 25, 2023 "A" Net revenue "A" \$ 147,388 "A" \$ 166,445 "A" \$ 295,316 "A" \$ 225,616 "A" Cost of goods sold "A" \$ 89,710 "A" \$ 68,645 "A" \$ 178,742 "A" \$ 145,149 "A" Gross profit "A" \$ 57,678 "A" \$ 97,800 "A" \$ 116,574 "A" \$ 80,467 "A" Operating expenses: "A" "A" "A" Selling, general and administrative "A" \$ 33,336 "A" \$ 23,908 "A" \$ 60,467 "A" \$ 47,853 "A" Shipping and distribution "A" \$ 7,203 "A" \$ 5,853 "A" \$ 14,799 "A" \$ 13,679 "A" Total operating expenses "A" \$ 40,539 "A" \$ 29,761 "A" \$ 75,266 "A" \$ 61,532 "A" Income from operations "A" \$ 17,139 "A" \$ 8,039 "A" \$ 41,383 "A" \$ 18,935 "A" Other income (expense), net: "A" "A" "A" Interest expense "A" (257) "A" (136) "A" (512) "A" (275) "A" Interest income "A" 1,316 "A" 450 "A" 2,404 "A" 790 "A" Other expense, net "A" (87) "A" (441) "A" (364) "A" (1,866) "A" Total other income (expense), net "A" \$ 972 "A" \$ (127) "A" \$ 1,528 "A" \$ (1,351) "A" Net income before income taxes "A" \$ 18,111 "A" \$ 7,912 "A" \$ 42,836 "A" \$ 17,584 "A" Income tax provision "A" \$ 1,772 "A" \$ 1,229 "A" \$ 4,744 "A" \$ 3,751 "A" Net income "A" \$ 16,339 "A" \$ 6,683 "A" \$ 38,092 "A" \$ 13,833 "A" Net income per share: "A" "A" "A" Basic: "A" \$ 0.38 "A" \$ 0.16 "A" \$ 0.84 "A" \$ 0.34 "A" Diluted: "A" \$ 0.36 "A" \$ 0.15 "A" \$ 0.79 "A" \$ 0.32 "A" Weighted average common shares outstanding: "A" "A" "A" Basic: "A" 42,500,355 "A" 40,448,365 "A" \$ 42,148,992 "A" 40,861,218 "A" Diluted: "A" 45,248,792 "A" 43,292,261 "A" \$ 44,600,401 "A" 43,359,993 "A" See accompanying notes to the unaudited condensed consolidated financial statements. 2 "A" VITAL FARMS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Amounts in thousands) (Unaudited) "A" 13-Weeks Ended "

thousands, except share and per share amounts) (Unaudited) Note 1. Nature of the Business and Basis of PresentationVital Farms, Inc. (the “Company”) was incorporated in Delaware on June 6, 2013 and is headquartered in Austin, Texas. The Company packages, markets and distributes shell eggs, butter and other products. These products are principally sold under the name Vital Farms in addition to other trade names, primarily to retail and foodservice channels in the United States. The accompanying unaudited condensed consolidated financial statements as of June 30, 2024 and for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”). In the opinion of management, the included disclosures are adequate, and the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, consolidated results of operations for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023, and consolidated cash flows for the 26-week periods ended June 30, 2024 and June 25, 2023. Such adjustments are of a normal and recurring nature and certain reclassifications of previously reported amounts have been made to conform to the current year presentation. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the audited annual financial statements. The condensed consolidated results of operations for the 13-week and 26-week periods ended June 30, 2024 are not necessarily indicative of the consolidated results of operations that may be expected for the fiscal year ending December 29, 2024. Fiscal Year: The Company’s fiscal year ends on the last Sunday in December and contains either 52 or 53 weeks. In a 52-week fiscal year, each of the Company’s fiscal quarters consist of 13 weeks. The additional week in a 53-week fiscal year is added to the fourth quarter, making such quarter consist of 14 weeks. Therefore, the financial results of certain 53-week fiscal years, and the associated 14-week quarters, will not be exactly comparable to the prior and subsequent 52-week fiscal years and the associated 13-week quarters. The fiscal quarters ended June 30, 2024 and June 25, 2023 both contain operating results for 13 weeks. The fiscal year ended December 31, 2023 consisted of 53 weeks. Note 2. Summary of Significant Accounting PoliciesThe significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Company’s Annual Report. Other than the adoption of the new accounting pronouncements and standards as further described below, there have been no material changes to the Company’s significant accounting policies during the 26-week period ended June 30, 2024. Recently Adopted Accounting PronouncementsThe new accounting pronouncements recently adopted by the Company are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 26-week period ended June 30, 2024. Recently Issued Accounting Pronouncements Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures (“ASU 2023-07”) in order to improve stockholders’ understanding of an entity’s business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require incremental and more detailed disclosure regarding segment expenses on both an annual and interim basis. For public companies ASU 2023-07 is effective 7 Å for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company plans to adopt the standard for the year ended December 29, 2024 and will thus include any additional disclosures, if necessary, in its Annual Report on Form 10-K for the current fiscal year. In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic 740) – Improvements to Income Tax Disclosures (“ASU 2023-09”) in order to enhance the transparency and usefulness of income tax disclosures. The guidance is applicable to all entities subject to income tax and it will require disclosure of certain categories within the rate reconciliation to improve consistency as well as disclosure of reconciling items which meet a certain quantitative threshold which will improve transparency. Additionally, entities must disclose the amount of taxes paid to federal, state and foreign municipalities. For public business entities ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2023-09 on its consolidated financial statements. Note 3. Investment SecuritiesThe following table summarizes the Company’s available-for-sale investment securities as of June 30, 2024: Å Amortized Cost Å Gross Unrealized Gains Å Gross Unrealized Losses Å Allowance for Credit Losses Å Fair Value Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å \$ 19,722 Å \$ 9 Å \$ (198) Å \$ Å \$ 19,533 Å Total Å \$ 19,722 Å \$ 9 Å \$ (198) Å \$ Å \$ 19,533 Å The following table summarizes the Company’s available-for-sale investment securities as of December 31, 2023: Å Amortized Cost Å Gross Unrealized Gains Å Gross Unrealized Losses Å Allowance for Credit Losses Å Fair Value Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å \$ 33,134 Å \$ 10 Å \$ (477) Å \$ Å \$ 32,667 Å Total Å \$ 33,134 Å \$ 10 Å \$ (477) Å \$ Å \$ 32,667 Å Proceeds from the sale of available-for-sale securities were \$0 for the 13-week and 26-week periods ended June 30, 2024 and \$1,907 for the 13-week and 26-week periods ended June 25, 2023. Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties. The amortized cost and fair value of the Company’s investments in available-for-sale securities as of June 30, 2024 by contractual maturity are as follows: Å Amortized Cost Å Fair Value Å Due within one year Å \$ 17,361 Å \$ 17,171 Å Due after one year through five years Å 2,361 Å 2,362 Å Total available-for-sale Å \$ 19,722 Å \$ 19,533 Å Å The following tables present the Company’s unrealized loss aging for available-for-sale securities by type and length of time the security was in a continuous unrealized loss position as of the periods presented: Å June 30, 2024 Å Less than 12 months Å 12 months or longer Å Total Å Fair Value Å Unrealized Losses Å Fair Value Å Unrealized Losses Å Fair Value Å Unrealized Losses Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å \$ 654 Å \$ (2) Å \$ 17,870 Å \$ (196) Å \$ 18,524 Å \$ (198) Å Total Å \$ 654 Å \$ (2) Å \$ 17,870 Å \$ (196) Å \$ 18,524 Å Å December 31, 2023 Å Less than 12 months Å 12 months or longer Å Total Å Fair Value Å Unrealized Losses Å Fair Value Å Unrealized Losses Å Fair Value Å Unrealized Losses Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å \$ 699 Å \$ (3) Å \$ 29,247 Å \$ (474) Å \$ 29,946 Å \$ (477) Å Total Å \$ 699 Å \$ (3) Å \$ 29,247 Å \$ (474) Å \$ 29,946 Å Å As of June 30, 2024, there were 31 diversified issuances in the Company’s securities portfolio in an unrealized loss position, with credit ratings ranging from BBB- to AA-. As of June 30, 2024, there are no individual bonds with unrealized losses exceeding \$25, and 30 issuances have been in a loss position greater than 12 months. The decline in fair value has resulted primarily from rising interest rates over the last 12 months, and the Company does not believe there has been any significant decline in the creditworthiness of the issuers. The Company also does not believe it is likely that a significant number of bonds will be called early, and it does not have current liquidity needs that would necessitate a sale of any material investments prior to maturity. Therefore, the Company has not recorded an allowance for credit losses on the investment securities as of June 30, 2024. The fair value and location of all investment securities are included in the Fair Value Measurements in Note 5 below. Note 4. Derivative Financial InstrumentsThe Company enters into derivative instruments to mitigate the impact of commodity price volatility. Such instruments may include call options on commodity price contracts. Realized and unrealized gains and losses on the Company’s commodity derivatives not designated as hedging instruments are recorded in other expense, net. The Company recognizes all derivative instruments as either assets or liabilities. The following table presents the aggregated outstanding notional amounts related to the Company’s derivative financial instruments for the periods presented: Å Metric Å June 30, 2024 Å December 31, 2023 Å Commodity: Å Corn Å Bushels (in thousands) Å 860 Å 2,351 Å Soybean Meal Å Tons Å 9 Å 25 Å For the 13-week periods ended June 30, 2024 and June 25, 2023, the pre-tax amount of commodity contract derivative losses recognized in other expense, net was \$87 and \$402, respectively. For the 26-week periods ended June 30, 2024 and June 25, 2023, the pre-tax amount of commodity contract derivative losses recognized in other expense, net in the unaudited condensed consolidated statements of operations was \$387 and \$1,817, respectively. 9 Å The fair value and location of all outstanding derivative financial instruments are included in the Fair Value Measurements in Note 5 below. Note 5. Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are defined below: Å Level 1 Å Quoted prices in active markets for identical assets or liabilities. Å Level 2 Å Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Å Level 3 Å Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Assets Measured at Fair Value on a Recurring BasisThe fair value hierarchy requires the use of observable market data when available. In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis for the periods presented: Å Fair Value Measurements as of June 30, 2024, Using: Å Level 1 Å Level 2 Å Level 3 Å Total Å Assets: Å Cash and cash equivalents: Å Å Å Money market Å \$ 101,703 Å \$ Å \$ 101,703 Å Investment securities, available-for-sale: Å Å Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å Å Å 19,533 Å Å Å 19,533 Å Prepaid expenses and other current assets: Å Å Å Å Å Å Å Å Derivative financial instruments Å Å Å 6 Å Å Å 6 Å Total assets measured at fair value Å \$ 101,703 Å \$ 19,539 Å \$ Å \$ 121,242 Å Å Fair Value Measurements as of December 31, 2023, Using: Å Level 1 Å Level 2 Å Level 3 Å Total Å Assets: Å Å Å Å Å Å Å Å Cash and cash equivalents: Å Å Å Å Å Å Å Å Money market Å \$ 64,498 Å \$ Å \$ 64,498 Å Investment securities, available-for-sale: Å Å Å Å Å Å Å Å U.S. corporate bonds and U.S. dollar Å denominated foreign bonds Å Å Å 32,667 Å Å Å 32,667 Å Derivative financial instruments Å Å Å 394 Å Å Å 394 Å Total assets measured at fair value Å \$ 64,498 Å \$ 33,061 Å \$ 97,559 Å Å During the 26-week period ended June 30, 2024, there were no transfers between fair value measurement levels. For additional information on concentrations of credit risk for the Company’s financial instruments, refer to the Investment Securities in Note 3. Fair Value of Other Financial InstrumentsThe carrying values of the Company’s short-term financial instruments not included above, including cash, trade receivables, other receivables and accounts payable, approximate their fair value due to their short-term nature. Note 6. Revenue RecognitionThe following table summarizes the Company’s net revenue by primary product for the periods presented: Å 13-Weeks Ended Å 26-Weeks Ended Å June 30, 2024 Å June 25, 2023 Å June 30, 2024 Å June 25, 2023 Å Net Revenue: Å Eggs and egg-related products Å \$ 142,941 Å \$ 101,785 Å \$ 286,701 Å \$ 214,575 Å Butter and butter-related products Å 4,447 Å 4,660 Å 8,615 Å 11,041 Å Net Revenue Å \$ 147,388 Å \$ 106,445 Å \$ 295,316 Å \$ 225,616 Å Net revenue is primarily generated from the sale of eggs and butter. The Company’s product offerings include shell eggs, hard-boiled eggs, liquid whole eggs and stick butter. The Company’s previous convenient breakfast product line (including egg bites and egg-based breakfast bars) was discontinued in 2022, and the Company’s ghee and spreadable tub butter product offerings were discontinued during the fiscal year ended December 31, 2023. The revenues related to the discontinued product lines were immaterial for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023. During the 13-week periods ended June 30, 2024 and June 25, 2023 and 26-week periods ended June 30, 2024 and June 25, 2023, the Company had a customer that individually exceeded 10% or more of the Company’s net revenue. The percentage of net revenue from significant customers during the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 is as follows: Å Net Revenue for the 13-Weeks Ended June 30, 2024 Å Net Revenue for the 13-Weeks Ended June 25, 2023 Å Net Revenue for the 26-Weeks Ended June 30, 2024 Å Net Revenue for the 26-Weeks Ended June 25, 2023 Å Customer A Å 23% Å 25% Å 24% Å 25% Å As of June 30, 2024 and December 31, 2023, the Company had customers that individually exceeded 10% or more of the Company’s accounts receivable. The percentage of accounts receivable, net due from significant customers as of June 30, 2024 and December 31, 2023 is as follows: Å Accounts Receivable, Net as of June 30, 2024 Å Accounts Receivable, Net as of December 31, 2023 Å Customer A Å 20% Å 18% Å Customer B Å 13% Å 12% Å Customer C Å * Å 11% Å Customer D Å 11% Å 11% * Accounts receivable, net was less than 10% Å Å 11 Å Note 7. Allowance for Credit LossesAs of June 30, 2024 and December 31, 2023, the Company had an allowance for credit losses of \$631 and \$777, respectively. The Company recognizes current estimated credit losses (the “CECL”) for accounts receivable and other receivables. The CECL for trade receivables are estimated based on the trade receivable aging category, credit risk of specific customers, past collection history, and management’s evaluation of accounts receivable. The Company also has other receivables which are classified within prepaid expenses and other current assets. The CECL for other receivables are estimated based on the other receivables aging category and the probability of default. Provisions for CECL are classified within selling, general and administrative costs. Changes in the allowance for credit losses for the 26-week period ended June 30, 2024 were as follows: Å Accounts Receivable Å Prepaid Expenses and other Current Assets Å Total Å As of December 31, 2023 Å \$ (550) Å \$ (227) Å \$ (777) Reductions (provisions) charged to operating results Å 284 Å Å (48) Å 236 Å Account write-offs Å Å 140 Å Å 140 Å As of March 31, 2024 Å \$ (266) Å \$ (135) Å \$ (401) (Provisions) reductions charged to operating results Å (248) Å 18 Å Å (230) Å Account write-offs Å Å Å Å Å As of June 30, 2024 Å \$ (514) Å \$ (117) Å \$ (631) Å Note 8. InventoriesInventory consisted of the following as of the periods presented: Å June 30, 2024 Å December 31, 2023 Å Eggs and egg-related products Å \$ 19,488 Å \$ 25,521 Å Butter and butter-related products Å 6,978 Å 1,697 Å Packaging Å 3,858 Å 4,988 Å Pullets Å 315 Å 289 Å Other Å 999 Å 896 Å Reserve for inventory obsolescence Å (190) Å (496) Å Inventories Å \$ 31,448 Å \$ 32,895 Å On a periodic basis, the Company compares the amount of inventory on hand with its latest forecasted requirements to determine whether provisions for excess or obsolete inventory reserves are required. Note 9. Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following as of the periods presented: Å June 30, 2024 Å December 31, 2023 Å Prepaid expenses Å \$ 2,568 Å \$ 2,357 Å Other receivables, net Å 1,956 Å 3,363 Å Derivative financial instruments Å 6 Å 394 Å Prepaid expenses and other current assets, net Å \$ 4,530 Å \$ 6,114 Å 12 Å Note 10. Property, Plant and EquipmentProperty, plant and equipment consisted of the following as of the periods presented: Å June 30, 2024 Å December 31, 2023 Å Land Å \$ 4,055 Å \$ 552 Å Land improvements Å 818 Å 818 Å Buildings and improvements Å 30,580 Å 30,532 Å Vehicles Å 1,100 Å 1,055 Å Machinery and equipment Å 55,618 Å 50,979 Å Leasehold improvements Å 491 Å 492 Å Furniture and fixtures Å 508 Å 461 Å Construction in progress Å 2,682 Å 3,001 Å Å 95,852 Å 87,890 Å Less: Accumulated depreciation and amortization Å (27,525) Å (21,051) Å Property, plant and equipment, net Å \$ 68,327 Å \$ 66,839 Å During the 13-week periods ended June 30, 2024 and June 25, 2023, depreciation of property, plant and equipment was approximately \$2,350 and \$1,850, respectively. During the 26-week periods ended June 30, 2024 and June 25, 2023, depreciation of property, plant and equipment was approximately \$4,647 and \$3,543, respectively. During the 13-week periods ended June 30, 2024 and June 25, 2023, amortization of property, plant and equipment was approximately \$938 and \$447, respectively. During the 26-week periods ended June 30, 2024 and June 25, 2023, amortization of property, plant and equipment was approximately \$1,852 and \$894, respectively. Refer to Note 11 for lease information. Note 11. LeasesOperating lease cost is recognized on a straight-line basis over the lease term and finance lease cost is recognized as amortization expense for the right-of-use (the “ROU”) assets and interest expense associated with the finance lease liabilities. The components of lease cost, classified within cost of goods sold, selling, general and administrative and interest expense for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 are below: Å 13-Weeks Ended Å 26-Weeks Ended Å June 30, 2024 Å June 25, 2023 Å June 30, 2024 Å June 25, 2023 Å Operating lease cost Å \$ 1,062 Å \$ 361 Å \$ 1,984 Å \$ 722 Å Finance lease cost Å amortization of right-of-use assets Å 938 Å 447 Å \$ 1,852 Å \$ 894 Å Finance lease cost Å interest on lease liabilities Å 238 Å 125 Å 485 Å 257 Å Short-term lease cost Å 37 Å 305 Å 69 Å 422 Å Variable lease cost Å 2,595 Å 2,115 Å \$ 5,102 Å 3,678 Å Variable lease cost Å long-term supply contracts Å 54,429 Å 47,064 Å \$ 110,432 Å 90,150 Å Total lease cost Å \$ 59,299 Å \$ 50,417 Å \$ 119,924 Å \$ 96,123 Å 13 Å Future undiscounted cash flows are as follows: Å As of June 30, 2024 Å Operating Leases Å Finance Leases Å 2024 Å \$

[illegible]

asset and lease liability as a cost of obtaining the embedded lease within the supplier contract, which is included in the Leases in Note 11. As of June 30, 2024, \$4.3 million has been paid out and \$1.3 million remains to be paid. Indemnification Agreements: In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and its executive officers that will 20 Å require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2024, the Company has not incurred any material costs as a result of such indemnification agreements. Litigation: The Company is subject to various claims and contingencies that are in the scope of ordinary and routine litigation incidental to its business, including those related to regulation, litigation, business transactions, employee-related matters and taxes, among others. When the Company becomes aware of a claim or potential claim, the likelihood of any loss or exposure is assessed. Based on these assessments and estimates, the Company may establish reserves, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may differ materially from the Company's assessments and estimates. On May 20, 2021, the Company and certain of its current and former officers were named as defendants in a class action complaint captioned Nicholas A. Usler et al. v. Vital Farms, Inc. et al. in the United States District Court for the Western District of Texas (the District Court). The plaintiffs alleged false advertising claims on behalf of themselves and a putative class of alleged consumers of the Company's eggs. The named officers of the Company were subsequently dismissed as defendants in this matter. On July 9, 2024, a U.S. Magistrate Judge issued both an order and report and recommendation, for review and adoption by the District Court. Collectively, the order and the report and recommendation (i) denied the plaintiffs' motion for class certification, (ii) excluded the testimony and report of the plaintiffs' damages expert and (iii) granted summary judgment for the Company with respect to two plaintiffs and three of the plaintiffs' state claims. The plaintiffs have filed objections to the order and report and recommendation, and the matter is ongoing. The Company believes the claims are without merit and is vigorously defending itself in this matter. Given the uncertainty of the litigation, the stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company is unable to reasonably estimate the possible loss or range of loss, if any, that may result from the claim. Although the Company maintains insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions and caps on amounts recoverable. Even if the Company believes a claim is covered by insurance, insurers may dispute the Company's entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of the Company's recovery. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company records a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the claim if the likelihood of a potential loss is reasonably possible. Note 21. Related Party Transactions Sandpebble Builders Preconstruction, Inc.: The Company utilizes Sandpebble Builders Preconstruction, Inc. and Sandpebble South, Inc. (collectively Sandpebble) for project management and related services associated with the construction and expansion of the Company's egg processing facilities, including site selection, project management and related services for the Company's planned egg packing facility in Seymour, Indiana. The Company's contract with Sandpebble for services related to the Company's planned egg packing facility in Seymour, Indiana was awarded after a competitive bidding process. Victor Canseco, the owner and principal of Sandpebble, is the father of Russell Diez-Canseco, the Company's President and Chief Executive Officer and a member of the Company's Board of Directors. In connection with the services described above, the Company paid Sandpebble \$292 and \$139 during the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and \$540 and \$255 during the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Amounts paid to Sandpebble are included in property, plant and equipment, net and selling, general and administrative costs. As of June 30, 2024 and June 25, 2023, amounts owed to Sandpebble were \$168 and \$1,126, respectively, and are included in accrued liabilities. 21 Å Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in the forward-looking statements as a result of various factors, including those set forth in Part II, Item 1A, Risk Factors, and Special Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report. The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report and the audited financial information and the notes thereto included in our Annual Report. Overview Our mission is to bring ethical food to the table, and we are disrupting the U.S. food system by developing a framework that challenges the norms of the incumbent food model, allowing us to bring high-quality products from our network of family farms to a national audience. This framework has enabled us to become the leading U.S. brand of pasture-raised eggs and the second-largest U.S. egg brand by retail dollar sales. Our ethics are exemplified by our focus on animal welfare and sustainable farming practices. We believe our standards produce happy hens with varied diets, which produce better eggs. There is a seismic shift in consumer demand for natural, traceable, clean-label, great-tasting and nutritious foods. Supported by a steadfast adherence to the values on which we were founded, we have designed our brand and products to appeal to this consumer movement. Our purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of each of our stakeholders (farmers and suppliers, customers and consumers, communities and the environment, crew members and stockholders). We make decisions based on what is sustainable for all our stakeholders. Our collective sustainable business practices will enable us to fulfill our purpose of improving the lives of people, animals, and the planet through food, now and long into the future. For us, it is not about short-term outcomes or a trade-off between purpose and profit. We are fierce business competitors who believe that prioritizing the long-term viability of all stakeholders will produce stronger outcomes, for everyone, over time. These principles guide our day-to-day operations and, we believe, help us deliver a more sustainable and successful business. Our approach has been validated by our financial performance and our January 2022 recertification as a Certified B Corporation, a designation reserved for businesses that balance profit and purpose to meet the highest verified standards of social and environmental performance, public transparency and legal accountability. We source our eggs from a network of over 350 family farms. The cream for our butter is sourced from a network of family farms contracted by our butter supplier. We have strategically designed our supply chain to ensure high production standards and optimal year-round operation. We are motivated by the positive impact we have on rural communities and enjoy a strong relationship and reputation with our network of farmers. We primarily work with our contracted egg farms pursuant to buy-sell contracts. Under these arrangements, the farmer is responsible for all of the working capital and investments required to produce the eggs and manage the farm, including purchasing the birds and feed supply. During the last quarter of fiscal 2023, as a result of increasing construction costs associated with our new egg farms, we incurred incremental farm recruitment costs that will be required to be paid in advance of these farms beginning to produce eggs, and we expect such incremental costs to continue through fiscal 2024. These costs are expected to be recognized over the term of the related buy-sell contracts with the new farms, which are generally four to five years in length. We believe the unfavorable impact to our working capital resulting from these upfront costs could range from \$10.0 million to \$12.0 million during fiscal 2024. The impact to fiscal year 2023 working capital was immaterial, and the impact to our gross margin is also expected to be immaterial during the term of these agreements. We are contractually obligated to purchase all of the eggs produced by the farmer during the term of the contract at an agreed-upon price that depends upon pallet weight and is adjusted quarterly for changes in feed cost. We believe we are a strategic and valuable partner to retailers. We have continued to command premium prices for our products, including our shell eggs. Our loyal and growing consumer base has fueled the expansion of our brand from the natural channel to the mainstream channel. We believe the success of our brand demonstrates that consumers are demanding premium products that meet a higher ethical standard of food production. We have a strong presence at The Kroger Co., or Kroger, Sprouts Farmers Market, or Sprouts, Target Corporation and Whole Foods Market, Inc., or Whole Foods, and we also sell our products at Albertsons Companies, Inc., Publix Super Markets, Inc. and Walmart, Inc. We offer 23 retail stock keeping units, or SKUs, through a multi-channel retail distribution network. We believe we have significant room for growth within the retail and foodservice channels through growing brand awareness, gaining additional points of distribution and new product innovation. Our shell eggs are collected from farmers by a third-party freight carrier and placed in cold storage until we pack them for shipping to our customers at our state-of-the-art shell egg processing facility, Egg Central Station, in Springfield, Missouri. This facility is approximately 153,000 square feet and utilizes highly automated equipment to grade and package our shell egg products. This facility is capable of packing approximately six million eggs per day and has an SQF Excellent rating, the highest level of such certification from the Global Food Safety Initiative. Additionally, in June 2024, we announced that we are planning to locate a second egg washing and packing facility in Seymour, Indiana, which we anticipate will be fully operational in 2027. We intend to build upon 22 Å the foundational key learnings and successes from our Egg Central Station facility in Missouri with this second facility and further expand our already resilient supply chain. To date in fiscal 2024, we have purchased approximately 391 acres of farmland in Indiana for approximately \$3.0 million. Our intent is to develop this farmland (along with other potential parcels to be purchased in the future) and utilize it to provide learning and development opportunities within our farm network and to help ensure adequate supply for our future egg washing and packing facility in Seymour, Indiana, while preserving the ability in the future to sell turnkey starter farms to interested farmers. Our products are distributed through a broker-distributor-retailer network whereby brokers represent our products to distributors and retailers, who will in turn sell our products to consumers. We serve the majority of natural channel customers through food distributors, which purchase, store, sell and deliver our products to our customers. We serve mainstream retailers by arranging for delivery of our products directly through their distribution centers. We also leverage distributor relationships to fulfill orders for certain independent grocers and other customers. We have experienced consistent sales growth. We had net revenue of \$147.4 million and \$106.4 million, net income of \$16.3 million and \$6.7 million, and Adjusted EBITDA of \$23.3 million and \$11.3 million in the 13-week periods ended June 30, 2024 and June 25, 2023, respectively. We had net revenue of \$295.3 million and \$225.6 million, net income of \$35.4 million and \$13.8 million, and Adjusted EBITDA of \$52.3 million and \$25.2 million in the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Adjusted EBITDA is a non-GAAP financial measure. See the section titled "Non-GAAP Financial Measures" Adjusted EBITDA below for the definition of Adjusted EBITDA, as well as a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure stated in accordance with GAAP. Known Trends, Events and Uncertainties Highly Pathogenic Avian Influenza (HPAI) Since the initial outbreaks of HPAI in early 2022, we have been closely following the progression of the virus and working with our farmers, veterinarians, government health officials and animal welfare auditors to ensure that our flocks are kept as safe as possible. To date, we have experienced outbreaks at five of our farms, one located in Missouri, one in Tennessee and three in Kansas. While we have not experienced material disruptions to our egg supply due to HPAI outbreaks, if a substantial portion of our farms or production facilities were affected, this could materially and negatively affect our supply chain and operating results. Additionally, HPAI has at times resulted in supply shortages and price increases across the egg market. We are confident in the measures we have taken to reduce the risk of HPAI on our farms and production facilities, as well as our ability to mitigate impacts on supply. However, given continued uncertainty about future outbreaks and governmental responses to such outbreaks, we cannot predict the ultimate impact that HPAI will have on our business. Economic Uncertainties The current inflationary environment may affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies, interest rates and overhead costs, may adversely affect our operating results. Elevated interest rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Additionally, some economic observers suggest that we should expect a higher recession risk over the next year, which, together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term, and which could negatively affect our operations. Furthermore, such economic conditions have at times produced downward pressure on share prices. We have experienced and may continue to experience increases in our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with global health pandemics, geopolitical tensions, and employee availability and wage increases, all of which may result in additional stress on our working capital resources. We work closely with our farmers, suppliers and third-party manufacturers to manage our supply chain activities and mitigate potential disruptions to our product supplies as a result of supply chain disruptions associated with such uncertainties. We currently expect to have an adequate supply of our products, packaging, and freight through fiscal year 2024. Liquidity and Capital Resources Overview With cash, cash equivalents and marketable securities of \$152.7 million as of June 30, 2024 and \$60.0 million available under our syndicated revolving credit facility agreement with JPMorgan Chase Bank, N.A. and the other lenders party thereto, or the JPMorgan Credit Facility, we anticipate having sufficient liquidity to make investments in our business to support our long-term growth strategy. We expect that our cash, cash equivalents and marketable securities as of June 30, 2024, together with cash provided by our operating activities and availability of borrowings under our JPMorgan Credit Facility, will be sufficient to fund our operating 23 Å expenses for at least the next 12 months. For additional information regarding our JPMorgan Credit Facility, see Long-Term Debt at Note 14 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. Our future capital requirements will depend on many factors, including our pace of new and existing customer growth, our investments in innovation, our investments in acquisitions or other growth opportunities, our investments in partnerships and unexplored channels and ongoing costs associated with expansions of our production capacity. We may be required to seek additional equity or debt financing. However, a significant disruption of global financial markets (including a disruption due to public health pandemics, geopolitical tensions and wars, inflation or other factors) may result in our inability to access additional capital, which could in the future negatively affect our operations. In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to expand our operations and invest in continued innovation and product expansion, we may not be able to compete successfully, which would harm our business, operations and results of operations. For additional information, see the section titled Liquidity and Capital Resources below. Our Fiscal Year We report on a 52-53-week fiscal year, ending on the last Sunday in December. In a 52-53-week fiscal year, each fiscal quarter consists of 13 weeks. The additional week in a 53-week fiscal year is added to the fourth quarter, making such quarter consist of 14 weeks. Our fiscal year 2024 will include 52 weeks and our fiscal year 2023 consisted of 53 weeks. See Nature of the Business and Basis of Presentation in Note 1 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for additional details related to our fiscal calendar. Key Factors Affecting Our Business We believe that the growth of our business and our future success are dependent upon many factors. While each of these factors presents significant opportunities for us, they also pose important challenges that we must successfully address to enable us to sustain the growth of our business and improve our results of operations. Expand Household Penetration We have positioned our brand to capitalize on growing consumer interest in natural, clean-label, traceable, ethical, great-tasting and nutritious foods. We believe there is substantial opportunity to grow our consumer base and increase the velocity at which households purchase our products. U.S. household penetration for the shell egg category is approximately 96.8%, while the household penetration for our shell eggs is approximately 8.2%. We intend to increase household penetration by continuing to invest significantly in sales and marketing to educate consumers about our brand, our values and the premium quality of our products. We believe these efforts will educate consumers on the attractive attributes of our products, generate further demand for our products and ultimately expand our consumer base. Our ability to attract new consumers will depend, among other things, on the perceived value and quality of our products, the offerings of our competitors and the effectiveness of our marketing efforts. Our performance depends significantly on factors that may affect the level and pattern of consumer spending in the U.S. natural food market in which we operate. Such factors include consumer preference, consumer confidence, consumer income, consumer perception of the safety and quality of our products and shifts in the perceived value for our products relative to alternatives. Grow Within the Retail Channel We believe that our ability to increase the number of customers that sell our products to consumers is an indicator of our market penetration and our future business opportunities. We define our customers as the entities that sell our products to consumers. With certain of our retail customers, like Whole Foods, we sell our products through distributors. We are not able to precisely attribute our net revenue to a specific retailer for products sold through such channels. We rely on third-party data to calculate the portion of retail sales attributable to such retailers, but this data is inherently imprecise because it is based on gross sales generated by our products sold at retailers, without accounting for price concessions, promotional activities or chargebacks, and because it measures retail sales for only the portion of our retailers serviced through distributors. Based on this third-party data and internal analysis, Whole Foods accounted for approximately 23% and 22% of our retail sales for the 13-week periods ended June 30, 2024 and June 25, 2023, respectively and 22% and 23% for the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. As of June 30, 2024, there were approximately 24,000 stores selling our products. We expect the retail channel to be our largest

source of net revenue for the foreseeable future. By capturing greater shelf space, driving higher product velocities and increasing our SKU count, we believe there is meaningful runway for further growth with existing retail customers. Additionally, we believe there is significant opportunity to gain incremental stores from existing customers as well as by adding new retail customers. We also believe there is significant further long-term opportunity in additional distribution channels, including the convenience, drugstore, club, military and international markets. Our ability to execute this strategy will increase our opportunities for incremental sales to consumers, and we also believe this growth will allow for margin expansion. To accomplish these objectives, we intend to continue 24 A leveraging consumer awareness of and demand for our brand, offering targeted sales incentives to our customers and utilizing customer-specific marketing tactics. Our ability to grow within the retail channel will depend on a number of factors, such as our customers’ satisfaction with the sales, product velocities and profitability of our products. Expand Footprint Across Foodservice We believe there is significant demand for our products in the foodservice channel since we offer versatile ingredients with high menu penetrations across commercial and non-commercial operator segments. We see considerable opportunity to continue to grow the channel in the medium- to long-term with our two-pronged sales approach to values-aligned foodservice operators and their distributors. We are working with Axcion Foodservice, a foodservice sales and marketing agency in the consumer packaged goods industry, to increase our category share in broad-line distribution and to get on national and regional restaurant menus. We are also leveraging foodservice as a critical consumer touchpoint to drive brand awareness, and we are investing in co-marketing to reach new households. We believe co-branding is mutually beneficial to foodservice operators because it helps to differentiate their brands, enhances their perceived customer value and drives loyalty. A multi-unit example from our successful foodservice program is True Food Kitchen, an award-winning restaurant brand and a pioneer of wellness-driven dining with locations across the United States that shares our values for improving the lives of people, animals, and the planet through ethically produced food. Expand Our Product Offerings We intend to continue to strengthen our product offerings by investing in innovation in new and existing categories. We have a history of product introductions and intend to continue to innovate by introducing new products from time to time. Eggs and egg-related products generated \$142.9 million, or approximately 97%, of net revenue in the 13-week period ended June 30, 2024. Eggs and egg-related products generated \$286.7 million, or approximately 97%, of net revenue in the 26-week period ended June 30, 2024. We expect eggs and egg-related products to be our largest source of net revenue for the foreseeable future. We believe that investments in innovation will contribute to our long-term growth, including by reinforcing our efforts to increase household penetration. Our ability to successfully develop, market and sell new products will depend on a variety of factors, including the availability of capital to invest in innovation, as well as changing consumer preferences and demand for food products. Key Components of Results of Operations Net Revenue We generate net revenue primarily from sales of our products, including eggs and butter, to our customers, which include natural retailers, mainstream retailers and foodservice customers. We sell our products to customers on a purchase-order basis. We serve the majority of our natural channel customers and certain independent grocers and other customers through food distributors, which purchase, store, sell and deliver our products to these customers. We periodically offer promotional incentives to our customers, including rebates, temporary price reductions, off-invoice discounts, retailer advertisements, product coupons and other trade activities. At the end of each accounting period, we recognize a liability for an estimated promotional allowance reserve. We periodically provide credits or discounts to our customers in the event that products do not conform to customer expectations upon delivery or expire at a customer’s site. We treat these credits and discounts as a reduction of the sales price of the related transaction at the time of sale. We anticipate that these promotional activities, credits and discounts could materially impact our net revenue and that changes in such activities could impact period-over-period results. Our shell eggs are sold to consumers at a premium price point, and when prices for commodity shell eggs fall relative to the price of our shell eggs (including due to any price increases we may implement), price-sensitive consumers may choose to purchase commodity shell eggs offered by our competitors instead of our eggs. As a result, low commodity shell egg prices may adversely affect our net revenue. We increased prices on certain of our products in each of fiscal year 2023 and fiscal year 2024. While we have not seen significant decreases in sales volume due to previous price increases, if we further increase prices to offset higher commodity prices or other costs, we could experience lower demand for our products, decreased ability to attract new customers and lower sales volumes. Net revenue may also vary from period to period depending on the purchase orders we receive, the volume and mix of our products sold, and the channels through which our products are sold. Cost of Goods Sold Cost of goods sold consists of the costs directly attributable to producing our products which include labor, raw material and packaging costs as well as overhead. The labor cost is comprised of wages and related costs for our processing crew members. The raw material is comprised of those items necessary to process our finished egg and butter products and the packaging costs are the cost 25 A of the packaging materials our finished products are sold in. Overhead costs in cost of goods sold include utilities, insurance, inbound freight and storage fees related to our warehouse. Selling, General and Administrative Selling, general and administrative expenses consist primarily of broker and contractor fees for sales and marketing, as well as personnel costs for sales and marketing, finance, human resources and other administrative functions, including salaries, benefits, bonuses, stock-based compensation expense and sales commissions. Selling, general and administrative expenses also include advertising and digital media costs, agency fees, travel and entertainment costs, and costs associated with consumer promotions, product samples, sales aids incurred to acquire new customers, retain existing customers and build our brand awareness, overhead costs for facilities, including associated depreciation and amortization expenses, and information technology-related expenses, including those associated with our implementation of a new enterprise resource planning system. Shipping and Distribution Shipping and distribution expenses consist primarily of costs related to third-party freight for our products. Even though shipping and distribution expenses have decreased in absolute dollars in the short-term, we expect shipping and distribution expenses to increase in absolute dollars in the medium-to-long term as we continue to scale our business, and there is a risk that such expenses could continue to increase due to economic uncertainty, geopolitical tensions or wars. A Results of Operations The results of operations data for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 have been derived from the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. Comparison of the 13-Week Periods Ended June 30, 2024 and June 25, 2023 The following table sets forth our consolidated statement of income data expressed as a percentage of net revenue for the periods presented: A A 13-Weeks Ended A A June 30,2024 A A June 25,2023 A A Amount A A % ofRevenue A A Amount A A % ofRevenue A A (dollars in thousands) A Net revenue A \$ 147,388 A A 100 % A \$ 106,445 A A 100 % Cost of goods sold(1) A \$ 89,710 A A 61 % A \$ 68,645 A A 64 % Gross profit A \$ 57,678 A A 39 % A \$ 37,800 A A 36 % Operating expenses: A A A A A A A A A A Selling, general and administrative(1) A \$ 33,336 A A 23 % A \$ 23,908 A A 22 % Shipping and distribution A \$ 7,203 A A 5 % A \$ 5,853 A A 5 % Total operating expenses A \$ 40,539 A A 28 % A \$ 29,761 A A 28 % Income from operations A \$ 17,139 A A 11 % A \$ 8,039 A A 8 % Other income (expense), net: A A A A A A A A A A Interest expense A \$ (257) A A A A \$ (136) A A A A Interest income A \$ 1,316 A A 1 % A \$ 450 A A A A A A Other expense, net A \$ (87) A A A A \$ (441) A A A A A A Total other income (expense), net A \$ 972 A A 1 % A \$ 1,127 A A A A A A Net income before income taxes A \$ 18,111 A A 12 % A \$ 9,912 A A 7 % Income tax provision A \$ 1,772 A A 1 % A \$ 1,229 A A 1 % Net income A \$ 16,339 A A 11 % A \$ 6,683 A A 6 % (1)Includes stock-based compensation expense of \$107 and \$80 in cost of goods sold for the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and \$2,809 and \$1,366 in selling, general and administrative for the 13-week periods then ended, respectively. 26 A Net Revenue A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A Net revenue A \$ 147,388 A A \$ 106,445 A A \$ 40,943 A A 38 % The increase in net revenue of \$40.9 million, or 38%, was primarily driven by volume-related increases of \$38.1 million and price-related increases of \$2.8 million. The volume favorability was driven by accelerated demand for existing products, expanded item offerings, and store distribution at existing customers. Net revenue from sales through our retail channel was \$141.9 million and \$99.1 million for the 13-week periods ended June 30, 2024 and June 25, 2023, respectively. Gross Profit and Gross Margin A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Gross profit A \$ 57,678 A A \$ 37,800 A A \$ 19,878 A A 53 % Gross margin A 39 % A 36 % A A A A The increase in gross profit of \$19.9 million, or 53%, was driven by higher net revenue generated during the period, as well as benefits of scale and enhanced operational efficiencies. The increase in gross margin during the 13-week period ended June 30, 2024 compared to the corresponding period in the prior year was primarily driven by price/mix benefits, including price increases on our organic egg portfolio in January 2024, as well as benefits of scale, operational efficiencies and more favorable commodity and diesel costs. This was partially offset by an increase in promotional rate as well as an increase in labor and overhead costs. Operating Expenses Selling, General and Administrative A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Selling, general and administrative A \$ 33,336 A A \$ 23,908 A A \$ 9,428 A A 39 % Percentage of net revenue A 23 % A 22 % A A A A The increase in selling, general and administrative expenses of \$9.4 million, or 39%, was primarily driven by: A A A A A A increase of \$5.7 million in employee-related costs, including stock-based compensation, and an overall increase in employee headcount to support our operations; A A A A A A increase of \$1.7 million in marketing-related expenses; A A A A A A increase of \$1.2 million in professional service expenses to support operational expansion; A A A A A A increase of \$0.5 million in technology and software-related expenses to support increased operations and employee headcount; and A A A A A A increase of \$0.3 million in brokerage-related expenses due to the expansion of the business. 27 A Shipping and Distribution A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Shipping and distribution A \$ 7,203 A A \$ 5,853 A A \$ 1,350 A A 23 % Percentage of net revenue A 5 % A 5 % A A A A The increase in shipping and distribution costs of \$1.4 million, or 23%, was driven by higher sales volumes, partially offset by favorable linehaul and fuel rates. Interest Expense A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Interest expense A \$ (257) A A \$ (136) A A \$ (121) A A 89 % The increase in interest expense of \$0.1 million, or 89%, was primarily driven by an increase in finance leases, which generated an increase in interest expense related to those leases. Interest Income A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Interest income A \$ 1,316 A A \$ 450 A A \$ 866 A A 192 % The increase in interest income of \$0.9 million, or 192%, was primarily driven by higher interest income on our available-for-sale securities and marketable securities portfolios resulting from a higher balance and higher interest rates. Other Expense, Net A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Other expense, net A \$ (87) A A \$ (441) A A \$ 354 A A (80) The decrease in other expense, net of \$0.4 million was primarily driven by a reduction in losses on our commodity derivative instruments during the 13-week period ended June 30, 2024 as compared to the 13-week period ended June 25, 2023. Income Tax Provision A A 13-Weeks Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Income tax provision A \$ 1,772 A A \$ 1,229 A A \$ 543 A A 44 % 28 A The increase in the income tax provision of \$0.5 million, or 44%, was related to an increase in net income for the 13-week period ended June 30, 2024 as compared to the same period in the prior year, partially offset by the tax benefit of a non-qualified stock option exercises and RSU releases that occurred during the 13-week period ended June 30, 2024. Comparison of the 26-Week Periods Ended June 30, 2024 and June 25, 2023 The following table sets forth our consolidated statement of income data expressed as a percentage of net revenue for the periods presented: A A 26-Week Period Ended A A June 30,2024 A A June 25,2023 A A Amount A A % ofRevenue A A Amount A A % ofRevenue A A (dollars in thousands) A Net revenue A \$ 295,316 A A 100 % A \$ 225,616 A A 100 % Cost of goods sold(1) A \$ 178,742 A A 61 % A \$ 145,149 A A 64 % Gross profit A \$ 116,574 A A 39 % A \$ 80,467 A A 36 % Operating expenses: A A A A A A A A A A Selling, general and administrative(1) A \$ 60,467 A A 20 % A \$ 47,853 A A 21 % Shipping and distribution A \$ 14,799 A A 5 % A \$ 13,679 A A 6 % Total operating expenses A \$ 75,266 A A 25 % A \$ 61,532 A A 27 % Income from operations A \$ 41,308 A A 14 % A \$ 18,935 A A 8 % Other income (expense), net: A A A A A A A A A A Interest expense A \$ (512) A A A A \$ (275) A A A A A A Interest income A \$ 2,404 A A 1 % A \$ 790 A A A A A A Other income (expense), net A \$ (1,866) A A A A \$ (1,866) A A -1 % Total other income (expense), net A \$ 1,528 A A 1 % A \$ 1,351 A A -1 % Net income before income taxes A \$ 42,836 A A 15 % A \$ 17,584 A A 8 % Income tax provision A \$ 7,474 A A 3 % A \$ 3,751 A A 2 % Net income A \$ 35,362 A A 12 % A \$ 13,833 A A 6 % (1)Includes stock-based compensation expense of \$154 and \$133 in cost of goods sold for the 26-week periods ended June 30, 2024 and June 25, 2023, respectively, and \$4,744 and \$3,554 in selling, general and administrative for the 26-week periods then ended, respectively. Net Revenue A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Net revenue A \$ 295,316 A A \$ 225,616 A A \$ 69,700 A A 31 % The increase in net revenue of \$69.7 million, or 31%, was primarily driven by volume-related increases of \$60.0 million and price-related increases of \$9.7 million. The volume favorability was primarily driven by increases at both new and existing customers. Net revenue from sales through our retail channel was \$284.1 million and \$207.8 million for the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Gross Profit and Gross Margin A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Gross profit A \$ 116,574 A A \$ 80,467 A A \$ 36,107 A A 45 % Gross margin A 39 % A 36 % A A A A A A 29 A The increase in gross profit of \$36.1 million, or 45%, was driven by higher net revenue generated during the period, as well as benefits of scale and enhanced operational efficiencies. The increase in gross margin during the 26-week period ended June 30, 2024 compared to the corresponding period in the prior year was primarily driven by price/mix benefits, including price increases on our organic egg portfolio in January 2024 and fully realizing our February 2023 price increase across the entire shell egg portfolio, as well as benefits of scale, operational efficiencies and more favorable commodity and diesel costs. This was partially offset by an increase in promotional rate as well as an increase in labor and overhead costs. Operating Expenses Selling, General and Administrative A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Selling, general and administrative A \$ 60,467 A A \$ 47,853 A A \$ 12,614 A A 26 % Percentage of net revenue A 20 % A 21 % A A A A A A The increase in selling, general and administrative expenses of \$12.6 million, or 26%, was primarily driven by: A A A A A A increase of \$6.6 million in employee-related costs, including stock-based compensation, driven by an overall increase in employee headcount to support our operations; A A A A A A increase of \$2.2 million in professional service expenses to support operational expansion; A A A A A A increase of \$2.1 million in marketing-related expenses; A A A A A A increase of \$0.8 million in technology and software-related expenses to support increased operations and employee headcount; and A A A A A A increase of \$0.8 million in brokerage-related expenses due to the expansion of the business. Shipping and Distribution A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Shipping and distribution A \$ 14,799 A A \$ 13,679 A A \$ 1,120 A A 8 % Percentage of net revenue A 5 % A 6 % A A A A A A The increase in shipping and distribution costs of \$1.1 million, or 8%, was driven by higher sales volumes, partially offset by favorable linehaul and fuel rates. Interest Expense A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A Interest expense A \$ (512) A A \$ (275) A A \$ (237) A A 86 % 30 A The increase in interest expense of \$0.2 million, or 86%, was primarily driven by an increase in finance leases, which generated an increase in interest expense related to those leases. Interest Income A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Interest income A \$ 2,404 A A \$ 790 A A \$ 1,614 A A 204 % The increase in interest income of \$1.6 million, or 204%, was primarily driven by higher interest income on our available-for-sale securities and marketable securities portfolios resulting from a higher balance and higher interest rates. Other Expense, Net A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Other expense, net A \$ (364) A A \$ (1,866) A A \$ 1,502 A A (80) The decrease in other expense, net of \$1.5 million was primarily driven by a reduction in losses on our commodity derivative instruments during the 26-week period ended June 30, 2024, as compared to those in the 26-week period ended June 25, 2023. Income Tax Provision A A 26-Week Period Ended A A A A A A June 30,2024 A A June 25,2023 A A \$ Change A A % Change A A (in thousands) A A A A A A Income tax provision A \$ 7,474 A A \$ 3,751 A A \$ 3,723 A A 99 % The increase in the income tax provision of \$3.7 million, or 99%, was driven by an increase in net income for the 26-week period ended June 30, 2024, as compared to the same period in the prior year, partially offset by the tax benefit of non-qualified option exercises and RSU releases that occurred during the 26-week period ended June 30, 2024. Liquidity and Capital Resources Since inception, we have funded our operations with proceeds from sales of our capital stock, proceeds from borrowings and cash flows from the sale of our products. We had net income of \$16.3 million and \$35.4 million in the 13-week and 26-week periods ended June 30, 2024, and retained earnings of \$65.1 million as of June 30, 2024. Funding Requirements We expect that our cash, cash equivalents and marketable securities, together with cash provided by our operating activities and available borrowings under our existing JPMorgan Credit Facility, will be sufficient to fund our operating expenses for at least the next 12 months. We further believe that we will be able to

fund potential operating expenses and cash obligations beyond the next 12 months, through a combination of existing cash, cash equivalents and marketable securities, cash provided by our operating activities and available borrowings under our JP Morgan Credit Facility. 31 A Our future capital requirements will depend on many factors, including our pace of new and existing customer growth, our investments in innovation, our investments in acquisitions, partnerships and unexplored channels and the potential costs associated with future expansion of our production capacity. As of June 30, 2024, future minimum lease payments under non-cancelable operating leases totaled \$9.1 million and future minimum lease payments under non-cancelable finance leases totaled \$14.8 million. In addition, as a result of increasing construction costs associated with our new farms, we incurred incremental farm recruitment costs that will be required to be paid in advance of these farms being able to produce eggs, and we expect such incremental costs to continue through fiscal 2024. These costs are expected to be recognized over the term of the related buy-sell contracts with the new farms, which are generally four to five years in length. Additionally, in April 2024 we signed an agreement to acquire land in Seymour, Indiana for a planned additional egg washing and packing facility. We anticipate that we will incur approximately \$8.0 million to \$12.0 million in capital expenditures related to the new egg washing and packing facility in the next 12 months and will incur further expenditures in the years following. We also anticipate that we will incur approximately \$20.0 million to \$30.0 million in capital expenditures over the next 12 months related to the development of farms on previously acquired farmland in Indiana or the purchase and development of future parcels, with further expenditures incurred in the years following. Finally, we anticipate increased expenditures in marketing during fiscal 2024 to support progress toward our long-term marketing goals. Credit Facility On April 9, 2024, we entered into the JPMorgan Credit Facility with JPMorgan Chase Bank, N.A. and the other lenders party thereto, which provides for a five-year, \$60.0 million revolving credit facility. The JPMorgan Credit Facility replaced the PNC Credit Facility, which terminated concurrently. The JPMorgan Credit Facility includes a \$5.0 million letter of credit sub-limit and an accordion option that would allow the Company to increase the aggregate revolving commitments or add incremental term loans in an aggregate amount not to exceed the greater of (i) \$35.0 million and (ii) an amount equal to 100% of consolidated adjusted EBITDA. Any borrowings under the JPMorgan Credit Facility bear interest, at our election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10% plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company's net leverage ratio, or (ii) an alternative base rate plus a margin or either 1.75%, 2.00% or 2.25%, depending on the Company's net leverage ratio. We are required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on our revolving exposure. Additionally, we are required to pay a participation fee on the account of each lender for each outstanding letter of credit at a rate equal to the applicable rate used to determine the interest rate applicable to term benchmark revolving loans. The JPMorgan Credit Facility is secured by liens on substantially all of our assets, including certain intellectual property assets and investment securities. It requires us to maintain (i) a net leverage ratio of no greater than 3.25 to 1.00, subject to two increases up to 4.00 to 1.00 for a certain period following material acquisitions, and (ii) a fixed charge coverage ratio of no less than 1.35 to 1.00. The JPMorgan Credit Facility contains other customary covenants, representations and events of default. As a result of the limitations contained in the JPMorgan Credit Facility, certain of the net assets on our consolidated balance sheet as of June 30, 2024 are restricted in use. As of June 30, 2024, there was no outstanding balance under the JPMorgan Credit Facility, and we were in compliance with all covenants under the JPMorgan Credit Facility. See [aLong-Term Debt](#) at Note 14 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for additional details related to the JPMorgan Credit Facility. Cash Flows The following table summarizes our cash flows for the 26-week period indicated: A 26-Week Period Ended A A June 30,2024 A A June 25,2023 A A (in thousands) A Net cash provided by operating activities A \$ 40,082 A A \$ 18,911 A Net cash provided by investing activities A \$ 5,753 A A \$ 17,012 A Net cash provided by (used in) financing activities A \$ 3,189 A A \$ (1,164) Net increase in cash and cash equivalents A \$ 49,024 A A \$ 34,759 A A 32 A Operating Activities The increase in net cash provided by operating activities during the 26-week period ended June 30, 2024 compared to the corresponding period in the prior year was due primarily to \$21.5 million higher net income earned in the current period due to gross margin improvements and better leverage of selling, general and administrative costs. Investing Activities The decrease in cash provided by investing activities is primarily due to an increase in purchases of property, plant and equipment during the 26-week period ended June 30, 2024 and fewer proceeds received on the maturities of available-for-sale debt securities, compared to the corresponding period in the prior year. Financing Activities The increase in cash provided by (used in) financing activities during the 26-week period ended June 30, 2024 compared to the corresponding period in the prior year was due primarily to an increase in the proceeds received from the exercise of stock options in the current period. Non-GAAP Financial Measures Adjusted EBITDA We report our financial results in accordance with GAAP. However, management believes that Adjusted EBITDA, a non-GAAP financial measure, provides investors with additional useful information in evaluating our performance. We calculate Adjusted EBITDA as net income, adjusted to exclude: [aDepreciation and amortization](#); [aStock-based compensation expense](#); [aBenefit or provision for income taxes as applicable](#); [aInterest expense](#); and [aInterest income](#). Adjusted EBITDA is a financial measure that is not required by, or presented in accordance with, GAAP. We believe that Adjusted EBITDA, when taken together with our financial results presented in accordance with GAAP, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is a measure used by management in assessing the health of our business, determining incentive compensation and evaluating our operating performance, as well as for internal planning and forecasting purposes. Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include the following: [aIt does not properly reflect capital commitments to be paid in the future](#); [aAlthough depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures](#); [aIt does not consider the impact of stock-based compensation expense, as such expenses in any specific period may not directly correlate to the underlying performance of our business operations and can vary significantly between periods as a result of the timing of grants of new stock-based awards](#); [aIt does not reflect other non-operating expenses, including interest expense](#); and [aIt does not reflect tax payments that may represent a reduction in cash available to us](#). 33 A In addition, our use of Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial measures, including our net income or loss and other results stated in accordance with GAAP. The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable financial measure stated in accordance with GAAP, for the periods presented: A A 13-Weeks Ended A A 26-Weeks Ended A A June 30,2024 A A June 25,2023 A A June 30,2024 A A June 25,2023 A A (in thousands) A (in thousands) A Net income A \$ 16,339 A A \$ 6,683 A A \$ 35,362 A A \$ 13,833 A Depreciation and amortization(1) A A \$ 3,288 A A \$ 2,297 A A \$ 6,499 A A \$ 4,437 A Stock-based compensation expense A A 2,916 A A \$ 1,446 A A \$ 4,898 A A \$ 3,687 A Income tax provision A A 1,772 A A \$ 1,229 A A \$ 7,474 A A \$ 3,751 A Interest expense A A 257 A A \$ 136 A A \$ 512 A A \$ 275 A Interest income A A (1,316) A A (450) A A (2,404) A A (790) Adjusted EBITDA A A \$ 23,256 A A \$ 11,341 A A \$ 52,341 A A \$ 25,193 A A (1) Amount also reflects finance lease amortization. Seasonality Demand for our products fluctuates in response to seasonal factors. Demand tends to increase with the start of the school year and is highest prior to holiday periods, particularly Thanksgiving, Christmas and Easter, and lowest during the summer months. As a result of these seasonal and quarterly fluctuations, comparisons of our sales and results of operations between different quarters within a single fiscal year are not necessarily meaningful comparisons. Critical Accounting Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and judgments that affect the amounts reported in the financial statements and related notes thereto. Critical accounting estimates are those estimates that involve a significant level of estimation uncertainty and have had, or are reasonably likely to have, a material impact on our unaudited condensed consolidated financial statements. Management has determined that our most critical accounting estimates are those relating to trade promotion accruals and income taxes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making these estimates, actual results reported in future periods could differ materially from those estimates. For further discussion about our accounting policies, see [aSummary of Significant Accounting Policies](#) in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. The significant accounting estimates used in preparation of the unaudited condensed consolidated financial statements are described in our audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in our Annual Report. Except as detailed in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, there have been no material changes to our significant accounting policies or critical accounting estimates during the 26-week period ended June 30, 2024. Recent Accounting Pronouncements See the sections titled [aSummary of Significant Accounting Policies](#) [Recently Adopted Accounting Pronouncements](#) and [aRecently Issued Accounting Pronouncements Not Yet Adopted](#) in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for a discussion of recent accounting pronouncements. Emerging Growth Company Status In April 2012, the Jumpstart Our Business Startups Act of 2012, or JOBS Act, was enacted. Section 107 of the JOBS Act provides that an [aemerging growth company](#) may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Therefore, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the 34 A extended transition period under the JOBS Act until such time that we are no longer an emerging growth company. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. We will cease to be an emerging growth company on the date that is the earliest of (1) the last day of the fiscal year in which we have total annual gross revenues of \$1.235 billion or more; (2) December 31, 2025; (3) the date on which we have issued more than \$1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not all of these exemptions. Based on the market value of our common stock held by non-affiliates as of the last business day of our fiscal quarter ending June 30, 2024, our emerging growth company status will expire on December 29, 2024 because we will qualify as a large accelerated filer under the rules of the SEC and will be required to provide, among other items, an auditor's attestation of management's assessment of internal control over financial reporting required under Sarbanes-Oxley Act Section 404(b) beginning with our annual report for the year ending December 29, 2024. Item 3. Quantitative and Qualitative Disclosures About Market Risk We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in raw materials, ingredients, inflation and interest rates. There have been no material changes in our exposure to market risk during the 13-week and 26-week periods ended June 30, 2024 from the information provided in Part II, Item 7A [Quantitative and Qualitative Disclosures About Market Risk](#) in our Annual Report. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain [aDisclosure controls and procedures](#), as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 35 A PART II [OTHER INFORMATION](#) Item 1. Legal Proceedings From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. For additional information regarding legal proceedings, if any, see Note 20 [Commitments and Contingencies](#) [Litigation](#) to our unaudited condensed consolidated financial statements included elsewhere in this report. We are not aware of any material pending or threatened legal proceedings, other than ordinary routine litigation incidental to the business, against us that we believe could have an adverse effect on our business, operating results or financial condition. Item 1A. Risk Factors Our operations and financial results are subject to various risks and uncertainties. The following is a description of the known factors that may materially affect our business, results of operations or financial condition. You should carefully consider the following risk factors, as well as the other information in this Quarterly Report. If any of the following risks actually occurs, our business, results of operations and financial condition could be adversely affected. In this case, the trading price of our common stock would likely decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may adversely affect our business, results of operations and financial condition. Summary of Selected Risks Associated with Our Business Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. These risks include, among others, the following: [aOur recent, rapid growth may not be indicative of our future growth, and if we continue to grow rapidly, we may not be able to effectively manage our growth or evaluate our future prospects](#). If we fail to effectively manage our growth or evaluate our future prospects, our business could be adversely affected. [aWe may not be able to maintain or increase our profitability in the future](#). [aSales of shell eggs constitute the vast majority of our revenue, and a reduction in these sales would have an adverse effect on our financial condition](#). [aFailure to introduce successful new products, successfully enter new product categories or successfully pursue growth by other means may adversely affect our ability to continue to grow](#). [aA substantial amount of our shell egg processing occurs at our existing Egg Central Station processing facility in Missouri. Any damage or disruption at this facility may harm our business](#). [aWe are dependent on the market for shell eggs, and fluctuations in this market, including the decline of commodity shell egg prices relative to the price of our shell eggs, could adversely affect our business, financial condition and results of operations](#). [aFluctuations in commodity prices and in the availability of feed grains could negatively impact our results of operations and financial condition](#). [aIf we fail to effectively expand our processing, manufacturing and production capacity as we continue to grow and scale our business, including through the successful development of our planned next egg washing and packing facility, our operating results and brand reputation could be harmed](#). [aOur planned egg washing and packing facility in Indiana or other future expansions of our processing capacity may not provide us with the benefits we expect to receive](#). [aIf we fail to effectively maintain relationships within our existing farm network or further expand our farm network, or if our plans for the purchase, development and potential sale of farms do not result in the benefits we anticipate, our business, operating results and brand reputation could be harmed](#). [aIf we fail to effectively price our products or implement price increases, our financial condition may be adversely affected](#). [aIncreased transportation and freight costs or failure by our transportation providers to pick up raw materials or deliver our products on time, in compliance with applicable governmental regulations or at all, have adversely impacted and are expected to continue to adversely impact our operating results](#). 36 A [Our future business, results of operations and financial condition may be adversely affected by reduced or limited availability of eggs, cream for our butter and other raw materials that meet our standards](#). [aWe may not be able to compete successfully in our highly competitive market](#). [aWe currently have a limited number of third-party co-manufacturers and cold storage providers. The loss of one or more of our co-manufacturers or cold storage providers or our failure to timely identify and establish new relationships could harm our business and impede our growth](#). [aOutbreaks of agricultural diseases, including avian influenza, the perception that outbreaks may occur or regulatory or market responses to outbreaks could reduce supply or demand for our products and harm our business](#). [aWe could be adversely affected by a change in consumer preferences, perception and spending habits in the natural food industry generally and with respect to animal-based products in particular. Any failure to develop or enrich our product offerings or gain market acceptance of our new products could have a negative effect on our business](#). [aA limited number of distributors represent a substantial portion of our sales, and disruptions affecting our significant distributors or our relationships with such distributors may adversely affect our results of operations](#). [aWe are dependent on hatcheries and pullet farms to supply our network of family farms with laying hens. Any disruption in that supply chain could materially and adversely affect](#)

our business, financial condition or results of operations. Elevated interest rates could adversely affect our business and the ability of our family farmers to access capital. Consolidation of retail customers or the loss of a significant retail customer could negatively impact our sales and profitability. We source substantially all of our shell egg cartons from a sole source supplier, and any disruptions may impact our ability to sell our eggs. Our brand and reputation may be diminished due to real or perceived quality or food safety issues with our products, which could have an adverse effect on our business, reputation, operating results and financial condition. Demand for shell eggs and butter is subject to seasonal fluctuations, which can adversely impact our results of operations in certain quarters. Packaging costs are volatile, have recently increased and may continue to increase, which may negatively impact our profitability, and reduced availability of packaging supplies may otherwise impact our business. If we fail to retain and motivate members of our management team or other key crew members or fail to attract, train, develop and retain additional qualified crew members to support our operations, our business and future growth prospects may be harmed. If we cannot maintain our company culture or focus on our purpose as we grow, our business and competitive position may be harmed. Disruptions in the worldwide economy may adversely affect our business, results of operations and financial condition. Failure to adequately respond to stakeholder scrutiny related to environmental, social and governance issues or failure to achieve our stated impact goals could adversely impact our reputation and brand. Food safety and food-borne illness incidents or advertising or product mislabeling may materially and adversely affect our business by exposing us to lawsuits, product recalls or regulatory enforcement actions, increasing our operating costs and reducing demand for our product offerings. Our operations are subject to FDA and USDA federal regulations, as well as other federal, state and local regulations, and there is no assurance that we will be in compliance with all applicable regulations. We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security and our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation (including class claims) and mass arbitration demands, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences. Our status as a public benefit corporation and a Certified B Corporation may not result in the benefits we anticipate, and we may be unable to maintain our Certified B Corporation status.

37 A If our data or information technology systems, or the data or information technology systems of third parties upon which we rely, were compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruption of our business operations, reputational harm and loss of revenue or profits. The implementation of a new enterprise resource planning system could cause disruption to our business, and we may not be able to effectively realize the benefits of this new system.

Risks Related to Our Growth and Capital Requirements

Our recent, rapid growth may not be indicative of our future growth, and if we continue to grow rapidly, we may not be able to effectively manage our growth or evaluate our future prospects. If we fail to effectively manage our growth or evaluate our future prospects, our business could be adversely affected. We have grown rapidly since inception and anticipate further growth. For example, our net revenue increased from \$106.4 million in the 13-week period ended June 25, 2023 to \$147.4 million in the 13-week period ended June 30, 2024, our net revenue increased from \$225.6 million in the 26-week period ended June 25, 2023 to \$295.3 million in the 26-week period ended June 30, 2024, and our net revenue increased from \$362.1 million in fiscal 2022 to \$471.9 million in fiscal 2023. This growth has placed significant demands on our management, financial, operational, technological and other resources. The continued growth and expansion of our business depends on a number of factors, including our ability to: increase awareness of our brand and successfully compete with other companies; price our products effectively so that we are able to attract new customers and consumers and expand sales to our existing customers and consumers; expand distribution to new points of sales with new and existing customers; continue to innovate and expand our product offerings; expand our supplier, co-manufacturing, co-packing, cold storage, processing and distribution capacities; invest in and effectively implement information technology systems and related improvements to our processes and procedures; and maintain quality control over our product offerings. The growth and expansion of our business has placed, and will continue to place, significant demands on our management and operations teams and will require significant additional resources, financial and otherwise, to meet our needs, which may not be available in a cost-effective manner or at all. We expect to continue to expend substantial resources on our current and future processing facilities, our sales and marketing efforts, product innovation and development and general administration associated with being a public company. These investments may not result in the continued growth of our business. Even if these investments do result in the growth of our business, if we do not effectively manage our growth, we may not be able to execute on our business plan, respond to competitive pressures, take advantage of market opportunities, satisfy customer requirements or maintain high-quality product offerings, any of which could adversely affect our business, financial condition and results of operations. We may not be able to maintain or increase our profitability in the future. Our ability to maintain or increase our profitability is subject to various factors, many of which are beyond our control. As we continue to expand our operations, we anticipate that our operating expenses and capital expenditures will increase substantially in the foreseeable future as we continue to invest to increase our household penetration, customer base, supplier network, marketing channels and product portfolio, expand and enhance our processing, manufacturing and distribution facilities, and hire additional crew members. Our ongoing expansion efforts may prove more expensive than we anticipate (including as a result of inflation, increases in input costs or disruptions in our supply chain relating to public health pandemics, trade wars, geopolitical tensions, or other factors), and we may not succeed in increasing our net revenue and margins sufficiently to offset the anticipated higher expenses. We have incurred significant expenses in connection with investing in our processing capacity, developing our co-manufacturing and co-packing relationships, and obtaining and storing raw materials, and we will continue to incur significant expenses in developing and marketing products. In addition, many of our expenses, including the costs associated with our existing and any future processing and manufacturing facilities, may be fixed. We expect to continue to incur significant legal, accounting and other expenses as we grow and mature as a public company. If we fail to grow our revenue at a greater rate than our costs and expenses, we may be unable to maintain or increase our profitability and may incur losses in the future. Sales of shell eggs constitute the vast majority of our net revenue, and a reduction in these sales would have an adverse effect on our financial condition. Shell eggs accounted for approximately 94% and 93% of our net revenue in the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and approximately 94% and 93% of our net revenue in the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Shell eggs are our flagship product and have been the focal point of our sales and marketing efforts, and we believe that sales of shell eggs will continue to constitute a significant portion of our net revenue, net income and cash flow for the foreseeable future. We cannot be certain that we will be able to continue to expand sales, processing and distribution of shell eggs, or that consumer and customer demand for our other existing and future products will expand to allow such products to represent a larger percentage of our revenue than they do currently. Accordingly, any factor adversely affecting sales of our shell eggs (including consumers' election to purchase lower-priced private-label or other economy brands during times of economic uncertainty) could have an adverse effect on our business, financial condition and results of operations. Failure to introduce successful new products, successfully enter into new product categories or successfully pursue growth by other means may adversely affect our ability to continue to grow. One element of our growth strategy involves the development and marketing of new products that meet our standards for quality and appeal to consumer preferences. The success of our innovation and product development efforts is affected by our ability to anticipate changes in consumer preferences, the technical capability of our crew members in developing and testing product prototypes, our ability to comply with applicable governmental regulations, and the success of our management, sales and marketing teams in introducing and marketing new products, including through current and new product categories. There can be no assurance that we will successfully develop and market new products or successfully introduce products in new categories. The development and introduction of new products requires substantial marketing expenditures, which we may be unable to recoup if the new products do not gain widespread market acceptance. If we introduce new or improved products that ultimately do not meet objectives for such products, it could impact our growth, sales and profitability. Any failure to successfully develop, market and launch future products or successfully enter into new product categories may lead to decreased growth, sales and profitability. Further risks are presented if we elect to pursue continued growth or enter new product categories by means other than new product introductions, including by acquisitions or investments in business or technologies that we believe could offer growth opportunities. The pursuit of such opportunities may divert the attention of management. Furthermore, it may cause us to incur various costs and expenses in identifying, investigating and pursuing such transactions, regardless of whether such opportunities are realized. Such acquisitions, transactions or investments may also result in potentially dilutive equity issuances, the incurrence of debt or contingent liabilities or challenges with integration, any of which could adversely affect our business, financial condition and results of operations. We estimate market opportunity and forecast market growth that may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all. Our estimates of market opportunity and growth forecasts included in this Quarterly Report and elsewhere, including in connection with the long-term financial goals we announced in 2023, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, particularly in light of economic uncertainties. The variables that go into the calculation of our market opportunity are subject to change over time, and there is no guarantee that any particular number or percentage of customers covered by our market opportunity estimates will purchase our products at all or generate any particular level of revenue for us. Any expansion in our market depends on a number of factors, including the cost and perceived value associated with our products and those of our competitors. Even if the market in which we compete meets the size estimates and growth forecast, our business could fail to grow at the rate we anticipate, if at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. Accordingly, our forecasts of market growth should not be taken as indicative of our future growth.

39 A We may require additional financing to achieve our goals, and the failure to obtain this necessary capital when needed on acceptable terms, or at all, may force us to delay, limit, reduce or terminate our product manufacturing and development, and other operations. We have funded our operations since inception primarily through equity financings, draws on our credit facilities and sales of our products. We have incurred and expect to continue to incur significant expenses related to the expansion of our processing capacity. We believe that we will continue to expend substantial resources for the foreseeable future as we consider additional markets we may choose to pursue and other growth opportunities. We expect that our existing cash, cash equivalents and marketable securities, together with cash provided by our operating activities and available borrowings under our syndicated credit facility with JPMorgan Chase Bank, N.A., or the JPMorgan Credit Facility, will be sufficient to fund our planned operating expenses and capital expenditure requirements through at least the next 12 months. However, our operating plan may change because of factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources. We may also seek financing in connection with potential new product introductions or acquisitions or investments in businesses or technologies that we believe could offer growth opportunities. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Our ability to access additional capital may further be affected by adverse or uncertain economic conditions. Weakness and volatility in the capital markets and the economy in general could make it more difficult to access the capital markets and could increase our cost of borrowing. The agreements governing our credit facility require us to meet certain covenants, which could restrict our operational and financial flexibility. The JPMorgan Credit Facility provides for a revolving line of credit with a maximum borrowing capacity of \$60.0 million. The JPMorgan Credit Facility contains certain restrictive covenants, in each case subject to certain exceptions. The restrictive covenants in the JPMorgan Credit Facility limit our ability to incur or guarantee additional indebtedness, incur liens, make distributions, pay dividends, make investments, enter into fundamental changes such as mergers or consolidations, engage in transactions with the Company's affiliates, change our fiscal year or substantially change the nature of our business. The JPMorgan Credit Facility also requires us to maintain two financial covenants: a fixed charge coverage ratio and a net leverage ratio. These provisions may affect our ability to pursue business opportunities we find attractive or to maintain flexibility in reacting to changes in business conditions. Our failure to comply with the covenants in the JPMorgan Credit Facility or other terms of any present or future indebtedness could result in an event of default under such indebtedness, which, if not cured or waived, could result in the lender or lenders under such indebtedness declaring all obligations, together with accrued and unpaid interest, immediately due and payable and taking control of any collateral securing such indebtedness. This may require us to amend or refinance our indebtedness on less favorable terms. If we are forced to amend or refinance the JPMorgan Credit Facility on less favorable terms or are unable to do so at all, our business, financial condition and results of operations could be adversely affected. In any such case, we may be unable to borrow under the JPMorgan Credit Facility or other indebtedness and may not be able to repay the amounts due thereunder. This could have an adverse effect on our business, financial condition, results of operations and prospects.

Risks Related to Our Business, Our Brand, Our Products and Our Industry

A substantial amount of our shell egg processing occurs at our existing Egg Central Station processing facility in Missouri. Any damage or disruption at this facility may harm our business. A substantial amount of our shell egg processing occurs at our existing Egg Central Station shell egg processing facility in Missouri. Any shutdown or period of reduced production at this facility, which may be caused by regulatory noncompliance or other issues, as well as factors beyond our control, such as natural disaster, weather, fire, power or other utility interruption, work stoppage, disease outbreaks or pandemics, equipment failure or delay in raw materials delivery, could significantly disrupt our ability to deliver our products in a timely manner, meet our contractual obligations and operate our business. Further, the processing equipment used for our shell eggs is costly to replace or repair, particularly because certain of such equipment is sourced internationally. We have at times seen pricing and capacity constraints related to internationally sourced equipment, and our equipment supply chains may be further disrupted in connection with public health pandemics, geopolitical tensions and wars (such as the ongoing war between Russia and 40 A Ukraine and the ongoing conflicts in the Middle East), inflation, trade wars or other factors. If any material amount of our machinery were damaged, we could be unable to predict when, if at all, we could replace or repair such machinery or find co-manufacturers with suitable alternative machinery, which could adversely affect our business, financial condition and operating results. The property and business disruption insurance we maintain may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms or at all. We are dependent on the market for shell eggs, and fluctuations in this market, including the decline of commodity shell egg prices relative to the price of our shell eggs, could adversely affect our business, financial condition and results of operations. We contract with family farms to purchase all of their egg production for the duration of our contracts. We are contractually obligated to purchase these eggs irrespective of our ability to sell such eggs. Periodically in our industry, there has been an oversupply of eggs, which has caused egg prices to contract, sometimes substantially so, and as a result we have sold or donated our excess supply at reduced prices or no cost. If we are unable to sell such eggs upon commercially reasonable terms, or at all, our gross margins, business, financial condition and operating results may be adversely affected. Conversely, there have at times in recent periods been supply shortages in the egg industry, with supply impacted by, among other things, avian influenza, increased demand for eggs and increases in feed and other input costs. Such supply shortages, together with price increases we or others in the industry have implemented or choose to implement in the future, could result in declining consumer demand for shell eggs or inability to fulfill customer demand, each of which could have a material impact on our financial condition and results and operations. We sell shell eggs to consumers at a premium price point, and when prices for commodity shell eggs fall relative to the price of our shell eggs (including due to price increases we may implement or supply expansions in the market for commodity shell eggs), price-sensitive consumers may choose to purchase commodity shell eggs offered by our competitors at a greater velocity than, or instead of, our shell eggs. As a result, low commodity shell egg prices relative to the price of our shell eggs may adversely affect our business, financial condition and results of operations. We also sell a small percentage of our shell eggs to wholesalers and egg breaking plants at commodity shell egg prices, which fluctuate widely and are outside our control. Small increases in production or small decreases in demand can have a large adverse effect on the prices at which these eggs are sold. Fluctuations in commodity prices and in the availability of feed grains could negatively impact our results of operations and financial condition. The price we pay to purchase shell eggs from farmers fluctuates based on pallet weight and is also adjusted quarterly for changes in feed cost, which may cause our agreed-upon pricing under these contracts to fluctuate on a quarterly basis. Therefore, our results of operations and financial condition, including our gross margin and profitability, fluctuate based on the cost and supply of commodities, including corn, soybean meal and other feed ingredients. Although feed ingredients are available from a number of sources, we have little, if any, control over the prices of these ingredients, which are affected by weather, speculators, export restrictions, various supply and demand factors, geopolitical tensions, inflation, transportation and storage costs, and agricultural and energy policies in the United States and internationally. We have seen increased prices for conventional and organic corn and soybean crops on a global basis, including increased prices resulting from the Russia-Ukraine war and measures taken in response thereto, inflation and supply chain shortages. It is possible that ongoing conflicts in the

Midle East and elsewhere may have similar effects. We have entered into commodity derivative instrument contracts related to conventional feed ingredients. If we are unable to successfully conduct this program to reduce the impact of commodity price fluctuations, our financial condition and results of operations may be impacted. We may not be able to increase our product prices enough or in a timely manner to sufficiently offset increased commodity costs due to consumer price sensitivity or the pricing postures of our competitors and, in many cases, our retailers may not accept a price increase or may require price increases to occur after a specified period of time elapses. Over time, if we are unable to price our products to cover increased costs, are unable to offset operating cost increases with continuous improvement savings or are unsuccessful in our current or any future commodity derivative instrument program, then commodity price volatility or increases could adversely affect our business, financial condition and results of operations. 41 A If we fail to effectively expand our processing, manufacturing and production capacity as we continue to grow and scale our business, including through the successful development of our planned next egg washing and packing facility, our operating results and brand reputation could be harmed. While our current supply, processing and manufacturing capabilities are sufficient to meet our present business needs, we are planning to expand these capabilities in the future as we continue to grow and scale our business. In June 2024, we announced plans to develop our second egg washing and packing facility in Seymour, Indiana. There is risk in our ability to effectively continue to scale production and processing and manage our supply chain requirements. We must accurately forecast demand for our products in order to ensure we have adequate processing and manufacturing capacity to effectively allocate product supply across our stock keeping units. Our forecasts are based on multiple assumptions that, if inaccurate, may affect our ability to maintain adequate processing and manufacturing capacities (or co-processing and co-manufacturing capacities) in order to meet the demand for our products, which could prevent us from meeting increased customer demand. If we fail to meet demand for our products and, as a result, consumers who have previously purchased our products may buy other brands and our retail customers may allocate shelf space to other brands, each of which could adversely affect our business, financial condition and results of operations. On the other hand, if we overestimate our demand or overbuild our capacity, we may have significantly underutilized supply or other assets and may experience reduced margins. If we do not accurately align our processing and manufacturing capabilities with demand, our business, financial condition and results of operations could be adversely affected. Our planned egg washing and packing facility in Indiana or other future expansions of our processing capacity may not provide us with the benefits we expect to receive. In June 2024, we announced plans to develop our second egg washing and packing facility in Seymour, Indiana. Constructing and opening this facility will require significant capital expenditures and the efforts and attention of our management and other crew members, which may divert resources from our existing business or operations. In addition, we will need to hire and retain more skilled crew members to operate the new facility, and we will need to recruit and retain additional family farms to supply the new facility. If we are unable to effectively staff and supply this facility, it may not meet our operational and financial expectations. Even if the new facility is brought up to full processing capacity, it may not provide us with all of the operational and financial benefits we expect to receive. If we fail to effectively maintain relationships within our existing farm network or further expand our farm network, or if our plans for the purchase, development and potential sale of farms do not result in the benefits we anticipate, our business, operating results and brand reputation could be harmed. We source our eggs from our network of family farms, which is the foundation of our supply chain. The cream for our butter is sourced from a network of family farms contracted by our butter supplier. If we are unable to maintain and expand this supply chain because of actions taken by farmers or other events outside of our control (including the failure of our butter supplier to maintain or expand its contracted farm network), we may be unable to timely supply distributors and customers with our products, which could lead to cancellation of purchase orders, damage to our commercial relationships and impairment of our brand. For example, we require our egg farmers to build and equip their farms to certain specifications, which requires a significant upfront capital investment, and any inability of farmers to obtain adequate financing on acceptable terms, including due to elevated interest rates, would impair their ability to contract with us. These and other factors, including economic uncertainty, may make it more difficult for us to recruit and attract new farmers to our network in a number sufficient to meet product demand. There are a number of factors that could impair our relationship with farmers, many of which are outside of our control. While we strive to operate our business in a manner that drives long-term and sustainable benefits for our stakeholders, including our farmers, we may make strategic decisions that our farmers disagree with and which could cause farmers to terminate their relationships with us. Reputational harm resulting from impairment of our relationship with existing farmers may also make it more difficult to attract new farmers to expand our network. If our relationship with our existing or future farmers is disrupted due to these or other factors, we may not be able to sustain the supply necessary to meet customer and consumer demand for our products, which would negatively impact our operating results. Further risks may be presented by our plans to develop farms on our previously acquired farmland in Indiana or to purchase and develop future parcels, with the possibility of selling such farms in the future to interested farmers. We may not be able to adequately build, develop or staff such farms, and they may not result in the benefits we anticipate. The purchase, development and potential sale of these farms will require significant capital expenditures and the efforts and attention of our management and other crew members, 42 A which may divert resources from our existing business or operations. Any failure to maintain or expand our farm network would adversely affect our business, financial condition and results of operations. If we fail to effectively price our products or implement price increases, our financial condition may be adversely affected. The prices of our products are driven by a number of factors, including supply constraints, customer and consumer demand, inflation, input costs and market conditions. In response to such conditions, we have periodically increased prices on certain of our products. While we have not yet seen significant decreases in sales volume due to such price increases, if we further increase prices, we could experience declining demand for our products, decreased ability to attract new customers and lower sales volumes. If price increases result in a greater spread between the price of our products and the price of conventional or private-label products, consumers may be less willing to pay a premium for our products, particularly in times of economic uncertainty. Additionally, our retail customers may not accept such price increases or may require increased promotional activity. If we cannot effectively price our products or carry out price increases, our business, financial condition and operating results could be adversely affected. Increased transportation and freight costs or failure by our transportation providers to pick up raw materials or deliver our products on time, in compliance with applicable governmental regulations or at all, have adversely impacted and are expected to continue to adversely impact our operating results. We rely upon third-party transportation providers for a significant portion of our raw material transportation and product shipments. Our utilization of pickup and delivery services for shipments is subject to risks, including increases in fuel prices, driver shortages, trucking capacity limitations due to general increases in freight demand, employee and contractor strikes or unavailability (including due to disease outbreaks or pandemics) or inclement weather, any of which could increase our transportation and freight costs. For example, due in part to increased labor costs and rising fuel costs due to international tensions and wars (including due to attacks on container ships in the Red Sea), we have seen at times during recent periods increased transportation and freight costs. Further increases in transportation and freight costs could have an adverse effect on our ability to increase or to maintain production on a profitable basis and could therefore adversely affect our operating results. We may not be able to price our products in a manner that sufficiently offsets increased transportation costs due to consumer price sensitivity or the pricing postures of our competitors, and in many cases, our retail customers may not accept a price increase or may require price increases to occur after a specified period of time elapses. In addition, if we increase prices to offset higher transportation and freight costs, we could experience lower demand for our products, decreased ability to attract new customers and lower sales volumes. Furthermore, noncompliance by our third-party transportation providers with applicable regulatory requirements may impact the ability of providers to provide delivery services that adequately meet our shipping needs. Due to increased costs or noncompliance by our transportation providers with applicable regulatory requirements, we may change shipping companies, and we could face logistical difficulties with any such change that could adversely affect deliveries. In addition, we could incur costs and expend resources in connection with such change. Moreover, we may not be able to obtain terms as favorable as those we receive from the third-party transportation providers that we currently use, which in turn would increase our costs and adversely affect our operating results. Our future business, results of operations and financial condition may be adversely affected by reduced or limited availability of eggs, cream for our butter and other raw materials that meet our standards. 43 A Our ability to ensure a continued supply of eggs, cream for our butter and other raw materials for our products at competitive prices depends on many factors beyond our control. In particular, we rely on the farms that supply us with eggs and cream to implement controls and procedures to manage the risk of exposing animals to harmful diseases, but outbreaks may occur despite their efforts. An outbreak of disease could result in increased government restriction on the sale and distribution of our products, and negative publicity could impact customer and consumer perception of our products, even if an outbreak does not directly impact the animals from which we source our products. Our farm network for our shell eggs is located in a geographic region we refer to as the Pasture Belt, which is a term we use that refers to the U.S. region where the weather is conducive to hens being outside as much as possible. The dairy farms that supply our cream are located primarily in Ireland. The occurrence of a natural disaster in any of these regions could have a significant negative impact on us, the farmers and our supply chain. Additionally, the animals from which our products are sourced, the crops on which we rely for feed and the pastures on which these animals are raised are vulnerable to adverse weather conditions and natural disasters, such as floods, droughts, frosts, earthquakes, hurricanes and pestilence. Disease, adverse weather conditions and natural disasters can adversely impact pasture quantity and quality, leading to reduced yields and quality, which in turn could reduce the available supply of, or increase the price of, our raw materials. If we raised prices for our products to account for this increase, we could experience decreased demand for our products and lower sales volumes, thereby adversely affecting our business, financial condition and results of operations. We also compete with other food companies in the procurement of eggs and cream, and this competition may increase in the future if consumer demand and increases for these items or products containing them or if competitors increasingly offer products in these market sectors. If supplies of eggs and cream that meet our quality standards are reduced or are in greater demand, we may not be able to obtain sufficient supply to meet our needs on favorable terms or at all. Our supply may also be affected by the number and size of farms that raise chickens and cows that meet our standards, changes in U.S. and global economic conditions and our ability to forecast our raw materials requirements. For example, in order to meet our standards, we require our contracted egg farms to invest in infrastructure at the outset of our relationship. The typical upfront investment for each of the farms is significant, and many farmers seek financing assistance from local and regional banks as well as federal government loans from the U.S. Department of Agriculture, or USDA, Farm Service Agency. Changes in U.S. and global economic conditions, elevated interest rates or a U.S. government shutdown could significantly affect the loans available to farmers. Many of these farmers have alternative income opportunities and the relative financial performance of raising chickens in accordance with our standards as compared to other potentially more profitable opportunities could affect their interest in working with us. Any of these factors could impact our ability to supply our products to distributors and customers and may adversely affect our business, financial condition and results of operations. We may not be able to compete successfully in our highly competitive market. We compete with large egg companies such as Cal-Maine, Inc. and large international food companies such as Ornuia Co-operative Limited (Kerrygold). We also compete with local and regional egg and dairy companies, as well as private-label products processed by other egg and dairy companies. These competitors may have substantially greater financial and other resources than us, and some of our competitors' products are well accepted in the marketplace today. Such competitors may also have lower operational costs, and as a result may be able to offer comparable or substitute products to customers at lower costs. This could put pressure on us to lower our prices, resulting in lower profitability or, in the alternative, cause us to lose market share if we fail to reduce prices. Conversely, if we were to increase prices, including as a result of fluctuations in the shell egg market, increased commodity or raw material costs, increased packaging or transportation costs or otherwise, any resulting decline in consumer demand for our products may be exacerbated by the competitiveness of our market. Generally, the food industry is dominated by multinational corporations with substantially greater resources and operations than we have. We cannot be certain that we will successfully compete with larger competitors that have greater financial, sales and technical resources. Conventional food companies may acquire our competitors or launch their own egg and butter products, and they may be able to use their resources and scale to respond to competitive pressures and changes in consumer preferences by introducing new products, reducing prices or increasing promotional activities, among other things. Retailers also market competitive products under their own private labels, which are generally sold at lower prices, and may change the merchandising of our products so they have less favorable placement. Larger competitors may also be less affected by economic disruption and uncertainty, including with respect to inflation, global economic conditions or agricultural diseases such as avian influenza, than we are. These competitive pressures could cause us to lose market share, which may require us to lower prices, increase marketing and advertising expenditures or increase the use of discounting or promotional campaigns, each of which could adversely affect our margins and could result in a decrease in our operating results and profitability. 44 A Failure to leverage our brand value propositions to compete against private-label products, especially during an economic downturn, may adversely affect our profitability. We compete not only with other well-advertised nationally branded products, but also with private-label products. Such private-label products generally are sold at lower prices than our products. Consumers are more likely to purchase our products if they believe that our products provide a higher quality and greater value than less expensive alternatives. If the difference in perceived value between our brands and private-label products narrows, or if there is a perception of such a narrowing, consumers may choose not to buy our products at prices that are profitable for us. In periods of economic uncertainty, particularly in periods of uncertainty driven by high inflation, consumers may purchase more often from lower-priced private-label or other economy brands. To the extent this occurs, we could experience a decrease in the sales volume of our higher margin products or a shift in our product mix to lower margin offerings. In addition, our foodservice product sales will be reduced if consumers reduce the amount of food that they consume away from home at our foodservice customers, including as a result of public health pandemics or economic uncertainty driven by inflation or other factors. We currently have a limited number of third-party co-manufacturers and cold storage providers. The loss of one or more of our co-manufacturers or cold storage providers or our failure to timely identify and establish new relationships with new co-manufacturers or cold storage providers could harm our business and impede our growth. A significant amount of our revenue is derived from products manufactured at facilities owned and operated by our co-manufacturers. We currently rely on one co-manufacturer for hard-boiled eggs, one co-manufacturer for bulk butter production, one co-manufacturer for stick butter, one co-manufacturer for liquid eggs and one co-packer for certain shell egg processing. While we currently have written manufacturing contracts with our co-manufacturer for bulk butter production and our co-manufacturer for stick butter, we do not currently have written manufacturing contracts with our other co-manufacturers or with our co-packer for certain shell egg processing. Due to the absence of written contracts with certain of our co-manufacturers, these co-manufacturers can generally seek to alter or terminate their relationships with us at any time, resulting in periods during which we may have limited or no ability to manufacture certain of our products. In addition, due to the limited number of co-manufacturers, any interruption in, or the loss of operations at, one or more of our co-manufacturing facilities, which may be caused by work stoppages, regulatory issues or noncompliance, disease outbreaks or pandemics, war, terrorism, fire, earthquakes, flooding or other weather or natural disasters, could delay, postpone or reduce production of some of our products, which could have an adverse effect on our business, financial condition and results of operations until such time as the interruption is resolved or an alternate source of production is secured, especially in times of low inventory. We believe there are a limited number of competent, high-quality co-manufacturers in our industry that meet our geographical requirements and our strict quality and control standards, and should we seek to obtain additional or alternative co-manufacturing arrangements in the future, there can be no assurance that we would be able to do so on satisfactory terms, in a timely manner, or at all. Therefore, the loss of one or more co-manufacturers, any disruption or delay at a co-manufacturer or any failure to identify and engage co-manufacturers for new products and product extensions could delay, postpone or reduce production of our products, which could have an adverse effect on our business, financial condition and results of operations. Additionally, we rely on a limited number of cold storage providers to store our products. Our financial performance depends in large part on our ability to obtain adequate cold storage facilities services in a timely manner. We are not assured of continued cold storage capacities. Certain of our cold storage providers could discontinue or seek to alter their relationship with us. In addition, we are not assured of sufficient capacities of these providers commensurate with increased product demand. Outbreaks of agricultural diseases, including avian influenza, the perception that outbreaks may occur or regulatory or market responses to outbreaks could reduce supply or demand for our products and harm our business. Our business activities are subject to a variety of agricultural risks, including pests and diseases such as avian influenza, the occurrence of which can materially and adversely affect the quality and quantity of products, including shell eggs, that we distribute. Since the initial outbreak of highly pathogenic avian influenza, or HPAI, in early 2022, we have been closely following the progression of the virus. To date, we have experienced outbreaks at five of our farms, one located in Missouri, one in Tennessee and three in Kansas. While we have not experienced material disruptions to our egg supply due to such outbreaks, if a substantial portion of our farms or production facilities were affected by an outbreak of HPAI, or a disease like it, this could have a material and adverse effect on our business, financial condition and results of operations. Additionally,

outbreaks of HPAI or similar diseases could limit our ability to utilize co-packers for our shell eggs due to increased biosecurity measures that may be implemented by such co-packers in the event of an outbreak. 45 Å Even if our farms and production facilities were not directly impacted by avian disease, we may nevertheless be negatively affected by resulting governmental restrictions on our operations and the sale and distribution of our products, as well as negative publicity and impacted consumer perceptions for our industry. Such impacts could result in decreased consumer demand for our products and impact our operating results. Additionally, certain states in which our family farms are located have at times recommended or required that farms keep hens indoors to help limit exposure to avian influenza. Prolonged requirements to keep our hens indoors could adversely impact consumer perception of our egg products in comparison to those of our competitors, which could have a negative effect on our business, financial condition and operating results. These impacts could be exacerbated in the event of widespread transmission of HPAI or other agricultural diseases to humans. While human cases of HPAI are rare and U.S. public health officials consider the risk of human infection with HPAI to be low, significant changes or increases to the circulation or transmission of HPAI or other agricultural diseases could adversely impact our business, including our ability to recruit and retain farmers. We could be adversely affected by a change in consumer preferences, perception and spending habits in the natural food industry generally and with respect to animal-based products, in particular. Any failure to develop or enrich our product offerings or gain market acceptance of our new products could have a negative effect on our business. We have positioned our brand to capitalize on growing consumer interest in natural, clean-label, traceable, ethically produced, great-tasting and nutritious foods. The market in which we operate is subject to changes in consumer preference, perception and spending habits. Our performance depends significantly on factors that may affect the level and pattern of consumer spending in the U.S. natural food industry market in which we operate. Such factors include consumer preference, consumer confidence, consumer income, consumer perception of the safety and quality of our products and shifts in the perceived value for our products relative to alternatives. Media coverage regarding the safety or quality of, or diet or health issues relating to, our products or the raw materials, ingredients or processes involved in their manufacturing may damage consumer confidence in our products. A general decline in the consumption of our products could occur at any time as a result of changes in consumer preference, perception, confidence and spending habits, including an unwillingness to pay a premium or an inability to purchase our products due to financial hardship or increased price sensitivity, which may be exacerbated by economic uncertainty and general inflationary trends. For example, we and many of our customers face pressure from animal rights groups to require all companies that supply food products to operate their business in a manner that treats animals in conformity with certain standards developed or approved by these animal rights groups. If consumer preferences shift away from animal-based products for these reasons, because of a preference for plant-based products or otherwise, our business, financial condition and results of operations could be adversely affected. The success of our products depends on a number of factors, including our ability to accurately anticipate changes in market demand and consumer preferences, our ability to differentiate the quality of our products from those of our competitors, and the effectiveness of our marketing and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and developing products that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our marketing and advertising campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory requirements or have quality problems, we may not be able to fully recover costs and expenses incurred in our operation, and our business, financial condition or results of operations could be materially and adversely affected. A limited number of distributors represent a substantial portion of our sales, and disruptions affecting our significant distributors or our relationships with such distributors may adversely affect our results of operations. Our products are distributed through a broker-distributor-retailer network whereby brokers represent our products to distributors and retailers who in turn sell our products to consumers. We serve the majority of natural channel customers through food distributors, such as United Natural Foods, Inc., or UNFI, which purchase, store, sell and deliver our products to retailer customers. In the 13-week periods ended June 30, 2024 and June 25, 2023, UNFI (which was Whole Foods® primary distributor) accounted for approximately 23% and 25% of our net revenue, respectively. In the 26-week periods ended June 30, 2024 and June 25, 2023, respectively, UNFI accounted for approximately 24% and 25% of our net revenue, respectively. Since these distributors act as intermediaries between us and the retail grocers or foodservice providers, who generally select the distributors, we do not have short-term or long-term commitments or minimum purchase volumes in our contracts with distributors that ensure future sales of our products. These distributors are able to decide on the products carried, and they may limit the products available for our retail customers to purchase. We expect that most of our sales will be made through a core number of distributors for the foreseeable future. The loss of one or more of our significant distributor relationships that cannot be replaced in a timely manner, under similar terms and conditions or at all could adversely affect our business, financial condition and results of operations. 46 Å We are dependent on hatcheries and pullet farms to supply our network of family farms with laying hens. Any disruption in that supply chain could materially and adversely affect our business, financial condition or results of operations. Under the terms of our contracts with our network of family farms, while we do not own laying hens, we are generally responsible for coordinating the acquisition and delivery of laying hens to the farmers. In order to meet these obligations, we place orders for chicks directly with hatcheries intended to supply a future year's production of eggs at least a year in advance. Once the chicks are hatched, they are delivered to a network of pullet farms, who rear the chicks to approximately 16 to 18 weeks of age, at which time they are delivered to our network of family farms to begin laying eggs. We work primarily with several pullet hatcheries that deliver chicks to a network of independent pullet farms. We do not have long-term supply contracts with these suppliers, and if a substantial portion of our current hatcheries or pullet farms were to cease doing business with us for any reason, we may have a difficult time finding and contracting with alternate hatcheries or pullet farms in sufficient scale to meet our needs, if at all. Pullet farms may also be subject to capacity constraints, and if we are unable to find independent pullet farms with sufficient capacity to receive chicks from our hatcheries, we may be unable to fulfill our customer commitments. Additionally, any disruption in the supply of laying hens for any reason, including agricultural disease such as avian influenza, natural disaster, fire, power or other utility interruption, work stoppage or other calamity, could have a material adverse effect on our business, financial condition and results of operations if we cannot replace these providers in a timely manner on acceptable terms or at all. Elevated interest rates could adversely affect our business and the ability of our family farmers to access capital. Our business and operating results could be harmed by factors such as the availability of credit and the terms of and increases in interest rates. These changes could cause our cost of doing business to increase and limit our ability to pursue growth opportunities. Disruptions and volatility in the global financial markets may lead to a contraction in credit availability, impacting our ability to finance our operations. A significant reduction in cash flows from operations or reduction in the availability of credit could materially and adversely affect our ability to achieve planned growth and operating results. Elevated interest rates may also adversely impact the ability of our family farmers to access capital. We require our egg farmers to build and equip their farms to certain specifications, which requires a significant upfront capital investment, and any inability of farmers to obtain adequate financing on acceptable terms, including as a result of elevated interest rates, would impair their ability to partner with us. If our relationship with these egg farmers is disrupted, we may not be able to fully recover our investments in birds and feed, which would negatively impact our operating results. Consolidation of retail customers or the loss of a significant retail customer could negatively impact our sales and profitability. Our retail customers include natural channel and mainstream channel stores, which have been undergoing consolidation in recent years. This consolidation has produced larger, more sophisticated organizations with increased negotiating and buying power that are able to resist price increases, operate with lower inventories, decrease the number of brands that they carry and increase their emphasis on private-label products, all of which could negatively impact our business. With certain of our retail customers, like Whole Foods, we sell our products through distributors. We are not able to precisely attribute our net revenue to a specific retailer for products sold through distributors. We rely on third-party data to calculate the portion of retail sales attributable to retailers, but this data is inherently imprecise because it is based on gross sales generated by our products sold at retailers, without accounting for price concessions, promotional activities or chargebacks, and because it measures retail sales for only the portion of our retailers serviced through distributors. Based on this third-party data and internal analysis, Whole Foods accounted for approximately 23% and 22% of our retail sales in each of the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and approximately 22% and 23% of our retail sales in each of the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Kroger accounted for approximately 11% and 11% of our retail sales in the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and approximately 11% and 11% of our retail sales in each of the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. The loss of Whole Foods, Kroger or any other large retail customer, or the reduction of purchasing levels or the cancellation of any business from any such customer for an extended length of time, could negatively impact our sales and profitability. A retailer may take actions that affect us for reasons that we cannot always anticipate or control, such as their financial condition, changes in their business strategy or operations, the introduction of competing products or the perceived quality of our products. Despite operating in different channel segments, our retail customers sometimes compete for the same consumers. Because of actual or perceived conflicts resulting from this competition, retailers may take actions that negatively affect us. Consequently, our financial results may fluctuate significantly from period to period based on the actions of one or more significant retailers. 47 Å We source substantially all of our shell egg cartons from a sole source supplier, and any disruptions may impact our ability to sell our eggs. We obtain substantially all of the packaging for our shell eggs from a sole source supplier. Any disruption in the supply of our shell egg cartons, including due to interruptions to global shipping, could delay our production and hinder our ability to meet our commitments to customers. If we are unable to obtain a sufficient quantity of our packaging on commercially reasonable terms or in a timely manner, or if we are unable to obtain alternative sources, sales of our products could be delayed or we may be required to redesign our products. For example, in connection with increased demand for shell eggs in relation to the COVID-19 pandemic in 2020, the supplier of substantially all of our shell egg cartons began to prioritize packaging for core egg products (such as 12-count packages), and we separately experienced certain quality issues with our 18-count egg cartons. As a result of these events, and in order to otherwise meet demand for our products, we began using recycled plastic packaging for certain of our shell egg products. While this change in packaging did not materially impact our operations, there is no guarantee that we will not experience similar packaging issues in the future, or that any such packaging issues will not impact our ability to meet product demand for our shell eggs. For example, consumers may be less likely to accept products packaged using certain materials, or modified packaging may make it more difficult for consumers to locate our products in stores. Any of these events could result in lost sales, price increases, reduced gross margins or damage to our customer or consumer relationships, which would have a material adverse effect on our business, financial condition and results of operations. Our brand and reputation may be diminished due to real or perceived quality or food safety issues with our products, which could have an adverse effect on our business, reputation, operating results and financial condition. We believe our consumers rely on us to provide them with high-quality products. Therefore, real or perceived quality or food safety concerns or failures to comply with applicable food regulations and requirements, whether or not ultimately based on fact and whether or not involving us (such as incidents involving our competitors), could cause negative publicity and reduced confidence in our company, brand or products, which could in turn harm our reputation and sales, and could adversely affect our business, financial condition and operating results. Our products may be subject to contamination by foreign materials or disease-producing organisms or pathogens, such as salmonella and E. coli. These organisms and pathogens are found generally in the environment and there is a risk that one or more could be present in our products, either as a result of food processing or as an inherent risk based on the nature of our products. These organisms and pathogens also can be introduced to our products as a result of improper handling at the further-processing, foodservice or consumer level. These risks may be controlled, but may not be eliminated, by adherence to current good manufacturing practices, or cGMPs, and finished product testing. Shipment of contaminated products, even if inadvertent, could result in a violation of law and lead to increased risk of exposure to product liability claims, product recalls, increased scrutiny by federal and state regulatory agencies, penalties and adverse publicity. In addition, products purchased from other producers, including co-manufacturers, could contain contaminants that we might inadvertently redistribute. If our products become contaminated, or if there is a potential health risk associated with our products, we or our co-manufacturers might decide or need to recall a product. Any product recall could result in a loss of consumer confidence in our products and adversely affect our reputation with existing and potential customers. For example, in December 2019, our co-manufacturer for hard-boiled eggs conducted a voluntary Class I recall of all hard-boiled eggs produced at its facility, including ours, due to potential listeria contamination at the production facility. In connection with the recall, our co-manufacturer elected to permanently close the affected production facility and move all production to a different facility. As a result, we were unable to supply customers with hard-boiled eggs for a period of time in the first quarter of fiscal 2020, which led to the loss of certain customer accounts for this product, the revenues from which were immaterial in the aggregate. We also have no control over our products once purchased by consumers. For example, consumers may store our products under conditions and for periods of time inconsistent with USDA, U.S. Food and Drug Administration, or FDA, and other governmental guidelines, which may adversely affect the quality and safety of our products. If consumers do not perceive our products to be of high quality or safe, then the value of our brand would be diminished, and our business, results of operations and financial condition would be adversely affected. Any loss of confidence on the part of consumers in the quality and safety of our products would be difficult and costly to overcome. Any such adverse effect could be exacerbated by our market positioning as a socially conscious purveyor of high-quality products and may significantly reduce our brand value. Issues regarding the safety of any of our products, regardless of the cause, may have an adverse effect on our brand, reputation and operating results. Further, the growing use of social and digital media by us, our consumers and third parties increases the speed and extent that information or misinformation and opinions can be shared. Negative publicity about us, our brands or our 48 Å products on social or digital media could seriously damage our brands and reputation. If we do not maintain a favorable perception of our brands, our business, financial condition and results of operations could be adversely affected. We must expend resources to maintain consumer awareness of our brand, build brand loyalty and generate interest in our products. Our marketing strategies and channels will evolve, and our programs may or may not be successful. In order to remain competitive and expand and keep shelf placement for our products, we have increased and may continue to increase our marketing and advertising spending to maintain and increase consumer awareness, protect and grow our existing market share or promote new products, which could impact our operating results. Further advertising and promotional expenditures may be required to maintain or improve our brand's market position or to introduce new products to the market, and participants in our industry are increasingly engaging with non-traditional media, including consumer outreach through social media and web-based channels, which may not prove successful. Increases in our marketing and advertising efforts may not maintain our current reputation or lead to increased brand awareness. Further, social media platforms frequently change the algorithms that determine the ranking and display of results of a user's search and may make other changes to the way results are displayed, or may increase the costs of such advertising, which can negatively affect the placement of our links and, therefore, reduce the number of visits to our website and social media channels or make such marketing cost prohibitive. In addition, social media platforms typically require compliance with their policies and procedures, which may be subject to change or new interpretation with limited ability to negotiate, which could negatively impact our marketing capabilities. If we are unable to maintain and promote a favorable perception of our brand and products on a cost-effective basis, our business, financial condition and results of operations could be adversely affected. If we fail to develop and maintain our brand, our business could suffer. We have developed a strong and trusted brand that has contributed significantly to the success of our business, and we believe our continued success depends on our ability to maintain and grow the value of the Vital Farms brand. Maintaining, promoting and positioning our brand and reputation will depend on, among other factors, the success of our product offerings, food safety, quality assurance, marketing and merchandising efforts, our continued focus on animal welfare, the environment and sustainability and our ability to provide a consistent, high-quality consumer and customer experience. Any negative publicity, regardless of its accuracy, could have an adverse effect on our business. Brand value is based on perceptions of subjective qualities, and any incident that erodes the loyalty of our consumers, customers, farmers, suppliers or co-manufacturers, including changes to our products or packaging, adverse publicity or a governmental investigation, litigation or regulatory enforcement action, could significantly reduce the value of our brand and significantly damage our business. If we fail to cost-effectively acquire new consumers or retain our existing consumers, our business could be adversely affected. Our success and our ability to increase revenue and operate profitably depend in part on our ability to cost-effectively acquire new consumers, retain existing consumers and keep existing consumers engaged so that they continue to purchase our products. While we intend to continue to invest significantly in sales and marketing to educate consumers about our brand, our values and our products, there is no assurance that these efforts will generate further demand for our products or expand our consumer base. Our ability to attract new consumers and retain our existing consumers depends on the perceived value and quality of our products, consumers' desire to purchase ethically produced products at a premium, offerings of our competitors, our ability to offer new and relevant products and the effectiveness of our marketing efforts, among other items. For example, because our shell eggs are sold to consumers at a premium price point, when prices for commodity shell eggs fall relative to the price of our shell eggs, we may be unable to entice price-sensitive consumers

to try our products. We may also lose loyal consumers to our competitors if we are unable to meet consumer demand in a timely manner. If we are unable to cost-effectively acquire new consumers, retain existing consumers and keep existing consumers engaged, our business, financial condition and operating results would be adversely affected. Our sales and profits are dependent upon our ability to expand existing customer relationships and acquire new customers. Our business depends on our ability to increase our household penetration, to expand the number of products sold through existing retail customers, to grow within the foodservice channel and to strengthen our product offerings through innovation in both new and existing categories. Any strategies we employ to pursue this growth are subject to numerous factors outside of our control. For example, retailers continue to aggressively market their private-label products, which could reduce demand for our products. The expansion of our business also depends on our ability over the long term to obtain customers in additional distribution channels, such as convenience, drugstore, club, military and international markets. Any growth in distribution channels may also affect our existing customer relationships and present additional challenges, including related to pricing strategies. Additionally, we may need to increase 49 A or reallocate spending on marketing and promotional activities, such as rebates, temporary price reductions, off-invoice discounts, retailer advertisements, product coupons and other trade activities, and these expenditures are subject to risks, including related to consumer acceptance of our efforts. Our failure to obtain new customers, or expand our business with existing customers, could have a material adverse effect on our business, financial condition, results of operations and cash flows. Demand for shell eggs and butter is subject to seasonal fluctuations, which can adversely impact our results of operations in certain quarters. Demand for shell eggs and butter fluctuates in response to seasonal factors. Demand tends to increase with the start of the school year and is highest prior to holiday periods, particularly Thanksgiving, Christmas and Easter, and lowest during the summer months. As a result of these seasonal and quarterly fluctuations, comparisons of our sales and operating results between different quarters within a single fiscal year are not necessarily meaningful comparisons. If we are not correct in predicting our future shell egg demand, we may experience a supply and demand shell egg imbalance. This imbalance between supply and demand can adversely impact our results of operations at certain times of the year. Packaging costs are volatile, have recently increased and may continue to increase, which may negatively impact our profitability, and reduced availability of packaging supplies may otherwise impact our business. Costs of packaging are volatile and can fluctuate due to conditions that are difficult to predict, including global competition for resources, weather conditions, consumer demand and changes in governmental trade. We saw higher packaging costs in fiscal 2023, and these elevated costs have continued into fiscal 2024. Volatility in the prices of supplies we and our co-manufacturers purchase could increase our cost of sales and reduce our profitability. Moreover, although we have not seen significant decreases in volume due to previous price increases, we may not be able to implement further price increases for our products to cover any increased costs, and any price increases we do implement may result in lower consumer demand, decreased ability to attract new customers and lower sales volumes. Additionally, if the availability of certain packaging supplies is limited due to factors beyond our control (including as a result of the public health pandemics or disruptions to global supply chains), or if packaging supplies do not meet our standards, we may make changes to our product packaging, which could negatively impact the perception of our brand. For example, in connection with increased demand for shell eggs in relation to the COVID-19 pandemic in 2020, the supplier of substantially all of our shell egg cartons began to prioritize packaging for core egg products (such as 12-count packages), and we separately experienced certain quality issues with our 18-count egg cartons. As a result of these events, and in order to otherwise meet demand for our products, we began using recycled plastic packaging for certain of our shell egg products. If we are not successful in managing our packaging costs or the supply of packaging that meets our standards to use for our products, if we are unable to increase our prices to cover increased costs or if such price increases reduce our sales volumes, any of these factors could adversely affect our business, financial condition, and results of operations. Our net revenue and earnings may fluctuate as a result of price actions, promotional activities and chargebacks. Retailers may require price concessions that would negatively impact our margins and our profitability. Alternatively, we may increase our prices to offset commodity inflation and potentially impact our margins and volume. In addition, we periodically offer sales incentives through various programs to customers and consumers, including rebates, temporary price reductions, off-invoice discounts, retailer advertisements, product coupons and other trade activities. Additionally, while we continue to work to optimize supply chain logistics, we are occasionally charged fees and/or fines by retailers for various delivery and order discrepancies. While we challenge and vet these charges, we may be subject to such charges that could be detrimental to our performance, particularly when combined with the effects of increased freight costs or the other risks outlined in this section. The cost associated with promotions and chargebacks is estimated and recorded as a reduction in net revenue. These price concessions, promotional activities and chargebacks could adversely impact our net revenue and changes in such activities could adversely impact period-over-period results. If we are not correct in predicting the performance of promotions, or if we are not correct in estimating chargebacks, our business, financial condition and results of operations would be adversely affected. If we fail to retain and motivate members of our management team or other key crew members or fail to attract, train, develop and retain additional qualified crew members to support our operations, our business and future growth prospects may be harmed. Our success and future growth depend largely upon the continued services of our executive officers as well as our other key crew members. These executives and key crew members are primarily responsible for determining the strategic direction of our 50 A business and for executing our growth strategy and are integral to our brand, culture and the reputation we enjoy with farmers, suppliers, co-manufacturers, distributors, customers and consumers. From time to time, there may be changes in our executive management team or other key crew members resulting from the hiring or departure of these personnel. The loss of one or more of our executive officers, or the failure by our executive team to effectively work with our crew members and lead our company, could harm our business. In addition, our success depends in part upon our ability to attract, train, develop and retain a sufficient number of crew members who understand and appreciate our culture and can represent our brand effectively and establish credibility with our business partners and consumers. If we are unable to win in a competitive market for top talent capable of meeting our business needs and expectations, our business and brand image may be impaired. For example, in Springfield, Missouri, where our existing Egg Central Station processing facility is located, there is a tight labor market. As a result of this tight labor market, we may be unable to attract and retain crew members with the skills we require. Additionally, substantially all of our crew members outside of our Egg Central Station facility are working remotely on a permanent basis. Although we believe we manage our operations to handle remote working conditions efficiently, it is possible that such remote work arrangements could adversely impact crew member cohesiveness, efficiency, professional development, operational agility and retention. Any failure to meet our staffing needs or any material increase in turnover rates of our crew members may adversely affect our business, financial condition and results of operations. If we cannot maintain our company culture or focus on our purpose as we grow, our business and competitive position may be harmed. We believe our culture and our purpose have been key contributors to our success to date and that the critical nature of the platform that we provide promotes a sense of greater purpose and fulfillment in our crew members. Any failure to preserve our culture or focus on our purpose could negatively affect our ability to retain and recruit personnel, which is critical to our growth, and to effectively focus on and pursue our corporate objectives. As we continue to grow and develop the infrastructure of a public company, we may find it difficult to maintain these important values. We may also have difficulty maintaining our company culture as substantially all of our crew members outside of our Egg Central Station facility are working remotely on a permanent basis. If we fail to maintain our company culture or focus on our purpose, our business and competitive position may be harmed. Our operations are geographically consolidated. A major tornado or other natural disaster within the regions in which we operate could seriously disrupt our entire business. Our existing Egg Central Station shell egg processing facility is located in Springfield, Missouri. This facility and our network of family farms supporting our shell egg business are concentrated in the midwestern portion of the Pasture Belt. The majority of cream for our butter is sourced from farms in Ireland. The impact of natural disasters such as tornadoes, drought or flood within these areas is difficult to predict, particularly given the potential of climate change to increase the frequency and intensity of such natural disasters, but a natural disaster could seriously disrupt our entire business. Our insurance may not adequately cover our losses and expenses in the event of a natural disaster. As a result, natural disasters within these areas could lead to substantial losses. Our inability to maintain our GFSI and SQF Select Site certifications may negatively affect our reputation. The Safe Quality Food Institute administers the SQF Program, which is a third-party auditing program that examines and certifies food producers with respect to certain aspects of the producer's business, including food safety, quality control and social, environmental and occupational health and safety management systems. The SQF Select Site certification is one of a number of available SQF certifications and involves both auditing for food safety issues and unannounced inspections by SQF personnel on an annual basis. The Global Food Safety Initiative, or GFSI, is a private organization established and managed by The Consumer Goods Forum, an international trade association. GFSI operates a benchmarking scheme whereby certification bodies, such as the SQF Program, are ~~ac~~recognized as meeting certain criteria maintained by GFSI. GFSI itself does not certify or accredit entities in the food industry. SQF Select Site certification and the GFSI recognition of the SQF Program do not themselves have any independent legal significance and do not necessarily signal regulatory compliance. As a practice matter, however, certain retailers, including some of our largest customers, require SQF certification or certification by another GFSI-recognized program as a condition for doing business. Loss of SQF Select Site certification could impair our ability to do business with these customers, which could materially and adversely affect our business, financial condition and operating results. 51 A Risks Related to Socioeconomic, Political and Environmental Factors Disruptions in the worldwide economy may adversely affect our business, results of operations and financial condition. Adverse and uncertain economic conditions, including uncertainty related to inflation, market volatility, outbreaks of contagious disease or pandemics, geopolitical tensions and wars, including the Russia-Ukraine war and ongoing conflicts in the Middle East, or disruption in global financial and credit markets due to uncertainty in the banking system or bank failures may impact distributor, retailer, foodservice and consumer demand for our products. In addition, our ability to manage normal commercial relationships with our farmers, suppliers, co-manufacturers, distributors, retailers, foodservice consumers and creditors may suffer. Consumers may shift purchases to lower-priced or other perceived value offerings, including private-label products, during economic downturns, and an economic downturn may cause customers to be less receptive to price increases on our products. Adverse economic conditions may also affect our farmers. For example, recent inflationary pressures have resulted in increased costs for our farmers to build, equip and operate their farms. If our relationship with our existing farmers, or our ability to attract new farmers, is disrupted due to economic conditions or otherwise, our operating results may be adversely affected. Further, our foodservice product sales will be reduced if consumers reduce the amount of food they consume away from home at our foodservice customers, including as a result of inflationary concerns or other economic uncertainty. Distributors and customers may become more conservative in response to these conditions and seek to reduce their inventories. Our results of operations depend upon, among other things, our ability to maintain and increase sales volume with our existing distributors, retailer and foodservice customers, our ability to attract new consumers, the financial condition of our consumers and our ability to provide products that appeal to consumers at the right price. Prolonged unfavorable economic conditions may have an adverse effect on our sales and profitability. In addition, historically, our deposit accounts have held deposits in excess of the amounts insured by the Federal Deposit Insurance Corporation, or FDIC. In the event of a bank failure at any of the institutions where we maintain deposits, there can be no assurance that regulators will agree to guarantee such deposits above and beyond amounts insured by the FDIC. Disruptions in international trade, including disruptions due to global health pandemics and geopolitical tensions, may have a material adverse impact on us, our suppliers and our network of farms, including our ability to expand our operations as planned. The COVID-19 pandemic, other global health pandemics, the Russia-Ukraine war, conflicts in the Middle East and other geopolitical tensions have disrupted international trade, resulting in increased shipping costs and delays in the import and export of goods to and from the United States and other countries. Specifically, the increased demand for international shipping has resulted in shortages of shipping containers and delays at international ports. Currently, we import cream for our butter from a supplier in Ireland, which may result in increased costs or shipment delays due to the recent disruptions in the international trade markets and may result in increased exposure to potential import restrictions, increased duties or tariffs or other factors described below. Additionally, we, our suppliers and our network of family farms are dependent on equipment and other supplies imported from Europe and other locations. To the extent that disruptions to global shipping, including disruptions due to global health pandemics or geopolitical tensions or wars, negatively impact our, our suppliers' and our network of family farms' ability to access necessary goods, we may not be able to expand our operations as planned, and our business, financial condition and results of operations would be materially and adversely affected. We and certain of our vendors use overseas sourcing to varying degrees to produce certain of the products we sell. Any event causing a sudden disruption of manufacturing or imports from such foreign countries, including changes in the United States' foreign trade policies resulting in the imposition of additional import restrictions, withdrawal from or material modifications to, international trade agreements, unanticipated political changes, increased customs duties or tariffs, labor disputes, health epidemics, adverse weather conditions, crop failure, acts of war or terrorism, legal or economic restrictions on overseas suppliers' ability to produce and deliver products, and natural disasters, could increase our costs and materially harm our business, financial condition and results of operations. Our business is also subject to a variety of other risks generally associated with indirectly sourcing goods from abroad, such as political instability, disruption of imports by labor disputes, currency fluctuations and local business practices. In addition, requirements imposed by the FDA compel importers to verify that food products and ingredients produced by a foreign supplier comply with all applicable legal and regulatory requirements enforced by the FDA, which could result in certain products being deemed ineligible for import. In addition, the Department of Homeland Security may at times prevent the importation or customs clearance of certain products and ingredients for reasons unrelated to food safety. 52 A U.S. federal government shutdown could have a material adverse impact on our results of operations and financial condition. The partial shutdown of the U.S. federal government that began in late 2018 and continued into 2019 adversely impacted many of our family farms' ability to access capital, as these farmers receive funding through farm loan programs of the USDA Farm Service Agency. The partial shutdown also impacted our ability to receive governmental approvals for products and labeling of new products. Another U.S. federal government shutdown of similar or greater duration could similarly impact our business, which could have a material adverse effect on our results of operations and financial condition. Climate change, or legal, regulatory or market efforts to address climate change, may negatively affect our business and operations. There is scientific consensus that carbon dioxide and other greenhouse gases emissions have had, and will continue to have, an adverse impact on global temperatures, weather conditions, and the frequency and severity of natural disasters. If climate change has a negative effect on agricultural productivity, we may be subject to decreased availability or less favorable pricing for certain raw materials that are necessary for our products, including corn, soybean meal and other feed ingredients. We may further be subject to unpredictable water availability due to the impact of climate change, and the lack of available water may adversely affect our business and operations. Additionally, extreme weather and natural disasters exacerbated by climate change may impact our business. The egg farms in our network are all geographically located in a region that provides an environment conducive to year-round raising of chickens. However, if climate change negatively impacts the year-round habitability of this region for chickens, we may be subject to decreased availability or less favorable pricing for our eggs. Adverse weather conditions and natural disasters, including those caused by climate change, can adversely impact pasture conditions, leading to reduced yields and quality. For example, elevated summer temperatures in the Pasture Belt have at times contributed to lower-than-normal shell egg yield at certain of our farms. Adverse weather conditions and natural disasters may also impact the habitability and pasture conditions of the farms where we source the cream for our butter products. Further, we may incur increased transportation, storage and processing costs if we are unable to source products within a certain distance from our processing and co-manufacturing facilities due to the effects of climate change. Governmental and market concern about climate change and its effects may result in additional legal or regulatory requirements to reduce or mitigate the effects of greenhouse gases or water usage. Such laws or regulations, to the extent applicable to us or our farmers, suppliers, co-manufacturers or service providers, may result in significant increases to our costs of operation, particularly the supply chain and distribution costs associated with our products. Failure to adequately respond to stakeholder scrutiny related to environmental, social and governance issues or failure to achieve our stated impact goals could adversely impact our reputation and brand. Our business faces scrutiny related to environmental, social and governance (ESG) issues, including sustainable development, product packaging, renewable resources, environmental stewardship, supply chain management, climate change, diversity and inclusion, workplace conduct, human rights, philanthropy and support for local communities. In December 2022, we announced a series of impact-related goals relating to, among other things, ecological impacts, diversity and inclusion, governance accountability and climate change, which we refer to as our Impact Goals. There is no assurance that we will be able to achieve these goals. Failure to achieve our Impact Goals could damage our reputation and brand image, and our business, financial condition and results of operations could be adversely impacted. Furthermore, there exists negative sentiment toward ESG measures among certain individuals and government institutions, and several states have enacted or proposed ~~an~~ESG legislation. While these policies and legislation are generally targeted to investment advisory firms and mutual funds, as we continue to pursue our Impact Goals and related initiatives, we could face a negative reaction that adversely impacts our

business. Implementation of our environmental and sustainability initiatives, including in connection with our Impact Goals and annual Impact Report, may require certain financial expenditures and crew member resources, and if we are unable to meet our goals or otherwise fail to meet stakeholder standards or expectations with respect to ESG issues or our Impact Goals, this could have a material adverse effect on our reputation and brand and negatively impact our relationship with our investors, crew members, farmers, suppliers, customers and consumers. 53 A Risks Related to Legal and Government Regulation Food safety and food-borne illness incidents or advertising or product mislabeling may materially and adversely affect our business by exposing us to lawsuits, product recalls or regulatory enforcement actions, increasing our operating costs and reducing demand for our product offerings. Selling food for human consumption involves inherent legal and other risks, and there is increasing governmental scrutiny of and public awareness regarding food safety. Illness, injury or death related to allergens, food-borne illnesses, foreign material contamination or other food safety incidents caused by our products, or involving our farmers or other suppliers, could result in the disruption or discontinuance of sales of these products or our relationships with such farmers or suppliers, or otherwise result in increased operating costs, regulatory enforcement actions or harm to our reputation. For example, in December 2019, our co-manufacturer for hard-boiled eggs conducted a voluntary Class I recall of all hard-boiled eggs produced at its facility, including ours, due to a potential listeria contamination at the production facility. Our co-manufacturer elected to permanently close the affected production facility and move all production to a different facility, which did not have sufficient capacity to meet product demand. As a result, we were unable to supply customers with hard-boiled eggs for a period of time in the first quarter of fiscal 2020. Shipment of adulterated or misbranded products, even if inadvertent, can result in criminal or civil liability. Such incidents could also expose us to product liability, negligence or other lawsuits, including consumer class action lawsuits. Any claims brought against us may exceed or be outside the scope of our existing or future insurance policy coverage or limits. Any judgment against us that is more than our policy limits or not covered by our insurance policies would have to be paid from our cash reserves, which would reduce our capital resources. The occurrence of food-borne illnesses or other food safety incidents could also adversely affect the price and availability of affected raw materials, resulting in higher costs, disruptions in supply and a reduction in our sales. Furthermore, any instances of food contamination or regulatory noncompliance, whether or not caused by our actions, could compel us, our farms or suppliers, our distributors or our customers, depending on the circumstances, to conduct a recall in accordance with FDA or USDA regulations and policies, and comparable state laws. Food recalls could result in significant losses due to their costs, the destruction of product inventory, lost sales due to the unavailability of the product for a period of time and potential loss of existing distributors or customers and a potential negative impact on our ability to attract new customers due to negative consumer experiences or because of an adverse impact on our brand and reputation. The costs of a recall could be outside the scope of our existing or future insurance policy coverage or limits. In addition, food companies have been subject to targeted, large-scale tampering as well as to opportunistic, individual product tampering, and we, like any food company, could be a target for product tampering. Forms of tampering could include the introduction of foreign material, chemical contaminants and pathological organisms into food products, as well as product substitution. Governmental regulations require companies like us to analyze, prepare and implement mitigation strategies specifically to address tampering designed to inflict widespread public health harm. If we do not adequately address the possibility, or any actual instance, of product tampering, we could face possible seizure or recall of our products and the imposition of civil or criminal sanctions, which could adversely affect our business, financial condition and operating results. Our operations are subject to FDA and USDA federal regulations, as well as other state and local regulations, and there is no assurance that we will be in compliance with all applicable regulations. Our operations are subject to extensive regulation by the FDA, the USDA and other federal, state and local authorities. With respect to eggs in particular, the FDA and the USDA split jurisdiction depending on the type of product involved. While the FDA has primary responsibility for the regulation of shell eggs, the USDA has primary responsibility for the regulation of dried, frozen or liquid eggs and other œegg products,Œ subject to certain exceptions. Specifically, our shell eggs, butter and hard-boiled egg products are subject to the requirements of the Federal Food, Drug, and Cosmetic Act, as amended, including by the Food Safety Modernization Act of 2011, or FSMA, and regulations promulgated thereunder by the FDA. This comprehensive regulatory program governs, among other things, the manufacturing, composition and ingredients, packaging, labeling and safety of most food products. The FDA requires that facilities that manufacture food products comply with a range of requirements, including but not limited to hazard analysis and preventive controls regulations, cGMPs and supplier verification requirements. Our shell egg operations are further subject to FDA regulatory requirements governing the production, storage and transportation of shell eggs for the control of salmonella. FDA-inspected processing facilities are subject to periodic and œfor causeŒ inspection by federal, state and local authorities. We are subject to requirements under FSMAŒ’s foreign supplier verification program and import tariffs, bond and other requirements imposed by U.S. Customs and Border Protection for our butter products, which are imported from Ireland. 54 A In addition, certain of our products, such as our liquid whole egg products, are subject to regulation by the USDA, including facility registration, inspection, manufacturing and labeling requirements. We do not control the manufacturing processes of, and rely upon, our co-manufacturers for compliance with cGMPs and other regulatory requirements for the manufacturing of our products that is conducted by our co-manufacturers. If we or our co-manufacturers cannot successfully manufacture products that conform to our specifications and the strict regulatory requirements of the FDA, the USDA or others, we or they may be subject to adverse inspectional findings or enforcement actions, which could materially impact our ability to market our products, result in our co-manufacturersŒ’s inability to continue manufacturing for us, result in a recall of our products that have already been distributed and result in damage to our brand and reputation. For example, in December 2019, our co-manufacturer for hard-boiled eggs conducted a voluntary Class I recall of all hard-boiled eggs produced at its facility, including ours, due to a potential listeria contamination at the production facility. We rely upon our co-manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the USDA or another regulatory authority determines that we or these co-manufacturers have not complied with the applicable regulatory requirements, our business may be adversely impacted. Our liquid whole eggs are subject to the requirements of the Egg Products Inspection Act, or EPIA, and regulations promulgated thereunder by the USDA. The USDA has comprehensive regulations in place that apply to establishments that break, dry and process shell eggs into liquid egg products. This regulatory scheme governs the manufacturing, processing, pasteurizations, packaging, labeling and safety of egg products. Under the EPIA and USDA regulations, establishments that manufacture egg products must comply with the USDAŒ’s requirements for sanitation, temperature control, pasteurization and labeling. In addition, in September 2020, the USDA announced that it had finalized its Egg Products Inspection Rule. Pursuant to the regulatory requirements established by this rule, we anticipate that our co-manufacturersŒ liquid whole egg establishment will be required to implement Hazard Analysis and Critical Control Point plans within two years after publication of the final rule in the Federal Register and will further be required to implement Sanitary Standard Operating Procedures within one year after publication in the Federal Register. We do not control the manufacturing processes of, and rely upon, our co-manufacturers for compliance with USDA regulations for the manufacturing of our liquid whole egg products, which is conducted by our co-manufacturers. If we or our co-manufacturers cannot successfully manufacture products that conform to our specifications and the strict regulatory requirements of the USDA or others, we or they may be subject to adverse inspectional findings or enforcement actions, which could materially impact our ability to market our products, could result in our co-manufacturersŒ’s inability to continue manufacturing for us, or could result in a recall of our product that has already been distributed. In addition, we rely upon our co-manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the USDA or a comparable foreign regulatory authority determines that we or these co-manufacturers have not complied with the applicable regulatory requirements, our business may be materially impacted. Our products that are labeled as œorganicŒ are subject to the requirements of the Organic Foods Production Act, or OFPA, and the USDAŒ’s National Organic Program, or NOP, regulations. The OFPA is a comprehensive regulatory scheme that mandates certain practices and prohibits other practices pertaining to the raising of animals and handling and processing of food products. We, and our network of family farms and co-manufacturers, contract with NOP-accredited certifying agents to ensure that our organic products are produced in compliance with the OFPA and NOP regulations. We do not control the farms where our products are raised and rely on the farms for compliance with the on-farm requirements of the OFPA and NOP regulations. Similarly, we do not control the manufacturing processes of, and we rely upon, our co-manufacturers for compliance with requirements of the OFPA and NOP regulations with respect to organic products handled and manufactured by our co-manufacturers. If we, the farms or the co-manufacturers cannot successfully raise and manufacture products that meet the strict regulatory requirements of the OFPA and the NOP, we or they may be subject to adverse inspectional findings or enforcement actions, which could materially impact our ability to market our products as œorganic,Œ could result in the farms or co-manufacturersŒ’s inability to continue to raise farm products or manufacture food for us, or we, the farms, or the co-manufacturer could lose the right to market products as œorganic,Œ and subject us, the farms, or co-manufacturers to civil monetary penalties. If the USDA or a comparable foreign regulatory authority determines that we or these co-manufacturers have not complied with the applicable regulatory requirements, our business may be materially impacted. We are also subject to state and local regulations, including product requirements, labeling requirements and import restrictions. If our products fail to meet such individual state standards or are restricted from being imported into a state by regulatory requirements, our business, financial condition or results of operations could be materially and adversely affected. We seek to comply with applicable regulations through a combination of employing internal experience and expert personnel to ensure quality assurance compliance (i.e., assuring that our products are not adulterated or misbranded) and contracting with third-party laboratories that conduct analyses of products to ensure compliance with nutrition labeling requirements and to identify any potential contaminants before distribution. Failure by us, the farms or the co-manufacturers to comply with applicable laws and regulations, pay any applicable fees or assessments or maintain permits, licenses or registrations relating to our or our co-manufacturersŒ’s operations could subject us to civil remedies or penalties, including fines, injunctions, recalls or seizures, warning letters, restrictions on the marketing or manufacturing of products, or refusals to permit the import or export of products, as well as potential criminal sanctions, which could result in increased operating costs resulting in a material effect on our operating results and 55 A business. See the section titled œGovernment RegulationŒ in Part I, Item 1, œBusiness,Œ of our Annual Report on Form 10-K for further information on the regulations to which we are subject. Changes in existing laws or regulations, or the adoption of new laws or regulations may increase our costs and otherwise adversely affect our business, results of operations and financial condition. The manufacture and marketing of food products is highly regulated. We, our farmers, our suppliers and our co-manufacturers are subject to a variety of laws and regulations. These laws and regulations apply to many aspects of our business, including the manufacture, packaging, labeling, distribution, advertising, sale, quality and safety of our products, as well as the health and safety of our crew members and the protection of the environment. In the United States, we are subject to regulation by various government agencies, including the FDA, the USDA, the Federal Trade Commission, or FTC, the Occupational Safety and Health Administration, and the Environmental Protection Agency, as well as various state and local agencies. We are also regulated outside the United States by various international regulatory bodies. In addition, we are subject to certain standards, such as GFSI standards and review by voluntary organizations, such as the Council of Better Business BureausŒ’s National Advertising Division. We could incur costs, including fines, penalties, assessments and third-party claims, because of any violations of, or liabilities under, such requirements, including any competitor or consumer challenges relating to compliance with such requirements. For example, in connection with the marketing and advertisement of our products, we could be the target of claims relating to false or deceptive advertising, including under the auspices of the FTC and the consumer protection statutes of some states. The regulatory environment in which we operate could change significantly and adversely in the future. Any change in manufacturing, labeling or packaging requirements for our products may lead to an increase in costs or interruptions in production, either of which could adversely affect our operations and financial condition. Changes in marketing or labeling requirements or standards related to our products could require us to revise or discontinue making certain claims or utilizing certain branding elements, which may make our products less appealing to consumers. New or revised government laws and regulations could result in additional compliance costs and, in the event of non-compliance, civil remedies, including fines, injunctions, withdrawals, recalls or seizures and confiscations, as well as potential criminal sanctions, any of which may adversely affect our business, financial condition and results of operations. Failure by our network of family farms, suppliers of raw materials or co-manufacturers to comply with food safety, environmental or other laws and regulations, or with the specifications and requirements of our products, may disrupt our supply of products and adversely affect our business. If any member of our network of family farms, suppliers or co-manufacturers fail to comply with food safety, environmental, health and safety or other laws and regulations, or face allegations of non-compliance, their operations may be disrupted and our reputation could be harmed. Additionally, the farms and co-manufacturers are required to maintain the quality of our products and to comply with our standards and specifications. In the event of actual or alleged non-compliance, we might be forced to find alternative farms, suppliers or co-manufacturers and we may be subject to lawsuits and/or regulatory enforcement actions related to such non-compliance by the farms, suppliers and co-manufacturers. As a result, our supply of eggs and other raw materials or finished inventory could be disrupted or our costs could increase, which would adversely affect our business, results of operations and financial condition. The failure of any contracted farmer or co-manufacturer to produce products that conform to our standards could adversely affect our reputation in the marketplace and result in product recalls, product liability claims, government or third-party actions and economic loss. For example, in December 2019, our co-manufacturer for hard-boiled eggs conducted a voluntary Class I recall of all hard-boiled eggs produced at its facility, including ours, due to a potential listeria contamination at the production facility. Additionally, actions we may take to mitigate the impact of any disruption or potential disruption in our supply of eggs and other raw materials or finished inventory, including increasing inventory in anticipation of a potential supply or production interruption, may adversely affect our business, financial condition and results of operations. We are subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings and investigations. Our business operations and ownership and past and present operation of real property are subject to stringent federal, state, and local environmental laws and regulations pertaining to the discharge of materials into the environment and natural resources. Violation of these laws and regulations could lead to substantial liabilities, fines and penalties or to capital expenditures related to pollution control equipment that could have a material adverse effect on our business. We could also experience in the future significant opposition from third parties with respect to our business, including environmental non-governmental organizations, neighborhood 56 A groups and municipalities. Additionally, new matters or sites may be identified in the future, including in connection with the potential expansion of our processing capacity, that will require additional environmental investigation, assessment, or expenditures, which could cause additional capital expenditures. Future discovery of contamination of property underlying or in the vicinity of our present or future properties, facilities or waste disposal sites could require us to incur additional expenses, delays to our business and to our proposed construction. The occurrence of any of these events, the implementation of new laws and regulations, or stricter interpretation of existing laws or regulations could adversely affect our business, financial condition and results of operations. Legal claims, government investigations or other regulatory enforcement actions could subject us to civil and criminal penalties. We operate in a highly regulated environment with constantly evolving legal and regulatory frameworks. Consequently, we are subject to a heightened risk of legal claims, government investigations or other regulatory enforcement actions. Although we have implemented policies and procedures designed to ensure compliance with existing laws and regulations, there can be no assurance that our crew members, consultants, independent contractors, farmers, suppliers, co-manufacturers or distributors will not violate our policies and procedures. Moreover, a failure to maintain effective control processes could lead to violations, unintentional or otherwise, of laws and regulations. Legal claims, government investigations or regulatory enforcement actions arising out of our failure or alleged failure to comply with applicable laws and regulations could subject us to civil and criminal penalties that could materially and adversely affect our product sales, reputation, financial condition and operating results. In addition, the costs and other effects of defending potential and pending litigation and administrative actions against us may be difficult to determine and could adversely affect our financial condition and operating results. Litigation or legal proceedings could expose us to significant liabilities and have a negative impact on our reputation or business. We are not currently party to any material litigation. However, from time to time, we may be party to various claims and litigation proceedings. We evaluate these claims and litigation proceedings to assess the likelihood of unfavorable outcomes and to estimate, if possible, the amount of potential losses. Based on these assessments and estimates, we may establish reserves, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. For example, we have not established a reserve against any potential losses related to a false advertising lawsuit filed in federal court in May 2021 by alleged consumers of our eggs on behalf of themselves and a putative class, as no class has been certified and, at this point, we cannot reasonably estimate the possible loss or range of loss, if any. Actual outcomes or losses may differ materially from any assessments and estimates we may make. Even when not merited, the defense of claims and litigation proceedings may divert our managementŒ’s attention, and we may incur significant expenses in defending these lawsuits. For example, we have expended both management time and monetary resources in defending the above-referenced lawsuit.

The results of litigation and other legal proceedings are inherently uncertain, and adverse judgments or settlements in any of these legal disputes may result in adverse monetary damages, penalties or injunctive relief against us, which could have a material adverse effect on our financial position, cash flows or results of operations. Any claims or litigation, even if fully indemnified or insured, could damage our reputation and make it more difficult to compete effectively or to obtain adequate insurance in the future. Furthermore, while we maintain insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions and caps on amounts recoverable. Even if we believe a claim is covered by insurance, insurers may dispute our entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of our recovery. We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation (including class claims) and mass arbitration demands, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse consequences. In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions and financial information, which we collectively refer to as "sensitive data." Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. 57 A We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our crew members or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections and similar actions), litigation (including class-action claims) and mass arbitration demands, additional reporting requirements and/or oversight, bans on processing personal data and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for significant statutory damages depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to loss of customers, inability to process personal data or to operate in certain jurisdictions, limited ability to develop or commercialize our products, expenditure of time and resources to defend any claim or inquiry, adverse publicity or substantial changes to our business model or operations. Risks Related to Our Status as a Certified B Corporation and Public Benefit Corporation Our status as a public benefit corporation and a Certified B Corporation may not result in the benefits that we anticipate, and we may be unable to maintain our Certified B Corporation status. We have elected to be classified as a public benefit corporation under Delaware law. As a public benefit corporation, we are required to balance the financial interests of our stockholders with the best interests of those stakeholders materially affected by our conduct, including particularly those affected by the specific benefit purposes set forth in our amended and restated certificate of incorporation. There is no assurance that the expected positive impact from being a public benefit corporation will be realized and our status as a public benefit corporation and compliance with our related obligations could negatively impact our ability to provide the highest possible return to our stockholders. As a public benefit corporation, we are required to publicly disclose a report at least biennially on our overall public benefit performance and on our assessment of our success in achieving our specific public benefit purpose. If we are not timely or are unable to provide this report, or if the report is not viewed favorably by parties doing business with us or regulators or others reviewing our credentials, our reputation and status as a public benefit corporation may be harmed. While not required by Delaware law or the terms of our certificate of incorporation, we have elected to have our social and environmental performance, accountability and transparency assessed against the proprietary criteria established by B Lab, an independent non-profit organization. As a result of this assessment, we have been designated as a "Certified B Corporation," which refers to companies that are certified as meeting certain levels of social and environmental performance, accountability and transparency. The standards for Certified B Corporation certification are B Lab and may change over time, and our continued certification is at the sole discretion of B Lab. To maintain our certification, we are required to update our assessment and verify our updated score with B Lab every three years. We were most recently recertified as a Certified B Corporation in January 2022. Our reputation could be harmed if we lose our status as a Certified B Corporation, whether by our choice or by our failure to continue to meet the certification requirements, particularly if that failure or change were to create a perception that we are more focused on financial performance and are no longer as committed to the values shared by Certified B Corporations, or if our publicly reported Certified B Corporation score declines. As a public benefit corporation, our duty to balance a variety of interests may result in actions that do not maximize stockholder value. As a public benefit corporation, our Board of Directors, has a duty to balance (i) the pecuniary interest of our stockholders, (ii) the best interests of those materially affected by our conduct and (iii) specific public benefits identified in our amended and restated certificate of incorporation. While we believe our public benefit designation and associated obligations will benefit our stockholders, in balancing these interests our Board of Directors may take actions that do not maximize stockholder value. Any benefits to stockholders resulting from our public benefit purposes may not materialize within the timeframe we expect or at all and may have negative effects. For example: we may choose to revise our policies in ways that we believe will be beneficial to stakeholders other than our stockholders, including farmers, suppliers, crew members and local communities, even though the changes may be costly; we may take actions, such as building state-of-the-art facilities with technology and quality control mechanisms that exceed the requirements of USDA and the FDA, even though these actions may be more costly than other alternatives; 58 A we may be influenced to pursue programs and services to demonstrate our commitment to the communities to which we serve and bringing ethical food to the table, even though there may be no immediate return to our stockholders; or we may be responding to a possible proposal to acquire the company, our Board of Directors may be influenced by the interests of stakeholders other than our stockholders, including farmers, suppliers, crew members and local communities, whose interests may be different from the interests of our stockholders. We may be unable to fully realize the benefits we expect from actions taken to benefit our stakeholders, including farmers, suppliers, crew members and local communities, which could adversely affect our business, financial condition and results of operations, which in turn could cause our stock price to decline. As a public benefit corporation, we may be subject to increased derivative litigation concerning our duty to balance stockholder and public benefit interests, the occurrence of which may have an adverse impact on our financial condition and results of operations. As a Delaware public benefit corporation, our stockholders (if they, individually or collectively, own at least 2% of our outstanding capital stock or shares having at least \$2 million in market value (whichever is less)) are entitled to file a derivative lawsuit claiming that our directors failed to balance stockholder and public benefit interests. This potential liability does not exist for traditional corporations. Therefore, we may be subject to the possibility of increased derivative litigation, which would require the attention of management and, as a result, may adversely impact management's ability to effectively execute our strategy. Any such derivative litigation may be costly and have an adverse impact on our financial condition and results of operations. Risks Related to Being a Public Company If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock. The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls over financial reporting, disclosure controls and procedures. We are required, under Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. When we lose our status as an "emerging growth company" after the end of our fiscal year ending December 29, 2024, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. This assessment must include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 will require that we continue to incur substantial expense and expend significant management efforts to ensure ongoing compliance. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm conducts its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, or Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. 59 A We are currently an "emerging growth company," and we cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors, and upon the expiration of our emerging growth company status, we will likely incur additional expenses in order to comply with enhanced reporting requirements. We will remain an "emerging growth company," as defined in the JOBS Act, until December 29, 2024, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section 107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations may not be comparable to the results of operations of certain other companies in our industry that have adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile. Effective as of December 29, 2024, we will be a large accelerated filer, which will increase our costs and demands on management. As a result of the market value of our common stock held by non-affiliates as of June 30, 2024, we will be a large accelerated filer as of December 29, 2024, and we will therefore no longer qualify as an emerging growth company. As a large accelerated filer, we will be subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to us due to our status as an emerging growth company. These requirements include, but are not limited to: the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002; compliance with any requirements that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements; compliance with the required public company effective dates for any new or revised accounting standards; the requirement that we provide full and more detailed disclosures regarding executive compensation; and the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved. We expect that compliance with the additional requirements of being a large accelerated filer will increase our legal and financial compliance costs and may cause management and other personnel to divert attention from operational and other business matters to devote increased time to public company reporting requirements. Due to the complexity and logistical difficulty of implementing the standards, rules and regulations that apply to a large accelerated filer, there is an increased risk that we may be found to be in non-compliance with such standards, rules and regulations or to have significant deficiencies or material weaknesses in our internal controls over financial reporting. Any failure to maintain effective disclosure controls and internal control over financial reporting could materially and adversely affect our business, results of operations, and financial condition and could cause a decline in the trading price of our common shares. Risks Related to Information Technology and Intellectual Property If our data or information technology systems, or the data or information technology systems of third parties upon which we rely, were compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruption of our business operations, reputational harm and loss of revenue or profits. In the ordinary course of our business, we and the third parties upon which we rely process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents. We also use mobile 60 A devices, social networking and other online activities and third parties to connect with our crew members, farmers, suppliers, co-manufacturers, distributors, customers and consumers. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities may threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer "hackers," threat actors, "hacktivists," organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors. Further, as we pursue new initiatives that improve our operations and cost structure, we also intend to expand and improve our information technologies, resulting in a larger technological presence and corresponding exposure to cybersecurity risk. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and could lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities' systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties' information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover

such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised. While we have implemented security measures designed to protect against cybersecurity incidents, there can be no assurance that these incident response measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. The theft, destruction, loss, misappropriation or release of sensitive information or intellectual property, or interference with our information technology systems or the technology systems of third parties on which we rely, could result in business disruption, negative publicity, brand damage, violation of privacy laws, loss of customers and distributors, potential liability and competitive disadvantage all of which could have an adverse effect on our business, financial condition or results of operations. Such risks may be increased by the fact that substantially all of our crew members outside of our Egg Central Station facility are working remotely on a permanent basis. Technologies and security systems in place at our crew members’ homes may be less secure than those used in a physical office, and while we have implemented controls and safeguards to help protect our systems as our crew members work from home, there can be no assurance that these measures will be effective. Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services. We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data. Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we or a third party upon whom we rely experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); competitive disadvantage; financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Further, use of artificial intelligence platforms by our crew members, whether authorized or unauthorized, may increase the risk that our intellectual property and other proprietary information will be unintentionally disclosed. If we fail to identify and address cybersecurity risks associated with new initiatives, we may become increasingly vulnerable to such risks. The implementation of a new enterprise resource planning system could cause disruption to our business, and we may not be able to effectively realize the benefits of this new system. We are in the process of transitioning to a new enterprise resource planning, or ERP, system, in order to support our future growth and more fully optimize our existing processes. The implementation of a new ERP system may prove to be more difficult, costly or time-consuming than expected, and it is possible that the system will not yield the benefits we anticipate. Any disruptions, delays or deficiencies related to the new ERP system could materially impact our operations and adversely affect our ability to process orders, manage our inventory, fulfill obligations to customers or otherwise operate our business. In addition, implementation of a new ERP system will require significant resources, including the time and attention of our management and key crew members, in order to fully realize the anticipated benefits. The loss of any registered trademark or other intellectual property could enable other companies to compete more effectively with us. We utilize intellectual property in our business. Our trademarks are valuable assets that reinforce our brand and consumers’ favorable perception of our products. We have invested a significant amount of money in establishing and promoting our trademarked brands. We also rely on unpatented proprietary expertise and copyright protection to develop and maintain our competitive position. Our continued success depends, to a significant degree, upon our ability to protect and preserve our intellectual property, including our trademarks and copyrights. We rely on confidentiality agreements and trademark and copyright law to protect our intellectual property rights. Our confidentiality agreements with our crew members and certain of our consultants, contract employees, suppliers and independent contractors, including some of our co-manufacturers who use our formulations to manufacture our products, generally require that all information made known to them be kept strictly confidential. Further, some of our formulations have been developed by or with our suppliers and co-manufacturers. As a result, we may not be able to prevent others from using similar formulations. We cannot be certain that the steps we have taken to protect our intellectual property rights are adequate, that our intellectual property rights can be successfully defended and asserted in the future or that third parties will not infringe upon or misappropriate any such rights. In addition, our trademark rights and related registrations may be challenged in the future and could be canceled or narrowed. Failure to protect our trademark rights could prevent us in the future from challenging third parties who use names and logos similar to our trademarks, which may in turn cause consumer confusion or negatively affect consumers’ perception of our brand and products. Moreover, intellectual property disputes and proceedings and infringement claims may result in a significant distraction for management and significant expense, which may not be recoverable regardless of whether we are successful. Such proceedings may be protracted with no certainty of success, and an adverse outcome could subject us to liabilities, force us to cease use of certain trademarks or other intellectual property or force us to enter into licenses with others. Any one of these occurrences may have an adverse effect on our business, financial condition and results of operations. Risks Related to Ownership of Our Common Stock and Other General Risks Our stock price may be volatile, and the value of our common stock may decline. The market price of our common stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control, including those described elsewhere in this “Risk Factors” section. Broad market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our common stock, particularly in light of uncertainties surrounding inflation, geopolitical tensions, disruption in global financial and credit markets, public health pandemics and related impacts. Sales of our common stock in the public market could cause the market price of our common stock to decline. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Many of our existing equity holders have substantial unrecognized gains on the value of the equity they hold, and therefore they may take steps to sell their shares or otherwise secure the unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market price of our common stock. In addition, as of June 30, 2024, there were 3,468,405 shares of common stock issuable upon the exercise of outstanding stock options or subject to vesting of outstanding restricted stock awards. We have registered all of the shares of common stock issuable upon exercise of outstanding stock options, vesting of outstanding restricted stock awards or other equity incentives we may grant in the future, for public resale under the Securities Act of 1933, as amended, or the Securities Act. The shares of common stock will become eligible for sale in the public market to the extent such options are exercised, subject to compliance with applicable securities laws. Further, based on shares outstanding as of June 30, 2024, holders of approximately 11.9 million shares of our capital stock and certain shares that may be issued in the future upon exercise or vesting of outstanding equity awards, have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We may be subject to significant liability that is not covered by insurance. Although we believe that the extent of our insurance coverage is consistent with industry practice, any claim under our insurance policies may be subject to certain exceptions, may not be honored fully, in a timely manner, or at all, and we may not have purchased sufficient insurance to cover all losses incurred. If we were to incur substantial liabilities or if our business operations were interrupted for a substantial period of time, we could incur costs and suffer losses. Such inventory and business interruption losses may not be covered by our insurance policies. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. Additionally, in the future, insurance coverage may not be available to us at commercially acceptable premiums, or at all. 63 Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, and provisions of Delaware law applicable to us as a public benefit corporation, may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: authorize our Board of Directors to issue, without further action by the stockholders, shares of undesignated preferred stock that may be senior to our common stock with terms, rights and preferences determined by our Board of Directors; require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; specify that special meetings of our stockholders can be called only by our Board of Directors, the chairperson of our Board of Directors or our Chief Executive Officer; establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our Board of Directors; establish that our Board of Directors is divided into three classes, with each class serving three-year staggered terms; prohibit cumulative voting in the election of directors; provide that our directors may be removed for cause only upon the vote of at least 66 2/3% of our outstanding shares of voting stock; and provide that vacancies on our Board of Directors may be filled only by a majority of directors then in office, even though less than a quorum. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or DGCL, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any “interested” stockholder for a period of three years following the date on which the stockholder became an “interested” stockholder. Also, as a public benefit corporation, our Board of Directors is required by the DGCL to manage or direct our business and affairs in a manner that balances the pecuniary interests of our stockholders, the best interests of those materially affected by our conduct, and the specific public benefits identified in our certificate of incorporation. Additionally, pursuant to our amended and restated certificate of incorporation, a vote of at least 66 2/3% of our outstanding shares of voting stock is required for matters directly or indirectly amending or removing our public benefit purpose, or to effect a merger or consolidation involving stock consideration with an entity that is not a public benefit corporation with an identical public benefit to ours. Such provisions could also limit the price that our investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers of our company, thereby reducing the likelihood that holders of our common stock would receive a premium for your shares of our common stock in an acquisition. Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware and, with respect to certain matters, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders, which could restrict our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers, or employees. Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for certain actions or proceedings under Delaware law, statutory or common law, including: any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; any action as to which the DGCL confers jurisdiction to the court of Chancery of the State of Delaware; or any action asserting a claim against us that is governed by the internal affairs doctrine. The provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act of 1934, as amended, or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. 64 Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations our amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. While Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us and our directors, officers or other employees in a venue other than in the federal district courts of the United States of America. In such instance, we would expect our efforts to defend the validity and enforceability of such provisions may require further significant additional costs associated with resolving the dispute in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions, any of which could seriously harm our business. 65 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities None. Use of Proceeds Use of Proceeds from the IPO On August 4, 2020, we completed our IPO, from which we received net proceeds of approximately \$99.7 million, after deducting underwriting discounts and commissions of \$7.8 million and offering expenses of \$3.4 million. The offer and sale of the shares in our IPO were registered under the Securities Act on Registration Statement on Form S-1 (Registration No. 333-239772), which was declared effective on July 30, 2020. There has been no material change in the planned use of proceeds from our IPO as described in the prospectus that formed a part of the Registration Statement. We invested the funds received in cash equivalents, other marketable securities and investments in accordance with our investment policy. As of June 30, 2024, we have used an aggregate of \$35.2 million of the IPO proceeds, including \$7.3 million to pay off our term loan, \$1.9 million to pay off our equipment loan in 2020 and \$26.0 million for the expansion of our Egg Central Station facility in Springfield, Missouri. Item 3. Defaults Upon Senior Securities Not applicable. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information Director and Officer Trading Arrangements During the 13-week period ended June 30, 2024, certain of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, as set forth in the table below: A A A Type of Trading Arrangement A A A Name and Position Action Adoption/Termination Date Rule 10b5-1* Non-Rule 10b5-1** Total Shares of Common Stock to be Sold A Total Shares of Common Stock to be Purchased Expiration Date Kathryn McKeon, Chief Marketing Officer Adoption May 28, 2024 X A A 47,164 A A February 28, 2025 Peter Pappas, Chief Sales Officer Adoption June 14, 2024 X A A 99,526 A A June 15, 2025 * Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act. 66 Item 6. Exhibits A Exhibit Number Description A A A 3.1 A Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-39411), filed with the SEC on August 4, 2020). A 3.2 A Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-39411), filed with the SEC on November 17, 2023). 10.1 A Transition Agreement between the Registrant and Jason Dale, dated as of April 3, 2024. 10.2 A Credit Agreement, by and among the Registrant, the other Loan Parties party thereto, the Lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent, dated as of April 9, 2024. 31.1 A Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer Pursuant

to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. A A 101.SCH A Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents A A 104 A Cover page formatted as Inline XBRL and contained in Exhibit 101 A + Indicates a management contract or compensatory plan. * Furnished herewith and not deemed to be æfiledæ for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. 67 A SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. A Vital Farms, Inc. A A Dated: August 8, 2024 By: /s/ Russell Diez-Canseco Russell Diez-Canseco President and Chief Executive Officer(Principal Executive Officer) A A Dated: August 8, 2024 By: /s/ Thilo Wrede Thilo Wrede Chief Financial Officer(Principal Financial and Accounting Officer) A EX-10.1 2 vitl-ex10.1.htm EX-10.1 EX-10.1 A Exhibit 10.1 A TRANSITION AGREEMENT A I, Jason Dale, acknowledge that my employment with Vital Farms, Inc. (the æCompanyæ) will terminate on August 31, 2024 (the æSeparation Dateæ), and the period of time between now and the Separation Date is referred to herein as the æTransition Period.æ During the Transition Period, I will continue to perform my job duties as the Companyæ™s Chief Operating Officer, transition these duties and responsibilities as requested by the Company, and continue to abide by all of my contractual and legal obligations to the Company and by the Companyæ™s policies and procedures; provided, however, if the Companyæ™s new Chief Supply Chain Officer (or other similarly titled successor to some or all of my current responsibilities) commences employment prior to August 31, 2024, I will immediately transition from my role as Chief Operating Officer and perform certain designated duties as Senior Advisor to the Chief Executive Officer for the remainder of the Transition Period. As part of this Transition Agreement (this æAgreementæ), the Company agrees that it will not terminate my employment before August 31, 2024 unless I engage in conduct constituting æCauseæ under my Second Amended and Restated Employment Agreement dated April 1, 2022, a copy of which is attached hereto as Exhibit B (the æEmployment Agreementæ). If my employment is terminated early for Cause, I acknowledge that I will be ineligible for the Severance Benefits below. If I timely return this fully executed Agreement to the Company, I perform my duties during the Transition Period, and on the Separation Date, I sign and return to the Company the Updated Release attached hereto as Exhibit A (and allow such release to become effective) (the æSeverance Preconditionsæ), then in accordance with Section 11(b) of my Employment Agreement, the Company will provide me with the Severance Benefits described in the Employment Agreement under the terms and conditions set forth therein (the æSeverance Benefitsæ). As an additional Severance Benefit, provided I satisfy the Severance Preconditions, the Company will, effective immediately upon the Separation Date, retain me as a non-employee Advisor through December 31, 2024 (the æAdvisory Periodæ). In this capacity, I will receive a monthly retainer of \$10,000, payable on the 15th of each month during the Advisory Period for such transition services as may be requested by the Company. I will be available ten (10) hours per week to provide services during the Advisory Period. I will receive a 1099 for my monthly retainer. The parties acknowledge that during the Advisory Period I shall be deemed to remain in Continuous Service (as defined in the Companyæ™s 2020 Equity Incentive Plan) with no interruptions, such that my outstanding equity (including incentive and non-qualified options, restricted stock units, and performance stock units) will continue to vest during the Advisory Period if I accept the Advisor role as described herein; provided, however, that any outstanding and unexercised incentive stock option that is not exercised within three (3) months following the Separation Date shall automatically convert to a non-qualified stock option and shall otherwise remain outstanding pursuant to the terms of such award. The Company agrees that it will not terminate the Advisory Period before December 31, 2024 unless I breach my obligations under this Agreement or any other agreement between me and the Company. At the end of the Advisory Period, my services with the Company will terminate, the vesting of my equity will cease, and the vested portion of my options will remain exercisable for the applicable post-termination exercise period (subject to terms of the option and the Employment Agreement). For avoidance of doubt, if I do not timely execute the Updated Release, or execute but then revoke my acceptance of the Updated Release, the Advisory Period will automatically terminate and I will no longer be eligible for the benefits described above. A A In consideration for the Transition Period, my eligibility for the Severance Benefits, and the other valuable consideration I am receiving under this Agreement which I would not otherwise be entitled to (including the Companyæ™s non-disparagement commitment below): (1) I agree to hold in confidence the terms of this Agreement; and (2) I hereby generally and completely release and discharge the Company and its parent, subsidiaries, predecessors, successors, affiliated entities, and assigns, and its and their respective current and former officers, directors, managers, members, partners, employees, stockholders, affiliates and agents (collectively, the æReleased Partiesæ), from any and all claims, liabilities, or obligations of every kind and nature, whether known or unknown, arising at any time prior to or at the time I sign this Agreement (collectively, the æReleased Claimsæ). The Released Claims include, but are not limited to: all federal and state constitutional, statutory and common law claims (including but not limited to claims arising under or based on the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended); the federal Family and Medical Leave Act (as amended) (the æFMLAæ); the Texas Human Rights Act; Chapter 21 of the Texas Labor Code; the Texas Anti-Retaliation Act; all claims arising out of or in any way related to my employment and the decision to terminate my employment; all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, other incentive compensation, vacation, sick leave, expense reimbursements, fringe benefits, paid time off, stock, stock options, or any other ownership or equity interests in the Company; and all claims for breach of contract or other promise, breach of the implied covenant of good faith and fair dealing, tort, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, wrongful termination, discharge in violation of public policy, or emotional distress. The Released Claims do not include: (1) any rights or claims for indemnification I may otherwise have, including under any Indemnification Agreement between me and the Company; (2) any rights which cannot be waived as a matter of law, including, without limitation, any rights I may have under applicable workersæ™ compensation laws; or (3) any claims arising from breach of this Agreement. In addition, I understand that nothing in this Agreement limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (æGovernment Agenciesæ). I further understand that this Agreement does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to the maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights I have waived by signing this Agreement. I acknowledge and will abide by my continuing obligations under my Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement dated April 1, 2022 (the æConfidential Information Agreementæ), a copy of which is attached hereto as Exhibit C, including, without limitation, to refrain from certain solicitation and competitive activities. Pursuant to the Confidential Information Agreement, I understand that I must not use or disclose any confidential or proprietary information of the Company. I also agree that on the Separation Date (or earlier if requested by the Company), I will immediately return to the Company all Company documents (and all copies thereof) and other Company property that I have had in my possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts, financial information, specifications, computer-recorded information, tangible property (including, but not limited to, computers, credit cards, entry cards, identification badges and keys); and any materials of any kind which contain or embody any proprietary information of the Company (and all reproductions thereof); provided, however that I may retain any property that the Company specifically authorizes me to retain in connection with the Advisory Period (which property I agree to return to the Company at the end of the Advisory Period or upon the Companyæ™s earlier request). Notwithstanding the foregoing, I understand that I will be permitted to retain my laptop and any ancillary hardware as my own personal property following the Advisory Period, provided that I 2. A ensure that such laptop and ancillary hardware are fully and completely wiped of all information relating to the Company as of the end of the Advisory Period (or earlier if otherwise required by the Company). Both the Company and I agree not to disparage the other party, and the other partyæ™s officers, directors, employees, stockholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both the Company and I will respond accurately to any inquiry or request for information when required by legal process. The Companyæ™s obligations under this paragraph are limited to Company representatives with knowledge of this provision. I hereby represent that as of the date I sign this Agreement: I have been paid all compensation owed and for all hours worked; I have received all the leave and leave benefits and protections for which I am eligible; and I have not suffered any on-the-job injury for which I have not already filed a workersæ™ compensation claim. Within ten (10) days after my Separation Date, I will submit my final documented expense reimbursement reflecting all business expenses I incurred through the Separation Date, if any, for which I seek reimbursement. The Company will reimburse me for such expenses pursuant to its regular business practices. I agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of my employment by the Company. Such cooperation includes, without limitation, making myself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse me for reasonable out-of-pocket expenses I incur in connection with any such cooperation (excluding fees for any personal attorney I may retain and foregone wages) and will make reasonable efforts to accommodate my scheduling needs. This Agreement, together with its exhibits, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein, and this Agreement supersedes any such promises or representations. This Agreement may only be modified by a writing signed by both me and a duly authorized officer of the Company. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures. I understand that, if I wish to accept the terms of this Agreement, then on or within seven (7) days after my receipt of this Agreement, I must sign below and return the original to the Company. If I fail to return the fully signed Agreement within that timeframe, the Companyæ™s offer contained herein, and my employment, will terminate. [Signature page to follow] A 3. A /s/ Jason Dale Jason Dale A 4/3/2024

Date A Agreed: Vital Farms, Inc. A By: /s/ Russell Diez-Canseco Name: Russell Diez-Canseco Title: President and Chief Executive Officer A A 4. A EXHIBIT A UPDATED RELEASE (To be signed and returned on, but no earlier than, the Separation Date.) A I understand that if I choose to sign this Updated Release (the æReleaseæ), then Vital Farms, Inc. (the æCompanyæ) will provide me with the Severance Benefits pursuant to the terms of the Transition Agreement between the Company and me. I understand that I am not entitled to the Severance Benefits unless I sign this Release within the stated time period. A In exchange for the Severance Benefits and other benefits to be provided to me pursuant to the terms of the Transition Agreement, I hereby extend the release and acknowledgements set forth in the Transition Agreement through the date I executed this Updated Release. I further acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the federal Age Discrimination in Employment Act (the æADEAæ) (æADEA Waiveræ). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (1) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (2) I should consult with an attorney prior to signing this Release; (3) I have been given at least twenty-one (21) calendar days to consider this Release; (4) I have seven (7) calendar days following the date I sign this Release to revoke it; and (5) this Release will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth calendar day after I sign this Release. This Updated Release, together with the Transition Agreement, sets forth the entirety of my agreement with the Company with regard to the subject matter hereof. By: Jason Dale Date: A A A EX-10.2 3 vitl-ex10.2.htm EX-10.2 EX-10.2 Exhibit 10.2 A EXECUTION Version A A CREDIT AGREEMENT Dated as of April 9, 2024among VITAL FARMS, INC., the other Loan Parties party hereto, A A the Lenders party hereto A A and A JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger A A A TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classification of Loans and Borrowings 38 SECTION 1.03. Terms Generally 38 SECTION 1.04. Accounting Terms; GAAP 39 SECTION 1.05. Pro Forma Adjustments 39 SECTION 1.06. Status of Obligations 41 SECTION 1.07. Interest Rates; Benchmark Notification 41 SECTION 1.08. Letter of Credit Amounts 42 SECTION 1.09. Divisions 42 ARTICLE II The Credits 42 SECTION 2.01. Revolving Commitments 42 SECTION 2.02. Loans and Borrowings 42 SECTION 2.03. Requests for Borrowings 43 SECTION 2.04. [Intentionally Omitted] 44 SECTION 2.05. Swingline Loans 44 SECTION 2.06. Letters of Credit 45 SECTION 2.07. Funding of Borrowings 50 SECTION 2.08. Interest Elections 51 SECTION 2.09. Termination and Reduction of Revolving Commitments; Increase in Revolving Commitments; Incremental Term Loans 52 SECTION 2.10. Repayment of Loans; Evidence of Debt 54 SECTION 2.11. Prepayment of Loans 55 SECTION 2.12. Fees 56 SECTION 2.13. Interest 57 SECTION 2.14. Alternate Rate of Interest 58 SECTION 2.15. Increased Costs 60 SECTION 2.16. Break Funding Payments 61 SECTION 2.17. Taxes 62 SECTION 2.18. Payments Generally; Allocation of Proceeds; Sharing of Set-offs 65 SECTION 2.19. Mitigation Obligations; Replacement of Lenders 67 SECTION 2.20. Defaulting Lenders 68 SECTION 2.21. Returned Payments 70 SECTION 2.22. Banking Services and Swap Agreements 70 ARTICLE III Representations and Warranties 71 SECTION 3.01. Organization; Powers 71 SECTION 3.02. Authorization; Enforceability 71 SECTION 3.03. Governmental Approvals; No Conflicts 71 SECTION 3.04. Financial Condition; No Material Adverse Change 71 SECTION 3.05. Properties 72 SECTION 3.06. Litigation and Environmental Matters 72 i A SECTION 3.07. Compliance with Laws and Agreements; No Default 72 SECTION 3.08. Investment Company Status 72 SECTION 3.09. Taxes 72 SECTION 3.10. ERISA 73 SECTION 3.11. Disclosure 73 SECTION 3.12. Material Agreements 73 SECTION 3.13. Solvency 73 SECTION 3.14. Insurance 74 SECTION 3.15. Capitalization and Subsidiaries 74 SECTION 3.16. Security Interest in Collateral 74 SECTION 3.17. Employment Matters 75 SECTION 3.18. Margin Regulations 75 SECTION 3.19. Use of Proceeds 75 SECTION 3.20. No Burdensome Restrictions 75 SECTION 3.21. Anti-Corruption Laws and Sanctions 75 SECTION 3.22. Affected Financial Institutions 75 SECTION 3.23. Plan Assets; Prohibited Transactions 75 SECTION 3.24. Sellersæ™ Lien Laws 76 ARTICLE IV Conditions 76 SECTION 4.01. Effective Date 76 SECTION 4.02. Each Credit Event 79 ARTICLE V Affirmative Covenants 79 SECTION 5.01. Financial Statements and Other Information 79 SECTION 5.02. Notices of Material Events 81 SECTION 5.03. Existence; Conduct of Business 82 SECTION 5.04. Payment of Obligations 82 SECTION 5.05. Maintenance of Properties 82 SECTION 5.06. Books and Records; Inspection Rights 83 SECTION 5.07. Compliance with Laws and Material Contractual Obligations 83 SECTION 5.08. Use of Proceeds 83 SECTION 5.09. Accuracy of Information 84 SECTION 5.10. Insurance 84 SECTION 5.11. Casualty and Condemnation 84 SECTION 5.12. Depository Banks 84 SECTION 5.13. Subsidiary Guarantors; Additional Collateral; Further Assurances 85 SECTION 5.14. Post-Closing Requirements 86 SECTION 5.15. Farm Products. 86 SECTION 5.16. Farm Credit System Equity 87 ARTICLE VI Negative Covenants 88 SECTION 6.01. Indebtedness 88 SECTION 6.02. Liens 90 SECTION 6.03. Fundamental Changes 91 SECTION 6.04. Investments, Loans, Advances, Guarantees and Acquisitions 91 SECTION 6.05. Asset Sales 94 SECTION 6.06. Sale and Leaseback Transactions 95 ii A SECTION 6.07. Swap Agreements 95 SECTION 6.08. Restricted Payments; Certain Payments of Indebtedness 96 SECTION 6.09. Transactions with Affiliates 97 SECTION 6.10. Restrictive Agreements 97 SECTION 6.11. Amendment of Material Documents 98 SECTION 6.12. Financial Covenants 98 ARTICLE VII Events of Default 98 ARTICLE VIII The Administrative Agent 102 SECTION 8.01. Authorization and Action 102 SECTION 8.02. Administrative Agentæ™s Reliance, Limitation of Liability, Indemnification, Etc. 104 SECTION 8.03. Posting of Communications 105 SECTION 8.04. The Administrative Agent Individually 107 SECTION 8.05. Successor Administrative Agent 107 SECTION 8.06. Acknowledgments of Lenders and Issuing Banks 108 SECTION 8.07. Collateral Matters 110 SECTION 8.08. Credit Bidding 110 SECTION 8.09. Certain ERISA Matters 111 SECTION 8.10. Flood Laws 112 SECTION 8.11. Borrower Communications 112 ARTICLE IX Miscellaneous 113 SECTION 9.01. Notices 113 SECTION 9.02. Waivers; Amendments 115 SECTION 9.03. Expenses; Limitation of Liability; Indemnity; Etc 118 SECTION 9.04. Successors and Assigns 120 SECTION 9.05. Survival 124 SECTION 9.06. Counterparts; Integration; Effectiveness; Electronic Execution 124 SECTION 9.07. Severability 125 SECTION 9.08. Right of Setoff 125 SECTION 9.09. Governing Law; Jurisdiction; Consent to Service of Process 126 SECTION 9.10. WAIVER OF JURY TRIAL 127 SECTION 9.11. Headings 127 SECTION 9.12. Confidentiality 127 SECTION 9.13. Several Obligations; Nonreliance; Violation of Law 129 SECTION 9.14. USA PATRIOT Act 129 SECTION 9.15. Disclosure 129

SECTION 9.16. Appointment for Perfection 129 SECTION 9.17. Interest Rate Limitation 129 SECTION 9.18. No Fiduciary Duty, etc. 129 SECTION 9.19. Marketing Consent 130 SECTION 9.20. Acknowledgment and Consent to Bail-In of Affected Financial Institutions 130 SECTION 9.21. Acknowledgement Regarding Any Supported QFCs 131 ARTICLE X Loan Guaranty 131 SECTION 10.01. Guaranty 131 iii A SECTION 10.02. Guaranty of Payment 131 SECTION 10.03. No Discharge or Diminishment of Loan Guaranty 132 SECTION 10.04. Defenses Waived 132 SECTION 10.05. Rights of Subrogation 133 SECTION 10.06. Reinstatement; Stay of Acceleration 133 SECTION 10.07. Information 133 SECTION 10.08. Release of Loan Guarantors 133 SECTION 10.09. Taxes 133 SECTION 10.10. Maximum Liability 134 SECTION 10.11. Contribution 134 SECTION 10.12. Liability Cumulative 135 SECTION 10.13. Keepwell 135 A iv A SCHEDULES: Commitment Schedule Schedule 3.05 â€“ Properties, etc. Schedule 3.12 â€“ Material Agreements Schedule 3.14 â€“ Insurance Schedule 3.15 â€“ Capitalization and Subsidiaries Schedule 5.14 â€“ Post-Closing Requirements Schedule 6.01 â€“ Existing Indebtedness Schedule 6.02 â€“ Existing Liens Schedule 6.04 â€“ Existing Investments Schedule 6.10 â€“ Existing Restrictions Schedule 9.04 â€“ Voting Participants EXHIBITS: Exhibit A â€“ Assignment and Assumption Exhibit B â€“ [Reserved] Exhibit C â€“ [Reserved] Exhibit D-1 â€“ U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) Exhibit D-2 â€“ U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes) Exhibit D-3 â€“ U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes) Exhibit D-4 â€“ U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes) Exhibit E â€“ Compliance Certificate Exhibit F â€“ Joinder Agreement A v A CREDIT AGREEMENT (as it may be amended, restated, supplemented or modified from time to time, this â€“Agreementâ€”), dated as of April 9, 2024, among VITAL FARMS, INC., as Borrower, the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent. The parties hereto agree as follows: ARTICLE I Definitions SECTION 1.01. Defined Terms. As used in this Agreement, the following terms have the meanings specified below: â€“ABRAâ€”, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, is bearing interest at a rate determined by reference to the Alternate Base Rate. â€“Accountâ€” has the meaning assigned to such term in the Security Agreement. â€“Account Debtorâ€” means any Person obligated on an Account. â€“Acquisitionâ€” means any transaction, or any series of related transactions, consummated on or after the Effective Date, by which any Loan Party or Subsidiary (a) acquires any going business or all or substantially all of the assets of any Person, whether through purchase of assets, merger or otherwise or (b) directly or indirectly acquires (in one transaction or as the most recent transaction in a series of transactions) at least a majority (in number of votes) of the Equity Interests of a Person which has ordinary voting power for the election of directors or other similar management personnel of a Person (other than Equity Interests having such power only by reason of the happening of a contingency) or a majority of the outstanding Equity Interests of a Person. â€“Adjusted Covenant Periodâ€” has the meaning assigned to such term in Section 6.12(a). â€“Adjusted Daily Simple SOFRAâ€” means, with respect to any RFR Borrowing, an interest rate per annum equal to (a) Daily Simple SOFR, plus (b) 0.10%; provided that if the Adjusted Daily Simple SOFR as so determined would be less than the Floor, such rate shall be deemed to be equal to the Floor for the purposes of this Agreement. â€“Adjusted Term SOFR Rateâ€” means, with respect to any Term Benchmark Borrowing for any Interest Period or for any ABR Borrowing based on the Adjusted Term SOFR Rate, an interest rate per annum equal to (a) the Term SOFR Rate for such Interest Period, plus (b) 0.10%; provided that if the Adjusted Term SOFR Rate as so determined would be less than the Floor, such rate shall be deemed to be equal to the Floor for the purposes of this Agreement. â€“Administrative Agentâ€” means JPMorgan Chase Bank, N.A. (or any of its designated branch offices or affiliates), in its capacity as administrative agent for the Lenders hereunder. â€“Administrative Questionnaireâ€” means an Administrative Questionnaire in a form supplied by the Administrative Agent. A v A â€“Affected Financial Institutionâ€” means (a) any EEA Financial Institution or (b) any UK Financial Institution. â€“Affiliateâ€” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the specified Person. â€“Agent-Related Personâ€” has the meaning assigned to it in Section 9.03(d). â€“Aggregate Revolving Exposureâ€” means, at any time, the aggregate Revolving Exposure of all the Lenders at such time. â€“ALTAâ€” means the American Land Title Association. â€“Alternate Base Rateâ€” means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the NYFRB Rate in effect on such day plus $\frac{1}{2}$ of 1%, and (c) the Adjusted Term SOFR Rate for a one-month Interest Period as published two U.S. Government Securities Business Days prior to such day (or if such day is not a U.S. Government Securities Business Day, the immediately preceding U.S. Government Securities Business Day) plus 1%; provided that, for the purpose of this definition, the Adjusted Term SOFR Rate for any day shall be based on the Term SOFR Reference Rate at approximately 5:00 a.m. Chicago time on such day (or any amended publication time for the Term SOFR Reference Rate, as specified by the CME Term SOFR Administrator in the Term SOFR Reference Rate methodology). Any change in the Alternate Base Rate due to a change in the Prime Rate, the NYFRB Rate or the Adjusted Term SOFR Rate shall be effective from and including the effective date of such change in the Prime Rate, the NYFRB Rate or the Adjusted Term SOFR Rate, respectively. If the Alternate Base Rate is being used as an alternate rate of interest pursuant to Section 2.14 (for the avoidance of doubt, only until the Benchmark Replacement has been determined pursuant to Section 2.14(b)), then the Alternate Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above. For the avoidance of doubt, if the Alternate Base Rate as determined pursuant to the foregoing would be less than 1.00% per annum, such rate shall be deemed to be 1.00% per annum for purposes of this Agreement. â€“Ancillary Documentâ€” has the meaning assigned to it in Section 9.06(b). â€“Anti-Corruption Lawsâ€” means all laws, rules, and regulations of any jurisdiction applicable to the Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption. â€“Applicable EBITDAâ€” means, at any time, Consolidated EBITDA for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP for the period of four consecutive fiscal quarters of the Borrower ended on or most recently prior to such time for which financial statements have been delivered (or are required to have been delivered) to the Administrative Agent pursuant to Section 5.01(a) or (b) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 5.01(a) or (b), the most recent financial statements referred to in Section 3.04(a)). â€“Applicable Partiesâ€” has the meaning assigned to it in Section 8.03(c). â€“Applicable Percentageâ€” means, at any time with respect to any Lender, a percentage equal to a fraction the numerator of which is such Lenderâ€”s Revolving Commitment at such time and the denominator of which is the aggregate Revolving Commitments at such time (provided that, if the Revolving Commitments have terminated or expired, the Applicable Percentages shall be determined based upon such Lenderâ€”s share of the Aggregate Revolving Exposure at such time); provided that, in accordance with 2 A Section 2.20, so long as any Lender shall be a Defaulting Lender, such Defaulting Lenderâ€”s Revolving Commitment shall be disregarded in the calculations above. â€“Applicable Rateâ€” means, for any day, with respect to any ABR Loan, Term Benchmark Loan or RFR Loan, as the case may be, the applicable rate per annum set forth below under the caption â€“ABR Spreadâ€” or â€“Term Benchmark and RFR Spreadâ€”, as the case may be, based upon the Net Leverage Ratio as of the most recent determination date, provided that, until the delivery to the Administrative Agent of the Financial Statements pursuant to Section 5.01(a) or (b) for the first fiscal quarter ending after the Effective Date, the â€“Applicable Rateâ€” shall be the applicable rates per annum set forth below in Category 1: Net Leverage Ratio ABR Spread Term Benchmark and RFR Spread Category 1 <A 1.00 to 1.00 0.75% 1.75% Category 2 > 1.00 to 1.00 but <A 2.00 to 1.00 1.00% 2.00% Category 3 > 2.00 to 1.00 1.25% 2.25% A For purposes of the foregoing, (a) the Applicable Rate shall be determined as of the end of each fiscal quarter of the Borrower, based upon the Financial Statements delivered pursuant to Section 5.01(a) or (b) for such fiscal quarter and (b) each change in the Applicable Rate resulting from a change in the Net Leverage Ratio shall be effective during the period commencing on and including the date that is three (3) Business Days after the date of delivery to the Administrative Agent of such Financial Statements indicating such change and ending on the date immediately preceding the effective date of the next such change, provided that, at the option of the Administrative Agent or at the request of the Required Lenders, if the Borrower fails to deliver the annual or quarterly Financial Statements required to be delivered by it pursuant to Section 5.01(a) or (b), the Net Leverage Ratio shall be deemed to be in Category 3 during the period from the expiration of the time for delivery thereof until such consolidated financial statements are delivered. If at any time the Administrative Agent determines that the Financial Statements upon which the Applicable Rate was determined were incorrect (whether based on a restatement, fraud or otherwise), or any ratio or compliance information in a Compliance Certificate or other certification was incorrectly calculated, relied on incorrect information or was otherwise not accurate, true or correct, the Borrower shall be required to retroactively pay any additional amount that the Borrower would have been required to pay if such Financial Statements, Compliance Certificate or other information had been accurate and/or computed correctly at the time they were delivered. â€“Approved Borrower Portalâ€” has the meaning assigned to it in Section 8.11(a). â€“Approved Electronic Platformâ€” has the meaning assigned to it in Section 8.03(a). â€“Approved Fundâ€” has the meaning assigned to the term in Section 9.04(b). â€“Arrangerâ€” means JPMorgan Chase Bank, N.A., in its capacity as sole bookrunner and sole lead arranger for the credit facility evidenced by this Agreement. 3 A â€“Assignment and Assumptionâ€” means an assignment and assumption entered into by a Lender and an assignee (with the consent of any party whose consent is required by Section 9.04), and accepted by the Administrative Agent, in the form of Exhibit A or any other form (including electronic records generated by the use of an electronic platform) approved by the Administrative Agent. â€“Availability Periodâ€” means the period from and including the Effective Date to but excluding the earlier of the Revolving Credit Maturity Date and the date of termination of the Revolving Commitments. â€“Available Tenorâ€” means, as of any date of determination and with respect to the then-current Benchmark, as applicable, any tenor for such Benchmark (or component thereof) or payment period for interest calculated with reference to such Benchmark (or component thereof), as applicable, that is or may be used for determining the length of an Interest Period for any term rate or otherwise, for determining any frequency of making payments of interest calculated pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of â€“Interest Periodâ€” pursuant to Section 2.14(e). â€“Bail-In Actionâ€” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution. â€“Bail-In Legislationâ€” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings). â€“Banking Servicesâ€” means each and any of the following bank services provided to any Loan Party or any Subsidiary by any Lender or any of its Affiliates: (a) credit cards for commercial customers (including, without limitation, â€“commercial credit cardsâ€” and purchasing cards), (b) stored value cards, (c) merchant processing services, and (d) treasury management services (including, without limitation, controlled disbursement, automated clearinghouse transactions, return items, any direct debit scheme or arrangement, overdrafts and interstate depository network services and cash pooling services). â€“Banking Services Obligationsâ€” means any and all obligations of the Loan Parties or its Subsidiaries, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor) in connection with Banking Services. â€“Bankruptcy Codeâ€” means Title 11 of the United States Code entitled â€“Bankruptcyâ€”, as now and hereafter in effect, or any successor thereto, as hereafter amended. â€“Bankruptcy Eventâ€” means, with respect to any Person, when such Person becomes the subject of a voluntary or involuntary bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its business, appointed for it, or, in the good faith determination of the Administrative Agent, has taken any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any such proceeding or appointment or has had any order for relief in such proceeding entered in respect thereof, provided that a Bankruptcy Event shall not result solely by virtue of any ownership interest, or the acquisition of any ownership interest, in such Person by a Governmental 4 A Authority or instrumentality thereof, unless such ownership interest results in or provides such Person with immunity from the jurisdiction of courts within the U.S. or from the enforcement of judgments or writs of attachment on its assets or permits such Person (or such Governmental Authority or instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements made by such Person. â€“Benchmarkâ€” means, initially, with respect to any (i) RFR Loan, Daily Simple SOFR or (ii) Term Benchmark Loan, the Term SOFR Rate; provided that, if a Benchmark Transition Event and the related Benchmark Replacement Date have occurred with respect to the Term SOFR Rate or Daily Simple SOFR, as applicable, or the then-current Benchmark, then â€“Benchmarkâ€” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.14(b). â€“Benchmark Replacementâ€” means, for any Available Tenor, the first alternative set forth in the order below that can be determined by the Administrative Agent for the applicable Benchmark Replacement Date: (1) the Adjusted Daily Simple SOFR; or (2) the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower as the replacement for the then-current Benchmark for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement for the then-current Benchmark for dollar-denominated syndicated credit facilities in the United States at such time; and (b) the related Benchmark Replacement Adjustment. If the Benchmark Replacement as determined pursuant to clause (1) or (2) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents. â€“Benchmark Replacement Adjustmentâ€” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement for any applicable Interest Period and Available Tenor for any setting of such Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date and/or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for syndicated credit facilities denominated in Dollars at such time. â€“Benchmark Replacement Conforming Changesâ€” means, with respect to any Benchmark Replacement and/or any Term Benchmark Loan, any technical, administrative or operational changes (including changes to the definition of â€“Alternate Base Rateâ€”, the definition of â€“Business Dayâ€”, the definition of â€“U.S. Government Securities Business Dayâ€”, the definition of â€“Interest Periodâ€”, timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, length of lookback periods, the applicability of breakage provisions, and other technical, administrative or operational matters) that the Administrative Agent decides 5 A may be appropriate to reflect the adoption and implementation of such Benchmark Replacement and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of such Benchmark Replacement exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents). â€“Benchmark Replacement Dateâ€” means, with respect to any Benchmark, the earliest to occur of the following events with respect to such then-current Benchmark: (1) in the case of clause (1) or (2) of the definition of â€“Benchmark Transition Eventâ€”, the later of (a) the date of the public statement or publication of information referenced therein and (b) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); or (2) in the case of clause (3) of the definition of â€“Benchmark Transition Eventâ€”, the first date on which such Benchmark (or the published component used in the calculation thereof) has been, or if such Benchmark is a term rate, all Available Tenors of such Benchmark (or component thereof) have been, determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be no longer representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (3) and even if such Benchmark (or component thereof), or if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof), continues to be provided on such date. For the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination and (ii) the â€“Benchmark Replacement Dateâ€” will be deemed to have occurred in the case of clause (1) or (2) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors

of such Benchmark (or the published component used in the calculation thereof). “Benchmark Transition Event” means, with respect to any Benchmark, the occurrence of one or more of the following events with respect to such then-current Benchmark: (1) a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); (2) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the NYFRRB, the CME Term SOFR Administrator, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component), in each case, which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); or (3) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such Benchmark (or such component thereof), or if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof), are no longer, or as of a specified future date will no longer be, representative. For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof). “Benchmark Unavailability Period” means, with respect to any Benchmark, the period (if any) (x) beginning at the time that a Benchmark Replacement Date pursuant to clauses (1) or (2) of that definition has occurred if, at such time, no Benchmark Replacement has replaced such then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.14 and (y) ending at the time that a Benchmark Replacement has replaced such then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.14. “Beneficial Ownership Certification” means a certification regarding beneficial ownership or control as required by the Beneficial Ownership Regulation. “Beneficial Ownership Regulation” means 31 C.F.R. Â§ 1010.230. “Benefit Plan” means any of (a) an “employee benefit plan” (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in and subject to Section 4975 of the Code to which Section 4975 of the Code applies, and (c) any Person whose assets include (for purposes of the Plan Asset Regulations or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such “employee benefit plan” or “plan”. “BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party. “Borrower” means Vital Farms, Inc., a Delaware public benefit corporation. “Borrower Communications” means, collectively, any Borrowing Request, request for a Swingline Loan, Interest Election Request, notice of prepayment, notice requesting the issuance, amendment or extension of a Letter of Credit or other notice, demand, communication, information, document or other material provided by or on behalf of the Borrower pursuant to any Loan Document or the transactions contemplated therein which is distributed by the Borrower to the Administrative Agent through an Approved Borrower Portal. “Borrowing” means (a) Revolving Loans of the same Type, made, converted or continued on the same date and, in the case of Term Benchmark Loans, as to which a single Interest Period is in effect or (b) a Swingline Loan. “Borrowing Request” means a request by the Borrower for a Borrowing in accordance with Section 2.03, which shall be substantially in a form approved by the Administrative Agent and separately provided to the Borrower. “Burdensome Restrictions” means any consensual encumbrance or restriction of the type described in clause (a) or (b) of Section 6.10. “Business Day” means, any day (other than a Saturday or a Sunday) on which banks are open for business in New York City; provided that, in addition to the foregoing, a Business Day shall be any such day that is only a U.S. Government Securities Business Day (a) in relation to RFR Loans and any interest rate settings, fundings, disbursements, settlements or payments of any such RFR Loan, or any other dealings of such RFR Loan and (b) in relation to Loans referencing the Adjusted Term SOFR Rate and any interest rate settings, fundings, disbursements, settlements or payments of any such Loans referencing the Adjusted Term SOFR Rate or any other dealings of such Loans referencing the Adjusted Term SOFR Rate. “Capital Expenditures” means, without duplication, any expenditure for any purchase or other acquisition of any asset which would be classified as a fixed or capital asset on a consolidated balance sheet of the Borrower and its Subsidiaries prepared in accordance with GAAP. “Capital Lease Obligations” of any Person, subject to Section 1.04(b), means the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as capital lease obligations or finance lease obligations on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. “Change in Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person or group (within the meaning of the Securities Exchange Act of 1934 and the rules of the SEC thereunder as in effect on the date hereof), of Equity Interests representing more than 40% of the aggregate ordinary voting power represented by the issued and outstanding Equity Interests of the Borrower; or (b) occupation at any time of a majority of the seats (other than vacant seats) on the board of directors of the Borrower by Persons who were not (i) directors of the Borrower on the date of this Agreement or nominated or appointed by the board of directors of the Borrower or (ii) nominated, approved or appointed by such directors. “Change in Law” means the occurrence after the date of this Agreement of any of the following: (a) the adoption of or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) compliance by any Lender or the Issuing Bank (or, for purposes of Section 2.15(b), by any lending office of such Lender or by such Lender’s or the Issuing Bank’s holding company, if any) with any request, rules, guideline, requirement or directive (whether or not having the force of law) of any Governmental Authority made or issued after the date of this Agreement; provided that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, requirements or directives thereunder or issued in connection therewith or in the implementation thereof, and (y) all requests, rules, guidelines, requirements and directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the U.S. or foreign regulatory authorities, in each 8 A case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted, issued or implemented. “Charges” has the meaning assigned to such term in Section 9.17. “Chase” means JPMorgan Chase Bank, N.A., a national banking association, in its individual capacity, and its successors. “Class”, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Revolving Loans or Swingline Loans. “CME Term SOFR Administrator” means CME Group Benchmark Administration Limited as administrator of the forward-looking term SOFR (or a successor administrator). “Code” means the Internal Revenue Code of 1986, as amended from time to time. “Collateral” means any and all property owned, leased or operated by a Person covered by the Collateral Documents and any and all other property of any Loan Party, now existing or hereafter acquired, that may at any time be, become or be intended to be, subject to a security interest or Lien in favor of the Administrative Agent, on behalf of itself and the other Secured Parties, to secure the Secured Obligations; provided that the Collateral shall not include any Excluded Property. “Collateral Access Agreement” has the meaning assigned to such term in the Security Agreement. “Collateral Documents” means, collectively, the Security Agreement, the Mortgages and Mortgage Instruments and all other agreements, instruments and documents executed, delivered or otherwise prepared in connection with this Agreement that are intended to create, perfect or evidence Liens to secure the Secured Obligations, including, without limitation, all other security agreements, pledge agreements, mortgages, deeds of trust, loan agreements, notes, guarantees, subordination agreements, pledges, powers of attorney, consents, assignments, contracts, fee letters, notices, leases, financing statements and all other written matter whether heretofore, now or hereafter executed by any Loan Party and delivered to the Administrative Agent. “Commitment Fee Rate” means, for any day with respect to the commitment fees payable hereunder, a rate per annum equal to (a) 0.375% if the Aggregate Revolving Exposure on such date (after giving pro forma effect to each Transaction occurring (or scheduled to occur) on such date) is less than an amount equal to 40% of the aggregate Revolving Commitments on such date or (b) 0.20% if the Aggregate Revolving Exposure on such date (after giving pro forma effect to each Transaction occurring (or scheduled to occur) on such date) is equal to or greater than an amount equal to 40% of the aggregate Revolving Commitments on such date. “Commitment Schedule” means the Schedule attached hereto identified as such. “Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. Â§ 1 et seq.), as amended from time to time, and any successor statute. “Commodity Hedge Agreement” means any commodity hedge agreement entered into by a Loan Party or Subsidiary in order to provide protection to, or minimize the impact upon, such Loan Party or Subsidiary of increasing prices with respect to certain commodities that are documented in a standard International Swap Dealers Association, Inc. Master Agreement or another reasonable and customary manner and is entered into for hedging, rather than speculative, purposes. 9 A “Commodity Hedge Liabilities” means the liabilities owing to the provider of any Commodity Hedge Agreement. “Communications” has the meaning assigned to such term in Section 8.03(c). “Compliance Certificate” means a certificate of a Financial Officer in substantially the form of Exhibit E. “Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes. “Consolidated EBITDA” means, for any period, Consolidated Net Income for such period, plus (a) without duplication and to the extent deducted (but not excluded) in determining Consolidated Net Income for such period, the sum of: (i) Consolidated Interest Expense for such period; (ii) income tax expense for such period; (iii) all amounts attributable to depreciation and amortization expense for such period; (iv) non-cash stock-based compensation expenses for such period; (v) any non-cash losses on sales of fixed assets, non-cash losses on Investments, non-cash write-downs of fixed or intangible assets or non-cash goodwill impairment charges; (vi) any other non-cash charges, expenses or losses for such period, including non-cash foreign exchange losses and non-cash stock based compensation charges (but excluding any non-cash charge in respect of an item that was included in Consolidated Net Income in a prior period); (vii) expenses, fees, costs and charges incurred in connection with the Transactions to occur on the Effective Date in an aggregate amount not exceed \$750,000; (viii) fees, costs and expenses that are actually incurred in connection with Permitted Acquisitions, other Investments permitted hereunder, issuances of Qualified Stock of the Borrower, asset sales, issuance of Indebtedness and Restricted Payments; provided that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (a)(viii) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (a)(ix), (a)(x) and (a)(xii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs); (ix) non-recurring charges, costs, losses, fees and expenses directly incurred or paid directly as a result of discontinued operations or any sale or Disposition of any asset of the Borrower or its Subsidiaries, in each case, to the extent factually supportable; provided that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (a)(ix) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (a)(viii) above and clauses (a)(x) and (a)(xii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs); 10 A (x) costs (including restructuring costs related to Acquisitions after the Effective Date), charges, accruals, reserves or expenses attributable to the undertaking and/or implementation of cost savings initiatives, operating expense reductions, integration, transition, digital transformation, ERP implementation, facilities opening and pre-opening, construction of facilities, business optimization and other restructuring and integration costs, charges, accruals, reserves and expenses (including, without limitation, inventory optimization programs, software development costs, costs related to the closure or consolidation of facilities, stores and distribution centers, curtailments, costs related to entry into new markets, costs related to preopening and opening of stores, distribution centers or other facilities, consulting fees, signing costs, retention or completion bonuses, relocation expenses, severance payments, modifications to pension and post-retirement employee benefit plans and new systems design and implementation costs, information technology costs, website rebranding and redesign costs and project startup costs) incurred during such period; provided that such cost savings initiatives, operating expense reductions, integration, transition, digital transformation, ERP implementation, facilities opening and pre-opening, business optimization and other restructuring and integration costs, charges, accruals, reserves and expenses are reasonably expected and factually supportable (in the good faith determination of the Borrower); provided further that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (a)(x) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (a)(viii) and (a)(ix) above and (a)(xii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs); (xi) any costs incurred during such period with respect to liability, casualty events or business interruption, in each case, to the extent such costs are actually reimbursed in cash by a third-party unaffiliated insurer during such period; (xii) expected cost savings, operating expense reductions, restructuring charges and expenses related to Permitted Acquisitions or other Investments consummated after the Effective Date, in each case, reasonably projected by the Borrower in good faith to be realized as a result of specified actions taken or committed to be taken within the twelve month period following the consummation thereof (or following the consummation of the squeeze-out merger in the case of an Acquisition structured as a two-step transaction) and to the extent such amounts are reasonably identifiable and factually supportable (in the good faith determination of the Borrower), reasonably attributable to the actions specified and reasonably anticipated to result from such actions, in each case, net of the amount of actual benefits realized during such period from such actions; provided that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (a)(xii) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (a)(viii), (a)(ix) and (a)(x) above for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs); (xiii) net non-cash losses (including all non-cash fees, non-cash expenses and non-cash charges related thereto) on the retirement or extinguishment of Indebtedness; (xiv) fees, expenses and settlement costs that directly arise out of defense of litigation or settlements; provided that the aggregate of all amounts added back to Consolidated EBITDA pursuant to this clause (a)(xiv) during any period shall not in the aggregate exceed an amount equal to 10% of Consolidated EBITDA for such period; (xv) fees, costs, charges and expenses incurred during such period relating to any amendment, restatement, waiver, consent or other modification of this Agreement or the other Loan Documents, whether 11 A or not consummated; provided that the aggregate of all amounts added back pursuant to this clause (a)(xv) shall not exceed \$750,000 in the aggregate for any period of four consecutive fiscal quarters of the Borrower; and (xvi) non-cash unrealized losses recognized during such period due to “mark-to-market” accounting in respect of Swap Agreements; minus (b) without duplication and to the extent included in Consolidated Net Income, the sum of: (i) any unusual or non-recurring gains or income for such period, and any non-cash gains or items of income for such period; and (ii) non-cash unrealized gains or income recognized during such period due to “mark-to-market” accounting in respect of Swap Agreements; and (iii) refunds of Taxes based on income or profits or capital, plus franchise taxes, plus foreign withholding taxes and foreign unreimbursed value added taxes and tariffs, of the Borrower and its Subsidiaries for such period (including, in each case, of any penalties and interest related to such taxes or arising from tax examinations), in each case, to the extent not netted in calculating Consolidated Net Income or from the amount included in clause (a)(ii) above, all calculated for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP. “Consolidated Fixed Charges” means, for any period, without duplication, the sum of (i) cash Consolidated Interest Expense, plus (ii) scheduled principal payments on Indebtedness (determined without giving effect to any reduction of such scheduled payments resulting from the application of any voluntary or mandatory prepayments made during the applicable period), plus (iii) expense for income taxes paid in cash, plus (iv) Restricted Payments paid in cash, plus (v) Capital Lease Obligation payments, in each case, for such period, and all calculated for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP. “Consolidated Interest Expense” means, for any period, total interest expense (including that attributable to Capital Lease Obligations) of the Borrower and its Subsidiaries for such period with respect to all outstanding Indebtedness of the Borrower and its Subsidiaries (including all commissions, discounts and other fees and charges owed with respect to letters of credit and bankers’ acceptances and net costs under Swap Agreements in respect of interest rates, to the extent such net costs are allocable to such period in accordance with GAAP), calculated for the Borrower and its Subsidiaries on a consolidated basis for such period in accordance with GAAP. “Consolidated Net Income” means, for any period, the consolidated net income (or loss) determined

for the Borrower and its Subsidiaries, on a consolidated basis in accordance with GAAP; provided that there shall be excluded (a) the income (or deficit) of any Person accrued prior to the date it becomes a Subsidiary or is merged into or consolidated with the Borrower or any of its Subsidiaries (except in connection with any pro forma calculations required in connection with a Permitted Acquisition, in which case any such income (or deficit) shall be included to the extent provided under Section 1.05(a)), (b) the income (or deficit) of any Person (other than a Subsidiary) in which the Borrower or any Subsidiary has an ownership interest, except to the extent that any such income is actually received by the Borrower or such Subsidiary in the form of dividends or similar distributions and (c) the undistributed earnings of any Subsidiary of the Borrower to the extent that the declaration or payment of dividends or similar distributions 12 Â by such Subsidiary is not at the time permitted by the terms of any contractual obligation (other than any Loan Document) or Requirement of Law applicable to such Subsidiary. â€œConsolidated Total Assetsâ€ means, as of any date of determination, total assets of the Borrower and its Subsidiaries on a consolidated basis calculated in accordance with GAAP as of the last day of the fiscal year of the Borrower ended on or most recently prior to such date of determination for which financial statements have been delivered (or are required to have been delivered) to the Administrative Agent pursuant to Section 5.01(a) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 5.01(a), the most recent financial statements referred to in Section 3.04(a)). â€œConsolidated Total Funded Indebtednessâ€ means, at any date, the aggregate principal amount of total Indebtedness described under any of clauses (a), (f), (h), (i) (to the extent of unreimbursed drawings in respect thereof), (j) (to the extent of unreimbursed drawings in respect thereof), (k) (to the extent past due for longer than three (3) Business Days) and (m) of the definition of â€œIndebtednessâ€, together with, without duplication, all Guarantees of any of the foregoing, all determined for the Borrower and its Subsidiaries on a consolidated basis at such date, in accordance with GAAP. Â â€œControlâ€ means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. â€œControllingâ€ and â€œControlledâ€ have meanings correlative thereto. â€œCorresponding Tenorâ€ with respect to any Available Tenor means, as applicable, either a tenor (including overnight) or an interest payment period having approximately the same length (disregarding business day adjustment) as such Available Tenor. â€œCovered Entityâ€ means any of the following: (i) a â€œcovered entityâ€ as that term is defined in, and interpreted in accordance with, 12 C.F.R. Â§ 252.82(b); (ii) a â€œcovered bankâ€ as that term is defined in, and interpreted in accordance with, 12 C.F.R. Â§ 382.2(b). â€œCovered Partyâ€ has the meaning assigned to it in Section 9.21. â€œCredit Partyâ€ means the Administrative Agent, the Issuing Bank, the Swingline Lender or any other Lender. â€œDaily Simple SOFRâ€ means, for any day (a â€œSOFR Rate Dayâ€), a rate per annum equal to SOFR for the day (such day, the â€œSOFR Determination Dateâ€) that is five (5) U.S. Government Securities Business Days prior to (i) if such SOFR Rate Day is a U.S. Government Securities Business Day, such SOFR Rate Day or (ii) if such SOFR Rate Day is not a U.S. Government Securities Business Day, the U.S. Government Securities Business Day immediately preceding such SOFR Rate Day, in each case, as such SOFR is published by the SOFR Administrator on the SOFR Administratorâ€™s Website. Any change in Daily Simple SOFR due to a change in SOFR shall be effective from and including the effective date of such change in SOFR without notice to the Borrower. If by 5:00 p.m. (New York City time) on the second (2nd) U.S. Government Securities Business Day immediately following any SOFR Determination Date, SOFR in respect of such SOFR Determination Date has not been published on the SOFR Administratorâ€™s Website 13 Â and a Benchmark Replacement Date with respect to the Daily Simple SOFR has not occurred, then SOFR for such SOFR Determination Date will be SOFR as published in respect of the first preceding U.S. Government Securities Business Day for which such SOFR was published on the SOFR Administratorâ€™s Website. â€œDefaultâ€ means any event or condition which constitutes an Event of Default or which upon notice, lapse of time or both would, unless cured or waived, become an Event of Default. â€œDefault Rightâ€ has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. Â§Â§ 252.81, 47.2 or 382.1, as applicable. â€œDefaulting Lenderâ€ means any Lender that (a) has failed, within two Business Days of the date required to be funded or paid, to (i) fund any portion of its Loans, (ii) fund any portion of its participations in Letters of Credit or Swingline Loans or (iii) pay over to any Credit Party any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in writing that such failure is the result of such Lenderâ€™s good faith determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied, (b) has notified the Borrower or any Credit Party in writing, or has made a public statement to the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such Lenderâ€™s good faith determination that a condition precedent (specifically identified and including the particular default, if any) to funding a Loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed, within three (3) Business Days after request by a Credit Party, acting in good faith, to provide a certification in writing from an authorized officer of such Lender that it will comply with its obligations (and is financially able to meet such obligations as of the date of certification) to fund prospective Loans and participations in then outstanding Letters of Credit and Swingline Loans under this Agreement, provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon such Credit Partyâ€™s receipt of such certification in form and substance satisfactory to it and the Administrative Agent, or (d) has become (or has a Parent that has become) the subject of (i) a Bankruptcy Event or (ii) a Bail-In Action. â€œDispositionâ€ or â€œDisposeâ€ means the sale, transfer, license, lease or other disposition (in one transaction or in a series of transactions and whether effected pursuant to a division or otherwise) of any property by any Person (including any Sale and Leaseback Transaction and any issuance of Equity Interests by a Subsidiary of such Person), including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith. â€œDisqualified Stockâ€ means any Equity Interest that, by its terms (or by the terms of any security or other Equity Interests into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (a) matures or is mandatorily redeemable (other than solely for Qualified Stock and cash in lieu of fractional shares), pursuant to a sinking fund obligation or otherwise (except as a result of a change of control, initial public offering or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control, initial public offering or asset sale event shall be subject to the prior Payment in Full of the Loans and all other Obligations (other than unasserted contingent indemnification obligations that by their terms survive)), (b) is redeemable at the option of the holder thereof (other than solely for Qualified Stock and cash in lieu of fractional shares and other than as a result of a change of control, initial public offering or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control, initial public offering or asset sale event shall be subject to the prior Payment in Full of the Loans and all other Obligations (other than unasserted contingent indemnification obligations that by their terms survive)), in whole or in part, or (c) is or becomes automatically or at the option of the holder convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute 14 Â Disqualified Stock, in the case of each of clauses (a), (b) and (c), prior to the date that is ninety-one (91) days after the Revolving Credit Maturity Date in effect at the time of issuance; provided that if such Equity Interests are issued to any current or former employees, consultants, directors, officers or members of management or pursuant to a plan for the benefit of current or former employees, consultants, directors, officers or members of management of the Borrower (or any direct or indirect parent thereof), or its Subsidiaries or by any such plan to such current or former employees, consultants, directors, officers or members of management, such Equity Interests shall not constitute Disqualified Stock solely because they may be required to be repurchased by the Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations or as a result of such employeesâ€™, consultantsâ€™, directorsâ€™, officersâ€™ or management membersâ€™ termination, death or disability. â€œDollarsâ€, â€œdollarsâ€ or â€œ\$â€ refers to lawful money of the U.S. â€œDomestic Subsidiaryâ€ means a Subsidiary organized under the laws of a jurisdiction located in the United States of America, other than a FSHCO. â€œECPâ€ means an â€œeligible contract participantâ€ as defined in Section 1(a)(18) of the Commodity Exchange Act or any regulations promulgated thereunder and the applicable rules issued by the Commodity Futures Trading Commission and/or the SEC. â€œEEA Financial Institutionâ€ means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent. â€œEEA Member Countryâ€ means any of the member states of the European Union, Iceland, Liechtenstein, and Norway. â€œEEA Resolution Authorityâ€ means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegate) having responsibility for the resolution of any EEA Financial Institution. â€œEffective Dateâ€ means the date on which the conditions specified in Section 4.01 are satisfied (or waived in accordance with Section 9.02). â€œElectronic Signatureâ€ means an electronic sound, symbol, or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record. â€œElectronic Systemâ€ means any electronic system, including e-mail, e-fax, web portal access for the Borrower and any other Internet or extranet-based site, whether such electronic system is owned, operated or hosted by the Administrative Agent or the Issuing Bank and any of its respective Related Parties or any other Person, providing for access to data protected by passcodes or other security system. â€œEnvironmental Lawsâ€ means all laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to (i) the environment, (ii) preservation or reclamation of natural resources, (iii) the management, Release or threatened Release of any Hazardous Material or (iv) health and safety matters. 15 Â â€œEnvironmental Liabilityâ€ means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any Subsidiary directly or indirectly resulting from or based upon (a) any violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) any exposure to any Hazardous Materials, (d) the Release or threatened Release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. â€œEquity Interestsâ€ means shares of capital stock, partnership interests, membership interests in a limited liability company, beneficial interests in a trust or other equity ownership interests in a Person, and any warrants, options or other rights entitling the holder thereof to purchase or acquire any of the foregoing, but excluding any debt securities convertible into any of the foregoing. â€œERISAâ€ means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder. â€œERISA Affiliateâ€ means any trade or business (whether or not incorporated) that, together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the Code or Section 4001(14) of ERISA or, solely for purposes of Section 302 of ERISA and Section 412 of the Code, is treated as a single employer under Section 414 of the Code. â€œERISA Eventâ€ means (a) any â€œreportable eventâ€, as defined in Section 4043 of ERISA or the regulations issued thereunder, with respect to a Plan (other than an event for which the 30 day notice period is waived); (b) the failure to satisfy the â€œminimum funding standardâ€ (as defined in Section 412 of the Code or Section 302 of ERISA), whether or not waived; (c) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (d) the incurrence by the Borrower or any ERISA Affiliate of any liability under Title IV of ERISA with respect to the termination of any Plan; (e) the receipt by the Borrower or any ERISA Affiliate from the PBGC or a plan administrator of any notice relating to an intention to terminate any Plan or Plans or to appoint a trustee to administer any Plan; (f) the incurrence by the Borrower or any ERISA Affiliate of any liability with respect to the withdrawal or partial withdrawal of the Borrower or any ERISA Affiliate from any Plan or Multiemployer Plan; or (g) the receipt by the Borrower or any ERISA Affiliate of any notice, or the receipt by any Multiemployer Plan from the Borrower or any ERISA Affiliate of any notice, concerning the imposition upon the Borrower or any ERISA Affiliate of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in critical status, within the meaning of Title IV of ERISA. â€œEU Bail-In Legislation Scheduleâ€ means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time. â€œEvent of Defaultâ€ has the meaning assigned to such term in Article VII. â€œExcluded Accountsâ€ means any (a) segregated withholding, tax, escrow, fiduciary and trust accounts exclusively for the benefit of third parties as cash collateral for obligations owing to such third parties or to establish or maintain escrow amounts for third-parties pursuant to transactions permitted under the Loan Documents, (b) deposit accounts exclusively used for payroll, payroll taxes, and other employee wage and benefit payments to or for the benefit of Grantorâ€™s or its Subsidiariesâ€™ employees, (c) Deposit Accounts holding cash collateral constituting a Lien permitted under Section 6.02(k) and (d) other deposit accounts and securities accounts with a balance not in excess of \$250,000 (individually for any such deposit account or securities account) and not in excess of \$1,000,000 (in the aggregate for all such deposit accounts and securities accounts). 16 Â â€œExcluded Propertyâ€ means: (i) motor vehicles and other assets subject to certificates of title (other than to the extent a Lien thereon can be perfected by the filing of a financing statement under the Uniform Commercial Code); (ii) any asset or property to the extent that the grant of a security interest is prohibited by applicable law, rule or regulation or requires a consent not obtained of any Governmental Authority pursuant to such applicable law, rule or regulation, in each case after giving effect to the applicable anti-assignment provisions of the UCC and other applicable law and other than proceeds and receivables thereof, the assignment of which is expressly deemed effective under the UCC or other applicable law notwithstanding such prohibition; (iii) any lease, license or other agreement or contract or any property subject to a purchase money security interest, Lien securing a Capital Lease Obligation or similar arrangement, in each case permitted to be incurred under this Agreement, to the extent that a grant of a security interest or Lien therein would require a consent not obtained of any Person (other than the Borrower or any Affiliate thereof) or violate or invalidate such lease, license or agreement or contract or purchase money arrangement, Capital Lease Obligation or similar arrangement or create a right of termination in favor of any other party thereto (other than the Borrower or any Affiliate thereof), in each case after giving effect to the applicable anti-assignment provisions of the UCC and other applicable law and other than proceeds and receivables thereof, the assignment of which is expressly deemed effective under the UCC or other applicable law notwithstanding such prohibition; provided that the foregoing shall cease to be treated as â€œExcluded Propertyâ€ (and shall constitute Collateral) immediately at such time as the contractual or legal prohibition shall no longer be applicable and to the extent severable, such security interest shall attach immediately to any portion of such lease, license, contract or other agreement not subject to the prohibitions specified in this clause (iii); (iv) any United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant, attachment or enforcement of a security interest therein would, under applicable federal law, impair the registrability of such applications or the validity or enforceability of registrations issuing from such applications; (v) Excluded Accounts; (vi) any tangible or intangible assets as to which the cost of obtaining a security interest or perfection thereof is excessive in relation to the benefit to the Administrative Agent and the Lenders of the security to be afforded thereby, as agreed by the Administrative Agent, acting reasonably, and the Borrower; and (vii) capital stock in any Foreign Subsidiary representing more than 65% of the total combined voting power of all classes of all voting stock of such corporation (within the meaning of Treasury Regulation section 1.956-2(c)). Notwithstanding the foregoing, â€œExcluded Propertyâ€ shall not include proceeds, substitutions or replacements of any Excluded Property unless such proceeds, substitutions or replacements would independently constitute Excluded Property. â€œExcluded Subsidiaryâ€ means (a) any Subsidiary formed or acquired after the Effective Date that is not a Material Subsidiary, (b) any Foreign Subsidiary or FSHCO and (c) any other Subsidiary with respect to which, in the reasonable judgment of the Administrative Agent and the Borrower, the cost or burden of providing a guarantee shall outweigh the benefits to be obtained by the Lenders therefrom. 17 Â â€œExcluded Swap Obligationâ€ means, with respect to any Loan Guarantor, any Swap Obligation if, and to the extent that, all or a portion of the Guarantee of such Loan Guarantor of, or the grant by such Loan Guarantor of a security interest to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Loan Guarantorâ€™s failure for any reason to constitute an ECP at the time the Guarantee of such Loan Guarantor or the grant of such security interest becomes or would become effective with respect to such Swap Obligation. If a Swap Obligation arises under a master agreement governing more than one swap, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to swaps for which such Guarantee or security interest is or becomes illegal. â€œExcluded Taxesâ€ means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan, Letter of Credit or Revolving Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan, Letter of Credit or Revolving Commitment (other than pursuant to an assignment request by the Borrower under Section 2.19(b)) or (ii) such Lender

changes its lending office, except in each case to the extent that, pursuant to Section 2.17, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender acquired the applicable interest in a Loan, Letter of Credit or Revolving Commitment or to such Lender immediately before it changed its lending office, (c) Taxes attributable to such Recipient’s failure to comply with Section 2.17(f) and (d) any withholding Taxes imposed under FATCA. Farm Credit Lender means a federally-chartered Farm Credit System lending institution organized under the Farm Credit Act of 1971, as the same may be amended or supplemented from time to time. Farm Credit System means the farm credit system of borrower-owned lending institutions organized under the Farm Credit Act of 1971, as the same may be amended or supplemented from time to time. Farm Credit System Equity means all stock, participation certificates, allocated or other surplus and any other equities registered in the name of or held for the account of the Borrower in any Farm Credit Lender or one of its Affiliates. Farm Products means all agricultural, livestock, poultry, seafood, milk, dairy, eggs, or other products sold to any Loan Party or Subsidiary by a Farm Products Seller, and all proceeds and products thereof, including without limitation (1) farm products as such term is defined in the Food Security Act and the UCC, (2) meats, meat food products, livestock, livestock products, poultry and poultry products as such terms are defined in the PSA, and (3) perishable agricultural commodities, as such term is defined in PACA. Farm Products Seller means any seller, supplier, or other Person that (a) is, or as determined by the Administrative Agent in the exercise of its reasonable discretion, could be, afforded the benefit of any Lien or trust upon any agricultural, livestock, poultry, seafood milk, dairy, eggs, or other products sold to any Loan Party or Subsidiary, directly or indirectly, and/or any proceeds of such products, under any Seller’s Lien Laws or (b) sells eggs to any Loan Party or Subsidiary for re-sale in the ordinary course of 18 A business who is not afforded the benefit of any Lien or trust upon the eggs sold to such Loan Party or Subsidiary, directly or indirectly, and/or any proceeds of such eggs, under any Seller’s Lien Laws. FATCA means Sections 1471 through 1474 of the Code as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreement entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code. Federal Funds Effective Rate means, for any day, the rate calculated by the NYFRB based on such day’s federal funds transactions by depository institutions, as determined in such manner as shall be set forth on the NYFRB’s Website from time to time, and published on the next succeeding Business Day by the NYFRB as the effective federal funds rate; provided that, if the Federal Funds Effective Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement. Federal Reserve Board means the Board of Governors of the Federal Reserve System of the United States of America. Financial Officer means the chief financial officer, principal accounting officer, treasurer or controller of the Borrower. Financial Statements has the meaning assigned to such term in Section 5.01. Fixed Charge Coverage Ratio means, for any period of four consecutive fiscal quarters of the Borrower, the ratio of (a) the difference of (i) Consolidated EBITDA for such period, minus (ii) Maintenance Capital Expenditures for such period, to (b) Consolidated Fixed Charges for such period, all calculated for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP. Flood Laws has the meaning assigned to such term in Section 8.10. Floor means the benchmark rate floor, if any, provided in this Agreement (as of the execution of this Agreement, the modification, amendment or renewal of this Agreement or otherwise) with respect to the Adjusted Term SOFR Rate or the Adjusted Daily Simple SOFR, as applicable. For the avoidance of doubt, the initial Floor for each of the Adjusted Term SOFR Rate and the Adjusted Daily Simple SOFR shall be zero. Foreign Lender means (a) if the Borrower is a U.S. Person, a Lender that is not a U.S. Person, and (b) if the Borrower is not a U.S. Person, a Lender that is resident or organized under the laws of a jurisdiction other than that in which the Borrower is resident for tax purposes. Foreign Subsidiary means any Subsidiary which is not a Domestic Subsidiary. FSHCO means any Subsidiary substantially all of the assets of which (directly or through one or more entities treated as disregarded for U.S. federal income tax purposes) consist of Equity Interests (or Equity Interests of and Indebtedness owed or treated as owned by (x) one or more Foreign Subsidiaries and/or (y) one or more entities otherwise described in this definition). Funding Account has the meaning assigned to such term in Section 4.01(h). GAAP means generally accepted accounting principles in the United States of America. 19 A Governmental Authority means the government of the U.S., any other nation or any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government. Guarantee of or by any Person (the guarantor) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the obligor) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as reasonably determined by the Borrower in good faith. Guaranteed Obligations means (i) with respect to the Borrower, the Specified Ancillary Obligations and (ii) with respect to any Subsidiary Guarantor, the Secured Obligations, and, in each case, all costs and expenses including, without limitation, all court costs and reasonable attorneys’ and paralegals’ fees (including allocated costs of in-house counsel and paralegals) and expenses paid or incurred by the Administrative Agent, the Issuing Bank and the Lenders in endeavoring to collect all or any part of the Secured Obligations from, or in prosecuting any action against, the Borrower, any Loan Guarantor or any other guarantor of all or any part of the Secured Obligations; provided that, in each case, the definition of Guaranteed Obligations shall not create any guarantee by any Loan Guarantor of (or grant of security interest by any Loan Guarantor to support, as applicable) any Excluded Swap Obligations of such Loan Guarantor for purposes of determining any obligations of any Loan Guarantor. Hazardous Materials means: (a) any substance, material, or waste that is included within the definitions of hazardous substances, hazardous materials, hazardous waste, toxic substances, toxic materials, toxic waste, or words of similar import in any Environmental Law; (b) those substances listed as hazardous substances by the United States Department of Transportation (or any successor agency) (49 C.F.R. 172.101 and amendments thereto) or by the Environmental Protection Agency (or any successor agency) (40 C.F.R. Part 302 and amendments thereto); and (c) any substance, material, or waste that is petroleum, petroleum-related, or a petroleum by-product, asbestos or asbestos-containing material, polychlorinated biphenyls, flammable, explosive, radioactive, freon gas, radon, or a pesticide, herbicide, or any other agricultural chemical. Hostile Acquisition means (a) the acquisition of the Equity Interests of a Person through a tender offer or similar solicitation of the owners of such Equity Interests which has not been approved (prior to such acquisition) by the board of directors (or any other applicable governing body) of such Person or by similar action if such Person is not a corporation and (b) any such acquisition as to which such approval has been withdrawn. Incremental Facility Amendment has the meaning assigned to such term in Section 2.09. Incremental Term Loan has the meaning assigned to such term in Section 2.09. 20 A Indebtedness of any Person means, without duplication, (a) all obligations of such Person for borrowed money or with respect to deposits or advances of any kind, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of property or services (excluding (i) accounts payable incurred in the ordinary course of business, (ii) any obligation of such Person, arising in the ordinary course of business, to pay a customer for inventory sold by such Person to such customer, which inventory is not sold by such customer and (iii) deferred compensation and severance, pension, health and welfare retirement and equivalent benefits to current or former employees, directors or managers of such Person and its Subsidiaries incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit, demand guarantees and similar independent undertakings, (j) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances, (k) obligations under any earn-out or similar obligation to the extent that the amount payable pursuant to such earn-out or similar obligation is reflected, or would otherwise be required to be reflected, on a balance sheet prepared in accordance with GAAP, (l) any other Off-Balance Sheet Liability, (m) all Disqualified Stock of such Person, (n) obligations, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor), under (i) any and all Swap Agreements, and (ii) any and all cancellations, buy backs, reversals, terminations or assignments of any Swap Agreement transaction and (o) Commodity Hedge Liabilities. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. Indemnified Taxes means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in the foregoing clause (a), Other Taxes. Indemnities has the meaning assigned to such term in Section 9.03(c). Ineligible Institution has the meaning assigned to such term in Section 9.04(b). Information has the meaning assigned to such term in Section 9.12. Interest Election Request means a request by the Borrower to convert or continue a Borrowing in accordance with Section 2.08, which shall be substantially in any form approved by the Administrative Agent and separately provided to the Borrower. Interest Payment Date means (a) with respect to any ABR Loan (other than a Swingline Loan), the first day of each calendar quarter and the Revolving Credit Maturity Date, (b) with respect to any RFR Loan, each date that is on the numerically corresponding day in each calendar month that is one month after the Borrowing of such Loan (or, if there is no such numerically corresponding day in such month, then the last day of such month) and the Revolving Credit Maturity Date, (c) with respect to any Term Benchmark Loan, the last day of the Interest Period applicable to the Borrowing of which such Loan is a part and, in the case of a Term Benchmark Borrowing with an Interest Period of more than three months’ duration, each day prior to the last day of such Interest Period that occurs at intervals of three months’ duration after the 21 A first day of such Interest Period and the Revolving Credit Maturity Date, and (d) with respect to any Swingline Loan, the day that such Loan is required to be repaid and the Revolving Credit Maturity Date. Interest Period means with respect to any Term Benchmark Borrowing, the period commencing on the date of such Borrowing and ending on the numerically corresponding day in the calendar month that is one, three or six months thereafter (in each case, subject to the availability for the Benchmark applicable to the relevant Loan or Revolving Commitment), as the Borrower may elect; provided that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period, and (iii) no tenor that has been removed from this definition pursuant to Section 2.14(e) shall be available for specification in such Borrowing Request or Interest Election Request. For purposes hereof, the date of a Borrowing initially shall be the date on which such Borrowing is made and thereafter, in the case of any Borrowing other than a Swingline Loan, shall be the effective date of the most recent conversion or continuation of such Borrowing. Inventory has the meaning assigned to such term in the Security Agreement. Investment has the meaning assigned to such term in Section 6.04. IRS means the United States Internal Revenue Service. Issuing Bank means, individually and collectively, each of Chase (or any of its designated branch offices or affiliates), in its capacity as the issuer of Letters of Credit hereunder, and any other Lender from time to time designated by the Borrower as an Issuing Bank, with the consent of such Lender and the Administrative Agent, and their respective successors in such capacity as provided in Section 2.06(i). Any Issuing Bank may, in its discretion, arrange for one or more Letters of Credit to be issued by its Affiliates, in which case the term Issuing Bank shall include any such Affiliate with respect to Letters of Credit issued by such Affiliate (it being agreed that such Issuing Bank shall, or shall cause such Affiliate to, comply with the requirements of Section 2.06 with respect to such Letters of Credit). At any time there is more than one Issuing Bank, all singular references to the Issuing Bank shall mean any Issuing Bank, either Issuing Bank, each Issuing Bank, the Issuing Bank that has issued the applicable Letter of Credit, or both (or all) Issuing Banks, as the context may require. Issuing Bank Sublimit means, as of the Effective Date, (i) \$5,000,000, in the case of Chase and (ii) in the case of any other Issuing Bank, such amount as shall be designated to the Administrative Agent and the Borrower in writing by such Issuing Bank; provided that any Issuing Bank shall be permitted at any time to increase or reduce its Issuing Bank Sublimit upon providing five (5) days’ prior written notice thereof to the Administrative Agent and the Borrower. Joinder Agreement means a Joinder Agreement in substantially the form of Exhibit F. LC Collateral Account has the meaning assigned to such term in Section 2.06(j). LC Disbursement means any payment made by an Issuing Bank pursuant to a Letter of Credit. LC Exposure means at any time, the sum of (a) the aggregate undrawn amount of all outstanding Letters of Credit at such time plus (b) the aggregate amount of all LC Disbursements that have not yet been 22 A reimbursed by or on behalf of the Borrower at such time. The LC Exposure of any Lender at any time shall be its Applicable Percentage of the aggregate LC Exposure at such time. Lender means, as of any date of determination, a Person listed on the Commitment Schedule (or, if the Revolving Commitments have terminated or expired, a Person holding Revolving Exposure), and any other Person that shall have become a Lender hereunder pursuant to Section 2.09 or an Assignment and Assumption or other documentation contemplated hereby, other than any such Person that ceases to be a Lender hereunder pursuant to an Assignment and Assumption or other documentation contemplated hereby. Unless the context otherwise requires, the term Lenders includes the Swingline Lender and the Issuing Bank. Lender-Related Person has the meaning assigned to such term in Section 9.03(b). Letter of Credit Agreement has the meaning assigned to it in Section 2.06(b). Letters of Credit means the letters of credit issued pursuant to this Agreement, and the term Letter of Credit means any one of them or each of them singularly, as the context may require. Liabilities means any losses, claims (including intraparty claims), demands, damages or liabilities of any kind. Lien means, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge, hypothecation, encumbrance, charge or security interest in, on or of such asset, (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having substantially the same economic effect as any of the foregoing) relating to such asset and (c) in the case of securities, any purchase option, call or similar right of a third party with respect to such securities. Limited Condition Transaction means any Permitted Acquisition or other Investment permitted hereunder that the Borrower or one or more of its Subsidiaries is contractually committed to consummate (it being understood that such commitment may be subject to conditions precedent, which conditions precedent may be amended, satisfied or waived in accordance with the terms of the applicable agreement) and whose consummation is not conditioned on the availability of, or on obtaining, third party financing; provided that, in the event the consummation of any such Permitted Acquisition or other Investment shall not have occurred within ninety (90) days following the signing of the applicable contractual commitment, such Permitted Acquisition or other Investment shall no longer constitute a Limited Condition Transaction for any purpose. Loan Documents means, collectively, this Agreement, each promissory note issued pursuant to this Agreement, each Letter of Credit Agreement, each Collateral Document, each Compliance Certificate, the Loan Guaranty and each other agreement, fee letter, instrument, document and certificate executed and delivered to, or in favor of, the Administrative Agent or any Lender and including each other pledge, power of attorney, consent, assignment, contract, notice, letter of credit agreement, letter of credit applications and any agreements between the Borrower and the Issuing Bank regarding the Issuing Bank’s Issuing Bank Sublimit or the respective rights and obligations between the Borrower and the Issuing Bank in connection with the issuance of Letters of Credit, and each other written matter whether heretofore, now or hereafter executed by or on behalf of any Loan Party, or any employee of any Loan Party, and delivered to the Administrative Agent or any Lender in connection with this Agreement or the commercial lending facility made available hereunder. Any reference in this Agreement or any other Loan Document to a Loan Document shall include all appendices, exhibits or schedules thereto, and all amendments, restatements, supplements or other modifications thereto, and shall refer to this

Agreement or such Loan Document as the same may be in effect at any and all times such reference becomes operative. 23 Å œLoan GuarantorÅ œ means each Loan Party. Å œLoan GuarantyÅ œ means Article X of this Agreement. Å œLoan PartiesÅ œ means, collectively, the Borrower and the Subsidiary Guarantors and their successors and assigns, and the term Å œLoan PartyÅ œ shall mean any one of them or all of them individually, as the context may require. Å œLoansÅ œ means the loans and advances made by the Lenders to the Borrower pursuant to this Agreement, including Swingline Loans. Å œMaintenance Capital ExpendituresÅ œ means, for any period, all Capital Expenditures for such period made in the ordinary course of business incurred relating to maintaining the condition, working order of and the general upkeep of property, plant and equipment or similar fixed asset accounts of the Borrower and its Subsidiaries, calculated for the Borrower and its Subsidiaries on a consolidated basis for such period in accordance with GAAP. Å œMargin StockÅ œ means margin stock within the meaning of Regulations T, U and X, as applicable. Å œMaterial AcquisitionÅ œ means any Permitted Acquisition having total consideration in excess of \$40,000,000. Å œMaterial Adverse EffectÅ œ means a material adverse effect on (a) the business, assets, operations or financial condition of the Borrower and its Subsidiaries taken as a whole, (b) the ability of any Loan Party to perform any of its Obligations, (c) the Collateral, or the Administrative AgentÅ œ s Liens (on behalf of itself and the other Secured Parties) on the Collateral or the priority of such Liens, or (d) the rights or benefits available to the Administrative Agent, the Issuing Bank or the Lenders under any of the Loan Documents. Å œMaterial IndebtednessÅ œ means Indebtedness (other than the Loans and Letters of Credit), or obligations in respect of one or more Swap Agreements, of any one or more of the Borrower and its Subsidiaries in an aggregate principal amount exceeding \$5,000,000. For purposes of determining Material Indebtedness, the Å œprincipal amountÅ œ of the obligations of the Borrower or any Subsidiary in respect of any Swap Agreement at any time shall be the maximum aggregate amount (giving effect to any netting agreements) that the Borrower or such Subsidiary would be required to pay if such Swap Agreement were terminated at such time. Å œMaterial Real PropertyÅ œ means any fee owned real property having a fair market value or purchase price equal to or greater than \$10,000,000 as reasonably determined in good faith by the Borrower in consultation with the Administrative Agent. Å œMaterial SubsidiaryÅ œ means, as of any date of determination, each Subsidiary (taken as a whole together with its Subsidiaries), which, (i) which, as of the end of the most recent fiscal quarter of the Borrower, for the period of four consecutive fiscal quarters then ended, for which financial statements have been delivered (or are required to have been delivered) pursuant to Section 5.01(a) or (b) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 5.01(a) or (b), the most recent financial statements referred to in Section 3.04(a)), contributed greater than ten percent (10%) of Consolidated EBITDA for such period or (ii) which contributed greater than ten percent (10%) of Consolidated Total Assets as of the end of such most recent fiscal quarter; provided that, if at any time the aggregate amount of Consolidated EBITDA or Consolidated Total Assets attributable to all Subsidiaries that are not Material Subsidiaries exceeds fifteen percent (15%) of Consolidated EBITDA for any such 24 Å œ period or fifteen percent (15%) of Consolidated Total Assets as of the end of any such fiscal quarter, the Borrower (or, in the event the Borrower has failed to do so within ten (10) days, the Administrative Agent) shall designate sufficient Domestic Subsidiaries as Å œMaterial SubsidiariesÅ œ to eliminate such excess, and such designated Subsidiaries shall for all purposes of this Agreement constitute Material Subsidiaries. Å œMaximum RateÅ œ has the meaning assigned to such term in Section 9.17. Å œMoodyÅ œ s Å œ means MoodyÅ œ s Investors Service, Inc. Å œMortgageÅ œ means any mortgage, deed of trust or other agreement which conveys or evidences a Lien in favor of the Administrative Agent, for the benefit of the Administrative Agent and the other Secured Parties, on Material Real Property of a Loan Party, including any amendment, restatement, modification or supplement thereto. Å œMortgage InstrumentsÅ œ means such title reports, ALTA title insurance policies (with endorsements), evidence of zoning compliance, property insurance, flood certifications and flood insurance (and, if applicable FEMA form acknowledgements of insurance), opinions of counsel, ALTA surveys, appraisals, environmental assessments and reports, mortgage tax affidavits and declarations and other similar information and related certifications as are requested by, and in form and substance reasonably acceptable to, the Administrative Agent from time to time. Å œMultiemployer PlanÅ œ means a multiemployer plan as defined in Section 4001(a)(3) of ERISA. Å œNet Leverage RatioÅ œ means, on any date, the ratio of (a) the difference of (i) Consolidated Total Funded Indebtedness on such date, minus (ii) the aggregate amount of Unrestricted Cash on such date that is in excess of \$10,000,000 (provided that the aggregate amount of Unrestricted Cash included in this clause (ii) shall not exceed an amount equal to 100% of Applicable EBITDA) to (b) Consolidated EBITDA for the period of four consecutive fiscal quarters of the Borrower ended on or most recently prior to such date, all calculated for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP. Å œNon-Consenting LenderÅ œ has the meaning assigned to such term in Section 9.02(d). Å œNot Otherwise AppliedÅ œ means, with reference to any amount of proceeds of any sale or issuance of Equity Interests or any other transaction or event that is proposed to be applied to a particular use or transaction, that such amount has not previously been (and is not simultaneously being) applied for any other purposes under this Agreement and the other Loan Documents, other than that such particular use or transaction. Å œNYFRBÅ œ means the Federal Reserve Bank of New York. Å œNYFRB RateÅ œ means, for any day, the greater of (a) the Federal Funds Effective Rate in effect on such day and (b) the Overnight Bank Funding Rate in effect on such day (or for any day that is not a Business Day, for the immediately preceding Business Day); provided that if none of such rates are published for any day that is a Business Day, the term Å œNYFRB RateÅ œ means the rate for a federal funds transaction quoted at 11:00 a.m. on such day received by the Administrative Agent from a federal funds broker of recognized standing selected by it; provided, further, that if any of the aforesaid rates or so determined would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement. Å œNYFRBÅ œ s WebsiteÅ œ means the website of the NYFRB at <http://www.newyorkfed.org>, or any successor source. 25 Å œObligated PartyÅ œ has the meaning assigned to such term in Section 10.02. Å œObligationsÅ œ means all unpaid principal of and accrued and unpaid interest on the Loans, all LC Exposure, all accrued and unpaid fees and all expenses, reimbursements, indemnities and other obligations and indebtedness (including interest and fees accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), obligations and liabilities of any of the Loan Parties to any of the Lenders, the Administrative Agent, the Issuing Bank or any Indemnitee, individually or collectively, existing on the Effective Date or arising thereafter, direct or indirect, joint or several, absolute or contingent, matured or unmatured, liquidated or unliquidated, secured or unsecured, arising by contract, operation of law or otherwise, arising or incurred under this Agreement or any of the other Loan Documents or in respect of any of the Loans made or reimbursement or other obligations incurred or any of the Letters of Credit or other instruments at any time evidencing any thereof; provided that the definition of Å œObligationsÅ œ shall not create or include any guarantee by any Loan Party of any Excluded Swap Obligations of such Loan Party for purposes of determining any obligations of any Loan Party. Å œOFACÅ œ means the Office of Foreign Assets Control of the United States Department of the Treasury. Å œOff-Balance Sheet LiabilityÅ œ of a Person means (a) any repurchase obligation or liability of such Person with respect to accounts or notes receivable sold by such Person, (b) any indebtedness, liability or obligation under any so-called Å œsynthetic leaseÅ œ transaction entered into by such Person, or (c) any indebtedness, liability or obligation arising with respect to any other transaction which is the functional equivalent of or takes the place of borrowing but which does not constitute a liability on the balance sheet of such Person (other than operating leases). Å œOriginal IndebtednessÅ œ has the meaning assigned to such term in Section 6.01(f). Å œOther Connection TaxesÅ œ means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Taxes (other than a connection arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to, or enforced, any Loan Document, or sold or assigned an interest in any Loan, Letter of Credit, or any Loan Document). Å œOther TaxesÅ œ means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 2.19). Å œOvernight Bank Funding RateÅ œ means, for any day, the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in Dollars by U.S.-managed banking offices of depository institutions (as such composite rate shall be determined by the NYFRB as set forth on the NYFRBÅ œ s Website from time to time) and published on the next succeeding Business Day by the NYFRB as an overnight bank funding rate. Å œPACAAÅ œ means the Perishable Agricultural Commodities Act, 1930, as amended, 7 U.S.C. Section 499a et. seq., as the same now exists or may hereafter from time to time be amended, modified, reclassified or supplemented, together with all rules and regulations thereunder. 26 Å œPaid in FullÅ œ or Å œPayment in FullÅ œ means, (i) the indefeasible payment in full in cash of all outstanding Loans and LC Disbursements, together with accrued and unpaid interest thereon, (ii) the termination, expiration, or cancellation and return of all outstanding Letters of Credit (or alternatively, with respect to each such Letter of Credit, the furnishing to the Administrative Agent of a cash deposit, or at the discretion of the Administrative Agent a back up standby letter of credit satisfactory to the Administrative Agent and the Issuing Bank, in an amount equal to 103% of the LC Exposure as of the date of such payment), (iii) the indefeasible payment in full in cash of the accrued and unpaid fees, (iv) the indefeasible payment in full in cash of all reimbursable expenses and other Secured Obligations (other than Unliquidated Obligations for which no claim has been made and other obligations expressly stated to survive such payment and termination of this Agreement), together with accrued and unpaid interest thereon, (v) the termination of all Revolving Commitments, and (vi) the termination of the Swap Agreement Obligations and the Banking Services Obligations or entering into other arrangements satisfactory to the Secured Parties counterparties thereto. Å œParentÅ œ means, with respect to any Lender, any Person as to which such Lender is, directly or indirectly, a subsidiary. Å œParticipantÅ œ has the meaning assigned to such term in Section 9.04(c). Å œParticipant RegisterÅ œ has the meaning assigned to such term in Section 9.04(c). Å œPaymentÅ œ has the meaning assigned to it in Section 8.06(c). Å œPayment NoticeÅ œ has the meaning assigned to it in Section 8.06(c). Å œPBGCAÅ œ means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions. Å œPermitted AcquisitionÅ œ means any Acquisition by the Borrower or any of its Subsidiaries in a transaction that satisfies each of the following requirements: (a) such Acquisition is not a Hostile Acquisition; (b) the business acquired in connection with such Acquisition is (i) located primarily in the U.S., (ii) organized primarily under applicable U.S. and state laws, and (iii) not engaged, directly or indirectly, in any line of business other than the businesses in which the Loan Parties are engaged on the Effective Date and any business activities that are substantially similar, related, supplemental or incidental thereto and reasonable extensions thereof; provided, that, with respect to any Acquisition of any Target, in no event shall (A) the aggregate amount of EBITDA of such Target and its consolidated subsidiaries arising from or otherwise attributable to assets, services or operations outside of the United States of America constitute more than twenty percent (20%) of the aggregate EBITDA of such Target and its subsidiaries on a consolidated basis or (B) the aggregate amount of consolidated total assets of such Target and its consolidated subsidiaries located outside of the United States of America constitute more than twenty percent (20%) of the aggregate consolidated total assets of such Target and its consolidated subsidiaries (in each case, as reasonably determined by the Borrower in good faith in consultation with the Administrative Agent); (c) both immediately before and immediately after giving effect (including giving effect on a pro forma basis) to such Acquisition and any Indebtedness incurred or assumed in connection therewith, (i) each of the representations and warranties in the Loan Documents is true 27 Å œ and correct in all material respects (except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date), and any representation or warranty which is subject to any materiality qualifier shall be required to be true and correct in all respects and (ii) no Default or Event of Default then exists or would result therefrom; (d) as soon as available, but not less than twenty (20) days prior to such Acquisition, the Borrower has provided the Administrative Agent (i) notice of such Acquisition and (ii) a copy of all material business and financial information reasonably requested by the Administrative Agent including, with respect to Acquisitions the consideration for which exceeds \$20,000,000, pro forma financial statements and statements of cash flow and a quality of earnings report for the business and/or Persons acquired in connection with such Acquisition prepared by an accounting firm of national reputation (or otherwise acceptable to the Administrative Agent) in form and substance reasonably satisfactory to the Administrative Agent; (e) both before and immediately after giving effect (including giving effect on a pro forma basis) to such Acquisition and the Loans (if any) requested to be made in connection therewith, the Net Leverage Ratio shall not be greater than 3.00 to 1.00; (f) if such Acquisition is an acquisition of the Equity Interests of a Person, such Acquisition is structured so that the acquired Person shall become a Subsidiary of a Loan Party pursuant to the terms of this Agreement; (g) if such Acquisition is an acquisition of Equity Interests, such Acquisition will not result in any violation of Regulation U; (h) if such Acquisition involves a merger or a consolidation involving any Loan Party, such Loan Party shall be the surviving entity (provided that any such merger or consolidation involving the Borrower shall result in the Borrower as the surviving entity); (i) no Loan Party shall, as a result of or in connection with any such Acquisition, assume or incur any direct or contingent liabilities (whether relating to environmental, tax, litigation, or other matters) that could have a Material Adverse Effect; (j) in connection with an Acquisition of the Equity Interests of any Person, all Liens on any property of such Person shall be terminated unless the Administrative Agent and the Lenders in their sole discretion consent otherwise, and in connection with an Acquisition of the assets of any Person, all Liens on such assets shall be terminated, in each case, other than Liens permitted by Section 6.02; (k) all actions required to be taken with respect to any newly acquired or formed Subsidiary of a Loan Party required under Section 5.13 shall have been taken; and (l) the Borrower shall have delivered to the Administrative Agent the final executed material documentation relating to such Acquisition promptly following the consummation thereof. Å œPermitted EncumbrancesÅ œ means: (a) Liens imposed by law for Taxes that are not yet due and delinquent for a period of more than 30 days or are being contested in compliance with Section 5.04; 28 Å œ (b) carriersÅ œ s Å œ, warehousemenÅ œ s Å œ, mechanicsÅ œ s Å œ, repairmenÅ œ s Å œ and other like Liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than thirty (30) days or are being contested in compliance with Section 5.04; (c) pledges and deposits (i) made in the ordinary course of business in compliance with workersÅ œ s Å œ compensation, unemployment insurance and other social security laws or regulations or employment laws or to secure other public, statutory or regulatory obligations and (ii) with respect to letters of credit, bank guarantees or similar instruments issued for the account of any Borrower or any Subsidiary in the ordinary course of business to the extent supporting obligations of the type set forth in clause (c)(i) above; (d) pledges and deposits to (i) secure the performance of bids, trade, commercial and government contracts, tenders leases, statutory or regulatory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business and (ii) in respect of letters of credit, bank guarantees or similar instruments issued for the account of any Borrower or any Subsidiary in the ordinary course of business to the extent supporting obligations of the type set forth in clause (d)(i); (e) judgment Liens in respect of judgments that do not constitute an Event of Default under clause (k) of Article VII; (f) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business that do not secure any monetary obligations and do not materially detract from the value of the affected property or interfere with the ordinary conduct of business of the Borrower or any Subsidiary; (g) any interest or title of a licensor under any license or sublicense entered into by any Borrower or any Subsidiary as a licensee or sublicensee in the ordinary course of its business; (h) leases, licenses, subleases or sublicenses of real property or equipment granted to others in the ordinary course of business which (i) do not interfere in any material respect with the business of any Borrower and its Subsidiaries, taken as a whole, and (ii) do not secure any Indebtedness; (i) non-exclusive licenses or sublicenses of intellectual property and exclusive licenses or sublicenses of intellectual property which are exclusive as to geographic location outside of the United States, in each case, granted by any Loan Party or a Subsidiary in the ordinary course of business that does not interfere in any material respect with the business of the Loan Parties and their Subsidiaries; (j) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods so long as such Liens attach only to the imported goods prior to possession by the Borrower or its Subsidiaries; and (k) purported Liens (other than Liens securing Indebtedness for borrowed money) incurred in the ordinary course of business and evidenced by the filing of precautionary UCC (or equivalent statute) financing statements or similar public filings; provided that the term Å œPermitted EncumbrancesÅ œ shall not include any Lien securing Indebtedness, except with respect to clause (e) above. 29 Å œ Å œPermitted InvestmentsÅ œ means: (a) direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the U.S. (or by any agency thereof to the extent such obligations are backed by the full faith and credit of the U.S.), in each case maturing within one year from the date of acquisition thereof; (b) investments in commercial paper maturing within 270 days from the date of acquisition thereof and having, at such date of acquisition, the highest credit rating obtainable from S&P or from MoodyÅ œ s Å œ; (c) investments in certificates of deposit, bankersÅ œ s Å œ acceptances and time deposits maturing within 180 days from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the U.S. or any state thereof which has a combined capital and surplus and undivided profits of not less than \$500,000,000; (d) fully collateralized repurchase agreements with a term of not more than 30 days for securities described in clause (a) above and entered into with a financial institution satisfying the criteria described in clause (c) above; (e) money market funds that (i) comply with the criteria set forth in Securities and Exchange Commission Rule 2a-

7 under the Investment Company Act of 1940, (ii) are rated AAA by S&P and Aaa by Moody’s and (iii) have portfolio assets of at least \$5,000,000,000; and (f) other investments made in accordance with the Borrower’s cash management or investment policy, in each case, to the extent reasonably approved by the Administrative Agent. Person means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. Plan means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which the Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under Section 4069 of ERISA be deemed to be) an employer as defined in Section 3(5) of ERISA. Plan Asset Regulations means 29 CFR    2510.3-101 et seq., as modified by Section 3(42) of ERISA, as amended from time to time. Prime Rate means the rate of interest last quoted by The Wall Street Journal as the Prime Rate in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the bank prime loan rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as determined by the Administrative Agent). Each change in the Prime Rate shall be effective from and including the date such change is publicly announced or quoted as being effective. Proceeding means any claim, litigation, investigation, action, suit, arbitration or administrative, judicial or regulatory action or proceeding in any jurisdiction. Projections has the meaning assigned to such term in Section 5.01(e). 30 A PSA shall mean the Packers and Stockyard Act of 1921, 7 U.S.C. Section 181 et seq., as the same now exists or may from time to time hereafter be amended, modified, recodified or supplemented, together with all rules, regulations and interpretations thereunder or related thereto. PTE means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time. QFC has the meaning assigned to the term qualified financial contract in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D). QFC Credit Support has the meaning assigned to it in Section 9.21. Qualified ECP Guarantor means, in respect of any Swap Obligation, each Loan Party that has total assets exceeding \$10,000,000 at the time the relevant Loan Guaranty or grant of the relevant security interest becomes or would become effective with respect to such Swap Obligation or such other person as constitutes an eligible contract participant under the Commodity Exchange Act or any regulations promulgated thereunder and can cause another person to qualify as an eligible contract participant at such time by entering into a keepwell under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act. Qualified Stock means any Equity Interest that is not Disqualified Stock. Recipient means, as applicable, (a) the Administrative Agent, (b) any Lender and (c) any Issuing Bank, or any combination thereof (as the context requires). Reference Time with respect to any setting of the then-current Benchmark means (1) if such Benchmark is the Term SOFR Rate, 5:00 a.m. (Chicago time) on the day that is two U.S. Government Securities Business Days preceding the date of such setting, (2) following a Benchmark Transition Event and a Benchmark Replacement Date with respect to the Term SOFR Rate, if such Benchmark is Daily Simple SOFR, then four U.S. Government Securities Business Days prior to such setting or (3) if such Benchmark is none of the Term SOFR Rate or Daily Simple SOFR, the time determined by the Administrative Agent in its reasonable discretion. Refinance Indebtedness has the meaning assigned to such term in Section 6.01(f). Register has the meaning assigned to such term in Section 9.04(b). Regulation D means Regulation D of the Federal Reserve Board, as in effect from time to time and all official rulings and interpretations thereunder or thereof. Regulation U means Regulation U of the Federal Reserve Board, as in effect from time to time and all official rulings and interpretations thereunder or thereof. Regulation X means Regulation X of the Federal Reserve Board, as in effect from time to time and all official rulings and interpretations thereunder or thereof. Related Parties means, with respect to any specified Person, such Person’s Affiliates and the respective directors, officers, partners, members, trustees, employees, agents, administrators, managers, representatives and advisors of such Person and such Person’s Affiliates. Release means any releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, migrating, disposing, or dumping of any substance into the environment. Relevant Governmental Body means the Federal Reserve Board and/or the NYFRB, or a committee officially endorsed or convened by the Federal Reserve Board and/or the NYFRB or, in each case, any successor thereto. Relevant Rate means (i) with respect to any Term Benchmark Borrowing, the Adjusted Term SOFR Rate, and (ii) with respect to any RFR Borrowing, Adjusted Daily Simple SOFR, as applicable. Required Lenders means, subject to Section 2.20: (a) at any time prior to the earlier of the Loans becoming due and payable pursuant to Article VII or the Revolving Commitments terminating or expiring, Lenders having Revolving Exposures and Unfunded Revolving Commitments representing more than 50% of the sum of the Aggregate Revolving Exposure and aggregate Unfunded Revolving Commitments at such time, provided that, solely for purposes of declaring the Loans to be due and payable pursuant to Article VII, the Unfunded Revolving Commitment of each Lender shall be deemed to be zero in determining the Required Lenders; and (b) for all purposes after the Loans become due and payable pursuant to Article VII or the Revolving Commitments expire or terminate, Lenders having Revolving Exposures representing more than 50% of the sum of the Aggregate Revolving Exposure at such time; provided that, in the case of clauses (a) and (b) above, the Revolving Exposure of any Lender that is a Swingline Lender shall be deemed to exclude any amount of its Swingline Exposure in excess of its Applicable Percentage of all outstanding Swingline Loans, adjusted to give effect to any reallocation under Section 2.20 of the Swingline Exposures of Defaulting Lenders in effect at such time, and the Unfunded Revolving Commitment of such Lender shall be determined on the basis of its Revolving Exposure excluding such excess amount; provided further, that, at all times when there are only two (2) unaffiliated Lenders, Required Lenders shall require both such unaffiliated Lenders. Requirement of Law means, with respect to any Person, (a) the charter, articles or certificate of organization or incorporation and bylaws or operating, management or partnership agreement, or other organizational or governing documents of such Person and (b) any statute, law (including common law), treaty, rule, regulation, code, ordinance, order, decree, writ, judgment, injunction or determination of any arbitrator or court or other Governmental Authority (including Environmental Laws), in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. Resolution Authority means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority. Responsible Officer means the president, Financial Officer or other executive officer of the Borrower. Restricted Payment means, as the case may be, any dividend or other distribution (whether in cash, securities or other property) with respect to any Equity Interests in the Borrower or any Subsidiary, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such Equity Interests in the Borrower or any Subsidiary or any option, warrant or other right to acquire any such Equity Interests in the Borrower or any Subsidiary. Revolving Commitment means, with respect to each Lender, the amount set forth on the Commitment Schedule opposite such Lender’s name as a Revolving Commitment, or in the Assignment 32 A and Assumption or other documentation or record (as such term is defined in Section 9-102(a)(70) of the New York UCC) as provided in Section 9.04(b)(ii)(C), pursuant to which such Lender shall have assumed its Revolving Commitment pursuant to the terms hereof, as applicable, as such Revolving Commitment may be reduced or increased from time to time pursuant to (a) Section 2.09 and (b) assignments by or to such Lender pursuant to Section 9.04; provided that at no time shall the Revolving Exposure of any Lender exceed its Revolving Commitment. The initial aggregate amount of the Lenders’ Revolving Commitments is \$60,000,000. Revolving Credit Maturity Date means April 9, 2029 (if the same is a Business Day, or if not then the immediately next succeeding Business Day), or any earlier date on which the Revolving Commitments are reduced to zero or otherwise terminated pursuant to the terms hereof. Revolving Exposure means, with respect to any Lender, at any time, the sum of the aggregate outstanding principal amount of such Lender’s Revolving Loans and its LC Exposure and its Swingline Exposure at such time. Revolving Loan means a Loan made pursuant to Section 2.01. RFR when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Adjusted Daily Simple SOFR (excluding, for the avoidance of doubt, any ABR Loan or Borrowing). S&P means Standard & Poor’s Rating Services, a Standard & Poor’s Financial Services LLC business. Sale and Leaseback Transaction has the meaning assigned to such term in Section 6.06. Sanctioned Country means, at any time, a country, region or territory which is itself the subject or target of any Sanctions (at the time of this Agreement, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, the Crimea, Zaporizhzhia and Kherson Regions of Ukraine, Cuba, Iran, North Korea and Syria). Sanctioned Person means, at any time, any Person subject or target of any Sanctions, including (a) any Person listed in any Sanctions-related list of designated Persons maintained by the U.S. government, including by OFAC, the U.S. Department of State or the U.S. Department of Commerce, or by the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of the United Kingdom or other relevant sanctions authority, (b) any Person operating, organized or resident in a Sanctioned Country, or (c) any Person owned or controlled by any such Person or Persons described in the foregoing clauses (a) or (b) (including, without limitation for purposes of defining a Sanctioned Person, as ownership and control may be defined and/or established in and/or by any applicable laws, rules, regulations, or orders). Sanctions means all economic or financial sanctions, trade embargoes or similar restrictions imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC, the U.S. Department of State or the U.S. Department of Commerce, or (b) the United Nations Security Council, the European Union, any European Union member state or His Majesty’s Treasury of the United Kingdom or other relevant sanctions authority. SEC means the Securities and Exchange Commission of the U.S. 33 A Secured Obligations means all Obligations, together with all Banking Services Obligations and Swap Agreement Obligations owing to one or more Lenders or their respective Affiliates; provided that the definition of Secured Obligations shall not create any guarantee by any Loan Guarantor of (or grant of security interest by any Loan Guarantor to support, as applicable) any Excluded Swap Obligations of such Loan Guarantor for purposes of determining any obligations of any Loan Guarantor. Secured Parties means (a) the Lenders, (b) the Administrative Agent, (c) each Issuing Bank, (d) each provider of Banking Services, to the extent the Banking Services Obligations in respect thereof constitute Secured Obligations, (e) each counterparty to any Swap Agreement, to the extent the obligations thereunder constitute Secured Obligations, (f) the beneficiaries of each indemnification obligation undertaken by any Loan Party under any Loan Document and (g) the successors and assigns of each of the foregoing. Security Agreement means that certain Pledge and Security Agreement (including any and all supplements thereto), dated as of the date hereof, among the Loan Parties and the Administrative Agent, for the benefit of the Administrative Agent and the other Secured Parties, and any other pledge or security agreement entered into, after the date of this Agreement by any other Loan Party (as required by this Agreement or any other Loan Document) or any other Person for the benefit of the Administrative Agent and the other Secured Parties, as the same may be amended, restated, supplemented or otherwise modified from time to time. Sellers Lien Laws means, collectively, all state, federal, and other applicable laws applicable to a Loan Party’s or Subsidiary’s purchase of Farm Products on credit from any selling party that creates a Lien or imposes a trust upon the agricultural, livestock, poultry, seafood, milk, dairy, egg, or other Farm Products sold and/or the proceeds and products thereof, for the benefit of such selling party, or a creditor thereof, to secure payment for such Farm Products, including without limitation, PACA, PSA, the Food Security Act, or any similar state or federal laws or regulations. Sellers Lien Law Notices shall have the meaning given in Section 3.24. SOFR means a rate per annum equal to the secured overnight financing rate as administered by the SOFR Administrator. SOFR Administrator means the NYFRB (or a successor administrator of the secured overnight financing rate). SOFR Administrator’s Website means the NYFRB’s Website, currently at <http://www.newyorkfed.org>, or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time. SOFR Rate Day has the meaning assigned to it under the definition of Daily Simple SOFR. Specified Ancillary Obligations means all obligations and liabilities (including interest and fees accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding) of any of the Subsidiaries, existing on the Effective Date or arising thereafter, direct or indirect, joint or several, absolute or contingent, matured or unmatured, liquidated or unliquidated, secured or unsecured, arising by contract, operation of law or otherwise, to the Lenders or any of their Affiliates in respect of any Swap Agreement Obligations or any Banking Services Obligations. 34 A Specified Representations means the representations and warranties in respect of the Loan Parties made pursuant to Sections 3.01, 3.02, 3.03(b) (solely as it relates to the organizational documents of the Loan Parties), 3.08, 3.13, 3.16 (provided that any such representation or warranty relating to perfection of Liens shall be limited in a customary manner for SunGard or certain funds conditionality), 3.18, 3.19 and 3.21. Statement has the meaning assigned to such term in Section 2.18(f). Subordinated Indebtedness of a Person means any Indebtedness of such Person, the payment of which is subordinated to payment of the Secured Obligations to the written reasonable satisfaction of the Administrative Agent. Subsidiary means, with respect to any Person (the parent) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, Controlled or held, or (b) that is, as of such date, otherwise Controlled, by the parent and/or one or more subsidiaries of the parent. Subsidiary means any direct or indirect subsidiary of the Borrower or of any other Loan Party, as applicable. Subsidiary Guarantor means the Borrower’s Subsidiaries party hereto as Subsidiary Guarantors as of the Effective Date and any other Subsidiary that becomes a party to this Agreement pursuant to a Joinder Agreement; provided that no Excluded Subsidiary shall be required to become a Subsidiary Guarantor. Supported QFC has the meaning assigned to it in Section 9.21. Swap Agreement means any agreement with respect to any swap, forward, spot, future, credit default or derivative transaction or option or similar agreement involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments or securities, or economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any similar transaction or any combination of these transactions; provided that no phantom stock or similar plan providing for payments only on account of services provided by current or former directors, officers, employees or consultants of the Borrower or the Subsidiaries shall be a Swap Agreement. Swap Agreement Obligations means any and all obligations of the Loan Parties and their Subsidiaries, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor), under (a) any Swap Agreement permitted hereunder with a Lender or an Affiliate of a Lender, and (b) any cancellations, buy backs, reversals, terminations or assignments of any Swap Agreement transaction permitted hereunder with a Lender or an Affiliate of a Lender. Swap Obligation means, with respect to any Loan Guarantor, any obligation to pay or perform under any agreement, contract or transaction that constitutes a swap within the meaning of section 1a(47) of the Commodity Exchange Act or any rules or regulations promulgated thereunder. 35 A Swingline Exposure means, at any time, the aggregate principal amount of all Swingline Loans outstanding at such time. The Swingline Exposure of any Lender at any time shall be the sum of (a) its Applicable Percentage of the aggregate principal amount of all Swingline Loans outstanding at such time (excluding, in the case of any Lender that is a Swingline Lender, Swingline Loans made by such Lender in its capacity as a Swingline Lender that are outstanding at such time to the extent that the other Lenders shall not have funded their participations in such Swingline Loans), adjusted to give effect to any reallocation under Section 2.20 of the Swingline Exposure of Defaulting Lenders in effect at such time, and (b) in the case of any Lender that is a Swingline Lender, the aggregate principal amount of all Swingline Loans made by such Lender as a Swingline Lender outstanding at such time, less the amount of participations funded by the other Lenders in such Swingline Loans. Swingline Lender means Chase (or any of its designated branch offices or affiliates), in its capacity as lender of Swingline Loans hereunder. Any consent required of the Administrative Agent or the Issuing Bank shall be deemed to be required of the Swingline Lender and any consent given by Chase in its capacity as Administrative Agent or Issuing Bank shall be deemed given by Chase in its capacity as Swingline Lender as well. Swingline Loan means a Loan made pursuant to Section 2.05. Target means any Person or business or asset group of any Person acquired or proposed to be acquired in an Acquisition. Taxes means any and all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), value added taxes, or any other goods and services, use or sales taxes, assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. Term Benchmark, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, bear interest at a rate determined by reference to the Adjusted Term SOFR Rate. Term SOFR Determination Day has the meaning assigned to it under the definition of Term SOFR Reference Rate. Term SOFR Rate means, with respect to any Term Benchmark Borrowing and for any tenor comparable to the applicable Interest Period, the Term SOFR Reference Rate at approximately 5:00 a.m., Chicago time, two U.S. Government Securities Business Days prior to the commencement of such tenor comparable to the applicable Interest Period, as such rate is published by the CME Term SOFR Administrator.

âTerm SOFR Reference Rateâ means, for any day and time (such day, the âTerm SOFR Determination Dayâ), with respect to any Term Benchmark Borrowing and for any tenor comparable to the applicable Interest Period, the rate per annum published by the CME Term SOFR Administrator and identified by the Administrative Agent as the forward-looking term rate based on SOFR. If by 5:00 pm (New York City time) on such Term SOFR Determination Day, the âTerm SOFR Reference Rateâ for the applicable tenor has not been published by the CME Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Rate has not occurred, then, so long as such day is otherwise a U.S. Government Securities Business Day, the Term SOFR Reference Rate for such Term SOFR Determination Day will be the Term SOFR Reference Rate as published in respect of the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate was published by the CME Term SOFR Administrator, so long as such first preceding U.S. Government 36 Â Securities Business Day is not more than five (5) U.S. Government Securities Business Days prior to such Term SOFR Determination Day. âTransactionsâ means the execution, delivery and performance by the Loan Parties of this Agreement and the other Loan Documents, the borrowing of Loans and other credit extensions, the use of the proceeds thereof and the issuance of Letters of Credit hereunder. âTypeâ, when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans comprising such Borrowing, is determined by reference to the Adjusted Term SOFR Rate, the Adjusted Daily Simple SOFR or the Alternate Base Rate. âUCCâ means the Uniform Commercial Code as in effect from time to time in the State of New York or in any other state, the laws of which are required to be applied in connection with the issue of perfection of security interests. âUK Financial Institutionsâ means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms. âUK Resolution Authorityâ means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution. âUnadjusted Benchmark Replacementâ means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment. âUnfunded Revolving Commitmentâ means, with respect to each Lender at any time, the Revolving Commitment of such Lender at such time, less its Revolving Exposure at such time. âUnliquidated Obligationsâ means, at any time, any Secured Obligations (or portion thereof) that are contingent in nature or unliquidated at such time, including any Secured Obligation that is: (i) an obligation to reimburse a bank for drawings not yet made under a letter of credit issued by it; (ii) any other obligation (including any guarantee) that is contingent in nature at such time; or (iii) an obligation to provide collateral to secure any of the foregoing types of obligations. âUnrestricted Cashâ means, as of any date of determination, an amount equal to the aggregate amount of the Loan Parties' unrestricted cash and Permitted Investments that is (a) on deposit with one or more financial institutions in the U.S. and (b) not encumbered by or subject to any other Lien, setoff, counterclaim, recoupment, defense or other right in favor of any Person (other than (i) a Lien securing the Secured Obligations, and (ii) banker's Liens relating to the establishment of depository relations in the ordinary course and not given in connection with the issuance of Indebtedness). âU.S.â means the United States of America. âU.S. Government Securities Business Dayâ means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities. 37 Â âU.S. Personâ means a âUnited States personâ within the meaning of Section 7701(a)(30) of the Code. âU.S. Special Resolution Regimeâ has the meaning assigned to it in Section 9.21. âU.S. Tax Compliance Certificateâ has the meaning assigned to such term in Section 2.17(f)(ii)(B)(3). âUSA PATRIOT Actâ means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001. âWithdrawal Liabilityâ means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. âWrite-Down and Conversion Powersâ means (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers. SECTION 1.02. Classification of Loans and Borrowings. For purposes of this Agreement, Loans may be classified and referred to by Class (e.g., a âRevolving Loanâ) or by Type (e.g., a âTerm Benchmark Loanâ) or by Class and Type (e.g., a âTerm Benchmark Revolving Loanâ). Borrowings also may be classified and referred to by Class (e.g., a âRevolving Borrowingâ) or by Type (e.g., a âTerm Benchmark Borrowingâ) or by Class and Type (e.g., a âTerm Benchmark Revolving Borrowingâ). SECTION 1.03. Terms Generally. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words âincludeâ and âincludesâ shall be deemed to be followed by the phrase âwithout limitationâ. The word âlawâ shall be construed as referring to all statutes, rules, regulations, codes and other laws (including official rulings and interpretations thereunder having the force of law or with which affected Persons customarily comply) and all judgments, orders and decrees of all Governmental Authorities. The word âwillâ shall be construed to have the same meaning and effect as the word âshallâ. Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth herein), (b) any definition of or reference to any statute, rule or regulation shall be construed as referring thereto as from time to time amended, supplemented or otherwise modified (including by succession of comparable successor laws), (c) any reference herein to any Person shall be construed to include such Person's successors and assigns (subject to any restrictions on assignments set forth herein) and, in the case of any Governmental Authority, any other Governmental Authority that shall have succeeded to any or all functions thereof, (d) the words âhereinâ and âhereofâ and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (e) all references herein to Articles, Sections, Exhibits and Schedules 38 Â shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement, (f) any reference in any definition to the phrase âat any timeâ or âfor any periodâ shall refer to the same time or period for all calculations or determinations within such definition, and (g) the words âassetâ and âpropertyâ shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights. SECTION 1.04. Accounting Terms; GAAP. (a) Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time; provided that, if after the date hereof there occurs any change in GAAP or in the application thereof on the operation of any provision hereof and the Borrower notifies the Administrative Agent that the Borrower requests an amendment to any provision hereof to eliminate the effect of such change in GAAP or in the application thereof (or if the Administrative Agent notifies the Borrower that the Required Lenders request an amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such change in GAAP or in the application thereof, then such provision shall be interpreted on the basis of GAAP as in effect and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made (i) without giving effect to any election under Financial Accounting Standards Board Accounting Standards Codification 825 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any Indebtedness or other liabilities of the Borrower or any Subsidiary at âfair valueâ, as defined therein and (ii) without giving effect to any treatment of Indebtedness under Financial Accounting Standards Board Accounting Standards Codification 470-20 or 2015-03 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof. (b) Notwithstanding anything to the contrary contained in Section 1.04(a) or in the definition of âCapital Lease Obligationsâ (any change in accounting for leases pursuant to GAAP resulting from the adoption of Financial Accounting Standards Board Accounting Standards Update No. 2016-02, Leases (Topic 842) (âFAS 842â)), to the extent such adoption would require treating any lease (or similar arrangement conveying the right to use) as a capital lease where such lease (or similar arrangement) would not have been required to be so treated under GAAP as in effect on December 31, 2015, such lease shall not be considered a capital lease, and all calculations and deliverables under this Agreement or any other Loan Document shall be made or delivered, as applicable, in accordance therewith. SECTION 1.05. Pro Forma Adjustments. (a) To the extent the Borrower or any Subsidiary (i) makes any acquisition permitted pursuant to Section 6.04 or Disposition of assets outside the ordinary course of business permitted by Section 6.05, in each case, in excess of \$5,000,000, during the period of four fiscal quarters of the Borrower most recently ended or (ii) consummates any transaction that requires any pro forma calculation as a condition thereto or in connection therewith under the terms of this Agreement, then, in each case, (A) the Net Leverage Ratio and Fixed Charge Coverage Ratio, in each case, shall be calculated after giving pro forma effect thereto (including pro forma adjustments arising out of events which are directly attributable to the acquisition or the Disposition of assets, are factually supportable and are expected to have a continuing impact, in each case as determined on a basis consistent with (but without giving effect to any âmanagement's adjustmentsâ under) Article 11 of Regulation S-X of the Securities Act of 1933, as amended, as interpreted by the SEC, and as certified by a Financial Officer), as if such acquisition, such Disposition or such other transaction 39 Â (and any related incurrence, repayment or assumption of Indebtedness) had occurred in the first day of such four-quarter period, but in all cases subject to the terms and conditions (including any caps or other limitations) set forth in the definition of Consolidated EBITDA and any defined terms used therein, (B) unless otherwise expressly required hereunder, such pro forma calculation shall be determined by reference to the financial statements for the period of four consecutive fiscal quarters ended on or most recently prior to such calculation for which financial statements have been delivered (or are required to have been delivered) to the Administrative Agent pursuant to Section 5.01(a) or (b) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 5.01(a) or (b), the most recent financial statements referred to in Section 3.04(a)) and (C) any such calculation made by reference to, or requiring pro forma compliance with, any of the financial covenants shall be made by reference to the applicable financial covenant levels required under Section 6.12 (without giving effect to any Adjusted Covenant Period (other than in the case of determining satisfaction of the conditions to (x) a Permitted Acquisition or (y) the incurrence of an Incremental Term Loan the proceeds of which are used solely to finance the concurrent consummation of a Permitted Acquisition)) for the quarter during which such acquisition, Disposition or other transaction was consummated (or, if there is no financial covenant required to be tested during such fiscal quarter, the financial covenant level for the first testing period scheduled to occur after the date of such calculation). In addition to the foregoing, and notwithstanding anything in this Agreement to the contrary, to the extent any Indebtedness is incurred or assumed in connection with any transaction permitted hereunder, any pro forma determination of the Net Leverage Ratio or compliance with the financial covenants required to be made under this Agreement in connection with such transaction shall be made without including the proceeds of such incurred or assumed Indebtedness as Unrestricted Cash. (b) In connection with any action being taken in connection with a Limited Condition Transaction, for purposes of: (i) determining compliance with any provision of this Agreement which requires the calculation of any financial ratio or test, including the Net Leverage Ratio and the Fixed Charge Coverage Ratio; (ii) testing availability under baskets set forth in this Agreement; or (iii) determining the accuracy of any representation or warranty or the existence of any Default or Event of Default, in each case, at the option of the Borrower (the Borrower's election to exercise such option in connection with any Limited Condition Transaction, an âLCT Electionâ), the date of determination of whether any such action is permitted hereunder shall be deemed to be the date the definitive agreement for such Limited Condition Transaction is entered into (the âLCT Test Dateâ), and if, after giving pro forma effect to the Limited Condition Transaction, the Borrower or any of its Subsidiaries would have been permitted to take such action on the relevant LCT Test Date in compliance with such ratio, test or basket or other provision, such ratio, test or basket shall be deemed to have been complied with; provided, however, that notwithstanding the foregoing and/or any LCT Election, (x) no Event of Default pursuant to clause (a), (b), (h), (i) or (m) of Article VII shall be continuing immediately prior to or after giving effect to the consummation of any Limited Condition Transaction on the date of such consummation and (y) the Borrower may not make any LCT Election in respect of the conditions set forth in Section 4.02 except as expressly set forth therein. For the avoidance of doubt, if the Borrower has made an LCT Election and any of the ratios, tests or baskets or other provision for which compliance was determined or tested as of the LCT Test Date would have failed to have been satisfied as a result of fluctuations in any such ratio, test or basket or other provision, including due to fluctuations in Consolidated EBITDA, at or prior to the consummation of the relevant transaction or action, such baskets, tests or ratios will not be deemed to have 40 Â failed to have been satisfied as a result of such fluctuations. If the Borrower has made an LCT Election for any Limited Condition Transaction, then in connection with any event or transaction occurring after the relevant LCT Test Date and prior to the earlier of the date on which such Limited Condition Transaction is consummated or the date that the definitive agreement for such Limited Condition Transaction is terminated or expires without consummation of such Limited Condition Transaction (a âSubsequent Transactionâ) in connection with which a condition, ratio, test or basket availability calculation must be made on a pro forma basis or giving effect (pro forma or otherwise) to such Subsequent Transaction, for purposes of determining whether such condition, ratio, test or basket availability has been complied with under this Agreement, any such condition, ratio, test or basket shall be required to be satisfied on a pro forma basis assuming such Limited Condition Transaction and the other transactions in connection therewith (including, without limitation, the incurrence or assumption of any Indebtedness and the funding of any Incremental Term Loans or commitments in respect thereof (which calculations shall assume that such Incremental Term Loans or commitments in respect thereof are fully funded, as the case may be)) have been consummated. SECTION 1.06. Status of Obligations. In the event that the Borrower or any other Loan Party shall at any time issue or have outstanding any Subordinated Indebtedness, the Borrower shall take or cause such other Loan Party to take all such actions as shall be necessary to cause the Secured Obligations to constitute senior indebtedness (however denominated) in respect of such Subordinated Indebtedness and to enable the Administrative Agent and the Lenders to have and exercise any payment blockage or other remedies available or potentially available to holders of senior indebtedness under the terms of such Subordinated Indebtedness. Without limiting the foregoing, the Secured Obligations are hereby designated as âsenior indebtednessâ and as âdesignated senior indebtednessâ and words of similar import under and in respect of any indenture or other agreement or instrument under which such Subordinated Indebtedness is outstanding and are further given all such other designations as shall be required under the terms of any such Subordinated Indebtedness in order that the Lenders may have and exercise any payment blockage or other remedies available or potentially available to holders of senior indebtedness under the terms of such Subordinated Indebtedness. SECTION 1.07. Interest Rates; Benchmark Notification. The interest rate on a Loan may be derived from an interest rate benchmark that may be discontinued or is, or may in the future become, the subject of regulatory reform. Upon the occurrence of a Benchmark Transition Event, Section 2.14(b) provides a mechanism for determining an alternative rate of interest. The Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission, performance or any other matter related to any interest rate used in this Agreement, or with respect to any alternative or successor rate thereto, or replacement rate thereof, including without limitation, whether the composition or characteristics of any such alternative, successor or replacement reference rate will be similar to, or produce the same value or economic equivalence of, the existing interest rate being replaced or have the same volume or liquidity as did any existing interest rate prior to its discontinuance or unavailability. The Administrative Agent and its affiliates and/or other related entities may engage in transactions that affect the calculation of any interest rate used in this Agreement or any alternative, successor or alternative rate (including any Benchmark Replacement) and/or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain any interest rate used in this Agreement, any component thereof, or rates referenced in the definition thereof, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other Person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service. 41 Â SECTION 1.08. Letter of Credit Amounts. Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit available to be

drawn at such time; provided that with respect to any Letter of Credit that, by its terms, provides for one or more automatic increases in the available amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum amount is available to be drawn at such time. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Article 29(a) of the Uniform Customs and Practice for Documentary Credits, International Chamber of Commerce Publication No. 600 (or such later version thereof as may be in effect at the applicable time) or Rule 3.13 or Rule 3.14 of the International Standby Practices, International Chamber of Commerce Publication No. 590 (or such later version thereof as may be in effect at the applicable time) or similar terms in the governing rules or laws or of the Letter of Credit itself, or if compliant documents have been presented but not yet honored, such Letter of Credit shall be deemed to be "outstanding" and "undrawn" in the amount so remaining available to be paid, and the obligations of the Borrower and each Lender shall remain in full force and effect until the Issuing Bank and the Lenders shall have no further obligations to make any payments or disbursements under any circumstances with respect to any Letter of Credit. SECTION 1.09. Divisions. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction's laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized and acquired on the first date of its existence by the holders of its Equity Interests at such time. ARTICLE II The Credits SECTION 2.01. Revolving Commitments. Subject to the terms and conditions set forth herein, each Lender severally (and not jointly) agrees to make Revolving Loans in dollars to the Borrower from time to time during the Availability Period in an aggregate principal amount that will not result (after giving effect to any application of proceeds of such Borrowing pursuant to Section 2.10(a)) in (i) such Lender's Revolving Exposure exceeding such Lender's Revolving Commitment or (ii) the Aggregate Revolving Exposure exceeding the aggregate Revolving Commitments. Within the foregoing limits and subject to the terms and conditions set forth herein, the Borrower may borrow, prepay and reborrow Revolving Loans. SECTION 2.02. Loans and Borrowings. (a) Each Loan (other than a Swingline Loan) shall be made as part of a Borrowing consisting of Loans of the same Type made by the Lenders ratably in accordance with their respective Revolving Commitments. The failure of any Lender to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that the Revolving Commitments of the Lenders are several and no Lender shall be responsible for any other Lender's failure to make Loans as required. Any Swingline Loan shall be made in accordance with the procedures set forth in Section 2.05. (b) Subject to Section 2.14, each Revolving Borrowing shall be comprised entirely of ABR Loans or Term Benchmark Loans as the Borrower may request in accordance herewith. Each Swingline Loan shall be an ABR Loan. Each Lender at its option may make any Loan by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan (and in the case of an Affiliate, the provisions 42 A of Sections 2.14, 2.15, 2.16 and 2.17 shall apply to such Affiliate to the same extent as to such Lender); provided that any exercise of such option shall not affect the obligation of the Borrower to repay such Loan in accordance with the terms of this Agreement. (c) At the commencement of each Interest Period for any Term Benchmark Borrowing, such Borrowing shall be in an aggregate amount that is an integral multiple of \$250,000 and not less than \$500,000. At the time that each ABR Borrowing or RFR Borrowing is made, such Borrowing shall be in an aggregate amount that is an integral multiple of \$250,000 and not less than \$500,000; provided that an ABR Revolving Borrowing may be in an aggregate amount that is equal to the entire unused balance of the total Revolving Commitments or that is required to finance the reimbursement of an LC Disbursement as contemplated by Section 2.06(e). Each Swingline Loan shall be in an amount that is an integral multiple of \$250,000 and not less than \$500,000. Borrowings of more than one Type may be outstanding at the same time; provided that there shall not at any time be more than a total of ten (10) Term Benchmark Borrowings and RFR Borrowings outstanding. (d) Notwithstanding any other provision of this Agreement, the Borrower shall not be entitled to request, or to elect to convert or continue, any Borrowing if the Interest Period requested with respect thereto would end after the Revolving Credit Maturity Date. (e) To the extent the Borrower directs the Administrative Agent or the Lenders to remit the proceeds of any Loans hereunder to a Person other than the Borrower, in each such case, the Borrower hereby acknowledges and agrees that (i) all Loans constitute direct obligations of the Borrower, (ii) all Loans are made for the account of the Borrower and (iii) the deposit of the proceeds of the Loans as so provided directly benefits the Borrower. SECTION 2.03. Requests for Borrowings. To request a Borrowing, the Borrower shall notify the Administrative Agent of such request by submitting a Borrowing Request signed by a Responsible Officer of the Borrower or through any Electronic System or an Approved Borrower Portal, in each case, if arrangements for doing so have been approved by the Administrative Agent, (a) in the case of a Term Benchmark Borrowing, not later than 10:00 a.m., New York City time, three U.S. Government Securities Business Days before the date of the proposed Borrowing (or, in the case of any Term Benchmark Borrowing to be made on the Effective Date, such shorter period as agreed by the Administrative Agent in its sole discretion) or (b) in the case of an ABR Borrowing, not later than 11:00 a.m., New York City time, on the date of the proposed Borrowing; provided that any such notice of an ABR Revolving Borrowing to finance the reimbursement of an LC Disbursement as contemplated by Section 2.06(e) may be given not later than 9:00 a.m., New York City time, on the date of the proposed Borrowing; provided further that, if such Borrowing Request is submitted through an Approved Borrower Portal, the foregoing signature requirement may be waived at the sole discretion of the Administrative Agent. Each such Borrowing Request shall be irrevocable. Each such Borrowing Request shall specify the following information in compliance with Section 2.02: (i) the aggregate principal amount of the requested Borrowing; (ii) the date of such Borrowing, which shall be a Business Day; (iii) whether such Borrowing is to be an ABR Borrowing or a Term Benchmark Borrowing; (iv) in the case of a Term Benchmark Borrowing, the initial Interest Period to be applicable thereto, which shall be a period contemplated by the definition of the term "Interest Period"; and 43 A (v) the location and number of the Borrower's account to which funds are to be disbursed, which shall comply with the requirements of Section 2.07, and a breakdown of the separate wires comprising such Borrowing. If no election as to the Type of Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period is specified with respect to any requested Term Benchmark Borrowing, then the Borrower shall be deemed to have selected an Interest Period of one month's duration. Promptly following receipt of a Borrowing Request in accordance with this Section, the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender's Loan to be made as part of the requested Borrowing. Notwithstanding the foregoing, in no event shall the Borrower be permitted to request an RFR Loan (it being understood and agreed that Adjusted Daily Simple SOFR shall only apply to the extent provided in Sections 2.14(a) and 2.14(f)). SECTION 2.04. [Intentionally Omitted]. SECTION 2.05. Swingline Loans. (a) Subject to the terms and conditions set forth herein, from time to time during the Availability Period, the Swingline Lender may agree, but shall have no obligation, to make Swingline Loans in dollars to the Borrower, in an aggregate principal amount at any time outstanding that will not result in (i) the aggregate principal amount of outstanding Swingline Loans exceeding \$5,000,000, (ii) the Swingline Lender's Revolving Exposure exceeding its Revolving Commitment, or (iii) the Aggregate Revolving Exposure exceeding the aggregate Revolving Commitments; provided that the Swingline Lender shall not be required to make a Swingline Loan to refinance an outstanding Swingline Loan. Within the foregoing limits and subject to the terms and conditions set forth herein, the Borrower may borrow, prepay and reborrow Swingline Loans. To request a Swingline Loan, the Borrower shall submit a written notice to the Administrative Agent of such request by fax or through any Electronic System or transmit by electronic communication including an Approved Borrower Portal, in each case, if arrangements for doing so have been approved by the Administrative Agent, not later than 12:00 noon, New York City time, on the day of a proposed Swingline Loan. Each such notice shall be in a form approved by the Administrative Agent, shall be irrevocable and shall specify the requested date (which shall be a Business Day) and amount of the requested Swingline Loan. The Administrative Agent will promptly advise the Swingline Lender of any such notice received from the Borrower. The Swingline Lender shall make each Swingline Loan available to the Borrower, to the extent the Swingline Lender elects to make such Swingline Loan, by means of a credit to the Funding Account(s) (or, in the case of a Swingline Loan made to finance the reimbursement of an LC Disbursement as provided in Section 2.06(e), by remittance to the Issuing Bank, and in the case of repayment of another Loan or fees or expenses as provided by Section 2.18(c), by remittance to the Administrative Agent to be distributed to the Lenders) by 2:00 p.m., New York City time, on the requested date of such Swingline Loan. (b) The Swingline Lender may by written notice given to the Administrative Agent require the Lenders to acquire participations on such Business Day in all or a portion of the Swingline Loans outstanding. Such notice shall specify the aggregate amount of Swingline Loans in which the Lenders will participate. Promptly upon receipt of such notice, the Administrative Agent will give notice thereof to each Lender, specifying in such notice such Lender's Applicable Percentage of such Swingline Loan or Loans. Each Lender hereby absolutely and unconditionally agrees, promptly upon receipt of such notice from the Administrative Agent (and in any event, if such notice is received by 11:00 a.m., New York City time, on a Business Day no later than 4:00 p.m., New York City time on such Business Day and if received after 11:00 a.m., New York City time, "on a Business Day" shall mean no later than 9:00 a.m., New York City 44 A time on the immediately succeeding Business Day), to pay to the Administrative Agent in dollars, for the account of the Swingline Lender, such Lender's Applicable Percentage of such Swingline Loan or Loans. Each Lender acknowledges and agrees that its obligations to acquire participations in Swingline Loans pursuant to this paragraph and to make payments in respect of such acquired participations are absolute and unconditional and shall not be affected by any circumstance whatsoever, including the occurrence and continuance of a Default or reduction or termination of the Revolving Commitments, and that each such payment shall be made without any offset, abatement, withholding or reduction whatsoever. Each Lender shall comply with its obligation under this paragraph by wire transfer in dollars of immediately available funds, in the same manner as provided in Section 2.07 with respect to Revolving Loans made by such Lender (and Section 2.07 shall apply, mutatis mutandis, to the payment obligations of the Lenders), and the Administrative Agent shall promptly pay to the Swingline Lender the amounts so received by it from the Lenders. The Administrative Agent shall notify the Borrower of any participations in any Swingline Loan acquired pursuant to this paragraph, and thereafter payments in respect of such Swingline Loan shall be made to the Administrative Agent and not to the Swingline Lender. Any amounts received by the Swingline Lender from the Borrower (or other party on behalf of the Borrower) in respect of a Swingline Loan after receipt by the Swingline Lender of the proceeds of a sale of participations therein shall be promptly remitted to the Administrative Agent; any such amounts received by the Administrative Agent shall be promptly remitted by the Administrative Agent to the Lenders that shall have made their payments pursuant to this paragraph and to the Swingline Lender, as their interests may appear; provided that any such payment so remitted shall be repaid to the Swingline Lender or to the Administrative Agent, as applicable, if and to the extent such payment is required to be refunded to the Borrower for any reason. The purchase of participations in a Swingline Loan pursuant to this paragraph shall not relieve the Borrower of any default in the payment thereof. (c) The Swingline Lender may be replaced at any time by written agreement among the Borrower, the Administrative Agent, the replaced Swingline Lender and the successor Swingline Lender. The Administrative Agent shall notify the Lenders of any such replacement of the Swingline Lender. At the time any such replacement shall become effective, the Borrower shall pay all unpaid interest accrued for the account of the replaced Swingline Lender pursuant to Section 2.13(a). From and after the effective date of any such replacement, (x) the successor Swingline Lender shall have all the rights and obligations of the replaced Swingline Lender under this Agreement with respect to Swingline Loans made thereafter and (y) references herein to the term "Swingline Lender" shall be deemed to refer to such successor or to any previous Swingline Lender, or to such successor and all previous Swingline Lenders, as the context shall require. After the replacement of the Swingline Lender hereunder, the replaced Swingline Lender shall remain a party hereto and shall continue to have all the rights and obligations of a Swingline Lender under this Agreement with respect to Swingline Loans made by it prior to its replacement, but shall not be required to make additional Swingline Loans. (d) Subject to the appointment and acceptance of a successor Swingline Lender, the Swingline Lender may resign as Swingline Lender at any time upon thirty days' prior written notice to the Administrative Agent, the Borrower and the Lenders, in which case, the Swingline Lender shall be replaced in accordance with Section 2.05(c) above. SECTION 2.06. Letters of Credit. (a) General. Subject to the terms and conditions set forth herein, the Borrower may request the issuance of, and the Issuing Bank shall issue, Letters of Credit denominated in dollars as the applicant thereof for the support of the Borrower's or its Subsidiaries' obligations, in a form reasonably acceptable to the Issuing Bank, at any time and from time to time during the Availability Period; provided that there shall not at any time be more than a total of twenty (20) Letters of Credit outstanding. 45 A (b) Notice of Issuance, Amendment, Extension; Certain Conditions. To request the issuance of a Letter of Credit (or the amendment or extension of an outstanding Letter of Credit), the Borrower shall hand deliver or fax (or transmit through any Electronic System or an Approved Borrower Portal, in each case, if arrangements for doing so have been approved by the Issuing Bank) to the Issuing Bank and the Administrative Agent (reasonably in advance of the requested date of issuance, amendment or extension, but in any event no less than three Business Days) a written notice requesting the issuance of a Letter of Credit, or identifying the Letter of Credit to be amended or extended, and specifying the date of issuance, amendment or extension (which shall be a Business Day), the date on which such Letter of Credit is to expire (which shall comply with paragraph (c) of this Section), the amount of such Letter of Credit, the name and address of the beneficiary thereof, and such other information as shall be necessary to prepare, amend or extend such Letter of Credit. In addition, as a condition to any such Letter of Credit issuance, the Borrower shall have entered into a continuing agreement (or other letter of credit agreement) for the issuance of letters of credit and/or shall submit a letter of credit application, in each case, as required by the Issuing Bank and using such Issuing Bank's standard form (each, a "Letter of Credit Agreement"). In the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of any Letter of Credit Agreement, the terms and conditions of this Agreement shall control. No Letter of Credit shall be issued, amended or extended unless (and upon issuance, amendment or extension of each Letter of Credit the Borrower shall be deemed to represent and warrant that), after giving effect to such issuance, amendment or extension (i) the aggregate LC Exposure shall not exceed \$5,000,000, (ii) no Lender's Revolving Exposure shall exceed its Revolving Commitment and (iii) the Aggregate Revolving Exposure shall not exceed the aggregate Revolving Commitments. Notwithstanding the foregoing or anything to the contrary contained herein, no Issuing Bank shall be obligated to issue or modify any Letter of Credit if, immediately after giving effect thereto, the outstanding LC Exposure in respect of all Letters of Credit issued by such Person and its Affiliates would exceed such Issuing Bank's Issuing Bank Sublimit. Without affecting the limitations contained herein, it is understood and agreed that the Borrower may from time to time request that an Issuing Bank issue Letters of Credit in excess of its individual Issuing Bank Sublimit in effect at the time of such request, and each Issuing Bank agrees to consider any such request in good faith. Any Letter of Credit so issued by an Issuing Bank in excess of its individual Issuing Bank Sublimit then in effect shall nonetheless constitute a Letter of Credit for all purposes of this Agreement, and shall not affect the Issuing Bank Sublimit of any other Issuing Bank, subject to the limitations set forth in clauses (i) through (iii) of this Section 2.06(b). The Issuing Bank shall not be under any obligation to issue, amend or extend any Letter of Credit if: (i) any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain the Issuing Bank from issuing, amending or extending such Letter of Credit, or request that the Issuing Bank refrain from issuing, amending or extending such Letter of Credit, or any Requirement of Law relating to the Issuing Bank or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the Issuing Bank shall prohibit, the issuance, amendment or extension of letters of credit generally or such Letter of Credit in particular, or any such order, judgment, decree, Requirement of Law, request or directive shall impose upon the Issuing Bank with respect to such Letter of Credit any restriction, reserve or capital or liquidity requirement (for which the Issuing Bank is not otherwise compensated hereunder) not in effect on the Effective Date, or shall impose upon the Issuing Bank any unreimbursed loss, cost or expense that was not applicable on the Effective Date and that the Issuing Bank in good faith deems material to it; or (ii) the issuance, amendment or extension of such Letter of Credit would violate one or more policies of the Issuing Bank applicable to letters of credit generally. 46 A (c) Expiration Date. Each Letter of Credit shall expire (or be subject to termination or non-extension by notice from the Issuing Bank to the beneficiary thereof) at or prior to the close of business on the earlier of (i) the date one year after the date of the issuance of such Letter of Credit (or, in the case of any extension of the expiration thereof, including, without limitation, any automatic extension provision, one year after such extension) and (ii) the date that is five Business Days prior to the Revolving Credit Maturity Date; provided that any Letter of Credit with a one-year tenor may provide for the extension thereof for additional one-year periods (which shall in no event extend beyond the date referred to in clause (ii) above). (d) Participations. By the issuance of a Letter of Credit (or an amendment to a Letter of Credit increasing the amount or extending the term thereof) and without any further action on the part of the Issuing Bank or the Lenders, the Issuing Bank hereby grants to each Lender, and each Lender hereby acquires from the Issuing Bank, a participation in such Letter of Credit equal to such Lender's Applicable Percentage of the aggregate amount available to be drawn under such Letter of Credit. In consideration and in furtherance of the foregoing, each Lender hereby absolutely and unconditionally agrees to pay to the Administrative Agent, for the account of the Issuing Bank, such Lender's Applicable Percentage of each LC Disbursement made by the Issuing Bank and not reimbursed by the Borrower on the date due as provided in paragraph (e) of this Section, or of any reimbursement payment required to be refunded to the Borrower for any reason, including after the Revolving Credit

Maturity Date. Each Lender acknowledges and agrees that its obligations to acquire participations pursuant to this paragraph in respect of Letters of Credit and to make payments in respect of such acquired participations are absolute and unconditional and shall not be affected by any circumstance whatsoever, including any amendment or extension of any Letter of Credit or the occurrence and continuance of a Default or reduction or termination of the Revolving Commitments, and that each such payment shall be made without any offset, abatement, withholding or reduction whatsoever. (e) Reimbursement. If the Issuing Bank shall make any LC Disbursement in respect of a Letter of Credit, the Borrower shall reimburse such LC Disbursement by paying to the Administrative Agent an amount equal to such LC Disbursement not later than 11:00 a.m., New York City time, on (i) the Business Day that the Borrower receives notice of such LC Disbursement, if such notice is received prior to 9:00 a.m., New York City time, on the day of receipt, or (ii) the Business Day immediately following the day that the Borrower receives such notice, if such notice is received after 9:00 a.m., New York City time, on the day of receipt; provided that, if such LC Disbursement is greater than or equal to \$1,000,000, the Borrower may, subject to the conditions to borrowing set forth herein, request in accordance with Section 2.03 or 2.05 that such payment be financed with an ABR Revolving Borrowing or Swingline Loan in an equivalent amount of such LC Disbursement and, to the extent so financed, the Borrower's obligation to make such payment shall be discharged and replaced by the resulting ABR Revolving Borrowing or Swingline Loan. If the Borrower fails to make such payment when due, the Administrative Agent shall notify each Lender of the applicable LC Disbursement, the payment then due from the Borrower in respect thereof, and such Lender's Applicable Percentage thereof. Promptly following receipt of such notice, each Lender shall pay to the Administrative Agent its Applicable Percentage of the payment then due from the Borrower, in the same manner as provided in Section 2.07 with respect to Loans made by such Lender (and Section 2.07 shall apply, mutatis mutandis, to the payment obligations of the Lenders), and the Administrative Agent shall promptly pay to the Issuing Bank the amounts so received by it from the Lenders. Promptly following receipt by the Administrative Agent of any payment from the Borrower pursuant to this paragraph, the Administrative Agent shall distribute such payment to the Issuing Bank or, to the extent that Lenders have made payments pursuant to this paragraph to reimburse the Issuing Bank, then to such Lenders and the Issuing Bank, as their interests may appear. Any payment made by a Lender pursuant to this paragraph to reimburse the Issuing Bank for any LC Disbursement (other than the funding of ABR Revolving Loans or a Swingline Loan as contemplated above) shall not constitute a Loan and shall not relieve the Borrower of its obligation to reimburse such LC Disbursement. 47 Â (f) Obligations Absolute. The Borrower's obligation to reimburse LC Disbursements as provided in paragraph (e) of this Section shall be absolute, unconditional and irrevocable, and shall be performed strictly in accordance with the terms of this Agreement under any and all circumstances whatsoever and irrespective of (i) any lack of validity or enforceability of any Letter of Credit, any Letter of Credit Agreement or this Agreement, or any term or provision therein or herein, (ii) any draft or other document presented under a Letter of Credit proving to be forged, fraudulent or invalid in any respect or any statement therein being untrue or inaccurate in any respect, (iii) any payment by the Issuing Bank under a Letter of Credit against presentation of a draft or other document that does not comply with the terms of such Letter of Credit, or (iv) any other event or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this Section, constitute a legal or equitable discharge of, or provide a right of setoff against, the Borrower's obligations hereunder. None of the Administrative Agent, the Lenders or the Issuing Bank, or any of their respective Related Parties, shall have any liability or responsibility by reason of or in connection with the issuance or transfer of any Letter of Credit, or any payment or failure to make any payment thereunder (irrespective of any of the circumstances referred to in the preceding sentence), or any error, omission, interruption, loss or delay in transmission or delivery of any draft, document, notice or other communication under or relating to any Letter of Credit (including any document required to make a drawing thereunder), any error in interpretation of technical terms, any error in translation or any consequence arising from causes beyond the control of the Issuing Bank; provided that the foregoing shall not be construed to excuse the Issuing Bank from liability to the Borrower to the extent of any direct damages (as opposed to special, indirect, consequential or punitive damages, claims in respect of which are hereby waived by the Borrower to the extent permitted by applicable law) suffered by the Borrower that are caused by the Issuing Bank's failure to exercise care when determining whether drafts and other documents presented under a Letter of Credit comply with the terms thereof. The parties hereto expressly agree that, in the absence of gross negligence or willful misconduct on the part of the Issuing Bank (as finally determined by a nonappealable judgment of a court of competent jurisdiction), the Issuing Bank shall be deemed to have exercised care in each such determination. In furtherance of the foregoing and without limiting the generality thereof, the parties agree that, with respect to documents presented which appear on their face to be in substantial compliance with the terms of a Letter of Credit, the Issuing Bank may, in its sole discretion, either accept and make payment upon such documents without responsibility for further investigation, regardless of any notice or information to the contrary, or refuse to accept and make payment upon such documents if such documents are not in strict compliance with the terms of such Letter of Credit. (g) Disbursement Procedures. The Issuing Bank for any Letter of Credit shall, within the time allowed by applicable law or the specific terms of such Letter of Credit following its receipt thereof, examine all documents purporting to represent a demand for payment under a Letter of Credit. The Issuing Bank shall promptly after such examination notify the Administrative Agent and the Borrower by telephone (confirmed by fax or through Electronic Systems) of such demand for payment and whether the Issuing Bank has made or will make an LC Disbursement thereunder; provided that such notice need not be given prior to payment by the Issuing Bank and any failure to give or delay in giving such notice shall not relieve the Borrower of its obligation to reimburse the Issuing Bank and the Lenders with respect to any such LC Disbursement. (h) Interim Interest. If the Issuing Bank shall make any LC Disbursement, then, unless the Borrower shall reimburse such LC Disbursement in full on the date such LC Disbursement is made, the unpaid amount thereof shall bear interest, for each day from and including the date such LC Disbursement is made to but excluding the date that the Borrower reimburses such LC Disbursement, at the rate per annum then applicable to ABR Revolving Loans and such interest shall be due and payable on the date when such reimbursement is due; provided that, if the Borrower fails to reimburse such LC Disbursement when due pursuant to paragraph (e) of this Section, then Section 2.13(d) shall apply. Interest accrued pursuant to this paragraph shall be for the account of the Issuing Bank, except that interest accrued on and after the date of 48 Â payment by any Lender pursuant to paragraph (e) of this Section to reimburse the Issuing Bank shall be for the account of such Lender to the extent of such payment. (i) Replacement and Resignation of the Issuing Bank. (i) The Issuing Bank may be replaced at any time by written agreement among the Borrower, the Administrative Agent, the replaced Issuing Bank and the successor Issuing Bank. The Administrative Agent shall notify the Lenders of any such replacement of the Issuing Bank. At the time any such replacement shall become effective, the Borrower shall pay all unpaid fees accrued for the account of the replaced Issuing Bank pursuant to Section 2.12(b). From and after the effective date of any such replacement, (x) the successor Issuing Bank shall have all the rights and obligations of the replaced Issuing Bank under this Agreement with respect to Letters of Credit to be issued thereafter and (y) references herein to the term "Issuing Bank" shall be deemed to refer to such successor or to any previous Issuing Bank, or to such successor and all previous Issuing Banks, as the context shall require. After the replacement of an Issuing Bank hereunder, the replaced Issuing Bank shall remain a party hereto and shall continue to have all the rights and obligations of an Issuing Bank under this Agreement with respect to Letters of Credit then outstanding and issued by it prior to such replacement, but shall not be required to issue additional Letters of Credit or extend or otherwise amend any existing Letter of Credit. (ii) Subject to the appointment and acceptance of a successor Issuing Bank, the Issuing Bank may resign as an Issuing Bank at any time upon thirty days' prior written notice to the Administrative Agent, the Borrower and the Lenders, in which case, such resigning Issuing Bank shall be replaced in accordance with Section 2.06(i)(i) above. (j) Cash Collateralization. If any Event of Default shall occur and be continuing, on the Business Day that the Borrower receives notice from the Administrative Agent or the Required Lenders (or, if the maturity of the Loans has been accelerated, Lenders with LC Exposure representing greater than 50% of the aggregate LC Exposure) demanding the deposit of cash collateral pursuant to this paragraph, the Borrower shall deposit in an account with the Administrative Agent, in the name of the Administrative Agent and for the benefit of the Lenders (the "LC Collateral Account"), an amount in cash in dollars equal to 103% of the amount of the LC Exposure as of such date plus any accrued and unpaid interest thereon; provided that the obligation to deposit such cash collateral shall become effective immediately, and such deposit shall become immediately due and payable, without demand or other notice of any kind, upon the occurrence of any Event of Default with respect to the Borrower described in clause (h) or (i) of Article VII. The Borrower also shall deposit cash collateral in accordance with this paragraph as and to the extent required by Section 2.11(b) or 2.20. Each such deposit shall be held by the Administrative Agent as collateral for the payment and performance of the Secured Obligations. In addition, and without limiting the foregoing or paragraph (c) of this Section, if any LC Exposure remains outstanding after the expiration date specified in said paragraph (c), the Borrower shall immediately deposit into the LC Collateral Account an amount in cash equal to 103% of such LC Exposure as of such date plus any accrued and unpaid interest thereon. The Administrative Agent shall have exclusive dominion and control, including the exclusive right of withdrawal, over the LC Collateral Account and the Borrower hereby grants the Administrative Agent a security interest in the LC Collateral Account and all moneys or other assets on deposit therein or credited thereto. Other than any interest earned on the investment of such deposits, which investments shall be made at the option and sole discretion of the Administrative Agent and at the Borrower's risk and expense, such deposits shall not bear interest. Interest or profits, if any, on such investments shall accumulate in such account. Moneys in such account shall be applied by the Administrative Agent to reimburse the Issuing Bank for LC Disbursements for which it has not been reimbursed, together with related fees, costs, and customary processing charges, and, to the extent not so applied, shall be held for the satisfaction of the reimbursement obligations of the Borrower for the LC Exposure at such time or, if the maturity of the Loans has been accelerated (but subject to the consent of Lenders with LC Exposure 49 Â representing greater than 50% of the aggregate LC Exposure), be applied to satisfy other Secured Obligations. If the Borrower is required to provide an amount of cash collateral hereunder as a result of the occurrence of an Event of Default, such amount (to the extent not applied as aforesaid) shall be returned to the Borrower within three (3) Business Days after all such Events of Default have been cured or waived as confirmed in writing by the Administrative Agent. (k) Issuing Bank Reports to the Administrative Agent. In the event Chase is not the only Issuing Bank, and unless otherwise agreed by the Administrative Agent, each Issuing Bank other than Chase shall, in addition to its notification obligations set forth elsewhere in this Section, report in writing to the Administrative Agent (i) periodic activity (for such period or recurrent periods as shall be requested by the Administrative Agent) in respect of Letters of Credit issued by such Issuing Bank, including all issuances, extensions and amendments, all expirations and cancellations and all disbursements and reimbursements, (ii) reasonably prior to the time that such Issuing Bank issues, amends or extends any Letter of Credit, the date of such issuance, amendment or extension, and the stated amount of the Letters of Credit issued, amended or extended by it and outstanding after giving effect to such issuance, amendment or extension (and whether the amounts thereof shall have changed), (iii) on each Business Day on which such Issuing Bank makes any LC Disbursement, the date and amount of such LC Disbursement, (iv) on any Business Day on which the Borrower fails to reimburse an LC Disbursement required to be reimbursed to such Issuing Bank on such day, the date of such failure and the amount of such LC Disbursement, and (v) on any other Business Day, such other information as the Administrative Agent shall reasonably request as to the Letters of Credit issued by such Issuing Bank. (l) Letters of Credit Issued for Account of Subsidiaries. Notwithstanding that a Letter of Credit issued or outstanding hereunder supports any obligations of, or is for the account of, a Subsidiary, or states that a Subsidiary is the "account party," "applicant," "end customer," "electing party," or the like of or for such Letter of Credit, and without derogating from any rights of the applicable Issuing Bank (whether arising by contract, at law, in equity or otherwise) against such Subsidiary in respect of such Letter of Credit, the Borrower (i) shall reimburse, indemnify and compensate the applicable Issuing Bank hereunder for such Letter of Credit (including to reimburse any and all drawings thereunder) as if such Letter of Credit had been issued solely for the account of the Borrower and (ii) irrevocably waives any and all defenses that might otherwise be available to it as a guarantor or surety of any or all of the obligations of such Subsidiary in respect of such Letter of Credit. The Borrower hereby acknowledges that the issuance of such Letters of Credit for its Subsidiaries inures to the benefit of the Borrower, and that the Borrower's business derives substantial benefits from the businesses of such Subsidiaries. SECTION 2.07. Funding of Borrowings. (a) Each Lender shall make each Loan to be made by such Lender hereunder on the proposed date thereof solely by wire transfer of immediately available funds by 1:00 p.m., New York City time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders in an amount equal to such Lender's Applicable Percentage; provided that Swingline Loans shall be made as provided in Section 2.05. The Administrative Agent will make such Loans available to the Borrower by promptly crediting the funds so received in the aforesaid account of the Administrative Agent to the Funding Account(s); provided that ABR Revolving Loans made to finance the reimbursement of an LC Disbursement as provided in Section 2.06(e) shall be remitted by the Administrative Agent to the Issuing Bank. (b) Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing that such Lender will not make available to the Administrative Agent such Lender's share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with paragraph (a) of this Section and may, in reliance upon 50 Â such assumption, make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower each severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (i) in the case of such Lender, the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation or (ii) in the case of the Borrower, the interest rate applicable to ABR Loans. If such Lender pays such amount to the Administrative Agent, then such amount shall constitute such Lender's Loan included in such Borrowing; provided, that any interest received from the Borrower by the Administrative Agent during the period beginning when Administrative Agent funded the Borrowing until such Lender pays such amount shall be solely for the account of the Administrative Agent. SECTION 2.08. Interest Elections. (a) Each Borrowing initially shall be of the Type specified in the applicable Borrowing Request and, in the case of a Term Benchmark Borrowing, shall have an initial Interest Period as specified in such Borrowing Request. Thereafter, the Borrower may elect to convert such Borrowing to a different Type or to continue such Borrowing and, in the case of a Term Benchmark Borrowing, may elect Interest Periods thereafter, all as provided in this Section. The Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Loans comprising such Borrowing, and the Loans comprising each such portion shall be considered a separate Borrowing. This Section shall not apply to Swingline Borrowings, which may not be converted or continued. (b) To make an election pursuant to this Section, the Borrower shall notify the Administrative Agent of such election either in writing (delivered by hand or fax) by delivering an Interest Election Request signed by a Responsible Officer of the Borrower or through any Electronic System or an Approved Borrower Portal, in each case, if arrangements for doing so have been approved by the Administrative Agent, by the time that a Borrowing Request would be required under Section 2.03 if the Borrower were requesting a Borrowing of the Type resulting from such election to be made on the effective date of such election; provided that, if such Interest Election Request is submitted through an Approved Borrower Portal, the foregoing signature requirement may be waived at the sole discretion of the Administrative Agent. Each such Interest Election Request shall be irrevocable. Notwithstanding any contrary provision herein, this Section shall not be construed to permit the Borrower to (i) elect an Interest Period for Term Benchmark Loans that does not comply with Section 2.02(d), or (ii) elect Adjusted Daily Simple SOFR (it being understood and agreed that Adjusted Daily Simple SOFR shall only apply to the extent provided in Sections 2.14(a) and 2.14(f)). (c) Each Interest Election Request (including requests submitted through any Electronic System) shall specify the following information in compliance with Section 2.02: (i) the Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) below shall be specified for each resulting Borrowing); (ii) the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day; 51 Â (iii) whether the resulting Borrowing is to be an ABR Borrowing or a Term Benchmark Borrowing; and (iv) if the resulting Borrowing is a Term Benchmark Borrowing, the Interest Period to be applicable thereto after giving effect to such election, which Interest Period shall be a period contemplated by the definition of the term "Interest Period." If any such Interest Election Request requests a Term Benchmark Borrowing but does not specify an Interest Period, then the Borrower shall be deemed to have selected an Interest Period of one month's duration. (d) Promptly following receipt of an Interest Election Request, the Administrative Agent shall advise each Lender of the details thereof and of such Lender's portion of each resulting Borrowing. (e) If the Borrower fails to deliver a timely Interest Election Request with respect to a Term Benchmark Borrowing prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as provided herein, at the end of such Interest Period such Borrowing shall be deemed to have an Interest Period that is one month. Notwithstanding any contrary provision hereof, if an Event of Default has occurred and is continuing and the Administrative Agent, at the request of the Required Lenders, so notifies the Borrower, then, so long as an Event of Default is continuing (i) no outstanding Borrowing may be converted to or continued as a Term Benchmark

Borrowing and (ii) unless repaid, (A) each Term Benchmark Borrowing shall be converted to an ABR Borrowing at the end of the Interest Period applicable thereto and (B) each RFR Borrowing shall be converted to an ABR Borrowing immediately. SECTION 2.09. Termination and Reduction of Revolving Commitments; Increase in Revolving Commitments; Incremental Term Loans. (a) Unless previously terminated, all the Revolving Commitments shall terminate on the Revolving Credit Maturity Date. (b) The Borrower may at any time terminate the Revolving Commitments upon the Payment in Full of the Secured Obligations. (c) The Borrower may at any time and from time to time reduce the Revolving Commitments; provided that (i) each reduction of the Revolving Commitments shall be in an amount that is an integral multiple of \$1,000,000 and not less than \$5,000,000 and (ii) the Borrower shall not terminate or reduce the Revolving Commitments if, after giving effect to any concurrent prepayment of the Revolving Loans in accordance with Section 2.11, (x) the Aggregate Revolving Exposure would exceed the aggregate Revolving Commitments or (y) the Revolving Exposure of any Lender would exceed the Revolving Commitment of such Lender. (d) The Borrower shall notify the Administrative Agent of any election to terminate or reduce the Revolving Commitments under paragraph (b) or (c) of this Section at least three (3) Business Days prior to the effective date of such termination or reduction, specifying such election and the effective date thereof. Promptly following receipt of any notice, the Administrative Agent shall advise the Lenders of the contents thereof. Each notice delivered by the Borrower pursuant to this Section shall be irrevocable; provided that a notice of termination of the Revolving Commitments delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities or other transactions specified therein, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Any termination or reduction of the Revolving Commitments shall be permanent. Each reduction of the Revolving Commitments shall be made ratably among the Lenders in accordance with their respective Revolving Commitments. 52 Å (e) The Borrower shall have the right to increase the Revolving Commitments or enter into one or more tranches of term loans (or increase any existing tranche of term loans) (each an "Incremental Term Loan"), in each case by obtaining additional Revolving Commitments or participations in such Incremental Term Loans, either from one or more of the Lenders or another lending institution (other than any Ineligible Institution), provided that (i) any such request for an increase or tranche of Incremental Term Loans shall be in a minimum amount of \$5,000,000, (ii) the Borrower may make a maximum of three (3) such requests during the term of this Agreement, (iii) after giving effect thereto, the sum of the total of the additional Revolving Commitments and Incremental Term Loans incurred pursuant to this Section 2.09 during the term of this Agreement does not exceed the greater of (A) \$35,000,000 and (B) an amount equal to 100% of Applicable EBITDA, (iv) the Administrative Agent and, only in the case of any increase in the Revolving Commitments, the Swingline Lender and the Issuing Bank have approved the identity of any such new Lender, such approvals not to be unreasonably withheld, conditioned or delayed, (v) any such new Lender assumes all of the rights and obligations of a "Lender" hereunder, and (vi) the procedures described in Section 2.09(f) have been satisfied. Nothing contained in this Section 2.09 shall constitute, or otherwise be deemed to be, a commitment on the part of any Lender to increase its Revolving Commitment or participate in any tranche of Incremental Term Loans hereunder at any time. (f) As a condition precedent to such an increase of the Revolving Commitments or tranche of Incremental Term Loans, (i) the Borrower shall deliver to the Administrative Agent a certificate of each Loan Party signed by an authorized officer of such Loan Party (A) certifying and attaching the resolutions adopted by such Loan Party approving or consenting to such increase or tranche, and (B) in the case of the Borrower, certifying as to the matters set forth in the following clause (ii), (ii) subject to Section 1.05, both before and immediately after giving effect (including giving effect on a pro forma basis) to such increase or tranche, (1) the representations and warranties contained in Article III and the other Loan Documents are true and correct in all material respects (except to the extent any representation or warranty is subject to any materiality qualifier, in which case such representation or warranty is true and correct in all respects) except to the extent that such representations and warranties specifically refer to an earlier date, such representation or warranty is true and correct in all material respects (except to the extent any representation or warranty is subject to any materiality qualifier, in which case such representation or warranty is true and correct in all respects) as of such earlier date, (2) no Default or Event of Default exists and (3) the Borrower is in compliance (on a pro forma basis) with the covenants contained in Section 6.12 (which calculations shall assume that such increase of the Revolving Commitments is fully drawn or such tranche of Incremental Term Loans is fully funded, as the case may be) and (iii) the Borrower shall deliver to the Administrative Agent legal opinions and documents consistent with those delivered on the Effective Date, to the extent requested by the Administrative Agent; provided that, subject to Section 1.05(b), in the case of any Incremental Term Loan the proceeds of which are, substantially concurrently with the receipt thereof, solely to be used by the Borrower or any Subsidiary to finance, in whole or in part, a Limited Condition Transaction, then (x) the foregoing clause (2) shall be limited to no Event of Default pursuant to clause (a), (b), (h), (i) or (m) of Article VII having occurred, being continuing or resulting therefrom, (y) the Borrower shall only be required to satisfy the requirements of the above clause (1) as of the date on which the binding agreement for such Limited Condition Transaction is entered into, and (z) the representations and warranties so given in respect of the funding of such Loan or Borrowing shall be limited to the Specified Representations. (g) On the effective date of any such increase or tranche of Incremental Term Loans, (i) any Lender increasing (or, in the case of any newly added Lender, extending) its Revolving Commitment shall make available to the Administrative Agent such amounts in immediately available funds as the Administrative Agent shall determine, for the benefit of the other Lenders, as being required in order to cause, after giving effect to such increase or addition and the use of such amounts to make payments to such other Lenders, each Lender's portion of the outstanding Revolving Loans of all the Lenders to equal its revised Applicable Percentage of such outstanding Revolving Loans, and the Administrative Agent shall 53 Å make such other adjustments among the Lenders with respect to the Revolving Loans then outstanding and amounts of principal, interest, commitment fees and other amounts paid or payable with respect thereto as shall be necessary, in the opinion of the Administrative Agent, in order to effect such reallocation and (ii) except in the case of any Incremental Term Loans, the Borrower shall be deemed to have repaid and reborrowed all outstanding Revolving Loans as of the date of any increase (or addition) in the Revolving Commitments (with such reborrowing to consist of the Types of Revolving Loans, with related Interest Periods if applicable, specified by the Borrower to the Administrative Agent). The deemed payments made pursuant to clause (ii) of the immediately preceding sentence shall be accompanied by payment of all accrued interest on the amount prepaid and, to the extent applicable, shall be subject to indemnification by the Borrower pursuant to the provisions of Section 2.16. The Incremental Term Loans (A) shall rank pari passu in right of payment with the Revolving Loans and any other tranche of Incremental Term Loans hereunder, (B) shall be evidenced by this Agreement, (C) shall not be secured by any assets other than the Collateral, (D) shall have no obligors (directly or indirectly) other than the Loan Parties, (E) shall not mature earlier than the Revolving Credit Maturity Date in effect at such time or any other maturity date applicable to any other Incremental Term Loans (if any) outstanding at such time (but may have amortization prior to such date so long as the weighted average life to maturity of any Incremental Term Loans shall be no shorter than the remaining weighted average life to maturity of any other Incremental Term Loans (if any) outstanding at such time) and (F) shall be treated substantially the same as (and in any event no more favorably than) and subject to the same terms and conditions as the Revolving Loans and any other Incremental Term Loans (if any) outstanding at such time; provided that (x) the terms and conditions applicable to any tranche of Incremental Term Loans maturing after the Revolving Credit Maturity Date (or such later maturity date applicable to any other Incremental Term Loans (if any) outstanding at such time, as the case may be) in effect at such time may provide for material additional or different financial or other covenants or prepayment requirements applicable only during periods after the Revolving Credit Maturity Date and after such later maturity date, as applicable, and (y) the Incremental Term Loans may be priced differently than the Revolving Loans and any other Incremental Term Loans (if any) outstanding at such time. (h) Subject to the foregoing conditions, any Incremental Term Loans or increase in the Revolving Commitments may be made hereunder pursuant to an amendment or restatement (an "Incremental Facility Amendment") of this Agreement and, as appropriate, the other Loan Documents, executed by the Borrower, each Lender participating in such tranche and the Administrative Agent. The Incremental Facility Amendment may, without the consent of any other Lenders, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate, in the reasonable opinion of the Administrative Agent, to effect the provisions of this Section 2.09 and reflect the applicable Incremental Term Loans and increase in the Revolving Commitments. Within a reasonable time after the effective date of any increase or addition, the Administrative Agent shall, and is hereby authorized and directed to, revise the Commitment Schedule to reflect such increase or addition and shall distribute such revised Commitment Schedule to each of the Lenders and the Borrower, whereupon such revised Commitment Schedule shall replace the old Commitment Schedule and become part of this Agreement. (i) In connection with any increase of the Revolving Commitments or Incremental Term Loans pursuant to this Section 2.09, any new lending institution becoming a party hereto shall (i) execute such documents and agreements as the Administrative Agent may reasonably request and (ii) provide to the Administrative Agent, its name, address, tax identification number and/or such other information as shall be necessary for the Administrative Agent to comply with "know your customer" and anti-money laundering rules and regulations, including without limitation, the USA PATRIOT Act. SECTION 2.10. Repayment of Loans; Evidence of Debt. 54 Å (a) The Borrower hereby unconditionally promises to pay in dollars (i) to the Administrative Agent for the account of each Lender the then unpaid principal amount of each Revolving Loan on the Revolving Credit Maturity Date, and (ii) to the Swingline Lender the then unpaid principal amount of each Swingline Loan on the earlier of the Revolving Credit Maturity Date and the fifth Business Day after such Swingline Loan is made; provided that on each date that a Revolving Loan is made, the Borrower shall repay all Swingline Loans then outstanding and the proceeds of any such Revolving Loan shall be applied by the Administrative Agent to repay any Swingline Loans outstanding. (b) Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the Indebtedness of the Borrower to such Lender resulting from each Loan made by such Lender, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder. (c) The Administrative Agent shall maintain accounts in which it shall record (i) the amount of each Loan made hereunder, the Type thereof and the Interest Period applicable thereto, if any, (ii) the amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent hereunder for the account of the Lenders and each Lender's share thereof. (d) The entries made in the accounts maintained pursuant to paragraph (b) or (c) of this Section shall be prima facie evidence of the existence and amounts of the obligations recorded therein; provided that the failure of any Lender or the Administrative Agent to maintain such accounts or any error therein shall not in any manner affect the Obligations. (e) Any Lender may request that Loans made by it be evidenced by a promissory note. In such event, the Borrower shall prepare, execute and deliver to such Lender a promissory note payable to such Lender (or, if requested by such Lender, to such Lender and its registered assigns) and in a form approved by the Administrative Agent. Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times (including after assignment pursuant to Section 9.04) be represented by one or more promissory notes in such form. SECTION 2.11. Prepayment of Loans. (a) The Borrower shall have the right at any time and from time to time to prepay any Borrowing in whole or in part, subject to prior notice in accordance with paragraph (c) of this Section and, if applicable, payment of any break funding expenses under Section 2.16. (b) In the event and on such occasion that the Aggregate Revolving Exposure exceeds the aggregate Revolving Commitments, the Borrower shall prepay the Revolving Loans, LC Exposure and/or Swingline Loans (or, if no such Borrowings are outstanding, deposit cash collateral in the LC Collateral Account in an aggregate amount equal to such excess, in accordance with Section 2.06(j)) in an aggregate principal amount sufficient to cause the aggregate principal amount of all Revolving Exposures to be less than or equal to the aggregate Revolving Commitments. (c) The Borrower shall notify the Administrative Agent (and, in the case of prepayment of a Swingline Loan, the Swingline Lender) by fax or through any Electronic System or an Approved Borrower Portal, in each case, if arrangements for doing so have been approved by the Administrative Agent, of any prepayment under this Section: (i) in the case of prepayment of a Term Benchmark Borrowing, not later than 10:00 a.m., New York City time, three (3) U.S. Government Securities Business Days before the date of prepayment, (ii) in the case of an RFR Borrowing, not later than 10:00 a.m., New York City time, five (5) U.S. Government Securities Business Days before the date of prepayment, (iii) in the case of prepayment 55 Å of an ABR Revolving Borrowing (other than a Swingline Loan), not later than 10:00 a.m., New York City time, on the date of prepayment or (iv) in the case of prepayment of a Swingline Loan, not later than 11:00 a.m., New York City time, on the date of prepayment. Each such notice shall be irrevocable and shall specify the prepayment date and the principal amount of each Borrowing or portion thereof to be prepaid; provided that if a notice of prepayment is given in connection with a conditional notice of termination of the Revolving Commitments as contemplated by Section 2.09, then such notice of prepayment may be revoked if such notice of termination is revoked in accordance with Section 2.09. Promptly following receipt of any such notice, the Administrative Agent shall advise the Lenders of the contents thereof. Each partial prepayment of any Borrowing shall be in an amount that would be permitted in the case of an advance of a Borrowing of the same Type as provided in Section 2.02 (or, in the case of any RFR Loan, in such amount that would be permitted in the case of an advance of an ABR Revolving Borrowing as provided in Section 2.02), except as necessary to apply fully the required amount of a mandatory prepayment. Each prepayment of a Borrowing shall be applied ratably to the Loans included in the prepaid Borrowing. Prepayments shall be accompanied by (i) accrued interest to the extent required by Section 2.13 and (ii) break funding payments pursuant to Section 2.16. SECTION 2.12. Fees. (a) The Borrower agrees to pay to the Administrative Agent a commitment fee for the account of each Lender, which shall accrue at the Commitment Fee Rate on the daily amount of the undrawn portion of the Revolving Commitment of such Lender during the period from and including the Effective Date to but excluding the date on which the Lender's Revolving Commitments terminate; it being understood that the LC Exposure of a Lender shall be included and the Swingline Exposure of a Lender shall be excluded in the drawn portion of the Revolving Commitment of such Lender for purposes of calculating the commitment fee; provided that, if such Lender continues to have any Revolving Exposure after its Revolving Commitment terminates, then such commitment fee shall continue to accrue on the daily amount of such Lender's Revolving Exposure from and including the date on which its Revolving Commitment terminates to but excluding the date on which such Lender ceases to have any Revolving Exposure. Commitment fees accrued through and including the last day of March, June, September and December of each year shall be payable in arrears on the fifteenth (15th) day following such last day and on the date on which the Revolving Commitments terminate, commencing on the first such date to occur after the date hereof; provided that any commitment fees accruing after the date on which the Revolving Commitments terminate shall be payable on demand. All commitment fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day and last day of each period but excluding the date on which the Revolving Commitments terminate). (b) The Borrower agrees to pay (i) to the Administrative Agent for the account of each Lender a participation fee with respect to its participations in each outstanding Letter of Credit, which shall accrue on the daily maximum stated amount then available to be drawn under such Letter of Credit at the same Applicable Rate used to determine the interest rate applicable to Term Benchmark Revolving Loans, during the period from and including the Effective Date to but excluding the later of the date on which such Lender's Revolving Commitment terminates and the date on which such Lender ceases to have any LC Exposure, and (ii) to the Issuing Bank for its own account a fronting fee, which shall accrue at the rate or rates per annum separately agreed upon between the Borrower and the Issuing Bank on the daily maximum stated amount then available to be drawn under each outstanding Letter of Credit, during the period from and including the Effective Date to but excluding the later of the date of termination of the Revolving Commitments and the date on which there ceases to be any LC Exposure, as well as the Issuing Bank's standard fees and commissions with respect to the issuance, amendment, cancellation, negotiation, transfer, presentment or extension of any Letter of Credit and other processing fees, and other standard costs and charges, of the Issuing Bank relating to Letters of Credit as from time to time in effect. Participation fees and fronting fees accrued through and including the last day of each March, June, September and December 56 Å of each year shall be payable on the fifteenth (15th) day following such last day, commencing on the first such date to occur after the Effective Date; provided that all such fees shall be payable on the date on which the Revolving Commitments terminate and any such fees accruing after the date on which the Revolving Commitments terminate shall be payable on demand. Any other fees payable to the Issuing Bank pursuant to this paragraph shall be payable within ten (10) days after demand. All participation fees and fronting fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day). (c) The Borrower agrees to pay to the Administrative Agent, for its own account, fees payable in the amounts and at the times separately agreed upon between the Borrower and the Administrative Agent. (d) All fees payable hereunder shall be paid in dollars on the dates due, in immediately available funds, to the Administrative Agent (or to the Issuing Bank, in the case of fees payable to it) for distribution, in the case of commitment fees and participation fees, to the Lenders entitled thereto. Fees paid shall not be refundable under any circumstances. SECTION 2.13. Interest. (a) The Loans comprising each ABR Borrowing (including each Swingline Loan) shall bear interest at the Alternate Base Rate plus the Applicable Rate. (b) The Loans comprising each Term Benchmark Borrowing shall bear interest at the Adjusted Term SOFR Rate for the Interest Period in effect for such Borrowing plus the Applicable Rate. (c) Each RFR Loan shall bear interest at a rate per annum equal to the Adjusted Daily Simple SOFR plus the Applicable Rate. (d) Notwithstanding the foregoing, (i) except as provided in the following clause (d)(ii), during the occurrence and continuance of an Event of Default, the Administrative Agent or the Required

Lenders may, at their option, by notice to the Borrower (which notice may be revoked at the option of the Required Lenders notwithstanding any provision of Section 9.02 requiring the consent of each Lender directly affected thereby for reductions in interest rates), declare that, or (ii) automatically, without any notice or other action from any party hereto, upon the occurrence of an Event of Default with respect to the Borrower described in clause (h) or (i) of Article VII, then, in each case, (A) all Loans shall bear interest at a rate per annum equal to 2% plus the rate otherwise applicable to such Loans as provided in the preceding paragraphs of this Section and (B) in the case of any other amount outstanding hereunder, such amount shall accrue interest at a rate per annum equal to 2% plus the rate applicable to ABR Loans as provided in Section 2.13(a). (e) Accrued interest on each Loan (for ABR Loans, accrued through the last day of the prior calendar month) shall be payable in arrears on each Interest Payment Date for such Loan and, in the case of Revolving Loans, upon termination of the Revolving Commitments; provided that (i) interest accrued pursuant to paragraph (d) of this Section shall be payable on demand, (ii) in the event of any repayment or prepayment of any Loan (other than a prepayment of an ABR Revolving Loan prior to the end of the Availability Period), accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment and (iii) in the event of any conversion of any Term Benchmark Loan prior to the end of the current Interest Period thereof, accrued interest on such Loan shall be payable on the effective date of such conversion. (f) All interest hereunder shall be computed on the basis of a year of 360 days, except that interest computed by reference to the Alternate Base Rate only at times when the Alternate Base Rate is 57 1/8 based on the Prime Rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. Any determination of the applicable Alternate Base Rate, Adjusted Term SOFR Rate, Term SOFR Rate, Adjusted Daily Simple SOFR or Daily Simple SOFR shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error. SECTION 2.14. Alternate Rate of Interest. (a) Subject to clauses (b), (c), (d), (e) and (f) of this Section 2.14, if: (i) the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) (A) prior to the commencement of any Interest Period for a Term Benchmark Borrowing that adequate and reasonable means do not exist for ascertaining the Adjusted Term SOFR Rate (including, without limitation, because the Term SOFR Reference Rate is not available or published on a current basis), for such Interest Period or (B) at any time, that adequate and reasonable means do not exist for ascertaining the applicable Adjusted Daily Simple SOFR for an RFR Loan; or (ii) the Administrative Agent is advised by the Required Lenders that (A) prior to the commencement of any Interest Period for a Term Benchmark Borrowing, the Adjusted Term SOFR Rate for the applicable Interest Period will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining their Loans (or Loan) included in such Borrowing for such Interest Period, or (B) at any time, the applicable Adjusted Daily Simple SOFR for an RFR Loan will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining their Loans (or its Loan) included in such Borrowing; then the Administrative Agent shall give notice thereof to the Borrower and the Lenders through any Electronic System as provided in Section 9.01 as promptly as practicable thereafter and, until (x) the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist with respect to the relevant Benchmark and (y) the Borrower delivers a new Interest Election Request in accordance with the terms of Section 2.08 or a new Borrowing Request in accordance with the terms of Section 2.03, (A) any Interest Election Request that requests the conversion of any Borrowing to, or continuation of any Borrowing as, a Term Benchmark Borrowing and any Borrowing Request that requests a Term Benchmark Borrowing shall instead be deemed to be an Interest Election Request or a Borrowing Request, as applicable, for (1) an RFR Borrowing so long as the Adjusted Daily Simple SOFR is not also the subject of Section 2.14(a)(i) or (ii) above or (2) an ABR Borrowing if the Adjusted Daily Simple SOFR also is the subject of Section 2.14(a)(i) or (ii) above, and (B) any outstanding RFR Borrowing shall be converted to an ABR Borrowing at such time. Furthermore, if any Term Benchmark Loan or RFR Loan is outstanding on the date of the Borrower's receipt of the notice from the Administrative Agent referred to in this Section 2.14(a) with respect to a Relevant Rate applicable to such Term Benchmark Loan or RFR Loan, then until (x) the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist with respect to the relevant Benchmark and (y) the Borrower delivers a new Interest Election Request in accordance with the terms of Section 2.08 or a new Borrowing Request in accordance with the terms of Section 2.03, (1) any Term Benchmark Loan shall on the last day of the Interest Period applicable to such Loan, be converted by the Administrative Agent to, and shall constitute, (x) an RFR Borrowing so long as the Adjusted Daily Simple SOFR is not also the subject of Section 2.14(a)(i) or (ii) above or (y) an ABR Loan if the Adjusted Daily Simple SOFR also is the subject of Section 2.14(a)(i) or (ii) above, on such day, and (2) any RFR Loan shall on and from such day be converted by the Administrative Agent to, and shall constitute, an ABR Loan. 58 A (b) Notwithstanding anything to the contrary herein or in any other Loan Document (and any Swap Agreement shall be deemed not to be a Loan Document for purposes of this Section 2.14), if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (1) of the definition of "Benchmark Replacement" for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark (including any related adjustments) for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (2) of the definition of "Benchmark Replacement" for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders. (c) Notwithstanding anything to the contrary herein or in any other Loan Document, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. (d) The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any occurrence of a Benchmark Transition Event, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes, (iv) the removal or reinstatement of any tenor of a Benchmark pursuant to Section 2.14(e) and (v) the commencement or conclusion of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.14, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.14. (e) Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Rate) and either (A) solely with respect to any such request for a Term Benchmark Borrowing, any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is or will be no longer representative, then the Administrative Agent may modify the definition of "Interest Period" for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of "Interest Period" for all Benchmark settings at or after such time to reinstate such previously removed tenor. 59 A (f) Upon the Borrower's receipt of notice of the commencement of a Benchmark Unavailability Period with respect to any Relevant Rate, (i) in the case of a Term Benchmark Borrowing, the Borrower may revoke any request for a Term Benchmark Borrowing of, conversion to or continuation of Term Benchmark Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to (A) an RFR Borrowing so long as the Adjusted Daily Simple SOFR is not the subject of a Benchmark Transition Event or (B) an ABR Borrowing if the Adjusted Daily Simple SOFR is the subject of a Benchmark Transition Event, and (ii) in the case of any outstanding RFR Borrowing, such Borrowing shall on and from such day be converted by the Administrative Agent to, and shall constitute, an ABR Loan. During any Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of ABR based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of ABR. Furthermore, if any Term Benchmark Loan or RFR Loan is outstanding on the date of the Borrower's receipt of notice of the commencement of a Benchmark Unavailability Period with respect to a Relevant Rate applicable to such Term Benchmark Loan or RFR Loan, then until such time as a Benchmark Replacement is implemented pursuant to this Section 2.14, (1) any Term Benchmark Loan shall on the last day of the Interest Period applicable to such Loan, be converted by the Administrative Agent to, and shall constitute, (x) an RFR Borrowing so long as the Adjusted Daily Simple SOFR is not the subject of a Benchmark Transition Event or (y) an ABR Loan if the Adjusted Daily Simple SOFR is the subject of a Benchmark Transition Event, on such day and (2) any RFR Loan shall on and from such day be converted by the Administrative Agent to, and shall constitute, an ABR Loan. SECTION 2.15. Increased Costs. (a) If any Change in Law shall: (i) impose, modify or deem applicable any reserve, special deposit, liquidity or similar requirement (including any compulsory loan requirement, insurance charge or other assessment) against assets of, deposits with or for the account of, or credit extended by, any Lender or the Issuing Bank; or (ii) impose on any Lender or the Issuing Bank or the applicable interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender or any Letter of Credit or participation therein; or (iii) subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; and the result of any of the foregoing shall be to increase the cost to such Lender, the Issuing Bank or such other Recipient of making, continuing, converting into or maintaining any Loan (or of maintaining its obligation to make any such Loan) or to increase the cost to such Lender, the Issuing Bank or such other Recipient of participating in, issuing or maintaining any Letter of Credit or to reduce the amount of any sum received or receivable by such Lender, the Issuing Bank or such other Recipient hereunder (whether of principal, interest or otherwise), then the Borrower will pay to such Lender, the Issuing Bank or such other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender, the Issuing Bank or such other Recipient, as the case may be, for such additional costs incurred or reduction suffered. 60 A (b) If any Lender or the Issuing Bank determines that any Change in Law regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender's or the Issuing Bank's capital or on the capital of such Lender's or the Issuing Bank's holding company, if any, as a consequence of this Agreement, the Revolving Commitments of or the Loans made by, or participations in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by the Issuing Bank, to a level below that which such Lender or the Issuing Bank or such Lender's or the Issuing Bank's holding company could have achieved but for such Change in Law (taking into consideration such Lender's or the Issuing Bank's policies and the policies of such Lender's or the Issuing Bank's holding company with respect to capital adequacy and liquidity), then from time to time the Borrower will pay to such Lender or the Issuing Bank, as the case may be, such additional amount or amounts as will compensate such Lender or the Issuing Bank or such Lender's or the Issuing Bank's holding company for any such reduction suffered. (c) A certificate of a Lender or the Issuing Bank setting forth the amount or amounts necessary to compensate such Lender or the Issuing Bank or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender or the Issuing Bank, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof. (d) Failure or delay on the part of any Lender or the Issuing Bank to demand compensation pursuant to this Section shall not constitute a waiver of such Lender's or the Issuing Bank's right to demand such compensation; provided that the Borrower shall not be required to compensate a Lender or the Issuing Bank pursuant to this Section for any increased costs or reductions incurred more than 270 days prior to the date that such Lender or the Issuing Bank, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender's or the Issuing Bank's intention to claim compensation therefor; provided further that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 270-day period referred to above shall be extended to include the period of retroactive effect thereof. SECTION 2.16. Break Funding Payments. (a) With respect to Loans that are not RFR Loans, in the event of (i) the payment of any principal of any Term Benchmark Loan other than on the last day of an Interest Period applicable thereto (including as a result of an Event of Default or as a result of any optional or mandatory prepayment of Loans), (ii) the conversion of any Term Benchmark Loan other than on the last day of the Interest Period applicable thereto, (iii) the failure to borrow, convert, continue or prepay any Term Benchmark Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under Section 2.09(d) and is revoked in accordance therewith), or (iv) the assignment of any Term Benchmark Loan other than on the last day of the Interest Period applicable thereto as a result of a request by the Borrower pursuant to Section 2.19 or 9.02(d), then, in any such event, the Borrower shall compensate each Lender for the loss, cost and expense attributable to such event. (b) With respect to RFR Loans, in the event of (i) the payment of any principal of any RFR Loan other than on the Interest Payment Date applicable thereto (including as a result of an Event of Default or an optional or mandatory prepayment of Loans), (ii) the failure to borrow or prepay any RFR Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under Section 2.09(d) and is revoked in accordance therewith), or (iii) the assignment of any RFR Loan other than on the Interest Payment Date applicable thereto as a result of a request by the Borrower pursuant to Section 2.19 or 9.02(d), then, in any such event, the Borrower shall compensate each Lender for the loss, cost and expense attributable to such event. 61 A (c) A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section 2.16 shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof. SECTION 2.17. Taxes. (a) Withholding of Taxes; Gross-Up; Payments Free of Taxes. Any and all payments by or on account of any obligation of any Loan Party under any Loan Document (including, without limitation, the Secured Obligations and Guaranteed Obligations of each Loan Party) shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable withholding agent) requires the deduction or withholding of any Tax from any such payment by a withholding agent, then the applicable withholding agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the applicable Loan Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2.17), the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made. (b) Payment of Other Taxes by Loan Parties. The Loan Parties shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for, Other Taxes. (c) Evidence of Payment. As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority pursuant to this Section 2.17, such Loan Party shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment, or other evidence of such payment reasonably satisfactory to the Administrative Agent. (d) Indemnification by the Loan Parties. The Loan Parties shall jointly and severally indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Loan Party by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. (e) Indemnification by the Lenders. Each Lender shall severally indemnify the Administrative Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that any Loan Party has not already

indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Parties to do so), (ii) any Taxes attributable to such Lender's failure to comply with the provisions of Section 9.04(c) relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all 62 A amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to such Lender from any other source against any amount due to the Administrative Agent under this paragraph (e). (f) Status of Lenders. (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 2.17(f)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender's reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. (ii) Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person, (A) any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), an executed copy of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax; (B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable: (1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the U.S. is a party (x) with respect to payments of interest under any Loan Document, an executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the "interest" article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the "business profits" or "other income" article of such tax treaty; (2) in the case of a Foreign Lender claiming that its extension of credit will generate U.S. effectively connected income, an executed copy of IRS Form W-8ECI; (3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit D-1 to the effect that such Foreign Lender is not a "bank" within the meaning of Section 881(c)(3)(A) of the Code, a 10 percent shareholder of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a "controlled foreign corporation" described in Section 881(c)(3)(C) of the Code (a "U.S. Tax Compliance Certificate") and (y) an executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable; or (4) to the extent a Foreign Lender is not the beneficial owner, an executed copy of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, a U.S. Tax Compliance Certificate substantially in the form of Exhibit D-2 or Exhibit D-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit D-4 on behalf of each such direct and indirect partner; (C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and (D) if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender's obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), "FATCA" shall include any amendments made to FATCA after the date of this Agreement. Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so. (g) Treatment of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.17 (including by the payment of additional amounts pursuant to this Section 2.17), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section 2.17 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to 64 A this paragraph (g) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (g) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts giving rise to such refund had never been paid. This paragraph (g) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. (h) Survival. Each party's obligations under this Section 2.17 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Revolving Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document (including the Payment in Full of the Secured Obligations). (i) Defined Terms. For purposes of this Section 2.17, the term "applicable law" includes FATCA. SECTION 2.18. Payments Generally; Allocation of Proceeds; Sharing of Set-offs. (a) Each Loan Party shall make each payment or prepayment required to be made by it hereunder (whether of principal, interest, fees or reimbursement of LC Disbursements, or of amounts payable under Sections 2.15, 2.16 or 2.17, or otherwise) prior to 2:00 p.m., New York City time, on the date when due or the date fixed for any prepayment hereunder, in immediately available funds, without setoff, recoupment or counterclaim. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the Administrative Agent at its offices at 10 S. Dearborn St., Chicago IL 60603, except payments to be made directly to the Issuing Bank or Swingline Lender as expressly provided herein and except that payments pursuant to Sections 2.15, 2.16, 2.17 and 9.03 shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following receipt thereof. Unless otherwise provided for herein, if any payment hereunder shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension. All payments hereunder shall be made in dollars. (b) All payments and any proceeds of Collateral received by the Administrative Agent (i) not constituting either (A) a specific payment of principal, interest, fees or other sum payable under the Loan Documents (which shall be applied as specified by the Borrower) or (B) a mandatory prepayment (which shall be applied in accordance with Section 2.11) or (ii) after an Event of Default has occurred and is continuing and the Administrative Agent so elects or the Required Lenders so direct, in each case, shall be applied first, to pay any fees, indemnities, or expense reimbursements including amounts then due to the Administrative Agent, the Swingline Lender and the Issuing Bank from the Borrower (other than in connection with Banking Services Obligations or Swap Agreement Obligations), ratably, second, to pay any fees, indemnities or expense reimbursements then due to the Lenders from the Loan Parties (other than in connection with Banking Services Obligations or Swap Agreement Obligations), ratably, third, to pay interest then due and payable on the Loans ratably, fourth, to prepay principal on the Loans and unreimbursed LC Disbursements, to pay an amount to the Administrative Agent equal to one hundred three percent (103%) of the aggregate LC Exposure, to be held as cash collateral for such Obligations, and to pay any amounts owing in respect of Swap Agreement Obligations and Banking Services Obligations up to and 65 A including the amount most recently provided to the Administrative Agent pursuant to Section 2.22, ratably, and fifth, to the payment of any other Secured Obligation due to the Administrative Agent or any Lender from the Borrower or any other Loan Party, ratably. Notwithstanding the foregoing, amounts received from any Loan Party shall not be applied to any Excluded Swap Obligation of such Loan Party. Notwithstanding anything to the contrary contained in this Agreement, unless so directed by the Borrower, or unless a Default is in existence, neither the Administrative Agent nor any Lender shall apply any payment which it receives to any Term Benchmark Loan, except (i) on the expiration date of the Interest Period applicable thereto, or (ii) in the event, and only to the extent, that there are no outstanding ABR Loans and, in any such event, the Borrower shall pay the break funding payment required in accordance with Section 2.16. The Administrative Agent and the Lenders shall have the continuing and exclusive right to apply and reverse and reapply any and all such proceeds and payments to any portion of the Secured Obligations. Notwithstanding the foregoing, Secured Obligations arising under Banking Services Obligations or Swap Agreement Obligations shall be excluded from the application described above and paid in clause fifth if the Administrative Agent has not received written notice thereof, together with such supporting documentation as the Administrative Agent may have reasonably requested from the applicable provider of such Banking Services or Swap Agreements. (c) At the election of the Administrative Agent, all payments of principal, interest, LC Disbursements, fees, premiums, reimbursable expenses (including, without limitation, all reimbursement for fees, costs and expenses pursuant to Section 9.03), and other sums payable under the Loan Documents, may be paid from the proceeds of Borrowings made hereunder, whether made following a request by the Borrower pursuant to Section 2.03 or 2.05 or a deemed request as provided in this Section or may be deducted from any deposit account of the Borrower maintained with the Administrative Agent. The Borrower hereby irrevocably authorizes (i) the Administrative Agent to make a Borrowing for the purpose of paying each payment of principal, interest and fees as it becomes due hereunder or any other amount due under the Loan Documents and agrees that all such amounts charged shall constitute Loans (including Swingline Loans), and that all such Borrowings shall be deemed to have been requested pursuant to Section 2.03 or 2.05, as applicable, and (ii) the Administrative Agent to charge any deposit account of the Borrower maintained with the Administrative Agent for each payment of principal, interest and fees as it becomes due hereunder or any other amount due under the Loan Documents. (d) If, except as otherwise expressly provided herein, any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal or of interest on any of its Loans or participations in LC Disbursements or Swingline Loans resulting in such Lender receiving payment of a greater proportion of the aggregate amount of its Loans and participations in LC Disbursements and Swingline Loans and accrued interest thereon than the proportion received by any other similarly situated Lender, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Loans and participations in LC Disbursements and Swingline Loans of other Lenders to the extent necessary so that the benefit of all such payments shall be shared by all such Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and participations in LC Disbursements and Swingline Loans; provided that (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this paragraph shall not be construed to apply to any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or any payment obtained by a Lender as consideration for the assignment or sale of a participation in any of its Loans or participations in LC Disbursements or Swingline Loans to any assignee or participant, other than to the Borrower or any Subsidiary or Affiliate thereof (as to which the provisions of this paragraph shall apply). The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against 66 A the Borrower rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower in the amount of such participation. This Section 2.18(d) shall not apply to any action taken by any Farm Credit Lender with respect to any Farm Credit Equity held by the Borrower. (e) Unless the Administrative Agent shall have received, prior to any date on which any payment is due to the Administrative Agent for the account of the relevant Lenders or the Issuing Bank pursuant to the terms hereof or any other Loan Document (including any date that is fixed for prepayment by notice from the Borrower to the Administrative Agent pursuant to Section 2.11(c)), notice from the Borrower that the Borrower will not make such payment or prepayment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Bank, as the case may be, the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders or the Issuing Bank, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or Issuing Bank with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. (f) The Administrative Agent may from time to time provide the Borrower with account statements or invoices with respect to any of the Secured Obligations (the "Statements"). The Administrative Agent is under no duty or obligation to provide Statements, which, if provided, will be solely for the Borrower's convenience. Statements may contain estimates of the amounts owed during the relevant billing period, whether of principal, interest, fees or other Secured Obligations. If the Borrower pays the full amount indicated on a Statement on or before the due date indicated on such Statement, the Borrower shall not be in default of payment with respect to the billing period indicated on such Statement; provided, that acceptance by the Administrative Agent, on behalf of the Lenders, of any payment that is less than the total amount actually due at that time (including but not limited to any past due amounts) shall not constitute a waiver of the Administrative Agent's or the Lenders' right to receive payment in full at another time. SECTION 2.19. Mitigation Obligations; Replacement of Lenders. (a) If any Lender requests compensation under Section 2.15, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or Affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.15 or 2.17, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. (b) If any Lender requests compensation under Section 2.15, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17, or if any Lender becomes a Defaulting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in Section 9.04), all its interests, rights (other than its existing rights to payments pursuant to Section 2.15 or 2.17) and obligations under this Agreement and other Loan Documents to an 67 A assignee (other than any Ineligible Institution) that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that (i) the Borrower shall have

received the prior written consent of the Administrative Agent (and in circumstances where its consent would be required under Section 9.04, the Issuing Bank and the Swingline Lender), which consent shall not unreasonably be withheld, conditioned or delayed, (ii) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and participations in LC Disbursements and Swingline Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts) and (iii) in the case of any such assignment resulting from a claim for compensation under Section 2.15 or payments required to be made pursuant to Section 2.17, such assignment will result in a reduction in such compensation or payments. A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. Each party hereto agrees that (x) an assignment required pursuant to this paragraph may be effected pursuant to an Assignment and Assumption executed by the Borrower, the Administrative Agent and the assignee (or, to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and such parties are participants), and (y) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to and be bound by the terms thereof; provided that, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender, provided that any such documents shall be without recourse to or warranty by the parties thereto. SECTION 2.20. Defaulting Lenders. Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender: (a) fees shall cease to accrue on the Unfunded Revolving Commitment of such Defaulting Lender pursuant to Section 2.12(a); (b) any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 2.18(b) or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 9.08 shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the Issuing Bank or Swingline Lender hereunder; third, to cash collateralize the LC Exposure with respect to such Defaulting Lender in accordance with this Section; fourth, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower, to be held in a deposit account and released pro rata in order to (x) satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Agreement and (y) cash collateralize the future LC Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Agreement, in accordance with this Section; sixth, to the payment of any amounts owing to the Lenders, the Issuing Bank or Swingline Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, the Issuing Bank or Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement or under any other Loan Document; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower 68 Å against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement or under any other Loan Document; and eighth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans or LC Disbursements in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in Section 4.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and LC Disbursements owed to, all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or LC Disbursements owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in the Borrower’s obligations corresponding to such Defaulting Lender’s LC Exposure and Swingline Loans are held by the Lenders pro rata in accordance with the Revolving Commitments without giving effect to clause (d) below. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post cash collateral pursuant to this Section shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto; (c) such Defaulting Lender shall not have the right to vote on any issue on which voting is required (other than to the extent expressly provided in Section 9.02(b)) and the Revolving Commitment and Revolving Exposure of such Defaulting Lender shall not be included in determining whether the Required Lenders have taken or may take any action hereunder or under any other Loan Document; provided that, except as otherwise provided in Section 9.02, this clause (c) shall not apply to the vote of a Defaulting Lender in the case of an amendment, waiver or other modification requiring the consent of such Lender or each Lender directly affected thereby; (d) if any Swingline Exposure or LC Exposure exists at the time such Lender becomes a Defaulting Lender then: (i) all or any part of the Swingline Exposure and LC Exposure of such Defaulting Lender (other than, in the case of a Defaulting Lender that is a Swingline Lender, the portion of such Swingline Exposure referred to in clause (b) of the definition of such term) shall be reallocated among the non-Defaulting Lenders in accordance with their respective Applicable Percentages but only to the extent that such reallocation does not, as to any non-Defaulting Lender, cause such non-Defaulting Lender’s Revolving Exposure to exceed its Revolving Commitment; (ii) if the reallocation described in clause (i) above cannot, or can only partially, be effected, the Borrower shall within one (1) Business Day following notice by the Administrative Agent (x) first, prepay such Swingline Exposure and (y) second, cash collateralize, for the benefit of the Issuing Bank, the Borrower’s obligations corresponding to such Defaulting Lender’s LC Exposure (after giving effect to any partial reallocation pursuant to clause (i) above) in accordance with the procedures set forth in Section 2.06(j) for so long as such LC Exposure is outstanding; (iii) if the Borrower cash collateralizes any portion of such Defaulting Lender’s LC Exposure pursuant to clause (ii) above, the Borrower shall not be required to pay any fees to such Defaulting Lender pursuant to Section 2.12(b) with respect to such Defaulting Lender’s LC Exposure during the period such Defaulting Lender’s LC Exposure is cash collateralized; (iv) if the LC Exposure of the non-Defaulting Lenders is reallocated pursuant to clause (i) above, then the fees payable to the Lenders pursuant to Sections 2.12(a) and 2.12(b) shall be adjusted in accordance with such non-Defaulting Lenders’ Applicable Percentages; and (v) if all or any portion of such Defaulting Lender’s LC Exposure is neither reallocated nor cash collateralized pursuant to clause (i) or (ii) above, then, without prejudice to any rights or 69 Å remedies of the Issuing Bank or any other Lender hereunder, all letter of credit fees payable under Section 2.12(b) with respect to such Defaulting Lender’s LC Exposure shall be payable to the Issuing Bank until and to the extent that such LC Exposure is reallocated and/or cash collateralized; and (e) so long as such Lender is a Defaulting Lender, the Swingline Lender shall not be required to fund any Swingline Loan and the Issuing Bank shall not be required to issue, amend, renew, extend or increase any Letter of Credit, unless it is satisfied that the related exposure and such Defaulting Lender’s then outstanding LC Exposure will be 100% covered by the Revolving Commitments of the non-Defaulting Lenders and/or cash collateral will be provided by the Borrower in accordance with Section 2.20(d), and Swingline Exposure related to any such newly made Swingline Loan or LC Exposure related to any newly issued or increased Letter of Credit shall be allocated among non-Defaulting Lenders in a manner consistent with Section 2.20(d)(i) (and such Defaulting Lender shall not participate therein). If (i) a Bankruptcy Event or a Bail-In Action with respect to the Parent of any Lender shall occur following the date hereof and for so long as such event shall continue or (ii) the Swingline Lender or the Issuing Bank has a good faith belief that any Lender has defaulted in fulfilling its obligations under one or more other agreements in which such Lender commits to extend credit, the Swingline Lender shall not be required to fund any Swingline Loan and the Issuing Bank shall not be required to issue, amend or increase any Letter of Credit, unless the Swingline Lender or the Issuing Bank, as the case may be, shall have entered into arrangements with the Borrower or such Lender, satisfactory to the Swingline Lender or the Issuing Bank, as the case may be, to defend any risk to it in respect of such Lender hereunder. In the event that each of the Administrative Agent, the Borrower, the Swingline Lender and the Issuing Bank agrees that a Defaulting Lender has adequately remedied all matters that caused such Lender to be a Defaulting Lender, then the Swingline Exposure and LC Exposure of the Lenders shall be readjusted to reflect the inclusion of such Lender’s Revolving Commitment and on the date of such readjustment such Lender shall purchase at par such of the Loans of the other Lenders (other than Swingline Loans) as the Administrative Agent shall determine may be necessary in order for such Lender to hold such Loans in accordance with its Applicable Percentage. SECTION 2.21. Returned Payments. If, after receipt of any payment which is applied to the payment of all or any part of the Obligations (including a payment effected through exercise of a right of setoff), the Administrative Agent or any Lender is for any reason compelled to surrender such payment or proceeds to any Person because such payment or application of proceeds is invalidated, declared fraudulent, set aside, determined to be void or voidable as a preference, impermissible setoff, or a diversion of trust funds, or for any other reason (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion), then the Obligations or part thereof intended to be satisfied shall be revived and continued and this Agreement shall continue in full force as if such payment or proceeds had not been received by the Administrative Agent or such Lender. The provisions of this Section 2.21 shall be and remain effective notwithstanding any contrary action which may have been taken by the Administrative Agent or any Lender in reliance upon such payment or application of proceeds. The provisions of this Section 2.21 shall survive the termination of this Agreement. SECTION 2.22. Banking Services and Swap Agreements. Each Lender or Affiliate thereof providing Banking Services for, or having Swap Agreements with, any Loan Party or any Subsidiary shall deliver to the Administrative Agent, promptly after entering into such Banking Services or Swap Agreements, written notice setting forth the aggregate amount of all Banking Services Obligations and Swap Agreement Obligations of such Loan Party or Subsidiary to such Lender or Affiliate (whether matured or unmatured, absolute or contingent). In furtherance of that requirement, each such Lender or Affiliate thereof shall furnish the Administrative Agent, from time to time after a significant change therein 70 Å or upon a request therefor, a summary of the amounts due or to become due in respect of such Banking Services Obligations and Swap Agreement Obligations. The most recent information provided to the Administrative Agent shall be used in determining which tier of the waterfall, contained in Section 2.18(b), such Banking Services Obligations and/or Swap Agreement Obligations will be placed. For the avoidance of doubt, so long as Chase or its Affiliate is the Administrative Agent, neither Chase nor any of its Affiliates providing Banking Services for, or having Swap Agreements with, any Loan Party or any Subsidiary of a Loan Party shall be required to provide any notice described in this Section 2.22 in respect of such Banking Services or Swap Agreements. ARTICLE IIIRepresentations and Warranties Each Loan Party represents and warrants to the Lenders that (and where applicable, agrees): SECTION 3.01. Organization; Powers. Each Loan Party and each Subsidiary is duly organized or formed, validly existing and in good standing under the laws of the jurisdiction of its organization, has all requisite power and authority to carry on its business as now conducted and, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every jurisdiction where such qualification is required. SECTION 3.02. Authorization; Enforceability. The Transactions are within each Loan Party’s corporate or other organizational powers and have been duly authorized by all necessary corporate or other organizational actions and, if required, actions by equity holders. Each Loan Document to which each Loan Party is a party has been duly executed and delivered by such Loan Party and constitutes a legal, valid and binding obligation of such Loan Party, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law. SECTION 3.03. Governmental Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority, except such as have been obtained or made and are in full force and effect and except for filings necessary to perfect Liens created pursuant to the Loan Documents, (b) will not violate any Requirement of Law applicable to any Loan Party or any Subsidiary, (c) will not violate or result in a default under any indenture, agreement or other instrument binding upon any Loan Party or any Subsidiary or the assets of any Loan Party or any Subsidiary, or give rise to a right thereunder to require any payment to be made by any Loan Party or any Subsidiary, and (d) will not result in the creation or imposition of, or other requirement to create, any Lien on any asset of any Loan Party or any Subsidiary, except Liens created pursuant to the Loan Documents. SECTION 3.04. Financial Condition; No Material Adverse Change. (a) The Borrower has heretofore furnished to the Lenders its consolidated balance sheet and statements of income, stockholders equity and cash flows as of and for the fiscal year ended December 31, 2023, reported on by KPMG LLP, independent public accountants. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of the Borrower and its consolidated Subsidiaries as of such dates and for such periods in accordance with GAAP. (b) No event, change or condition has occurred that has had, or could reasonably be expected to have, a Material Adverse Effect, since December 31, 2023. 71 Å SECTION 3.05. Properties. (a) As of the date of this Agreement, Schedule 3.05 sets forth the address of each parcel of real property that is owned or leased by any Loan Party. Except as could not reasonably be expected to result in a Material Adverse Effect, each of such leases and subleases is (i) valid and enforceable in accordance with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law and (ii) in full force and effect. Except to the extent any such default could not reasonably be expected to result in a Material Adverse Effect, (i) no default by any Loan Party to any such lease or sublease exists and (ii) to each Loan Party’s knowledge, no default by any other party to any such lease or sublease exists. Each of the Loan Parties and each Subsidiary has good and indefeasible title to, or valid leasehold interests in, all of its real and personal property, free of all Liens other than those permitted by Section 6.02 except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. (b) Each Loan Party and each Subsidiary owns, or is licensed to use, all trademarks, tradenames, copyrights, patents and other intellectual property necessary to its business as currently conducted, a correct and complete list of which, as of the date of this Agreement, is set forth on Schedule 3.05, and, to the knowledge of the Loan Parties, the use thereof by each Loan Party and each Subsidiary does not infringe upon the rights of any other Person, except for any such infringements that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. SECTION 3.06. Litigation and Environmental Matters. (a) Except as set forth on Schedule 3.06, there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or, to the knowledge of any Loan Party, threatened against or affecting any Loan Party or any Subsidiary (i) as to which there is a reasonable possibility of an adverse determination and that, if adversely determined, could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or (ii) that involve any Loan Document or the Transactions. (b) Except with respect to any matters that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect (i) no Loan Party or any Subsidiary has received notice of any claim with respect to any Environmental Liability or knows of any basis for any Environmental Liability and (ii) no Loan Party or any Subsidiary (A) has failed to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law (B) has become subject to any Environmental Liability, (C) has received notice of any claim with respect to any Environmental Liability or (D) knows of any basis for any Environmental Liability. SECTION 3.07. Compliance with Laws and Agreements; No Default. Except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, each Loan Party and each Subsidiary is in compliance with (i) all Requirements of Law applicable to it or its property and (ii) all indentures, agreements and other instruments binding upon it or its property. No Default has occurred and is continuing. SECTION 3.08. Investment Company Status. No Loan Party or any Subsidiary is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940. SECTION 3.09. Taxes. Each Loan Party and each Subsidiary has timely filed or caused to be filed all Tax returns and reports required to have been filed and has paid or caused to be paid all Taxes required 72 Å to have been paid by it, except (a)(i) Taxes that are being contested in good faith by appropriate proceedings and (ii) for which such Loan Party or such Subsidiary, as applicable, has set aside on its books adequate reserves or (b) to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect. SECTION 3.10. ERISA. No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect. The present value of all accumulated benefit obligations under each Plan (based on the assumptions used for purposes of Statement of Financial Accounting Standards No. 87) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of such Plan, and the present value of all accumulated benefit obligations of all underfunded Plans (based on the assumptions used for purposes of Statement of Financial Accounting Standards No. 87 or subsequent reidentification thereof, as applicable) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of all such underfunded Plans, in each case, except as could not reasonably be expected to result in a Material Adverse Effect. SECTION 3.11. Disclosure. (a) The Loan Parties have disclosed to the Lenders all agreements, instruments and corporate or other restrictions to which any Loan Party or any Subsidiary is

subject, and all other matters known to it, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other written information (other than the Projections, any other projected financial information, forward looking statements and statements of a general economic or industry nature) furnished by or on behalf of any Loan Party or any Subsidiary to the Administrative Agent or any Lender in connection with the negotiation of this Agreement or any other Loan Document (as modified or supplemented by other information so furnished), taken as a whole, contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not materially misleading; provided that, with respect to the Projections and other projected financial information, the Loan Parties represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time delivered and, if such projected financial information was delivered prior to the Effective Date, as of the Effective Date, it being understood and agreed that such Projections and other projected financial information are subject to uncertainties and contingencies, many of which are beyond the control of the Loan Parties, and as such, such Projections and other projected financial information is not a guarantee of financial performance and such differences may be material. (b) As of the Effective Date, to the best knowledge of the Borrower, the information included in the Beneficial Ownership Certification provided on or prior to the Effective Date to any Lender in connection with this Agreement is true and correct in all respects. SECTION 3.12. Material Agreements. All material agreements and contracts, the loss, termination, or breach of which could reasonably be expected to have a Material Adverse Effect, to which any Loan Party or any Subsidiary is a party or is bound as of the date of this Agreement are listed on Schedule 3.12. No Loan Party or any Subsidiary is in default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in (i) any agreement to which it is a party or (ii) any agreement or instrument evidencing or governing Indebtedness, in each case, except as could not reasonably be expected to result in a Material Adverse Effect. SECTION 3.13. Solvency. 73 A (a) Immediately after the consummation of the Transactions to occur on the Effective Date, and immediately after the making of each Loan and each issuance of a Letter of Credit hereunder, (i) the fair value of the assets of the Borrower and its Subsidiaries, on a consolidated basis, at a fair valuation, will exceed its debts and liabilities, subordinated, contingent or otherwise; (ii) the present fair saleable value of the property of the Borrower and its Subsidiaries, on a consolidated basis, will be greater than the amount that will be required to pay the probable liability of their debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute and matured; (iii) the Borrower and its Subsidiaries, on a consolidated basis, will be able to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured; and (iv) the Borrower and its Subsidiaries, on a consolidated basis, will not have unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted after the Effective Date. (b) No Loan Party intends to, nor will permit any Subsidiary to, and no Loan Party believes that it or any Subsidiary will, incur debts beyond its ability to pay such debts as they mature, taking into account the timing of and amounts of cash to be received by it or any such Subsidiary and the timing of the amounts of cash to be payable on or in respect of its Indebtedness or the Indebtedness of any such Subsidiary. SECTION 3.14. Insurance. Schedule 3.14 sets forth a description of all insurance maintained by or on behalf of the Loan Parties and their Subsidiaries as of the Effective Date. As of the Effective Date, all premiums in respect of such insurance have been paid to the extent then due and payable. The Loan Parties believe that the insurance maintained by or on behalf of the Loan Parties and their Subsidiaries is adequate and is customary for companies engaged in the same or similar businesses operating in the same or similar locations. SECTION 3.15. Capitalization and Subsidiaries. As of the Effective Date, Schedule 3.15 sets forth (a) a correct and complete list of the name and relationship to the Borrower of each Subsidiary, (b) a true and complete listing of each class of each of the Borrower's authorized Equity Interests, of which all of such issued Equity Interests are validly issued, outstanding, fully paid and non-assessable, and owned beneficially and of record by the Persons identified on Schedule 3.15, (c) the type of entity of the Borrower and each Subsidiary, and (d) whether such Subsidiary is a Loan Party, Domestic Subsidiary and/or Foreign Subsidiary. All of the issued and outstanding Equity Interests owned by any Loan Party have been (to the extent such concepts are relevant with respect to such ownership interests) duly authorized and issued and are fully paid and non-assessable. SECTION 3.16. Security Interest in Collateral. The provisions of this Agreement and the other Loan Documents create legal and valid Liens on all the Collateral in favor of the Administrative Agent, for the benefit of the Secured Parties, and upon the filing of UCC financing statements, the delivery to the Administrative Agent of any stock or equivalent certificates or promissory notes required to be delivered pursuant to the applicable Loan Documents, the recording of Mortgages with respect to real property, filings with the United States Patent and Trademark Office with respect to the Loan Parties' patents and trademarks, and filings with the United States Copyright Office with respect to the Loan Parties' copyrights, such Liens constitute perfected and continuing Liens on the Collateral, to the extent perfection can be obtained by the filing of an initial UCC financing statement, the delivery of any such certificate or instrument, the recording of a Mortgage or a filing with the United States Patent & Trademark Office or the United States Copyright Office, as applicable, securing the Secured Obligations, enforceable against the applicable Loan Party (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors' rights generally and subject to general principles of equity, regardless, of whether considered in a proceeding in equity or at law), and having priority over all other Liens on the Collateral except in the case of (a) Liens permitted by Section 6.02, to the extent any such Liens would 74 A have priority over the Liens in favor of the Administrative Agent pursuant to any applicable law or to the extent otherwise permitted by this Agreement and (b) Liens perfected only by possession (including possession of any certificate of title), to the extent the Administrative Agent has not obtained or does not maintain possession of such Collateral. SECTION 3.17. Employment Matters. As of the Effective Date, there are no strikes, lockouts or slowdowns against any Loan Party or any Subsidiary pending or, to the knowledge of any Loan Party, threatened in writing. The hours worked by and payments made to employees of the Loan Parties and their Subsidiaries have not been in violation of the Fair Labor Standards Act or any other applicable federal, state, local or foreign law dealing with such matters, in each case, except as could not reasonably be expected to result in a Material Adverse Effect. All payments due from any Loan Party or any Subsidiary, or for which any claim may be made against any Loan Party or any Subsidiary, on account of wages and employee health and welfare insurance and other benefits, have been paid or accrued as a liability on the books of such Loan Party or such Subsidiary except as could not reasonably be expected to result in a Material Adverse Effect. SECTION 3.18. Margin Regulations. No Loan Party is engaged and will not engage, principally or as one of its important activities, in the business of purchasing or carrying Margin Stock, or extending credit for the purpose of purchasing or carrying Margin Stock, and no part of the proceeds of any Borrowing or Letter of Credit hereunder will be used to buy or carry any Margin Stock. Following the application of the proceeds of each Borrowing or drawing under each Letter of Credit, not more than 25% of the value of the assets (either of any Loan Party only or of the Loan Parties and their Subsidiaries on a consolidated basis) will be Margin Stock. Neither the making of any Loan hereunder nor the use of proceeds thereof will violate the provisions of Regulation U or X of the Federal Reserve Board. SECTION 3.19. Use of Proceeds. The proceeds of the Loans have been used and will be used, whether directly or indirectly, as set forth in Section 5.08. SECTION 3.20. No Burdensome Restrictions. No Loan Party is subject to any Burdensome Restrictions except Burdensome Restrictions permitted under Section 6.10. SECTION 3.21. Anti-Corruption Laws and Sanctions. Each Loan Party has implemented and maintains in effect policies and procedures reasonably designed to ensure compliance by such Loan Party, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions. Each Loan Party, its Subsidiaries and their respective officers and directors, and, to the knowledge of such Loan Party, its employees and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects and are not knowingly engaged in any activity that could reasonably be expected to result in any Loan Party being designated as a Sanctioned Person. None of (a) any Loan Party, any Subsidiary or any of their respective directors, officers or employees, or (b) to the knowledge of any such Loan Party or Subsidiary, any agent of such Loan Party or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Borrowing or Letter of Credit, use of proceeds, Transaction or other transaction contemplated by this Agreement or the other Loan Documents will violate Anti-Corruption Laws or applicable Sanctions. SECTION 3.22. Affected Financial Institutions. No Loan Party is an Affected Financial Institution. SECTION 3.23. Plan Assets; Prohibited Transactions. None of the Loan Parties or any of their Subsidiaries is an entity deemed to hold certain assets (within the meaning of the Plan Asset Regulations), and neither the execution, delivery nor performance of the transactions contemplated under this Agreement, 75 A including the making of any Loan and the issuance of any Letter of Credit hereunder, will give rise to a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Code. SECTION 3.24. Sellers' Lien Laws. (a) As of the Effective Date, no Loan Party or Subsidiary has received any written notice pursuant to any Sellers' Lien Laws from (i) any Farm Products Seller or (ii) any lender to any Farm Products Seller or any other Person with a security interest in the assets of any Farm Products Seller or (iii) the Secretary of State (or equivalent official) or other Governmental Authority of any State, Commonwealth or political subdivision thereof in which any Farm Products purchased by such Loan Party or Subsidiary are produced, in any case advising or notifying such Loan Party or Subsidiary of the intention of such Farm Products Seller or other Person to preserve the benefits of any trust applicable to any assets of any Loan Party or Subsidiary established in favor of such Farm Products Seller or other Person under the provisions of any Seller's Lien Law or claiming a Lien upon or other claim or encumbrance with respect to any Farm Products which may be, or have been, purchased by a Loan Party or Subsidiary or any related or other assets of such Loan Party or Subsidiary (all of the foregoing, together with any such notices as any Loan Party or Subsidiary may at any time hereafter receive, collectively, the Sellers' Lien Law Notices). (b) As of the Effective Date, no Loan Party or Subsidiary has knowledge of any credible claim by any Farm Products Seller against any Loan Party or Subsidiary under any Sellers' Lien Laws. (c) As of the Effective Date, (i) no Loan Party or Subsidiary is a live poultry dealer (as such term is defined in the PSA), and (ii) the Loan Parties and Subsidiaries do not purchase livestock pursuant to cash sales as such term is defined in the PSA. ARTICLE IV Conditions SECTION 4.01. Effective Date. The obligations of the Lenders to make Loans and of the Issuing Bank to issue Letters of Credit hereunder shall not become effective until the date on which each of the following conditions is satisfied (or waived in accordance with Section 9.02): (a) Credit Agreement and Loan Documents. The Administrative Agent (or its counsel) shall have received (i) from each party hereto, a counterpart of this Agreement signed on behalf of such party (which, subject to Section 9.06(b), may include any Electronic Signatures transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page) and (ii) duly executed copies of the Loan Documents and such other legal opinions, certificates, documents, instruments and agreements as the Administrative Agent shall reasonably request in connection with the Transactions and the other Loan Documents, including any promissory notes requested by a Lender pursuant to Section 2.10 payable to the order of each such requesting Lender and a written opinion of the Loan Parties' counsel, addressed to the Administrative Agent, the Issuing Bank and the Lenders, all in form and substance satisfactory to the Administrative Agent. (b) Financial Statements and Projections. The Lenders shall have received (i) audited consolidated financial statements of the Borrower and its Subsidiaries for the 2022 and 2023 fiscal years and (ii) satisfactory Projections through 2029. (c) Closing Certificates; Certified Certificate of Incorporation; Good Standing Certificates. The Administrative Agent shall have received (i) a certificate of each Loan Party, dated the Effective Date and executed by its Secretary or Assistant Secretary, which shall (A) certify the resolutions of its Board of 76 A Directors, members or other governing body authorizing the execution, delivery and performance of the Loan Documents to which it is a party, (B) identify by name and title and bear the signatures of the officers of such Loan Party authorized to sign the Loan Documents to which it is a party and, in the case of the Borrower, its Financial Officers, and (C) contain appropriate attachments, including the charter, articles or certificate of organization or incorporation of each Loan Party certified by the relevant authority of the jurisdiction of organization of such Loan Party and a true and correct copy of its bylaws or operating, management or partnership agreement, or other organizational or governing documents, and (ii) a long form good standing certificate for each Loan Party from its jurisdiction of organization. (d) No Default Certificate. The Administrative Agent shall have received a certificate, signed by a Financial Officer of the Borrower, dated as of the Effective Date (i) stating that no Default has occurred and is continuing as of such date, (ii) stating that the representations and warranties contained in the Loan Documents are true and correct in all material respects as of such date (or if any representation and warranty is made as of a specified date stating such representation and warranty was true and correct as of such specified date and if any representation or warranty is subject to any materiality qualifier, such representation or warranty is true and correct in all respects), and (iii) certifying as to any other factual matters as may be reasonably requested by the Administrative Agent. (e) Fees. The Lenders and the Administrative Agent shall have received all fees required to be paid, and all expenses required to be reimbursed for which invoices have been presented (including the reasonable fees and expenses of legal counsel), on or before the Effective Date. All such amounts will be paid with proceeds of Loans made on the Effective Date and will be reflected in the funding instructions given by the Borrower to the Administrative Agent on or before the Effective Date. (f) Lien and IP Searches. The Administrative Agent shall have received the results of a recent lien search in the jurisdiction of organization of each Loan Party and each jurisdiction where assets of the Loan Parties are located, and the results of search reports in respect of the intellectual property of the Loan Parties, and such searches shall reveal no Liens on any of the assets of the Loan Parties except for liens permitted by Section 6.02 or discharged on or prior to the Effective Date pursuant to a pay-off letter or other documentation reasonably satisfactory to the Administrative Agent. (g) Pay-Off and Release Letter. The Administrative Agent shall have received satisfactory pay-off and release letters for all existing Indebtedness required to be repaid (including, without limitation, the credit facility evidenced by the Revolving Credit and Security Agreement, dated as of October 4, 2017, among the Borrower, the Subsidiaries of the Borrower party thereto, the lenders party thereto and PNC Bank, National Association, as administrative agent, as amended or otherwise modified prior to the date hereof) and which confirms that all Liens securing such Indebtedness and all Guarantees in respect thereof will be terminated and released concurrently with such payment and all letters of credit issued or guaranteed as part of such Indebtedness shall have been cash collateralized or supported by a Letter of Credit. (h) Funding Account. The Administrative Agent shall have received a notice (which notice shall be in the form of a Borrowing Request or such other form or method as approved by the Administrative Agent) setting forth the deposit account of the Borrower (as may be updated from time to time by written notice from the Borrower to the Administrative Agent, the Funding Account) to which the Administrative Agent is authorized by the Borrower to transfer the proceeds of any Borrowings requested or authorized pursuant to this Agreement and which, in the case of a Borrowing Request, shall be delivered in accordance with Section 2.03, together with a customary funding indemnification letter to the extent any such Loan will be a Term Benchmark Loan. (i) [Reserved]. 77 A (j) Solvency. The Administrative Agent shall have received a solvency certificate signed by a Financial Officer dated the Effective Date in form and substance reasonably satisfactory to the Administrative Agent. (k) Pledged Equity Interests; Stock Powers; Pledged Notes. The Administrative Agent shall have received (i) the certificates representing the Equity Interests pledged pursuant to the Security Agreement, together with an undated stock power for each such certificate executed in blank by a duly authorized officer of the pledgor thereof and (ii) each promissory note and other instrument or possessory collateral (if any) pledged to the Administrative Agent pursuant to the Security Agreement, endorsed (without recourse) in blank (or accompanied by an executed transfer form in blank) by the pledgor thereof or accompanied by allonges or other acknowledgements signed in blank, as applicable. (l) Filings, Registrations and Recordings. Each document (including any Uniform Commercial Code financing statements and federal intellectual property filings) required by the Collateral Documents or under law or reasonably requested by the Administrative Agent to be filed, registered or recorded in order to create in favor of the Administrative Agent, for the benefit of the Secured Parties, a perfected Lien on the Collateral described therein, prior and superior in right to any other Person (other than with respect to Liens expressly permitted by Section 6.02 to the extent any such Liens would have priority over the Liens in favor of the Administrative Agent pursuant to any applicable law), shall be in proper form for filing, registration or recordation. (m) Insurance. Subject to Section 5.14, the Administrative Agent shall have received evidence of insurance coverage in form, scope, and substance reasonably satisfactory to the Administrative Agent and otherwise in compliance with the terms of Section 5.10 of this Agreement and the Security Agreement. (n) Due Diligence. The Administrative Agent and its counsel shall have completed all legal due diligence, the results of which shall be satisfactory to Administrative Agent in its sole discretion. (o) USA PATRIOT Act, Etc. At least five (5) days prior to the Effective Date, (i) the Administrative Agent and Lenders shall have received (x) all documentation and other information regarding the Loan Parties requested in connection with applicable know your customer and anti-money laundering rules and regulations, including the USA PATRIOT Act, to the extent requested in writing of the Borrower at least ten (10) days prior to the Effective Date and (y) a properly completed and signed IRS Form W-8 or W-9, as applicable, for each Loan Party and (ii) to the extent the Borrower qualifies as a legal entity customer under the Beneficial Ownership Regulation, any Lender that has requested, in a written notice to the Borrower at least ten (10) days prior to the Effective Date, a Beneficial Ownership Certification in relation to the Borrower shall have received such Beneficial Ownership Certification (provided that, upon the execution and delivery by such Lender of its signature page to this Agreement, the condition set forth in this clause (ii) shall be deemed to be satisfied). (p) Other Documents. The Administrative Agent shall have received such other documents as the Administrative Agent, the

Issuing Bank, any Lender or their respective counsel may have reasonably requested (including, without limitation, a properly completed letter of credit application (whether standalone or pursuant to a master agreement, as applicable) if the issuance of a Letter of Credit will be required on the Effective Date, together with an executed copy of the Issuing Bank's master agreement for the issuance of commercial Letters of Credit). Without limiting the generality of the provisions of Section 9.02, for purposes of determining compliance with the conditions specified in this Section 4.01 on the Effective Date, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory 78 Å to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Effective Date specifying its objection thereto. The Administrative Agent shall notify the Loan Parties, the Lenders and the Issuing Bank of the Effective Date, and such notice shall be conclusive and binding. SECTION 4.02. Each Credit Event. The obligation of each Lender to make a Loan on the occasion of any Borrowing, and of the Issuing Bank to issue, amend or extend any Letter of Credit, is subject to the satisfaction of the following conditions: (a) The representations and warranties of the Loan Parties set forth in the Loan Documents shall be true and correct in all material respects with the same effect as though made on and as of the date of such Borrowing or the date of issuance, amendment or extension of such Letter of Credit, as applicable (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified date, and that any representation or warranty which is subject to any materiality qualifier shall be required to be true and correct in all respects). (b) At the time of and immediately after giving effect to such Borrowing or the issuance, amendment or extension of such Letter of Credit, as applicable, no Default or Event of Default shall have occurred and be continuing. Each Borrowing and each issuance, amendment or extension of a Letter of Credit shall be deemed to constitute a representation and warranty by the Borrower on the date thereof as to the matters specified in paragraphs (a) and (b) of this Section; provided that, in the case of any Incremental Term Loan the proceeds of which are, substantially concurrently with the receipt thereof, solely to be used by the Borrower or any Subsidiary to finance, in whole or in part, a Limited Condition Transaction, then (1) the foregoing clause (b) shall be limited to no Event of Default pursuant to clause (a), (b), (h), (i) or (m) of Article VII having occurred, being continuing or resulting therefrom, (2) the Borrower shall only be required to satisfy the requirements of the above clause (a) as of the date on which the binding agreement for such Limited Condition Transaction is entered into, and (3) the representations and warranties so given in respect of the funding of such Loan or Borrowing shall be limited to the Specified Representations. Notwithstanding the failure to satisfy the conditions precedent set forth in paragraphs (a) or (b) of this Section, unless otherwise directed by the Required Lenders, the Administrative Agent may, but shall have no obligation to, continue to make Loans and an Issuing Bank may, but shall have no obligation to, issue, amend or extend, or cause to be issued, amended or extended, any Letter of Credit for the ratable account and risk of Lenders from time to time if the Administrative Agent believes that making such Loans or issuing, amending or extending, or causing the issuance, amendment or extension of, any such Letter of Credit is in the best interests of the Lenders. ARTICLE V Affirmative Covenants Until all of the Secured Obligations shall have been Paid in Full, each Loan Party executing this Agreement covenants and agrees, jointly and severally with all of the other Loan Parties, with the Lenders that: SECTION 5.01. Financial Statements and Other Information. The Borrower will furnish to the Administrative Agent and each Lender: 79 Å (a) within one hundred twenty (120) days after the end of each fiscal year of the Borrower (or, if earlier, by the date that the Annual Report on Form 10-K of the Borrower for such fiscal year would be required to be filed under the rules and regulations of the SEC, giving effect to any automatic extension available thereunder for the filing of such form) (commencing with the fiscal year ending December 31, 2024), its audited consolidated balance sheet and related statements of operations, stockholders' equity and cash flows as of the end of and for such year, setting forth in each case in comparative form the figures for the previous fiscal year, all reported on by independent public accountants of recognized national standing (without a "going concern" or like qualification, commentary or exception, and without any qualification or exception as to the scope of such audit) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied; (b) within forty-five (45) days after the end of each of the first three fiscal quarters of each fiscal year of the Borrower (or, if earlier, by the date that the Quarterly Report on Form 10 Q of the Borrower for such fiscal quarter would be required to be filed under the rules and regulations of the SEC, giving effect to any automatic extension available thereunder for the filing of such form) (commencing with the fiscal quarter ending March 31, 2024), its consolidated balance sheet and related statements of operations, stockholders' equity and cash flows as of the end of and for such fiscal quarter and the then elapsed portion of such fiscal year, setting forth in each case in comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous fiscal year, all certified by a Financial Officer as presenting fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes; (c) concurrently with any delivery of financial statements under clause (a) or (b) above (commencing with the fiscal quarter ending March 31, 2024) (collectively or individually, as the context requires, the "Financial Statements"), a Compliance Certificate (i) certifying, in the case of the Financial Statements delivered under clause (a) or (b) above, as presenting fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes, (ii) certifying as to whether a Default has occurred and, if a Default has occurred, specifying the details thereof and any action taken or proposed to be taken with respect thereto, (iii) setting forth reasonably detailed calculations demonstrating compliance with Section 6.12 (to the extent required hereunder for such period) and (iv) stating whether any change in GAAP or in the application thereof has occurred since the date of the audited financial statements referred to in Section 3.04 and, if any such change has occurred, specifying the effect of such change on the Financial Statements accompanying such certificate; (d) [reserved]; (e) no later than 75 days after the end of, each fiscal year of the Borrower, a copy of the plan and forecast (including a projected consolidated balance sheet for each quarter, and income statement and cash flow statement for each month) of the Borrower for the upcoming fiscal year (the "Projections") in form reasonably satisfactory to the Administrative Agent; (f) promptly following any request therefor, (x) such other information regarding the operations, changes in ownership of Equity Interests, business affairs and financial condition of any Loan Party or any Subsidiary, or compliance with the terms of this Agreement, as the Administrative Agent or any Lender (through the Administrative Agent) may reasonably request and (y) information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance 80 Å with applicable "know your customer" and anti-money laundering rules and regulations, including the USA PATRIOT Act and the Beneficial Ownership Regulation; (g) promptly after any request therefor by the Administrative Agent or any Lender, copies of (i) any documents described in Section 101(k)(1) of ERISA that the Borrower or any ERISA Affiliate may request with respect to any Multiemployer Plan and (ii) any notices described in Section 101(l)(1) of ERISA that the Borrower or any ERISA Affiliate may request with respect to any Multiemployer Plan; provided that if the Borrower or any ERISA Affiliate has not requested such documents or notices from the administrator or sponsor of the applicable Multiemployer Plan, the Borrower or the applicable ERISA Affiliate shall promptly make a request for such documents and notices from such administrator or sponsor and shall provide copies of such documents and notices promptly after receipt thereof; and (h) promptly after the same become publicly available, copies of all periodic and other reports, proxy statements and other materials filed by any Loan Party or any Subsidiary with the SEC, or any Governmental Authority succeeding to any or all of the functions of the SEC, or with any national securities exchange, or distributed by the Borrower to its shareholders generally, as the case may be. Documents required to be delivered pursuant to clauses (a), (b) or (h) of this Section 5.01 (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which such materials are publicly available as posted on the Electronic Data Gathering, Analysis and Retrieval system (EDGAR) or (ii) on which such documents are posted on the Borrower's behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether made available by the Administrative Agent); provided that upon written request by the Administrative Agent (or any Lender through the Administrative Agent) to the Borrower, the Borrower shall deliver paper copies of such documents to the Administrative Agent or such Lender until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender. The Administrative Agent shall have no obligation to request the delivery of or to maintain paper copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any such request by a Lender for delivery, and each Lender shall be solely responsible for timely accessing posted documents or requesting delivery of paper copies of such document to it and maintaining its copies of such documents. Notwithstanding the foregoing, neither the Borrower nor any of its Subsidiaries shall be required to disclose (i) materials protected by the attorney-client privilege, (ii) materials which the Borrower or such Subsidiary, as applicable, may not disclose without violation of a confidentiality obligation binding upon it and entered into in good faith without the intent to hinder or delay disclosure to the Administrative Agent and Lenders or the disclosure of which is prohibited by law or (iii) information that constitutes non-financial trade secrets or non-financial proprietary information that is not reasonably related to the actual or projected financial results or results of operations of the Borrower and its Subsidiaries; provided that, if the Borrower or its Subsidiaries rely on any of the immediately foregoing clauses (i) through (iii) for any reason, the Borrower shall advise the Lenders thereof. SECTION 5.02. Notices of Material Events. The Borrower will furnish to the Administrative Agent and each Lender prompt (but in any event within any time period that may be specified below) written notice of the following: (a) the occurrence of any Default or Event of Default; 81 Å (b) receipt of any notice of any investigation by a Governmental Authority or any Proceeding commenced or threatened in writing against any Loan Party or any Subsidiary that could reasonably be expected to result in a Material Adverse Effect; (c) any material change in accounting or financial reporting practices by the Borrower or any Subsidiary; (d) the occurrence of any ERISA Event that could reasonably be expected to result in a Material Adverse Effect; (e) within two (2) Business Days after the occurrence thereof, any Loan Party entering into a Swap Agreement or an amendment to a Swap Agreement (other than Swap Agreements entered into with a Lender or an Affiliate of a Lender), together with copies of all agreements evidencing such Swap Agreement or amendment; (f) any other development that results in, or could reasonably be expected to result in, a Material Adverse Effect; and (g) any change in the information provided in the Beneficial Ownership Certification delivered to such Lender that would result in a change to the list of beneficial owners identified in such certification. Each notice delivered under this Section 5.02 (i) shall be in writing, (ii) shall contain a heading or a reference line that reads "Notice under Section 5.02 of Vital Farms, Inc. Credit Agreement dated April 9, 2024" and (iii) shall be accompanied by a statement of a Financial Officer or other executive officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. SECTION 5.03. Existence; Conduct of Business. Each Loan Party will, and will cause each Subsidiary to, (a) do or cause to be done all things necessary to preserve, renew and keep in full force and effect its (i) legal existence and good standing in the jurisdiction of its organization and (ii) except to the extent that the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, the rights, qualifications, licenses, permits, privileges, franchises, governmental authorizations, intellectual property rights, licenses and permits material to the conduct of its business, and maintain all requisite authority to conduct its business in each jurisdiction in which its business is conducted; provided that the foregoing shall not prohibit any merger, consolidation, liquidation or dissolution permitted under Section 6.03 and (b) carry on and conduct its business in substantially the same manner and in substantially the same fields of enterprise as it is presently conducted. SECTION 5.04. Payment of Obligations. Each Loan Party will, and will cause each Subsidiary to, pay or discharge all Material Indebtedness and all other material liabilities and obligations, including Taxes, before the same shall become delinquent or in default, except where (a)(i) the validity or amount thereof is being contested in good faith by appropriate proceedings, and (ii) such Loan Party or Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP or (b) the failure to make any such payment could not reasonably be expected to result in a Material Adverse Effect; provided, however, that each Loan Party will, and will cause each Subsidiary to, remit withholding taxes and other payroll taxes to appropriate Governmental Authorities as and when claimed to be due, notwithstanding the foregoing exceptions. SECTION 5.05. Maintenance of Properties. Each Loan Party will, and will cause each Subsidiary to, keep and maintain all property material to the conduct of its business in good working order and condition, ordinary wear and tear excepted. 82 Å SECTION 5.06. Books and Records; Inspection Rights. Each Loan Party will, and will cause each Subsidiary to, (a) keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities and (b) permit any representatives designated by the Administrative Agent or any Lender (including employees of the Administrative Agent, any Lender or any consultants, accountants, lawyers, agents and appraisers retained by the Administrative Agent), upon reasonable prior notice and during normal business hours, to visit and inspect its properties, conduct at the Loan Party's premises field examinations of the Loan Party's assets, liabilities, books and records, including examining and making extracts from its books and records, environmental assessment reports and Phase I or Phase II studies, and to discuss its affairs, finances and condition with its officers and independent accountants (and hereby authorizes the Administrative Agent and each Lender to contact its independent accountants directly) and to provide contact information for each bank where each Loan Party has a depository and/or securities account and each such Loan Party hereby authorizes the Administrative Agent and each Lender to contact the bank(s) in order to request bank statements and/or balances, all at such reasonable times and as often as reasonably requested; provided, that (i) absent the existence of an Event of Default, any inspection under this Section 5.06 shall be limited to one (1) per calendar year and the Borrower shall only be required to reimburse the Administrative Agent and the Lenders for one (1) such inspection per calendar year, and (ii) notwithstanding anything to the contrary in this Section 5.06, neither the Borrower nor its Subsidiaries will be required to disclose, permit the inspection, examination or making copies or abstracts of, or discussion of, any document, information or other matter that consists of (x) materials protected by the attorney-client privilege, (y) materials which the Borrower or such Subsidiary, as applicable, may not disclose without violation of a confidentiality obligation binding upon it and entered into in good faith without the intent to hinder or delay disclosure to the Administrative Agent and Lenders or the disclosure of which is prohibited by law or (z) information that constitutes non-financial trade secrets or non-financial proprietary information that is not reasonably related to the actual or projected financial results or results of operations of the Borrower and its Subsidiaries; provided further, that, if the Borrower or its Subsidiaries rely on any of the immediately foregoing clause (ii) for any reason, the Borrower shall advise the Lenders thereof. The Loan Parties acknowledge that the Administrative Agent, after exercising its rights of inspection, may prepare and distribute to the Lenders certain reports pertaining to the Loan Parties' assets for internal use by the Administrative Agent and the Lenders. SECTION 5.07. Compliance with Laws and Material Contractual Obligations. Each Loan Party will, and will cause each Subsidiary to, (i) comply with its organizational documents, (ii) comply with each other Requirement of Law applicable to it or its property (including without limitation Environmental Laws) and (iii) perform its obligations under agreements to which it is a party, except, in the cases of the foregoing clauses (ii) and (iii), as could not reasonably be expected to result in a Material Adverse Effect. Each Loan Party will maintain in effect and enforce policies and procedures designed to ensure compliance by such Loan Party, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions. SECTION 5.08. Use of Proceeds. (a) The proceeds of the Loans and the Letters of Credit will be used only to finance the working capital needs and general corporate purposes of the Borrower and its Subsidiaries in the ordinary course of business (including, without limitation, Permitted Acquisitions). No part of the proceeds of any Loan and no Letter of Credit will be used, whether directly or indirectly, for any purpose that entails a violation of any of the regulations of the Federal Reserve Board, including Regulations T, U and X. (b) The Borrower will not request any Borrowing or Letter of Credit, and the Borrower shall not use, and shall procure that its Subsidiaries and its or their respective directors, officers, employees and agents shall not use, the proceeds of any Borrowing or Letter of Credit (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to 83 Å any Person in violation of any Anti-Corruption Laws, (ii) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country, except to the extent permitted for a Person required to comply with Sanctions, or (iii) in any manner that would result in the violation of any Sanctions applicable to any party hereto. SECTION 5.09. Accuracy of Information. The Loan Parties will ensure that any written information, including financial statements or other documents (other than Projections, other projected financial information, forward looking statements and statements of a general economic or industry nature), furnished to the Administrative Agent or the Lenders in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof or waiver hereunder or thereunder, when taken as a whole, contains no material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not materially misleading, and the furnishing of such information shall be deemed to be a representation and warranty by the Borrower on the date thereof as to the matters specified in this Section 5.09; provided that, with respect to the Projections or other projected financial information, the Loan Parties will cause the Projections to be prepared in

good faith based upon assumptions believed to be reasonable at the time it being understood and agreed that such Projections and other projected financial information are subject to uncertainties and contingencies, many of which are beyond the control of the Loan Parties, and as such, such Projections and other projected financial information is not a guarantee of financial performance and actual results may differ from such Projections and other projected financial information and such difference may be material. SECTION 5.10. Insurance. Each Loan Party will, and will cause each Subsidiary to, maintain with financially sound and reputable carriers having a financial strength rating of at least A- by A.M. Best Company (a) insurance in such amounts (with no greater risk retention) and against such risks (including loss or damage by fire and loss in transit; theft, burglary, pilferage, larceny, embezzlement, and other criminal activities; business interruption; and general liability) and such other hazards, as is customarily maintained by companies of established repute engaged in the same or similar businesses operating in the same or similar locations and (b) all insurance required pursuant to the Collateral Documents. The Borrower will furnish to the Lenders, upon request of the Administrative Agent, information in reasonable detail as to the insurance so maintained. SECTION 5.11. Casualty and Condemnation. The Borrower will furnish to the Administrative Agent and the Lenders prompt written notice of any casualty or other insured damage to any material portion of the Collateral or the commencement of any action or proceeding for the taking of any material portion of the Collateral or interest therein under power of eminent domain or by condemnation or similar proceeding. SECTION 5.12. Depository Banks. Not later than one hundred twenty (120) days after the Effective Date (or such later date as agreed by the Administrative Agent in its sole discretion), the Borrower and each Subsidiary will maintain the Administrative Agent as its (a) principal depository bank, including for the maintenance of operating, administrative, cash management, collection activity, and other deposit accounts for the conduct of its business and (b) principal provider of other bank products; provided, that the Borrower may maintain investment and money market accounts with providers other than Administrative Agent as long as any such accounts are subject to a control agreement in favor of Administrative Agent (other than Excluded Accounts) not later than sixty (60) days after the Effective Date (or such later date as agreed by the Administrative Agent in its sole discretion). 84 Å SECTION 5.13. Subsidiary Guarantors; Additional Collateral; Further Assurances. (a) As promptly as possible but in any event within forty-five (45) days (or such later date as may be agreed upon by the Administrative Agent) after any Person becomes a Domestic Subsidiary (other than an Excluded Subsidiary), the Borrower shall (i) provide the Administrative Agent with written notice thereof setting forth information in reasonable detail describing the material assets of such Person and (ii) cause each such Domestic Subsidiary to execute and deliver to the Administrative Agent a Joinder Agreement and a joinder to the Security Agreement (in the form contemplated thereby) pursuant to which such Subsidiary agrees to be bound by the terms and provisions thereof, which shall be accompanied by appropriate organizational resolutions, other organizational documentation and legal opinions in form and substance reasonably satisfactory to the Administrative Agent and its counsel. In connection therewith, the Administrative Agent shall have received all documentation and other information regarding such newly formed or acquired Subsidiaries as may be required to comply with the applicable “know your customer” rules and regulations, including the USA Patriot Act. Each such Person delivering a Joinder Agreement (x) shall automatically become a Subsidiary Guarantor hereunder and thereupon shall have all of the rights, benefits, duties, and obligations in such capacity under the Loan Documents and (y) will grant Liens to the Administrative Agent, for the benefit of the Administrative Agent and the other Secured Parties, in any property of such Loan Party which constitutes Collateral. (b) Each Loan Party will cause, and will cause each other Loan Party to cause, all of its owned property (other than Excluded Property) to be subject at all times to first priority, perfected Liens in favor of the Administrative Agent for the benefit of the Secured Parties to secure the Secured Obligations in accordance with the terms and conditions of the Collateral Documents, subject in any case to Liens permitted by Section 6.02 to the extent any such Liens would have priority over the Liens in favor of the Administrative Agent pursuant to any applicable law or to the extent otherwise permitted by this Agreement. Without limiting the generality of the foregoing, each Loan Party (x) will cause 100% of the issued and outstanding Equity Interests of each of its directly-owned Subsidiaries (other than Excluded Property) to be subject at all times to a first priority, perfected Lien (subject to Liens permitted by Section 6.02) in favor of the Administrative Agent for the benefit of the Administrative Agent and the other Secured Parties to secure the Secured Obligations in accordance with the terms and conditions of the Collateral Documents or other pledge or security documents as the Administrative Agent shall reasonably request and (y) will deliver Mortgages and all related Mortgage Instruments and other deliveries requested by the Administrative Agent with respect to Material Real Property owned by such Loan Party to the extent, and within such time period as is, reasonably required by the Administrative Agent. Notwithstanding the foregoing, (i) no such Mortgages and Mortgage Instruments are required to be delivered hereunder as of the Effective Date and (ii) no such pledge agreement in respect of the Equity Interests of a Foreign Subsidiary shall be required hereunder to the extent the Administrative Agent or its counsel determines that such pledge would not provide material credit support for the benefit of the Secured Parties pursuant to legally valid, binding and enforceable pledge agreements. (c) Without limiting the foregoing, each Loan Party will, and will cause each Subsidiary to, execute and deliver, or cause to be executed and delivered, to the Administrative Agent such documents, agreements and instruments, and will take or cause to be taken such further actions (including the filing and recording of financing statements, fixture filings, Mortgages, Mortgage Instruments, deeds of trust and other documents and such other actions or deliveries of the type required by Section 4.01, as applicable), which may be required by any Requirement of Law or which the Administrative Agent may, from time to time, reasonably request to carry out the terms and conditions of this Agreement and the other Loan Documents and to ensure perfection and priority of the Liens created or intended to be created by the Collateral Documents, all in form and substance reasonably satisfactory to the Administrative Agent and all at the expense of the Loan Parties. 85 Å (d) If any material assets (other than Excluded Property) are acquired by any Loan Party after the Effective Date (other than assets constituting Collateral under the Security Agreement that become subject to the Lien under the Security Agreement upon acquisition thereof), the Borrower will (i) notify the Administrative Agent and the Lenders thereof, and, if requested by the Administrative Agent or the Required Lenders, cause such assets to be subjected to a Lien securing the Secured Obligations and (ii) take, and cause each applicable Loan Party to take, such actions as shall be necessary or reasonably requested by the Administrative Agent to grant and perfect such Liens, including actions described in paragraphs (b) and (c) of this Section, all at the expense of the Loan Parties. (e) Notwithstanding anything in this Agreement or the other Loan Documents to the contrary, the Administrative Agent may (but shall not be obligated to) determine in its sole and reasonable discretion that the cost to the Loan Parties of granting and perfecting any Lien is disproportionate to the benefit to be realized by the Administrative Agent, the Lenders and the other Secured Parties by perfecting a Lien in a given asset or group of assets included in the Collateral and, in such case, the Administrative Agent shall be permitted to, without the consent of the Lenders or Required Lenders, waive any requirement of perfection of any such Lien required under the Loan Documents. SECTION 5.14. Post-Closing Requirements. Not later than the dates set forth in Schedule 5.14 (or such later dates as the Administrative Agent shall agree in its sole discretion) or as otherwise required thereunder, the Loan Parties shall take the actions set forth on Schedule 5.14. SECTION 5.15. Farm Products. (a) Each Loan Party shall, and shall cause each Subsidiary to, at all times comply in all material respects with all existing and future Sellers’ Lien Law Notices during their periods of effectiveness under the applicable Sellers’ Lien Laws, including, without limitation, to the extent applicable, directions to make payments to the Farm Products Seller by issuing payment instruments directly to the secured party with respect to any assets of the Farm Products Seller or jointly payable to the Farm Products Seller and any secured party with respect to the assets of such Farm Products Seller, as specified in the Sellers’ Lien Law Notice, so as to terminate or release the security interest in any Farm Products maintained by such Farm Products Seller or any secured party with respect to the assets of such Farm Products Seller under the applicable Sellers’ Lien Laws. (b) Each Loan Party shall, and shall cause each Subsidiary to, take all other actions as may be reasonably required, if any, to ensure that any Farm Products are purchased free and clear of any Lien arising under any Sellers’ Lien Law. (c) Each Loan Party shall, and shall cause each Subsidiary to, promptly notify the Administrative Agent in writing after (i) obtaining knowledge of any credible claim by any Farm Product Seller against any Loan Party or Subsidiary or under any Seller Lien Laws and (ii) receipt by or on behalf of such Loan Party or Subsidiary of any Sellers’ Lien Law Notice or amendment to a previous Sellers’ Lien Law Notice, and including any notice from any Farm Products Seller of the intention of such Farm Products Seller to preserve the benefits of any trust applicable to any assets of any Loan Party or Subsidiary under the provisions of the Sellers Lien Laws or any other applicable law and upon the request of the Administrative Agent, such Loan Party or Subsidiary shall promptly provide the Administrative Agent with a true, correct and complete copy of such Sellers’ Lien Law Notice or amendment, as the case may be, and other information delivered to or on behalf of such Loan Party or Subsidiary pursuant to the Sellers’ Lien Laws. (d) To the extent that a Loan Party or Subsidiary purchases any Farm Products from a Person who produces such Farm Products in a state with a central filing system certified by the United States 86 Å Secretary of Agriculture, such Loan Party or Subsidiary shall promptly register, as a buyer, with the Secretary of State of such state (or the designated system operator). Each Loan Party shall, and shall cause each Subsidiary to, forward promptly to the Administrative Agent upon its request a copy of such registration as well as a copy of all relevant portions of the master list periodically distributed by any such Secretary of State (or the designated system operator). Each Loan Party shall, and shall cause each Subsidiary to, comply with any payment of obligations in connection with the purchase of any Farm Products imposed by a secured party as a condition of the waiver or release of a security interest effective under the Food Security Act or other applicable law whether or not as a result of direct notice or the filing under any applicable central filing system. Each Loan Party shall, and shall cause each Subsidiary to, also provide to the Administrative Agent from time to time upon its request true and correct copies of all state filings recorded in any such central filing system in respect of a Person from whom a Loan Party or Subsidiary has purchased Farm Products within the preceding twelve (12) months. SECTION 5.16. Farm Credit System Equity. (a) So long as a Farm Credit Lender is a Lender hereunder, the Borrower will acquire equity in such Farm Credit Lender or one of its Affiliates in such amounts and at such times as such Farm Credit Lender may require in accordance with such Farm Credit Lender’s bylaws and capital plan or similar documents (as each may be amended from time to time), except that the maximum amount of equity that the Borrower may be required to purchase in such Farm Credit Lender or one of its Affiliates in connection with the portion of the Loans made by such Farm Credit Lender may not exceed the maximum amount permitted by the applicable bylaws, capital plan and related documents (x) at the time this Agreement is entered into or (y) in the case of a Farm Credit Lender that becomes a Lender as a result of an assignment, at the time of the closing of the related assignment. The Borrower acknowledges receipt of documents from each Farm Credit Lender that describe the nature of the Farm Credit System Equity as well as applicable capitalization requirements, and agrees to be bound by the terms thereof. (b) Each party hereto acknowledges that each Farm Credit Lender’s bylaws, capital plan and similar documents (as each may be amended from time to time) shall govern (x) the rights and obligations of the parties with respect to the Farm Credit System Equity and any patronage refunds or other distributions made on account thereof or on account of the Borrower’s patronage with such Farm Credit Lender, (y) the Borrower’s eligibility for patronage distributions from such Farm Credit Lender (in the form of Farm Credit System Equity and cash) and (z) patronage distributions, if any, in the event of a sale of a participation interest. Each Farm Credit Lender reserves the right to assign or sell participations in all or any part of its Commitments or outstanding Loans hereunder on a non-patronage basis (and/or to a Lender that pays no patronage or pays patronage that is lower than the patronage paid by the transferring Farm Credit Lender) in accordance with this Agreement. (c) Each party hereto acknowledges that each Farm Credit Lender has a statutory first lien pursuant to the Farm Credit Act of 1971 (as amended from time to time) on all Farm Credit System Equity of such Farm Credit Lender (or one of its Affiliates) that the Borrower may now own or hereafter acquire, which statutory lien shall be for such Farm Credit Lender’s sole and exclusive benefit. Notwithstanding anything herein or in any other Loan Document to the contrary, the Farm Credit System Equity of a particular Farm Credit Lender shall not constitute security for the Obligations due to any other Lender. To the extent that any of the Loan Documents create a Lien on the Farm Credit System Equity of a Farm Credit Lender or on patronage accrued by such Farm Credit Lender for the account of the Borrower (including, in each case, proceeds thereof), such Lien shall be for such Farm Credit Lender’s sole and exclusive benefit and shall not be subject to pro rata sharing hereunder. Neither the Farm Credit System Equity nor any accrued patronage shall be offset against the obligations hereunder except that, in the event of an Event of Default that is continuing, a Farm Credit Lender may elect, solely at its discretion, upon prior written notice to the Borrower, to apply the cash portion of any patronage distribution or retirement of equity, made with 87 Å respect to such Farm Credit Lender’s Farm Credit Equities, to amounts owing to such Farm Credit Lender under this Agreement, whether or not such amounts are currently due and payable. The Borrower acknowledges that any corresponding tax liability associated with such application is the sole responsibility of the Borrower. No Farm Credit Lender shall have an obligation to retire the Farm Credit System Equity of such Farm Credit Lender upon any Default, either for application to the Obligations or otherwise. ARTICLE VI Negative Covenants Until all of the Secured Obligations shall have been Paid in Full, each Loan Party executing this Agreement covenants and agrees, jointly and severally with all of the other Loan Parties, with the Lenders that: SECTION 6.01. Indebtedness. No Loan Party will, nor will it permit any Subsidiary to, create, incur, assume or suffer to exist any Indebtedness, except: (a) the Secured Obligations; (b) Indebtedness existing on the date hereof and set forth in Schedule 6.01 and any Refinance Indebtedness in respect thereof; (c) Indebtedness of the Borrower to any Subsidiary and of any Subsidiary to the Borrower or any other Subsidiary, provided that (i) Indebtedness of any Subsidiary that is not a Loan Party to the Borrower or any other Loan Party shall be subject to Section 6.04 and (ii) Indebtedness of any Loan Party to any Subsidiary that is not a Loan Party shall be subordinated to the Secured Obligations on terms reasonably satisfactory to the Administrative Agent; (d) Guarantees by the Borrower of Indebtedness of any Subsidiary and by any Subsidiary of Indebtedness of the Borrower or any other Subsidiary, provided that (i) the Indebtedness so Guaranteed is permitted by this Section 6.01, (ii) Guarantees by the Borrower or any other Loan Party of Indebtedness of any Subsidiary that is not a Loan Party shall be subject to Section 6.04 and (iii) Guarantees permitted under this clause (d) shall be subordinated to the Secured Obligations on the same terms as the Indebtedness so Guaranteed is subordinated to the Secured Obligations; (e) Indebtedness of the Borrower or any Subsidiary incurred to finance the acquisition, construction, repair, replacement or improvement of any fixed or capital assets (whether or not constituting purchase money Indebtedness), including Capital Lease Obligations and any Indebtedness assumed in connection with the acquisition of any such assets or secured by a Lien on any such assets prior to the acquisition thereof, and extensions, renewals and replacements of any such Indebtedness in accordance with clause (f) below; provided that (i) such Indebtedness is incurred prior to or within 180 days after such acquisition or the completion of such construction or improvement and (ii) the aggregate principal amount of Indebtedness permitted by this clause (e), together with any Refinance Indebtedness in respect thereof permitted by clause (f) below, shall not exceed \$25,000,000 at any time outstanding; (f) Indebtedness which represents extensions, renewals, refinancing or replacements (such Indebtedness being so extended, renewed, refinanced or replaced being referred to herein as the “Original Indebtedness”); provided that (i) such Refinance Indebtedness does not increase the principal amount or interest rate of the Original Indebtedness, (ii) any Liens securing such Refinance Indebtedness are not extended to any additional property of any Loan Party or any Subsidiary, 88 Å (iii) no Loan Party or any Subsidiary that is not originally obligated with respect to repayment of such Original Indebtedness is required to become obligated with respect to such Refinance Indebtedness, (iv) such Refinance Indebtedness does not result in a shortening of the average weighted maturity of such Original Indebtedness, (v) the terms of such Refinance Indebtedness are not materially less favorable to the obligor thereunder than the original terms of such Original Indebtedness and (vi) if such Original Indebtedness was subordinated in right of payment to the Obligations or any of the other Secured Obligations, then the terms and conditions of such Refinance Indebtedness must include subordination terms and conditions that are at least as favorable to the Administrative Agent and the Lenders as those that were applicable to such Original Indebtedness; (g) Indebtedness owed to any Person providing workers’ compensation, health, disability or other employee benefits or property, casualty or liability insurance, pursuant to reimbursement or indemnification obligations to such Person, in each case incurred in the ordinary course of business; (h) Indebtedness of any Loan Party in respect of performance bonds, bid bonds, appeal bonds, surety bonds and similar obligations, in each case provided in the ordinary course of business; (i) Subordinated Indebtedness in an aggregate principal amount not exceeding \$5,000,000 at any time outstanding; (j) Indebtedness of any Person that becomes a Subsidiary after the date hereof; provided that (i) such Indebtedness exists at the time such Person becomes a Subsidiary and is not created in contemplation of or in connection with such Person becoming a Subsidiary and (ii) the aggregate principal amount of Indebtedness permitted by this clause (j), together with any Refinance Indebtedness in respect thereof permitted by clause (f) above, shall not exceed \$5,000,000 at any time outstanding; (k) Commodity Hedge Liabilities in an aggregate principal amount not exceeding \$10,000,000 at any time outstanding; (l) other unsecured Indebtedness in an aggregate principal amount not exceeding \$5,000,000 at any time outstanding; (m) Indebtedness in connection with corporate credit cards issued to the Borrower and its Subsidiaries in the ordinary course of business; (n) Indebtedness in respect of netting services, overdraft protections, payment processing, automatic clearinghouse arrangements, arrangements in respect of pooled deposit or sweep accounts, check endorsement guarantees and otherwise in connection with deposit accounts or cash management services, in each case, incurred in the ordinary course of business; (o) Indebtedness consisting of insurance premium financing incurred in the ordinary course of business and not exceeding the actual amount of such premiums; (p)

Indebtedness under Swap Agreements permitted by Section 6.07; (q) Guarantees of customary and reasonable indemnity obligations or entered into in connection with any Acquisition or Disposition permitted under this Agreement (other than any such obligations with respect to Indebtedness); and (r) unsecured Indebtedness in the form of (i) customary purchase price adjustments or (ii) earn outs, deferred compensation, or other arrangements representing acquisition consideration or deferred 89 A payments of a similar nature incurred in connection with Permitted Acquisitions in an aggregate principal amount not exceeding \$10,000,000 at any time outstanding. SECTION 6.02. Liens. No Loan Party will, nor will it permit any Subsidiary to, create, incur, assume or permit to exist any Lien on any property or asset now owned or hereafter acquired by it, or assign or sell any income or revenues (including Accounts) or rights in respect of any thereof, except: (a) Liens created pursuant to any Loan Document; (b) Permitted Encumbrances; (c) any Lien on any property or asset of the Borrower or any Subsidiary existing on the date hereof and set forth in Schedule 6.02; provided that (i) such Lien shall not apply to any other property or asset of the Borrower or any Subsidiary and (ii) such Lien shall secure only those obligations which it secures on the date hereof and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof; (d) Liens on fixed or capital assets acquired, constructed or improved and the proceeds thereof by the Borrower or any Subsidiary; provided that (i) such Liens secure Indebtedness permitted by Section 6.01(e), (ii) such Liens and the Indebtedness secured thereby are incurred prior to or within 180 days after such acquisition or the completion of such construction or improvement, (iii) the Indebtedness secured thereby does not exceed the cost of acquiring, constructing or improving such fixed or capital assets and (iv) such Liens shall not apply to any other property or assets of the Borrower or any Subsidiary; (e) any Lien existing on any property or asset prior to the acquisition thereof by the Borrower or any Subsidiary or existing on any property or asset of any Person that becomes a Loan Party after the date hereof prior to the time such Person becomes a Loan Party; provided that (i) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Loan Party, as the case may be, (ii) such Lien shall not apply to any other property or assets of any Loan Party or Subsidiary and (iii) such Lien shall secure only those obligations which it secures on the date of such acquisition or the date such Person becomes a Loan Party, as the case may be, and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof; (f) Liens of a collecting bank arising in the ordinary course of business under Section 4-210 of the UCC in effect in the relevant jurisdiction covering only the items being collected upon; (g) Liens arising out of Sale and Leaseback Transactions permitted by Section 6.06; (h) Liens granted by a Subsidiary that is not a Loan Party in favor of the Borrower or another Loan Party in respect of Indebtedness owed by such Subsidiary; (i) all Liens arising by statute, regulation, contract or otherwise in favor of any Farm Credit Lender in or on the Farm Credit System Equity; (j) Liens securing Indebtedness and other obligations in an aggregate outstanding amount not to exceed at any time \$5,000,000; (k) Liens on cash collateral securing Commodity Hedge Liabilities permitted under Section 6.01(k); 90 A (l) Liens on earnest money deposits of cash or cash equivalents made, or escrow or similar arrangements entered into, in connection with any Permitted Acquisition or other Investment permitted pursuant to Section 6.04; (m) Liens in the nature of the right of setoff in favor of counterparties to contractual agreements with Borrower or any Subsidiary in the ordinary course of business; (n) Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods the Borrower or any Subsidiary in the ordinary course of business, other than Liens on Collateral and solely to the extent encumbering the assets subject to such transaction; (o) Liens on insurance policies and the proceeds thereof securing Indebtedness permitted by Section 6.01(o); and (p) Liens securing Indebtedness permitted by Section 6.01(p) in an aggregate outstanding amount not to exceed at any time \$1,000,000. SECTION 6.03. Fundamental Changes. (a) No Loan Party will, nor will it permit any Subsidiary to, merge into or consolidate with any other Person, or permit any other Person to merge into or consolidate with it, or otherwise Dispose of all or substantially all of its assets, or all or substantially all of the Equity Interests of any of its Subsidiaries (in each case, whether now owned or hereafter acquired), or liquidate or dissolve, except that, if at the time thereof and immediately after giving effect thereto no Event of Default shall have occurred and be continuing, (i) any Subsidiary of the Borrower may merge into the Borrower in a transaction in which the Borrower is the surviving entity, (ii) any Loan Party (other than the Borrower) may merge into any other Loan Party in a transaction in which the surviving entity is a Loan Party, (iii) any Subsidiary that is not a Loan Party may merge into any other Subsidiary that is not a Loan Party or into any Loan Party (provided that any such transaction involving a Loan Party shall result in a Loan Party as the surviving entity), (iv) any Loan Party (other than the Borrower) may Dispose of all its assets to another Loan Party, (v) any Subsidiary that is not a Loan Party may Dispose of all its assets to another Subsidiary that is not a Loan Party or to any Loan Party, (vi) any Subsidiary may liquidate or dissolve if such Subsidiary first Disposes of all of its assets to a Loan Party, and the Borrower determines in good faith that such liquidation or dissolution is in the best interests of the Borrower and is not materially disadvantageous to the Lenders (as reasonably determined by the Administrative Agent) and (vii) the Loan Parties and their Subsidiaries may consummate Permitted Acquisitions; provided that any such merger or consolidation involving a Person that is not a wholly-owned Subsidiary immediately prior to such merger or consolidation shall not be permitted unless also permitted by Section 6.04. (b) No Loan Party will, nor will it permit any Subsidiary to, engage in any business other than businesses of the type conducted by the Borrower and its Subsidiaries on the date hereof and businesses reasonably related, supplemental or incidental thereto and reasonable extensions thereof. (c) No Loan Party will, nor will it permit any Subsidiary to change its fiscal year or any fiscal quarter from the basis in effect on the Effective Date. (d) No Loan Party will change the accounting basis upon which its financial statements are prepared. SECTION 6.04. Investments, Loans, Advances, Guarantees and Acquisitions. No Loan Party will, nor will it permit any Subsidiary to, form any subsidiary after the Effective Date, or purchase, hold or 91 A acquire (including pursuant to any merger or consolidation with any Person that was not a Loan Party and a wholly-owned Subsidiary prior to such merger or consolidation) any Equity Interests, evidences of indebtedness or other securities (including any option, warrant or other right to acquire any of the foregoing) of, make or permit to exist any loans or advances to, Guarantee any obligations of, or make or permit to exist any investment or any other interest in, any other Person, or purchase or otherwise acquire (in one transaction or a series of transactions) any Person or any assets of any other Person constituting a business unit (whether through purchase of assets, merger or otherwise) (any of the foregoing, an "Investment"), except: (a) Permitted Investments; (b) Investments in existence on the date hereof and described in Schedule 6.04 and any modification, replacement, renewal or extension thereof to the extent not involving any additional Investment; provided that the amount of any such Investment is not increased from the amount of such Investment on the Effective Date except pursuant to the terms of such Investment (including in respect of any unused commitment), plus any accrued but unpaid interest (including any portion thereof which is payable in kind in accordance with the terms of such modified, extended, renewed, refinanced or replaced Investment) and premium payable by the terms of such Investment thereon and fees and expenses associated therewith, in each case, as in existence on the Effective Date; (c) Investments made by the Borrower and the Subsidiaries in Equity Interests in their respective Subsidiaries, provided that (i) any such Equity Interests held by a Loan Party shall be pledged pursuant to the Security Agreement (subject to the limitations in Section 5.13) and (ii) the aggregate outstanding amount of Investments by Loan Parties in Subsidiaries that are not Loan Parties (together with outstanding principal amount of intercompany loans permitted under clause (ii) of the proviso to Section 6.04(d) and outstanding principal amount of Indebtedness subject to Guarantees permitted under the proviso to Section 6.04(e)) shall not exceed \$5,000,000 at any time outstanding (in each case determined without regard to any write-downs or write-offs); (d) loans or advances made by any Loan Party to any Subsidiary and made by any Subsidiary to a Loan Party or any other Subsidiary, provided that (i) to the extent any such loans and advances made by a Loan Party are evidenced by a promissory note, they shall be pledged to the extent required by the terms of the Security Agreement, (ii) the outstanding principal amount of such loans and advances made by Loan Parties to Subsidiaries that are not Loan Parties (together with outstanding Investments permitted under clause (ii) of the proviso to Section 6.04(c) and the outstanding principal amount of Indebtedness subject to Guarantees permitted under the proviso to Section 6.04(e)) shall not exceed \$5,000,000 at any time outstanding (in each case determined without regard to any write-downs or write-offs) and (iii) such loans or advances shall be subordinated to the Secured Obligations on terms and conditions reasonably satisfactory to the Administrative Agent; (e) Guarantees constituting Indebtedness permitted by Section 6.01, provided that the aggregate outstanding principal amount of Indebtedness of Subsidiaries that are not Loan Parties that is Guaranteed by any Loan Party (together with outstanding Investments permitted under clause (ii) of the proviso to Section 6.04(c) and outstanding principal amount of intercompany loans permitted under clause (ii) of the proviso to Section 6.04(d)) shall not exceed \$5,000,000 at any time outstanding (in each case determined without regard to any write-downs or write-offs); (f) (i) loans or advances made by a Loan Party to its employees on an arms-length basis in the ordinary course of business consistent with past practices for travel and entertainment expenses, relocation costs and similar purposes up to a maximum principal amount of \$500,000 in the aggregate at any one time outstanding and (ii) loans to employees, officers or directors relating to the purchase of Qualified Stock of 92 A the Borrower and its Subsidiaries pursuant to employee equity purchase agreements approved by the Borrower's or such Subsidiary's board of directors; provided that (A) the proceeds of such loans are substantially contemporaneously contributed to a Loan Party or (B) no cash or cash equivalents are advanced in connection with such loan; (g) notes payable, or stock or other securities issued by Account Debtors to a Loan Party pursuant to negotiated agreements with respect to settlement of such Account Debtor's Accounts in the ordinary course of business, consistent with past practices; (h) Investments in the form of Swap Agreements permitted by Section 6.07 and Commodity Hedge Liabilities permitted by Section 6.01(k); (i) Investments of any Person existing at the time such Person becomes a Subsidiary of the Borrower or consolidates or merges with the Borrower or any Subsidiary (including in connection with a Permitted Acquisition), so long as such Investments were not made in contemplation of such Person becoming a Subsidiary or of such merger; (j) Investments received in connection with the Disposition of assets permitted by Section 6.05; (k) Investments constituting deposits described in clauses (c) and (d) of the definition of the term "Permitted Encumbrances"; (l) Permitted Acquisitions; (m) Investments in Farm Credit System Equity and any other stock or securities, or Investment in, any Farm Credit Lender or its investment services or programs that the Borrower has acquired pursuant to this Agreement; (n) other Investments in an aggregate amount not to exceed at any time outstanding (in each case determined without regard to any write-downs or write-offs) \$10,000,000; (o) extensions of trade credit to customers in the ordinary course of business; (p) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; (q) Investments consisting of notes receivable of customers and suppliers in the ordinary course of business; provided that this clause (q) shall not apply to Investments of the Borrower in any Subsidiary; (r) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrowers' business; (s) minority equity Investments, joint ventures or strategic alliances provided that the aggregate outstanding amount of all Investments made in reliance on this clause (s) does not exceed \$5,000,000 at any time; and (t) other Investments so long as at the time of making each such Investment and immediately after giving effect (including giving effect on a pro forma basis) thereto (A) no Default or Event of Default 93 A shall have occurred and be continuing or would result therefrom, (B) the Borrower is in compliance with the financial covenants set forth in Section 6.12 and (C) the Net Leverage Ratio is not greater than 2.75 to 1.00; provided that the aggregate outstanding amount of all Investments in Subsidiaries that are not Loan Parties made in reliance on this clause (t) shall not exceed \$5,000,000 at any time. SECTION 6.05. Asset Sales. No Loan Party will, nor will it permit any Subsidiary to, Dispose of any asset, including any Equity Interest owned by it, nor will the Borrower permit any Subsidiary to issue any additional Equity Interest in such Subsidiary (other than to the Borrower or another Subsidiary in compliance with Section 6.04), except: (a) Dispositions of (i) Inventory in the ordinary course of business, (ii) used, obsolete, worn out or surplus equipment or property in the ordinary course of business, (iii) property no longer used or useful to the business of the Loan Parties and their respective Subsidiaries in the ordinary course of business, and (iv) equipment or real property of such Loan Party or Subsidiary to the extent that (A) such property is exchanged for credit against the purchase price of similar replacement property of such Loan Party or Subsidiary or (B) the proceeds of such Dispositions are reasonably promptly applied to the purchase price of such replacement property of such Loan Party or Subsidiary; (b) Dispositions of assets to the Borrower or any Subsidiary; provided that (i) any such Dispositions involving a Subsidiary that is not a Loan Party shall be made in compliance with Section 6.09 and (ii) the aggregate fair market value of all assets Disposed by Loan Parties to Subsidiaries that are not Loan Parties during the term of this Agreement shall not exceed \$5,000,000; (c) Dispositions of Accounts (excluding Dispositions in a factoring arrangement) in connection with the compromise, settlement or collection thereof; (d) (i) Dispositions of cash, Permitted Investments and other Investments permitted by clauses (i) and (k) of Section 6.04 and (ii) Dispositions constituting Investments permitted under Section 6.04 (other than Section 6.04(j)); (e) Sale and Leaseback Transactions permitted by Section 6.06; (f) Dispositions resulting from any casualty or other insured damage to, or any taking under power of eminent domain or by condemnation or similar proceeding of, any property or asset of the Borrower or any Subsidiary; (g) transactions permitted by Section 6.03(a); (h) so long as at the time of making such Disposition and immediately after giving effect (including giving effect on a pro forma basis) thereto no Default or Event of Default then exists or would result therefrom, other Dispositions of assets (other than Equity Interests in a Subsidiary unless all Equity Interests in such Subsidiary are sold) that are not permitted by any other clause of this Section; provided that (i) the aggregate fair market value (determined at the time of the applicable Disposition) of all assets Disposed of in reliance upon this paragraph (h) during any fiscal year of the Borrower shall not exceed an amount equal to five percent (5%) of Consolidated Total Assets and (ii) with respect to any such Disposition for which the Borrower and its Subsidiaries (individually or collectively) receive proceeds in excess of \$5,000,000, at least 75% of the consideration receive by the Borrower and its Subsidiaries for any such Disposition made in reliance on this paragraph (h) shall consist of cash and/or Permitted Investments; (i) the granting of Liens pursuant to Section 6.02; 94 A (j) leases or subleases of real property granted in the ordinary course of business (and in the ordinary course of such Person's business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than intellectual property) granted in the ordinary course of business, in each case, if the leases, subleases, licenses and sublicenses do not (i) do not materially interfere with the ordinary conduct of business of any Borrower or any Subsidiary or (ii) prohibit granting the Administrative Agent, on behalf of itself, the Lenders and other Secured Parties, a security interest therein; (k) non-exclusive licenses of intellectual property granted to third parties in the ordinary course of business, and licenses of intellectual property in the ordinary course of business that could not result in a legal transfer of title of licensed property that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discrete geographical areas outside of the United States so long as such licenses do not interfere in any material respect with the business of the Loan Parties and their Subsidiaries; (l) the sale, assignment, transfer, disposal, abandonment, cancellation or lapse of any intellectual property, which, in the reasonable good faith determination of the Borrower is uneconomical or not material to the conduct of the business of the Borrower and/or its Subsidiaries; and (m) so long as no Event of Default then exists or would result therefrom, Dispositions of non-core assets acquired in connection with a Permitted Acquisition; provided that (i) the fair market value of such non-core assets shall not exceed 5% of the cash purchase price paid for all such assets acquired pursuant to such Permitted Acquisition and (ii) with respect to any such Disposition for which the Borrower and its Subsidiaries (individually or collectively) receive proceeds in excess of \$5,000,000, 75% of the consideration received from such Disposition shall be in the form of cash. Notwithstanding the foregoing, no Loan Party or any Subsidiary shall consummate any transaction that results in the Disposition (whether by way of any Restricted Payment, Investment, Lien, sale, conveyance, transfer or other Disposition, and whether in a single transaction or a series of transactions) of intellectual property that is material to the business of the Borrower and its Subsidiaries to any Subsidiary that is not a Loan Party; provided that the Borrower and its Subsidiaries may grant non-exclusive licenses of any intellectual property to any Subsidiary that is not a Loan Party in the ordinary course of business so long as the Borrower or such Subsidiary retains the beneficial ownership and the same rights to use such intellectual property as held prior to such license. SECTION 6.06. Sale and Leaseback Transactions. No Loan Party will, nor will it permit any Subsidiary to, enter into any arrangement, directly or indirectly, whereby it shall sell or transfer any property, real or personal, used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property sold or transferred (a "Sale and Leaseback Transaction"), except for any such sale of any fixed or capital assets by the Borrower or any Subsidiary that is made for cash consideration in an amount not less than the fair value of such fixed or capital asset and is consummated within 180 days after the Borrower or such Subsidiary acquires or completes the construction of such fixed or capital asset. SECTION 6.07. Swap Agreements. No Loan Party will, nor will it permit any Subsidiary to, enter into any Swap Agreement, except (a) Swap Agreements entered into to hedge or mitigate risks to which the Borrower or any Subsidiary has actual exposure (other than those in respect of Equity Interests of the Borrower or any Subsidiary), and (b) Swap Agreements entered into in order to effectively cap, collar or exchange interest rates (from floating to fixed rates, from one floating rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of the Borrower or any Subsidiary. 95 A SECTION 6.08. Restricted Payments; Certain Payments of Indebtedness. (a) No Loan Party will, nor will it permit any Subsidiary to, declare or make, or agree to declare or make, directly or indirectly, any Restricted Payment, except: (i) the Borrower may declare and pay dividends with respect to its Qualified Stock payable solely in additional shares of its Qualified Stock, and, with respect to its Disqualified Stock,

payable solely in additional shares of such Disqualified Stock (to the extent permitted under Section 6.01) or in shares of its Qualified Stock; (ii) Subsidiaries may declare and pay dividends ratably with respect to their Qualified Stock; (iii) so long as at the time of making such Restricted Payment and immediately after giving effect (including giving effect on a pro forma basis) thereto no Default or Event of Default then exists or would result therefrom, the Borrower may make Restricted Payments, not exceeding \$5,000,000 during any fiscal year, pursuant to and in accordance with stock option plans or other benefit plans for management or employees of the Borrower and its Subsidiaries; (iv) other Restricted Payments so long as at the time of making each such Restricted Payment and immediately after giving effect (including giving effect on a pro forma basis) thereto (A) no Default or Event of Default shall have occurred and be continuing or would result therefrom, (B) the Borrower is in compliance with the financial covenants set forth in Section 6.12 and (C) the Net Leverage Ratio is not greater than 2.50 to 1.00; (v) the Borrower may convert its convertible securities in accordance with the terms thereof so long as such convertible securities are not converted to Disqualified Stock or Indebtedness that is prohibited by Section 6.01 hereof; (vi) so long as at the time of making such Restricted Payment and immediately after giving effect (including giving effect on a pro forma basis) thereto no Default or Event of Default pursuant to clause (a), (b), (h), (i) or (m) of Article VII then exists or would result therefrom, Restricted Payments made in connection with equity compensation that consist solely of the withholding of shares to any employee (or other provider of services) in an amount equal to the employee's (or other provider of services') tax obligation on such compensation and the payment in cash to the applicable Governmental Authority of an amount equal to such tax obligation; and (vii) so long as at the time of making such Restricted Payment and immediately after giving effect (including giving effect on a pro forma basis) thereto no Default or Event of Default pursuant to clause (a), (b), (h), (i) or (m) of Article VII then exists or would result therefrom, Borrower may (i) repurchase fractional shares of its Equity Interests arising out of stock dividends, splits or combinations, business combinations or conversions of convertible securities, exercises of warrants or options, or settlements of restricted stock units or (ii) exercise or share settle warrants or options; provided that the aggregate amount of all Restricted Payments made in reliance on this clause (vii) shall not exceed \$10,000,000 during the term of this Agreement. (b) No Loan Party will, nor will it permit any Subsidiary to, make or agree to pay or make, directly or indirectly, any payment or other distribution (whether in cash, securities or other property) of or in respect of principal or of interest on any Subordinated Indebtedness, or any payment or other distribution (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any Subordinated 96 A Indebtedness, except as permitted by the subordination or intercreditor agreement applicable thereto (so long as such subordination provisions are reasonably acceptable to the Administrative Agent at the time of incurrence or assumption of such Subordinated Indebtedness). SECTION 6.09. Transactions with Affiliates. No Loan Party will, nor will it permit any Subsidiary to, sell, lease or otherwise transfer any property or assets to, or purchase, lease or otherwise acquire any property or assets from, or otherwise engage in any other transactions with, any of its Affiliates, except (a) transactions that (i) are in the ordinary course of business and (ii) are at prices and on terms and conditions not less favorable to such Loan Party or such Subsidiary than could be obtained on an arm's length basis from unrelated third parties, (b) transactions between or among the Loan Parties not involving any other Affiliate, (c) any investment permitted by Sections 6.04(c) or 6.04(d), (d) any Indebtedness permitted under Section 6.01(c), (e) any Restricted Payment permitted by Section 6.08, (f) loans or advances to employees permitted under Section 6.04(f), (g) the payment of reasonable fees to directors of the Borrower or any Subsidiary who are not employees of the Borrower or any Subsidiary, and compensation and employee benefit arrangements paid to, and indemnities provided for the benefit of, directors, officers or employees of the Borrower or its Subsidiaries in the ordinary course of business, (h) any issuances of securities or other payments, awards or grants in cash, securities or otherwise pursuant to, or the funding of, employment agreements, stock options and stock ownership plans approved by the Borrower's board of directors and (i) transactions with Sandpebble Builders Preconstruction, Inc. and Sandpebble South, Inc. (or their respective Affiliates) for project management and related services associated with egg packing, processing, and related activities, including in connection with Borrower's construction and expansion of egg processing facilities, including site selection, project management and related services for the Borrower's potential future egg packing facility. SECTION 6.10. Restrictive Agreements. No Loan Party will, nor will it permit any Subsidiary to, directly or indirectly enter into, incur or permit to exist any agreement or other arrangement that prohibits, restricts or imposes any condition upon (a) the ability of such Loan Party or any Subsidiary to create, incur or permit to exist any Lien upon any of its property or assets, or (b) the ability of any Subsidiary to pay dividends or other distributions with respect to any Equity Interests or to make or repay loans or advances to the Borrower or any other Subsidiary or to Guarantee Indebtedness of the Borrower or any other Subsidiary; provided that (i) the foregoing shall not apply to restrictions and conditions imposed by any applicable law or by any Loan Document, (ii) the foregoing shall not apply to restrictions and conditions existing on the date hereof identified on Schedule 6.10 (but shall apply to any extension or renewal of, or any amendment or modification expanding the scope of, any such restriction or condition), (iii) the foregoing shall not apply to customary restrictions and conditions contained in agreements relating to the sale of assets or a Subsidiary pending such sale, provided such restrictions and conditions apply only to such assets or the Subsidiary that is to be sold and such sale is permitted hereunder, (iv) clause (a) of the foregoing shall not apply to restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Agreement if such restrictions or conditions apply only to the property or assets securing such Indebtedness, (v) clause (a) of the foregoing shall not apply to customary provisions in leases and other contracts restricting the assignment thereof or restricting the grant of Liens in such lease or other contract, (vi) the foregoing shall not apply to any agreement or restriction or condition in effect at the time any Person becomes a Subsidiary of Borrower, so long as such agreement was not entered into solely in contemplation of such Person becoming a Subsidiary of Borrower, and (vii) the foregoing shall not apply to customary provisions in joint venture agreements and other similar agreements applicable to joint ventures so long as such restrictions apply solely to the Equity Interests of the applicable joint venture. No Loan Party shall, nor shall it permit any Subsidiary to, sell, transfer, assign, mortgage, pledge, lease, grant a security interest in or otherwise encumber (other than Permitted Encumbrances and Liens permitted pursuant to Section 6.02(e)) any real property owned by any Loan Party or Subsidiary to an unaffiliated third party without the prior written consent of the Required Lenders. 97 A SECTION 6.11. Amendment of Material Documents. No Loan Party will, nor will it permit any Subsidiary to, amend or modify, or waive any of its rights under, (a) any agreement relating to any Subordinated Indebtedness (except as otherwise expressly permitted under the terms of the subordination agreement applicable thereto so long as such subordination provisions are reasonably acceptable to the Administrative Agent at the time of incurrence or assumption of such Subordinated Indebtedness), or (b) its charter, articles or certificate of organization or incorporation and bylaws or operating, management or partnership agreement, or other organizational or governing documents, in each case, to the extent any such amendment, modification or waiver would reasonably be expected to be materially adverse to the Lenders. SECTION 6.12. Financial Covenants. (a) Net Leverage Ratio. The Borrower will not permit the Net Leverage Ratio, on the last day of any fiscal quarter ending on or after March 31, 2024, to be greater than 3.25 to 1.00; provided that (i) so long as no Event of Default exists at such time or would result therefrom, the Borrower may, not more than two times during the term of this Agreement, elect to increase the maximum Net Leverage Ratio permitted under Section 6.12(a) to 4.00 to 1.00 for a period of four consecutive fiscal quarters in connection with a Material Acquisition occurring during the first of such four fiscal quarters (each such period of four consecutive fiscal quarters, an Adjusted Covenant Period) and (ii) notwithstanding the foregoing clause (i), (A) the Borrower may not elect an Adjusted Covenant Period in respect of any Material Acquisition if, immediately after giving effect (including giving effect on a pro forma basis) to the consummation of such Material Acquisition, the Net Leverage Ratio exceeds 3.00 to 1.00 and (B) the Borrower may not elect a new Adjusted Covenant Period for at least one (1) full fiscal quarter following the end of another Adjusted Covenant Period. (b) Fixed Charge Coverage Ratio. The Borrower will not permit the Fixed Charge Coverage Ratio, for any period of four consecutive fiscal quarters ending on the last day of any fiscal quarter ending on or after March 31, 2024, to be less than 1.35 to 1.00. ARTICLE VII Events of Default If any of the following events (Events of Default) shall occur: (a) the Borrower shall fail to pay any principal of any Loan or any reimbursement obligation in respect of any LC Disbursement when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; (b) the Borrower shall fail to pay any interest on any Loan or any fee or any other amount (other than an amount referred to in clause (a) of this Article) payable under this Agreement or any other Loan Document, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of five (5) Business Days; (c) any representation or warranty made or deemed made by or on behalf of any Loan Party or any Subsidiary in, or in connection with, this Agreement or any other Loan Document or any amendment or modification hereof or thereof or waiver hereunder or thereunder, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof or waiver hereunder or thereunder, shall prove to have been materially incorrect when made or deemed made; 98 A (d) any Loan Party shall fail to observe or perform any covenant, condition or agreement contained in Section 5.02(a), 5.03 (with respect to a Loan Party's existence), 5.08 or 5.14, or in Article VI or in Article X; (e) any Loan Party shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified in clause (a), (b) or (d) of this Article) or any other Loan Document, and such failure shall continue unremedied for a period of (i) five (5) days after the earlier of any Loan Party's knowledge of such breach or notice thereof from the Administrative Agent (which notice will be given at the request of any Lender) if such breach relates to terms or provisions of Section 5.01, 5.02 (other than Section 5.02(a)), 5.03 (other than with respect to a Loan Party's existence) through 5.07, 5.10 or 5.11 of this Agreement or (ii) thirty (30) days after the earlier of any Loan Party's knowledge of such breach or notice thereof from the Administrative Agent (which notice will be given at the request of any Lender) if such breach relates to terms or provisions of any other Section of this Agreement or any other Loan Document; (f) any Loan Party or any Subsidiary shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of any Material Indebtedness, when and as the same shall become due and payable (after giving effect to any cure or grace period and to the extent not waived); (g) any event or condition occurs that results in any Material Indebtedness becoming due prior to its scheduled maturity or that enables or permits (after giving effect to any cure or grace period and to the extent not waived) the holder or holders of any Material Indebtedness or any trustee or agent on its or their behalf to cause any Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this clause (g) shall not apply to (i) secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness to the extent such sale or transfer is permitted by the terms of Section 6.05 or (ii) Indebtedness of any Person whose Equity Interests are being acquired in a Permitted Acquisition and which Indebtedness becomes due because of such Permitted Acquisition; (h) an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or other relief in respect of a Loan Party or Material Subsidiary or its debts, or of a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for any Loan Party or any Material Subsidiary or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall be entered; (i) any Loan Party or any Material Subsidiary shall (i) voluntarily commence any proceeding or file any petition seeking liquidation, reorganization or other relief under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in clause (h) of this Article, (iii) apply for or consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for such Loan Party or Material Subsidiary of any Loan Party or for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors or (vi) take any action for the purpose of effecting any of the foregoing; (j) any Loan Party or any Material Subsidiary shall become unable, admit in writing its inability, or publicly declare its intention not to, or fail generally, to pay its debts as they become due; 99 A (k) one or more judgments for the payment of money in an aggregate amount in excess of \$5,000,000 (to the extent not covered by independent third-party insurance as to which the insurer has been notified of the claim and does not dispute coverage) shall be rendered against any Loan Party, any Subsidiary or any combination thereof and the same shall remain undischarged or unpaid for a period of thirty (30) consecutive days during which execution shall not be effectively stayed or bonded, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Loan Party or any Subsidiary to enforce any such judgment or any Loan Party or any Subsidiary shall fail within thirty (30) days to discharge one or more non-monetary judgments or orders which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect, which judgments or orders, in any such case, are not stayed on appeal or otherwise being appropriately contested in good faith by proper proceedings diligently pursued; (l) an ERISA Event shall have occurred that, in the opinion of the Required Lenders, when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in a Material Adverse Effect; (m) a Change in Control shall occur; (n) [reserved]; (o) the Loan Guaranty shall fail to remain in full force or effect (other than pursuant to the terms hereof or thereof) or any action shall be taken to discontinue or to assert the invalidity or unenforceability of the Loan Guaranty or any Loan Guarantor shall fail to comply with any of the terms or provisions of the Loan Guaranty, or any Loan Guarantor shall deny that it has any further liability under the Loan Guaranty, or shall give notice to such effect, including, but not limited to notice of termination delivered pursuant to Section 10.08; (p) except as permitted by the terms of any Collateral Document, (i) any Collateral Document shall for any reason fail to create a valid security interest in any portion of the Collateral having a fair market value, individually or in the aggregate, of \$5,000,000 or more purported to be covered thereby, or (ii) any Lien securing any Secured Obligation shall cease to be a perfected, first priority Lien; (q) any Collateral Document shall fail to remain in full force or effect (other than pursuant to the terms hereof or thereof) or any action shall be taken to discontinue or to assert the invalidity or unenforceability of any Collateral Document; or (r) any material provision of any Loan Document for any reason ceases to be valid, binding and enforceable in accordance with its terms (or any Loan Party shall challenge the enforceability of any Loan Document or shall assert in writing, or engage in any action or inaction that evidences its assertion, that any provision of any of the Loan Documents has ceased to be or otherwise is not valid, binding and enforceable in accordance with its terms); then, and in every such event (other than an event with respect to the Borrower described in clause (h) or (i) of this Article), and at any time thereafter during the continuance of such event, the Administrative Agent may, and at the request of the Required Lenders shall, by notice to the Borrower, take any or all of the following actions, at the same or different times: (i) terminate the Revolving Commitments, whereupon the Revolving Commitments shall terminate immediately, (ii) declare the Loans then outstanding to be due and payable in whole (or in part, but ratably as among the Loans at the time outstanding, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), whereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Secured Obligations (including, for the avoidance of doubt, any break funding 100 A payment) accrued hereunder and under the other Loan Documents, shall become due and payable immediately, in each case without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Loan Parties, (iii) require cash collateral for the LC Exposure in accordance with Section 2.06(j) hereof and (iv) exercise all other rights and remedies of the Secured Parties under the Loan Documents and applicable law; and in the case of any event with respect to the Borrower described in clause (h) or (i) of this Article, the Revolving Commitments shall automatically terminate and the principal of the Loans then outstanding and cash collateral for the LC Exposure, together with accrued interest thereon and all fees and other Secured Obligations (including, for the avoidance of doubt, any break funding payment) accrued hereunder and under the other Loan Documents, shall automatically become due and payable, and the obligation of the Borrower to cash collateralize the LC Exposure as provided in clause (iii) above shall automatically become effective, in each case without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Loan Parties. Upon the occurrence and during the continuance of an Event of Default, the Administrative Agent may, and at the request of the Required Lenders shall, increase the rate of interest applicable to the Loans and other Obligations as set forth in this Agreement and exercise any rights and remedies provided to the Administrative Agent under the Loan Documents or at law or equity, including all remedies provided under the UCC. In addition to any other rights and remedies granted to the Administrative Agent and the Lenders in the Loan Documents, the Administrative Agent on behalf of the Secured Parties may exercise all rights and remedies of a secured party under the UCC or any other applicable law. Without limiting the generality of the foregoing, the Administrative Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Loan Party or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived by the Borrower on behalf of itself and its Subsidiaries), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, or consent to the use by any Loan Party of any cash collateral arising in respect of the Collateral on such terms as the Administrative Agent deems reasonable, and/or may forthwith sell, lease, assign give an option or options to purchase or otherwise dispose of and deliver, or acquire by credit bid on behalf of the Lenders, the Collateral or any part thereof (or contract to do any of the

forgoing), in one or more parcels at public or private sale or sales, at any exchange, brokerâ€™s board or office of the Administrative Agent or any Lender or elsewhere, upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery, all without assumption of any credit risk. The Administrative Agent or any Lender shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Loan Party, which right or equity is hereby waived and released by the Borrower on behalf of itself and its Subsidiaries. The Borrower further agrees on behalf of itself and its Subsidiaries, at the Administrative Agentâ€™s request, to assemble the Collateral and make it available to the Administrative Agent at places which the Administrative Agent shall reasonably select, whether at the premises of the Borrower, another Loan Party or elsewhere. The Administrative Agent shall apply the net proceeds of any action taken by it pursuant to this Article VII, after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any other way relating to the Collateral or the rights of the Administrative Agent and the Lenders hereunder, including reasonable attorneysâ€™ fees and disbursements, to the payment in whole or in part of the obligations of the Loan Parties under the Loan Documents, in such order as the Administrative Agent may elect, and only after such application and after the payment by the Administrative Agent of any other amount required by any provision of law, including Section 9-615(a)(3) of the UCC, need the Administrative Agent account for the surplus, if any, to any Loan Party. To the extent permitted by applicable law, the Borrower on behalf of itself and its Subsidiaries waives all Liabilities it may acquire against the Administrative Agent or any Lender arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral 101 Â shall be required by law, such notice shall be deemed reasonable and proper if given at least 10 days before such sale or other disposition. ARTICLE VIIIThe Administrative Agent SECTION 8.01. Authorization and Action. (a) Each Lender, on behalf of itself and any of its Affiliates that are Secured Parties and each Issuing Bank hereby irrevocably appoints the entity named as Administrative Agent in the heading of this Agreement and its successors and assigns to serve as the administrative agent and collateral agent under the Loan Documents and each Lender and each Issuing Bank authorizes the Administrative Agent to take such actions as agent on its behalf and to exercise such powers under this Agreement and the other Loan Documents as are delegated to the Administrative Agent under such agreements and to exercise such powers as are reasonably incidental thereto. In addition, to the extent required under the laws of any jurisdiction other than within the United States, each Lender and each Issuing Bank hereby grants to the Administrative Agent any required powers of attorney to execute and enforce any Collateral Document governed by the laws of such jurisdiction on such Lenderâ€™s or such Issuing Bankâ€™s behalf. Without limiting the foregoing, each Lender and each Issuing Bank hereby authorizes the Administrative Agent to execute and deliver, and to perform its obligations under, each of the Loan Documents to which the Administrative Agent is a party, and to exercise all rights, powers and remedies that the Administrative Agent may have under such Loan Documents. (b) As to any matters not expressly provided for herein and in the other Loan Documents (including enforcement or collection), the Administrative Agent shall not be required to exercise any discretion or take any action, but shall be required to act or to refrain from acting (and shall be fully protected in so acting or refraining from acting) upon the written instructions of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, pursuant to the terms in the Loan Documents), and, unless and until revoked in writing, such instructions shall be binding upon each Lender and each Issuing Bank; provided, however, that the Administrative Agent shall not be required to take any action that (i) the Administrative Agent in good faith believes exposes it to liability unless the Administrative Agent receives an indemnification and is exculpated in a manner satisfactory to it from the Lenders and the Issuing Banks with respect to such action or (ii) is contrary to this Agreement or any other Loan Document or applicable law, including any action that may be in violation of the automatic stay under any applicable law relating to bankruptcy, insolvency or reorganization or relief of debtors or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any applicable law relating to bankruptcy, insolvency or reorganization or relief of debtors; provided, further, that the Administrative Agent may seek clarification or direction from the Required Lenders prior to the exercise of any such instructed action and may refrain from acting until such clarification or direction has been provided. Except as expressly set forth in the Loan Documents, the Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower, any other Loan Party, any Subsidiary or any Affiliate of any of the foregoing that is communicated to or obtained by the Person serving as Administrative Agent or any of its Affiliates in any capacity. Nothing in this Agreement shall require the Administrative Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it shall have reasonable grounds for believing that repayment of such funds or adequate indemnity against such risk or liability is not reasonably assured to it. (c) In performing its functions and duties hereunder and under the other Loan Documents, the Administrative Agent is acting solely on behalf of the Lenders and the Issuing Banks (except in limited 102 Â circumstances expressly provided for herein relating to the maintenance of the Register), and its duties are entirely mechanical and administrative in nature. The motivations of the Arranger and the Administrative Agent are commercial in nature and not to invest in the general performance or operations of the Borrower. Without limiting the generality of the foregoing: (i) the Administrative Agent does not assume and shall not be deemed to have assumed any obligation or duty or any other relationship as the agent, fiduciary or trustee of or for any Lender, Issuing Bank, any other Secured Party or holder of any other Secured Obligation other than as expressly set forth herein and in the other Loan Documents, regardless of whether a Default or an Event of Default has occurred and is continuing (and it is understood and agreed that the use of the term â€œagentâ€ (or any similar term) herein or in any other Loan Document with reference to the Administrative Agent is not intended to connote any fiduciary duty or other implied (or express) obligations arising under agency doctrine of any applicable law, and that such term is used as a matter of market custom and is intended to create or reflect only an administrative relationship between contracting parties); additionally, each Lender agrees that it will not assert any claim against the Administrative Agent based on an alleged breach of fiduciary duty by the Administrative Agent in connection with this Agreement and the transactions contemplated hereby; (ii) where the Administrative Agent is required or deemed to act as a trustee in respect of any Collateral over which a security interest has been created pursuant to a Loan Document expressed to be governed by the laws of any country, or is required or deemed to hold any Collateral â€œon trustâ€ pursuant to the foregoing, the obligations and liabilities of the Administrative Agent to the Secured Parties in its capacity as trustee shall be excluded to the fullest extent permitted by applicable law; and (iii) nothing in this Agreement or any Loan Document shall require the Administrative Agent to account to any Lender for any sum or the profit element of any sum received by the Administrative Agent for its own account. (d) The Administrative Agent may perform any of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any of their respective duties and exercise their respective rights and powers through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities pursuant to this Agreement. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agent. (e) The Arranger shall not have obligations or duties whatsoever in such capacity under this Agreement or any other Loan Document and shall incur no liability hereunder or thereunder in such capacity, but all such persons shall have the benefit of the indemnities provided for hereunder. (f) In case of the pendency of any proceeding with respect to any Loan Party under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, the Administrative Agent (irrespective of whether the principal of any Loan or any reimbursement obligation in respect of any LC Disbursement shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered (but not obligated) by intervention in such proceeding or otherwise: 103 Â (i) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, LC Disbursements and all other Secured Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the Issuing Banks and the Administrative Agent (including any claim under Sections 2.12, 2.13, 2.15, 2.17 and 9.03) allowed in such judicial proceeding; and (ii) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; and any custodian, receiver, assignee, trustee, liquidator, sequestator or other similar official in any such proceeding is hereby authorized by each Lender, each Issuing Bank and each other Secured Party to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, the Issuing Banks or the other Secured Parties, to pay to the Administrative Agent any amount due to it, in its capacity as the Administrative Agent, under the Loan Documents (including under Section 9.03). Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or Issuing Bank any plan of reorganization, arrangement, adjustment or composition affecting the Secured Obligations or the rights of any Lender or Issuing Bank or to authorize the Administrative Agent to vote in respect of the claim of any Lender or Issuing Bank in any such proceeding. (g) The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the Issuing Banks, and, except solely to the extent of the Borrowerâ€™s rights to consent pursuant to and subject to the conditions set forth in this Article, none of the Borrower or any Subsidiary, or any of their respective Affiliates, shall have any rights as a third party beneficiary under any such provisions. Each Secured Party, whether or not a party hereto, will be deemed, by its acceptance of the benefits of the Collateral and of the Guarantees of the Secured Obligations provided under the Loan Documents, to have agreed to the provisions of this Article. SECTION 8.02. Administrative Agentâ€™s Reliance, Limitation of Liability, Indemnification, Etc.. (a) Neither the Administrative Agent nor any of its Related Parties shall be (i) liable for any action taken or omitted to be taken by such party, the Administrative Agent or any of its Related Parties under or in connection with this Agreement or the other Loan Documents (x) with the consent of or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in the Loan Documents) or (y) in the absence of its own gross negligence or willful misconduct (such absence to be presumed unless otherwise determined by a court of competent jurisdiction by a final and nonappealable judgment) or (ii) responsible in any manner to any of the Lenders for any recitals, statements, representations or warranties made by any Loan Party or any officer thereof contained in this Agreement or any other Loan Document or in any certificate, report, statement or other document referred to or provided for in, or received by the Administrative Agent under or in connection with, this Agreement or any other Loan Document or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document (including, for the avoidance of doubt, in connection with the Administrative Agentâ€™s reliance on any Electronic Signature transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page) or for any failure of any Loan Party to perform its obligations hereunder or thereunder. (b) The Administrative Agent shall be deemed not to have knowledge of any (x) notice of any of the events or circumstances set forth or described in Section 5.02 unless and until written notice thereof stating that it is a â€œnotice under Section 5.02â€ in respect of this Agreement and identifying the specific clause under said Section is given to the Administrative Agent by the Borrower, or (y) notice of any Default 104 Â or Event of Default unless and until written notice thereof (stating that it is a â€œnotice of Defaultâ€ or a â€œnotice of an Event of Defaultâ€) is given to the Administrative Agent by the Borrower, a Lender or an Issuing Bank. Further, the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with any Loan Document, (ii) the contents of any certificate, report or other document delivered thereunder or in connection therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth in any Loan Document or the occurrence of any Default or Event of Default, (iv) the sufficiency, validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement, instrument or document, (v) the satisfaction of any condition set forth in Article IV or elsewhere in any Loan Document, other than to confirm receipt of items (which on their face purport to be such items) expressly required to be delivered to the Administrative Agent or satisfaction of any condition that expressly refers to the matters described therein being acceptable or satisfactory to the Administrative Agent, or (vi) the creation, perfection or priority of Liens on the Collateral. Notwithstanding anything herein to the contrary, the Administrative Agent shall not be liable for, or be responsible for any Liability, cost or expense suffered by the Borrower, any other Loan Party, any Subsidiary, any Lender or the Issuing Bank as a result of, any determination of any Revolving Exposure, any of the component amounts thereof or any portion thereof attributable to each Lender or the Issuing Bank. (c) Without limiting the foregoing, the Administrative Agent (i) may treat the payee of any promissory note as its holder until such promissory note has been assigned in accordance with Section 9.04, (ii) may rely on the Register to the extent set forth in Section 9.04(b), (iii) may consult with legal counsel (including counsel to the Borrower), independent public accountants and other experts selected by it, and shall not be liable for any action taken or omitted to be taken in good faith by it in accordance with the advice of such counsel, accountants or experts, (iv) makes no warranty or representation to any Lender or Issuing Bank and shall not be responsible to any Lender or Issuing Bank for any statements, warranties or representations made by or on behalf of any Loan Party in connection with this Agreement or any other Loan Document, (v) in determining compliance with any condition hereunder to the making of a Loan, or the issuance of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or an Issuing Bank, may presume that such condition is satisfactory to such Lender or Issuing Bank unless the Administrative Agent shall have received notice to the contrary from such Lender or Issuing Bank sufficiently in advance of the making of such Loan or the issuance of such Letter of Credit and (vi) shall be entitled to rely on, and shall incur no liability under or in respect of this Agreement or any other Loan Document by acting upon, any notice, consent, certificate or other instrument or writing (which writing may be a fax, any electronic message, Internet or intranet website posting or other distribution) or any statement made to it orally or by telephone and believed by it to be genuine and signed or sent or otherwise authenticated by the proper party or parties (whether or not such Person in fact meets the requirements set forth in the Loan Documents for being the maker thereof). SECTION 8.03. Posting of Communications. (a) The Borrower agrees that the Administrative Agent may, but shall not be obligated to, make any Communications available to the Lenders and the Issuing Banks by posting the Communications on IntraLinksâ„¢, DebtDomain, SyndTrak, ClearPar or any other electronic system chosen by the Administrative Agent to be its electronic transmission system (the â€œApproved Electronic Platformâ€). (b) Although the Approved Electronic Platform and its primary web portal are secured with generally-applicable security procedures and policies implemented or modified by the Administrative Agent from time to time (including, as of the Effective Date, a user ID/password authorization system) and the Approved Electronic Platform is secured through a per-deal authorization method whereby each user may access the Approved Electronic Platform only on a deal-by-deal basis, each of the Lenders, each of the Issuing Banks and the Borrower acknowledges and agrees that the distribution of material through an 105 Â electronic medium is not necessarily secure, that the Administrative Agent is not responsible for approving or vetting the representatives or contacts of any Lender that are added to the Approved Electronic Platform, and that there may be confidentiality and other risks associated with such distribution. Each of the Lenders, each of the Issuing Banks and the Borrower hereby approves distribution of the Communications through the Approved Electronic Platform and understands and assumes the risks of such distribution. (c) THE APPROVED ELECTRONIC PLATFORM AND THE COMMUNICATIONS ARE PROVIDED â€œAS ISâ€ AND â€œAS AVAILABLEâ€. THE APPLICABLE PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE COMMUNICATIONS, OR THE ADEQUACY OF THE APPROVED ELECTRONIC PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE APPROVED ELECTRONIC PLATFORM AND THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE APPLICABLE PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE APPROVED ELECTRONIC PLATFORM. IN NO EVENT SHALL THE ADMINISTRATIVE AGENT, THE ARRANGER OR ANY OF THEIR RESPECTIVE RELATED PARTIES (COLLECTIVELY, â€œAPPLICABLE PARTIESâ€) HAVE ANY LIABILITY TO ANY LOAN PARTY, ANY LENDER, ANY ISSUING BANK OR ANY OTHER PERSON OR ENTITY FOR DAMAGES OF ANY KIND, INCLUDING DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF ANY LOAN PARTYâ€™S OR THE ADMINISTRATIVE AGENTâ€™S TRANSMISSION OF COMMUNICATIONS THROUGH THE INTERNET OR THROUGH AN ELECTRONIC SYSTEM OR THE APPROVED ELECTRONIC PLATFORM, EXCEPT TO THE EXTENT SUCH DAMAGES ARE FOUND BY A FINAL, NON-APPEALABLE JUDGMENT OF A COURT OF COMPETENT JURISDICTION TO RESULT FROM THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF SUCH APPLICABLE PARTY. â€œCommunicationsâ€ means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of any Loan Party pursuant to any Loan Document or the transactions contemplated therein which is distributed by the Administrative Agent, any Lender or any Issuing Bank by means of electronic communications pursuant to this Section, including through an Approved Electronic Platform. (d) Each Lender and

each Issuing Bank agrees that notice to it (as provided in the next sentence) specifying that Communications have been posted to the Approved Electronic Platform shall constitute effective delivery of the Communications to such Lender for purposes of the Loan Documents. Each Lender and Issuing Bank agrees (i) to notify the Administrative Agent in writing (which could be in the form of electronic communication) from time to time of such Lender's or Issuing Bank's (as applicable) email address to which the foregoing notice may be sent by electronic transmission and (ii) that the foregoing notice may be sent to such email address. (e) Each of the Lenders, each of the Issuing Banks and the Borrower agrees that the Administrative Agent may, but (except as may be required by applicable law) shall not be obligated to, store the Communications on the Approved Electronic Platform in accordance with the Administrative Agent's generally applicable document retention procedures and policies. (f) Nothing herein shall prejudice the right of the Administrative Agent, any Lender or any Issuing Bank to give any notice or other communication pursuant to any Loan Document in any other manner specified in such Loan Document.

106 SECTION 8.04. The Administrative Agent Individually. With respect to its Revolving Commitment, Loans (including Swingline Loans) and Letters of Credit, the Person serving as the Administrative Agent shall have and may exercise the same rights and powers hereunder and is subject to the same obligations and liabilities as and to the extent set forth herein for any other Lender or Issuing Bank, as the case may be. The terms "Issuing Banks", "Lenders", "Required Lenders" and any similar terms shall, unless the context clearly otherwise indicates, include the Administrative Agent in its individual capacity as a Lender, Issuing Bank or as one of the Required Lenders, as applicable. The Person serving as the Administrative Agent and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of banking, trust or other business with, any Loan Party, any Subsidiary or any Affiliate of any of the foregoing as if such Person was not acting as the Administrative Agent and without any duty to account therefor to the Lenders or the Issuing Banks.

SECTION 8.05. Successor Administrative Agent. (a) The Administrative Agent may resign at any time by giving 30 days' prior written notice thereof to the Lenders, the Issuing Banks and the Borrower, whether or not a successor Administrative Agent has been appointed. Upon any such resignation, the Required Lenders shall have the right to appoint a successor Administrative Agent. If no successor Administrative Agent shall have been so appointed by the Required Lenders, and shall have accepted such appointment, within thirty (30) days after the retiring Administrative Agent's giving of notice of resignation, then the retiring Administrative Agent may, on behalf of the Lenders and the Issuing Banks, appoint a successor Administrative Agent, which shall be a bank with an office in New York, New York or an Affiliate of any such bank. In either case, such appointment shall be subject to the prior written approval of the Borrower (which approval may not be unreasonably withheld, conditioned or delayed and shall not be required while an Event of Default has occurred and is continuing). Upon the acceptance of any appointment as Administrative Agent by a successor Administrative Agent, such successor Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Administrative Agent. Upon the acceptance of appointment as Administrative Agent by a successor Administrative Agent, the retiring Administrative Agent shall be discharged from its duties and obligations under this Agreement and the other Loan Documents. Prior to any retiring Administrative Agent's resignation hereunder as Administrative Agent, the retiring Administrative Agent shall take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as Administrative Agent under the Loan Documents. (b) Notwithstanding paragraph (a) of this Section, in the event no successor Administrative Agent shall have been so appointed and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its intent to resign, the retiring Administrative Agent may give notice of the effectiveness of its resignation to the Lenders, the Issuing Banks and the Borrower, whereupon, on the date of effectiveness of such resignation stated in such notice, (i) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents; provided that, solely for purposes of maintaining any security interest granted to the Administrative Agent under any Collateral Document for the benefit of the Secured Parties, the retiring Administrative Agent shall continue to be vested with such security interest as collateral agent for the benefit of the Secured Parties, and continue to be entitled to the rights set forth in such Collateral Document and Loan Document, and, in the case of any Collateral in the possession of the Administrative Agent, shall continue to hold such Collateral, in each case until such time as a successor Administrative Agent is appointed and accepts such appointment in accordance with this Section (it being understood and agreed that the retiring Administrative Agent shall have no duty or obligation to take any further action under any Collateral Document, including any action required to maintain the perfection of any such security interest), and (ii) the Required Lenders shall succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent; provided further that (A) all payments required to be made 107 hereunder or under any other Loan Document to the Administrative Agent for the account of any Person other than the Administrative Agent shall be made directly to such Person and (B) all notices and other communications required or contemplated to be given or made to the Administrative Agent shall directly be given or made to each Lender and each Issuing Bank. Following the effectiveness of the Administrative Agent's resignation from its capacity as such, the provisions of this Article, Section 2.17(d) and Section 9.03, as well as any exculpatory, reimbursement and indemnification provisions set forth in any other Loan Document, shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent and in respect of the matters referred to in the first proviso to the first sentence of this Section 8.05(b).

SECTION 8.06. Acknowledgments of Lenders and Issuing Banks. (a) Each Lender represents and warrants that (i) the Loan Documents set forth the terms of a commercial lending facility, (ii) in participating as a Lender, it is engaged in making, acquiring or holding commercial loans and in providing other facilities set forth herein as may be applicable to such Lender or Issuing Bank, in each case, in the ordinary course of business, and not for the purpose of investing in the general performance or operations of the Borrower, or for the purpose of purchasing, acquiring or holding any other type of financial instrument such as a security (and each Lender agrees not to assert a claim in contravention of the foregoing, such as a claim under federal or state securities laws), (iii) it has, independently and without reliance upon the Administrative Agent, the Arranger or any other Lender, or any of the Related Parties of any of the foregoing, and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement as a Lender, and to make, acquire or hold Loans hereunder and (iv) it is sophisticated with respect to decisions to make, acquire and/or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender, and either it, or the Person exercising discretion in making its decision to make, acquire and/or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring or holding such commercial loans or providing such other facilities. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent, the Arranger or any other Lender, or any of the Related Parties of any of the foregoing, and based on such documents and information (which may contain material, non-public information within the meaning of the United States securities laws concerning the Borrower and its Affiliates) as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. (b) Each Lender, by delivering its signature page to this Agreement on the Effective Date, or delivering its signature page to an Assignment and Assumption or any other Loan Document pursuant to which it shall become a Lender hereunder, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be delivered to, or be approved by or satisfactory to, the Administrative Agent or the Lenders on the Effective Date or the effective date of any such Assignment and Assumption or any other Loan Document pursuant to which it shall have become a Lender hereunder. (c) (i) Each Lender hereby agrees that (x) if the Administrative Agent notifies such Lender that the Administrative Agent has determined in its sole discretion that any funds received by such Lender from the Administrative Agent or any of its Affiliates (whether as a payment, prepayment or repayment of principal, interest, fees or otherwise; individually and collectively, a "Payment") were erroneously transmitted to such Lender (whether or not known to such Lender), and demands the return of such Payment (or a portion thereof), such Lender shall promptly, but in no event later than one Business Day thereafter (or such later date as the Administrative Agent, in its sole discretion, may specify in writing), return to the Administrative Agent the amount of any such Payment (or portion thereof) as to which such a demand was 108 made in same day funds, together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect, and (y) to the extent permitted by applicable law, such Lender shall not assert, and hereby waives, as to the Administrative Agent, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Payments received, including without limitation any defense based on discharge for value or any similar doctrine. A notice of the Administrative Agent to any Lender under this Section 8.06(c) shall be conclusive, absent manifest error. (ii) Each Lender hereby further agrees that if it receives a Payment from the Administrative Agent or any of its Affiliates (x) that is in a different amount than, or on a different date from, that specified in a notice of payment sent by the Administrative Agent (or any of its Affiliates) with respect to such Payment (a "Payment Notice") or (y) that was not preceded or accompanied by a Payment Notice, it shall be on notice, in each such case, that an error has been made with respect to such Payment. Each Lender agrees that, in each such case, or if it otherwise becomes aware a Payment (or portion thereof) may have been sent in error, such Lender shall promptly notify the Administrative Agent of such occurrence and, upon demand from the Administrative Agent, it shall promptly, but in no event later than one (1) Business Day thereafter (or such later date as the Administrative Agent, in its sole discretion, may specify in writing), return to the Administrative Agent the amount of any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. (iii) The Borrower and each other Loan Party hereby agrees that (x) in the event an erroneous Payment (or portion thereof) are not recovered from any Lender that has received such Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights of such Lender with respect to such amount and (y) an erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any other Loan Party. (iv) Each Party's obligations under this Section 8.06(c) shall survive the resignation or replacement of the Administrative Agent or any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Revolving Commitments or the repayment, satisfaction or discharge of all Obligations under any Loan Document. (d) Each Lender hereby agrees that (i) it has requested a copy of each report prepared by or on behalf of the Administrative Agent; (ii) the Administrative Agent (A) makes no representation or warranty, express or implied, as to the completeness or accuracy of any report or any of the information contained therein or any inaccuracy or omission contained in or relating to a report and (B) shall not be liable for any information contained in any report; (iii) the reports are not comprehensive audits or examinations, and that any Person performing any field examination will inspect only specific information regarding the Loan Parties and will rely significantly upon the Loan Parties' books and records, as well as on representations of the Loan Parties' personnel and that the Administrative Agent undertakes no obligation to update, correct or supplement the reports; (iv) it will keep all reports confidential and strictly for its internal use, not share the report with any Loan Party or any other Person except as otherwise permitted pursuant to this Agreement; and (v) without limiting the generality of any other indemnification provision contained in this Agreement, (A) it will hold the Administrative Agent and any such other Person preparing a report harmless from any action the indemnifying Lender may take or conclusion the indemnifying Lender may reach or 109 draw from any report in connection with any extension of credit that the indemnifying Lender has made or may make to the Borrower, or the indemnifying Lender's participation in, or the indemnifying Lender's purchase of, a Loan or Loans; and (B) it will pay and protect, and indemnify, defend, and hold the Administrative Agent and any such other Person preparing a report harmless from and against, the claims, actions, proceedings, damages, costs, expenses, and other amounts (including reasonable attorneys' fees) incurred by the Administrative Agent or any such other Person as the direct or indirect result of any third parties who might obtain all or part of any report through the indemnifying Lender.

SECTION 8.07. Collateral Matters. (a) Except with respect to the exercise of setoff rights in accordance with Section 9.08 or with respect to a Secured Party's right to file a proof of claim in an insolvency proceeding, no Secured Party shall have any right individually to realize upon any of the Collateral or to enforce any Guarantee of the Secured Obligations, it being understood and agreed that all powers, rights and remedies under the Loan Documents may be exercised solely by the Administrative Agent on behalf of the Secured Parties in accordance with the terms thereof. In its capacity, the Administrative Agent is a representative of the Secured Parties within the meaning of the term "secured party" as defined in the UCC. In the event that any Collateral is hereafter pledged by any Person as collateral security for the Secured Obligations, the Administrative Agent is hereby authorized, and hereby granted a power of attorney, to execute and deliver on behalf of the Secured Parties any Loan Documents necessary or appropriate to grant and perfect a Lien on such Collateral in favor of the Administrative Agent on behalf of the Secured Parties. (b) In furtherance of the foregoing and not in limitation thereof, no arrangements in respect of Banking Services the obligations under which constitute Secured Obligations and no Swap Agreement the obligations under which constitute Secured Obligations, will create (or be deemed to create) in favor of any Secured Party that is a party thereto any rights in connection with the management or release of any Collateral or of the obligations of any Loan Party under any Loan Document. By accepting the benefits of the Collateral, each Secured Party that is a party to any such arrangement in respect of Banking Services or Swap Agreement, as applicable, shall be deemed to have appointed the Administrative Agent to serve as administrative agent and collateral agent under the Loan Documents and agreed to be bound by the Loan Documents as a Secured Party thereunder, subject to the limitations set forth in this paragraph.

SECTION 8.08. Credit Bidding. The Secured Parties hereby irrevocably authorize the Administrative Agent, at the direction of the Required Lenders, to credit bid all or any portion of the Secured Obligations (including by accepting some or all of the Collateral in satisfaction of some or all of the Secured Obligations pursuant to a deed in lieu of foreclosure or otherwise) and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (a) at any sale thereof conducted under the provisions of the Bankruptcy Code, including under Sections 363, 1123 or 1129 of the Bankruptcy Code, or any similar laws in any other jurisdictions to which a Loan Party is subject, or (b) at any other sale, foreclosure or acceptance of collateral in lieu of debt conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with any applicable law. In connection with any such credit bid and purchase, the Secured Obligations owed to the Secured Parties shall be entitled to be, and shall be, credit bid by the Administrative Agent at the direction of the Required Lenders on a ratable basis (with Secured Obligations with respect to contingent or unliquidated claims receiving contingent interests in the acquired assets on a ratable basis that shall vest upon the liquidation of such claims in an amount proportional to the liquidated portion of the contingent claim amount used in allocating the contingent interests) for the asset or assets so purchased (or for the equity interests or debt instruments of the acquisition vehicle or vehicles that are issued in connection with such purchase). In connection with any such bid (i) the Administrative Agent shall be authorized to form one or more acquisition vehicles and to assign any successful credit bid to such acquisition vehicle or vehicles (ii) each of the Secured Parties' ratable interests in the Secured Obligations which were credit bid 110 shall be deemed without any further action under this Agreement to be assigned to such vehicle or vehicles for the purpose of closing such sale, (iii) the Administrative Agent shall be authorized to adopt documents providing for the governance of the acquisition vehicle or vehicles (provided that any actions by the Administrative Agent with respect to such acquisition vehicle or vehicles, including any Disposition of the assets or equity interests thereof, shall be governed, directly or indirectly, by, and the governing documents shall provide for, control by the vote of the Required Lenders or their permitted assignees under the terms of this Agreement or the governing documents of the applicable acquisition vehicle or vehicles, as the case may be, irrespective of the termination of this Agreement and without giving effect to the limitations on actions by the Required Lenders contained in Section 9.02 of this Agreement), (iv) the Administrative Agent on behalf of such acquisition vehicle or vehicles shall be authorized to issue to each of the Secured Parties, ratably on account of the relevant Secured Obligations which were credit bid, interests, whether as equity, partnership interests, limited partnership interests or membership interests, in any such acquisition vehicle and/or debt instruments issued by such acquisition vehicle, all without the need for any Secured Party or acquisition vehicle to take any further action, and (v) to the extent that Secured Obligations that are assigned to an acquisition vehicle are not used to acquire Collateral for any reason (as a result of another bid being higher or better, because the amount of Secured Obligations assigned to the acquisition vehicle exceeds the amount of Secured Obligations credit bid by the acquisition vehicle or otherwise), such Secured Obligations shall automatically be reassigned to the Secured Parties pro rata with their original interest in such Secured Obligations and the equity interests and/or debt instruments issued by any acquisition vehicle on account of such Secured Obligations shall automatically be cancelled, without the need for any Secured Party or any acquisition vehicle to take any further action. Notwithstanding that the ratable portion of the Secured Obligations of each Secured Party are deemed assigned

The acquisition vehicle or vehicles as set forth in clause (ii) above, each Secured Party shall execute such documents and provide such information regarding the Secured Party (and/or any designee of the Secured Party which will receive interests in or debt instruments issued by such acquisition vehicle) as the Administrative Agent may reasonably request in connection with the formation of any acquisition vehicle, the formulation or submission of any credit bid or the consummation of the transactions contemplated by such credit bid.

SECTION 8.09. Certain ERISA Matters. (a) Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Arranger and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that at least one of the following is and will be true: (i) such Lender is not using "œœplan assets" (within the meaning of the Plan Asset Regulations) of one or more Benefit Plans in connection with the Loans, the Letters of Credit, the Revolving Commitments or this Agreement, (ii) the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender's entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Revolving Commitments and this Agreement, (iii) (A) such Lender is an investment fund managed by a Qualified Professional Asset Manager (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager 111 A made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Letters of Credit, the Revolving Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Revolving Commitments and this Agreement satisfies the requirements of subsections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender's entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Revolving Commitments and this Agreement, or (iv) such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.

(b) In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant as provided in sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Arranger and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that none of the Administrative Agent or the Arranger or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender in connection with the Loans, the Letters of Credit, the Revolving Commitments or this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related to hereto or thereto).

(c) The Administrative Agent and the Arranger hereby informs the Lenders that each such Person is not undertaking to provide investment advice or to give advice in a fiduciary capacity, in connection with the transactions contemplated hereby, and that such Person has a financial interest in the transactions contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with respect to the Loans, the Letters of Credit, the Revolving Commitments, this Agreement and any other Loan Documents, (ii) may recognize a gain if it extended the Loans, the Letters of Credit or the Revolving Commitments for an amount less than the amount being paid for an interest in the Loans, the Letters of Credit or the Revolving Commitments by such Lender or (iii) may receive fees or other payments in connection with the transactions contemplated hereby, the Loan Documents or otherwise, including structuring fees, commitment fees, arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees, agency fees, administrative agent or collateral agent fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or alternate transaction fees, amendment fees, processing fees, term out premiums, banker's acceptance fees, breakage or other early termination fees or fees similar to the foregoing.

SECTION 8.10. Flood Laws. Chase has adopted internal policies and procedures that address requirements placed on federally regulated lenders under the National Flood Insurance Reform Act of 1994 and related legislation (the "Flood Laws"). Chase, as administrative agent or collateral agent on a syndicated facility, will post on the applicable electronic platform (or otherwise distribute to each Lender in the syndicate) documents that it receives in connection with the Flood Laws. However, Chase reminds each Lender and Participant in the facility that, pursuant to the Flood Laws, each federally regulated Lender (whether acting as a Lender or Participant in the facility) is responsible for assuring its own compliance with the flood insurance requirements.

SECTION 8.11. Borrower Communications. (a) The Administrative Agent, the Lenders and the Issuing Bank agree that the Borrower may, but shall not be obligated to, make any Borrower Communication to the Administrative Agent through an 112 A electronic platform chosen by the Administrative Agent to be its electronic transmission system (the "Approved Borrower Portal"). (b) Although the Approved Borrower Portal and its primary web portal are secured with generally-applicable security procedures and policies implemented or modified by the Administrative Agent from time to time (including, as of the Effective Date, a user ID/password authorization system), each of the Lenders, the Issuing Bank and the Borrower acknowledges and agrees that the distribution of material through an electronic medium is not necessarily secure, that the Administrative Agent is not responsible for approving or vetting the representatives or contacts of the Borrower that are added to the Approved Borrower Portal, and that there may be confidentiality and other risks associated with such distribution. Each of the Lenders, the Issuing Bank and the Borrower hereby approves distribution of Borrower Communications through the Approved Borrower Portal and understands and assumes the risks of such distribution. (c) THE APPROVED BORROWER PORTAL IS PROVIDED "AS IS" AND "AS AVAILABLE". THE APPLICABLE PARTIES DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER COMMUNICATION, OR THE ADEQUACY OF THE APPROVED BORROWER PORTAL AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE APPROVED BORROWER PORTAL AND THE BORROWER COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE APPLICABLE PARTIES IN CONNECTION WITH THE BORROWER COMMUNICATIONS OR THE APPROVED BORROWER PORTAL. IN NO EVENT SHALL ANY APPLICABLE PARTY HAVE ANY LIABILITY TO ANY LOAN PARTY, ANY LENDER, THE ISSUING BANK OR ANY OTHER PERSON OR ENTITY FOR DAMAGES OF ANY KIND, INCLUDING DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF THE BORROWER'S TRANSMISSION OF BORROWER COMMUNICATIONS THROUGH THE INTERNET OR THE APPROVED BORROWER PORTAL. (d) Each of the Lenders, the Issuing Bank and the Borrower agrees that the Administrative Agent may, but (except as may be required by applicable law) shall not be obligated to, store the Borrower Communications on the Approved Borrower Portal in accordance with the Administrative Agent's generally applicable document retention procedures and policies. (e) Nothing herein shall prejudice the right of the Borrower to give any notice or other communication pursuant to any Loan Document in any other manner specified in such Loan Document.

ARTICLE IX MISCELLANEOUS SECTION 9.01. Notices. (a) Except in the case of notices and other communications expressly permitted to be given by fax or Electronic Systems (and subject in each case to paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by Electronic Systems, as follows: (i) if to any Loan Party, to it in care of the Borrower at: 113 A Vital Farms, Inc. 3601 South Congress Avenue, Suite C100 Austin, Texas 78704 Attention: Chief Financial Officer; (ii) if to the Administrative Agent, the Swingline Lender, or Chase in its capacity as an Issuing Bank, to JPMorgan Chase Bank, N.A. at: If to the Administrative Agent or Swingline Lender: A JPMorgan Chase Bank, N.A. 131 S Dearborn St, Floor 04 Chicago, IL, 60603-5506 Attention: Loan and Agency Servicing Email: jpm.agency.cri@jpmorgan.com A Agency Withholding Tax Inquiries: Email: agency.tax.reporting@jpmorgan.com A Agency Compliance/Financials/Intralinks: Email: covenant.compliance@jpmchase.com A If to the Issuing Bank: A JPMorgan Chase Bank, N.A. 131 S Dearborn St, Floor 04 Chicago, IL, 60603-5506 Attention: LC Agency Team Tel: 800-364-1969 Fax: 856-294-5267 114 A Email: chicago.lc.agency.activity.team@jpmchase.com A With a copy to: JPMorgan Chase Bank, N.A. 131 S Dearborn St, Floor 04 Chicago, IL, 60603-5506 Attention: Loan and Agency Servicing Email: jpm.agency.cri@jpmorgan.com (iii) if to any other Lender or Issuing Bank, to it at its address or fax number set forth in its Administrative Questionnaire. All such notices and other communications (i) sent by hand or overnight courier service, or mailed by certified or registered mail shall be deemed to have been given when received, (ii) sent by fax shall be deemed to have been given when sent, provided that if not given during normal business hours for the recipient, such notice or communication shall be deemed to have been given at the opening of business on the next Business Day of the recipient, or (iii) delivered through any Electronic Systems or Approved Electronic Platforms or Approved Borrower Portals, as applicable, to the extent provided in paragraph (b) below shall be effective as provided in such paragraph (b). (b) Notices and other communications to any Loan Party, the Administrative Agent, the Issuing Bank or any Lender hereunder may be delivered or furnished by using Electronic Systems or Approved Electronic Platforms or Approved Borrower Portals, as applicable, in each case, pursuant to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices pursuant to Article II or to compliance and no Default certificates delivered pursuant to Section 5.01(c) unless otherwise agreed by the Administrative Agent and the applicable Lender. Each of the Administrative Agent and the Borrower (on behalf of the Loan Parties) may, in its discretion, agree to accept notices and other communications to it hereunder by using Electronic Systems or Approved Electronic Platforms, as applicable, pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular notices or communications. Unless the Administrative Agent otherwise proscribes, all such notices and other communications (i) sent to an e-mail address shall be deemed received upon the sender's receipt of an acknowledgement from the intended recipient (such as by the return receipt requested function, as available, return e-mail or other written acknowledgement), provided that if not given during the normal business hours of the recipient, such notice or communication shall be deemed to have been given at the opening of business on the next Business Day for the recipient, and (ii) posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address as described in the foregoing clause (i), of notification that such notice or communication is available and identifying the website address therefore; provided that, for both clauses (i) and (ii) above, if such notice, e-mail or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day of the recipient. (c) Any party hereto may change its address, facsimile number or e-mail address for notices and other communications hereunder by notice to the other parties hereto.

SECTION 9.02. Waivers; Amendments. (a) No failure or delay by the Administrative Agent, the Issuing Bank or any Lender in exercising any right or power hereunder or under any other Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent, the Issuing Bank and the Lenders hereunder and under any other Loan Document are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of any Loan Document or consent to any departure by any Loan Party therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan or issuance of a Letter of Credit shall not be construed as a waiver of any Default, regardless of whether the Administrative Agent, any Lender or the Issuing Bank may have had notice or knowledge of such Default at the time. (b) Except as provided in Section 2.09 with respect to any Incremental Facility Amendment or modification of the Commitment Schedule, and subject to Sections 2.14(b) and (c) and Sections 9.02(c) and (e), neither this Agreement nor any other Loan Document nor any provision hereof or thereof may be waived, amended or modified except (i) in the case of this Agreement, pursuant to an agreement or agreements in writing entered into by the Borrower and the Required Lenders or (ii) in the case of any other Loan Document, pursuant to an agreement or agreements in writing entered into by the Administrative Agent and the Loan Party or Loan Parties that are parties thereto; provided that no such waiver, amendment, modification, consent or other agreement shall (A) increase, extend or re-instate the Revolving Commitment of any Lender without the written consent of such Lender (including any such Lender that is a Defaulting Lender), (B) reduce or forgive the principal amount of any Loan or LC Disbursement or reduce the rate of interest thereon, or reduce or forgive any interest or fees payable hereunder or under any other Loan Document or extend the timing of payments of such fees, interest or other amounts, in each case, without the written consent of each Lender (including any such Lender that is a Defaulting Lender) directly affected thereby (except that any amendment or modification of the financial covenants in this Agreement (or defined terms used in the financial covenants in this Agreement) shall not constitute a reduction in the rate of interest or fees for purposes of this clause (B)), (C) postpone any scheduled date of payment of the principal amount of any Loan or LC Disbursement, or any date for the payment of any interest, fees or other Secured Obligations payable hereunder or under any other Loan Document, or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date of expiration of any Revolving Commitment, in each case, without the written consent of each Lender (including any such Lender that is a Defaulting Lender) directly affected thereby, (D) amend, modify or change (or consent to any departure from) Section 2.09(d) or Section 2.18(b) or (d) in a manner that would alter the ratable reduction of Revolving Commitments or the manner in which payments are shared, in each case, without the written consent of each Lender (other than any Defaulting Lender), (E) amend, modify or change any of the provisions of this Section or the definition of "Required Lenders" or any other provision of any Loan Document specifying the number or percentage of Lenders required to waive, amend or modify any rights hereunder or thereunder or make any determination or grant any consent hereunder or thereunder, in each case, without the written consent of each Lender (other than any Defaulting Lender) (it being understood that, solely with the consent of the parties prescribed by Section 2.09 to be parties to an Incremental Facility Amendment, Incremental Term Loans and additional Revolving Commitments may be included in the determination of Required Lenders on substantially the same basis as the initial Revolving Commitments and Loans are included on the Effective Date), (F) (x) release the Borrower from its obligations under the Loan Documents or (y) release any Loan Guarantor from its obligation under its Loan Guaranty (except as otherwise permitted herein or in the other Loan Documents as in effect on the date hereof), in each case, without the written consent of each Lender (other than any Defaulting Lender), (G) except as provided in clause (

without the prior written authorization of the Required Lenders or, to the extent required by Section 9.02(b), all of the Lenders. Any such release shall not in any manner discharge, affect, or impair the Secured Obligations or any Liens (other than those expressly being released) upon (or obligations of the Loan Parties in respect of) all interests retained by the Loan Parties, including the proceeds of any sale, all of which shall continue to constitute part of the Collateral. Any execution and delivery by the Administrative Agent of documents in connection with any such release shall be without recourse to or warranty by the Administrative Agent. In addition, each of the Secured Parties, on behalf of itself and any of its Affiliates that are Secured Parties, irrevocably authorizes the Administrative Agent (or its designee), at its option and in its discretion, (x) to subordinate any Lien on any assets granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by Section 6.02(h) or 6.02(d) (each as in effect on the date hereof), or (y) in the event that the Borrower shall have advised the Administrative Agent that, notwithstanding the use by the Borrower of commercially reasonable efforts to obtain the consent of such holder (but without the requirement to pay any sums to obtain such consent) to permit the Administrative Agent to retain its liens (on a subordinated basis as contemplated by clause (x) above), the holder of such other Indebtedness requires, as a condition to the extension of such credit, that the Liens on such assets granted to or held by the Administrative Agent under any Loan Document be released, to release the Administrative Agent's Liens on such assets. The 117 Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent's Lien thereon or any certificate prepared by any Loan Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders or any other Secured Party for any failure to monitor or maintain any portion of the Collateral. (d) If, in connection with any proposed amendment, restatement, supplement, modification, waiver or consent requiring the consent of each Lender directly affected thereby, the consent of the Required Lenders is obtained, but the consent of other necessary Lenders is not obtained (any such Lender whose consent is necessary but has not been obtained being referred to herein as a Non-Consenting Lender), then the Borrower may elect to replace a Non-Consenting Lender as a Lender party to this Agreement, provided that, concurrently with such replacement, (i) another bank or other entity (other than any Ineligible Institution) which is reasonably satisfactory to the Borrower, the Administrative Agent, the Swingline Lender and the Issuing Bank shall agree, as of such date, to purchase for cash the Loans and other Obligations due to the Non-Consenting Lender pursuant to an Assignment and Assumption and to become a Lender for all purposes under this Agreement and to assume all obligations of the Non-Consenting Lender to be terminated as of such date and to comply with the requirements of clause (b) of Section 9.04, (ii) such replacement Lender agrees to the applicable proposed amendment, restatement, supplement, modification, waiver or consent and (iii) the Borrower shall pay to such Non-Consenting Lender in same day funds on the day of such replacement (1) all interest, fees and other amounts then accrued but unpaid to such Non-Consenting Lender by the Borrower hereunder to and including the date of termination, including without limitation payments due to such Non-Consenting Lender under Sections 2.15 and 2.17, and (2) an amount, if any, equal to the payment which would have been due to such Lender on the day of such replacement under Section 2.16 had the Loans of such Non-Consenting Lender been prepaid on such date rather than sold to the replacement Lender. Each party hereto agrees that (a) an assignment required pursuant to this paragraph may be effected pursuant to an Assignment and Assumption executed by the Borrower, the Administrative Agent and the assignee (or, to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and such parties are participants), and (b) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to and be bound by the terms thereof; provided that, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender, provided that any such documents shall be without recourse to or warranty by the parties thereto. (e) Notwithstanding anything to the contrary herein the Administrative Agent may, with the consent of the Borrower only, amend, modify or supplement this Agreement or any of the other Loan Documents to cure any ambiguity, omission, mistake, defect or inconsistency. SECTION 9.03. Expenses; Limitation of Liability; Indemnity; Etc. (a) Expenses. The Loan Parties, jointly and severally, shall pay all (i) reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates, including the reasonable fees, charges and disbursements of counsel for the Administrative Agent, in connection with the syndication and distribution (including, without limitation, via the internet or through an Electronic System or Approved Electronic Platform) of the credit facility provided for herein, the preparation and administration of the Loan Documents and any amendments, modifications or waivers of the provisions of the Loan Documents (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) reasonable out-of-pocket expenses incurred by the Issuing Bank in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) out-of-pocket expenses incurred by the Administrative Agent, the Issuing Bank or any Lender, including the fees, charges and 118 disbursements of any counsel for the Administrative Agent, the Issuing Bank or any Lender, in connection with the enforcement, collection or protection of its rights in connection with the Loan Documents, including its rights under this Section, or in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit. (b) Limitation of Liability. To the extent permitted by applicable law (i) neither the Borrower nor any other Loan Party shall assert, and the Borrower and each other Loan Party hereby waives, any claim against the Administrative Agent, the Arranger, the Issuing Bank and any Lender, and any Related Party of any of the foregoing Persons (each such Person being called a Lender-Related Person) for any Liabilities arising from the use by others of information or other materials (including, without limitation, any personal data) obtained through telecommunications, electronic or other information transmission systems (including the Internet, any Approved Electronic Platform and any Approved Borrower Portal), except to the extent they are found by a final, non-appealable judgment of a court of competent jurisdiction to result from the willful misconduct or gross negligence of such Lender-Related Person and (ii) no party hereto shall assert, and each such party hereby waives, any Liabilities against any other party hereto, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby or thereby, the Transactions, any Loan or Letter of Credit or the use of the proceeds thereof; provided that, nothing in this Section 9.03(b) shall relieve the Borrower or any other Loan Party of any obligation it may have to indemnify an Indemnitee, as provided in Section 9.03(c), against any special, indirect, consequential or punitive damages asserted against such Indemnitee by a third party. (c) Indemnity. The Loan Parties, jointly and severally, shall indemnify the Administrative Agent, the Arranger, the Issuing Bank and each Lender, and each Related Party of any of the foregoing Persons (each such Person being called an Indemnitee) against, and hold each Indemnitee harmless from, any and all Liabilities and related expenses, including the fees, charges and disbursements of any counsel for any Indemnitee, incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of (i) the execution or delivery of the Loan Documents or any agreement or instrument contemplated thereby, the performance by the parties hereto of their respective obligations thereunder or the consummation of the Transactions or any other transactions contemplated hereby, (ii) any Loan or Letter of Credit or the use of the proceeds therefrom (including any refusal by the Issuing Bank to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or Release of Hazardous Materials on or from any property owned or operated by a Loan Party or a Subsidiary, or any Environmental Liability related in any way to a Loan Party or a Subsidiary, or (iv) any actual or prospective Proceeding relating to any of the foregoing, whether or not such Proceeding is brought by any Loan Party or their respective equity holders, Affiliates, creditors or any other third Person and whether based on contract, tort or any other theory and regardless of whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such Liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted primarily from the gross negligence or willful misconduct of such Indemnitee or (y) arise from any disputes solely among Indemnitees (other than any claims against an Indemnitee in its capacity or in fulfilling its role as the Arranger, the Issuing Bank, the Swingline Lender, the Administrative Agent, or any other agent or any other similar role under this Agreement) and not arising out of any act or omission of the Borrower or any of its Affiliates. This Section 9.03(c) shall not apply with respect to Taxes other than any Taxes that represent losses, claims or damages arising from any non-Tax claim. WITHOUT LIMITATION OF THE FOREGOING, IT IS THE INTENTION OF THE BORROWER AND THE BORROWER AGREES THAT THE FOREGOING INDEMNITIES SHALL APPLY TO EACH INDEMNITEE WITH RESPECT TO LOSSES, CLAIMS, DAMAGES, PENALTIES, LIABILITIES 119 A AND RELATED EXPENSES (INCLUDING, WITHOUT LIMITATION, ALL EXPENSES OF LITIGATION OR PREPARATION THEREFOR), WHICH IN WHOLE OR IN PART ARE CAUSED BY OR ARISE OUT OF THE NEGLIGENCE OF SUCH (AND/OR ANY OTHER) INDEMNITEE. (d) Lender Reimbursement. Each Lender severally agrees to pay any amount required to be paid by any Loan Party under paragraphs (a), (b) or (c) of this Section 9.03 to the Administrative Agent, the Swingline Lender and the Issuing Bank, and each Related Party of any of the foregoing Persons (each, an Agent-Related Person) (to the extent not reimbursed by the Loan Parties and without limiting the obligation of any Loan Party to do so), ratably according to their respective Applicable Percentage in effect on the date on which such payment is sought under this Section (or, if such payment is sought after the date upon which the Revolving Commitments shall have terminated and the Loans shall have been paid in full, ratably in accordance with such Applicable Percentage immediately prior to such date), and agrees to indemnify and hold each Agent-Related Person harmless from and against any and all Liabilities and related expenses, including the fees, charges and disbursements of any kind whatsoever that may at any time (whether before or after the payment of the Loans) be imposed on, incurred by or asserted against such Agent-Related Person in any way relating to or arising out of the Revolving Commitments, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by such Agent-Related Person under or in connection with any of the foregoing; provided that the unreimbursed expense or Liability or related expense, as the case may be, was incurred by or asserted against such Agent-Related Person in its capacity as such; provided, further, that no Lender shall be liable for the payment of any portion of such Liabilities, costs, expenses or disbursements that are found by a final and non-appealable decision of a court of competent jurisdiction to have resulted primarily from such Agent-Related Person's gross negligence or willful misconduct. The agreements in this Section shall survive the termination of this Agreement and Payment in Full of the Secured Obligations. (e) Payments. All amounts due under this Section 9.03 shall be payable promptly after written demand therefor. SECTION 9.04. Successors and Assigns. (a) The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby (including any Affiliate of the Issuing Bank that issues any Letter of Credit), except that (i) no Loan Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by any Loan Party without such consent shall be null and void) and (ii) no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby (including any Affiliate of the Issuing Bank that issues any Letter of Credit), Participants (to the extent provided in paragraph (c) of this Section) and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent, the Issuing Bank and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. (b) (i) Subject to the conditions set forth in paragraph (b)(ii) below, any Lender may assign to one or more Persons (other than an Ineligible Institution) all or a portion of its rights and obligations under this Agreement (including all or a portion of its Revolving Commitment, participation in Letters of Credit and the Loans at the time owing to it) with the prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) of: 120 A (A) the Borrower, provided that the Borrower shall be deemed to have consented to an assignment of all or a portion of the Revolving Loans and Revolving Commitments unless it shall object thereto by written notice to the Administrative Agent within ten (10) Business Days after having received notice thereof, and provided further that no consent of the Borrower shall be required for an assignment to a Lender, an Affiliate of a Lender, an Approved Fund or, if an Event of Default has occurred and is continuing, any other assignee; (B) the Administrative Agent; provided that no consent of the Administrative Agent shall be required for an assignment to an assignee that is a Lender (other than a Defaulting Lender) with a Revolving Commitment immediately prior to giving effect to such assignment; (C) the Issuing Bank; provided that no consent of the Issuing Bank shall be required if (x) an Event of Default has occurred with respect to the Borrower under clause (h) or (i) of Article VII and (y) the Issuing Bank has no outstanding Letters of Credit at that time; and (D) the Swingline Lender; provided that no consent of the Swingline Lender shall be required if (x) an Event of Default has occurred with respect to the Borrower under clause (h) or (i) of Article VII and (y) the Swingline Lender has no outstanding Swingline Loans at that time. (ii) Assignments shall be subject to the following additional conditions: (A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an Approved Fund or an assignment of the entire remaining amount of the assigning Lender's Revolving Commitment or Loans, the amount of the Revolving Commitment or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent) shall not be less than \$5,000,000, aggregated across Affiliates and Approved Funds, unless each of the Borrower and the Administrative Agent otherwise consent, provided that no such consent of the Borrower shall be required if an Event of Default has occurred and is continuing; (B) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender's rights and obligations under this Agreement; (C) the parties to each assignment shall execute and deliver to the Administrative Agent (x) an Assignment and Assumption or (y) to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and the parties to the Assignment and Assumption are participants, together with a processing and recordation fee of \$3,500; and (D) the assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire in which the assignee designates one or more credit contacts to whom all syndicate-level information (which may contain material non-public information about the Borrower, the other Loan Parties and their Related Parties or their respective securities) will be made available and who may receive such information in 121 A accordance with the assignee's compliance procedures and applicable laws, including federal and state securities laws. For the purposes of this Section 9.04(b), the terms Approved Fund and Ineligible Institution have the following meanings: Approved Fund means any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. Ineligible Institution means a (a) natural person, (b) Defaulting Lender or its Parent, (c) holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person or relative(s) thereof; provided that, with respect to clause (c), such holding company, investment vehicle or trust shall not constitute an Ineligible Institution if it (x) has not been established for the primary purpose of acquiring any Loans or Revolving Commitments, (y) is managed by a professional advisor, who is not such natural person or a relative thereof, having significant experience in the business of making or purchasing commercial loans, and (z) has assets greater than \$25,000,000 and a significant part of its activities consist of making or purchasing commercial loans and similar extensions of credit in the ordinary course of its business, or (d) a Loan Party or a Subsidiary or other Affiliate of a Loan Party. (iii) Subject to acceptance and recording thereof pursuant to paragraph (b)(iv) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender's rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Sections 2.15, 2.16, 2.17 and 9.03). Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 9.04 shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (c) of this Section. (iv) The Administrative Agent, acting for this purpose as an agent of the Borrower, shall maintain at one of its offices a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Revolving Commitment of, and principal amount (and stated interest) of the Loans and LC Disbursements owing to, each Lender pursuant to the terms hereof from time to time (the Register). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent, the Issuing Bank and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower, the Issuing Bank and any Lender, at any reasonable time and from time to time upon reasonable prior notice. (v) Upon its receipt of (x) a duly completed Assignment and Assumption executed by an assigning Lender and an assignee or (y) to the extent applicable, an agreement

incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and the parties to the Assignment and Assumption are participants, the assignee[®]™s completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in paragraph (b) of this Section and any written consent to such assignment required by paragraph (b) of this Section, the Administrative Agent shall accept such 122 A Assignment and Assumption and record the information contained therein in the Register; provided that if either the assigning Lender or the assignee shall have failed to make any payment required to be made by it pursuant to Section 2.05, 2.06(d) or (e), 2.07(b), 2.18(d) or 9.03(d), the Administrative Agent shall have no obligation to accept such Assignment and Assumption and record the information therein in the Register unless and until such payment shall have been made in full, together with all accrued interest thereon. No assignment shall be effective for purposes of this Agreement unless it has been recorded in the Register as provided in this paragraph. (c) Any Lender may, without the consent of, or notice to, the Borrower, the Administrative Agent, the Swingline Lender or the Issuing Bank, sell participations to one or more banks or other entities (a [®]Participant[®]) other than an Ineligible Institution in all or a portion of such Lender[®]™s rights and obligations under this Agreement (including all or a portion of its Revolving Commitment and the Loans owing to it); provided that (i) such Lender[®]™s obligations under this Agreement shall remain unchanged; (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations; and (iii) the Borrower, the Administrative Agent, the Issuing Bank and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender[®]™s rights and obligations under this Agreement. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in the first proviso to Section 9.02(b) that affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.15, 2.16 and 2.17 (subject to the requirements and limitations therein, including the requirements under Sections 2.17(f) and (g) (it being understood that the documentation required under Section 2.17(f) shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of Sections 2.18 and 2.19 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Section 2.15 or 2.17 with respect to any participation than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation. Each Lender that sells a participation agrees, at the Borrower[®]™s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 2.19(b) with respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.08 as though it were a Lender, provided such Participant agrees to be subject to Section 2.18(d) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant[®]™s interest in the Loans or other obligations under this Agreement or any other Loan Document (the [®]Participant Register[®]); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant[®]™s interest in any Revolving Commitments, Loans, Letters of Credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such Revolving Commitment, Loan, Letter of Credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. 123 A Notwithstanding the preceding paragraphs or anything in this Agreement to the contrary, any Participant that is a Farm Credit Lender that (i) has purchased a participation in a minimum amount of \$5,000,000, (ii) has been designated as a voting Participant (a [®]Voting Participant[®]) in a notice (a [®]Voting Participant Notice[®]) sent by the relevant Lender (including any existing Voting Participant) to the Administrative Agent and (iii) receives, prior to becoming a Voting Participant, the consent of the Administrative Agent (such consent to be required only to the extent and under the circumstances it would be required if such Voting Participant were to become a Lender pursuant to an assignment in accordance with Section 9.04(b) and such consent is not required for an assignment to an existing Voting Participant), shall be entitled to vote as if such Voting Participant were a Lender on all matters subject to a vote by Lenders, and the voting rights of the selling Lender (including any existing Voting Participant) shall be correspondingly reduced, on a dollar-for-dollar basis. Each Voting Participant Notice shall include, with respect to each Voting Participant, the information that would be included by a prospective Lender in an Assignment and Acceptance. Notwithstanding the foregoing, each Farm Credit Lender designated as a Voting Participant in Schedule 9.04 attached hereto shall be a Voting Participant without delivery of a Voting Participation Notification and without the prior written consent of the Administrative Agent or any other party to this Agreement. The selling Lender (including any existing Voting Participant) and the purchasing Voting Participant shall notify the Administrative Agent and the Borrower within three (3) Business Days of any termination, reduction or increase of the amount of, such participation (each such notification, a [®]Voting Participation Notification[®]). The Administrative Agent and the Borrower shall be entitled to conclusively rely on information contained in Voting Participant Notices and all other notices delivered pursuant hereto. The voting rights of each Voting Participant are solely for the benefit of such Voting Participant. (d) Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including without limitation any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply to any such pledge or assignment of a security interest; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. SECTION 9.05. Survival. All covenants, agreements, representations and warranties made by the Loan Parties in the Loan Documents and in the certificates or other instruments delivered in connection with or pursuant to this Agreement or any other Loan Document shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of the Loan Documents and the making of any Loans and issuance of any Letters of Credit, regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent, the Issuing Bank or any Lender may have had notice or knowledge of any Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect until Payment in Full of the Secured Obligations. The provisions of Sections 2.15, 2.16, 2.17 and 9.03 and Article VIII shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Letters of Credit and the Revolving Commitments or the termination of this Agreement or any other Loan Document or any provision hereof or thereof. SECTION 9.06. Counterparts; Integration; Effectiveness; Electronic Execution. (a) This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, the other Loan Documents and any separate letter agreements with respect to (i) fees payable to the Administrative Agent and (ii) increases or reductions of the Issuing Bank Sublimit of the Issuing Bank constitute the entire contract among the parties relating to the subject 124 A matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof which, when taken together, bear the signatures of each of the other parties hereto, and thereafter shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. (b) Delivery of an executed counterpart of a signature page of (x) this Agreement, (y) any other Loan Document and/or (z) any document, amendment, approval, consent, information, notice (including, for the avoidance of doubt, any notice delivered pursuant to Section 9.01), certificate, request, statement, disclosure or authorization related to this Agreement, any other Loan Document and/or the transactions contemplated hereby and/or thereby (each an [®]Ancillary Document[®]) that is an Electronic Signature transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement, such other Loan Document or such Ancillary Document, as applicable. The words [®]execution[®], [®]assigned[®], [®]signature[®], [®]delivery[®], [®]and words of like import in or relating to this Agreement, any other Loan Document and/or any Ancillary Document shall be deemed to include Electronic Signatures, deliveries or the keeping of records in any electronic form (including deliveries by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page), each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be; provided that nothing herein shall require the Administrative Agent to accept Electronic Signatures in any form or format without its prior written consent and pursuant to procedures approved by it; provided, further, without limiting the foregoing, (i) to the extent the Administrative Agent has agreed to accept any Electronic Signature, the Administrative Agent and each of the Lenders shall be entitled to rely on such Electronic Signature purportedly given by or on behalf of the Borrower or any other Loan Party without further verification thereof and without any obligation to review the appearance or form of any such Electronic Signature and (ii) upon the request of the Administrative Agent or any Lender, any Electronic Signature shall be promptly followed by a manually executed counterpart. Without limiting the generality of the foregoing, the Borrower and each Loan Party hereby (A) agrees that, for all purposes, including without limitation, in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Administrative Agent, the Lenders, the Borrower and the Loan Parties, Electronic Signatures transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page and/or any electronic images of this Agreement, any other Loan Document and/or any Ancillary Document shall have the same legal effect, validity and enforceability as any paper original, (B) the Administrative Agent and each of the Lenders may, at its option, create one or more copies of this Agreement, any other Loan Document and/or any Ancillary Document in the form of an imaged electronic record in any format, which shall be deemed created in the ordinary course of such Person[®]™s business, and destroy the original paper document (and all such electronic records shall be considered an original for all purposes and shall have the same legal effect, validity and enforceability as a paper record), (C) waives any argument, defense or right to contest the legal effect, validity or enforceability of this Agreement, any other Loan Document and/or any Ancillary Document based solely on the lack of paper original copies of this Agreement, such other Loan Document and/or such Ancillary Document, respectively, including with respect to any signature pages thereto and (D) waives any claim against any Lender-Related Person for any Liabilities arising solely from the Administrative Agent[®]™s and/or any Lender[®]™s reliance on or use of Electronic Signatures and/or transmissions by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page, including any Liabilities arising as a result of the failure of the Borrower and/or any Loan Party to use any available security measures in connection with the execution, delivery or transmission of any Electronic Signature. THIS WRITTEN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL 125 A AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES. SECTION 9.07. Severability. Any provision of any Loan Document held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions thereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction. SECTION 9.08. Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender, the Issuing Bank, and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final and in whatever currency denominated) at any time held, and other obligations at any time owing, by such Lender, the Issuing Bank or any such Affiliate, to or for the credit or the account of any Loan Party against any and all of the Secured Obligations now or hereafter existing and owing to such Lender or the Issuing Bank or their respective Affiliates, irrespective of whether or not such Lender, the Issuing Bank or such Affiliate shall have made any demand under this Agreement or any other Loan Document and although such obligations of the Loan Parties may be contingent or unmatured or are owed to a branch office or Affiliate of such Lender or the Issuing Bank different from the branch office or Affiliate holding such deposit or obligated on such indebtedness; provided that, in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.20 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent, the Issuing Banks, and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Secured Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The applicable Lender, the Issuing Bank or such Affiliate shall notify the Borrower and the Administrative Agent of such setoff or application; provided that the failure to give such notice shall not affect the validity of such setoff or application under this Section. The rights of each Lender, the Issuing Bank and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender, the Issuing Bank or their respective Affiliates may have. Notwithstanding the foregoing, nothing shall require any Farm Credit Lender to set-off against any Farm Credit System Equity or obligate such Lender to share in any proceeds or amounts obtained from the set-off of such Farm Credit System Equity. SECTION 9.09. Governing Law; Jurisdiction; Consent to Service of Process. (a) The Loan Documents (other than those containing a contrary express choice of law provision) shall be governed by and construed in accordance with the law of the State of New York. (b) Each of the Lenders and the Administrative Agent hereby irrevocably and unconditionally agrees that, notwithstanding the governing law provisions of any applicable Loan Document, any claims brought against the Administrative Agent by any Secured Party relating to this Agreement, any other Loan Document, the Collateral or the consummation or administration of the transactions contemplated hereby or thereby shall be construed in accordance with and governed by the law of the State of New York. (c) Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the United States District Court for the Southern District of New York sitting in the Borough of Manhattan (or if such court lacks subject matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan), and any appellate court from any thereof, in any action or proceeding arising out of or relating to any Loan Documents, the transactions 126 A relating hereto or thereto, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may (and any such claims, cross-claims or third party claims brought against the Administrative Agent or any of its Related Parties may only) be heard and determined in such Federal (to the extent permitted by law) or New York State court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or any other Loan Document shall (i) affect any right that the Administrative Agent, the Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against any Loan Party or its properties in the courts of any jurisdiction, (ii) waive any statutory, regulatory, common law, or other rule, doctrine, legal restriction, provision or the like providing for the treatment of bank branches, bank agencies, or other bank offices as if they were separate juridical entities for certain purposes, including UCC Sections 4-106, 4-A-105(1)(b), and 5-116(b), UCP 600 Article 3 and ISP98 Rule 2.02, and URDG 758 Article 3(a), or (iii) affect which courts have or do not have personal jurisdiction over the issuing bank or beneficiary of any Letter of Credit or any advising bank, nominated bank or assignee of proceeds thereunder or proper venue with respect to any litigation arising out of or relating to such Letter of Credit with, or affecting the rights of, any Person not a party to this Agreement, whether or not such Letter of Credit contains its own jurisdiction submission clause. (d) Each Loan Party hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document in any court referred to in paragraph (c) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. (e) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 9.01. Each Foreign Subsidiary that is a party hereto irrevocably designates and appoints the Borrower, as its authorized agent, to accept and acknowledge on its behalf, service of any and all process which may be served in any suit, action or proceeding of the nature referred to in Section 9.09(c) in any federal or New York State court sitting in New York City. The Borrower hereby represents, warrants and confirms that the Borrower has agreed to accept such appointment. Said designation and appointment shall be irrevocable by each such Foreign Subsidiary until Payment in Full of the Secured Obligations. Each Foreign Subsidiary party thereto

hereby consents to process being served in any suit, action or proceeding of the nature referred to in Section 9.09(c) in any federal or New York State court sitting in New York City by service of process upon the Borrower as provided in this Section 9.09(e); provided that, to the extent lawful and possible, notice of said service upon such agent shall be mailed by registered or certified air mail, postage prepaid, return receipt requested, to the Borrower and (if applicable to) such Foreign Subsidiary at its address set forth herein or in the Joinder Agreement pursuant to which such Foreign Subsidiary became a party hereto, as applicable, or to any other address of which such Foreign Subsidiary shall have given written notice to the Administrative Agent (with a copy thereof to the Borrower). Each Foreign Subsidiary party hereto irrevocably waives, to the fullest extent permitted by law, all claim of error by reason of any such service in such manner and agrees that such service shall be deemed in every respect effective service of process upon such Foreign Subsidiary in any such suit, action or proceeding and shall, to the fullest extent permitted by law, be taken and held to be valid and personal service upon and personal delivery to such Foreign Subsidiary. To the extent any Foreign Subsidiary party hereto has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether from service or notice, attachment prior to judgment, attachment in aid of execution of a judgment, execution or otherwise), each Foreign Subsidiary hereby irrevocably waives such immunity in respect of its obligations under the Loan Documents. Nothing in this Agreement or any other Loan Document will affect the right of any party to this Agreement to serve process in any other manner permitted by law. 127 Â SECTION 9.10. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OR OTHER AGENT (INCLUDING ANY ATTORNEY) OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. SECTION 9.11. Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only, are not part of this Agreement and shall not affect the construction of, or be taken into consideration in interpreting, this Agreement. SECTION 9.12. Confidentiality. Each of the Administrative Agent, the Issuing Bank and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and their respective directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any Governmental Authority (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by any applicable law or by any subpoena or similar legal process, (d) to any other party to this Agreement, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any suit, action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (x) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (y) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Loan Parties and their obligations, (g) on a confidential basis to (1) any rating agency in connection with rating the Borrower or its Subsidiaries or the credit facility provided for herein or (2) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers with respect to the credit facility provided for herein, (h) with the consent of the Borrower, (i) to any Person providing a Guarantee of all or any portion of the Secured Obligations, or (j) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, the Issuing Bank or any Lender on a non-confidential basis from a source other than the Borrower. For the purposes of this Section, "Information" means all information received from the Borrower relating to the Borrower or its business, other than any such information that is available to the Administrative Agent, the Issuing Bank or any Lender on a non-confidential basis prior to disclosure by the Borrower and other than information pertaining to this Agreement provided by arrangers to data service providers, including league table providers, that serve the lending industry; provided that, in the case of information received from the Borrower after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. For the avoidance of doubt, nothing in this Section 9.12 shall prohibit any Person from voluntarily disclosing or providing any Information within the scope of this confidentiality provision to any 128 Â governmental, regulatory or self-regulatory organization (any such entity, a "Regulatory Authority") to the extent that any such prohibition on disclosure set forth in this Section 9.12 shall be prohibited by the laws or regulations applicable to such Regulatory Authority. EACH LENDER ACKNOWLEDGES THAT INFORMATION AS DEFINED IN SECTION 9.12 FURNISHED TO IT PURSUANT TO THIS AGREEMENT MAY INCLUDE MATERIAL NON-PUBLIC INFORMATION CONCERNING THE BORROWER, THE OTHER LOAN PARTIES AND THEIR RELATED PARTIES OR THEIR RESPECTIVE SECURITIES, AND CONFIRMS THAT IT HAS DEVELOPED COMPLIANCE PROCEDURES REGARDING THE USE OF MATERIAL NON-PUBLIC INFORMATION AND THAT IT WILL HANDLE SUCH MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH THOSE PROCEDURES AND APPLICABLE LAW, INCLUDING FEDERAL AND STATE SECURITIES LAWS. ALL INFORMATION, INCLUDING REQUESTS FOR WAIVERS AND AMENDMENTS, FURNISHED BY THE BORROWER OR THE ADMINISTRATIVE AGENT PURSUANT TO, OR IN THE COURSE OF ADMINISTERING, THIS AGREEMENT WILL BE SYNDICATE-LEVEL INFORMATION, WHICH MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION ABOUT THE BORROWER, THE OTHER LOAN PARTIES AND THEIR RELATED PARTIES OR THEIR RESPECTIVE SECURITIES. ACCORDINGLY, EACH LENDER REPRESENTS TO THE BORROWER AND THE ADMINISTRATIVE AGENT THAT IT HAS IDENTIFIED IN ITS ADMINISTRATIVE QUESTIONNAIRE A CREDIT CONTACT WHO MAY RECEIVE INFORMATION THAT MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH ITS COMPLIANCE PROCEDURES AND APPLICABLE LAW, INCLUDING FEDERAL AND STATE SECURITIES LAWS. SECTION 9.13. Several Obligations; Nonreliance; Violation of Law. The respective obligations of the Lenders hereunder are several and not joint and the failure of any Lender to make any Loan or perform any of its obligations hereunder shall not relieve any other Lender from any of its obligations hereunder. Each Lender hereby represents that it is not relying on or looking to any margin stock (as defined in Regulation U of the Federal Reserve Board) for the repayment of the Borrowings provided for herein. Anything contained in this Agreement to the contrary notwithstanding, neither the Issuing Bank nor any Lender shall be obligated to extend credit to the Borrower in violation of any Requirement of Law. SECTION 9.14. USA PATRIOT Act. Each Lender that is subject to the requirements of the USA PATRIOT Act hereby notifies each Loan Party that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record information that identifies such Loan Party, which information includes the name and address of such Loan Party and other information that will allow such Lender to identify such Loan Party in accordance with the USA PATRIOT Act. SECTION 9.15. Disclosure. Each Loan Party, each Lender and the Issuing Bank hereby acknowledges and agrees that the Administrative Agent and/or its Affiliates from time to time may hold investments in, make other loans to or have other relationships with, any of the Loan Parties and their respective Affiliates. SECTION 9.16. Appointment for Perfection. Each Lender hereby appoints each other Lender as its agent for the purpose of perfecting Liens, for the benefit of the Administrative Agent and the Secured Parties, in assets which, in accordance with Article 9 of the UCC or any other applicable law can be perfected only by possession or control. Should any Lender (other than the Administrative Agent) obtain possession or control of any such Collateral, such Lender shall notify the Administrative Agent thereof, and, promptly upon the Administrative Agent's request therefor shall deliver such Collateral to the 129 Â Administrative Agent or otherwise deal with such Collateral in accordance with the Administrative Agent's instructions. SECTION 9.17. Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts which are treated as interest on such Loan under applicable law (collectively the "Charges"), shall exceed the maximum lawful rate (the "Maximum Rate") which may be contracted for, charged, taken, received or reserved by the Lender holding such Loan in accordance with applicable law, the rate of interest payable in respect of such Loan hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable as a result of the operation of this Section shall be cumulated and the interest and Charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the NYFRB rate to the date of repayment, shall have been received by such Lender. SECTION 9.18. No Fiduciary Duty, etc.. (a) Each Loan Party acknowledges and agrees, and acknowledges its Subsidiaries' understanding, that no Credit Party will have any obligations except those obligations expressly set forth herein and in the other Loan Documents and each Credit Party is acting solely in the capacity of an arm's length contractual counterparty to the Loan Parties with respect to the Loan Documents and the transactions contemplated therein and not as a financial advisor or a fiduciary to, or an agent of, any Loan Party or any other person. Each Loan Party agrees that it will not assert any claim against any Credit Party based on an alleged breach of fiduciary duty by such Credit Party in connection with this Agreement and the transactions contemplated by the Loan Documents. Additionally, each Loan Party acknowledges and agrees that no Credit Party is advising the Loan Parties as to any legal, tax, investment, accounting, regulatory or any other matters in any jurisdiction. Each Loan Party shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated by the Loan Documents, and the Credit Parties shall have no responsibility or liability to any Loan Party with respect thereto. (b) Each Loan Party further acknowledges and agrees, and acknowledges its Subsidiaries' understanding, that each Credit Party, together with its Affiliates, in addition to providing or participating in commercial lending facilities such as that provided hereunder, is a full service securities or banking firm engaged in securities trading and brokerage activities as well as providing investment banking and other financial services. In the ordinary course of business, any Credit Party may provide investment banking and other financial services to, and/or acquire, hold or sell, for its own accounts and the accounts of customers, equity, debt and other securities and financial instruments (including bank loans and other obligations) of, any Loan Party or its Affiliates and other companies with which any Loan Party may have commercial or other relationships. With respect to any securities and/or financial instruments so held by any Credit Party or any of its customers, all rights in respect of such securities and financial instruments, including any voting rights, will be exercised by the holder of the rights, in its sole discretion. (c) In addition, each Loan Party acknowledges and agrees, and acknowledges its Subsidiaries' understanding, that each Credit Party and its affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of which a Loan Party or its Subsidiaries may have conflicting interests regarding the transactions described herein and otherwise. No Credit Party will use confidential information obtained from the Borrower by virtue of the transactions contemplated by the Loan Documents or its other relationships with the Borrower or its Subsidiaries in connection with the performance by such Credit Party of services for other companies, and no Credit Party will furnish any such information to other companies. Each Loan Party also acknowledges that no Credit Party has any obligation to use in connection with the transactions contemplated by the Loan Documents, or to furnish to any Loan Party, confidential information obtained from other companies. 130 Â SECTION 9.19. Marketing Consent. The Borrower hereby authorizes Chase and its affiliates (collectively, the "Chase Parties"), at their respective sole expense, and without any prior approval by the Borrower, to include the Borrower's name and logo in advertising, marketing, marketing, tombstones, case studies and training materials, and to give such other publicity to this Agreement as Chase Parties may from time to time determine in their sole discretion. The foregoing authorization shall remain in effect unless the Borrower notifies Chase in writing that such authorization is revoked. SECTION 9.20. Acknowledgment and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: (a) the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and (b) the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent entity, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority. SECTION 9.21. Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Swap Agreements or any other agreement or instrument that is a QFC (such support "QFC Credit Support") and each such QFC a "Supported QFC"), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the "U.S. Special Resolution Regime") in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States): In the event a Covered Entity that is party to a Supported QFC (each, a "Covered Party") becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might 131 Â otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support. ARTICLE X Loan Guaranty SECTION 10.01. Guaranty. Each Loan Guarantor hereby agrees that it is jointly and severally liable for, and, as a primary obligor and not merely as surety, absolutely, unconditionally and irrevocably guarantees to the Secured Parties, the prompt payment when due, whether at stated maturity, upon acceleration or otherwise, and at all times thereafter, of the Guaranteed Obligations of such Loan Guarantor. Each Loan Guarantor further agrees that the Guaranteed Obligations may be extended or renewed in whole or in part without notice to or further assent from it, and that it remains bound upon its guarantee notwithstanding any such extension or renewal. All terms of this Loan Guaranty apply to and may be enforced by or on behalf of any domestic or foreign branch or Affiliate of any Lender that extended any portion of the Guaranteed Obligations. SECTION 10.02. Guaranty of Payment. This Loan Guaranty is a guaranty of payment and not of collection. Each Loan Guarantor waives any right to require the Administrative Agent, the Issuing Bank or any Lender to sue the Borrower, any Loan Guarantor, any other guarantor of, or any other Person obligated for all or any part of the Guaranteed Obligations (each, an "Obligated Party"), or otherwise to enforce its payment against any collateral securing all or any part of the Guaranteed Obligations. SECTION 10.03. No Discharge or Diminishment of Loan Guaranty. (a) Except as otherwise provided for herein, the obligations of each Loan Guarantor hereunder are unconditional and absolute and not subject to any reduction, limitation, impairment or termination for any reason (other than the Payment in Full of the Secured Obligations), including: (i) any claim of waiver, release, extension, renewal, settlement, surrender, alteration, or compromise of any of the Guaranteed Obligations, by operation of law or otherwise; (ii) any change in the existence, structure or ownership of the Borrower or any other Obligated Party liable for any of the Guaranteed Obligations; (iii) any insolvency, bankruptcy, reorganization or other similar proceeding affecting any Obligated Party, or their assets or any resulting release or discharge of any obligation of any Obligated Party; or (iv) the existence of any claim, setoff or other rights which any Loan Guarantor may have at any time against any Obligated Party, the Administrative Agent, the Issuing Bank, any Lender, or any other Person, whether in connection herewith or in any unrelated transactions. (b) The obligations of each Loan Guarantor hereunder are not subject to any defense or setoff, counterclaim, recoupment, or termination whatsoever by reason of the invalidity, illegality, or unenforceability of any of

the Guaranteed Obligations or otherwise, or any provision of applicable law or regulation purporting to prohibit payment by any Obligated Party, of the Guaranteed Obligations or any part thereof. (c) Further, the obligations of any Loan Guarantor hereunder are not discharged or impaired or otherwise affected by: (i) the failure of the Administrative Agent, the Issuing Bank or any Lender to assert any claim or demand or to enforce any remedy with respect to all or any part of the Guaranteed Obligations; (ii) any waiver or modification of or supplement to any provision of any agreement relating to 132 Å the Guaranteed Obligations; (iii) any release, non-perfection, or invalidity of any indirect or direct security for the obligations of the Borrower for all or any part of the Guaranteed Obligations or any obligations of any other Obligated Party liable for any of the Guaranteed Obligations; (iv) any action or failure to act by the Administrative Agent, the Issuing Bank or any Lender with respect to any collateral securing any part of the Guaranteed Obligations; or (v) any default, failure or delay, willful or otherwise, in the payment or performance of any of the Guaranteed Obligations, or any other circumstance, act, omission or delay that might in any manner or to any extent vary the risk of such Loan Guarantor or that would otherwise operate as a discharge of any Loan Guarantor as a matter of law or equity (other than the Payment in Full of the Secured Obligations). SECTION 10.04. Defenses Waived. To the fullest extent permitted by applicable law, each Loan Guarantor hereby waives any defense based on or arising out of any defense of the Borrower or any Loan Guarantor or the unenforceability of all or any part of the Guaranteed Obligations from any cause, or the cessation from any cause of the liability of the Borrower, any Loan Guarantor or any other Obligated Party, other than the Payment in Full of the Secured Obligations. Without limiting the generality of the foregoing, each Loan Guarantor irrevocably waives acceptance hereof, presentment, demand, protest and, to the fullest extent permitted by law, any notice not provided for herein, as well as any requirement that at any time any action be taken by any Person against any Obligated Party, or any other Person. Each Loan Guarantor confirms that it is not a surety under any state law and shall not raise any such law as a defense to its obligations hereunder. The Administrative Agent may, at its election, foreclose on any Collateral held by it by one or more judicial or nonjudicial sales, accept an assignment of any such Collateral in lieu of foreclosure or otherwise act or fail to act with respect to any collateral securing all or a part of the Guaranteed Obligations, compromise or adjust any part of the Guaranteed Obligations, make any other accommodation with any Obligated Party or exercise any other right or remedy available to it against any Obligated Party, without affecting or impairing in any way the liability of such Loan Guarantor under this Loan Guaranty, except to the extent the Secured Obligations have been Paid in Full. To the fullest extent permitted by applicable law, each Loan Guarantor waives any defense arising out of any such election even though that election may operate, pursuant to applicable law, to impair or extinguish any right of reimbursement or subrogation or other right or remedy of any Loan Guarantor against any Obligated Party or any security. SECTION 10.05. Rights of Subrogation. No Loan Guarantor will assert any right, claim or cause of action, including, without limitation, a claim of subrogation, contribution or indemnification that it has against any Obligated Party, or any collateral, until the Loan Parties and the Loan Guarantors have fully performed all their obligations to the Administrative Agent, the Issuing Bank and the Lenders. SECTION 10.06. Reinstatement; Stay of Acceleration. If at any time any payment of any portion of the Guaranteed Obligations (including a payment effected through exercise of a right of setoff) is rescinded, or must otherwise be restored or returned upon the insolvency, bankruptcy or reorganization of the Borrower or otherwise (including pursuant to any settlement entered into by a Secured Party in its discretion), each Loan GuarantorÅ™s obligations under this Loan Guaranty with respect to that payment shall be reinstated at such time as though the payment had not been made and whether or not the Administrative Agent, the Issuing Bank and the Lenders are in possession of this Loan Guaranty. If acceleration of the time for payment of any of the Guaranteed Obligations is stayed upon the insolvency, bankruptcy or reorganization of the Borrower, all such amounts otherwise subject to acceleration under the terms of any agreement relating to the Guaranteed Obligations shall nonetheless be payable by the Loan Guarantors forthwith on demand by the Administrative Agent. SECTION 10.07. Information. Each Loan Guarantor assumes all responsibility for being and keeping itself informed of the BorrowerÅ™s financial condition and assets, and of all other circumstances bearing upon the risk of nonpayment of the Guaranteed Obligations and the nature, scope and extent of the 133 Å risks that each Loan Guarantor assumes and incurs under this Loan Guaranty, and agrees that none of the Administrative Agent, the Issuing Bank or any Lender shall have any duty to advise any Loan Guarantor of information known to it regarding those circumstances or risks. SECTION 10.08. Release of Loan Guarantors. (a) A Subsidiary Guarantor shall automatically be released from its obligations under the Loan Guaranty upon the consummation of any transaction permitted by this Agreement as a result of which such Subsidiary Guarantor ceases to be a Subsidiary; provided that, if so required by this Agreement, the Required Lenders shall have consented to such transaction and the terms of such consent shall not have provided otherwise. In connection with any termination or release pursuant to this Section, the Administrative Agent shall (and is hereby irrevocably authorized by each Lender to) execute and deliver to any Loan Party, at such Loan PartyÅ™s expense, all documents that such Loan Party shall reasonably request to evidence such termination or release. Any execution and delivery of documents pursuant to this Section shall be without recourse to or warranty by the Administrative Agent. (b) Upon Payment in Full of all Secured Obligations, the Loan Guaranty and all obligations (other than those expressly stated to survive such termination) of each Loan Guarantor thereunder shall automatically terminate, all without delivery of any instrument or performance of any act by any Person. SECTION 10.09. Taxes. Each payment of the Guaranteed Obligations will be made by each Loan Guarantor without withholding for any Taxes, unless such withholding is required by law. If any Loan Guarantor determines, in its sole discretion exercised in good faith, that it is so required to withhold Taxes, then such Loan Guarantor may so withhold and shall timely pay the full amount of withheld Taxes to the relevant Governmental Authority in accordance with applicable law. If such Taxes are Indemnified Taxes, then the amount payable by such Loan Guarantor shall be increased as necessary so that, net of such withholding (including such withholding applicable to additional amounts payable under this Section), the Administrative Agent, Lender or Issuing Bank (as the case may be) receives the amount it would have received had no such withholding been made. SECTION 10.10. Maximum Liability. Notwithstanding any other provision of this Loan Guaranty, the amount guaranteed by each Loan Guarantor hereunder shall be limited to the extent, if any, required so that its obligations hereunder shall not be subject to avoidance under Section 548 of the Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act, Uniform Voidable Transactions Act or similar statute or common law. In determining the limitations, if any, on the amount of any Loan GuarantorÅ™s obligations hereunder pursuant to the preceding sentence, it is the intention of the parties hereto that any rights of subrogation, indemnification or contribution which such Loan Guarantor may have under this Loan Guaranty, any other agreement or applicable law shall be taken into account. SECTION 10.11. Contribution. (a) To the extent that any Loan Guarantor shall make a payment under this Loan Guaranty (a Å€Guarantor PaymentÅ€) which, taking into account all other Guarantor Payments then previously or concurrently made by any other Loan Guarantor, exceeds the amount which otherwise would have been paid by or attributable to such Loan Guarantor if each Loan Guarantor had paid the aggregate Guaranteed Obligations satisfied by such Guarantor Payment in the same proportion as such Loan GuarantorÅ™s Å€Allocable AmountÅ€ (as defined below) (as determined immediately prior to such Guarantor Payment) bore to the aggregate Allocable Amounts of each of the Loan Guarantors as determined immediately prior to the making of such Guarantor Payment, then, following indefeasible payment in full in cash of the Guarantor Payment, the Payment in Full of the Secured Obligations and the termination of this Agreement, such Loan 134 Å Guarantor shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other Loan Guarantor for the amount of such excess, pro rata based upon their respective Allocable Amounts in effect immediately prior to such Guarantor Payment. (b) As of any date of determination, the Å€Allocable AmountÅ€ of any Loan Guarantor shall be equal to the excess of the fair saleable value of the property of such Loan Guarantor over the total liabilities of such Loan Guarantor (including the maximum amount reasonably expected to become due in respect of contingent liabilities, calculated, without duplication, assuming each other Loan Guarantor that is also liable for such contingent liability pays its ratable share thereof), giving effect to all payments made by other Loan Guarantors as of such date in a manner to maximize the amount of such contributions. (c) This Section 10.11 is intended only to define the relative rights of the Loan Guarantors, and nothing set forth in this Section 10.11 is intended to or shall impair the obligations of the Loan Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Loan Guaranty. (d) The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Loan Guarantor or Loan Guarantors to which such contribution and indemnification is owing. (e) The rights of the indemnifying Loan Guarantors against other Loan Guarantors under this Section 10.11 shall be exercisable upon the Payment in Full of the Secured Obligations and the termination of this Agreement. SECTION 10.12. Liability Cumulative. The liability of each Loan Party as a Loan Guarantor under this Article X is in addition to and shall be cumulative with all liabilities of each Loan Party to the Administrative Agent, the Issuing Bank and the Lenders under this Agreement and the other Loan Documents to which such Loan Party is a party or in respect of any obligations or liabilities of the other Loan Parties, without any limitation as to amount, unless the instrument or agreement evidencing or creating such other liability specifically provides to the contrary. SECTION 10.13. Keepwell. Each Qualified ECP Guarantor hereby jointly and severally absolutely, unconditionally and irrevocably undertakes to provide such funds or other support as may be needed from time to time by each other Loan Party to honor all of its obligations under this Guarantee in respect of a Swap Obligation (provided, however, that each Qualified ECP Guarantor shall only be liable under this Section 10.13 for the maximum amount of such liability that can be hereby incurred without rendering its obligations under this Section 10.13 or otherwise under this Loan Guaranty voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). Except as otherwise provided herein, the obligations of each Qualified ECP Guarantor under this Section 10.13 shall remain in full force and effect until the termination of all Swap Obligations. Each Qualified ECP Guarantor intends that this Section 10.13 constitute, and this Section 10.13 shall be deemed to constitute, a Å€keepwell, support, or other agreementÅ€ for the benefit of each other Loan Party for all purposes of Section 1a(18)(A)(v)(II) of the Commodity Exchange Act. [Signature Page Follows] 135 Å IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective authorized officers as of the day and year first above written. VITAL FARMS, INC., as the Borrower By: /s/ Thilo Wrede Name: Thilo Wrede Title: Chief Financial Officer Vital Farms of Missouri, LLC, as a Subsidiary Guarantor By: /s/ Thilo Wrede Name: Thilo Wrede Title: Member-Appointed Manager Å Signature Page to Credit AgreementVital Farms, Inc. Å JPMORGAN CHASE BANK, N.A., individually as a Lender, and as Administrative Agent, Swingline Lender and Issuing Bank By: /s/ Poonam N. Patel Name: Poonam N. PatelTitle: Authorized Officer Signature Page to Credit AgreementVital Farms, Inc. Å PNC BANK, NATIONAL ASSOCIATION, as a Lender By: /s/ Michael Cuccia Name: Michael CucciaTitle: Senior Vice President Signature Page to Credit AgreementVital Farms, Inc. Å COMPEER FINANCIAL, PCA, as a Lender By: /s/ Dan Terrill Name: Dan TerrillTitle: Director, Capital Markets Signature Page to Credit AgreementVital Farms, Inc. Å COA-PERATIEVE RABOBANK U.A., NEW YORK BRANCH, as a Lender By: /s/ Shane Bownds Name: Shane BowndsTitle: Managing Director By: /s/ Hunter Odom Name: Hunter OdomTitle: Vice President Å Signature Page to Credit AgreementVital Farms, Inc. Å COMMITMENT SCHEDULE Lender Revolving Commitment JPMorgan Chase Bank, N.A. \$18,000,000 PNC Bank, National Association \$14,000,000 Comer Financial, PCA \$14,000,000 CoAþperatieve Rabobank U.A., New York Branch \$14,000,000 Total \$60,000,000 Å Commitment Schedule Å EXHIBIT AASSIGNMENT AND ASSUMPTION Å This Assignment and Assumption (this Å€Assignment and AssumptionÅ€) is dated as of the Effective Date set forth below and is entered into by and between [Insert name of Assignor] (the Å€AssignorÅ€) and [Insert name of Assignee] (the Å€AssigneeÅ€). Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (as amended, supplemented or otherwise modified from time to time, the Å€Credit AgreementÅ€), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full. For an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee, and the Assignee hereby irrevocably purchases and assumes from the Assignor, subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of the AssignorÅ™s rights and obligations in its capacity as a Lender under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of the Assignor under the facility identified below (including any letters of credit and guarantees and swingline loans included in such facility) and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and other rights of the Assignor (in its capacity as a Lender) against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned pursuant to clauses (i) and (ii) above being referred to herein collectively as the Å€Assigned InterestÅ€). Such sale and assignment is without recourse to the Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by the Assignor. 1. Assignor: _____ 2. Assignee: _____ [and is an Affiliate/Approved Fund of [identify Lender]] 3. Borrower: Vital Farms, Inc. 4. Administrative Agent: JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement 5. Credit Agreement: The Credit Agreement dated as of April 9, 2024 among Vital Farms, Inc., the other Loan Parties party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent 6. Assigned Interest: A-1 Å Aggregate Amount of Revolving Commitment/Loans for all Lenders Amount of Revolving Commitment/Loans Assigned Percentage Assigned of Revolving Commitment/Loans \$ \$ % \$ % \$ % \$ % Å Effective Date: _____, 20____ [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.] The Assignee agrees to deliver to the Administrative Agent a completed Administrative Questionnaire in which the Assignee designates one or more credit contacts to whom all syndicate-level information (which may contain material non-public information about the Borrower, the Loan Parties and their Related Parties or their respective securities) will be made available and who may receive such information in accordance with the AssigneeÅ™s compliance procedures and applicable laws, including federal and state securities laws. The terms set forth in this Assignment and Assumption are hereby agreed to: ASSIGNOR[NAME OF ASSIGNOR] By: _____ Name: _____ Title: _____ ASSIGNEE[NAME OF ASSIGNEE] By: _____ Name: _____ Title: _____ A A-2 Å [Consented to and] Accepted: JPMORGAN CHASE BANK, N.A., as Administrative Agent, Issuing Bank and Swingline Lender Å By: _____ Name: _____ Title: _____ Å [Consented to:] Vital Farms, Inc. Å By: _____ Name: _____ Title: _____ A-3 Å ANNEX 1 toASSIGNMENT AND ASSUMPTION STANDARD TERMS AND CONDITIONS FORASSIGNMENT AND ASSUMPTION 1. Representations and Warranties. 1.1 Assignor. The Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any Subsidiary or Affiliate or any other Person obligated in respect of any Loan Document, (iv) any requirements under applicable law for the Assignee to become a lender under the Credit Agreement or any other Loan Document or to charge interest at the rate set forth therein from time to time or (v) the performance or observance by the Borrower, any Subsidiary or Affiliate, or any other Person of any of their respective obligations under any Loan Document. 1.2 Assignee. The Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it satisfies the requirements, if any, specified in the Credit Agreement and under applicable law that are required to be satisfied by it in order to acquire the Assigned Interest and become a Lender, (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire the Assigned Interest, is experienced in acquiring assets of this type, (v) it has received a copy of the Credit Agreement, together with copies of the most recent financial statements delivered pursuant to Sections 5.01(a) and 5.01(b) thereof, as applicable, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest on the basis of which it has made such analysis and decision independently and without reliance on the Administrative Agent, the Arranger, the Assignor or any other Lender or their respective Related Parties, and (vi) attached to the Assignment and Assumption is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by the Assignee; and (b) agrees that (i) it will, independently and without reliance on the Administrative Agent, the Arranger, the Assignor or any other

Lender or their respective Related Parties, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender. Without limiting the foregoing, the Assignee represents and warrants, and agrees to, each of the matters set forth in Section 8.06 of the Credit Agreement, including that the Loan Documents set out the terms of a commercial lending facility. 2. Payments. From and after the Effective Date, the Administrative Agent shall make all payments in respect of the Assigned Interest (including payments of principal, interest, fees and other amounts) to the Assignor for amounts which have accrued to but excluding the Effective Date and to the Assignee for amounts which have accrued from and after the Effective Date. Annex 1-1 A 3. General Provisions. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument. Acceptance and adoption of the terms of this Assignment and Assumption by the Assignee and the Assignor by Electronic Signature (as defined in the Credit Agreement) or delivery of an executed counterpart of a signature page of this Assignment and Assumption by any Approved Electronic Platform (as defined in the Credit Agreement) shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York. Annex 1-2 A EXHIBIT B OPINION OF COUNSEL FOR THE LOAN PARTIES A [Attached.] B-1 A EXHIBIT C [Reserved] A C-2-1 A EXHIBIT D-1 U.S. TAX COMPLIANCE CERTIFICATE(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) Reference is hereby made to the Credit Agreement dated as of April 9, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the a€Credit Agreementa€), among Vital Farms, Inc., as Borrower, the other Loan Parties party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and each lender from time to time party thereto. Pursuant to the provisions of Section 2.17 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. The undersigned has furnished the Administrative Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate prior to the first payment to be made to the undersigned, or in either of the two calendar years preceding such payments. Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. [NAME OF LENDER] A

By: Name: Title: A Date: , 20[] D-1-1 A EXHIBIT D-2 U.S. TAX COMPLIANCE CERTIFICATE(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes) Reference is hereby made to the Credit Agreement dated as of April 9, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the a€Credit Agreementa€), among Vital Farms, Inc., as Borrower, the other Loan Parties party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and each lender from time to time party thereto. Pursuant to the provisions of Section 2.17 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate prior to the first payment to be made to the undersigned, or in either of the two calendar years preceding such payments. Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. [NAME OF PARTICIPANT] By: Name: Title: A Date: , 20[] D-2-1 A EXHIBIT D-3 U.S. TAX COMPLIANCE CERTIFICATE(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes) Reference is hereby made to the Credit Agreement dated as of April 9, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the a€Credit Agreementa€), among Vital Farms, Inc., as Borrower, the other Loan Parties party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and each lender from time to time party thereto. Pursuant to the provisions of Section 2.17 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect to such participation, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, or (ii) an IRS Form W-8IMY accompanied by a withholding statement together with an IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, from each of such partnera€™s/membera€™s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate prior to the first payment to be made to the undersigned, or in either of the two calendar years preceding such payments. Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. [NAME OF PARTICIPANT] By: Name: Title: A Date: , 20[] D-3-1 A EXHIBIT D-4 U.S. TAX COMPLIANCE CERTIFICATE(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes) Reference is hereby made to the Credit Agreement dated as of April 9, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the a€Credit Agreementa€), among Vital Farms, Inc., as Borrower, the other Loan Parties party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and each lender from time to time party thereto. Pursuant to the provisions of Section 2.17 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Credit Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. The undersigned has furnished the Administrative Agent and the Borrower with IRS Form W a€IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, or (ii) an IRS Form W-8IMY accompanied by a withholding statement together with an IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, from each of such partnera€™s/membera€™s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate prior to the first payment to be made to the undersigned, or in either of the two calendar years preceding such payments. Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. [NAME OF LENDER]

By: Name: Title: A Date: , 20[] D-4-1 A EXHIBIT E COMPLIANCE CERTIFICATE To: The Lenders party to theCredit Agreement described below This Compliance Certificate (this a€Certificatea€), for the period ended [] , is furnished pursuant to that certain Credit Agreement dated as of April 9, 2024 (as amended, modified, renewed or extended from time to time, the a€Credit Agreementa€) among Vital Farms, Inc. (the a€Borrowera€), the other Loan Parties party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent for the Lenders and as the Issuing Bank and Swingline Lender. Unless otherwise defined herein, capitalized terms used in this Certificate have the meanings ascribed thereto in the Agreement. THE UNDERSIGNED HEREBY CERTIFIES THAT: 1. I am the [] of the Borrower and I am authorized to deliver this Certificate on behalf of the Borrower and its Subsidiaries; 2. I have reviewed the terms of the Agreement and I have made, or have caused to be made under my supervision, a detailed review of the compliance of the Borrower and its Subsidiaries with the Agreement during the accounting period covered by the attached financial statements (the a€Relevant Perioda€); 3. The attached financial statements of the Borrower and, as applicable, its Subsidiaries and/or Affiliates for the Relevant Period: (a) have been prepared on an accounting basis (the a€Accounting Methoda€) consistent with the requirements of the Agreement and, except as may have been otherwise expressly agreed to in the Agreement, present fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, and (b) to the extent that the attached are not the Borrowera€™s annual fiscal year end statements, are subject to normal year-end audit adjustments and the absence of footnotes; 4. The examinations described in paragraph 2 did not disclose and I have no knowledge of, except as set forth below, (a) the existence of any condition or event which constitutes a Default or an Event of Default under the Agreement or any other Loan Document during or at the end of the Relevant Period or as of the date of this Certificate or (b) any change in the Accounting Method or in the application thereof that has occurred since the date of the annual financial statements delivered to the Administrative Agent in connection with the closing of the Agreement or subsequently delivered as required in the Agreement; 5. I hereby certify that, except as set forth below, no Loan Party has changed (i) its name, (ii) its chief executive office, (iii) its principal place of business, (iv) the type of entity it is or (v) its state of incorporation or organization without having given the Administrative Agent the notice required by the Security Agreement; 6. Schedule I attached hereto sets forth financial data and computations evidencing the Borrowera€™s compliance with certain covenants of the Agreement, all of which data and computations are true, complete and correct; and E-1 A 7. Schedule II hereto sets forth the computations necessary to determine the Applicable Rate commencing on the Business Day this Certificate is delivered. Described below are the exceptions, if any, referred to in paragraph 4 hereof by listing, in detail, the (i) nature of the condition or event, the period during which it has existed and the action which the Borrower has taken, is taking, or proposes to take with respect to each such condition or event or (ii) change in the Accounting Method or the application thereof and the effect of such change on the attached financial statements:

The foregoing certifications, together with the computations set forth in Schedule I and Schedule II hereto and the financial statements delivered with this Certificate in support hereof, are made and delivered this day of . . . A By: Name: Title: E-2 A Schedule I to Compliance Certificate Compliance as of [] withProvisions of Section 6.12 of the Agreement The computations set forth in this Schedule I are designed to facilitate the calculation of financial covenants and certain other provisions in the Agreement relating to the information set forth in the Borrowera€™s consolidated financial statements delivered with this Certificate. The computations set forth in this Schedule I have been made in accordance with GAAP. The use of abbreviated terminology and/or descriptions in the computations below are not in any way intended to override or eliminate the more detailed descriptions for such computations set forth in the relevant provisions of the Agreement, all of which shall be deemed to control. In addition, the failure to identify any specific provisions or terms of the Agreement in this Schedule I does not in any way affect their applicability during the periods covered by such financial statements or otherwise, which shall in all cases be governed by the Agreement. A Consolidated EBITDA for the most recently ended 4 fiscal quarters A A A A With reference to any period: A A A A (i) Consolidated Net Income for such period \$ A A A plus, without duplication and to the extent deducted in determining Consolidated Net Income, A A A A (ii) Consolidated Interest Expense for such period + \$ A A A (iii) income tax expense for such period + \$ A A A (iv) all amounts attributable to depreciation and amortization expense for such period + \$ A A A (v) non-cash stock-based compensation expenses for such period + \$ A A A (vi) any non-cash losses on sales of fixed assets, non-cash losses on Investments, non-cash write-downs of fixed or intangible assets or non-cash goodwill impairment charges for such period A + \$ A A A (vii) any other non-cash charges, expenses or losses for such period, including non-cash foreign exchange losses and non-cash stock based compensation charges (but excluding any non-cash + \$ A A A charge in respect of an item that was included in Consolidated Net Income in a prior period) A A A A (viii) expenses, fees, costs and charges incurred in connection with the Transactions to occur on the Effective Date in an aggregate amount not exceed \$750,000 + \$ A A A (ix) fees, costs and expenses that are actually incurred in connection with Permitted Acquisitions, other Investments permitted under the Credit Agreement, issuances of Qualified Stock of the Borrower, asset sales, issuance of Indebtedness and Restricted Payments; providedA that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (ix) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (x), (xi) and (xiii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs) + \$ A A A A (x) non-recurring charges, costs, losses, fees and expenses directly incurred or paid directly as a result of discontinued operations or any sale or Disposition of any asset of the Borrower or its Subsidiaries, in each case, to the extent factually supportable; providedA that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (x) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (ix) above and clauses (xi) and (xiii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs) + \$ A A A A (xi) costs (including restructuring costs related to Acquisitions after the Effective Date), charges, accruals, reserves or expenses attributable to the undertaking and/or implementation of cost savings initiatives, operating expense reductions, integration, transition, digital transformation, ERP implementation, facilities opening and pre-opening, construction of facilities, business optimization and other restructuring and integration costs, charges, accruals, reserves and expenses (including, without limitation, inventory optimization programs, software development costs, costs related to the closure or consolidation of facilities, stores and distribution centers, curtailments, costs related to entry into new markets, costs related to preopening and + \$ A A A opening of stores, distribution centers or other facilities, consulting fees, signing costs, retention or completion bonuses, relocation expenses, severance payments, modifications to pension and post-retirement employee benefit plans and new systems design and implementation costs, information technology costs, website rebranding and redesign costs and project startup costs) incurred during such period; providedA that such cost savings initiatives, operating expense reductions, integration, transition, digital transformation, ERP implementation, facilities opening and pre-opening, business optimization and other restructuring and integration costs, charges, accruals, reserves and expenses are reasonably expected and factually supportable (in the good faith determination of the Borrower); provided furtherA that the aggregate of all amounts added-back to Consolidated EBITDA pursuant to this clause (xi) during any period of four consecutive fiscal quarters of the Borrower, when taken together with the aggregate of all amounts added back to Consolidated EBITDA pursuant to any of clauses (ix) and (x) above and (xiii) below for such period, shall not in the aggregate exceed an amount equal to 20% of Consolidated EBITDA for such period (calculated before giving effect to such add-backs) A A A A (xii) any costs incurred during such period with respect to liability, casualty events or business interruption, in each case, to the extent such costs are actually reimbursed in cash by a third-party unaffiliated insurer during such period + \$ A A A A (xiii) expected cost savings, operating expense reductions, restructuring charges and expenses related to Permitted Acquisitions or other Investments consummated after the Effective Date, in each case, reasonably projected by the Borrower in good faith to be realized as a result of specified actions taken or committed to be taken within the twelve month period following the consummation thereof (or following the consummation of the squeeze-out merger in the case of an Acquisition structured as a two-step transaction) and to the extent such amounts are reasonably identifiable and factually supportable (in the good faith determination

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thilo Wrede, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of Vital Farms, Inc. A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

A (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

A 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2024 By: /s/ Russell Diez-Cansoco Russell Diez-Cansoco President and Chief Executive Officer(Principal Executive Officer)

EX-31.2.5 vitl-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thilo Wrede, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of Vital Farms, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

A (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

A 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2024 By: /s/ Thilo Wrede Thilo Wrede Chief Financial Officer(Principal Financial Officer)

EX-32.1 6 vitl-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Russell Diez-Cansoco, President and Chief Executive Officer of Vital Farms, Inc. (the "Company"), and Thilo Wrede, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: 1. The Company's Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and 2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 8, 2024 IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8th day of August, 2024. /s/ Russell Diez-Cansoco /s/ Thilo Wrede Russell Diez-Cansoco Thilo Wrede President and Chief Executive Officer(Principal Executive Officer) Chief Financial Officer(Principal Financial Officer) This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vital Farms, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. A GRAPHIC 7 img14060505 .jpg GRAPHIC begin 644 img14060505 .jpg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j6(VFY-MOF=H3B)=JJEIT1D0+J&I!,Y=@/TJ,!>'HHUW:8T:M#\$'QD9&:& O+B(1+!<9J)>/LSG/RYYYS%&MLRN2V=&E R ZSS2G*T8 MJCT3?67U7[<QW0&GLD,B[D=>A'KA'4][V2TM(T;>_0J1(A!=1SBMS7!HEIT!M+.#HJ!MKH'GRHW(SAB&6/Z&U\$ [#BG]I+=EZB[E.K:S8QWMC,LL&X8= MO8CL.O4WUO.-LJPHHH\$%%%% !1104&BD)P* ,Q+X,MOS&VGI9W,TD2I M(0!T>.Y'3J*RKCP!>VWFWSYJE[,..@Q@[R1]%&(PKOUOQCHN.<.(V431 MS=W-6:I?Q*>5-6CTV.2?>4XC,JBS5ZDN.R:UUFJ3LIK%'GS03Y5?IW+W U MGX3BTW4=R%L[YADN[3S*!JUSX'MBCLO,-3+4IF78 M'PJN KJNHROXD]>[KRMJ/L9\$B +(+4.W -JBPXC=MO!PKXFMOR9EO9I0 MR-G2[A(X=>0)Q450>ST?7'>?WH,R G#G.N/GKV\$X?Z=X=N=<S\$,ES[!) MF8MW(QOTQCBLXOB'BMPO9V'437,K'L'FJVL,C/N/AO ME#E4GHZ2IB/RIPDV6Y?�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z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

M6;M1\$R\$4/E/ PA=U|I=/N/+M8ENM1^~(\$K6(RZ-R5C&X<_AUKV;3;*V1 M'>#F#L#W9EF?N[GJ?SKRWX<A+>XVDGU0IT5YHV,4C#>3G/?%=>XSU>;Q3 M|,A70Vt,P: [F0Y50>|J, DH.U|>QUX^E*F1AAK6A|J7;|>9L #4#>2U; M1KN^U^=Y1+P KY=2:73M M4BF3=F.56;CD|, U|-XR90S2^#IVBR>+>O4%|?^|@|JOK?|A|J\$|>|W|I^>+>6V%UBTTZ/Y8K>|<*. @ MS7? < "2-&=>J\$, %|/A|F|,VKC BOX7U*U|1-L1,6>=>-X +D\$*EF4CO@4ZE* M2HN^|WPT^|,IRQ4G|L4U25;39?|P|-8YU(4^1N^>KL^>T22&?QC827C|4DN M1EFZ5WVE>^ \$GBGVTRTUN V&DV**<>23D|=..U|WB+X7Z5&=VES!|C|JAg6 M:G|=~<=CL|J4|5.64=D9T,|QH4|>P|>16MNRTW,XL:RM|KH|F7|, M\$&=BCIGVZ;PIXMA|>J,TJN>|O|NF>^891")>+>BXG& M|J|@>GL|>K%>CX1T^1#3KTWEI|>O^>QSQVQ&A0^<K+ M:6M|KOSI(|@UCX>+Z_-HZ:NT4ES?73|>G GWX|>K6Y1NA^>?)|MIMA|J|VG: M18J P=0.1QT|T5ZWVZU|>6#SGHQA0>=>UMY&FV|JQ?>O-U|J9 MK7B,20#>|DMNW?W2K& P#|PGS, P! M0^&O&NF^*5G;3Q>B X?Y\$|JME634|+7 M>47,9|WJDY.FO6Q0 8!..U|..(**" BBB@ HI#1P@>:PW+BS1E|>@SK6GA M-1^|BJW;7TEF)&+>.&.\$# ^|V?WO#?>?72|>=> KSWA&#<^3\$%OH/05TU^|SFL MU2@L6! \$*O16Y%>5 \$/Q/K>E>)+>QT 419P.\$&+>; >2>1.^?R|:TN6|>->QI MEU5|JGL^1-|ZM|/0N1ZG2M1;|WI-A8(?XICT_#|>:50H^BJZ8? VGXL/9|B MLH5O WCS^E5?|EWJ>=>EW M^X|@74|9|W.W8K?|>|>O4^>O+>#J5KXFA|22;- RMR2L|Y5|H5X^CZ^L|5(PLY7=^_J^GAJE:4XTE!|,1+K M4+|JE>1 M|JM+(TKN? 8=>Q+>XMVQ|QJMO:2KV**=>PBS@>|DXIV^GXU|U^*MQ%&|& MA:4#|>0, -Q#^H4B^P&=|==> RMYK|Y>+>Q>E:5XVFBMKH?9K9QMMRHVN^..O Y QQQNN^M;Q;&#X@%V|^..^FJU^?^ F9OC MGPO=>W^>BZ3|>6BZR-9VH#0%>AN|SN49P?<5M #3Q-#K=G<6S64>O>08|QH4| B4 M^HVIT-97B5Z_ UOV^VWQ=>V:6D B^N|E?|>N>W| EOXS^T2T^|4X|RDZ^> M5F<K|@=>^UC%|K=|^#5|J G^>5^5VNT|&K:|J7LSM?&O&C=9X@M%>M%> 1110 M4ZWD5D OE M2,Y|Z5Z|R1F|G|>LZM-5%>9GSA,4-M,N;+>PDB^>M+> KU7;1MZ>U3^A^3NS6E MF6|H4Q4|>|LW;ZM^>9PD^P26?P 87Z|>I2RK-RM|O+>P7X>=>|>5NZAI EVMZ0? M7V,M?Y0 +>5C1<8Z?>Q>VWG:7%5&G&C;QC4QE|H|REWM|J|JNYR,4X M1K+1H&|>|WSV|T4Q523X<6VH\$6^-U76|J|VQ|^>|>5Z5V^VC^3B|J|OCBJ M^X^H^B 7J3E4?X^<K<+>1,X,Z YS7S>=>G?>M%>=>TFY\$889;VX&|,1>M^>|,|6|CJFC%>+15F 4444 %>%%> 1110 4444 %>%%> 1110 4444 %>%%> 1110 4444 %>%%> 1110 4F:6F^KO! 9 end GRAPHIC 8 img14984026 0.jpg GRAPHIC begin 644 img14984026 0.jpg M_JC_X 02D9|>| @ 0 ! # VP|! @&|@<@&|0@<|P!<^0@<#10-# L+ M#>!D28P4!H7A^T^!P|@>^XG(^|>L(QP<#?7#|>7#A|6&AXB|B|3E|66EYB9F?|C1^6FIZB|P^|SM+6VM|BYNL+^A7B& MQC|RM+>3U-76U|C9VN^BX^3EYN?HZ>KQ|O|T|?>W^>GZ 0 P\$ P\$! O\$! M 0\$! 0\$! P0\$P@>|<@>OH+> 0 M|\$ @>1\$! 0#> !>0 0|W \$> 0 \$>S!\$2Q|A|>40=A^1,B,H\$(>%1H!|!>2,S40 58G+1 QD,7&S;E|>1&8&1HF M|>R@>^C4V\$5U>D-1\$49>2\$E*U155E=865C|C9&5F9VA|G: T=79W>E^>H \$ MAB8:B^F^D|A.E9:F7F:H|D|:G^*FJLK|T:WN+>FZPL>Q<|>R,G^T^M4| MU7=>3N>JXN|DY>;GZ,GJ|O|T|?>W^>GZ JH #^| 1(Q 3\$ /P#W^>O_ B1?Z MQX:TR4>=,U|J|5|H1^4R|&|5%&4|Q|P|DSV4F01^W^~ (V7 # +>P^|>2P MUN=>A^X16N\$=L30-3KVG|Y2MA=>XY @>0,D#5|JN|>M2^4NX|J|N|ZTU^W+6M MDD58@A5R^R-VY3Z=L4O@>W-D2|>Z XO \$>5+X|L>6^>0^7 T Z=>G%> M+O7?%MCTZ>U>=>(>V^*>?RUF,(&#&D?>#ZT|>)=>4 [JTN;FJCUC29I-C9^ ML =>=TSQU=> M: M?R3.5+<<20J\$097>R^*5 Z,O|XUZE2X M>_D2| XICU|>09K& NQ|>E<=>1^?P\$SH8D>S5S|C07IM |LS2V9 P|G|E6 MP R0V,LE>RAC^>+X^U| (2P6?7,C|K|>1|Z|U| M^>B^,R^R; XG>N>U^1N HKM=>#TV|>#ZW\$L9+|\$ \$^*G? 0^M,M5U?Q|9W- J6K7\$IMY +6|5C5&T^&M^|Y|B E>BUYC\$ ^1=U^ KZ^ H^U,5|>^?>8HH@->GH5%<3X@TS5 #VBW&K:1K^H32VBF62^>99HY4+>H^|IQZ^ MM6C|H.L|XV+PWE05W|Z|5RP(|Y|Z>^*+A8Z6B0=>^|>6^>|XMXU MP|;74E|Q|X5=L6UCND<@>#.%>R%>@<@<5K6S/Q TCQE96|>|>M|JNESG|J|,L A M\$& 70J0<8|>+A8|>|HMS>3Q|J|GBKQ +X>T^R|DL-|J| V^> #S9?1."0=H^W^ MYFF>|,|60 7V4=>J6Y0,60Q36U^1^X,R^&P&0^#WN^CTNB0^|BU|2+>6 M E^<|= :75X+>|>WJ9 ,!EZCC XX|J?PE9ZUXJ|T^|U9|U\$4|>|AVF&T80^ MB XSC3&G^2M1<4+>H->?>+>#?>NNM67Q#N0^FIWS?7|U9BF4E|UVKN|RISE>N|>M|G0%GU>2^|>JQK&GZK=VL9C01+L7+ \$>C^DY|Y|>+A8|2B0|^H_ \$OC3P|:3V M^>K^?V5|&^Y4+A81+> <2KPS>=>LO>LWA77+L7PW.B3% "&^ M|>@>Q7L>G9%PL>|T44Q4\$W=>L|TJ4Q\$W=>|>1ZD=1UKSWT|ABK9|> M7O_ \$J5F|VX<^>JESXB|J.EU+>3|HN6^>SNOF^>QD6|S6C|JL^)|>U_P ? MW-E93|>|TF% -EFNGOR2,<|>I0\$|76|>|>J&K?X|^*#>+>#>|>C|B P^0140B MK D4M8 Z|Y? \$ USOBA^%NGWGFVBVOA6%3|>B.5<*<8(\$A=HZZC ^M7Q? M &U2Z@:,S/J+NR#P>2<4P.&^>#>BVF|>|Y|EKC7T.^&ZDB M^&B|>K#=>=AZ9X3T+2+@>W-GITZ^Y,|DR2?|?3\$FNA |J^BCP|%/8WFB| M:7\$PDV,Z3? |R|C@&MCQ\$|XPCDT_ (1= R%R|)!<^<|<O>X>N<4EL#W M. MQKFO#>K^>#?>M^>+>FTN\$#PS7-Y&ZGN#|>(#6Q?7|>:):6P^V77 *R&K;|J\$N:M7 M|^^(M2L+M^>UG2UA DEF62X25P2|E0M| YSECS|4P|O^>M^>X? <|>4X^N\$|^L=,ET\$XI *DE8&66(\$9 M^>+>3QG@>|! 6CL,Z7Q40^6L\$G^>Q|R?|JUP P 8|>8>J\$YK|4-OIG8, T MK9|07>N>)>M|>FT?3-3N|>W0N:ZOF10|B0|P5Y#H^AWQGHWC^Y^0 M2Z+>S&Z,IEB6|<|>S,NX|/0>5Z^W\$O|&L^E2,H|>D>=>^<^|X|:PZ=HWAAP D, S99HN8%AM|>9^>F3K3Q7,4XZ0=>U 40^>SDT8W|JTS>7Y^|T?|>#P| @>C|CK6Y;7&R|5 M|>#GB3OY4RMCZ# J;H>IWTMS^>O^>274C-|I|L\$5+|>0%&|ZD \$KE|U|CQ M9XUC^>M9K:1|JWE8|5OFDDP>=>@>O,E|G^H5&S;X@>^|I4TZY79=>#>B=A|Q|U (M_>|D8<|>P4 X3C0=>M^>M^>MW|B|>N6Z41H^+|>^|>^<1^>(+):75 MYFR|CLRQ|LR|64KG@>A>=> >U0|F>+>|J7,|Q?^EC=>22L|K|>^TJ|H#>|BWE|JY MP.#Z#11T&:G|P L|J|^ +>_C&KCD Y.^|>G-|>|X2 H6@>160Z^>M^>+> <^,B7^MYA|SM|>3DGFN5^PYXT|C_ /X2E-SMU;\$= P|G-XW=>FS^>UW MQ1T0=3U^>BHK=>Y+Q>=>R9609|KMP;8V,1D=><=>M%>422T444 %>%%> 1110 44 %>%%> 1110 4444 %> (V=|IUCQ2T4 >?>|?>DGBG|C^>J^>M#>|>P\$>POEM\$ MJ,B8Z8|7|R/6NAUQ \$=>=082|JMG|<=>=O+Y^>Q^>#>#>|>G|T|Y|J|A|1M6D\$FH:7| M7;@>Z|>X\$^WY|:CLO^N@=>:; M31|^53E780+>?>^E|C9 VTB72/^A26.6(7 C%)<11RC#1& EX-101.SCH 9 vitl-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Investment Securities - Summary of Contractual Maturities of Investment Securities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Allowance for Credit Losses link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Goodwill and Other Assets link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Allowance for Credit Losses (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Goodwill and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Investment Securities - Summary of Available-for-sale Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Investment Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Investment Securities - Summary of Contractual Maturities of Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Investment Securities - Schedule of Unrealized Loss Aging for Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Derivative Financial Instruments - Schedule Of Notional Amounts of Outstanding Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Derivative Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Revenue Recognition - Summary of Net Revenue by Primary Product (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Allowance for Credit Losses - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Inventories - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Property, Plant and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Leases - Schedule of Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Goodwill and Other Assets - Schedule of Goodwill and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Goodwill and Other Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Long-Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996175 - Disclosure - Stock-Based Compensation - Summary of PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996185 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996195 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996205 - Disclosure - Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect (Details) link:presentationLink link:calculationLink link:definitionLink 996215 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 996225 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 996235 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996245 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996255 - Disclosure - Subsequent Event - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Lessee, Operating Lease, Liability, to be Paid, Year One Operating leases 2025Collaborative Arrangement and Arrangement Other than Collaborative [Domain]Document Transition ReportDocument Transition ReportShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermWeighted Average Remaining Contractual Life (Years), BalanceMoney marketMoney Market Funds [Member]Noncontrolling Interest [Member]Noncontrolling InterestsStock options - vest yearShare-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting PeriodTotal available-for-sale Fair ValueFair ValueDebt Securities, Available-for-SaleInvestment securities, available-for-saleJP morgan credit facilityJP Morgan Credit Facility [Member]JPMorgan Credit FacilityOther Liabilities, NoncurrentOther liabilitiesOther Liabilities, Noncurrent, TotalRedeemable Noncontrolling Interest, Equity, Carrying AmountNet Ending balanceBeginning balanceRedeemable noncontrolling interestRedeemable Noncontrolling Interest, Equity, Carrying Amount, TotalRestricted Stock Units (RSUs) [Member]RSUsUnvested RSUsFair Value, Inputs, Level 1 [Member]Level 1Receivable Type [Axis]Distribution fees and freightAccrued distribution fees and freight current.Accrued Distribution Fees And Freight CurrentFair Value MeasurementsFair Value Disclosures [Text Block]Finance Lease, Liability, to be PaidTotal lease paymentsRevenue from Contract with Customer, Excluding Assessed TaxNet revenueRevenue from Contract with Customer, Excluding Assessed Tax, TotalPrepaid Expense and Other Assets, Current [Abstract]Rule 10b51 arr modified flag.Rule 10b51 Arr Modified FlagDisaggregation of Revenue [Table Text Block]Summary of Net Revenue by Primary ProductConcentration Risk Type [Axis]Concentration Risk TypeFinance Lease, Liability, to be Paid, Remainder of Fiscal YearFinance leases 2024Pullets member:Pullets [Member]PulletsLine of credit facility covenant complianceLine of Credit Facility, Covenant ComplianceDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 MonthsUnrealized losses, less than 12 monthsUnrealized losses, less than 12 monthsLetter of credit sub limitLetter of Credit Sub LimitLetter of credit sub-limitSubsequent EventsSubsequent Events [Text Block]Contract cost payableContract Cost PayableContract cost payableSoybean MealSoybean MealSoybean Meal [Member]Soybean Meal,Operating Lease, Liability, NoncurrentOperating lease liabilities, non-currentSchedule of Stock by Class [Table]Schedule Of Stock By Class [Table]Debt Securities, Available-for-Sale [Table]Debt Securities Available For Sale [Table]Finance lease liabilities, non-currentFinance Lease, Liability, NoncurrentClass of Stock [Link Items]Class Of Stock [Link Items]Related Party Transactions [Abstract]Assets, CurrentTotal current assetsTotal liabilities and stockholders' equityLiabilities and EquityEntity Address, State or ProvinceEntity Address, State or ProvinceDerivative Financial InstrumentsDerivative Instruments and Hedging Activities Disclosure [Text Block]Long-Term DebtLong-Term Debt [Text

Block]Kathryn MckeonKathryn McKeon [Member]Kathryn McKeon.Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberNumber of Options, Ending balanceNumber of Options, Beginning balanceInventory Disclosure [Text Block]InventoriesTrading SymbolTrading SymbolCommon Stock, Shares, IssuedCommon stock, shares issuedCommon Stock, Shares, Issued, TotalDebt Securities, Available-for-Sale [Line Items]Schedule Of Available For Sale Securities [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair ValueFair value of shares vestedPrepaid expenses and other current assets, netPrepaid expenses and other current assets, netPrepaid expenses and other current assets, net of allowance for credit losses of \$117 and \$227 as of June 30, 2024 and December 31, 2023, respectivelyPrepaid Expense and Other Assets, CurrentDeferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]Consolidated Entities [Domain]Consolidated EntitiesNet Income (Loss) Attributable to Parent [Abstract]Numerator:Percentage of debt instrument face amount.Percentage of Debt Instrument Face AmountPercentage of debt instrument face amountSchedule of Long-Term Debt Instruments [Table]Line of Credit Facility, Remaining Borrowing CapacityLine of Credit Facility, Remaining Borrowing CapacityLessee, Operating Lease, Liability, to be Paid, Year ThreeOperating leases 2027Common Stock, Capital Shares Reserved for Future IssuanceCommon stock for issuanceAccumulated other comprehensive incomeAOCI Attributable to Parent [Member]Accumulated Other Comprehensive LossNet other comprehensive income (loss)Other Comprehensive Income (Loss), Net of TaxOther comprehensive income loss, netOther comprehensive income, net of taxAccumulated Other Comprehensive Income (Loss) [Line Items]Unusual Risk or Uncertainty, Nature [Domain]Entity Address, City or TownEntity Address, City or TownRelated Party Transaction [Line Items]Related Party Transaction [Line Items]Property, Plant and Equipment [Table Text Block]Schedule of Property, Plant and EquipmentUnrealized net holding gain, TaxOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, TaxUnrealized net holding gain, TaxShare-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]Summary of PSU activityAmortization of available-for-sale debt securities.Amortization Of Available For Sale Debt SecuritiesAmortization of available-for-sale debt securitiesSubsequent Event [Member]Subsequent EventSubsequent Event Type [Axis]Finance Lease, Principal PaymentsPrincipal payments under finance lease obligationsShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise PriceWeighted-Average Exercise Price, Options CancelledAdditional Paid-in Capital [Member]Additional Paid-In CapitalMaturities and call redemptions of available-for-sale debt securitiesProceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-SaleAllowance for Credit Loss [Abstract]Liabilities, Current [Abstract]Current liabilities:Goodwill and other assetsGoodwill and other assetsGoodwill and Other AssetsGoodwill and other assets.Net income (loss) per share attributable to Vital Farms, Inc. stockholdersNet (loss) income Earnings per share attributable to parent [Absract]Net (loss) income earnings per share attributable to parent.Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or LongerUnrealized losses, 12 months or longerUnrealized losses, 12 months or longerAssets, Current [Abstract]Current assets:Accounts Receivable, Allowance for Credit Loss, CurrentAccounts Receivable, net of allowance for credit lossesPreferred Stock, Par or Stated Value Per SharePreferred stock, par valueAmounts reclassified for realized losses to earnings, Before TaxAmounts reclassified from accumulated other comprehensive loss to earningsReclassification from Accumulated Other Comprehensive Income, Current Period, before TaxAmounts reclassified from accumulated other comprehensive loss to earningsStatement of Stockholders' Equity [Abstract]Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise PriceOperating lease liabilities, currentOperating Lease, Liability, CurrentLender Name [Axis]Debt Instrument, Maturity DateMaturity of long term debtDerivative Contract [Domain]Property, Plant and Equipment, NetProperty, plant and equipment, netProperty, plant and equipment, netProperty, Plant and Equipment, Net, Beginning BalanceProperty, Plant and Equipment, Net, Ending BalanceLessee operating and finance lease liability maturity table text block.Lessee Operating And Finance Lease Liability Maturity Table [Text Block]Summary of Operating and Finance Leases Future Undiscounted Cash FlowsClass of Stock [Domain]Class of StockRecently issued accounting pronouncements not yet adopted.Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]Recently Issued Accounting Pronouncements Not Yet AdoptedFair Value Measurement Inputs and Valuation Techniques [Line Items]Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year OneDue within one year Amortized CostReductions (provisions) charged to operating resultsAccounts Receivable, Credit Loss Expense (Reversal)(Provisions) reductions charged to operating resultsAggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueStatement of Comprehensive Income [Abstract]Collaborative Arrangement and Arrangement Other than Collaborative [Axis]Credit facility.Credit Facility [Member]Credit FacilityEntity Central Index KeyEntity Central Index KeyStock Issued During Period, Value, Restricted Stock Award, Net of ForfeituresShares withheld for tax liability on vested restricted stock unitsVesting of restricted stock unitsFinance lease liabilities, currentFinance Lease, Liability, CurrentPlan Name [Domain]Plan NameAssets, Fair Value Disclosure, TotalAssets, Fair Value DisclosureAssets measured at fair valuePreferred Stock, Shares Outstanding, Beginning BalancePreferred Stock, Shares Outstanding, Ending BalancePreferred Stock, Shares OutstandingPreferred stock, shares outstandingLiabilities, CurrentTotal current liabilitiesEntity Tax Identification NumberEntity Tax Identification NumberIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestNet income before income taxesTerm loan.Term Loan [Member]Term LoanSixth amendment.Sixth Amendment [Member]Sixth AmendmentSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]Financial Instruments [Domain]Financial InstrumentsLong Term Supply Contracts CostsLong-term supply contracts costs.Long-term supply contracts costsAvailable-for-Sale Debt SecuritiesAOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]Gains (Losses) on available-for-sale securitiesConstruction in Progress [Member]Construction in ProgressStock Issued During Period, Value, Employee Stock Purchase PlanStock Issued During Period, Value, Employee Stock Purchase PlanAmounts reclassified for realized gains (losses) to earningsOther Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before TaxRestricted StockRestricted Stock [Member]Software development costsCapitalized Computer Software, NetCapitalized Computer Software, Net, Ending BalanceCapitalized Computer Software, Net, Beginning BalanceCapitalized Computer Software, Net, TotalPlan Name [Axis]Plan NamePromotions and customer deductionsAccrued promotions and customer deductions.Accrued Promotions And Customer DeductionsDerivative Instrument [Axis]AssetsTotal assetsOperating Lease, Right-of-Use AssetOperating lease right-of-use assetsRight-of-use assetAFS SecuritiesAFS Securities [Member]AFS securities.Unrecognized stock-based compensation expenseShare-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, AmountEntity Registrant NameEntity Registrant NameRelated Party, Type [Domain]Related PartyRetained Earnings (Accumulated Deficit)Retained earningsRetained Earnings (Accumulated Deficit), TotalRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), Ending BalanceDerivative premiumsAccrued Derivative PremiumsAccrued derivative premiums.Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated LossFair value, less than 12 monthsSupplemental Cash Flow Information [Abstract]Supplemental disclosure of cash flow information:Eggs and egg related products.Eggs And Egg Related Products [Member]Eggs and Egg Related ProductsRetained EarningsRetained Earnings [Member]Class of Stock [Axis]Class of StockUnvested as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberUnvested as of December 31, 2023Equity, Including Portion Attributable to Noncontrolling InterestEnding balanceBeginning balanceTotal stockholders' equityFair value liabilities transfers, Level 2 to Level 1Fair Value Liability Level2 To Level1 Transfers AmountFair value liability level2 to level1 transfers amountStock Issued During Period, Shares, Employee Stock Purchase PlansStock Issued During Period, Shares, Employee Stock Purchase PlansMinimum [Member]MinimumInvestments Classified by Contractual Maturity Date [Table Text Block]Summary of Contractual Maturities of Investment SecuritiesParent [Member]Total Stockholders' Equity Attributable to Vital Farms, Inc. StockholdersProceeds from Stock Options ExercisedProceeds from exercise of stock optionsSignificant Accounting Policies [Text Block]Summary of Significant Accounting PoliciesDerivative Instruments and Hedging Activities Disclosure [Abstract]Schedule of prepaid expenses and other current assetsDeferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]Operating Lease, LiabilityTotal present value of lease liabilitiesTotal operating lease liabilitiesLease liabilityPeter PappasPeter Pappas [Member]Peter Pappas.Debt instrument covenant minimum fixed charge coverage ratioDebt Instrument Covenant Minimum Fixed Charge Coverage RatioMinimum fixed charge coverage ratioFinance Lease, LiabilityTotal present value of lease liabilitiesTotal finance lease liabilitiesLand Improvements [Member]Land improvementsFair Value Measurement Inputs and Valuation Techniques [Table]Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]Equity Component [Domain]Equity ComponentOptions to Purchase Common StockAvailable-for-sale debt securities, before taxOther Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, before Tax, Portion Attributable to ParentLand [Member]LandPackaging.Packaging [Member]PackagingAdjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile net income to net cash provided by operating activities:Measurement Frequency [Axis]Measurement FrequencyDebt instrument covenant terms leverage ratioDebt Instrument Covenant Terms Leverage RatioLeverage ratioDebt Disclosure [Abstract]Employee stock purchase plan member.Employee Stock Purchase Plan [Member]Employee Stock Purchase PlanShare-Based Payment Arrangement, Decrease for Tax Withholding ObligationShares withheld for tax liability on vested restricted stock unitsShares withheld for tax liability on vested restricted stock unitsDebt instrument basis spread on variable rateDebt Instrument, Basis Spread on Variable RateBuilding and Building Improvements [Member]Buildings and ImprovementsEntity Current Reporting StatusEntity Current Reporting StatusCommon Stock, Shares AuthorizedCommon stock, shares authorizedAssets [Abstract]AssetsShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantNumber of shares available for future grantsCommon stock, \$0.0001 par value per share, 310,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 42,971,988 and 41,684,649 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectivelyCommon Stock, Value, IssuedCommon Stock, Value, Issued, TotalCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, Ending BalanceProceeds from Sale of Property, Plant, and EquipmentProceeds from the sale of property, plant and equipmentProceeds from Sale of Property, Plant, and Equipment, TotalProperty, plant and equipmentAccrued property, plant and equipment current.Accrued Property Plant And Equipment CurrentFurniture and Fixtures [Member]Furniture and FixturesAccrued Liabilities, CurrentAccrued liabilitiesAccrued liabilitiesAmounts owed to related partyCurrent Fiscal Year End DateCurrent Fiscal Year End DateShare-Based Payment Arrangement, Noncash ExpenseStock-based compensation expenseShare-based Payment Arrangement, Noncash Expense, TotalProceeds from issuance of common stock under employee stock purchase planProceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option ExercisedOperating Income (Loss)Income from operationsEntity Ex Transition PeriodEntity Ex Transition PeriodDeferred Income Tax Expense (Benefit)Deferred taxesDeferred Income Tax Expense (Benefit), TotalIncome Tax Expense (Benefit)Income Tax Expense (Benefit), TotalIncome tax provisionCommodity Contract [Member]Commodity Contract [Member]Accounts Payable and Accrued Liabilities Disclosure [Text Block]Accrued LiabilitiesConcentration Risk, PercentageConcentration risk percentageShare based compensation arrangement by share based payment award options cancelled in period total intrinsic value.Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Total Intrinsic ValueAggregate Intrinsic Value, CancelledShare-Based Payment Arrangement, ExpenseStock-based compensation expensePayment, Tax Withholding, Share-Based Payment ArrangementPayment of tax withholding obligation on vested RSU sharesDisaggregation of Revenue [Table]Disaggregation Of Revenue [Table]Taxes Payable, CurrentIncome taxes payableTaxes Payable, Current, TotalAccounting Standards Update 2016-02 [Member]ASU 2016-02Revenue from Contract with Customer [Text Block]Revenue RecognitionFinance Lease, Liability, Undiscounted Excess AmountLess imputed interestAggregate Intrinsic Value, Ending balanceAggregate Intrinsic Value, Beginning balanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueAggregate Intrinsic ValueDebt instrument face amountDebt Instrument, Face AmountSchedule Of Notional Amounts of Outstanding Derivative InstrumentsSchedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]Financing Receivable, Allowance for Credit Loss [Line Items]Other Nonoperating Income (Expense)Other Nonoperating Income (Expense), TotalOther expense, netPrepaid Expenses and Other Current AssetsPrepaid Expenses and Other Current Assets [Text Block]Prepaid expenses and other current assets.Operating Expenses [Abstract]Operating expenses:Property, Plant and Equipment [Abstract]Subsequent Events [Abstract]Debt Securities, Available-for-Sale [Table Text Block]Summary of Available-for-sale Investment SecuritiesSummary of significant accounting policies.Summary Of Significant Accounting Policies [Line Items]Summary of Significant Accounting Policies [Line Items]Derivative Instruments, Gain (Loss) [Table]Commitments and Contingencies Disclosure [Abstract]Other non-current assetsOther Assets, NoncurrentShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, GrossNumber of Options, GrantedOther Accrued Liabilities, CurrentOtherEquity [Table Block]Common StockInterest Paid, Excluding Capitalized Interest, Operating ActivitiesCash paid for interestEarnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]Earnings Per Share Basic [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award, DescriptionShare-based compensation award, descriptionPNC bank national association.P N C Bank National Association [Member]PNC Bank, National AssociationDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before TaxUnrealized GainsTenth AmendmentTenth Amendment [Member]Tenth amendment.Derivative [Line Items]Derivative [Line Items]Derivative [Line Items]Equity, Attributable to Parent [Abstract]Stockholders' equity:Lease, Cost [Table Text Block]Schedule of Components of Lease CostEntity [Domain]Inventory [Domain]InventoryLine of credit facility maximum borrowing capacityLine of Credit Facility, Maximum Borrowing CapacityShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair ValueFair value of shares vestedCost of Goods and Services SoldCost of goods soldCost of Goods and Services Sold, TotalRestated employment agreement description.Restated Employment Agreement DescriptionRestated Employment Agreement DescriptionEarnings Per Share [Abstract]Net income per share:Share based compensation arrangement by share based payment award percentage of number of shares earned.Share Based Compensation Arrangement by Share Based Payment Award Percentage of Number of Shares EarnedPercentage of number of shares earnedDividends, Common StockCommon stock dividend declared or paidDividends, Common Stock, TotalAccounting Policies [Abstract]Finance Lease, Liability, to be Paid, Year TwoFinance leases 2026Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Summary of significant accounting policies.Summary Of Significant Accounting Policies [Table]Summary Of Significant Accounting Policies [Table]Revolving Line of CreditRevolving Credit Facility [Member]Earnings Per Share, BasicBasic:Basic:Earnings Per Share, Basic, TotalCustomer Concentration Risk [Member]Customer Concentration RiskCommitments and contingencies (Note 20)Commitments and ContingenciesIncome Statement [Abstract]Property, Plant and Equipment Disclosure [Text Block]Property, Plant and EquipmentRelated Party, Type [Axis]Related PartyPerformance Shares [Member]PSUsUnvested PSUsOperating Lease, CostOperating lease costShort-Term Lease, CostShort-term lease costNumber of Options, Options vested and expected to vest as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, NumberStatistical Measurement [Domain]Statistical MeasurementNet Cash Provided by (Used in) Operating ActivitiesNet cash provided by operating activitiesDocument Period End DateDocument Period End DateStatistical Measurement [Axis]Statistical MeasurementAccounts Receivable, Allowance for Credit Loss, Ending BalanceAccounts Receivable, Allowance for Credit Loss, Beginning BalanceAccounts Receivable, Allowance for Credit LossAllowance for credit lossesAllowance for credit losses, Beginning balanceAllowance for credit losses, Ending balanceOther Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]Other comprehensive income, before tax:Commitments and Contingencies Disclosure [Text Block]Commitments and ContingenciesUnusual Risk or Uncertainty, Nature [Axis]Earnings Per Share, DilutedDiluted:Diluted:Earnings Per Share, Diluted, TotalProduct and Service [Domain]Product and ServiceCost of Sales [Member]Cost of Goods SoldConcentration Risk Benchmark [Domain]Concentration Risk BenchmarkRepayment of revolving line of creditRepayment of revolving line of creditRepayments of Long-Term Lines of CreditRevenue from Contract with Customer [Abstract]Debt Instrument, Name [Domain]Fair Value Hierarchy and NAV [Domain]Fair Value Hierarchy and NAVNumber of Options, Options exercisable as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, NumberRecurringFair Value, Recurring [Member]Additional Paid in Capital, Common StockAdditional paid-in capitalAdditional Paid in Capital, Common Stock, Beginning BalanceAdditional Paid in Capital, Common Stock, Ending BalanceU.S. corporate bonds and U.S. dollar denominated foreign bondsUS corporate bonds and US denominated foreign bonds.U S Corporate Bonds And U S Denominated Foreign Bonds [Member]U.S. TreasuryUS Treasury Securities [Member]Equipment loan.Equipment Loan [Member]Equipment LoanSchedule of Accumulated Other Comprehensive IncomeReclassification out of Accumulated Other Comprehensive Income [Table Text Block]Equity, Attributable to Noncontrolling InterestNoncontrolling interestsStockholders' Equity Attributable to Noncontrolling Interest, TotalStockholders' Equity Attributable to Noncontrolling Interest, Beginning BalanceStockholders' Equity Attributable to Noncontrolling Interest, Ending BalanceNet change in operating assets and

liabilitiesIncrease (Decrease) in Operating CapitalNet change in operating assets and liabilitiesWeighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]Weighted average effect of potentially dilutive securities:Proceeds from borrowing under revolving line of creditProceeds from Long-Term Lines of CreditShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodExercise of stock options, SharesNumber of Options, ExercisedDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year OneDue within one year Fair ValueLiabilities and Stockholders' EquityLiabilities and Equity [Abstract]Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]Schedule Of Earnings Per Share Basic By Common Class [Table]Entity Address, Postal Zip CodeEntity Address, Postal Zip CodeEntity Interactive Data CurrentEntity Interactive Data CurrentCredit Facility [Domain]Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]Schedule of Unrealized Loss Aging for Available-for-sale SecuritiesEquity [Abstract]Lessee, Operating Lease, Liability, Undiscounted Excess AmountLess imputed interestShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodGrantedDebt Securities, Available-for-Sale, Allowance for Credit LossDebt Securities, Available-for-Sale, Allowance for Credit Loss, Ending BalanceDebt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning BalanceDebt Securities, Available-for-Sale, Allowance for Credit Loss, TotalAllowance for Credit LossesShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceWeighted-Average Exercise Price, Options ExercisedEntity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeDerivative Instruments, Gain (Loss) [Line Items]Equity Components [Axis]Equity ComponentsInvestments, Debt and Equity Securities [Abstract]Inventory Disclosure [Abstract]Other receivables, netOther Receivables, Net, CurrentOther Receivables, Net, Current, TotalWeighted-Average Grant Date Fair Value, VestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair ValueLocal Phone NumberLocal Phone NumberProperty, Plant and Equipment [Line Items]Property Plant And Equipment [Line Items]Sale of Stock [Axis]Weighted-Average Exercise Price, Options exercisable as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise PriceInventory Valuation ReservesReserve for inventory obsolescencelInventory Valuation Reserves, Beginning BalanceInventory Valuation Reserves, Ending BalanceStock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, TotalStock Issued During Period, Shares, Restricted Stock Award, Net of ForfeituresVesting of restricted stock units, SharesGoodwillGoodwill, Ending BalanceGoodwill, Beginning BalanceGoodwill, TotalLine of credit facility covenant termsLine of Credit Facility, Covenant TermsFinancing Receivable, Allowance for Credit Loss [Table]Statement of Cash Flows [Abstract]Organization, Consolidation and Presentation of Financial Statements [Abstract]Net Loss Included in AOIBalance, end of periodBalance, beginning of periodAccumulated Other Comprehensive Income (Loss), Net of TaxAccumulated other comprehensive lossAccumulated Other Comprehensive Income (Loss), Net of Tax, TotalGross ProfitGross profitInventory [Line Items]Inventory [Line Items]Concentration Risk Benchmark [Axis]Concentration Risk BenchmarkTwenty twenty equity incentive plan.Twenty Twenty Equity Incentive Plan [Member]2020 Equity Incentive PlanDebt instrument eliminated.Debt Instrument Eliminated Month And YearDebt Instrument eliminatedCommon Stock, Par or Stated Value Per ShareCommon stock, par valueShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionExpected weighted-average period of recognitionLong-Lived Tangible Asset [Axis]Long-Lived Tangible AssetWeighted Average Remaining Contractual Life (Years), Options vested and expected to vest as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedMaximum number of shares issuableSchedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Maximum [Member]MaximumRedeemable noncontrolling interest.Redeemable Noncontrolling Interest [Member]Redeemable Noncontrolling InterestFair Value, Inputs, Level 3 [Member]Level 3Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNet increase in cash and cash equivalentsReturn of investment in variable interest entityProceeds from Equity Method Investment, Distribution, Return of CapitalPayables and Accruals [Abstract]Effect of potentially dilutive stock optionsIncremental Common Shares Attributable to Dilutive Effect of Share-Based Payment ArrangementsIncremental Common Shares Attributable to Share-based Payment Arrangements, TotalShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in PeriodNumber of Options, CancelledSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Schedule of Common Shares Excluded from Computation of Diluted Earnings Per ShareSchedule of Inventory, Current [Table Text Block]Schedule of Inventory Schedule of Component of Other Comprehensive IncomeComprehensive Income (Loss) [Table Text Block]Unrealized loss on derivative instrumentsGain (Loss) on Derivative Instruments, Net, PretaxGain (Loss) on Derivative Instruments, Net, Pretax, TotalCity Area CodeCity Area CodeInventory, NetInventoriesInventoriesNet Cash Provided by (Used in) Operating Activities [Abstract]Cash flows from operating activities:Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]Investment SecuritiesCommon Stock, Voting RightsCommon stock voting rightsCustomer [Domain]CustomerAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentLess: Accumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceSelling, General and Administrative Expenses [Member]Selling, General and AdministrativeWeighted Average Number of Shares Outstanding, BasicBasic:Weighted average common shares outstanding — basicWeighted Average Number of Shares Outstanding, Basic, TotalEmployee Stock [Member]Employee Stock Purchase Plan [Member]Net Cash Provided by (Used in) Financing Activities [Abstract]Cash flows from financing activities:Variable lease cost - long-term supply contractsLong Term Variable Lease CostLong term variable lease cost.Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]Summary of RSU ActivityEgg central station.Egg Central Station [Member]Egg Central StationStatement [Table]Statement [Table]Share-Based Payment Arrangement, Option, Activity [Table Text Block]Summary of Stock Option ActivityAccounts Receivable [Member]Accounts ReceivableSchedule of Related Party Transactions, by Related Party [Table]Schedule Of Related Party Transactions By Related Party [Table]Document Fiscal Period FocusDocument Fiscal Period FocusLessee, Operating Lease, Liability, to be PaidTotal lease paymentsNon designated [Member]Not Designated as Hedging Instrument [Member]Related Party Transactions Disclosure [Text Block]Related Party TransactionsNumber of securities issuances for unrealized losses.Number Of Securities Issuances For Unrealized LossesNumber of Securities Issuances for unrealized lossesPurchases of inventoryAccrued purchases of inventory, current.Accrued Purchases Of Inventory CurrentLessee, Operating Lease, Liability, to be Paid, Year TwoOperating leases 2026Professional feesAccrued Professional Fees, CurrentStatement [Line Items]Statement [Line Items]Payment of financing costsPayments of Financing CostsAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountAntidilutive securities excluded from computation of earnings per share, amountMachinery and Equipment [Member]Machinery and EquipmentLease, CostTotal lease costSubsequent Event [Line Items]Entity Incorporation, Date of IncorporationDate of incorporationAsset Class [Domain]Asset ClassAccounts receivable, net of allowance for credit losses of \$514 and \$550 as of June 30, 2024 and December 31, 2023, respectivelyAccounts Receivable, after Allowance for Credit Loss, CurrentAccounts Receivable, after Allowance for Credit Loss, Current, TotalCustomer [Axis]CustomerCommon Stock [Member]Common StockDebt Instrument [Line Items]Cash and Cash Equivalents, at Carrying ValueCash and cash equivalentsCash and Cash Equivalents, at Carrying Value, TotalCash and Cash Equivalents, at Carrying Value, Beginning BalanceCash and Cash Equivalents, at Carrying Value, Ending BalanceFinancing Receivable, Allowance for Credit Loss [Table Text Block]Schedule of Changes in Allowance for Credit LossesSummary of Recognized Stock - Based Compensation ExpenseShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Aggregate Intrinsic Value, Options exercisable as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic ValueDisclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]Schedule of Reserved Shares of Common Stock for IssuancePrepaid expensesPrepaid Expense, CurrentPrepaid Expense, Current, Total] P morgan chase bank N A.J P Morgan Chase Bank N A [Member]JP Morgan Chase Bank N AEntity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingAmounts owed to related partyAccounts PayableAccounts Payable, TotalProceeds from the sale of available-for-sale securitiesProceeds from Sale of Debt Securities, Available-for-SaleSales of available-for-sale debt securitiesTrade Accounts Receivable [Member]Trade Receivable [Member]Antidilutive Securities, Name [Domain]Derivative financial instrumentsDerivative Financial Instruments, Assets [Member]Other comprehensive loss, before taxOther Comprehensive Income (Loss), before Tax, Portion Attributable to ParentOther comprehensive income, before taxCover [Abstract]Selling, General and Administrative ExpenseSelling, general and administrativeSelling, General and Administrative Expense, TotalDocument Fiscal Year FocusDocument Fiscal Year FocusComprehensive Income (Loss) Note [Text Block]Accumulated Other Comprehensive IncomeIncome Taxes Paid, NetCash paid for income taxesIncome Taxes Paid, Net, TotalAllowance for Credit Losses [Text Block]Allowance for Credit LossesIncrease in debt instrument covenant terms leverage ratioIncrease in Debt Instrument Covenant Terms Leverage RatioIncrease in leverage ratioSale of Stock [Domain]Butter and butter related products.Butter And Butter Related Products [Member]Butter and Butter Related ProductsIncome taxes receivableIncome Taxes Receivable, CurrentWeighted-Average Grant Date Fair Value, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueSecurity Exchange NameSecurity Exchange NameStock options - date of grant and expireShare-Based Compensation Arrangement by Share-Based Payment Award, Expiration PeriodNew Accounting Pronouncements, Policy [Policy Text Block]Recently Adopted Accounting PronouncementsPreferred Stock, Shares IssuedPreferred stock, shares issuedPreferred Stock, Shares AuthorizedPreferred stock, shares authorizedExpense paid to related partyOperating Costs and ExpensesOperating Costs and Expenses, TotalProperty, Plant and Equipment, GrossProperty, plant and equipment, grossProperty, Plant and Equipment, Gross, TotalProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, Ending BalanceROU assets obtained in exchange for new operating lease obligationsRight-of-Use Asset Obtained in Exchange for Operating Lease LiabilityCustomer A.Customer A [Member]Customer A Hedging Designation [Domain]Eleventh Amendment MemberEleventh Amendment [Member]Eleventh AmendmentIncome tax benefit (expense) related to items of other comprehensive incomeOther Comprehensive Income (Loss), Tax, TotalIncome tax benefit related to items of other comprehensive lossOther Comprehensive Income (Loss), TaxOther Comprehensive Income (Loss), Tax, TotalLegal Entity [Axis]Financial Instrument [Axis]Financial InstrumentWeighted Average Number of Shares Outstanding, Diluted [Abstract]Weighted average common shares outstanding:Denominator:Finance Lease, Liability, to be Paid, Year OneFinance leases 2025Stock Issued During Period, Value, Stock Options ExercisedExercise of stock optionsEntity Emerging Growth CompanyEntity Emerging Growth CompanyShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic ValueAggregate Intrinsic Value, ExercisedAmendment FlagAmendment FlagSchedule of Accrued Liabilities [Table Text Block]Schedule of Accrued LiabilitiesMarketing and broker commissionsAccrued Marketing Costs, CurrentLessee, operating and finance leases.Lessee Operating And Finance Leases [Text Block]LeasesDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before TaxUnrealized LossesUnrealized LossesAccounting Standards Update [Domain]Accounting Standards UpdateAmortization of property, plant and equipmentFinance lease cost - amortization of right-of-use assetsFinance Lease, Right-of-Use Asset, AmortizationLeases [Abstract]Change in fair value of derivative instrumentsPre-tax amount of derivative lossesDerivative, Gain (Loss) on Derivative, NetDerivative, Gain (Loss) on Derivative, Net, TotalNet realized losses on derivative instrumentsVariable Rate [Domain]Unrealized losses, TotalDebt Securities, Available-for-Sale, Unrealized Loss PositionAggregate unrealized lossesDebt Securities, Available-for-sale, Unrealized Loss Position, TotalUnrealized losses, TotalCustomer D.Customer D [Member]Customer DSchedule of supplemental balance sheet information table text block.Schedule Of Supplemental Balance Sheet Information Table [Text Block]Summary of Supplemental Balance Sheet Information Related to LeasesTax (expense) benefitReclassification from AOCl, Current Period, TaxReclassification from AOCl, Current Period, Tax, TotalTax (expense) benefitAmounts reclassified for realized losses to earningsAmounts reclassified for realized losses to earningsSecurities Act File NumberEntity File NumberLessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal YearOperating leases 2024Goodwill and Intangible Assets Disclosure [Abstract]OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after TaxUnrealized net holding gain, After TaxShare-Based Payment Arrangement [Abstract]Schedule of supplemental cash flow information table text block.Schedule Of Supplemental Cash Flow Information Table [Text Block]Summary of Cash Flow Information related to LeasesAccounts Payable, CurrentAccounts payableAccounts Payable, Current, TotalDebt Instrument [Axis]Weighted-Average Grant Date Fair Value, Ending balanceWeighted-Average Grant Date Fair Value, Beginning balanceShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueDebt Instrument, Periodic Payment, TotalDebt Instrument, Periodic PaymentMonthly paymentSchedule of Goodwill and Other AssetsSchedule of Intangible Assets and Goodwill [Table Text Block]Operating ExpensesTotal operating expensesSchedules of Concentration of Risk, by Risk Factor [Table Text Block]Summary of Percentage of Net Revenue and Accounts Receivable, Net Due from Significant CustomersVariable Interest Entity, Primary Beneficiary [Member]Variable Interest Entity, Primary BeneficiaryEntity Address, Address Line TwoEntity Address, Address Line TwoPreferred stock, \$0.0001 par value per share, 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023Preferred Stock, Value, IssuedEntity Small BusinessEntity Small BusinessEntity Shell CompanyEntity Shell Company2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan ("2020 ESPP")Twenty twenty equity incentive plan and twenty twenty employee stock purchase plan.Twenty Twenty Equity Incentive Plan And Twenty Twenty Employee Stock Purchase Plan [Member]Sandpebble Builders Preconstruction, Incorporation.Sandpebble Builders Preconstruction Incorporation [Member]Sandpebble Builders Preconstruction, IncShare-Based Payment Arrangement, Shares Withheld for Tax Withholding ObligationShares of common stock withheld to cover taxesShares withheld for tax liability on vested restricted stock units, SharesShares withheld for tax liability on vested restricted stock units, SharesDerivative financial instrumentsDerivative Asset, CurrentEarnings Per Share [Text Block]Net Income Per ShareEntity Address, Address Line OneEntity Address, Address Line OneRevenue Benchmark [Member]Net RevenueShipping and distribution expense.Shipping And Distribution ExpenseShipping and distributionAntidilutive Securities [Axis]Notional amounts of derivative financial instrumentsDerivative, Nonmonetary Notional AmountSubsequent Event Type [Domain]Income Statement Location [Axis]Income Statement LocationOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and TaxUnrealized net holding gainUnrealized net holding gain, Before TaxVariable Lease, CostVariable lease costNet Income (Loss), Including Portion Attributable to Noncontrolling InterestNet (loss) incomeNet incomeNet incomeLine of Credit Facility, Lender [Domain]Fair Value, Inputs, Level 2 [Member]Level 2APIC, Share-Based Payment Arrangement, Option, Increase for Cost RecognitionStock-based compensation expenseROU assets obtained in exchange for new finance lease obligationsRight-of-Use Asset Obtained in Exchange for Finance Lease LiabilityDepreciation, Depletion and AmortizationDepreciation and amortizationDepreciation and amortization of property, plant and equipmentDepreciation, Depletion and Amortization, TotalProduct and Service [Axis]Product and ServiceTitle of 12(b) SecuritySecurity 12b TitleFair Value, Assets Measured on Recurring Basis [Table Text Block]Schedule of Financial Assets Measured at Fair ValueAccounting Standards Update [Axis]Accounting Standards UpdatePrepaid Expenses and Other Current Assets [Member]Prepaid Expenses and other Current Assets [Member]Net Cash Provided by (Used in) Investing Activities [Abstract]Cash flows from investing activities:Amortization of debt issuance costsAmortization of Debt Issuance CostsCustomer B.Customer B [Member]Customer BDerivative [Table]Outstanding DebtLong-Term Line of CreditLong-Term Line of Credit, TotalLong-Lived Tangible Asset [Domain]Long-Lived Tangible AssetSubsequent Event [Table]Other Comprehensive Income (Loss) before Reclassifications, Tax [Abstract]Receivable [Domain]Purchases and settlements of derivative instrumentsPayments for Derivative Instrument, Investing ActivitiesAlternate base rate.Alternate Base Rate [Member]Alternate Base RateOther Operating Activities, Cash Flow StatementOther Vehicles [Member]VehiclesDue after one year through five years Fair ValueDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through FiveNet of taxNet of taxAmounts reclassified for realized losses to earnings, After TaxNet of taxReclassification from Accumulated Other Comprehensive Income Current Period After TaxReclassification from accumulated other comprehensive income current period after tax.Net of taxInterest expenseInterest Expense, DebtInterest expenseInterest Expense, Debt, TotalFair value, TotalDebt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated LossFair value, TotalWeighted Average Remaining Contractual Life (Years), Options exercisable as of June 30, 2024Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual TermCommon Stock, Shares, OutstandingCommon stock, shares outstandingBeginning Balance, SharesEnding Balance, SharesTerm Loan and Equipment Loan.Term Loan And Equipment Loan [Member]Term Loan And Equipment LoanShare-Based Payment Arrangement [Text Block]Stock-Based CompensationWeighted-Average Grant Date Fair Value, ForfeitedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair ValueConcentration Risk Type [Domain]Concentration Risk TypeIncome Statement Location [Domain]Income Statement LocationShare-Based Compensation

Accumulated other comprehensive loss	(168)	(377)
Total stockholders' equity	238,421	192,677
Total liabilities and stockholders' equity	\$ 320,489	\$ 275,178

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD (\$) \$ in Thousands	Jun. 30, 2024 Dec. 31, 2023	
Statement of Financial Position [Abstract]		

Accounts Receivable, net of allowance for credit losses	\$ 514	\$ 550
Prepaid expenses and other current assets, net of allowance for credit losses	\$ 117	\$ 227
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	310,000,000	310,000,000
Common stock, shares issued	42,971,988	41,684,649
Common stock, shares outstanding	42,971,988	41,684,649

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD (\$) \$ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023

Income Statement [Abstract]				
Net revenue	\$ 147,388	\$ 106,445	\$ 295,316	\$ 225,616
Cost of goods sold	89,710	68,645	178,742	145,149
Gross profit	57,678	37,800	116,574	80,467
Operating expenses:				
Selling, general and administrative	33,336	23,908	60,467	47,853
Shipping and distribution	7,203	5,853	14,799	13,679
Total operating expenses	40,539	29,761	75,266	61,532
Income from operations	17,139	8,039	41,308	18,935
Other income (expense), net:				
Interest expense	(257)	(136)	(512)	(275)
Interest income	1,316	450	2,404	790
Other expense, net	(87)	(441)	(364)	(1,866)
Total other income (expense), net	972	(127)	1,528	(1,351)
Net income before income taxes	18,111	7,912	42,836	17,584
Income tax provision	1,772	1,229	7,474	3,751
Net income	\$ 16,339	\$ 6,683	\$ 35,362	\$ 13,833
Net income per share:				
Basic:	\$ 0.38	\$ 0.16	\$ 0.84	\$ 0.34
Diluted:	\$ 0.36	\$ 0.15	\$ 0.79	\$ 0.32
Weighted average common shares outstanding:				
Basic:	42,500,355	40,948,365	42,148,992	40,861,218
Diluted:	45,248,792	43,292,261	44,600,401	43,359,993

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD (\$) \$ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023

Statement of Comprehensive Income [Abstract]				
Net income	\$ 16,339	\$ 6,683	\$ 35,362	\$ 13,833
Other comprehensive income, before tax:				
Unrealized net holding gain	134	128	278	645
Amounts reclassified for realized gains (losses) to earnings	0	95	(1)	129
Available-for-sale debt securities, before tax	134	223	277	774
Other comprehensive income, before tax	134	223	277	774
Income tax benefit (expense) related to items of other comprehensive income	(33)	(61)	(68)	(191)
Other comprehensive income, net of tax	101	162	209	583
Comprehensive income	\$ 16,440	\$ 6,845	\$ 35,571	\$ 14,416

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited) - USD (\$) \$ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning Balance at Dec. 25, 2022	\$ 158,332	\$ 4	\$ 155,716	\$ 4,159	\$ (1,547)
Beginning Balance, Shares at Dec. 25, 2022		40,746,990			
Vesting of restricted stock units, Shares		127,595			
Shares withheld for tax liability on vested restricted stock units, Shares		(35,535)			
Stock-based compensation expense	1,627		1,627		
Other comprehensive income loss, net	421				421
Net income	7,150			7,150	
Ending Balance at Mar. 26, 2023	167,530	\$ 4	157,343	11,309	(1,126)
Ending Balance, Shares at Mar. 26, 2023		40,839,050			
Beginning Balance at Dec. 25, 2022	158,332	\$ 4	155,716	4,159	(1,547)
Beginning Balance, Shares at Dec. 25, 2022		40,746,990			
Other comprehensive income loss, net	583				
Ending Balance at Jun. 25, 2023	176,044	\$ 4	159,012	17,992	(964)
Ending Balance, Shares at Jun. 25, 2023		41,232,667			
Beginning Balance at Mar. 26, 2023	167,530	\$ 4	157,343	11,309	(1,126)
Beginning Balance, Shares at Mar. 26, 2023		40,839,050			
Exercise of stock options	110		110		
Exercise of stock options, Shares		307,500			
Vesting of restricted stock units, Shares		79,030			
Shares withheld for tax liability on vested restricted stock units	(636)		(636)		
Shares withheld for tax liability on vested restricted stock units, Shares		(3,924)			
Stock Issued During Period, Shares, Employee Stock Purchase Plans		11,011			

Stock Issued During Period, Value, Employee Stock Purchase Plan	135		135		
Stock-based compensation expense	2,060		2,060		
Other comprehensive income loss, net	162				162
Net income	6,683			6,683	
Ending Balance at Jun. 25, 2023	176,044	\$ 4	159,012	17,992	(964)
Ending Balance, Shares at Jun. 25, 2023		41,232,667			
Beginning Balance at Dec. 31, 2023	\$ 192,677	\$ 4	163,325	29,725	(377)
Beginning Balance, Shares at Dec. 31, 2023	41,684,649	41,684,649			
Exercise of stock options	\$ 824		824		
Exercise of stock options, Shares		180,086			
Vesting of restricted stock units, Shares		201,702			
Shares withheld for tax liability on vested restricted stock units	(1,310)		(1,310)		
Shares withheld for tax liability on vested restricted stock units, Shares		(62,781)			
Stock-based compensation expense	1,982		1,982		
Other comprehensive income loss, net	108				108
Net income	19,023			19,023	
Ending Balance at Mar. 31, 2024	213,304	\$ 4	164,821	48,748	(269)
Ending Balance, Shares at Mar. 31, 2024		42,003,656			
Beginning Balance at Dec. 31, 2023	\$ 192,677	\$ 4	163,325	29,725	(377)
Beginning Balance, Shares at Dec. 31, 2023	41,684,649	41,684,649			
Exercise of stock options, Shares	1,091,691				
Other comprehensive income loss, net	\$ 209				
Ending Balance at Jun. 30, 2024	\$ 238,421	\$ 4	173,498	65,087	(168)
Ending Balance, Shares at Jun. 30, 2024	42,971,988	42,971,988			
Beginning Balance at Mar. 31, 2024	\$ 213,304	\$ 4	164,821	48,748	(269)
Beginning Balance, Shares at Mar. 31, 2024		42,003,656			
Exercise of stock options	5,624		5,624		
Exercise of stock options, Shares		911,605			
Vesting of restricted stock units, Shares		41,316			
Shares withheld for tax liability on vested restricted stock units	(41)		(41)		
Shares withheld for tax liability on vested restricted stock units, Shares		(1,432)			
Stock Issued During Period, Shares, Employee Stock Purchase Plans		16,843			
Stock Issued During Period, Value, Employee Stock Purchase Plan	178		178		
Stock-based compensation expense	2,916		2,916		
Other comprehensive income loss, net	101				101
Net income	16,339			16,339	
Ending Balance at Jun. 30, 2024	\$ 238,421	\$ 4	\$ 173,498	\$ 65,087	\$ (168)
Ending Balance, Shares at Jun. 30, 2024	42,971,988	42,971,988			

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD (\$) \$ in Thousands	6 Months Ended		
	Jun. 30, 2024 Jun. 25, 2023		
Cash flows from operating activities:			
Net income	\$ 35,362	\$ 13,833	
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	4,647	3,543	
Reduction in the carrying amount of right-of-use assets	3,510	1,588	
Amortization of available-for-sale debt securities	76	230	
Amortization of debt issuance costs	19	0	
Stock-based compensation expense	4,898	3,687	
Deferred taxes	0	767	
Unrealized loss on derivative instruments	346	847	
Other	(132)	524	
Net change in operating assets and liabilities	(8,644)	(6,108)	
Net cash provided by operating activities	40,082	18,911	
Cash flows from investing activities:			
Purchases of property, plant and equipment	(6,914)	(4,292)	
Purchases and settlements of derivative instruments	(669)	(662)	
Sales of available-for-sale debt securities	0	1,907	
Maturities and call redemptions of available-for-sale debt securities	13,335	18,453	
Proceeds from the sale of property, plant and equipment	1	1,054	
Return of investment in variable interest entity	0	552	
Net cash provided by investing activities	5,753	17,012	
Cash flows from financing activities:			
Proceeds from exercise of stock options	6,448	110	
Proceeds from issuance of common stock under employee stock purchase plan	178	135	
Payment of tax withholding obligation on vested RSU shares	(1,351)	(636)	
Principal payments under finance lease obligations	(1,672)	(773)	
Payment of financing costs	(414)	0	
Net cash provided by (used in) financing activities	3,189	(1,164)	
Net increase in cash and cash equivalents	49,024	34,759	
Cash and cash equivalents at beginning of the period	84,149	12,914	
Cash and cash equivalents at end of the period	133,173	47,673	
Supplemental disclosure of cash flow information:			
Cash paid for interest	512	268	
Cash paid for income taxes	11,344	1,070	
Supplemental disclosure of non-cash investing and financing activities:			
Purchases of property, plant and equipment included in accounts payable and accrued liabilities	150	1,266	
Revolving Line of Credit			
Cash flows from financing activities:			
Proceeds from borrowing under revolving line of credit	0	7,500	
Repayment of revolving line of credit	\$ 0	\$ (7,500)	

XML 18 R8.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD (\$) \$ in Thousands	3 Months Ended			
	Jun. 30, 2024 Mar. 31, 2024 Jun. 25, 2023 Mar. 26, 2023			
Pay vs Performance Disclosure				
Net Income (Loss)	\$ 16,339	\$ 19,023	\$ 6,683	\$ 7,150

XML 19 R9.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended	
	Jun. 30, 2024	
	shares	
Trading		
Arrangements, by		
Individual		

Material Terms of Trading Arrangement

Director and Officer Trading Arrangements

During the 13-week period ended June 30, 2024, certain of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, as set forth in the table below:

		Type of Trading Arrangement			Total Shares of Common Stock to be Sold	Total Shares of Common Stock to be Purchased	Expiration Date
Name and Position	Action	Adoption/ Termination Date	Rule 10b5-1*	Non-Rule 10b5-1**			
Kathryn McKeon, Chief Marketing Officer	Adoption	May 28, 2024	X		47,164		
Peter Pappas, Chief Sales Officer	Adoption	June 14, 2024	X		99,526		June 15, 2025

* Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.

Kathryn McKeon

Trading Arrangements, by Individual

Name	Kathryn McKeon
Title	Chief Marketing Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 28, 2024
Arrangement Duration	276 days
Aggregate Available	47,164
Trade Arrangement Expiration Date	February 28, 2025

Peter Pappas

Trading Arrangements, by Individual

Name	Peter Pappas
Title	Chief Sales Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Arrangement Duration	366 days
Aggregate Available	99,526
Trade Arrangement Expiration Date	June 15, 2025

XML 20 R10.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of the Business and Basis of Presentation

Note 1. Nature of the Business and Basis of Presentation

Vital Farms, Inc. (the “Company”) was incorporated in Delaware on June 6, 2013 and is headquartered in Austin, Texas. The Company packages, markets and distributes shell eggs, butter and other products. These products are principally sold under the name Vital Farms in addition to other trade names, primarily to retail and foodservice channels in the United States.

The accompanying unaudited condensed consolidated financial statements as of June 30, 2024 and for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”).

In the opinion of management, the included disclosures are adequate, and the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2024, consolidated results of operations for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023, and consolidated cash flows for the 26-week periods ended June 30, 2024 and June 25, 2023. Such adjustments are of a normal and recurring nature and certain reclassifications of previously reported amounts have been made to conform to the current year presentation. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the audited annual financial statements. The condensed consolidated results of operations for the 13-week and 26-week periods ended June 30, 2024 are not necessarily indicative of the consolidated results of operations that may be expected for the fiscal year ending December 29, 2024.

Fiscal Year: The Company’s fiscal year ends on the last Sunday in December and contains either 52 or 53 weeks. In a 52-week fiscal year, each of the Company’s fiscal quarters consist of 13 weeks. The additional week in a 53-week fiscal year is added to the fourth quarter, making such quarter consist of 14 weeks. Therefore, the financial results of certain 53-week fiscal years, and the associated 14-week quarters, will not be exactly comparable to the prior and subsequent 52-week fiscal years and the associated 13-week quarters. The fiscal quarters ended June 30, 2024 and June 25, 2023 both contain operating results for 13 weeks. The fiscal year ended December 31, 2023 consisted of 53 weeks.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Company’s Annual Report. Other than the adoption of the new accounting pronouncements and standards as further described below, there have been no material changes to the Company’s significant accounting policies during the 26-week period ended June 30, 2024.

Recently Adopted Accounting Pronouncements

The new accounting pronouncements recently adopted by the Company are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 26-week period ended June 30, 2024.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures (“ASU 2023-07”) in order to improve stockholders’ understanding of an entity’s business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require incremental and more detailed disclosure regarding segment expenses on both an annual and interim basis. For public companies ASU 2023-07 is effective

for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company plans to adopt the standard for the year ended December 29, 2024 and will thus include any additional disclosures, if necessary, in its Annual Report on Form 10-K for the current fiscal year.

In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures (“ASU 2023-09”) in order to enhance the transparency and usefulness of income tax disclosures. The guidance is applicable to all entities subject to income tax and it will require disclosure of certain categories within the rate reconciliation to improve consistency as well as disclosure of reconciling items which meet a certain quantitative threshold which will improve transparency. Additionally, entities must disclose the amount of taxes paid to federal, state and foreign municipalities. For public business entities ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2023-09 on its consolidated financial statements.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Investment Securities

Investments, Debt and Equity Securities [Abstract]

Investment Securities

Note 3. Investment Securities

The following table summarizes the Company’s available-for-sale investment securities as of June 30, 2024:

Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Allowance for Credit Losses	Fair Value
U.S. corporate bonds and U.S. dollar				

denominated foreign bonds	\$ 19,722	\$ 9	\$ (198)	\$ —	\$ 19,533
Total	\$ 19,722	\$ 9	\$ (198)	\$ —	\$ 19,533

The following table summarizes the Company’s available-for-sale investment securities as of December 31, 2023:

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Allowance for Credit Losses	Fair Value
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 33,134	\$ 10	\$ (477)	\$ —	\$ 32,667
Total	\$ 33,134	\$ 10	\$ (477)	\$ —	\$ 32,667

Proceeds from the sale of available-for-sale securities were \$0 for the 13-week and 26-week periods ended June 30, 2024 and \$1,907 for the 13-week and 26-week periods ended June 25, 2023.

Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties. The amortized cost and fair value of the Company’s investments in available-for-sale securities as of June 30, 2024 by contractual maturity are as follows:

	Amortized Cost	Fair Value
Due within one year	\$ 17,361	\$ 17,171
Due after one year through five years	2,361	2,362
Total available-for-sale	\$ 19,722	\$ 19,533

The following tables present the Company’s unrealized loss aging for available-for-sale securities by type and length of time the security was in a continuous unrealized loss position as of the periods presented:

	Less than 12 months		June 30, 2024 12 months or longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 654	\$ (2)	\$ 17,870	\$ (196)	\$ 18,524	\$ (198)
Total	\$ 654	\$ (2)	\$ 17,870	\$ (196)	\$ 18,524	\$ (198)

	Less than 12 months		December 31, 2023 12 months or longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 699	\$ (3)	\$ 29,247	\$ (474)	\$ 29,946	\$ (477)
Total	\$ 699	\$ (3)	\$ 29,247	\$ (474)	\$ 29,946	\$ (477)

As of June 30, 2024, there were 31 diversified issuances in the Company's securities portfolio in an unrealized loss position, with credit ratings ranging from BBB- to AA-. As of June 30, 2024, there are no individual bonds with unrealized losses exceeding \$25, and 30 issuances have been in a loss position greater than 12 months.

The decline in fair value has resulted primarily from rising interest rates over the last 12 months, and the Company does not believe there has been any significant decline in the creditworthiness of the issuers. The Company also does not believe it is likely that a significant number of bonds will be called early, and it does not have current liquidity needs that would necessitate a sale of any material investments prior to maturity. Therefore, the Company has not recorded an allowance for credit losses on the investment securities as of June 30, 2024.

The fair value and location of all investment securities are included in “Fair Value Measurements” in Note 5 below.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments

Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Financial Instruments

Note 4. Derivative Financial Instruments

The Company enters into derivative instruments to mitigate the impact of commodity price volatility. Such instruments may include call options on commodity price contracts. Realized and unrealized gains and losses on the Company's commodity derivatives not designated as hedging instruments are recorded in other expense, net. The Company recognizes all derivative instruments as either assets or liabilities.

The following table presents the aggregated outstanding notional amounts related to the Company’s derivative financial instruments for the periods presented:

	Metric	June 30, 2024	December 31, 2023
Commodity:			
Corn	Bushels (in thousands)	860	2,351
Soybean Meal	Tons	9	25

For the 13-week periods ended June 30, 2024 and June 25, 2023, the pre-tax amount of commodity contract derivative losses recognized in other expense, net was \$87 and \$402, respectively. For the 26-week periods ended June 30, 2024 and June 25, 2023, the pre-tax amount of commodity contract derivative losses recognized in other expense, net in the unaudited condensed consolidated statements of operations was \$387 and \$1,817, respectively.

The fair value and location of all outstanding derivative financial instruments are included in “Fair Value Measurements” in Note 5 below.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

Fair Value Disclosures [Abstract] Fair Value Measurements

Note 5. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are defined below:

- Level 1 - Quoted prices in active markets for identical assets or liabilities.
- Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 - Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Assets Measured at Fair Value on a Recurring Basis

The fair value hierarchy requires the use of observable market data when available. In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis for the periods presented:

	Fair Value Measurements as of June 30, 2024, Using:			
	Level 1	Level 2	Level 3	Total
Assets:				
Cash and cash equivalents:				
Money market	\$ 101,703	\$ —	\$ —	\$ 101,703
Investment securities, available-for-sale:				
U.S. corporate bonds and U.S. dollar denominated foreign bonds	—	19,533	—	19,533
Prepaid expenses and other current assets:				
Derivative financial instruments	—	6	—	6
Total assets measured at fair value	\$ 101,703	\$ 19,539	\$ —	\$ 121,242

	Fair Value Measurements as of December 31, 2023, Using:			
	Level 1	Level 2	Level 3	Total
Assets:				
Cash and cash equivalents:				
Money market	\$ 64,498	\$ —	\$ —	\$ 64,498
Investment securities, available-for-sale:				
U.S. corporate bonds and U.S. dollar denominated foreign bonds	—	32,667	—	32,667
Derivative financial instruments	—	394	—	394
Total assets measured at fair value	\$ 64,498	\$ 33,061	\$ —	\$ 97,559

During the 26-week period ended June 30, 2024, there were no transfers between fair value measurement levels. For additional information on concentrations of credit risk for the Company’s financial instruments, refer to “Investment Securities” in Note 3.

Fair Value of Other Financial Instruments

The carrying values of the Company’s short-term financial instruments not included above, including cash, trade receivables, other receivables and accounts payable, approximate their fair value due to their short-term nature.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Revenue Recognition

[Revenue from Contract with Customer \[Abstract\]](#)
[Revenue Recognition](#)

**6 Months Ended
Jun. 30, 2024**

Note 6. Revenue Recognition

The following table summarizes the Company’s net revenue by primary product for the periods presented:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Net Revenue:				
Eggs and egg-related products	\$ 142,941	\$ 101,785	\$ 286,701	\$ 214,575
Butter and butter-related products	4,447	4,660	8,615	11,041
Net Revenue	\$ 147,388	\$ 106,445	\$ 295,316	\$ 225,616

Net revenue is primarily generated from the sale of eggs and butter. The Company’s product offerings include shell eggs, hard-boiled eggs, liquid whole eggs and stick butter. The Company’s previous convenient breakfast product line (including egg bites and egg-based breakfast bars) was discontinued in 2022, and the Company’s ghee and spreadable tub butter product offerings were discontinued during the fiscal year ended December 31, 2023. The revenues related to the discontinued product lines were immaterial for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023.

During the 13-week periods ended June 30, 2024 and June 25, 2023 and 26-week periods ended June 30, 2024 and June 25, 2023, the Company had a customer that individually exceeded 10% or more of the Company’s net revenue. The percentage of net revenue from significant customers during the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 is as follows:

	Net Revenue for the 13-Weeks Ended June 30, 2024	Net Revenue for the 13-Weeks Ended June 25, 2023	Net Revenue for the 26-Weeks Ended June 30, 2024	Net Revenue for the 26-Weeks Ended June 25, 2023
Customer A	23%	25%	24%	25%

As of June 30, 2024 and December 31, 2023, the Company had customers that individually exceeded 10% or more of the Company’s accounts receivable. The percentage of accounts receivable, net due from significant customers as of June 30, 2024 and December 31, 2023 is as follows:

	Accounts Receivable, Net as of June 30, 2024	Accounts Receivable, Net as of December 31, 2023
Customer A	20%	18%
Customer B	13%	12%
Customer C	*	11%
Customer D	11%	11%
* Accounts receivable, net was less than 10%		

XML 26 R16.htm IDEA: XBRL DOCUMENT

Allowance for Credit Losses

[Allowance for Credit Loss \[Abstract\]](#)
[Allowance for Credit Losses](#)

**6 Months Ended
Jun. 30, 2024**

Note 7. Allowance for Credit Losses

As of June 30, 2024 and December 31, 2023, the Company had an allowance for credit losses of \$631 and \$777, respectively.

The Company recognizes current estimated credit losses (“CECL”) for accounts receivable and other receivables. The CECL for trade receivables are estimated based on the trade receivable aging category, credit risk of specific customers, past collection history, and management’s evaluation of accounts receivable. The Company also has other receivables which are classified within prepaid expenses and other current assets. The CECL for other receivables are estimated based on the other receivables aging category and the probability of default. Provisions for CECL are classified within selling, general and administrative costs

Changes in the allowance for credit losses for the 26-week period ended June 30, 2024 were as follows:

	Accounts Receivable	Prepaid Expenses and other Current Assets	Total
As of December 31, 2023	\$ (550)	\$ (227)	\$ (777)
Reductions (provisions) charged to operating results	284	(48)	236
Account write-offs	—	140	140
As of March 31, 2024	\$ (266)	\$ (135)	\$ (401)
(Provisions) reductions charged to operating results	(248)	18	(230)
Account write-offs	—	—	—
As of June 30, 2024	\$ (514)	\$ (117)	\$ (631)

XML 27 R17.htm IDEA: XBRL DOCUMENT

Inventories

[Inventory Disclosure \[Abstract\]](#)
[Inventories](#)

**6 Months Ended
Jun. 30, 2024**

Note 8. Inventories

Inventory consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Eggs and egg-related products	\$ 19,488	\$ 25,521
Butter and butter-related products	6,978	1,697
Packaging	3,858	4,988
Pullets	315	289
Other	999	896
Reserve for inventory obsolescence	(190)	(496)
Inventories	\$ 31,448	\$ 32,895

On a periodic basis, the Company compares the amount of inventory on hand with its latest forecasted requirements to determine whether provisions for excess or obsolete inventory reserves are required.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets

Note 9. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Prepaid expenses	\$ 2,568	\$ 2,357
Other receivables, net	1,956	3,363
Derivative financial instruments	6	394
Prepaid expenses and other current assets, net	\$ 4,530	\$ 6,114

XML 29 R19.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Note 10. Property, Plant and Equipment

Property, plant and equipment consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Land	\$ 4,055	\$ 552
Land improvements	818	818
Buildings and improvements	30,580	30,532
Vehicles	1,100	1,055
Machinery and equipment	55,618	50,979
Leasehold improvements	491	492
Furniture and fixtures	508	461
Construction in progress	2,682	3,001
	95,852	87,890
Less: Accumulated depreciation and amortization	(27,525)	(21,051)
Property, plant and equipment, net	\$ 68,327	\$ 66,839

During the 13-week periods ended June 30, 2024 and June 25, 2023, depreciation of property, plant and equipment was approximately \$2,350 and \$1,850, respectively. During the 26-week periods ended June 30, 2024 and June 25, 2023, depreciation of property, plant and equipment was approximately \$4,647 and \$3,543, respectively. During the 13-week periods ended June 30, 2024 and June 25, 2023, amortization of property, plant and equipment was approximately \$938 and \$447, respectively. During the 26-week periods ended June 30, 2024 and June 25, 2023, amortization of property, plant and equipment was approximately \$1,852 and \$894, respectively. Refer to Note 11 “Leases” below for further information.

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases

Leases [Abstract]

Leases

Note 11. Leases

Operating lease cost is recognized on a straight-line basis over the lease term and finance lease cost is recognized as amortization expense for the right-of-use (“ROU”) assets and interest expense associated with the finance lease liabilities.

The components of lease cost, classified within cost of goods sold, selling, general and administrative and interest expense for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 are below:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Operating lease cost	\$ 1,062	\$ 361	\$ 1,984	\$ 722
Finance lease cost - amortization of right-of-use assets	938	447	\$ 1,852	894
Finance lease cost - interest on lease liabilities	238	125	\$ 485	257
Short-term lease cost	37	305	\$ 69	422
Variable lease cost	2,595	2,115	\$ 5,102	3,678
Variable lease cost - long-term supply contracts	54,429	47,064	\$ 110,432	90,150
Total lease cost	\$ 59,299	\$ 50,417	\$ 119,924	\$ 96,123

Future undiscounted cash flows are as follows:

	As of June 30, 2024	
	Operating Leases	Finance Leases
2024	\$ 2,879	\$ 2,203
2025	3,234	4,442
2026	3,018	4,474
2027	—	3,685
Total lease payments	9,131	14,804
Less imputed interest	(659)	(1,591)
Total present value of lease liabilities	\$ 8,472	\$ 13,213

During the 26-week periods ended June 30, 2024 and June 25, 2023, ROU assets obtained in exchange for new finance lease obligations were \$1,173 and \$4, respectively. During the 26-week periods ended June 30, 2024 and June 25, 2023, ROU assets obtained in exchange for new operating lease obligations were \$5,228 and \$0, respectively.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Goodwill and Other Assets

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Assets

Note 12. Goodwill and Other Assets

Goodwill and other assets consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Goodwill	\$ 3,858	\$ 3,858
Software development costs	1,544	—
Other non-current assets	72	46
Goodwill and other assets	\$ 5,474	\$ 3,904

As of June 30, 2024, the Company has capitalized costs of \$1,544 relating to development of internal-use software. This software has been developed by third-party and internal labor and has passed the preliminary project stage prior to capitalization. Amortization of the internal-use software development costs will begin once the software is placed in service.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

Payables and Accruals [Abstract]

Accrued Liabilities

Note 13. Accrued Liabilities

Accrued liabilities consisted of the following as of the periods presented:

6 Months Ended Jun. 30, 2024

6 Months Ended Jun. 30, 2024

6 Months Ended Jun. 30, 2024

6 Months Ended Jun. 30, 2024

6 Months Ended Jun. 30, 2024

	June 30, 2024	December 31, 2023
Employee-related costs	\$ 8,725	\$ 9,131
Promotions and customer deductions	6,896	6,982
Distribution fees and freight	2,187	2,876
Marketing and broker commissions	2,613	3,627
Purchases of inventory	1,654	525
Professional fees	1,650	1,066
Other	2,203	11
Accrued liabilities	\$ 25,928	\$ 24,218

XML 33 R23.htm IDEA: XBRL DOCUMENT

Long-Term Debt

Debt Disclosure
[Abstract]
Long-Term Debt

6 Months Ended
Jun. 30, 2024

Note 14. Long-Term Debt

PNC Credit Facility

In October 2017, the Company entered into a credit facility agreement with PNC Bank, National Association (the "PNC Credit Facility"), which was modified at various times between fiscal 2018 and fiscal 2023. Such amendments included (i) amendments to various definitions and covenants, (ii) waiver of a technical default in May 2020, (iii) increased borrowing capacity, (iv) elimination of a term loan and equipment loan, and (v) extension of the maturity date.

The maximum borrowing capacity under the revolving line of credit was \$20.0 million, prior to its termination in April 2024 when the Company entered into a syndicated credit agreement with JPMorgan Chase Bank, N.A. and the other lenders party thereto (the "JPMorgan Credit Facility"). Interest on borrowings under the PNC Credit Facility's revolving line of credit, as well as loan advances thereunder, accrued at a rate, at the Company's election at the time of borrowing, equal to (i) the secured overnight financing rate as administered by the Federal Reserve Bank of New York plus 2.00% or (ii) 1.00% plus the alternate base rate, as defined in the PNC Credit Facility.

The PNC Credit Facility was secured by all of the Company's assets (other than real property and certain other property excluded pursuant to the terms of the PNC Credit Facility) and required the Company to maintain three financial covenants: a fixed charge coverage ratio, a leverage ratio and a minimum tangible net worth requirement. The PNC Credit Facility also contained various covenants relating to limitations on indebtedness, acquisitions, mergers, consolidations and the sale of properties and liens. The PNC Credit Facility also contained other customary covenants, representations and events of default.

JPMorgan Credit Facility

On April 9, 2024, the Company entered into the JPMorgan Credit Facility, which provides for a five-year, \$60.0 million revolving credit facility.

The JPMorgan Credit Facility includes a \$5.0 million letter of credit sub-limit and an accordion option that would allow the Company to increase the aggregate revolving commitments or add incremental term loans in an aggregate amount not to exceed the greater of (i) \$35.0 million and (ii) an amount equal to 100% of consolidated adjusted EBITDA.

Any borrowings under the JPMorgan Credit Facility bear interest, at the Company's election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10% plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company's net leverage ratio or (ii) an alternative base rate plus a margin of either 1.75%, 2.00% or 2.25%, depending on the Company's net leverage ratio. The Company is required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on the Company's revolving exposure. Additionally, the Company is required to pay a participation fee on the account of each lender for each outstanding letter of credit at a rate equal to the applicable rate used to determine the interest rate applicable to term benchmark revolving loans.

The JPMorgan Credit Facility is secured by liens on substantially all of the Company's assets, including certain intellectual property assets and investment securities. It requires the Company to maintain (i) a net leverage ratio of no greater than 3.25 to 1.00, subject to two increases up to 4.00 to 1.00 for a certain period following material acquisitions, and (ii) a fixed charge coverage ratio of no less than 1.35 to 1.00. As a result of the limitations contained in the JPMorgan Credit Facility, certain of the net assets on the Company's consolidated balance sheet as of June 30, 2024 are restricted in use. The Company's wholly owned subsidiaries are non-operating and have no restricted net assets within the meaning of Rule 4-08(e)(3) or Rule 12-04 of Regulation S-X. As of June 30, 2024, the Company was in compliance with all covenants under the JPMorgan Credit Facility.

As of June 30, 2024, there were no outstanding amounts under the JPMorgan Credit Facility. During the 13-week periods ended June 30, 2024 and June 25, 2023, the Company recognized no interest expense related to draws on our revolving lines of credit. During the 26-week periods ended June 30, 2024 and June 25, 2023, the Company recognized interest expense related to draws on our revolving lines of credit of \$0 and \$7, respectively.

XML 34 R24.htm IDEA: XBRL DOCUMENT

Common Stock

Equity [Abstract]
Common Stock

6 Months Ended
Jun. 30, 2024

Note 15. Common Stock

As of June 30, 2024, the Company's amended and restated certificate of incorporation authorized the Company to issue 310,000,000 shares of common stock, par value \$0.0001 per share, of which 42,971,988 shares were issued and outstanding.

The voting, dividend and liquidation rights of the holders of the Company's common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock, if any. Each share of the Company's common stock is entitled to one vote on all matters submitted to a vote of the Company's stockholders. Holders of the Company's common stock are entitled to receive dividends as may be declared by the Company's Board of Directors, if any, subject to the preferential dividend rights of preferred stock, if any. No cash dividends were declared or paid during the periods presented.

As of each balance sheet date, the Company had reserved shares of common stock for issuance in connection with the following:

	June 30, 2024	December 31, 2023
Options to purchase common stock	2,773,253	5,123,860
Restricted stock units ("RSUs")	695,152	675,029
Performance stock units ("PSUs")	244,522	—
Shares available for grant under the 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan ("2020 ESPP")	14,913,861	12,796,409
Total	18,626,788	18,595,298

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stock-Based
Compensation
Share-Based Payment
Arrangement
[Abstract]
Stock-Based
Compensation

6 Months Ended
Jun. 30, 2024

Note 16. Stock-Based Compensation

The Company measures compensation expense for all stock-based awards based on the estimated fair values on the date of the grant. Stock options generally vest ratably over three years from the date of grant, subject to the recipient's continued service over such period, and expire 10 years from the date of grant. RSUs generally vest ratably over three years from the date of grant, subject to the recipient's continued service over such period, and contain no other service or performance conditions. PSUs vest at the end of a three-year period based on the achievement of certain Company performance metrics and the recipient's continued service over such period. The Company's policy is to recognize stock-based compensation expense on a straight-line basis over the requisite service or vesting period. For awards that are contingent upon performance metrics, the probability of achievement is taken into account in the calculation of the expense to be recognized and modified as needed. Forfeitures for stock options and restricted stock awards, including RSUs and PSUs, are recognized as they occur.

The Company recognized stock-based compensation expense in the condensed consolidated statements of operations for the periods presented:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Cost of goods sold	\$ 107	\$ 80	\$ 154	\$ 133
Selling, general and administrative expense	2,809	1,366	4,744	3,554
Total	\$ 2,916	\$ 1,446	\$ 4,898	\$ 3,687

Stock Option Activity

The following table summarizes the Company's stock option activity since December 31, 2023:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	3,920,485	\$ 10.07		\$ 28,749
Granted	—	\$ —		
Exercised	(1,091,691)	\$ 5.91		\$ 28,952
Cancelled/Forfeited	(55,541)	\$ 22.94		\$ 154
Outstanding as of June 30, 2024	2,773,253	\$ 11.45	5.8	\$ 97,955

Options exercisable as of June 30, 2024	2,008,751	\$	11.04	5.4	\$	71,781
Options vested and expected to vest as of June 30, 2024	2,773,034	\$	11.45	5.8	\$	97,955

The fair value of stock options vested during the 13-week periods ended June 30, 2024 and June 25, 2023 was \$240 and \$257, respectively. The fair value of stock options vested during the 26-week periods ended June 30, 2024 and June 25, 2023 was \$1,900 and \$1,272, respectively. As of June 30, 2024, total unrecognized stock-based compensation expense related to unvested stock options was \$1,796, which is expected to be recognized over a weighted-average period of 1.46 years.

Restricted Stock Unit Activity

The following table summarizes the Company’s RSU activity since December 31, 2023:

	Number of RSUs	Weighted-Average Grant Date Fair Value
Unvested as of December 31, 2023	565,376	\$ 14.24
Granted	407,494	\$ 20.99
Vested ¹	(243,018)	\$ 14.39
Forfeited	(34,700)	\$ 16.61
Unvested as of June 30, 2024	695,152	\$ 17.92

¹ Includes 64,213 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant to the 2020 Equity Incentive Plan.

The fair value of RSU shares vested during the 13-week periods ended June 30, 2024 and June 25, 2023 was \$677 and \$1,258, respectively. The fair value of RSU shares vested during the 26-week periods ended June 30, 2024 and June 25, 2023 was \$3,580 and \$2,913, respectively. As of June 30, 2024, total unrecognized stock-based compensation expense related to the RSUs was \$10,156, which is expected to be recognized over a weighted-average period of 2.28 years.

Performance Stock Unit Activity

In fiscal year 2024, the Company granted PSUs to certain of its officers and other employees. These PSUs vest at the end of a three-year period dependent upon the level of achievement of certain Company performance metrics and the recipient’s continued service over such period. The number of shares that can be earned will range from 0% to 200% of the granted PSUs, based upon the Company’s level of achievement of the stated performance metrics. The number of PSUs expected to vest and for which compensation cost has been recognized is based on the number of awards that the Company believes are probable to vest as of June 30, 2024.

The following table summarizes the Company’s PSU activity since December 31, 2023:

	Number of PSUs	Weighted-Average Grant Date Fair Value
Unvested as of December 31, 2023	—	
Granted	247,499	\$ 20.99
Forfeited	(2,977)	\$ 20.99
Unvested as of June 30, 2024	244,522	\$ 20.99

The fair value of PSU shares vested during the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 was \$- as no shares have vested as of such periods. As of June 30, 2024, total unrecognized stock-based compensation expense related to the PSUs was \$8,861, which is expected to be recognized over a weighted-average period of 2.49 years.

2020 Equity Incentive Plan: In July 2020, the Company’s Board of Directors adopted the 2020 Equity Incentive Plan (“2020 Incentive Plan”), which was subsequently approved by the Company’s stockholders and became effective on July 30, 2020. Initially, the maximum number of the Company’s common stock that may be issued under the 2020 Incentive Plan was 8,595,871 shares. The 2020 Incentive Plan provides that the number of shares reserved and available for issuance under the 2020 Incentive Plan will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 4% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s Board of Directors. As of June 30, 2024, 12,367,778 shares were available for future grants of the Company’s common stock, which includes 1,667,385 shares of stock that were automatically added to the available reserve on January 1, 2024. Awards issued under the 2020 Incentive Plan generally have a three-year ratable vesting period beginning on the date of grant.

Employee Stock Purchase Plan: In July 2020, the Company’s Board of Directors adopted the 2020 ESPP, which was subsequently approved by the Company’s stockholders and became effective on July 30, 2020. The 2020 ESPP authorizes the initial issuance of up to 900,000 shares of the Company’s common stock to eligible employees of the Company or, as designated by the Company’s Board of Directors, employees of a related company. The 2020 ESPP provides that the number of shares reserved and available for issuance under the 2020 ESPP will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to the lesser of (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31 and (ii) 900,000, or such lesser number of shares as determined by the Company’s Board of Directors. As of June 30, 2024, 2,546,083 shares of the Company’s common stock were available for future issuance under the 2020 ESPP, which includes 416,846 shares of common stock that were automatically added to the available reserve on January 1, 2024. The Company’s Board of Directors authorizes six-month offering periods, with the most recent beginning on November 16, 2023.

XML 36 R26.htm IDEA: XBRL DOCUMENT

Income Taxes

[Income Tax Disclosure \[Abstract\]](#)
[Income Taxes](#)

Note 17. Income Taxes

The Company’s effective tax rate for the 13-week periods ended June 30, 2024 and June 25, 2023 was approximately 10% and 16%, respectively. The Company’s effective tax rate for the 26-week periods ended June 30, 2024 and June 25, 2023 was approximately 17% and 21%, respectively. The Company’s effective tax rate for the 13-week and 26-week periods ended June 30, 2024 differs from the statutory rate due primarily to discrete tax benefits related to the exercise of non-qualified stock options and the vesting of restricted stock units.

For interim periods, the Company’s income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions, and other items. The Company’s estimated annual effective tax rate differs from the federal statutory rate of 21% due to state taxes, permanent differences related to incentive stock options and the impact of compensation deduction limitations under Internal Revenue Code Section 162(m).

XML 37 R27.htm IDEA: XBRL DOCUMENT

Net Income Per Share

[Earnings Per Share \[Abstract\]](#)
[Net Income Per Share](#)

Note 18. Net Income Per Share

Basic and diluted net income per share attributable to Vital Farms, Inc. common stockholders were calculated as follows:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Numerator:				
Net income	\$ 16,339	\$ 6,683	\$ 35,362	\$ 13,833
Denominator:				
Weighted average common shares outstanding — basic	42,500,355	40,948,365	42,148,992	40,861,218
Weighted average effect of potentially dilutive securities:				
Effect of potentially dilutive stock options	2,139,855	2,227,020	2,044,539	2,324,262
Effect of potentially dilutive RSUs	389,866	106,478	317,531	160,193
Effect of potentially dilutive PSUs	207,040	—	71,398	—
Effect of potentially dilutive common stock issuable pursuant to the ESPP	11,676	10,398	17,941	14,320
Weighted average common shares outstanding — diluted	45,248,792	43,292,261	44,600,401	43,359,993
Net income per share attributable to Vital Farms, Inc. stockholders				
Basic	\$ 0.38	\$ 0.16	\$ 0.84	\$ 0.34
Diluted	\$ 0.36	\$ 0.15	\$ 0.79	\$ 0.32

The Company excluded the following shares of common stock, outstanding at each period end, from the computation of diluted net income per share attributable to Vital Farms, Inc. common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Options to purchase common stock	1,933	36,865	1,401	21,629
Unvested RSUs	602	12,286	1,411	40,078
Unvested PSUs	525	-	174	-
	3,060	49,151	2,986	61,707

XML 38 R28.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income

6 Months Ended
Jun. 30, 2024

Note 19. Accumulated Other Comprehensive Income

The amounts reclassified from accumulated other comprehensive income (“AOCI”) to the unaudited consolidated statements of operations were as follows (in thousands):

		Amounts Reclassified from AOCI	
		13-Week Period Ended	
		June 30, 2024	June 25, 2023
AOCI Component	Statement of Income Classification		
Losses on available-for-sale securities	Other expense, net	\$ —	\$ 95
	Total before tax	\$ —	\$ 95
	Tax benefit	\$ —	\$ (26)
	Net of tax	\$ —	\$ 69

		Amounts Reclassified from AOCI	
		26-Week Period Ended	
		June 30, 2024	June 25, 2023
AOCI Component	Statement of Income Classification		
Losses on available-for-sale securities	Other expense, net	\$ (1)	\$ 129
	Total before tax	(1)	129
	Tax benefit	—	(32)
	Net of tax	\$ (1)	\$ 97

The gross amount and related tax (expense) benefit recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):

		13-Weeks Ended					
		June 30, 2024			June 25, 2023		
		Before Tax	Tax	After Tax	Before Tax	Tax	After Tax
Available-for-sale debt securities:							
	Unrealized net holding gain	134	\$ (33)	\$ 101	\$ 128	\$ (35)	\$ 93
	Amounts reclassified for realized losses to earnings	—	—	—	95	(26)	69
	Total other comprehensive income	\$ 134	\$ (33)	\$ 101	\$ 223	\$ (61)	\$ 162

		26-Weeks Ended					
		June 30, 2024			June 25, 2023		
		Before Tax	Tax	After Tax	Before Tax	Tax	After Tax
Available-for-sale debt securities:							
	Unrealized net holding gain	\$ 278	\$ (68)	\$ 210	\$ 645	\$ (159)	\$ 486
	Amounts reclassified for realized losses to earnings	(1)	-	(1)	129	(32)	97
	Total other comprehensive income	\$ 277	\$ (68)	\$ 209	\$ 774	\$ (191)	\$ 583

XML 39 R29.htm IDEA: XBRL DOCUMENT

**6 Months Ended
Jun. 30, 2024**

Note 20. Commitments and Contingencies

Supplier Contracts: The Company purchases its egg inventories under long-term supply contracts with farms. Purchase commitments contained in these arrangements are variable and dependent on the quantity of eggs produced by the farms. Accordingly, there are no estimable future purchase commitments associated with these supplier contracts and there are no minimum payments associated with these long-term supply contracts. The Company records the total cost of eggs into inventory and they are expensed to cost of goods sold when the associated eggs are sold to customers and are also reported as part of the Company’s variable lease cost.

The Company has entered into agreements with certain qualifying suppliers to provide a one-time payment of up to \$200,000, for the purpose of funding costs associated with farm start up. As of June 30, 2024, the Company has executed 31 such agreements, 2 of which were in fiscal year 2023. The payment of these incremental costs is contingent upon the achievement of certain milestones and is to be made no later than 90 days prior to the pullet placement date specified in each supplier agreement. Upon the achievement of such milestones, the Company recognizes an operating ROU asset and lease liability as a cost of obtaining the embedded lease within the supplier contract, which is included in “Leases” in Note 11. As of June 30, 2024, \$4.3 million has been paid out and \$1.3 million remains to be paid.

Indemnification Agreements: In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and its executive officers that will

require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2024, the Company has not incurred any material costs as a result of such indemnification agreements.

Litigation: The Company is subject to various claims and contingencies that are in the scope of ordinary and routine litigation incidental to its business, including those related to regulation, litigation, business transactions, employee-related matters and taxes, among others. When the Company becomes aware of a claim or potential claim, the likelihood of any loss or exposure is assessed. Based on these assessments and estimates, the Company may establish reserves, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may differ materially from the Company’s assessments and estimates.

On May 20, 2021, the Company and certain of its current and former officers were named as defendants in a class action complaint captioned *Nicholas A. Usler et al. v. Vital Farms, Inc. et al.* in the United States District Court for the Western District of Texas (the “District Court”). The plaintiffs alleged false advertising claims on behalf of themselves and a putative class of alleged consumers of the Company’s eggs. The named officers of the Company were subsequently dismissed as defendants in this matter. On July 9, 2024, a U.S. Magistrate Judge issued both an order and report and recommendation, for review and adoption by the District Court. Collectively, the order and the report and recommendation (i) denied the plaintiffs’ motion for class certification, (ii) excluded the testimony and report of the plaintiffs’ damages expert and (iii) granted summary judgment for the Company with respect to two plaintiffs and three of the plaintiffs’ state claims. The plaintiffs have filed objections to the order and report and recommendation, and the matter is ongoing. The Company believes the claims are without merit and is vigorously defending itself in this matter. Given the uncertainty of the litigation, the stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company is unable to reasonably estimate the possible loss or range of loss, if any, that may result from the claim.

Although the Company maintains insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions and caps on amounts recoverable. Even if the Company believes a claim is covered by insurance, insurers may dispute the Company’s entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of the Company’s recovery. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company records a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the claim if the likelihood of a potential loss is reasonably possible.

XML 40 R30.htm IDEA: XBRL DOCUMENT

**6 Months Ended
Jun. 30, 2024**

Note 21. Related Party Transactions

Sandpebble Builders Preconstruction, Inc.: The Company utilizes Sandpebble Builders Preconstruction, Inc. and Sandpebble South, Inc. (collectively “Sandpebble”) for project management and related services associated with the construction and expansion of the Company’s egg processing facilities, including site selection, project management and related services for the Company’s planned egg packing facility in Seymour, Indiana. The Company’s contract with Sandpebble for services related to the Company’s planned egg packing facility in Seymour, Indiana was awarded after a competitive bidding process. Victor Canseco, the owner and principal of Sandpebble, is the father of Russell Diez-Canseco, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors. In connection with the services described above, the Company paid Sandpebble \$292 and \$139 during the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and \$540 and \$255 during the 26-week periods ended June 30, 2024 and June 25, 2023, respectively. Amounts paid to Sandpebble are included in property, plant and equipment, net and selling, general and administrative costs. As of June 30, 2024 and June 25, 2023, amounts owed to Sandpebble were \$168 and \$1,126, respectively, and are included in accrued liabilities.

XML 41 R31.htm IDEA: XBRL DOCUMENT

**6 Months Ended
Jun. 30, 2024**

Recently Adopted Accounting Pronouncements

The new accounting pronouncements recently adopted by the Company are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 26-week period ended June 30, 2024.

[Recently Issued Accounting Pronouncements Not Yet Adopted](#)

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures (“ASU 2023-07”) in order to improve stockholders’ understanding of an entity’s business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require incremental and more detailed disclosure regarding segment expenses on both an annual and interim basis. For public companies ASU 2023-07 is effective

for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company plans to adopt the standard for the year ended December 29, 2024 and will thus include any additional disclosures, if necessary, in its Annual Report on Form 10-K for the current fiscal year.

In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures (“ASU 2023-09”) in order to enhance the transparency and usefulness of income tax disclosures. The guidance is applicable to all entities subject to income tax and it will require disclosure of certain categories within the rate reconciliation to improve consistency as well as disclosure of reconciling items which meet a certain quantitative threshold which will improve transparency. Additionally, entities must disclose the amount of taxes paid to federal, state and foreign municipalities. For public business entities ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2023-09 on its consolidated financial statements.

XML 42 R32.htm IDEA: XBRL DOCUMENT

Investment Securities
(Tables)

[Investments, Debt and Equity Securities \[Abstract\]](#)

[Summary of Available-for-sale Investment Securities](#)

6 Months Ended
Jun. 30, 2024

The following table summarizes the Company’s available-for-sale investment securities as of June 30, 2024:

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Allowance for Credit Losses	Fair Value
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 19,722	\$ 9	\$ (198)	\$ —	\$ 19,533
Total	\$ 19,722	\$ 9	\$ (198)	\$ —	\$ 19,533

The following table summarizes the Company’s available-for-sale investment securities as of December 31, 2023:

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Allowance for Credit Losses	Fair Value
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 33,134	\$ 10	\$ (477)	\$ —	\$ 32,667
Total	\$ 33,134	\$ 10	\$ (477)	\$ —	\$ 32,667

[Summary of Contractual Maturities of Investment Securities](#)

The amortized cost and fair value of the Company’s investments in available-for-sale securities as of June 30, 2024 by contractual maturity are as follows:

	Amortized Cost	Fair Value
Due within one year	\$ 17,361	\$ 17,171
Due after one year through five years	2,361	2,362
Total available-for-sale	\$ 19,722	\$ 19,533

[Schedule of Unrealized Loss Aging for Available-for-sale Securities](#)

The following tables present the Company’s unrealized loss aging for available-for-sale securities by type and length of time the security was in a continuous unrealized loss position as of the periods presented:

	June 30, 2024					
	Less than 12 months		12 months or longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 654	\$ (2)	\$ 17,870	\$ (196)	\$ 18,524	\$ (198)
Total	\$ 654	\$ (2)	\$ 17,870	\$ (196)	\$ 18,524	\$ (198)

	December 31, 2023					
	Less than 12 months		12 months or longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
U.S. corporate bonds and U.S. dollar denominated foreign bonds	\$ 699	\$ (3)	\$ 29,247	\$ (474)	\$ 29,946	\$ (477)
Total	\$ 699	\$ (3)	\$ 29,247	\$ (474)	\$ 29,946	\$ (477)

XML 43 R33.htm IDEA: XBRL DOCUMENT

Derivative Financial
Instruments (Tables)

[Derivative Instruments and Hedging Activities Disclosure \[Abstract\]](#)

[Schedule Of Notional Amounts of Outstanding Derivative Instruments](#)

6 Months Ended
Jun. 30, 2024

The following table presents the aggregated outstanding notional amounts related to the Company’s derivative financial instruments for the periods presented:

Metric		June 30, 2024	December 31, 2023
Commodity:			
Corn	Bushels (in thousands)	860	2,351
Soybean Meal	Tons	9	25

XML 44 R34.htm IDEA: XBRL DOCUMENT

Fair Value
Measurements
(Tables)

[Fair Value Disclosures \[Abstract\]](#)

[Schedule of Financial Assets Measured at Fair Value](#)

6 Months Ended
Jun. 30, 2024

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis for the periods presented:

Assets:	Fair Value Measurements as of June 30, 2024, Using:			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents:				
Money market	\$ 101,703	\$ —	\$ —	\$ 101,703
Investment securities, available-for-sale:				
U.S. corporate bonds and U.S. dollar denominated foreign bonds	—	19,533	—	19,533
Prepaid expenses and other current assets:				
Derivative financial instruments	—	6	—	6
Total assets measured at fair value	\$ 101,703	\$ 19,539	\$ —	\$ 121,242

Assets:	Fair Value Measurements as of December 31, 2023, Using:			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents:				
Money market	\$ 64,498	\$ —	\$ —	\$ 64,498
Investment securities, available-for-sale:				
U.S. corporate bonds and U.S. dollar denominated foreign bonds	—	32,667	—	32,667
Derivative financial instruments	—	394	—	394
Total assets measured at fair value	\$ 64,498	\$ 33,061	\$ —	\$ 97,559

Revenue Recognition
(Tables)

[Revenue from Contract with Customer \[Abstract\]](#)
[Summary of Net Revenue by Primary Product](#)

6 Months Ended
Jun. 30, 2024

The following table summarizes the Company's net revenue by primary product for the periods presented:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Net Revenue:				
Eggs and egg-related products	\$ 142,941	\$ 101,785	\$ 286,701	\$ 214,575
Butter and butter-related products	4,447	4,660	8,615	11,041
Net Revenue	<u>\$ 147,388</u>	<u>\$ 106,445</u>	<u>\$ 295,316</u>	<u>\$ 225,616</u>

[Summary of Percentage of Net Revenue and Accounts Receivable, Net Due from Significant Customers](#)

The percentage of net revenue from significant customers during the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023 is as follows:

	Net Revenue for the 13-Weeks Ended June 30, 2024	Net Revenue for the 13-Weeks Ended June 25, 2023	Net Revenue for the 26-Weeks Ended June 30, 2024	Net Revenue for the 26-Weeks Ended June 25, 2023
Customer A	23%	25%	24%	25%

As of June 30, 2024 and December 31, 2023, the Company had customers that individually exceeded 10% or more of the Company's accounts receivable. The percentage of accounts receivable, net due from significant customers as of June 30, 2024 and December 31, 2023 is as follows:

	Accounts Receivable, Net as of June 30, 2024	Accounts Receivable, Net as of December 31, 2023
Customer A	20%	18%
Customer B	13%	12%
Customer C	*	11%
Customer D	11%	11%
* Accounts receivable, net was less than 10%		

Allowance for Credit Losses (Tables)

[Allowance for Credit Loss \[Abstract\]](#)
[Schedule of Changes in Allowance for Credit Losses](#)

6 Months Ended
Jun. 30, 2024

Changes in the allowance for credit losses for the 26-week period ended June 30, 2024 were as follows:

	Accounts Receivable	Prepaid Expenses and other Current Assets	Total
As of December 31, 2023	\$ (550)	\$ (227)	\$ (777)
Reductions (provisions) charged to operating results	284	(48)	236
Account write-offs	—	140	140
As of March 31, 2024	\$ (266)	\$ (135)	\$ (401)
(Provisions) reductions charged to operating results	(248)	18	(230)
Account write-offs	—	—	—
As of June 30, 2024	<u>\$ (514)</u>	<u>\$ (117)</u>	<u>\$ (631)</u>

Inventories (Tables)

[Inventory Disclosure \[Abstract\]](#)
[Schedule of Inventory](#)

6 Months Ended
Jun. 30, 2024

Inventory consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Eggs and egg-related products	\$ 19,488	\$ 25,521
Butter and butter-related products	6,978	1,697
Packaging	3,858	4,988
Pullets	315	289
Other	999	896
Reserve for inventory obsolescence	(190)	(496)
Inventories	<u>\$ 31,448</u>	<u>\$ 32,895</u>

Prepaid Expenses and Other Current Assets (Tables)

[Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure \[Abstract\]](#)
[Schedule of prepaid expenses and other current assets](#)

6 Months Ended
Jun. 30, 2024

Prepaid expenses and other current assets consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Prepaid expenses	\$ 2,568	\$ 2,357
Other receivables, net	1,956	3,363
Derivative financial instruments	6	394
Prepaid expenses and other current assets, net	<u>\$ 4,530</u>	<u>\$ 6,114</u>

Property, Plant and Equipment (Tables)

[Property, Plant and Equipment \[Abstract\]](#)
[Schedule of Property, Plant and Equipment](#)

6 Months Ended
Jun. 30, 2024

Property, plant and equipment consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Land	\$ 4,055	\$ 552
Land improvements	818	818
Buildings and improvements	30,580	30,532
Vehicles	1,100	1,055
Machinery and equipment	55,618	50,979
Leasehold improvements	491	492
Furniture and fixtures	508	461
Construction in progress	2,682	3,001
	<u>95,852</u>	<u>87,890</u>
Less: Accumulated depreciation and amortization	(27,525)	(21,051)
Property, plant and equipment, net	<u>\$ 68,327</u>	<u>\$ 66,839</u>

Leases (Tables)

[Leases \[Abstract\]](#)
[Schedule of Components of Lease](#)

6 Months Ended
Jun. 30, 2024

The components of lease cost, classified within cost of goods sold, selling, general and administrative and interest expense for the 13-week and 26-week periods ended June 30, 2024 and June 25,

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Operating lease cost	\$ 1,062	\$ 361	\$ 1,984	\$ 722
Finance lease cost - amortization of right-of-use assets	938	447	\$ 1,852	894
Finance lease cost - interest on lease liabilities	238	125	\$ 485	257
Short-term lease cost	37	305	\$ 69	422
Variable lease cost	2,595	2,115	\$ 5,102	3,678
Variable lease cost - long-term supply contracts	54,429	47,064	\$ 110,432	90,150
Total lease cost	\$ 59,299	\$ 50,417	\$ 119,924	\$ 96,123

Summary of Operating
and Finance Leases
Future Undiscounted
Cash Flows

Future undiscounted cash flows are as follows:

	As of June 30, 2024	
	Operating Leases	Finance Leases
2024	\$ 2,879	\$ 2,203
2025	3,234	4,442
2026	3,018	4,474
2027	—	3,685
Total lease payments	9,131	14,804
Less imputed interest	(659)	(1,591)
Total present value of lease liabilities	\$ 8,472	\$ 13,213

XML 51 R41.htm IDEA: XBRL DOCUMENT

Goodwill and Other
Assets (Tables)

6 Months Ended
Jun. 30, 2024

Goodwill and
Intangible Assets
Disclosure [Abstract]
Schedule of Goodwill
and Other Assets

Goodwill and other assets consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Goodwill	\$ 3,858	\$ 3,858
Software development costs	1,544	—
Other non-current assets	72	46
Goodwill and other assets	\$ 5,474	\$ 3,904

As of June 30, 2024, the Company has capitalized costs of \$1,544 relating to development of internal-use software. This software has been developed by third-party and internal labor and has passed the preliminary project stage prior to capitalization. Amortization of the internal-use software development costs will begin once the software is placed in service.

XML 52 R42.htm IDEA: XBRL DOCUMENT

Accrued Liabilities
(Tables)

6 Months Ended
Jun. 30, 2024

Payables and
Accruals [Abstract]
Schedule of Accrued
Liabilities

Accrued liabilities consisted of the following as of the periods presented:

	June 30, 2024	December 31, 2023
Employee-related costs	\$ 8,725	\$ 9,131
Promotions and customer deductions	6,896	6,982
Distribution fees and freight	2,187	2,876
Marketing and broker commissions	2,613	3,627
Purchases of inventory	1,654	525
Professional fees	1,650	1,066
Other	2,203	11
Accrued liabilities	\$ 25,928	\$ 24,218

XML 53 R43.htm IDEA: XBRL DOCUMENT

Common Stock
(Tables)

6 Months Ended
Jun. 30, 2024

Equity [Abstract]
Schedule of Reserved
Shares of Common
Stock for Issuance

As of each balance sheet date, the Company had reserved shares of common stock for issuance in connection with the following:

	June 30, 2024	December 31, 2023
Options to purchase common stock	2,773,253	5,123,860
Restricted stock units ("RSUs")	695,152	675,029
Performance stock units ("PSUs")	244,522	—
Shares available for grant under the 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan ("2020 ESPP")	14,913,861	12,796,409
Total	18,626,788	18,595,298

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based
Compensation
(Tables)

6 Months Ended
Jun. 30, 2024

Share-Based Payment
Arrangement
[Abstract]
Summary of Recognized
Stock - Based
Compensation Expense

The Company recognized stock-based compensation expense in the condensed consolidated statements of operations for the periods presented:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Cost of goods sold	\$ 107	\$ 80	\$ 154	\$ 133
Selling, general and administrative expense	2,809	1,366	4,744	3,554
Total	\$ 2,916	\$ 1,446	\$ 4,898	\$ 3,687

Summary of Stock
Option Activity

The following table summarizes the Company's stock option activity since December 31, 2023:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	3,920,485	\$ 10.07		\$ 28,749
Granted	—	\$ —		
Exercised	(1,091,691)	\$ 5.91		\$ 28,952
Cancelled/Forfeited	(55,541)	\$ 22.94		\$ 154
Outstanding as of June 30, 2024	2,773,253	\$ 11.45	5.8	\$ 97,955
Options exercisable as of June 30, 2024	2,008,751	\$ 11.04	5.4	\$ 71,781
Options vested and expected to vest as of June 30, 2024	2,773,034	\$ 11.45	5.8	\$ 97,955

Summary of RSU
Activity

The following table summarizes the Company's RSU activity since December 31, 2023:

Weighted-Average

	Number of RSUs	Grant Date Fair Value
Unvested as of December 31, 2023	565,376	\$ 14.24
Granted	407,494	\$ 20.99
Vested ¹	(243,018)	\$ 14.39
Forfeited	(34,700)	\$ 16.61
Unvested as of June 30, 2024	695,152	\$ 17.92

¹ Includes 64,213 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant to the 2020 Equity Incentive Plan.

Summary of PSU activity

The following table summarizes the Company’s PSU activity since December 31, 2023:

	Number of PSUs	Weighted-Average Grant Date Fair Value
Unvested as of December 31, 2023	—	
Granted	247,499	\$ 20.99
Forfeited	(2,977)	\$ 20.99
Unvested as of June 30, 2024	244,522	\$ 20.99

XML 55 R45.htm IDEA: XBRL DOCUMENT

Net Income Per Share (Tables)

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income Per Share

6 Months Ended
Jun. 30, 2024

Basic and diluted net income per share attributable to Vital Farms, Inc. common stockholders were calculated as follows:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Numerator:				
Net income	\$ 16,339	\$ 6,683	\$ 35,362	\$ 13,833
Denominator:				
Weighted average common shares outstanding — basic	42,500,355	40,948,365	42,148,992	40,861,218
Weighted average effect of potentially dilutive securities:				
Effect of potentially dilutive stock options	2,139,855	2,227,020	2,044,539	2,324,262
Effect of potentially dilutive RSUs	389,866	106,478	317,531	160,193
Effect of potentially dilutive PSUs	207,040	—	71,398	—
Effect of potentially dilutive common stock issuable pursuant to the ESPP	11,676	10,398	17,941	14,320
Weighted average common shares outstanding — diluted	45,248,792	43,292,261	44,600,401	43,359,993
Net income per share attributable to Vital Farms, Inc. stockholders				
Basic	\$ 0.38	\$ 0.16	\$ 0.84	\$ 0.34
Diluted	\$ 0.36	\$ 0.15	\$ 0.79	\$ 0.32

Schedule of Common Shares Excluded from Computation of Diluted Earnings Per Share

The Company excluded the following shares of common stock, outstanding at each period end, from the computation of diluted net income per share attributable to Vital Farms, Inc. common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	13-Weeks Ended		26-Weeks Ended	
	June 30, 2024	June 25, 2023	June 30, 2024	June 25, 2023
Options to purchase common stock	1,933	36,865	1,401	21,629
Unvested RSUs	602	12,286	1,411	40,078
Unvested PSUs	525	-	174	-
	3,060	49,151	2,986	61,707

XML 56 R46.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Tables)

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income

6 Months Ended
Jun. 30, 2024

The amounts reclassified from accumulated other comprehensive income (“AOCI”) to the unaudited consolidated statements of operations were as follows (in thousands):

		Amounts Reclassified from AOCI 13-Week Period Ended	
AOCI Component	Statement of Income Classification	June 30, 2024	June 25, 2023
Losses on available-for-sale securities	Other expense, net	\$ —	\$ 95
	Total before tax	\$ —	\$ 95
	Tax benefit	\$ —	(26)
	Net of tax	\$ —	69

		Amounts Reclassified from AOCI 26-Week Period Ended	
AOCI Component	Statement of Income Classification	June 30, 2024	June 25, 2023
Losses on available-for-sale securities	Other expense, net	\$ (1)	\$ 129
	Total before tax	(1)	129
	Tax benefit	—	(32)
	Net of tax	\$ (1)	\$ 97

Schedule of Component of Other Comprehensive Income

The gross amount and related tax (expense) benefit recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):

		13-Weeks Ended					
		June 30, 2024			June 25, 2023		
		Before Tax	Tax	After Tax	Before Tax	Tax	After Tax
Available-for-sale debt securities:							
Unrealized net holding gain		134	\$ (33)	\$ 101	\$ 128	\$ (35)	\$ 93
Amounts reclassified for realized losses to earnings		—	—	—	95	(26)	69
Total other comprehensive income		\$ 134	\$ (33)	\$ 101	\$ 223	\$ (61)	\$ 162

		26-Weeks Ended					
		June 30, 2024			June 25, 2023		
		Before Tax	Tax	After Tax	Before Tax	Tax	After Tax
Available-for-sale debt securities:							
Unrealized net holding gain		\$ 278	\$ (68)	\$ 210	\$ 645	\$ (159)	\$ 486
Amounts reclassified for realized losses to earnings		(1)	-	(1)	129	(32)	97
Total other comprehensive income		\$ 277	\$ (68)	\$ 209	\$ 774	\$ (191)	\$ 583

XML 57 R47.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation - Additional Information (Details)

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Date of incorporation

XML 58 R48.htm IDEA: XBRL DOCUMENT

Investment Securities

6 Months Ended

Jun. 30, 2024

Jun. 06, 2013

- Summary of Available-for-sale Investment Securities (Details) - USD (\$)	Jun. 30, 2024 Dec. 31, 2023	
Schedule Of Available For Sale Securities [Line Items]		
Total available-for-sale Amortized Cost	\$ 19,722,000	\$ 33,134,000
Unrealized Gains	9,000	10,000
Unrealized Losses	(198,000)	(477,000)
Allowance for Credit Losses	0	0
Fair Value	19,533,000	32,667,000
U.S. corporate bonds and U.S. dollar denominated foreign bonds		
Schedule Of Available For Sale Securities [Line Items]		
Total available-for-sale Amortized Cost	19,722,000	33,134,000
Unrealized Gains	9,000	10,000
Unrealized Losses	(198,000)	(477,000)
Allowance for Credit Losses	0	0
Fair Value	\$ 19,533,000	\$ 32,667,000

XML 59 R49.htm IDEA: XBRL DOCUMENT

Investment Securities - Additional Information (Details)	3 Months Ended		6 Months Ended		Dec. 31, 2023
	Jun. 30, 2024 USD (\$) Security Position	Jun. 25, 2023 USD (\$)	Jun. 30, 2024 USD (\$) Security Position	Jun. 25, 2023 USD (\$)	
Schedule Of Available For Sale Securities [Line Items]					
Proceeds from the sale of available-for-sale securities	\$ 0	\$ 1,907,000	\$ 0	\$ 1,907,000	
Unrealized Losses	\$ 198,000		\$ 198,000		\$ 477,000
Unrealized Loss Position greater than 12 months Position	30		30		
Allowance for Credit Losses	\$ 0		\$ 0		\$ 0
Maximum					
Schedule Of Available For Sale Securities [Line Items]					
Unrealized Losses	\$ 25,000		\$ 25,000		
AFS Securities					
Schedule Of Available For Sale Securities [Line Items]					
Number of Securities Issuances for unrealized losses Security	31		31		

XML 60 R50.htm IDEA: XBRL DOCUMENT

Investment Securities - Summary of Contractual Maturities of Investment Securities (Details) - USD (\$)	Jun. 30, 2024 Dec. 31, 2023	
\$ in Thousands		
Investments, Debt and Equity Securities [Abstract]		

Due within one year Amortized Cost	\$ 17,361	
Due after one year through five years Amortized Cost	2,361	
Total available-for-sale Amortized Cost	19,722	\$ 33,134
Due within one year Fair Value	17,171	
Due after one year through five years Fair Value	2,362	
Total available-for-sale Fair Value	\$ 19,533	\$ 32,667

XML 61 R51.htm IDEA: XBRL DOCUMENT

Investment Securities - Schedule of Unrealized Loss Aging for Available-for-sale Securities (Details) - USD (\$)	Jun. 30, 2024 Dec. 31, 2023	
\$ in Thousands		
Schedule Of Available For Sale Securities [Line Items]		

Fair value, less than 12 months	\$ 654	\$ 699
Unrealized losses, less than 12 months	(2)	(3)
Fair value, 12 months or longer	17,870	29,247
Unrealized losses, 12 months or longer	(196)	(474)
Fair value, Total	18,524	29,946
Unrealized losses, Total	(198)	(477)

U.S. corporate bonds and U.S. dollar denominated foreign bonds

Schedule Of Available For Sale Securities [Line Items]		
Fair value, less than 12 months	654	699
Unrealized losses, less than 12 months	(2)	(3)
Fair value, 12 months or longer	17,870	29,247
Unrealized losses, 12 months or longer	(196)	(474)
Fair value, Total	18,524	29,946
Unrealized losses, Total	\$ (198)	\$ (477)

XML 62 R52.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Schedule Of Notional Amounts of Outstanding Derivative Instruments (Details)	Jun. 30, 2024 Dec. 31, 2023	
bu in Thousands	bu T	T bu

Corn		
Derivative [Line Items]		
Notional amounts of derivative financial instruments bu	860	2,351
Soybean Meal		
Derivative [Line Items]		
Notional amounts of derivative financial instruments T	9	25

XML 63 R53.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Additional Information (Details) - USD (\$)	3 Months Ended		6 Months Ended	
\$ in Thousands	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023
Commodity Contract [Member] Non designated [Member]				
Derivative Instruments, Gain (Loss) [Line Items]				

Pre-tax amount of derivative losses	\$ 87	\$ 402	\$ 387	\$ 1,817
-------------------------------------	-------	--------	--------	----------

XML 64 R54.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) -	Jun. 30, 2024 Dec. 31, 2023	
---	-----------------------------	--

Recurring - USD (\$) \$ in Thousands		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	\$ 121,242	\$ 97,559
Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	101,703	64,498
Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	19,539	33,061
Money market		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	101,703	64,498
Money market Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	101,703	64,498
U.S. corporate bonds and U.S. dollar denominated foreign bonds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	19,533	32,667
U.S. corporate bonds and U.S. dollar denominated foreign bonds Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	19,533	32,667
Derivative financial instruments		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	6	394
Derivative financial instruments Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]		
Assets measured at fair value	\$ 6	\$ 394

XML 65 R55.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details)		Jun. 30, 2024 USD (\$)			
Fair Value Disclosures [Abstract]					
Fair value liabilities transfers, Level 2 to Level 1 \$ 0					
XML 66 R56.htm IDEA: XBRL DOCUMENT					
Revenue Recognition - Summary of Net Revenue by Primary Product (Details) - USD (\$)		3 Months Ended		6 Months Ended	
\$ in Thousands		Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023

Disaggregation Of Revenue [Line Items]					
Net revenue	\$ 147,388	\$ 106,445	\$ 295,316	\$ 225,616	
Eggs and Egg Related Products					
Disaggregation Of Revenue [Line Items]					
Net revenue	142,941	101,785	286,701	214,575	
Butter and Butter Related Products					
Disaggregation Of Revenue [Line Items]					
Net revenue	\$ 4,447	\$ 4,660	\$ 8,615	\$ 11,041	

XML 67 R57.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers (Details)		3 Months Ended		6 Months Ended	
		Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023

[Customer Concentration Risk | Net Revenue | Customer A](#)

Disaggregation Of Revenue [Line Items]					
Concentration risk percentage		23.00%	25.00%	24.00%	25.00%

XML 68 R58.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers (Details) - Customer Concentration Risk - Accounts Receivable		6 Months Ended		12 Months Ended	
		Jun. 30, 2024	Dec. 31, 2023		

[Customer A](#)

Disaggregation Of Revenue [Line Items]					
Concentration risk percentage	20.00%	18.00%			

[Customer B](#)

Disaggregation Of Revenue [Line Items]					
Concentration risk percentage	13.00%	12.00%			

[Customer C](#)

Disaggregation Of Revenue [Line Items]					
Concentration risk percentage		11.00%			

[Customer D](#)

Disaggregation Of Revenue [Line Items]					
Concentration risk percentage	11.00%	11.00%			

XML 69 R59.htm IDEA: XBRL DOCUMENT

Allowance for Credit Losses - Additional Information (Details) - USD (\$)		Jun. 30, 2024		Mar. 31, 2024	
\$ in Thousands					

Allowance for Credit Loss [Abstract]					
Allowance for credit losses	\$ 631	\$ 401	\$ 777		

XML 70 R60.htm IDEA: XBRL DOCUMENT

Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses (Details) - USD (\$)		3 Months Ended			
\$ in Thousands				Jun. 30, 2024	Mar. 31, 2024

[Financing Receivable, Allowance for Credit Loss \[Line Items\]](#)

Allowance for credit losses, Beginning balance	\$ (401)	\$ (777)		
Reductions (provisions) charged to operating results	(230)	236		
Account write-off	0	140		

Allowance for credit losses,Ending balance	(631)	(401)
Trade Receivable [Member]		
Financing Receivable, Allowance for Credit Loss [Line Items]		
Allowance for credit losses, Beginning balance	(266)	(550)
Reductions (provisions) charged to operating results	(248)	284
Account write-off	0	0
Allowance for credit losses,Ending balance	(514)	(266)
Prepaid Expenses and other Current Assets [Member]		
Financing Receivable, Allowance for Credit Loss [Line Items]		
Allowance for credit losses, Beginning balance	(135)	(227)
Reductions (provisions) charged to operating results	18	(48)
Account write-off		140
Allowance for credit losses,Ending balance	\$ (117)	\$ (135)

XML 71 R61.htm IDEA: XBRL DOCUMENT

Inventories -
Schedule of Inventory
(Details) - USD (\$)
\$ in Thousands

Jun. 30, 2024Dec. 31, 2023

Inventory [Line Items]		
Reserve for inventory obsolescence	\$ (190)	\$ (496)
Inventories	31,448	32,895
Eggs and Egg Related Products		
Inventory [Line Items]		
Inventory gross	19,488	25,521
Butter and Butter Related Products		
Inventory [Line Items]		
Inventory gross	6,978	1,697
Packaging		
Inventory [Line Items]		
Inventory gross	3,858	4,988
Pulleys		
Inventory [Line Items]		
Inventory gross	315	289
Other		
Inventory [Line Items]		
Inventory gross	\$ 999	\$ 896

XML 72 R62.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and
Other Current Assets
- Schedule of prepaid
expenses and other
current assets
(Details) - USD (\$)
\$ in Thousands

Jun. 30, 2024Dec. 31, 2023

Prepaid Expense and Other Assets, Current [Abstract]		
Prepaid expenses	\$ 2,568	\$ 2,357
Other receivables, net	1,956	3,363
Derivative financial instruments	6	394
Prepaid expenses and other current assets, net	\$ 4,530	\$ 6,114

XML 73 R63.htm IDEA: XBRL DOCUMENT

Property, Plant and
Equipment - Schedule
of Property, Plant and
Equipment (Details) -
USD (\$)
\$ in Thousands

Jun. 30, 2024Dec. 31, 2023

Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	\$ 95,852	\$ 87,890
Less: Accumulated depreciation and amortization	(27,525)	(21,051)
Property, plant and equipment, net	68,327	66,839
Land		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	4,055	552
Land improvements		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	818	818
Buildings and Improvements		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	30,580	30,532
Vehicles		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	1,100	1,055
Machinery and Equipment		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	55,618	50,979
Leasehold Improvements		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	491	492
Furniture and Fixtures		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	508	461
Construction in Progress		
Property Plant And Equipment [Line Items]		
Property, plant and equipment, gross	\$ 2,682	\$ 3,001

XML 74 R64.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment - Additional Information (Details) - USD (\$) \$ in Thousands	3 Months Ended	6 Months Ended		
	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023
Property Plant And Equipment [Line Items]				
Depreciation and amortization of property, plant and equipment	\$ 2,350	\$ 1,850	\$ 4,647	\$ 3,543
Amortization of property, plant and equipment	\$ 938	\$ 447	\$ 1,852	\$ 894

XML 75 R65.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Components of Lease Cost (Details) - USD (\$) \$ in Thousands	3 Months Ended	6 Months Ended		
	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023
Leases [Abstract]				

Operating lease cost	\$ 1,062	\$ 361	\$ 1,984	\$ 722
Finance lease cost - amortization of right-of-use assets	938	447	1,852	894
Finance lease cost - interest on lease liabilities	238	125	485	257
Short-term lease cost	37	305	69	422
Variable lease cost	2,595	2,115	5,102	3,678
Variable lease cost - long-term supply contracts	54,429	47,064	110,432	90,150
Total lease cost	\$ 59,299	\$ 50,417	\$ 119,924	\$ 96,123

XML 76 R66.htm IDEA: XBRL DOCUMENT

Leases - Summary of Operating and Finance Leases

Future Undiscounted Cash Flows (Details)

\$ in Thousands

Jun. 30, 2024

USD (\$)

Leases [Abstract]	
Operating leases 2024	\$ 2,879
Operating leases 2025	3,234
Operating leases 2026	3,018
Operating leases 2027	0
Total lease payments	9,131
Less imputed interest	(659)
Total present value of lease liabilities	8,472
Finance leases 2024	2,203
Finance leases 2025	4,442
Finance leases 2026	4,474
Finance leases 2027	3,685
Total lease payments	14,804
Less imputed interest	(1,591)
Total present value of lease liabilities	\$ 13,213

XML 77 R67.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Details)

- USD (\$)

\$ in Thousands

6 Months Ended

Jun. 30, 2024 Jun. 25, 2023

Leases [Abstract]		
ROU assets obtained in exchange for new finance lease obligations	\$ 1,173	\$ 4
ROU assets obtained in exchange for new operating lease obligations	\$ 5,228	\$ 0

XML 78 R68.htm IDEA: XBRL DOCUMENT

Goodwill and Other Assets - Schedule of Goodwill and Other Assets (Details) - USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]		
Goodwill	\$ 3,858	\$ 3,858
Software development costs	1,544	0
Other non-current assets	72	46
Goodwill and other assets	\$ 5,474	\$ 3,904

XML 79 R69.htm IDEA: XBRL DOCUMENT

Goodwill and Other Assets - Additional Information (Details)

- USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]		
Software development costs	\$ 1,544	\$ 0

XML 80 R70.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

Payables and Accruals [Abstract]		
Employee-related costs	\$ 8,725	\$ 9,131
Promotions and customer deductions	6,896	6,982
Distribution fees and freight	2,187	2,876
Marketing and broker commissions	2,613	3,627
Purchases of inventory	1,654	525
Professional fees	1,650	1,066
Other	2,203	11
Accrued liabilities	\$ 25,928	\$ 24,218

XML 81 R71.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Additional Information (Details)	3 Months Ended			6 Months Ended	
	Jun. 30, 2024	Mar. 31, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023
	-				
Revolving Line of Credit					
Debt Instrument [Line Items]					
Proceeds from borrowing under revolving line of credit				\$ 0	\$ 7,500
Repayment of revolving line of credit				0	7,500
Interest expense	\$ 0	\$ 0	\$ 0		\$ 7
PNC Bank, National Association Revolving Line of Credit Sixth Amendment					
Debt Instrument [Line Items]					
Line of credit facility maximum borrowing capacity		\$ 20,000			
PNC Bank, National Association Revolving Line of Credit Tenth Amendment Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate					
Debt Instrument [Line Items]					

Debt instrument basis spread on variable rate		2.00%	
PNC Bank, National Association Revolving Line of Credit Tenth Amendment Alternate Base Rate			
Debt Instrument [Line Items]			
Debt instrument basis spread on variable rate		1.00%	
PNC Bank, National Association Credit Facility			
Debt Instrument [Line Items]			
Line of credit facility covenant terms		The PNC Credit Facility was secured by all of the Company's assets (other than real property and certain other property excluded pursuant to the terms of the PNC Credit Facility) and required the Company to maintain three financial covenants: a fixed charge coverage ratio, a leverage ratio and a minimum tangible net worth requirement. The PNC Credit Facility also contained various covenants relating to limitations on indebtedness, acquisitions, mergers, consolidations and the sale of properties and liens.	
JP Morgan Chase Bank NA Revolving Line of Credit			
Debt Instrument [Line Items]			
Line of credit facility maximum borrowing capacity	\$ 60,000		
JPMorgan Credit Facility			
Debt Instrument [Line Items]			
Debt instrument face amount	\$ 35,000		
Percentage of debt instrument face amount	100.00%		
Outstanding Debt		\$ 0	\$ 0
Letter of credit sub-limit	\$ 5,000		
Revolving credit facility interest rate description	Any borrowings under the JPMorgan Credit Facility bear interest, at the Company's election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10% plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company's net leverage ratio or (ii) an alternative base rate plus a margin or either 1.75%, 2.00% or 2.25%, depending on the Company's net leverage ratio. The Company is required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on the Company's revolving exposure.		
Leverage ratio	3.25%		
Increase in leverage ratio	4.00%		
Minimum fixed charge coverage ratio	1.35%		
JPMorgan Credit Facility Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate			
Debt Instrument [Line Items]			
Debt instrument basis spread on variable rate	0.10%		
XML 82 R72.htm IDEA: XBRL DOCUMENT			
Common Stock - Additional Information (Details) - USD (\$)		6 Months Ended	
		Jun. 30, 2024	Dec. 31, 2023
Class Of Stock [Line Items]			
Common stock, shares authorized	310,000,000		310,000,000
Common stock, par value	\$ 0.0001		\$ 0.0001
Common stock, shares issued	42,971,988		41,684,649
Common stock, shares outstanding	42,971,988		41,684,649
Common stock voting rights	Each share of the Company's common stock is entitled to one vote on all matters submitted to a vote of the Company's stockholders.		
Common stock dividend declared or paid	\$ 0		
XML 83 R73.htm IDEA: XBRL DOCUMENT			
Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares		Jun. 30, 2024	Dec. 31, 2023
Class Of Stock [Line Items]			
Common stock for issuance		18,626,788	18,595,298
Employee Stock Option			
Class Of Stock [Line Items]			
Common stock for issuance		2,773,253	5,123,860
RSUs			
Class Of Stock [Line Items]			
Common stock for issuance		695,152	675,029
PSUs			
Class Of Stock [Line Items]			
Common stock for issuance		244,522	
Shares Available for Grant 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan ("2020 ESPP")			
Class Of Stock [Line Items]			
Common stock for issuance		14,913,861	12,796,409
XML 84 R74.htm IDEA: XBRL DOCUMENT			
Stock-Based Compensation - Additional Information (Details) - USD (\$)	1 Months Ended	3 Months Ended	6 Months Ended
\$ in Thousands	Jan. 01, 2024	Jun. 30, 2024	Jun. 25, 2023
	Jul. 31, 2020		Dec. 31, 2023
Share Based Compensation			

Arrangement By
Share Based
Payment Award
[Line Items]

Fair value of shares vested	\$ 0			
Common stock for issuance	18,626,788	18,626,788		18,595,298
Employee Stock Option				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Unrecognized stock-based compensation expense	\$ 1,796	\$ 1,796		
Fair value of shares vested	\$ 240	\$ 257	\$ 1,900	\$ 1,272
Expected weighted-average period of recognition		1 year 5 months 15 days		
Stock options - vest year		3 years		
Stock options - date of grant and expire		10 years		
Common stock for issuance	2,773,253	2,773,253		5,123,860
RSUs				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Unrecognized stock-based compensation expense	\$ 10,156	\$ 10,156		
Fair value of shares vested	\$ 677	\$ 1,258	\$ 3,580	2,913
Vested		(243,018)		
Expected weighted-average period of recognition		2 years 3 months 10 days		
Stock options - vest year		3 years		
Common stock for issuance	695,152	695,152		675,029
PSUs				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Unrecognized stock-based compensation expense	\$ 8,861	\$ 8,861		
Fair value of shares vested				\$ 0
Vested	0			0
Expected weighted-average period of recognition		2 years 5 months 26 days		
Stock options - vest year		3 years		
Common stock for issuance	244,522	244,522		
PSUs Maximum				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Percentage of number of shares earned		200.00%		
PSUs Minimum				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Percentage of number of shares earned		0.00%		
2020 Equity Incentive Plan Common Stock				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Maximum number of shares issuable	8,595,871			
Percentage of outstanding common stock	4.00%			
Share-based compensation award description	Initially, the maximum number of the Company's common stock that may be issued under the 2020 Incentive Plan was 8,595,871 shares. The 2020 Incentive Plan provides that the number of shares reserved and available for issuance under the 2020 Incentive Plan will automatically increase each January 1, beginning on January 1,			

Number of shares available for future grants	12,367,778	12,367,778	
Number of new shares issued	1,667,385		
2020 Employee Stock Purchase Plan Common Stock			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Maximum number of shares issuable	900,000		
Percentage of outstanding common stock	1.00%		
Share-based compensation award, description			The 2020 ESPP authorizes the initial issuance of up to 900,000 shares of the Company's common stock to eligible employees of the Company or, as designated by the Company's Board of Directors, employees of a related company. The 2020 ESPP provides that the number of shares reserved and available for issuance under the 2020 ESPP will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to the lesser of (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31 and (ii) 900,000, or such lesser number of shares as determined by the Company's Board of Directors.
Number of new shares issued	416,846		
Common stock for issuance	2,546,083	2,546,083	

[1] Includes 64,213 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant to the 2020 Equity Incentive Plan.

XML 85 R75.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details) - USD (\$) \$ in Thousands Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation expense Cost of Goods Sold Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation expense Selling, General and Administrative Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation expense	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 25, 2023	Jun. 30, 2024	Jun. 25, 2023
Stock-based compensation expense	\$ 2,916	\$ 1,446	\$ 4,898	\$ 3,687
Cost of Goods Sold				
Stock-based compensation expense	107	80	154	133
Selling, General and Administrative				
Stock-based compensation expense	\$ 2,809	\$ 1,366	\$ 4,744	\$ 3,554

XML 86 R76.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD (\$) \$ / shares in Units, \$ in Thousands Share-Based Payment Arrangement [Abstract] Number of Options, Beginning balance Number of Options, Granted Number of Options, Exercised Number of Options, Cancelled Number of Options, Ending balance Number of Options, Options exercisable as of June 30, 2024 Number of Options, Options vested and expected to vest as of June 30, 2024 Weighted-Average Exercise Price, Beginning balance Weighted-Average Exercise Price, Options Granted Weighted-Average Exercise Price, Options Exercised Weighted-Average Exercise Price, Options Cancelled Weighted-Average Exercise Price, Ending balance Weighted-Average Exercise Price, Options exercisable as of June 30, 2024 Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2024 Weighted Average Remaining Contractual Life (Years), Balance Weighted Average Remaining Contractual Life (Years), Options exercisable as of June 30, 2024 Weighted Average Remaining Contractual Life (Years), Options vested and expected to vest as of June 30, 2024 Aggregate Intrinsic Value, Beginning balance Aggregate Intrinsic Value, Exercised Aggregate Intrinsic Value, Cancelled Aggregate Intrinsic Value, Ending balance Aggregate Intrinsic Value, Options exercisable as of June 30, 2024 Aggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2024	6 Months Ended			
	Jun. 30, 2024			
Number of Options, Beginning balance	3,920,485			
Number of Options, Granted	0			
Number of Options, Exercised	(1,091,691)			
Number of Options, Cancelled	(55,541)			
Number of Options, Ending balance	2,773,253			
Number of Options, Options exercisable as of June 30, 2024	2,008,751			
Number of Options, Options vested and expected to vest as of June 30, 2024	2,773,034			
Weighted-Average Exercise Price, Beginning balance	\$ 10.07			
Weighted-Average Exercise Price, Options Granted	0			
Weighted-Average Exercise Price, Options Exercised	5.91			
Weighted-Average Exercise Price, Options Cancelled	22.94			
Weighted-Average Exercise Price, Ending balance	11.45			
Weighted-Average Exercise Price, Options exercisable as of June 30, 2024	11.04			
Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2024	\$ 11.45			
Weighted Average Remaining Contractual Life (Years), Balance	5 years 9 months 18 days			
Weighted Average Remaining Contractual Life (Years), Options exercisable as of June 30, 2024	5 years 4 months 24 days			
Weighted Average Remaining Contractual Life (Years), Options vested and expected to vest as of June 30, 2024	5 years 9 months 18 days			
Aggregate Intrinsic Value, Beginning balance	\$ 28,749			
Aggregate Intrinsic Value, Exercised	28,952			
Aggregate Intrinsic Value, Cancelled	154			
Aggregate Intrinsic Value, Ending balance	97,955			
Aggregate Intrinsic Value, Options exercisable as of June 30, 2024	71,781			
Aggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2024	\$ 97,955			

XML 87 R77.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of RSU Activity (Details) - RSUs Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Unvested as of December 31, 2023 shares Granted shares Vested shares Forfeited shares Unvested as of June 30, 2024 shares Weighted-Average Grant Date Fair Value, Beginning balance \$ / shares Weighted-Average Grant Date Fair Value, Granted \$ / shares Weighted-Average Grant Date Fair Value, Vested \$ / shares Weighted-Average Grant Date Fair Value, Forfeited \$ / shares Weighted-Average Grant Date Fair Value, Ending balance \$ / shares	6 Months Ended			
	Jun. 30, 2024			
Unvested as of December 31, 2023 shares	565,376			
Granted shares	407,494			
Vested shares	(243,018)	[1]		
Forfeited shares	(34,700)			
Unvested as of June 30, 2024 shares	695,152			
Weighted-Average Grant Date Fair Value, Beginning balance \$ / shares	\$ 14.24			
Weighted-Average Grant Date Fair Value, Granted \$ / shares	20.99			
Weighted-Average Grant Date Fair Value, Vested \$ / shares	14.39	[1]		
Weighted-Average Grant Date Fair Value, Forfeited \$ / shares	16.61			
Weighted-Average Grant Date Fair Value, Ending balance \$ / shares	\$ 17.92			

[1] Includes 64,213 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant to the 2020 Equity Incentive Plan.

XML 88 R78.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of RSU Activity	6 Months Ended			
	Jun. 30, 2024			

(Parenthetical) (Details)	shares			
RSUs				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Shares of common stock withheld to cover taxes	64,213			
XML 89 R79.htm IDEA: XBRL DOCUMENT				
Stock-Based Compensation - Summary of PSU Activity (Details) - PSUs	6 Months Ended Jun. 30, 2024 \$ / shares shares			
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Unvested as of December 31, 2023	0			
Granted	247,499			
Forfeited	(2,977)			
Unvested as of June 30, 2024	244,522			
Weighted-Average Grant Date Fair Value, Granted \$ / shares	\$ 20.99			
Weighted-Average Grant Date Fair Value, Forfeited \$ / shares	20.99			
Weighted-Average Grant Date Fair Value, Ending balance \$ / shares	\$ 20.99			
XML 90 R80.htm IDEA: XBRL DOCUMENT				
Income Taxes - Additional Information (Details)	3 Months Ended Jun. 30, 2024	Jun. 25, 2023	6 Months Ended Jun. 30, 2024	Jun. 25, 2023
Income Tax Disclosure [Abstract]				
Effective tax rate	10.00%	16.00%	17.00%	21.00%
XML 91 R81.htm IDEA: XBRL DOCUMENT				
Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands	3 Months Ended Jun. 30, 2024 Jun. 25, 2023 6 Months Ended Jun. 30, 2024 Jun. 25, 2023			
Numerator:				
Net income	\$ 16,339	\$ 6,683	\$ 35,362	\$ 13,833
Denominator:				
Weighted average common shares outstanding — basic	42,500,355	40,948,365	42,148,992	40,861,218
Weighted average effect of potentially dilutive securities: Weighted average common shares outstanding — diluted	45,248,792	43,292,261	44,600,401	43,359,993
Net income (loss) per share attributable to Vital Farms, Inc. stockholders				
Basic	\$ 0.38	\$ 0.16	\$ 0.84	\$ 0.34
Diluted	\$ 0.36	\$ 0.15	\$ 0.79	\$ 0.32
Employee Stock Option				
Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options	2,139,855	2,227,020	2,044,539	2,324,262
RSUs				
Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options	389,866	106,478	317,531	160,193
Employee Stock Purchase Plan				
Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options	11,676	10,398	17,941	14,320
PSUs				
Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options	207,040		71,398	
XML 92 R82.htm IDEA: XBRL DOCUMENT				
Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect (Details) - shares	3 Months Ended Jun. 30, 2024 Jun. 25, 2023 6 Months Ended Jun. 30, 2024 Jun. 25, 2023			
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Antidilutive securities excluded from computation of earnings per share, amount	3,060	49,151	2,986	61,707
Options to Purchase Common Stock				
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Antidilutive securities excluded from computation of earnings per share, amount	1,933	36,865	1,401	21,629
Unvested RSUs				
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Antidilutive securities excluded from computation of earnings per share, amount	602	12,286	1,411	40,078
Unvested PSUs				
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Antidilutive securities excluded from computation of earnings per share, amount	525		174	
XML 93 R83.htm IDEA: XBRL DOCUMENT				
Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details) - USD (\$) \$ in Thousands	3 Months Ended Jun. 30, 2024 Jun. 25, 2023 6 Months Ended Jun. 30, 2024 Jun. 25, 2023			
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Amounts reclassified from accumulated other comprehensive loss to earnings	\$ 0	\$ 95	\$ (1)	\$ 129
Tax (expense) benefit	0	(26)	0	(32)
Net of tax	0	69	(1)	97
Gains (Losses) on available-for-sale securities				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Amounts reclassified from accumulated other comprehensive loss to earnings	\$ 0	\$ 95	\$ (1)	\$ 129
XML 94 R84.htm IDEA: XBRL DOCUMENT				
Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details) - USD (\$) \$ in Thousands	3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 25, 2023 Mar. 26, 2023 6 Months Ended Jun. 30, 2024 Jun. 25, 2023			
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Unrealized net holding gain, Before Tax	\$ 134		\$ 128	\$ 278
Unrealized net holding gain, Tax	(33)		(35)	(68)
Unrealized net holding gain, After Tax	101		93	210
Amounts reclassified from accumulated other comprehensive loss to earnings	0		95	(1)
				129

[illegible]

[illegible]

MTKJ>IE,HT)IUM7VO-K SP9 \$X>GJ-OX7700>6,UBU@SSR:(3L5 9JB... M01H'84' <'IXYQ=YEJ'>896#W6U01Y'PF,3J6UEX#=#9&+?7H8(1B)T2'26'>7LY/G\$(!
 MT)N#&1_BT:(XT5'8';U;L&S)=\|\"BPO\"N RY,RW) /<6- USK+?>GR M 3,C,R&R'X'Q'@Q\$Q!) /1VWEI(<\"F P C.W.+?>,\"EE\"[020?V-L&.R87)52 M_<
 M%#9P97HF<\".64RZJAIKJ66?#\"U#? 9 'K&GQ,~=(. -ISE+>B|_J- M_Q_ C&R'X'XIX, U04NNS#H4OGCJ+>*OTOWJ_YJ?D4A01#?+?>7R8LDQOBBT(M ?
 E.Y8I;OV0A;>L&13%668,,>#5ZWUOJLW4A(ITY@5T)3A1#L_P,5Z>P-HZ356BT?R29 M\"R\"SRK;>X1G1B3UD:XJ|@=+\"W...N5X1X:17VR&/691\"\"\"\"I)IO
 M2+&X.081D1Y1%&@\"\$9HGFQJFJ[07F]\"BF<~?+>408L2+13FV<0HP~?F4:4 M+NJ&B098!2S,,AD(('\$*)>OTH:6WZUDF5<G>C.MGJ|K|:|@.2:|@IWK? M4+K@&1(\$<
 <40A\"P.2A)/RF+U|4JR0#~96Z#FL3'B&11IUU-@|(YOZNLQVGF MOY.%+GJ|'OJG'D'UE@/Q1<-&Q'U>YX,G05;Y74L9J?Z?>C|X1L17W0E&M(EUD?75AY(0)AH-&.;,76\".0I\"DCKJ
 C\"116>ND\"ER9J+K;H?=>EP4D M(D#B WCR6M#N(BF19P?8ZY?P\$5)X!17DDA<#B@&~=>56KAG= => MNJN19U MBFQI'CM\"U>M;(X07BJV= YQ639J;|SH6+ X5&K
 M6I2\"SPQLT\"YA0&1 INP7B 5J\"TWJ,|JJA MOI39S#N1<\"GWXZ-TZ5 \"C5ZHVEVXOGBF ANR M/5C5\"C%IEI2?7Y;X93J)M5|V|N\"WS#P5TP5JW+?P2%02P,\$% @ RSL| M66JN>8(U
 P_<@< ID I_X|JW;W&KULE55- M<|LV&+WK5<PPGIQDD:(H6W4DSCP:BZ,0)F=TR2YB&A=1>AKT|NUZ:EI34<+&?M74M|,U_<KQ-?1=H
 ML-|1|BKR& &ZV8@=>WB/JV=Q9MM(190U:B+I)H05;29TUEGWCX?>X\"T_6 MKJ7DQGSQOQMMR9626>#\"HLR\",(7CW@>2KE<9&CUXQS&E+ZP*7K_H003MKR87?<
 M&Z,& RY?752(H,2M:15)/-O7L-2D1I=>R3Y9J|JCK#B|>H\"WAE-E8-7=8GE|_B8 M.OW((Q7\"GMUA@G3|@>H>#>7G.8#9>S1->1\"C>,>DQ?>S9?\".ITO X M,(MF,%T)/R>UJD4|3-
 Z..MC;ZO&BMJ5X|T_4#3?WHP#FIN3-T_0@5\"RQ\$<TDH+2U/H#<06<+&?XMP'D&#F6>V45R M%:P6ZKQU\"X7-X\$\"ND&,R3(74AF/DCTQ'VTO@>XH#%\"B1&QNV?&#C
 M=95=>9FY(G)QPY;7YA>A_\"(1RU;DD,8WJ)\"# IDY<4UM+76XJ/XD1\"H\"O\"S<SOH:Q4WA>8-O\"EG@Y@Q- Q\$F68UW@>R J_YJ3=U8&W\"G+?F
 MFX4 W+L RCMFA8P#A5L.32?PAL-Z4|@TP3JF-NB.-L6%&8T/K?A|:|A% M-L,G,&Z57?>I02P,\$% @ RSL(68XP,W+M @ 208 ID 1\"X|JW;W&
 M&ULC57?JLV\$|W7W60@SUID439L1+9I0\"COSZQ;S|\"T WFFU5 K1-(6G6E9 M7706-2M1Y&S|VRYN50|=K13\"JUR2TN|BTR0D5<~>J)41B~L.KGH@LW*V|V9Z
 MLU#E#E.#K08SM\"W7+P|H<32.1.GR>0RD=M Q\$-|X 93\$>ZP,Y|_K07CM1*CL.R6 B-\"S<-B ME MDL:L|J|TS2 1\$Y+YR6V6%;11G-S-EJQ>LX*?A9#\"\"C2KR!P'VX|*\"CM M\",>+<
 G@076V,2\"J|JZ,3XB0A,KJLKJEIT\"/_H+B-&0V QFY |2R>5J<+& MW\\&N=>2#3 NPJ9J_<-3&\"OI7?Q|20*(.#-Z&KEVO2Q 5 0610/V&P
 M\">5-DL6 G>\$IG C.SZ_\"J\"@.IRF\">R\"\$EZ2>F.&SRRR&8?|D|CR:J|L U\"M<215LNAV,PKK4C*\";2A7H_-!<K>@!1;N@G MO L2P&L#1!0 (<L|\"D5,(=HLP@) 6 9
 >+PO>VJR-W-H965T MCE3A; 6'PIVU_ML9+K13|>6R.Z_9?|>=>85214J\"V1I MXF-E,ED1D\"\"_W#9|1;TL+V=6WJ/2L.7ZJUM;|G/879>J>?>7UD580
 MN_ZA+ZOZOP_376A:N 6C_ |K<4AMR1;C|MI|B|D_|TQ|;|ZT|>U|\"*3|A1> F\$EVEY\"OIP-< &M6 ;D&0&Q8R9X8#|B M-IA-7K\$;AP,\"N AO_LOK|N@\"Q#2\$N|N&Q/WG6W<
 M\$5Z*>\"S7>CP+X\"S24+>JHIE U+@C33?NN\$S23A;CVWF;|0A6?E1/1|/N|NQ|_>QOW MUJ7KA1&1@Y,55<K9>Q,XYE| U<-2>O|D?C MGGBL8<8\$X@/=S(B@KDQ(?<
 ZJ?T.TVVK&M-M_\"U_\"(\"SVV4D)G60\"06\$M4A MAYA)S\"E\"Z-INY3V\$|DL~T\"X\"G8B\"VAS1Z;#JHUCS09BXR\">K K9J5.A*J
 MT,CG&*1D&=>66&D8@OJMTB5'F8:Z/9(RYY\"DD0LHMA\"F2J'Y+Y+H\"KB\"P|J MZ66UW+>WJ)\"FCM%\"I=H2&#&-M/;BTWIBL|I|V| M1FN76 (BDNL@\" 1Q,
 M/419X|C37J15_\"#NBK* GDRZ>T&XHT_#3@MA0&E\$Y16<\"FH5VH4_>J.P1B M%NP#>+\"3M+J4B-M_>M\$>!/QX79+>J|_SL/(D+\"0U#7 1\"=AA2&E-&C\"J|J
 MHE\$52?TEC2@KYRMD|648PZK~W\"B.VJ'C;#>|H G50?U8@H_>U4013 M(S008?9?*\$6\$&W5_S5H1VBZ&F+|\"K1|>3U(K|>2D|GK-&S00_\"|@>Y
 ME,104NTJ|RRQ|Q\$>H070MC@>4L\"VXSU<(<4L\"HCHYSS_\"J\"RHRWGWB|J74 MSZYB\"CACA<\";WABZQE05M971*@CF<@J|5J16H/HXV\"(LC=)|MN7;(&1) MK7T1|_<(NR;%
 |HEJZB|U\"KVY|BIO(9Z<=>..W4|@YK<G<+&|J|U\"MU \"PD M_1 G+8DMJ4J+|IMC,K,C5U|Z@>P>P>-(R6*6\"OBLU\"GTU/>3:3C12BBS+N=2 MAK+&(>
 (1%614YZA>WE|Y|JQ62?0|KGE.PMZ'8)>|&|DKJY\"M?0\".E47>+&H M*\".QH9G;ET:TWS>B_4#1X5BF%>G4Q?/WEI H#WK#1J\"A&1 8S7U# C/HG9V\\ MZ;* ,LZ@>Z-3-
 T20/E9,F-79YUJYJ7E2J|(M500?75,\"FOMTJ_9P-89A&Q\"1_M,BP(OV1L.KHTH(9\"MQHIFSC.M I.4-B>P>=>M&0P+BAE=&8?1W|/\"MAD|E?R6 E;FN8|=>=&K\$K1 M';>2>ZC\$ZS9RS?<
 <6J|J.D82T0-F,|<|<0,3E?7|I3HE2B3\" MOMTXJ,IW:|@W7|WTZ1Y\"Q2S= 9|Q&1+X>:RH*Y;Q|:D@O_QPJLK+>J|_FH M|G/@=&18\"EIX2SX:R-K9J53K9<
 0&GBNEBW<=&18WTDQ21Y2A3\$A5S1<-M M\"SZ|XR3OETH:6H69>#B0?9G9?CP?FA.CH+YQZ>P>P>=>R8|OUKJ8VH\"_\"^1(MO_116R.H<
 <8-T\"UD\"O<H\"XSV4B\"38=UO\"SN1\$AR\"P2&Q|O\"&3ND M# 67#0<+&~J_EOB\"RHG74QZ>6@FC8Q,>@>OLMGUW\"K-SHW<G&B-N<D|2(1 J MJ|K-IJZV3?5;N1=O<|ZEPEL(1Z?_*|
 /Z?\"U|U(AYX\$X\$J3Y+>E+Q->|B MN;?K9SZW7RKB9\"K_5?N|QJCK=<=<-2:B,Z MPL7OG \$FV\"*_4YM0(_EPLEPOF:@>UL ME5;;;N,V\$WW5PRTQ:(%!N2|XEM(+=BM|\\N@V2W?<
 2CZ0\$MBCPU\"B1EK_OU M5#RHBLSL\"U(3%)(S9XU-V7P9S<=>(<J81_4_@_V\"G0-M7J|J|@7|Q9|Q6QJJB<28& M|9?U+ O6Z-1F8F5?>J+&(<
 &ZT>=>Y2V5;>+70:<@.61L& A403>1X|J|MRJ|5|63GUW+|*(<+<12M16 TN_GVP0-M|7M7=ROQL\"GY2TNBBS|F6'VVG J3'HZ MR9=5?<

[illegible]

[illegible]

Q5/H/S;B+^144<0%Y2C515-853-9\$4+\$.B;Y?F85[KI>4IYI/<1(6%7^IHUH/H-O&^^5A@.GX+V+@9CR^ MEW^14<0 WWZC8GP758*D-MFL^1^7EO/ALH;V1H-
^UHC4K^BN=Q3DE)^M^ZCG6Z;BV1W4\$ 0ZGSZ^151+ P04 ^#+.PA9GCA100.\$18%<@.60 M^AL+W=OL3^K;I>-.WP\$Z M0\$DHM=I T^%2?LPI8..7^1J\$F>V
WU^JN\$00(M9NUUR0-/<+<?H5..<2>M^@E1E8L CHSK& S0MUY=6V+;Y^CMB5^=.0031:SYHB+6(HQ64AD)PJ49Z9C M68&9X10PYVE.UJMJ3\$^EXEA.PH(A\$30HW1>0D?
W.L(WCP^VZV7(ZG.<=1M^Q4\$N.3BSF08D62^GJ6D0136.^4(OHYL5P4Q>4<INSL&LFE1+1R^&NBDIEA MR8P@<YA+^BR^<K^+).<H-^<?CF5^\$Z^1H^<?1Q80R0%<
(6^Y+1GB9\$.S&M^DI@C.N.WY/19Z<7Y\$N^F&1.7>.)16L9^*X8)WD-%AGD:7^XOLIU(=?1>..X-2^132S^%S%/2LD>41DMV.2%JKY^ MBWJEA6R4%?B:21P7/ZKZ.61(B8YH^50M-
1B^N<36HF&14\$H.%FCZ#<6^1@02 MM^Y+K15.4RB0?..1#FZ^;@.Z:L8.M1JKN\$S7^2L1C4^JKR^N.13 MT1M-RZP1R677E17^RAAD^P@.B+1A9PWWOR^<^<UOR^F?
3URR..1K\$T\$Z34K M^0P\$0Y@E H^H8^1A.SNP2NP32^=9D1.LTD36D0M^K1Z&5V^>3L14^FD(R.DPL) M1RE+<7ZB71\$^=5P2M4^3<6^JPD3D1ANIEH1-35WY^1%EE#..9 M1^Y@Z#(H1L?2
61E1U(4101J+Q500Q).^<2?25AM^HOK>+V MKTZR4^=91(F14)400R1^R^<=3JDR542191(QF.M6D^UK)O1.^<1<=V.M\$U\$T\$N<\$X^M^U\$E1V1BBZ^<M^P^O1U.^<H1^ZLTT.Q
910U>Y7^H1UQ5H/P.MM.^13K0)UFD8.REP:318/(N^<@>B4T1=9^=9^..LD@364M^VS1MA:Q03QUHJW^M\$101&14D.TXW=>1.L10GTO/E6=9HW.H1HMF^T2PQ>1A1A^%M15BM;
M1J4MFL765L(Y^>6^P^1T1E1\$ZV4^M1(NM+>A14VT/;O3^%Q1R+US1=-RN M^M^VG=^?=-.8^KEMIW0^9^<B=-..H1DHG^B^H=#CF.T.7244=1G7%.^WIA MIXR^H14G<.=Z
1GK^M^P1B1FYC16D0E78W\$NNGAT@PPTFF1N34>=>KPGAGQOLY7T^1A^4\$1^#10<L1^1%E2>1^INAP.T.9 M^<@>PO=V1R.W-H965T23A.WHUT1X<S^D;3^M^&B?Y^<U;2J+1P
Q1^Y68^<PZ0133CQCFL2>2.L81-ZE M&W@-6%1+>W2D-RPQRX^K1CB1D^RLF.U.F12XZ&=<55T3LQ2M9^#2#N1WAA M.691D\$&D#010P^QWD6&6S^<2
Q1>?1&1<@>S^R^Y^31YVUK^?H^C6@<?276D0 Q=23B.YV^1LBC36P9\$JVV.Y.(X^A1X4R1U82P^7C7WGOZXT\$D6M^DFV&HCL&31M^<G+@.M^A^<UPHK?
1115C^<1>#F61^<1%&4HYH^4A^H@41^CGGCFZ.FH2MDU&XU.35=MDL1X.FY(3^1^Q31^H^YX;R^<M^<A^F6 M^<16P^%<ANDMC13M^T=BV&G+G^<5Y^1PZ6K^RW6Z?/11-?
Z^UO^LYIH>NH3Y M\$PIK6_BS)(K.)JWDM4UFEIVZ+AM=EVZ?L;KD;1^*#&9,=>1^9Y#=#)W1^1&6 M-(T7Q&%.0%0%)H1TF1M1?/RT10Y^%0Y^M1B(IR=)5DZ6K^_LN1HR84.2A4.2
MK08B.TG8K&8G1^V^/GA5M199T31E9FN2V2NLL(NTSG3)=G^<12^%<J0 M4#11\$HW980P9/VV7+1^<=1R^V^M5K=7^JHQ>TOEQE0T01Y1Y3Q>8R&45;3 M^#38EK?
Y1M#&5Y2O>2^<1TPD>3^T1^MXZ1(L.51+ P04 ^#+.PA9 M12K1\$1^#Z0^<0^AL+W=O3G0QEH1T^31J1L-KLFD.GT0M@<#VA9Q1^4C1Z1R+OX E M.Y15^>P1Z36GZ1YK1-7?
D>PK76.^P\$1H1W1^<K1A.W1^..@CA1^<1L81-V1L@<0Q1H1MVV2=810^41^WH6F721Q3^LBU^<N1^BR.40R4.D\$13178=C.M1A18E0^ZX^T7+1^07087Z.EGFV01^*%<V19 FC1^T-
KD=^E13L7.^<A1E&=<QW.O^X\$1.168.M1Y1^192=^%WEEGYHCB>Q+.^8\$1L3^101Q3^F1B^HGL2L5^Q218F1^21HJUI M@<1\$&4AD1@B=1+1WH18G\$<X^KO1^P1IP>@1V
1#13@%P#D7T^D-G71^MX181UP^KP1XPJQ1=H4U830L1^19KY-LJHGL12108F.O51601.9L42N8W3 M=6>.*4C71.CHX114D.Y^B&(S:71(N+>+*#2^G_86 D8F_3@<F^<@<1&
M499R\$73.D1^N^<^<H1+O5.ENM57R>=>KZLUZK4Y^1N8L&EZA:6M91A4V1 M^<61E5N^M^WS2G^28YQ7%<HXL1XUNQ1V=<@>91JOK^AV1Q>4ZOT9Q15C@<M16_6-
E#>R^Y1R16<M53^N4^<713W0612109M\$5D^<@F+ MK15.H1Z35^BB1^1ZBT4V^821 M^EQ=<#D..5H^N.6MZU00S&S0Q86^<31Q1^M^WKK1N1&6A&E^MVEFVAV1R
M376QG9>8>1^<?Y^M1MZO1>5 W\$1L3E>=>WUNW\$4CSWAX1^1^SH^<?1^CZ&1FE1%<X^1QH^7&X^1^T^T^M^90WC^S^<=<82;G^<19W^H^OB^<O=ID N5QY_124\$1M^110<1H
M^P^E:S U^<P^<0%9^<PO=V1R.W-H965T2.DIA7^4X0152^6@H/B>1>1^7W2B;R=>1^UXH^<1+G+27V9A)4UM^786CR^@0U5XZ&B3^K06UEN-5E M^&H
M11@H=Q^%6AHS&P6>K/EC1+56.YD14Q#1^4^1^ZZYDV01IN6^E9 M=Q1F:4U+N^14^U1H(>16^1&^%\$<WK23=7.12%<^#OC8FKTU<4Y62CVZ.MS4TQ^21G^#CDUB^%0?
&Q@<#1P103Q1..>D17N+>1>H7^TWM+BAJ8^Z=>#M^14L^<MS>1>1>TGZ/R^5ZNN^1-9O^11@>V.5Z)11@6^R?=>GK@Y1^7%M^N\$F^ONR7R^S4LZ&5S.DNTB8FTM_16?
3^81E^1NK9AG1WZ2@AFLF1@P1J1L62C4&TTF: M6A3EH.A\$1&K1<1^13P&6DK0\$1(H1^TFSN^=XYF14G SXV1(H18FC M^>S0^1A2D^SP1ZPK130XP1JU(1+9G^N3^1^1JBNC-
7XN?T51V69^28Q^>1^<MM.E1Q1<1>1R WD^007U2X^>1>WRR>@<NC4^C9Q^R7+2PM:8-6^7F1P2@VN M^C^W1X1EK^<Q^<R^#M1DV_X2V1
27C71L6XD1^Q1Y24U9>8B1Q1C0<8^<QYB3 MGGCY1<9GNN^P@QY87SPDC\$16BF15B2^K1G0P^M02P.\$%<RSL(68#1E/F @<^OD-ID1X;1W.W)K&ULK59M;1HP\$/XK5E9-
K=0U(2^1L91^MVF=5@F5=0LP18-)^K#1J MV)GM0/OO9SLA YHRM04+1T_Z U1E^ MQMX;2^6PEEMC9)3.^VPD^NTYXW@F(^<0^..16<0%Z4\$.DPPE:<3NW2+2^
M&^/5K06L1.2A1Q<@ZE.HQ+1Z4PQ55M\$212H1-L^4VE.T.JR11R4^<Q M^K<#>1^RB1^K^P1^150^ OC1@/10%1@F1A14@19^5&1&=174A.W MP@K^7<121AKS68&
OL6K?<#F^DG4R71+M\$5%1^=0Q12.^<1%\$1@<9G\$MH02 M141^5FC^FZYN69..41^B^A.HS:31^<1^<1@6A^0B1@<231^\$89G.M.3C1H0?
353H14.GB^M1^2^<U^0%9C=966688)OPRKO1R1T+(<K^A3^TE&K4 M^T@<1^<20^<0Z035^<ZB1.1SX1PD^<P^1^=XYCT.(AG> 3H1.O^<1^<1414H0.S MB=<^<1^61^TTF1
TVR16N2C5^<1^>ZHB^<1^>E9MB M^=6D1M^M-R5K\$^Y72^1VJG1NT1M=1F^SERC1TEFW^>JW1+9T105>1.L M^>OL9+YB2B1A^<1^<5C81B1H18H21M^1VZM>1L?>
=>NN1M8^K6QECN17KPY..(5TCZY11DU M+3^LS51JPV5C)EJ50M8CLC^T^<A^#16S12E1P1(OBQ1^E138KH^=>49S6L@-ME2+N=3H7%(NR7@HE^5U>1>H1L2C\$B_#471CD?
D61ZG1D>1JRB+W9V1 M+16Y>A1^<F1DY1^7G58T>..>ZN@ M1^K<1Y18^<TH&Q96^3=2%2^1PU>=>8AJ@=DPNE76Z?P?<=1@<1@<1M6H1X@C846-851>VXX;
(1^H^A1WZTKZW^N&KZY.MP=U1JG12=>MFB19 MA.9#P01PH.E17>1>CJAA^8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.2Q+T^#1^>81%61_XOK_1E1+ P04 ^#+.M.PA9EX1J_3 @<^P^1JR96QS+RYR96QSG9^Y.LP#1_Q=>..70 M(8@S9?<S61D151@V1%BD6=OZ_17&0^OEY3P2W^Y1O.TX1+>11C1\$>H1
M6M6K44B1V81HS1^KM0L^C61DZ^SVV^<1^M1H1D N&6^W0601FW.D5XA^/E.G.<2@&A1E8U1&H&SFGOG=>2U?..<1^E2D^1V4Q^U09E/2SL=Z1QH.O&K1^07151M^8P
M1Z2N31M^K^<1^H1Y819=015#<T^31OR&W MV171M/7815U3<1^<1A9V5%ZC)OW1XAB>=>1^<T8C1(I#R SL<F+<1\$1F@G^<1^<P.G0\$?<1^<8D1DK1^L2Y(1Q259T@<DZFS&K
MEJ.P# MAW1^YD1E126^<1&C1@<T^1H^<E2\$M0\$^<1^<Q\$<1^<6(37^11A9V^MVM M+1PL1W=01RA-384Y2101BG6&GF1A13BB19 M1D8^M3\$M@RHQ1^?>
4.

[EQUITY\(Unaudited\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunauditedCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY\(Unaudited\)Statements6 falsefalseR7.htm100080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS](#)
(Unaudited)Sheet[http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSUnauditedCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \(Unaudited\)Statements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance](#)
[Disclosuresheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Nature of the Business and Basis of PresentationSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationNature of the Business and Basis of PresentationNotes10 falsefalseR11.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - Investment SecuritiesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesInvestment SecuritiesNotes12 falsefalseR13.htm995485 - Disclosure - Derivative Financial InstrumentsSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsDerivative Financial InstrumentsNotes13 falsefalseR14.htm995495 - Disclosure - Fair Value MeasurementsSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes14 falsefalseR15.htm995505 - Disclosure - Revenue RecognitionSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionRevenue RecognitionNotes15 falsefalseR16.htm995515 - Disclosure - Allowance for Credit LossesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesAllowance for Credit LossesNotes16 falsefalseR17.htm995525 - Disclosure - InventoriesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesInventoriesNotes17 falsefalseR18.htm995535 - Disclosure - Prepaid Expenses and Other Current AssetsSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaid Expenses and Other Current AssetsNotes18 falsefalseR19.htm995545 - Disclosure - Property, Plant and EquipmentSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentEquipmentNotes19 falsefalseR20.htm995555 - Disclosure - LeasesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesLeasesNotes20 falsefalseR21.htm995565 - Disclosure - Goodwill and Other AssetsSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsGoodwill and Other AssetsNotes21 falsefalseR22.htm995575 - Disclosure - Accrued LiabilitiesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesAccrued LiabilitiesNotes22 falsefalseR23.htm995585 - Disclosure - Long-Term DebtSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtLong-Term DebtNotes23 falsefalseR24.htm995595 - Disclosure - Common StockSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockCommon StockNotes24 falsefalseR25.htm995605 - Disclosure - Stock-Based CompensationSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStock-Based CompensationNotes25 falsefalseR26.htm995615 - Disclosure - Income TaxesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes26 falsefalseR27.htm995625 - Disclosure - Net Income Per ShareSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareNet Income Per ShareNotes27 falsefalseR28.htm995635 - Disclosure - Accumulated Other Comprehensive IncomeSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome3Accumulated Other Comprehensive IncomeNotes28 falsefalseR29.htm995645 - Disclosure - Commitments and ContingenciesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes29 falsefalseR30.htm995655 - Disclosure - Related Party TransactionsSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes30 falsefalseR31.htm995675 - Disclosure - Summary of Significant Accounting Policies \(Policies\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies \(Policies\)PoliciesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies31 falsefalseR32.htm995685 - Disclosure - Investment Securities \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesTablesInvestment Securities \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecurities32 falsefalseR33.htm995695 - Disclosure - Derivative Financial Instruments \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsTablesDerivative Financial Instruments \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstruments33 falsefalseR34.htm995705 - Disclosure - Fair Value Measurements \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTablesFair Value Measurements \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurements34 falsefalseR35.htm995715 - Disclosure - Revenue Recognition \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionTablesRevenue Recognition \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognition35 falsefalseR36.htm995725 - Disclosure - Allowance for Credit Losses \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesTablesAllowance for Credit Losses \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLosses36 falsefalseR37.htm995735 - Disclosure - Inventories \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesTablesInventories \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventories37 falsefalseR38.htm995745 - Disclosure - Prepaid Expenses and Other Current Assets \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTablesPrepaid Expenses and Other Current Assets \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets38 falsefalseR39.htm995755 - Disclosure - Property, Plant and Equipment \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTablesProperty, Plant and Equipment \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTablesLeases \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeases40 falsefalseR41.htm995775 - Disclosure - Goodwill and Other Assets \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsTablesGoodwill and Other Assets \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssets41 falsefalseR42.htm995785 - Disclosure - Accrued Liabilities \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesTablesAccrued Liabilities \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilities42 falsefalseR43.htm995795 - Disclosure - Common Stock \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockTablesCommon Stock \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStock43 falsefalseR44.htm995805 - Disclosure - Stock-Based Compensation \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTablesStock-Based Compensation \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation44 falsefalseR45.htm995815 - Disclosure - Net Income Per Share \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareTablesNet Income Per Share \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShare45 falsefalseR46.htm995825 - Disclosure - Accumulated Other Comprehensive Income \(Tables\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTablesAccumulated Other Comprehensive Income \(Tables\)TablesSheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome346 falsefalseR47.htm995835 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetailsNature of the Business and Basis of Presentation - Additional Information \(Details\)Details47 falsefalseR48.htm995855 - Disclosure - Investment Securities - Summary of Available-for-sale Investment Securities \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetailsInvestment Securities - Summary of Available-for-sale Investment Securities \(Details\)Details48 falsefalseR49.htm995865 - Disclosure - Investment Securities - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetailsInvestment Securities - Additional Information \(Details\)Details49 falsefalseR50.htm995875 - Disclosure - Investment Securities - Summary of Contractual Maturities of Investment Securities \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfContractualMaturitiesOfInvestmentSecuritiesDetailsInvestment Securities - Summary of Contractual Maturities of Investment Securities \(Details\)Details50 falsefalseR51.htm995885 - Disclosure - Investment Securities - Schedule of Unrealized Loss Aging for Available-for-sale Securities \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetailsInvestment Securities - Schedule of Unrealized Loss Aging for Available-for-sale Securities \(Details\)Details51 falsefalseR52.htm995895 - Disclosure - Derivative Financial Instruments - Schedule of Notional Amounts of Outstanding Derivative Instruments \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails Financial Instruments - Schedule of Notional Amounts of Outstanding Derivative Instruments \(Details\)Details52 falsefalseR53.htm995905 - Disclosure - Derivative Financial Instruments - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetailsDerivative Financial Instruments - Additional Information \(Details\)Details53 falsefalseR54.htm995915 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetailsFair Value Measurements - Schedule of Financial Assets Measured at Fair Value \(Details\)Details54 falsefalseR55.htm995925 - Disclosure - Fair Value Measurements - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetailsFair Value Measurements - Additional Information \(Details\)Details55 falsefalseR56.htm995935 - Disclosure - Revenue Recognition - Summary of Net Revenue by Primary Product \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetailsRevenue Recognition - Summary of Net Revenue by Primary Product \(Details\)Details56 falsefalseR57.htm995955 - Disclosure - Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetailsRevenue Recognition - Summary of Percentage of Net Revenue from Significant Customers \(Details\)Details57 falsefalseR58.htm995965 - Disclosure - Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomer Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers \(Details\)Details58 falsefalseR59.htm995975 - Disclosure - Allowance for Credit Losses - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesAdditionalInformationDetailsAllowance for Credit Losses - Additional Information \(Details\)Details59 falsefalseR60.htm995985 - Disclosure - Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetailsAllowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses \(Details\)Details60 falsefalseR61.htm995995 - Disclosure - Inventories - Schedule of Inventory \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetailsInventories - Schedule of Inventory \(Details\)Details61 falsefalseR62.htm996005 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of prepaid expenses and other current assets \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsPrep Expenses and Other Current Assets - Schedule of prepaid expenses and other current assets \(Details\)Details62 falsefalseR63.htm996015 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetailsProperty, Plant and Equipment - Schedule of Property, Plant and Equipment \(Details\)Details63 falsefalseR64.htm996025 - Disclosure - Property, Plant and Equipment - Additional Information \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetailsProperty, Plant and Equipment - Additional Information \(Details\)Details64 falsefalseR65.htm996035 - Disclosure - Leases - Schedule of Components of Lease Cost \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetailsLeases - Schedule of Components of Lease Cost \(Details\)Details65 falsefalseR66.htm996045 - Disclosure - Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows \(Details\)Sheethttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetailsLeases -](#)

[Summary of Operating and Finance Leases Future Undiscounted Cash Flows \(Details\)Details66 falsefalseR67.htm996055 - Disclosure - Leases - Additional Information](#)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetailsLeases-Additional-Information-\(Details\)Details67](http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetailsLeases-Additional-Information-(Details)Details67) falsefalseR68.htm996065 - Disclosure - Goodwill and Other Assets - Schedule of Goodwill and Other Assets

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsScheduleOfGoodwillAndOtherAssetsDetailsGoodwill-and-Other-Assets-Schedule-of-Goodwill-and-Other-Assets-\(Details\)Details68 falsefalseR69.htm996075 - Disclosure - Goodwill and Other Assets - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsScheduleOfGoodwillAndOtherAssetsDetailsGoodwill-and-Other-Assets-Schedule-of-Goodwill-and-Other-Assets-(Details)Details68 falsefalseR69.htm996075 - Disclosure - Goodwill and Other Assets - Additional Information)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsAdditionalInformationDetailsGoodwill-and-Other-Assets-Additional-Information-\(Details\)Details69 falsefalseR70.htm996085 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities](http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsAdditionalInformationDetailsGoodwill-and-Other-Assets-Additional-Information-(Details)Details69 falsefalseR70.htm996085 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetailsAccrued-Liabilities-Schedule-of-Accrued-Liabilities-\(Details\)Details70 falsefalseR71.htm996095 - Disclosure - Long-Term Debt - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetailsAccrued-Liabilities-Schedule-of-Accrued-Liabilities-(Details)Details70 falsefalseR71.htm996095 - Disclosure - Long-Term Debt - Additional Information)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetailsLong-Term-Debt-Additional-Information-\(Details\)Details71 falsefalseR72.htm996105 - Disclosure - Common Stock - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetailsLong-Term-Debt-Additional-Information-(Details)Details71 falsefalseR72.htm996105 - Disclosure - Common Stock - Additional Information)

(Details)Sheethhttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetailsCommon-Stock-Additional-Information

(Details)Details72 falsefalseR73.htm996115 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Issuance

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetailsCommon-Stock-Schedule-of-Reserved-Shares-of-Common-Stock-for-Issuance-\(Details\)Details73 falsefalseR74.htm996125 - Disclosure - Stock-Based Compensation - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetailsCommon-Stock-Schedule-of-Reserved-Shares-of-Common-Stock-for-Issuance-(Details)Details73 falsefalseR74.htm996125 - Disclosure - Stock-Based Compensation - Additional Information)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetailsStock-Based-Compensation-Additional-Information-\(Details\)Details74 falsefalseR75.htm996135 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense](http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetailsStock-Based-Compensation-Additional-Information-(Details)Details74 falsefalseR75.htm996135 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetailsStock-Based-Compensation-Summary-of-Recognized-Stock-Based-Compensation-Expense-\(Details\)Details75 falsefalseR76.htm996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity](http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetailsStock-Based-Compensation-Summary-of-Recognized-Stock-Based-Compensation-Expense-(Details)Details75 falsefalseR76.htm996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetailsStock-Based-Compensation-Summary-of-Stock-Option-Activity-\(Details\)Details76 falsefalseR77.htm996155 - Disclosure - Stock-Based Compensation - Summary of RSU Activity](http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetailsStock-Based-Compensation-Summary-of-Stock-Option-Activity-(Details)Details76 falsefalseR77.htm996155 - Disclosure - Stock-Based Compensation - Summary of RSU Activity)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRSUActivityDetailsStock-Based-Compensation-Summary-of-RSU-Activity-\(Details\)Details77 falsefalseR78.htm996165 - Disclosure - Stock-Based Compensation - Summary of RSU Activity \(Parenthetical\)](http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRSUActivityDetailsStock-Based-Compensation-Summary-of-RSU-Activity-(Details)Details77 falsefalseR78.htm996165 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Parenthetical))

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPSUActivityDetailsStock-Based-Compensation-Summary-of-PSU-Activity-\(Details\)Details79 falsefalseR80.htm996185 - Disclosure - Income Taxes - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPSUActivityDetailsStock-Based-Compensation-Summary-of-PSU-Activity-(Details)Details79 falsefalseR80.htm996185 - Disclosure - Income Taxes - Additional Information)

(Details)Sheethhttp://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetailsIncome-Taxes-Additional-Information

(Details)Details80 falsefalseR81.htm996195 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetailsNet-Income-Per-Share-Schedule-of-Basic-and-Diluted-Net-Income-Per-Share-\(Details\)Details81 falsefalseR82.htm996205 - Disclosure - Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect](http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetailsNet-Income-Per-Share-Schedule-of-Basic-and-Diluted-Net-Income-Per-Share-(Details)Details81 falsefalseR82.htm996205 - Disclosure - Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetailsNet-Income-Per-Share-Schedule-of-Excluded-Common-Shares-Including-at-Anti-dilutive-Effect-\(Details\)Details82 falsefalseR83.htm996215 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income](http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetailsNet-Income-Per-Share-Schedule-of-Excluded-Common-Shares-Including-at-Anti-dilutive-Effect-(Details)Details82 falsefalseR83.htm996215 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetailsAccumulated-Other-Comprehensive-Income-Schedule-of-Accumulated-Other-Comprehensive-Income-\(Details\)Details83 falsefalseR84.htm996225 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income](http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetailsAccumulated-Other-Comprehensive-Income-Schedule-of-Accumulated-Other-Comprehensive-Income-(Details)Details83 falsefalseR84.htm996225 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetailsAccumulated-Other-Comprehensive-Income-Schedule-of-Component-of-Other-Comprehensive-Income-\(Details\)Details84 falsefalseR85.htm996235 - Disclosure - Commitments and Contingencies - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetailsAccumulated-Other-Comprehensive-Income-Schedule-of-Component-of-Other-Comprehensive-Income-(Details)Details84 falsefalseR85.htm996235 - Disclosure - Commitments and Contingencies - Additional Information)

(Details)Sheeth[http://vitalfarms.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments-and-Contingencies-Additional-Information-\(Details\)Details85 falsefalseR86.htm996245 - Disclosure - Related Party Transactions - Additional Information](http://vitalfarms.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments-and-Contingencies-Additional-Information-(Details)Details85 falsefalseR86.htm996245 - Disclosure - Related Party Transactions - Additional Information)

(Details)Sheeth

```
"baseRef": "viti-20240630.htm", "first": true, "unique": true }, { "R10": { "role":  
"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureNatureOfBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Nature of the Business and Basis of Presentation", "shortName": "Nature of the Business and Basis of Presentation", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureInvestmentSecurities", "longName": "995475 - Disclosure - Investment Securities", "shortName": "Investment Securities", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstruments", "longName": "995485 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurements", "longName": "995495 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureRevenueRecognition", "longName": "995505 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLosses", "longName": "995515 - Disclosure - Allowance for Credit Losses", "shortName": "Allowance for Credit Losses", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:AllowanceForCreditLossesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:AllowanceForCreditLossesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureInventories", "longName": "995525 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995535 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosurePropertyPlantAndEquipment", "longName": "995545 - Disclosure - Property, Plant and Equipment", "shortName": "Property, Plant and Equipment", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureLeases", "longName": "995555 - Disclosure - Leases", "shortName": "Leases", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "vitl:LesseOperatingAndFinanceLeasesTextBlock", "unitRef": null, "xsiNil
```

```
"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureDisclosureCommitmentsAndContingenciesTables","longName":"995645-Disclosure-CommitmentsAndContingenciesTables","shortName":"CommitmentsAndContingencies","isDefault":"false","groupType":"disclosure","subGroupType":"","menuCat":"","Notes":"","order":"29","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"body":{"html":{"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"body":{"html":{"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R30":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables","longName":"995655-Disclosure-Related Party Transactions","shortName":"Related Party Transactions","isDefault":"false","groupType":"disclosure","subGroupType":"","menuCat":"","Notes":"","order":"30","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:RelatedPartyTransactionsDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"body":{"html":{"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:RelatedPartyTransactionsDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"body":{"html":{"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R31":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesTables","longName":"995675-Disclosure-Summary Of Significant Accounting Policies (Policies)","shortName":"Summary Of Significant Accounting Policies (Policies)","isDefault":"false","groupType":"disclosure","subGroupType":"","menuCat":"","Policies":"","order":"31","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:SignificantAccountingPoliciesTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R32":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables","longName":"995685-Disclosure-Investment Securities (Tables)","shortName":"Investment Securities (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"32","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R33":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsTables","longName":"995695-Disclosure-Derivative Financial Instruments (Tables)","shortName":"Derivative Financial Instruments (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"33","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:ScheduleOFNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R34":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables","longName":"995705-Disclosure-Fair Value Measurements (Tables)","shortName":"Fair Value Measurements (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"34","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:FairValueDisclosuresTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R35":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionTables","longName":"995715-Disclosure-Revenue Recognition (Tables)","shortName":"Revenue Recognition (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"35","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:DisaggregationOFRevenueTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:RevenueFromContractWithCustomerTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R36":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesTables","longName":"995725-Disclosure-Allowance For Credit Losses (Tables)","shortName":"Allowance For Credit Losses (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"36","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:AllowanceForCreditLossesTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R37":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesTables","longName":"995735-Disclosure-Inventories (Tables)","shortName":"Inventories (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"37","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:InventoryDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R38":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables","longName":"995745-Disclosure-Prepaid Expenses And Other Current Assets (Tables)","shortName":"Prepaid Expenses And Other Current Assets (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"38","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"viti:PrepaidExpensesAndOtherCurrentAssetsTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"viti:PrepaidExpensesAndOtherCurrentAssetsTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R39":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables","longName":"995755-Disclosure-Property Plant and Equipment (Tables)","shortName":"Property Plant and Equipment (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"39","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R40":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTables","longName":"995765-Disclosure-Leases (Tables)","shortName":"Leases (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"40","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:LeaseCostTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"viti:LesseOperatingAndFinanceLeasesTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:LeaseCostTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"viti:LesseOperatingAndFinanceLeasesTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R41":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsTables","longName":"995775-Disclosure-Goodwill And Other Assets (Tables)","shortName":"Goodwill And Other Assets (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"41","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R42":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables","longName":"995785-Disclosure-Accrued Liabilities (Tables)","shortName":"Accrued Liabilities (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"42","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R43":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockTables","longName":"995795-Disclosure-Common Stock (Tables)","shortName":"Common Stock (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"43","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:StockholdersEquityNoteDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R44":{"role":"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables","longName":"995805-Disclosure-Stock Based Compensation (Tables)","shortName":"Stock Based Compensation (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"","Tables":"","order":"44","firstAnchor":{"contextRef":"C_ce1ea735-6a80-4922-bc59-3088d0dc160e","name":"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOFRecognizedPeriodCostsTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"div":{"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"viti-20240630.htm","first":true,"unique":true},"R45":{"role":"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareTables","longName":"995815-Disclosure
```

"menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:EarningsPerShareTableTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:EarningsPerShareTableTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R46": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables", "longName": "995825 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "shortName": "Accumulated Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "Tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:ComprehensiveIncomeNoteTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:ComprehensiveIncomeNoteTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R47": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "longName": "995835 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ce1ea735-6a80-4922-bc59-3088d0dc160e", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R48": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails", "longName": "995855 - Disclosure - Investment Securities - Summary of Available for Sale Investment Securities (Details)", "shortName": "Investment Securities - Summary of Available for Sale Investment Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "unique": true }, "R49": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails", "longName": "995865 - Disclosure - Investment Securities - Additional Information (Details)", "shortName": "Investment Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "R50": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfContractualMaturitiesOfInvestmentSecuritiesDetails", "longName": "995875 - Disclosure - Investment Securities - Summary of Contractual Maturities of Investment Securities (Details)", "shortName": "Investment Securities - Summary of Contractual Maturities of Investment Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R51": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableForSaleSecuritiesDetails", "longName": "995885 - Disclosure - Investment Securities - Schedule of Unrealized Loss Aging for Available for Sale Securities (Details)", "shortName": "Investment Securities - Schedule of Unrealized Loss Aging for Available for Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R52": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails", "longName": "995895 - Disclosure - Derivative Financial Instruments - Schedule of Notional Amounts of Outstanding Derivative Instruments (Details)", "shortName": "Derivative Financial Instruments - Schedule of Notional Amounts of Outstanding Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_2d6160c6-7cfc-4fcf-b188-790b55dc480c", "name": "us-gaap:DerivativeNonmonetaryNotionalAmount", "unitRef": "U_bu", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "div": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d6160c6-7cfc-4fcf-b188-790b55dc480c", "name": "us-gaap:DerivativeNonmonetaryNotionalAmount", "unitRef": "U_bu", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "div": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R53": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails", "longName": "995905 - Derivative Financial Instruments - Additional Information (Details)", "shortName": "Derivative Financial Instruments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_a4d506fb-9b0d-4c9b-a14a-686e72fa6cb2", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4d506fb-9b0d-4c9b-a14a-686e72fa6cb2", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R54": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffinancialAssetsMeasuredAtFairValueDetails", "longName": "995915 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details)", "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_477f6817-1a25-4440-958c-4a4946c6cac", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_477f6817-1a25-4440-958c-4a4946c6cac", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R55": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995925 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "viti:FairValueLiabilityLevel2ToLevel1TransfersAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "viti:FairValueLiabilityLevel2ToLevel1TransfersAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R56": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails", "longName": "995935 - Disclosure - Revenue Recognition - Summary of Net Revenue by Primary Product (Details)", "shortName": "Revenue Recognition - Summary of Net Revenue by Primary Product (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R57": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails", "longName": "995955 - Disclosure - Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers (Details)", "shortName": "Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_81e05789-e3d7-44c2-ae5b-f63d16fe9305", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_81e05789-e3d7-44c2-ae5b-f63d16fe9305", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R58": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails", "longName": "995965 - Disclosure - Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers (Details)", "shortName": "Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_3a7b7194-6b99-d499-9000-5d0bc1369d3db", "name": "us-

```

us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "span": "p", "td": "tr", "table": "ix:continuation", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a7b7194-6b99-4d99-9000-5b0c1369d3db", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "span": "p", "td": "tr", "table": "ix:continuation", "div": "us-gaap:RevenueFromContractWithCustomerTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R59": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesAdditionalInformationDetails", "longName": "995975 - Disclosure - Allowance for Credit Losses - Additional Information (Details)", "shortName": "Allowance for Credit Losses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:AllowanceForCreditLossesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails", "longName": "995985 - Disclosure - Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses (Details)", "shortName": "Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_278c3a87-6ecd-4ad2-a5fc-4d7e987a55b2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "div": "us-gaap:AllowanceForCreditLossesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "div": "us-gaap:AllowanceForCreditLossesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "unique": true }, "R61": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetails", "longName": "995995 - Disclosure - Inventories - Schedule of Inventory (Details)", "shortName": "Inventories - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:InventoryValuationReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div": "us-gaap:InventoryDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:InventoryValuationReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div": "us-gaap:InventoryDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R62": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "996005 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of prepaid expenses and other current assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of prepaid expenses and other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div": "viti:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div": "viti:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R63": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "longName": "996015 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R64": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "996025 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails", "longName": "996035 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)", "shortName": "Leases - Schedule of Components of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:LeaseCostTableTextBlock", "div": "viti:LesseeOperatingAndFinanceLeasesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0f43b184-a2d4-4a0d-a961-fc7a03c32d66", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "viti:LesseeOperatingAndFinanceLeasesTextBlock", "div": "viti:LesseeOperatingAndFinanceLeasesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R66": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "longName": "996045 - Disclosure - Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows (Details)", "shortName": "Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "viti:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "div": "viti:LesseeOperatingAndFinanceLeasesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7d5270a8-fcb3-47fb-a26a-3bc579ff2779", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "viti:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "div": "viti:LesseeOperatingAndFinanceLeasesTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "R67": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996
```

C-7d5270a8-fcb3-47fb-a26a-3bc579ff2779, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "C-4f6374bc-ca33-428d-be8e-52daa998b107", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R74": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "996125 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R75": { "role": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetails", "longName": "996135 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R76": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails", "longName": "996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C-6d9f55f5-1fcb-461d-9ac7-d26ae85691d5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R77": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockbasedCompensationSummaryOfRSUActivityDetails", "longName": "996155 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)", "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C-3eda2879-48fe-4ffc-8220-08e69cc711bc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R78": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockbasedCompensationSummaryOfRSUActivityParenteticalDetails", "longName": "996165 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Parentetical) (Details)", "shortName": "Stock-Based Compensation - Summary of RSU Activity (Parentetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parentetical", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C-5e1f56e1-c628-4ecc-a836-9017afb56a43", "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R79": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockbasedCompensationSummaryOfPSUActivityDetails", "longName": "996175 - Disclosure - Stock-Based Compensation - Summary of PSU Activity (Details)", "shortName": "Stock-Based Compensation - Summary of PSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C-68789f75-5d86-4731-b4dc-857fb072669f", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R80": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996185 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": "null", "decimals": "2", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:IncomeTaxDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R81": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails", "longName": "996195 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)", "shortName": "Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div": "us-gaap:EarningsPerShareTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R82": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAntiDilutiveEffectDetails", "longName": "996205 - Disclosure - Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect (Details)", "shortName": "Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div": "us-gaap:EarningsPerShareTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R83": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetails", "longName": "996215 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details)", "shortName": "Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div": "us-gaap:ComprehensiveIncomeNoteTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }, "R84": { "role": "http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetails", "longName": "996225 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details)", "shortName": "Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C-0f43b184-a2d4-4a0d-a961-fe7a03c32d66", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "id": "tr", "table": "us-gaap:ScheduleOfOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "unitRef": "U

"uniqueAnchor": {"contextRef": "C ce1ea/35-6a80-4922-bc59-3088d0dc160e", "name": "viti:LongTermSupplyContractsCosts", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"span": "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"}, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "r86": {"role": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "996245 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": {"contextRef": "C 9e53bfae-7406-4895-a13a-0ff2c3aea4b6", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"span": "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"}, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "C 9e53bfae-7406-4895-a13a-0ff2c3aea4b6", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"span": "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"}, "reportCount": 1, "baseRef": "viti-20240630.htm", "first": true, "unique": true } }}, {"tag": {"us-gaap:AccountingPoliciesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": {"en-us": {"role": {"label": "Accounting Policies Abstract"} }}, {"auth_ref": {}}, {"us-gaap:AccountingStandardsUpdate201602Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201602Member", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)", "auth_ref": {"r570": {}}, {"us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails"}, "lang": {"en-us": {"role": {"label": "Receivable Type Axis", "documentation": "Information by type of receivable." }}, {"auth_ref": {"r37": {}}, {"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilities"}, "lang": {"en-us": {"role": {"label": "Accounts Payable and Accrued Liabilities Disclosure Text Block", "terseLabel": "Accrued Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." }}, {"auth_ref": {"r26": {}}, {"us-gaap:AccountsPayableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}, "lang": {"en-us": {"role": {"label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": {"r25": {"r845": {}}, {"us-gaap:AccountsPayableCurrentAndNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Amounts owed to related party", "label": "Accounts Payable", "totalLabel": "Accounts Payable, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "auth_ref": {"r109": {"r1052": {}}, {"us-gaap:AccountsReceivableMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails"}, "lang": {"en-us": {"role": {"label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "auth_ref": {"r803": {}}, {"us-gaap:AccountsReceivableNetCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}, "lang": {"en-us": {"role": {"terseLabel": "Accounts receivable, net of allowance for credit losses of \$514 and \$550 as of June 30, 2024 and December 31, 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "auth_ref": {"r298": {"r299": {}}, {"viti:AccruedDerivativePremiums": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AccruedDerivativePremiums", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Derivative premiums", "label": "Accrued Derivative Premiums", "documentation": "Accrued derivative premiums.", "auth_ref": {}}, {"viti:AccruedDistributionFeesAndFreightCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AccruedDistributionFeesAndFreightCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Distribution fees and freight", "documentation": "Accrued distribution fees and freight current.", "label": "Accrued Distribution Fees And Freight Current", "auth_ref": {}}, {"us-gaap:AccruedLiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities", "verboseLabel": "Amounts owed to related party", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": {"r30": {}}, {"us-gaap:AccruedMarketingCostsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Marketing and broker commissions", "label": "Accrued Marketing Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": {}}, {"us-gaap:AccruedProfessionalFeesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": {"r30": {}}, {"viti:AccruedPromotionsAndCustomerDeductions": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AccruedPromotionsAndCustomerDeductions", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Promotions and customer deductions", "documentation": "Accrued promotions and customer deductions", "label": "Accrued Promotions And Customer Deductions", "auth_ref": {}}, {"viti:AccruedPropertyPlantAndEquipmentCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AccruedPropertyPlantAndEquipmentCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"label": "Property, plant and equipment", "documentation": "Accrued property, plant and equipment current", "label": "Accrued Property Plant And Equipment Current", "auth_ref": {}}, {"viti:AccruedPurchasesOfInventoryCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AccruedPurchasesOfInventoryCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Purchases of inventory", "documentation": "Accrued purchases of inventory, current", "label": "Accrued Purchases Of Inventory Current", "auth_ref": {}}, {"us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"}, "lang": {"en-us": {"role": {"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "auth_ref": {"r62": {"r199": {"r667": {}}, {"us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Available for Sale Debt Securities", "label": "AOGI, Accumulated Gain (Loss), Debt Securities, Available for Sale, Parent [Member]", "verboseLabel": "Gains (Losses) on available-for-sale securities", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "auth_ref": {"r212": {"r213": {"r214": {"r216": {"r224": {"r225": {"r954": {}}, {"us-gaap:AccumulatedOtherComprehensiveIncomeLossLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetails"}, "lang": {"en-us": {"role": {"label": "Accumulated Other Comprehensive Income (Loss) Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": {"r223": {"r224": {"r557": {"r559": {"r560": {"r561": {"r562": {"r563": {}}, {"us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}, "lang": {"en-us": {"role": {"verboseLabel": "Net Loss Included in AOCI", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "auth_ref": {"r39": {"r40": {"r128": {"r206": {"r663": {"r691": {"r695": {}}, {"us-gaap:AccumulatedOtherComprehensiveIncomeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited"}, "lang": {"en-us": {"role": {"verboseLabel": "Accumulated other comprehensive income", "label": "AOGI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "auth_ref": {"r2": {"r22": {"r13": {"r40": {"r522": {"r525": {"r591": {"r686": {"r687": {"r954": {"r955": {"r956": {"r964": {"r965": {"r966": {}}, {"ecd_Additional402vDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure"}}, "auth_ref": {"r897"}}, "us-gaap-AdditionalPaidInCapitalCommonStock": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}, "lang": {"en-us": {"role": {"label": "Additional Paid-in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "periodStartLabel": "Additional Paid-in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid-in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."}}, "auth_ref": {"r118"}}, "us-gaap-AdditionalPaidInCapitalMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited"}, "lang": {"en-us": {"role": {"label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."}}, "auth_ref": {"r481", "r482", "r483", "r709", "r964", "r965", "r966", "r1037", "r1059"}}, "ecd-AdjToCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation Amount"}}, "auth_ref": {"r903}}, "ecd-AdjToCompAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation"}}, "auth_ref": {"r903}}, "ecd-AdjToNonPeeoCompFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"}}, "auth_ref": {"r903}}, "ecd-AdjToPeeoCompFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeeoCompFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote"}}, "auth_ref": {"r903}}, "us-gaap-AdjustmentsForNewAccountingPronouncementsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update", "documentation": "Information by amendment to accounting standards."}}, "auth_ref": {"r189", "r190", "r191", "r192", "r193", "r249", "r250", "r251", "r252", "r261", "r301", "r302", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r373", "r481", "r482", "r483", "r491", "r492", "r493", "r494", "r504", "r505", "r506", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r550", "r551", "r553", "r554", "r555", "r556", "r565", "r566", "r571", "r572", "r573", "r574", "r582", "r588", "r589", "r590", "r591", "r634", "r635", "r636", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695"}}, "us-gaap-AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited"}, "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "terseLabel": "Shares withheld for tax liability on vested restricted stock units", "negatedLabel": "Shares withheld for tax liability on vested restricted stock units", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."}}, "auth_ref": {}}, "us-gaap-AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited"}, "lang": {"en-us": {"role": {"label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."}}, "auth_ref": {}}, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}, "lang": {"en-us": {"role": {"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities."}}, "auth_ref": {}}, "vitl-AfsSecuritiesMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AfsSecuritiesMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureInvestmentSecuritiesAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "AFS Securities", "label": "AFS Securities [Member]", "documentation": "AFS securities."}}, "auth_ref": {}}, "ecd-AggtErrCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}, "lang": {"en-us": {"role": {"label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount"}}, "auth_ref": {"r868", "r879", "r889", "r914"}}, "ecd-AggtErrCompNotYetDeterminedTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}, "lang": {"en-us": {"role": {"label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"}}, "auth_ref": {"r871", "r882", "r892", "r917"}}, "ecd-AllAdjToCompMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation"}}, "auth_ref": {"r903}}, "ecd-AllExecutiveCategoriesMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "All Executive Categories", "label": "All Executive Categories [Member]", "documentation": "All individuals."}}, "auth_ref": {"r910}}, "ecd-AllIndividualsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": {"en-us": {"role": {"label": "All Individuals [Member]", "terseLabel": "All Individuals"}}, "auth_ref": {"r875", "r883", "r893", "r910", "r918", "r922", "r930"}}, "ecd-AllTradingArrangementsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}, "lang": {"en-us": {"role": {"label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements"}}, "auth_ref": {"r928}}, "us-gaap-AllocatedShareBasedCompensationExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."}}, "auth_ref": {"r476", "r484}}, "us-gaap-AllowanceForCreditLossAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossAbstract", "lang": {"en-us": {"role": {"label": "Allowance for Credit Loss [Abstract]", "terseLabel": "Allowance for Credit Loss"}}, "auth_ref": {}}, "vitl-AllowanceForCreditLossPrepaidExpensesAndOtherCurrentAsset": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AllowanceForCreditLossPrepaidExpensesAndOtherCurrentAsset", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical"}, "lang": {"en-us": {"role": {"label": "Allowance for credit loss prepaid expenses and other current asset", "label": "Allowance for Credit Loss Prepaid Expenses and Other Current Asset", "terseLabel": "Prepaid expenses and other current assets, net of allowance for credit losses"}}, "auth_ref": {}}, "us-gaap-AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesTables"}, "lang": {"en-us": {"role": {"label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Changes in Allowance for Credit Losses", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable."}}, "auth_ref": {"r590", "r980"}}, "us-gaap-AllowanceForCreditLossesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossesTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLosses"}, "lang": {"en-us": {"role": {"label": "Allowance for Credit Losses [Text Block]", "terseLabel": "Allowance for Credit Losses", "documentation": "The entire disclosure for allowance for credit losses."}}, "auth_ref": {"r58}}, "us-gaap-AllowanceForDoubtfulAccountsReceivable": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "documentation": "Amount of allowance for credit loss on accounts receivable."}}, "auth_ref": {"r207", "r300", "r349", "r352", "r355", "r1054"}}, "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical"}, "lang": {"en-us": {"role": {"label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable, net of allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."}}, "auth_ref": {"r207", "r300", "r349"}}, "us-gaap-AllowanceForDoubtfulAccountsReceivableWriteOffs": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails"}, "lang": {"en-us": {"role": {"label": "Account write-off", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."}}, "auth_ref": {"r354"}}, "vitl-AlternateBaseRateMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AlternateBaseRateMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Documentation", "label": "Alternate base rate", "label": "Alternate Base Rate [Member]", "terseLabel": "Alternate Base Rate"}}, "auth_ref": {}}, "dei-AmendmentFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-DocumentDocumentAndEntityInformation"}, "lang": {"en-us": {"role": {"label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission."}}, "auth_ref": {}}, "vitl-AmortizationOfAvailableForSaleDebtSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "AmortizationOfAvailableForSaleDebtSecurities", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}, "lang": {"en-us": {"role": {"label": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs."}}, "auth_ref": {"r131", "r405", "r568", "r959"}}, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetails"}, "lang": {"en-us": {"role": {"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or

```


decrease loss per share or unit amounts for the period presented." } } } , "auth_ref": "r274" } } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetails": { "lang": { "en-us": { "role": { "label": "AntidilutiveSecuritiesAxis", "documentation": "Information by type of antidilutive security." } } } , "auth_ref": { "r51" } } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetails": { "lang": { "en-us": { "role": { "label": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r51" } } } , "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAtAntidilutiveEffectDetails": { "lang": { "en-us": { "role": { "label": "AntidilutiveSecuritiesNameDomain", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } , "auth_ref": { "r51" } } } , "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } , "auth_ref": { "r507" } } } , "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } , "auth_ref": { "r163", "r202", "r243", "r281", "r289", "r293", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r509", "r513", "r552", "r659", "r744", "r845", "r859", "r998", "r999", "r1043" } } } , "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "AssetsAbstract", "terseLabel": "Assets" } } } , "auth_ref": { "r98" } } } , "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } , "auth_ref": { "r195", "r210", "r243", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r509", "r513", "r552", "r845", "r998", "r999", "r1043" } } } , "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Assets, Current Abstract", "terseLabel": "Current assets" } } } , "auth_ref": { "r98" } } } , "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure, Total", "totalLabel": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured at fair value", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } , "auth_ref": { "r98" } } } , "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } , "auth_ref": { "r310" } } } , "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } , "auth_ref": { "r311" } } } , "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Amortized Cost", "totalLabel": "Total available-for-sale Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } , "auth_ref": { "r307", "r359", "r658" } } } , "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r980" } } } , "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r315", "r656" } } } , "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due within one year Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r979" } } } , "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due within one year Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r314", "r655" } } } , "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/RoleStatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due within one year Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r314", "r655" } } } , "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "


```

```

http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } }}, "auth_ref": {"r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475"}}, "ecd_AwardUndrlygSecuritiesAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities"} }}, "auth_ref": {"r924"}}, "ecd_AwardsCloseToMnpiDiscIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name"} }}, "auth_ref": {"r923"}}, "ecd_AwardsCloseToMnpiDiscTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures"} }}, "auth_ref": {"r922"}}, "ecd_AwardsCloseToMnpiDiscTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"} }}, "auth_ref": {"r922"}}, "us-gaap_BuildingAndBuildingImprovementsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"}], "lang": {"en-us": {"role": {"label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and Improvements", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } }}, "auth_ref": {"r113", "r144", "r145"}}, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"}], "lang": {"en-us": {"role": {"label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."} }}, "auth_ref": {"r113", "r144", "r145"}}, "vitl_ButterAndButterRelatedProductsMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ButterAndButterRelatedProductsMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails"}}, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails"}], "lang": {"en-us": {"role": {"label": "Butter and butter related products.", "terseLabel": "Butter And Butter Related Products [Member]", "documentation": "Butter and butter related products." } }}, "auth_ref": {"r47", "r48", "r49"}}, "us-gaap_CapitalizedComputerSoftwareNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsAdditionalInformationDetails"}}, {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsScheduleOfGoodwillAndOtherAssetsDetails"}], "lang": {"en-us": {"role": {"label": "Software development costs.", "terseLabel": "Capitalized Computer Software, Net", "periodEndLabel": "Capitalized Computer Software, Net, Ending Balance", "periodStartLabel": "Capitalized Computer Software, Net, Beginning Balance", "totalLabel": "Capitalized Computer Software, Net, Total", "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } }}, "auth_ref": {"r808"}}, "us-gaap_CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}], "lang": {"en-us": {"role": {"label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } }}, "auth_ref": {"r45", "r197", "r810"}}, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}], "lang": {"en-us": {"role": {"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } }}, "auth_ref": {"r45", "r141", "r144"}}, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities." } }}, "auth_ref": {"r1", "r141"}}, "us-gaap_ChangedPeerGroupFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote"} }}, "auth_ref": {"r901"}}, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}], "lang": {"en-us": {"role": {"label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }}, "auth_ref": {"r203", "r204", "r205", "r270", "r409", "r410", "r411", "r413", "r416", "r423", "r552", "r698", "r699", "r700", "r701", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r732", "r739", "r777", "r796", "r797", "r798", "r799", "r800", "r937", "r960", "r967"}}, "us-gaap_ClassOfStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"}}, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}], "lang": {"en-us": {"role": {"label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }}, "auth_ref": {"r203", "r204", "r205", "r270", "r409", "r410", "r411", "r413", "r416", "r423", "r552", "r698", "r699", "r700", "r701", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r732", "r739", "r777", "r796", "r797", "r798", "r799", "r800", "r937", "r960", "r967"}}, "us-gaap_ClassOfStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"}}, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}], "lang": {"en-us": {"role": {"label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }}, "auth_ref": {"r203", "r204", "r205", "r270", "r409", "r410", "r411", "r413", "r416", "r423", "r552", "r698", "r699", "r700", "r701", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r732", "r739", "r777", "r796", "r797", "r798", "r799", "r800", "r937", "r960", "r967"}}, "us-gaap_ClassOfStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"}}, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}], "lang": {"en-us": {"role": {"label": "Class of Stock [Line
```

CommonStockMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role- DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited", "lang": { "en-us": { "role": { "label": "Common
Stock {Member}", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." }, "auth_ref": { "r848": "r849", "r850":
"r852", "r853", "r854", "r855", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r14

"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetails",
"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Cost of Sales [Member]", "terseLabel": "Cost of Goods Sold", "documentation": "Primary financial statement caption encompassing cost of sales."}}}, "auth_ref": [{"dei_CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"label": "Cover [Abstract]", "documentation": "Cover page."}}}, "auth_ref": [{"us-gaap_CreditFacilityAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}}, "lang": {"en-us": {"role": {"label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."}}}, "auth_ref": [{"us-gaap_CreditFacilityDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}}, "lang": {"en-us": {"role": {"label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."}}}, "auth_ref": [{"viti_CreditFacilityMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "CreditFacilityMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}}, "lang": {"en-us": {"role": {"label": "Credit facility", "label": "Credit Facility [Member]", "terseLabel": "Credit Facility"}}, "auth_ref": [{"dei_CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--"}}, "auth_ref": [{"viti_CustomerAMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "CustomerAMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails": {"en-us": {"role": {"documentation": "Customer A", "label": "Customer A [Member]", "terseLabel": "Customer A"}}, "auth_ref": [{"viti_CustomerBMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "CustomerBMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails": {"lang": {"en-us": {"role": {"documentation": "Customer B", "label": "Customer B [Member]", "terseLabel": "Customer B"}}, "auth_ref": [{"viti_CustomerCMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "CustomerCMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails": {"lang": {"en-us": {"role": {"documentation": "Customer C", "label": "Customer C [Member]", "terseLabel": "Customer C"}}, "auth_ref": [{"us-gaap_CustomerConcentrationRiskMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails": {"en-us": {"role": {"label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."}}}, "auth_ref": [{"55": "r297"}], "viti_CustomerDMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "CustomerDMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails": {"lang": {"en-us": {"role": {"documentation": "Customer D", "label": "Customer D [Member]", "terseLabel": "Customer D"}}, "auth_ref": [{"us-gaap_DebtDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": {"en-us": {"role": {"label": "Debt Disclosure [Abstract]", "documentation": "Debt instrument basis spread on variable rate"}}, "auth_ref": [{"us-gaap_DebtInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."}}}, "auth_ref": [{"r23": "r114", "r115", "r164", "r165", "r245", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r569", "r821", "r822", "r823", "r824", "r825", "r961"}], "us-gaap_DebtInstrumentBasisSpreadOnVariableRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt instrument basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."}}}, "auth_ref": [{"viti_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio": {"xbrltype": "percentItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"documentation": "Debt instrument covenant minimum fixed charge coverage ratio", "label": "Debt Instrument Covenant Minimum Fixed Charge Coverage Ratio", "terseLabel": "Minimum fixed charge coverage ratio"}}, "auth_ref": [{"viti_DebtInstrumentCovenantTermsLeverageRatio": {"xbrltype": "percentItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "DebtInstrumentCovenantTermsLeverageRatio", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"documentation": "Debt instrument covenant terms leverage ratio", "label": "Debt Instrument Covenant Terms Leverage Ratio", "terseLabel": "Leverage ratio"}}, "auth_ref": [{"viti_DebtInstrumentEliminatedMonthAndYear": {"xbrltype": "gYearMonthItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "DebtInstrumentEliminatedMonthAndYear", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"documentation": "Debt instrument eliminated", "label": "Debt Instrument Eliminated Month And Year", "terseLabel": "Debt instrument eliminated"}}, "auth_ref": [{"us-gaap_DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt instrument face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance."}}}, "auth_ref": [{"r103", "r105", "r390", "r569", "r822", "r823"}], "us-gaap_DebtInstrumentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": [{"r245", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r569", "r821", "r822", "r823", "r824", "r825", "r961"}], "us-gaap_DebtInstrumentMaturityDate": {"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity of long term debt", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."}}}, "auth_ref": [{"r103", "r821", "r1038"}], "us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."}}}, "auth_ref": [{"r32", "r245", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r569", "r821", "r822", "r823", "r824", "r825", "r961"}], "us-gaap_DebtInstrumentPeriodicPayment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": {"lang": {"en-us": {"role": {"totalLabel": "Debt Instrument, Periodic Payment, Total", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly payment", "documentation": "Amount of the required periodic payments including both interest and principal payments."}}}, "auth_ref": [{"r32", "r112"}], "us-gaap_DebtInstrumentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."}}}, "auth_ref": [{"r32", "r70", "r73", "r102", "r103", "r105", "r111", "r153", "r154", "r245", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r569", "r821", "r822", "r823", "r824", "r825", "r961"}], "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "terseLabel": "Allowance for Credit Losses", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}, "auth_ref": [{"r309", "r359", "r366", "r367"}], "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableForSaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Unrealized losses, 12 months or longer", "negatedLabel": "Unrealized losses, 12 months or longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": [{"r176", "r363", "r819"}], "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableForSaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Fair value, 12 months or longer", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": [{"r176", "r363"}], "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOffPositions": {"xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOffPositions", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Unrealized Loss Position greater than 12 months", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": [{"

"r990"}}, {"us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Unrealized losses, less than 12 months", "negatedLabel": "Unrealized losses, less than 12 months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": {"r176", "r363", "r819"}}, {"us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Fair value, less than 12 months", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": {"r176", "r363"}}, {"us-gaap_DebtSecuritiesAvailableForSaleTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."}}}, "auth_ref": {"r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317"}}, {"us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available-for-sale Investment Securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."}}}, "auth_ref": {"r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983"}}, {"us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Aggregate unrealized losses", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total", "negatedLabel": "Unrealized losses, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."}}}, "auth_ref": {"r174", "r361", "r819"}}, {"us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails": {"lang": {"en-us": {"role": {"label": "Fair value, Total", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": {"r175", "r362"}}, {"us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables": {"lang": {"en-us": {"role": {"label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Unrealized Loss Aging for Available-for-sale Securities", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."}}}, "auth_ref": {"r173", "r819", "r989"}}, {"us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": {"en-us": {"role": {"label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "documentation": "Deferred Income Tax Expense (Benefit)", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": {"lang": {"en-us": {"role": {"label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes", "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."}}}, "auth_ref": {"r9", "r157", "r181", "r497", "r498", "r963"}}, {"us-gaap_DepreciationDepletionAndAmortization": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": {"lang": {"en-us": {"role": {"label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization of property, plant and equipment", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."}}}, "auth_ref": {"r9", "r285"}}, {"us-gaap_DerivativeAssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {"lang": {"en-us": {"role": {"label": "Derivative financial instruments", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."}}}, "auth_ref": {"r211"}}, {"us-gaap_DerivativeContractTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."}}}, "auth_ref": {"r721", "r723", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r746", "r747", "r748", "r765", "r766", "r767", "r768", "r771", "r772", "r773", "r774", "r789", "r790", "r791", "r792", "r848", "r850"}}, {"us-gaap_DerivativeFinancialInstrumentsAssetsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsAssetsMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffinancialAssetsMeasuredAtFairValueDetails": {"lang": {"en-us": {"role": {"label": "Derivative financial instruments", "label": "Derivative Financial Instruments, Assets [Member]", "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."}}}, "auth_ref": {"r1035"}}, {"us-gaap_DerivativeInstrumentRiskAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract."}}}, "auth_ref": {"r89", "r91", "r92", "r93", "r96", "r97", "r515"}}, {"us-gaap_DerivativeInstrumentsGainLossLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."}}}, "auth_ref": {"r15", "r89", "r92", "r93", "r96", "r97", "r515"}}, {"us-gaap_DerivativeInstrumentsGainLossLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r515"}}, {"us-gaap_DerivativeLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails": {"lang": {"

```

{"role": "text", "label": "Derivative [Line Items]", "totalLabel": "Derivatives", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "authRef": "r528", "us-gaap": "DerivativeNonmonetaryNotionalAmount", "xbrlType": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DerivativeNonmonetaryNotionalAmount", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails", "lang": "en-us", "role": "terseLabel": "Notional amounts of derivative financial instruments", "label": "Derivative, Nonmonetary Notional Amount", "documentation": "Nominal number of units used to calculate payment on derivative."}], "authRef": "r406", "r421", "r528", "r1033", "r1034", "us-gaap": "DerivativeTable", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DerivativeTable", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails", "lang": "en-us", "role": "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."}], "authRef": "r15", "r84", "r85", "r87", "r88", "r90", "r92", "r94", "r95", "r97", "r528", "us-gaap": "DisaggregationOfRevenueLineItems", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DisaggregationOfRevenueLineItems", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails", "lang": "en-us", "role": "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}], "authRef": "r434", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "us-gaap": "DisaggregationOfRevenueTable", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DisaggregationOfRevenueTable", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails", "lang": "en-us", "role": "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."}], "authRef": "r434", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "us-gaap": "DisaggregationOfRevenueTableTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DisaggregationOfRevenueTableTextBlock", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionTables", "lang": "en-us", "role": "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Net Revenue by Primary Product", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."}], "authRef": "r1003", "us-gaap": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "lang": "en-us", "role": "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement."}], "authRef": "r445", "r449", "r477", "r478", "r480", "r838", "us-gaap": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "lang": "en-us", "role": "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-Based Compensation Arrangements By Share-Based Payment Award Text Block", "documentation": "Disclosure of share-based compensation arrangements by share-based payment award."}], "authRef": "r11", "r75", "us-gaap": "DividendsCommonStock", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "DividendsCommonStock", "crdr": "debit", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "lang": "en-us", "role": "label": "Dividends, Common Stock", "terseLabel": "Common stock dividend declared or paid", "totalLabel": "Dividends, Common Stock, Total", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."}], "authRef": "r6", "r155", "dei": "DocumentFiscalPeriodFocus", "xbrlType": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentFiscalPeriodFocus", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."}], "authRef": "r1", "dei": "DocumentFiscalYearFocus", "xbrlType": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentFiscalYearFocus", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."}], "authRef": "r1", "dei": "DocumentPeriodEndDate", "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentPeriodEndDate", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K; the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A; the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."}], "authRef": "r1", "dei": "DocumentQuarterlyReport", "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentQuarterlyReport", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report."}], "authRef": "r863", "dei": "DocumentTransitionReport", "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentTransitionReport", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report."}], "authRef": "r896", "dei": "DocumentType", "xbrlType": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localName": "DocumentType", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Document Type", "verboseLabel": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."}], "authRef": "r1", "us-gaap": "EarningsPerShareAbstract", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EarningsPerShareAbstract", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited", "lang": "en-us", "role": "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share."}], "authRef": "r1", "us-gaap": "EarningsPerShareBasic", "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EarningsPerShareBasic", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails", "lang": "en-us", "role": "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."}], "authRef": "r229", "r253", "r254", "r255", "r256", "r257", "r263", "r265", "r271", "r272", "us-gaap": "EarningsPerShareBasicLineItems", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EarningsPerShareBasicLineItems", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails", "lang": "en-us", "role": "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share Basic [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}], "authRef": "r265", "r269", "r271", "us-gaap": "EarningsPerShareDiluted", "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EarningsPerShareDiluted", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited", "lang": "en-us", "role": "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."}], "authRef": "r229", "r253", "r254", "r255", "r256", "r257", "r263", "r265", "r271", "r272", "us-gaap": "EarningsPerShareTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EarningsPerShareTextBlock", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShare", "lang": "en-us", "role": "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share", "documentation": "The entire disclosure for earnings per share."}], "authRef": "r262", "r274", "r275", "r276", "us-gaap": "EffectiveIncomeTaxRateContinuingOperations", "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localName": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "lang": "en-us", "role": "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."}], "authRef": "r487", "vitl": "EggCentralStationMember", "xbrlType": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localName": "EggCentralStationMember", "presentation": [{"url": "http://vitalfarms.com/20240630/taxonomy/role/Role_Disc
```

"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted-average period of recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."}}}, "auth_ref": {"r479"}}, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Unrecognized stock-based compensation expense", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."}}}, "auth_ref": {"r1032"}}, "us-gaap_EmployeeStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHPLOWSUnaudited"}], "lang": {"en-us": {"role": {"label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."}}}, "auth_ref": {"}}, "us-gaap_EmployeeStockOptionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAntidilutiveEffectDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Options to Purchase Common Stock", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."}}}, "auth_ref": {"}}, "vital_EmployeeStockPurchasePlanMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]", "documentation": "Employee Stock Purchase Plan"}}, "auth_ref": {"}}, "vital_EmployeeStockPurchasePlanMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails"}], "lang": {"en-us": {"role": {"label": "Employee stock purchase plan member", "terseLabel": "Employee Stock Purchase Plan [Member]", "documentation": "Employee Stock Purchase Plan"}}, "auth_ref": {"}}, "dei_EntityAddressAddressLine1": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name"}}, "auth_ref": {"}}, "dei_EntityAddressAddressLine2": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number"}}, "auth_ref": {"}}, "dei_EntityAddressCityOrTown": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town"}}, "auth_ref": {"}}, "dei_EntityAddressPostalZipCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code"}}, "auth_ref": {"}}, "dei_EntityAddressStateOrProvince": {"xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province."}}}, "auth_ref": {"}}, "dei_EntityCentralIndexKey": {"xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."}}}, "auth_ref": {"r861"}}, "dei_EntityCommonStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."}}}, "auth_ref": {"}}, "dei_EntityCurrentReportingStatus": {"xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}, "auth_ref": {"}}, "dei_EntityDomain": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."}}}, "auth_ref": {"}}, "dei_EntityEmergingGrowthCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria."}}}, "auth_ref": {"r861"}}, "dei_EntityExTransitionPeriod": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."}}}, "auth_ref": {"r936"}}, "dei_EntityFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."}}}, "auth_ref": {"}}, "dei_EntityFilerCategory": {"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}, "auth_ref": {"r861"}}, "dei_EntityIncorporationDateOfIncorporation": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Date of Incorporation", "documentation": "Date when an entity was incorporated."}}}, "auth_ref": {"}}, "dei_EntityIncorporationStateCountryCode": {"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation."}}}, "auth_ref": {"}}, "dei_EntityInteractiveDataCurrent": {"xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}, "auth_ref": {"r935"}}, "dei_EntityRegistrantName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}}, "auth_ref": {"r861"}}, "dei_EntityShellCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}}, "auth_ref": {"r861"}}, "dei_EntitySmallBusiness": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."}}, "auth_ref": {"r861"}}, "dei_EntityTaxIdentificationNumber": {"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}}, "auth_ref": {"r861"}}, "vital_EquipmentLoanMember": {"xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Equipment Loan [Member]", "terseLabel": "Equipment Loan", "documentation": "Equipment loan."}}}, "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": {"en-us": {"role": {"label": "Equity [Abstract]", "auth_ref": {"}}, "us-gaap_EquityComponentDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}}, "auth_ref": {"r14", "r191", "r223", "r224", "r225", "r246", "r247", "r248", "r250", "r258", "r260", "r278", "r342", "r348", "r424", "r481", "r482", "r483", "r493", "r494", "r520", "r522", "r523", "r524", "r525", "r527", "r538", "r557", "r559", "r560", "r561", "r562", "r563", "r591", "r686", "r687", "r688", "r709", "r777"}}, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote"}}, "auth_ref": {"r904"}},

"ecd_ErrCompAnalysisTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": {"xbrl": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": {"en-us": {"role": {"label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis"}}, "auth_ref": {"r868", "r879", "r889", "r914"}}, "ecd_ErrCompRecoveryTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": {"xbrl": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": {"en-us": {"role": {"label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery"}}, "auth_ref": {"r865", "r876", "r886", "r911"}}, "ecd_ExecutiveCategoryAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": {"xbrl": "http://xbrl.sec.gov/ecd/role/RvpDisclosure", "lang": {"en-us": {"role": {"label": "Executive Category [Axis]", "terseLabel": "Executive Category"}}, "auth_ref": {"r910"}}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, "auth_ref": {"}}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}, "auth_ref": {"r16"}}, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables", "lang": {"en-us": {"role": {"label": "Fair Value Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Measured at Fair Value", "documentation": "Tabular disclosure of assets, including [financial instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."}}, "auth_ref": {"r98", "r160"}}, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Asset Class [Domain]", "terseLabel": "Asset Class", "documentation": "Class of asset."}}, "auth_ref": {"r17"}}, "us-gaap_FairValueByAssetClassAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Asset Class [Axis]", "terseLabel": "Asset Class", "documentation": "Information by class of asset."}}, "auth_ref": {"r98", "r99"}}, "us-gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."}}, "auth_ref": {"r398", "r437", "r438", "r439", "r440", "r441", "r442", "r544", "r605", "r606", "r607", "r822", "r823", "r834", "r835", "r836"}}, "us-gaap_FairValueByMeasurementFrequencyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency."}}, "auth_ref": {"r543", "r544", "r545", "r546", "r547"}}, "us-gaap_FairValueDisclosuresAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": {"en-us": {"role": {"label": "Fair Value Disclosures [Abstract]", "terseLabel": ""}, "auth_ref": {"}}, "us-gaap_FairValueDisclosuresTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurements", "lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."}}, "auth_ref": {"r542"}}, "us-gaap_FairValueInputsLevel1Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."}}, "auth_ref": {"r398", "r437", "r442", "r544", "r605", "r834", "r835", "r836"}}, "us-gaap_FairValueInputsLevel2Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."}}, "auth_ref": {"r398", "r437", "r442", "r544", "r606", "r822", "r823", "r834", "r835", "r836"}}, "us-gaap_FairValueInputsLevel3Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."}}, "auth_ref": {"r398", "r437", "r438", "r439", "r440", "r441", "r442", "r544", "r607", "r822", "r823", "r834", "r835", "r836"}}, "viti_FairValueLiabilityLevel2ToLevel1TransfersAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "FairValueLiabilityLevel2ToLevel1TransfersAmount", "crdr": "debit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "lang": {"en-us": {"role": {"terseLabel": "Fair value liabilities transfers, Level 2 to Level 1", "label": "Fair Value Liability Level2 To Level1 Transfers Amount", "documentation": "Fair value liability level2 to level1 transfers amount"}}, "auth_ref": {"}}, "us-gaap_FairValueMeasurementFrequencyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency."}}, "auth_ref": {"}}, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."}}, "auth_ref": {"r398", "r437", "r438", "r439", "r440", "r441", "r442", "r605", "r606", "r607", "r822", "r823", "r834", "r835", "r836"}}, "us-gaap_FairValueMeasurementsRecurringMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialAssetsMeasuredAtFairValueDetails", "lang": {"en-us": {"role": {"terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."}}, "auth_ref": {"r542", "r547"}}, "us-gaap_FinanceLeaseInterestExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeasesCostDetails", "lang": {"en-us": {"role": {"label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease cost - interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability."}}, "auth_ref": {"r577", "r580", "r844"}}, "us-gaap_FinanceLeaseLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": {"en-us": {"role": {"label": "Finance Lease, Liability", "terseLabel": "Total present value of lease liabilities", "totalLabel": "Total finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."}}, "auth_ref": {"r576", "r586"}}, "us-gaap_FinanceLeaseLiabilityCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": {"en-us": {"role": {"terseLabel": "Finance lease liabilities, current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."}}, "auth_ref": {"r576"}}, "us-gaap_FinanceLeaseLiabilityNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": {"en-us": {"role": {"terseLabel": "Finance lease liabilities, non-current", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."}}, "auth_ref": {"r576"}}, "us-gaap_FinanceLeaseLiabilityPaymentsDue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": {"en-us": {"role": {"label": "Finance Lease, Liability, To Be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."}}, "auth_ref": {"r586"}}, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": {"xbrl": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": {"en-us": {"role": {"label": "Finance Lease, Liability, To Be Paid, Year One", "terseLabel": "Finance leases 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, "auth_ref": {"r586"}}, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {"xbrltype":

```

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": "en-us", "role": "Finance Lease, Liability, to be Paid, Year Three", "terselabel": "Finance leases 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r586", "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": "en-us", "role": "Finance Lease, Liability, to be Paid, Year Two", "terselabel": "Finance leases 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r586", "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOffiscalYear": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOffiscalYear", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": "en-us", "role": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terselabel": "Finance leases 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "auth_ref": "r1041", "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails", "lang": "en-us", "role": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "auth_ref": "r586", "us-gaap_FinanceLeasePrincipalPayments": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited", "lang": "en-us", "role": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments under finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease.", "auth_ref": "r578", "r584", "us-gaap_FinanceLeaseRightOfUseAssetAmortization": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails", "lang": "en-us", "role": "Amortization of property, plant and equipment", "verboseLabel": "Finance lease cost - amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "auth_ref": "r577", "r580", "r844", "us-gaap_FinancialInstrumentAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails", "lang": "en-us", "role": "Financial Instrument [Axis]", "terselabel": "Financial Instrument", "documentation": "Information by type of financial instrument.", "auth_ref": "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765",
```

"us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "terseLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r177": "r182", "r259": "r260", "r286": "r486", "r496": "r676" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes", "totalLabel": "Income Taxes Paid, Net, Total", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": { "r46": { "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes receivable", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": { "r108": "r950" } } }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Net change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net change in operating assets and liabilities", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": { "r8": { "vitl_IncreaseInDebtInstrumentCovenantTermsLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "IncreaseInDebtInstrumentCovenantTermsLeverageRatio", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net change in operating assets and liabilities", "label": "Increase in Debt Instrument Covenant Terms Leverage Ratio", "terseLabel": "Increase in leverage ratio" } } }, "auth_ref": { "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive stock options", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share-based payment arrangements using the treasury stock method." } } }, "auth_ref": { "r266": "r267", "r268": "r273", "r448" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "IndividualAxis", "terseLabel": "Individual", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r875": "r883", "r893": "r910", "r918", "r922", "r930" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements (Line Items)", "terseLabel": "Insider Trading Arrangements", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r864": "r934" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures (Line Items)", "terseLabel": "Insider Trading Policies and Procedures", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r864": "r934" } }, "ecd_InsiderTradingPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted (Text Block)", "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r864": "r934" } }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "label": "Interest Expense", "totalLabel": "Interest Expense, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": { "r184": "r179", "r226": "r284", "r567": "r762", "r857": "r1058" } }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Debt, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": { "r137": "r403", "r407": "r824", "r825" } }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Operating", "totalLabel": "Interest Income, Operating, Total", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": { "r132": "r754", "r794": "r795", "r856": "r857", "r1061" } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r234": "r239", "r239" } }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryCurrentTable", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails": { "lang": { "en-us": { "role": { "label": "Inventory, Current (Table)", "terseLabel": "Inventory Current (Table)", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure (Abstract)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventory gross", "label": "Inventory, Gross", "totalLabel": "Inventory, Gross, Total", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r952" } }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails": { "lang": { "en-us": { "role": { "label": "Inventory (Line Items)", "terseLabel": "Inventory (Line Items)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails": { "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r208": "r811", "r845" } }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails": { "lang": { "en-us": { "role": { "label": "Inventory Valuation Reserves", "negatedLabel": "Reserve for inventory obsolescence", "periodStartLabel": "Inventory Valuation Reserves, Beginning Balance", "periodEndLabel": "Inventory Valuation Reserves, Ending Balance", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": { "r60": "r952" } }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables": { "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity Date (Table Text Block)", "terseLabel": "Summary of Contractual Maturities of Investment Securities", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": { "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities (Abstract)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecurities": { "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure (Text Block)", "terseLabel": "Investment Securities", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r162": "r171", "r172", "r186": "r303", "r305", "r548", "r549" } }, "vitl_JPMorganChaseBankNAMember": { "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "JPMorganChaseBankNAMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "JP morgan chase bank N A", "label": "JP Morgan Chase Bank N A (Member)", "terseLabel": "JP Morgan Chase Bank N A", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "vitl_JPMorganCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "JP Morgan Credit Facility Member", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "JP morgan credit facility", "label": "JP Morgan Credit Facility (Member)", "terseLabel": "JP Morgan Credit Facility", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "vitl_KathrynMcKeonMember": { "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "KathrynMcKeonMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Kathryn McKeon", "label": "Kathryn McKeon (Member)", "documentation": "Kathryn McKeon." } } }, "auth_ref": { "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Land Improvements (Member)", "terseLabel": "Land improvements", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": { "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Land (Member)", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": { "r1004" } }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": { "lang": { "en-us": { "role": { "label": "Lease, Cost",

"totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } } , "auth_ref": { "r579": "r844" } } } , "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTables": { "lang": { "en-us": { "role": { "label": "Lease_Cost [Table Text Block]", "terseLabel": "Schedule of Components of Lease Cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } } , "auth_ref": { "r1040": { "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } } , "auth_ref": { "r149": { "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "documentation": "Leases operating and finance lease liability maturity table text block." } } } , "auth_ref": { "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Legal Entity Axis", "documentation": "The set of legal entities associated with a report." } } } , "auth_ref": { "vit_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://vitalfarms.com/20240630", "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTables": { "lang": { "en-us": { "role": { "documentation": "Lessee operating and finance lease liability maturity table text block." } } } , "label": "Lessee Operating And Finance Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Operating and Finance Leases Future Undiscounted Cash Flows" } } } , "auth_ref": { "vit_LesseeOperatingAndFinanceLeasesTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://vitalfarms.com/20240630", "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeases": { "lang": { "en-us": { "role": { "documentation": "Lessee, operating and finance leases." } } } , "label": "Lessee Operating And Finance Leases [Text Block]", "terseLabel": "Leases" } } } , "auth_ref": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } } , "auth_ref": { "r586": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating leases 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r586": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating leases 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r586": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating leases 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": { "r586": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Operating leases 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } } , "auth_ref": { "r1041": { "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingAndFinanceLeasesFutureUndiscountedCashFlowsDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } } , "auth_ref": { "r586": { "vit_LetterOfCreditSubLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "LetterOfCreditSubLimit", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Letter of credit sub limit", "label": "Letter of Credit Sub Limit", "terseLabel": "Letter of credit sub-limit" } } } , "auth_ref": { "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } } , "auth_ref": { "r29": "r243", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r510", "r513", "r514", "r552", "r730", "r816", "r859", "r998", "r1043", "r1044" } } } , "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } , "auth_ref": { "r122", "r167", "r666", "r845", "r962", "r987", "r1039" } } } , "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } } , "auth_ref": { "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } , "auth_ref": { "r31", "r196", "r243", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r510", "r513", "r514", "r552", "r845", "r998", "r1043", "r1044" } } } , "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities", "documentation": "Current liabilities." } } } , "auth_ref": { "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Debt", "label": "Long-Term Line of Credit", "totalLabel": "Long-Term Line of Credit, Total", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } } , "auth_ref": { "r23", "r16

"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" }, {"lang": {"en-us": {"role": {"label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, {"auth_ref": {} }, {"us-gaap_LongTermDebtTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebt" }, {"lang": {"en-us": {"role": {"label": "Long-Term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, {"auth_ref": {"r151"} }, {"vital_LongTermSupplyContractsCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "LongTermSupplyContractsCosts", "crdr": "debit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" }, {"lang": {"en-us": {"role": {"label": "Long-Term Supply Contracts Costs", "documentation": "Long-term supply contracts costs." }, "terseLabel": "Long-term supply contracts costs" } } }, {"auth_ref": {} }, {"vital_LongTermVariableLeaseCost": {"xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "LongTermVariableLeaseCost", "crdr": "debit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" }, {"lang": {"en-us": {"role": {"label": "Variable lease cost - long-term supply contracts", "label": "Long-Term Variable Lease Cost", "documentation": "Long-term variable lease cost." } } }, {"auth_ref": {} }, {"us-gaap_MachineryAndEquipmentMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" }, {"lang": {"en-us": {"role": {"label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, {"auth_ref": {} }, {"srt_MajorCustomersAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails" }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails" }, {"lang": {"en-us": {"role": {"label": "Customer [Axis]", "terseLabel": "Customer" } } }, {"auth_ref": {"r297", "r829", "r1003", "r1055", "r1056"} }, {"srt_MaximumMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails" }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": {"en-us": {"role": {"label": "Maximum [Member]", "terseLabel": "Maximum" } } }, {"auth_ref": {"r377", "r378", "r379", "r380", "r444", "r632", "r683", "r722", "r723", "r785", "r786", "r787", "r788", "r793", "r806", "r807", "r818", "r826", "r837", "r847", "r1002", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050"} }, {"ecd_MeasureAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Measure [Axis]", "terseLabel": "Measure" } } }, {"auth_ref": {"r902"} }, {"ecd_MeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Measure Name", "terseLabel": "Name" } } }, {"auth_ref": {"r902"} }, {"srt_MinimumMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": {"en-us": {"role": {"label": "Minimum [Member]", "terseLabel": "Minimum" } } }, {"auth_ref": {"r377", "r378", "r379", "r380", "r444", "r632", "r683", "r722", "r723", "r785", "r786", "r787", "r788", "r793", "r806", "r807", "r818", "r826", "r837", "r847", "r1002", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050"} }, {"us-gaap_MinorityInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" }, {"lang": {"en-us": {"role": {"label": "Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, {"auth_ref": {"r38", "r166", "r243", "r338", "r381", "r383", "r384", "r385", "r388", "r389", "r552", "r665", "r734"} }, {"ecd_MnpiDiscTimedForCompValFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {} }, {"http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {} }, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, {"lang": {"en-us": {"role": {"label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, {"auth_ref": {"r921"} }, {"us-gaap_MoneyMarketFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" }, {"lang": {"en-us": {"role": {"label": "Money market", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, {"auth_ref": {"r1005"} }, {"ecd_MtrITermsOfTrdArrTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrITermsOfTrdArrTextBlock", "presentation": {} }, {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, {"lang": {"en-us": {"role": {"label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, {"auth_ref": {"r929"} }, {"srt_NameOfMajorCustomerDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfAccountsReceivableNetDueFromSignificantCustomersDetails" }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails" }, {"lang": {"en-us": {"role": {"label": "Customer [Domain]", "terseLabel": "Customer" } } }, {"auth_ref": {"r297", "r829", "r1003", "r1055", "r1056"} }, {"ecd_NamedExecutiveOfficersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, {"auth_ref": {"r903"} }, {"us-gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, {"auth_ref": {"r237"} }, {"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities." } } }, {"auth_ref": {} }, {"us-gaap_NetCashProvidedByUsedInInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net Cash Provided by (Used in) Investing Activities", "label": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, {"auth_ref": {"r237"} }, {"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities." } } }, {"auth_ref": {} }, {"us-gaap_NetCashProvidedByUsedInOperatingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "debit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net Cash Provided by (Used in) Operating Activities", "label": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, {"auth_ref": {"r141", "r142", "r143"} }, {"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" }, {"lang": {"en-us": {"role": {"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities." } } }, {"auth_ref": {} }, {"us-gaap_NetIncomeLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" }, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net income", "totalLabel": "Net income attributable to Vital Farms, Inc. common stockholders", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, {"auth_ref": {"r130", "r143", "r169", "r194", "r218", "r221", "r225", "r243", "r249", "r253", "r254", "r255", "r256", "r259", "r260", "r270", "r281", "r288", "r292", "r294", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r540", "r552", "r671", "r752", "r775", "r776", "r817", "r857", "r998"} }, {"us-gaap_NetIncomeLossAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails" }, {"lang": {"en-us": {"role": {"label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator" } } }, {"auth_ref": {} }, {"vital_NetLossIncomeEarningsPerShareAttributableToParentAbsract": {"xbrltype": "stringItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "NetLossIncomeEarningsPerShareAttributableToParentAbsract", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails" }, {"lang": {"en-us": {"role": {"label": "Net Income (loss) per share attributable to Vital Farms, Inc. stockholders", "label": "Net (loss) income Earnings per share attributable to parent [Abstract]", "documentation": "Net (loss) income earnings per share attributable to parent." } } }, {"auth_ref": {} }, {"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {} }, {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" }, {"lang": {"en-us": {"role": {"label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, {"auth_ref": {} }, {"ecd_NonGaapMeasureDescriptionTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, {"auth_ref": {"r902"} }, {"ecd_NonNeosMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, {"lang": {"en-us": {"role": {"label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, {"auth_ref": {"r872", "r883", "r893", "r910", "r918"} }, {"ecd_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {} }, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, {"auth_ref": {"r900"} }, {"ecd_NonPeoNeoAvgTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, {"auth_ref": {"r899"} }, {"ecd_NonPeoNeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": {} }, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": {"en-us": {"role": {"label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, {"auth_ref": {"r910"} }, {"vital_NonRule10B51ArrModifiedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "NonRule10B51ArrModifiedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, {"lang": {"en-us": {"role": {"label": "Non-Rule 10b51 Arr modified flag", "label": "Non Rule 10b51 Arr Modified Flag" } } }, {"auth_ref": {} }, {"ecd_NonRule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, {"lang": {"en-us": {"role": {"label": "Non-Rule 10b51 Arr Adopted Flag" } } }, {"auth_ref": {} } }

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "verboseLabel": "Unrealized net holding gain, \"terseLabel\": \"Unrealized net holding gain, Before Tax\", \"documentation\": \"Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale.\" } } }, \"auth_ref\": { \"r212\", \"r215\", \"r337\" } }, \"us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetails\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax\", \"terseLabel\": \"Unrealized net holding gain, After Tax\", \"documentation\": \"Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale.\" } } }, \"auth_ref\": { \"r212\", \"r215\", \"r337\" } }, \"us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax\", \"crdr\": \"debit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetails\", \"lang\": { \"en-us\": { \"role\": { \"negatedLabel\": \"Unrealized net holding gain, Tax\", \"label\": \"OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax\", \"terseLabel\": \"Unrealized net holding gain, Tax\", \"documentation\": \"Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale.\" } } }, \"auth_ref\": { \"r3\", \"r213\" } }, \"us-gaap-OtherLiabilitiesNoncurrent\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherLiabilitiesNoncurrent\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBALANCESHEETS\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Other Liabilities, Noncurrent\", \"terseLabel\": \"Other Liabilities\", \"totalLabel\": \"Other Liabilities, Noncurrent, Total\", \"documentation\": \"Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.\" } } }, \"auth_ref\": { \"r33\" } }, \"vitl-OtherMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"OtherMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureInventoriesScheduleOfInventoryDetails\", \"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements\", \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"Other\", \"label\": \"Other [Member]\", \"terseLabel\": \"Other\" } } }, \"auth_ref\": { \"us-gaap-OtherNonoperatingIncomeExpense\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherNonoperatingIncomeExpense\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Other Nonoperating Income (Expense)\", \"totalLabel\": \"Other Nonoperating Income (Expense), Total\", \"terseLabel\": \"Other expense, net\", \"documentation\": \"Amount of income (expense) related to nonoperating activities, classified as other.\" } } }, \"auth_ref\": { \"r138\" } }, \"us-gaap-OtherOperatingActivitiesCashFlowStatement\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherOperatingActivitiesCashFlowStatement\", \"crdr\": \"debit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedSTATEMENTSOFCASHFLOWSUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Other Operating Activities, Cash Flow Statement\", \"terseLabel\": \"Other\", \"documentation\": \"Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).\" } } }, \"auth_ref\": { \"ecd-OtherPerfMeasureAmt\": { \"xbrltype\": \"decimalItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"OtherPerfMeasureAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Other Performance Measure, Amount\", \"terseLabel\": \"Other Performance Measure, Amount\" } } }, \"auth_ref\": { \"r902\" } }, \"vitl-OtherReceivablesMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"OtherReceivablesMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails\", \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"Other receivables\", \"label\": \"Other Receivables [Member]\", \"terseLabel\": \"Other Receivables [Member]\" } } }, \"auth_ref\": { \"us-gaap-OtherReceivablesNetCurrent\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"OtherReceivablesNetCurrent\", \"crdr\": \"debit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Other receivables, net\", \"label\": \"Other Receivables, Net, Current\", \"totalLabel\": \"Other Receivables, Net, Current, Total\", \"documentation\": \"Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.\" } } }, \"auth_ref\": { \"ecd-OutstandingAggtErrCompAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"OutstandingAggtErrCompAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Outstanding Aggregate Erroneous Compensation Amount\", \"terseLabel\": \"Outstanding Aggregate Erroneous Compensation Amount\" } } }, \"auth_ref\": { \"r870\", \"r881\", \"r891\", \"r916\" } }, \"ecd-OutstandingRecoveryCompAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"OutstandingRecoveryCompAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Outstanding Recovery Compensation Amount\", \"terseLabel\": \"Compensation Amount\" } } }, \"auth_ref\": { \"r873\", \"r884\", \"r894\", \"r919\" } }, \"ecd-OutstandingRecoveryIndName\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"OutstandingRecoveryIndName\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Outstanding Recovery, Individual Name\", \"terseLabel\": \"Name\" } } }, \"auth_ref\": { \"r873\", \"r884\", \"r894\", \"r919\" } }, \"vitl-PNCBankNationalAssociationMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"PNCBankNationalAssociationMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails\", \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"PNC bank national association\", \"label\": \"P N C Bank National Association [Member]\", \"terseLabel\": \"PNC Bank, National Association\" } } }, \"auth_ref\": { \"vitl-PackagingMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"PackagingMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureInventoriesScheduleOfInventoryDetails\", \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"Packaging\", \"label\": \"Packaging [Member]\", \"terseLabel\": \"Packaging\" } } }, \"auth_ref\": { \"us-gaap-ParentMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"ParentMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Parent [Member]\", \"terseLabel\": \"Total Stockholders' Equity Attributable to Vital Farms, Inc. Stockholders\", \"documentation\": \"Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.\" } } }, \"auth_ref\": { \"ecd-PayVsPerformanceDisclosureLineItems\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PayVsPerformanceDisclosureLineItems\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Pay vs Performance Disclosure [Line Items]\", \"terseLabel\": \"Pay vs Performance Disclosure\" } } }, \"auth_ref\": { \"r898\" } }, \"us-gaap-PayablesAndAccrualsAbstract\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PayablesAndAccrualsAbstract\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Payables and Accruals [Abstract]\" } } }, \"auth_ref\": { \"us-gaap-PaymentsForDerivativeInstrumentInvestingActivities\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PaymentsForDerivativeInstrumentInvestingActivities\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedSTATEMENTSOFCASHFLOWSUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"negatedLabel\": \"Purchases and settlements of derivative instruments\", \"label\": \"Payments for Derivative Instrument, Investing Activities\", \"documentation\": \"The cash outflow for derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.\" } } }, \"auth_ref\": { \"r958\" } }, \"us-gaap-PaymentsOffinancingCosts\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PaymentsOffinancingCosts\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedSTATEMENTSOFCASHFLOWSUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"negatedLabel\": \"Payment of financing costs\", \"label\": \"Payments of Financing Costs\", \"documentation\": \"The cash outflow for loan and debt issuance costs.\" } } }, \"auth_ref\": { \"r43\" } }, \"us-gaap-PaymentsRelatedToTaxWithholdingForShareBasedCompensation\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PaymentsRelatedToTaxWithholdingForShareBasedCompensation\", \"crdr\": \"credit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedSTATEMENTSOFCASHFLOWSUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Payment, Tax Withholding, Share-Based Payment Arrangement\", \"negatedLabel\": \"Payment of tax withholding obligation on vested RSU shares\", \"documentation\": \"Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.\" } } }, \"auth_ref\": { \"r233\" } }, \"us-gaap-PaymentsToAcquirePropertyPlantAndEquipment\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PaymentsToAcquirePropertyPlantAndEquipment\", \"crdr\": \"debit\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedSTATEMENTSOFCASHFLOWSUnaudited\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Payments to Acquire Property, Plant, and Equipment\", \"negatedLabel\": \"Purchases of property, plant and equipment\", \"totalLabel\": \"Payments to Acquire Property, Plant, and Equipment, Total\", \"documentation\": \"The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets.\" } } }, \"auth_ref\": { \"r140\" } }, \"ecd-PeerGroupIssuersFnTextBlock\": { \"xbrltype\": \"textBlockItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeerGroupIssuersFnTextBlock\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Peer Group Issuers, Footnote [Text Block]\", \"terseLabel\": \"Peer Group Issuers, Footnote\" } } }, \"auth_ref\": { \"r901\" } }, \"ecd-PeerGroupTotalShareholderRtnAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeerGroupTotalShareholderRtnAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Peer Group Total Shareholder Return Amount\", \"terseLabel\": \"Peer Group Total Shareholder Return Amount\" } } }, \"auth_ref\": { \"r901\" } }, \"ecd-PeoActuallyPaidCompAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeoActuallyPaidCompAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"PEO Actually Paid Compensation Amount\", \"terseLabel\": \"PEO Actually Paid Compensation Amount\" } } }, \"auth_ref\": { \"r900\" } }, \"ecd-PeoMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeoMember\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"PEO [Member]\", \"terseLabel\": \"PEO\" } } }, \"auth_ref\": { \"r910\" } }, \"ecd-PeoName\": { \"xbrltype\": \"normalizedStringItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeoName\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"PEO Name\", \"terseLabel\": \"PEO Name\" } } }, \"auth_ref\": { \"r903\" } }, \"ecd-PeoTotalCompAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2023\", \"localname\": \"PeoTotalCompAmt\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"PEO Total Compensation Amount\", \"terseLabel\": \"PEO Total Compensation Amount\" } } }, \"auth_ref\": { \"r899\" } }, \"vitl-PercentageOfDebtInstrumentFaceAmount\": { \"xbrltype\": \"percentItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"PercentageOfDebtInstrumentFaceAmount\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails\", \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"Percentage of debt instrument face amount\", \"label\": \"Percentage of Debt Instrument Face Amount\", \"terseLabel\": \"Percentage of debt instrument face amount\" } } }, \"auth_ref\": { \"us-gaap-PerformanceSharesMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PerformanceSharesMember\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails\", \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAntidilutiveEffectDetails\", \"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPspActivityDetails\", \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails\", \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Performance Shares [Member]\", \"terseLabel\": \"PSUs\", \"verboseLabel\": \"Unvested PSUs\", \"documentation\": \"Share-based payment arrangement awarded for meeting performance target.\" } } }, \"auth_ref\": { \"vitl-PeterPappasMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://vitalfarms.com/20240630\", \"localname\": \"PeterPappasMember\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Peter Pappas\", \"label\": \"Peter Pappas [Member]\", \"documentation\": \"Peter Pappas.\" } } }, \"auth_ref\": { \"us-gaap-PlanNameAxis\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2023\", \"localname\": \"PlanNameAxis\", \"presentation\": { \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails\", \"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails\", \"lang\": { \"en-us\": { \"role\": { \"label\": \"Plan Name [Axis]\", \"terseLabel\": \"Plan Name\", \"documentation\": \"Information by plan name for share-based payment arrangement.\" } } }, \"auth_ref\": { \"r1006\", \"r1007\", \"r1008\", \"r1009\", \"r1010\", \"r1011\", \"r1012\", \"r1013\", \"r1014\", \"r1015\", \"r1016\", \"r1017\", \"r1018\", \"r1019\", \"r1020\", \"r1021\", \"r1022\", \"r1023\", \"r1024\", \"r1025\", \"r1026\", \"r1027\",

"r1028", "r1029", "r1030", "r1031" }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } }, "auth_ref": { "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031" } }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } }, "auth_ref": { "r116", "r409" } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } }, "auth_ref": { "r116", "r732" } }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } }, "auth_ref": { "r116", "r409" } }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "lang": { "en-us": { "role": { "label": "Period Start Label", "terseLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "documentation": "Preferred Stock, Shares Outstanding, Ending Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } }, "auth_ref": { "r116", "r732", "r750", "r1059", "r1060" } }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.0001 par value per share, 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r116", "r661", "r845" } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Prepaid expenses and other current assets, net", "verboseLabel": "Prepaid expenses and other current assets, net", "terseLabel": "Prepaid expenses and other current assets, net of allowance for credit losses of \$117 and \$227 as of June 30, 2024 and December 31, 2023, respectively", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } }, "auth_ref": { "r953" } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } }, "auth_ref": { } }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "totalLabel": "Prepaid Expense, Current, Total", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } }, "auth_ref": { "r209", "r369", "r370", "r812" } }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails": { "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } }, "auth_ref": { "viti_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Prepaid Expenses and Other Current Assets [Text Block]", "documentation": "Prepaid expenses and other current assets." } }, "auth_ref": { "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Return of investment in variable interest entity", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } }, "auth_ref": { "r236", "r957" } }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } }, "auth_ref": { "r4", "r20" } }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowing under revolving line of credit", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } }, "auth_ref": { "r42" } }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Maturities and call redemptions of available-for-sale debt securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } }, "auth_ref": { "r231", "r232", "r971" } }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesAdditionalInformationDetails": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of available-for-sale securities", "label": "Proceeds from Sale of Debt Securities, Available for Sale", "verboseLabel": "Sales of available-for-sale debt securities", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } }, "auth_ref": { "r41", "r231", "r304", "r336" } }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of property, plant and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } }, "auth_ref": { "r139" } }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } }, "auth_ref": { "r4", "r20" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails": { "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } }, "auth_ref": { "r295", "r633", "r677", "r678", "r679", "r680", "r681", "r682", "r809", "r827", "r846", "r940", "r995", "r996", "r1003", "r1055" } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfNetRevenueByPrimaryProductDetails": { "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } }, "auth_ref": { "r295", "r633", "r677", "r678", "r679", "r680", "r681", "r682", "r809", "r827", "r846", "r940", "r995", "r996", "r1003", "r1055" } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited", "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net (loss) income", "terseLabel": "Net income", "totalLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } }, "auth_ref": { "r194", "r218", "r221", "r235", "r243", "r249", "r259", "r260", "r281", "r288", "r292", "r294", "r338", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r508", "r511", "r512", "r540", "r552", "r654", "r670", "r708", "r752", "r775", "r776", "r817", "r841", "r842", "r858", "r956", "r998" } }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } }, "auth_ref": { "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } }, "auth_ref": { "r10" } }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": {

"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment"}}, {"label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, {"auth_ref": "r148", "r178", "r179", "r180"} } }, {"us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"}}, {"label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, {"auth_ref": "r149", "r198", "r668"} } }, {"us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails"}, {"label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": "r10", "r657", "r668", "r845"} } }, {"us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"}, {"label": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, {"auth_ref": "r10", "r657", "r668", "r845"} } }, {"us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables"}}, {"label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, {"auth_ref": "r10"} } }, {"us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails"}, {"label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, {"auth_ref": "r149"} } }, {"us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails"}}, {"label": "Reductions (provisions) charged to operating results", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provisions) reductions charged to operating results", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, {"auth_ref": "r230", "r353"} } }, {"us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryAxis", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails"}}, {"label": "Inventory [Axis]", "terseLabel": "Inventory", "documentation": "Information by type of inventory held." } } }, {"auth_ref": "r951"} } }, {"us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails"}}, {"label": "Inventory [Domain]", "terseLabel": "Inventory", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, {"auth_ref": "r951"} } }, {"vital_PulletsMember": { "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "PulletsMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoryDetails"}}, {"label": "Pullets [Member]", "terseLabel": "Pullets"} } }, {"auth_ref": "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025", "r2026", "r2027", "r2028", "r2029", "r2030", "r2031", "r2032", "r2033", "r2034", "r2035", "r2036", "r2037", "r2038", "r2039", "r2040", "r2041", "r2042", "r2043", "r2044", "r2045", "r2046", "r2047", "r2048", "r2049", "r2050", "r2051", "r2052", "r2053", "r2054", "r2055", "r2056", "r2057", "r2058", "r2059", "r2060", "r2061", "r2062", "r2063", "r2064", "r2065", "r2066", "r2067", "r2068", "r2069", "r2070", "r2071", "r2072", "r2073", "r2074", "r2075", "r2076", "r2077", "r2078", "r2079", "r2080", "r2081", "r2082", "r2083", "r2084", "r2085", "r2086", "r2087", "r2088", "r2089", "r2090", "r2091", "r2092", "r2093", "r2094", "r2095", "r2096", "r2097", "r2098", "r2099", "r2100", "r2101", "r2102", "r2103", "r2104", "r2105", "r2106", "r2107", "r2108", "r2109", "r2110", "r2111", "r2112", "r2113", "r2114", "r2115", "r2116", "r2117", "r2118", "r2119", "r2120", "r2121", "r2122", "r2123", "r2124", "r2125", "r2126", "r2127", "r2128", "r2129", "r2130", "r2131", "r2132", "r2133", "r2134", "r2135", "r2136", "r2137", "r2138", "r2139", "r2140", "r2141", "r2142", "r2143", "r2144", "r2145", "r2146", "r2147", "r2148", "r2149", "r2150", "r2151", "r2152", "r2153", "r2154", "r2155", "r2156", "r2157", "r2158", "r2159", "r2160", "r2161", "r2162", "r2163", "r2164", "r2165", "r2166", "r2167", "r2168", "r2169", "r2170", "r2171", "r2172", "r2173", "r2174", "r2175", "r2176", "r2177", "r2178", "r2179", "r2180", "r2181", "r2182", "r2183", "r2184", "r2185", "r2186", "r2187", "r2188", "r2189", "r2190", "r2191", "r2192", "r2193", "r2194", "r2195", "r2196", "r2197", "r2198", "r2199", "r2200", "r2201", "r2202", "r2203", "r2204", "r2205", "r2206", "r2207", "r2208", "r2209", "r2210", "r2211", "r2212", "r2213", "r2214", "r2215", "r2216", "r2217", "r2218", "r2219", "r2220", "r2221", "r2222", "r2223", "r2224", "r2225", "r2226", "r2227", "r2228", "r2229", "r2230", "r2231", "r2232", "r2233", "r2234", "r2235", "r2236", "r2237", "r2238", "r2239", "r2240", "r2241", "r2242", "r2243", "r2244", "r2245", "r2246", "r2247", "r2248", "r2249", "r2250", "r2251", "r2252", "r2253", "r2254", "r2255", "r2256", "r2257", "r2258", "r2259", "r2260", "r2261", "r2262", "r2263", "r2264", "r2265", "r2266", "r2267", "r2268", "r2269", "r2270", "r2271", "r2272", "r2273", "r2274", "r2275", "r2276", "r2277", "r2278", "r2279", "r2280", "r2281", "r2282", "r2283", "r2284", "r2285", "r2286", "r2287", "r2288", "r2289", "r2290", "r2291", "r2292", "r2293", "r2294", "r2295", "r2296", "r2297", "r2298", "r2299", "r2300", "r2301", "r2302", "r2303", "r2304", "r2305", "r2306", "r2307", "r2308", "r2309", "r2310", "r2311", "r2312", "r2313", "r2314", "r2315", "r2316", "r2317", "r2318", "r2319", "r2320", "r2321", "r2322", "r2323", "r2324", "r2325", "r2326", "r2327", "r2328", "r2329", "r2330", "r2331", "r2332", "r2333", "r2334", "r2335", "r2336", "r2337", "r2338", "r2339", "r2340", "r2341", "r2342", "r2343", "r2344", "r2345", "r2346", "r2347", "r2348", "r2349", "r2350", "r2351", "r2352", "r2353", "r2354", "r2355", "r2356", "r2357", "r2358", "r2359", "r2360", "r2361", "r2362", "r2363", "r2364", "r2365", "r2366", "r2367", "r2368", "r2369", "r2370", "r2371", "r2372", "r2373", "r2374", "r2375", "r2376", "r2377", "r2378", "r2379", "r2380", "r2381", "r2382", "r2383", "r2384", "r2385", "r2386", "r2387", "r2388", "r2389", "r2390", "r2391", "r2392", "r2393", "r2394", "r2395", "r2396", "r2397", "r2398", "r2399", "r2400", "r2401", "r2402", "r2403", "r2404", "r2405", "r2406", "r2407", "r2408", "r2409", "r2410", "r2411", "r2412", "r2413", "r2414", "r2415

```

entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": { "r443", "r595", "r596", "r725", "r726", "r727", "r728", "r729", "r749", "r751", "r784" }, "us-gaap_RelatedPartyTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsLineItems", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r757", "r758", "r761" } }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "auth_ref": { "r595", "r596", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r725", "r726", "r727", "r728", "r729", "r749", "r751", "r784", "r1042" } } }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": { "r592", "r593", "r594", "r596", "r597", "r704", "r705", "r706", "r759", "r760", "r761", "r781", "r783" } }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Repayment of revolving line of credit", "negatedLabel": "Repayment of revolving line of credit", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": { "r44", "r11", "viti_RestatedEmploymentAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "RestatedEmploymentAgreementDescription", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Restated employment agreement description.", "label": "Restated Employment Agreement Description", "terseLabel": "Restated Employment Agreement Description" } } }, "auth_ref": { "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date", "auth_ref": { "r866", "r877", "r887", "r912" }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": { "r867", "r878", "r888", "r913" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require recovery" } } }, "auth_ref": { "r874", "r885", "r895", "r920" } }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": { "r51" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails", "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "verboseLabel": "Unvested RSUs", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "r51" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "totalLabel": "Retained Earnings (Accumulated Deficit) Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit) Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit) Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r119", "r155", "r664", "r690", "r695", "r702", "r733", "r845" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r191", "r246", "r247", "r248", "r250", "r258", "r260", "r342", "r348", "r481", "r482", "r483", "r493", "r494", "r520", "r523", "r524", "r527", "r538", "r686", "r688", "r709", "r1059" } }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "auth_ref": { "r282", "r283", "r287", "r290", "r291", "r295", "r296", "r297", "r433", "r434", "r633" } } }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognition", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": { "r184", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435" } }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Revolving Line of Credit", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { "r297", "r938" } }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new finance lease obligations", "label": "Right of Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right of use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r585", "r844" } }, "viti_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "Rule10B51ArrModifiedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "documentation": "Rule 10b51 arr modified flag", "label": "Rule 10b51 Arr Modified Flag" } } }, "auth_ref": { "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r929" } }, "ecd_Rule10b51ArrTrmndtFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmndtFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r929" } } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedStatementsOfCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfPercentageOfNetRevenueFromSignificantCustomersDetails",
```

"lang": {"en-us": {"role": {"label": "Schedule of Accrued Liabilities {Table Text Block}", "terseLabel": "Schedule of Accrued Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": {"r1": {"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfExcludedCommonSharesIncludingAntidilutiveEffectDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share {Table}", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": {"r51": {"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareTables"}, "lang": {"en-us": {"role": {"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share {Table Text Block}", "terseLabel": "Schedule of Common Shares Excluded from Computation of Diluted Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": {"r51": {"us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableForSaleSecuritiesDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Available For Sale Securities {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r306": {"r307": {"r308": {"r309": {"r310": {"r311": {"r312": {"r313": {"r314": {"r315": {"r316": {"r317": {"us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables"}, "lang": {"en-us": {"role": {"terseLabel": "Schedule of Component of Other Comprehensive Income", "label": "Comprehensive Income (Loss) {Table Text Block}", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref": {"r127": {"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareTables"}, "lang": {"en-us": {"role": {"label": "Schedule of Earnings Per Share, Basic and Diluted {Table Text Block}", "terseLabel": "Schedule of Basic and Diluted Net Income Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": {"r968": {"us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method {Table}", "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class {Table}", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": {"r50": {"r52": {"r265": {"r269": {"r271": {"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}, "lang": {"en-us": {"role": {"terseLabel": "Summary of Recognized Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount {Table Text Block}", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": {"r78": {"us-gaap_ScheduleOffinancingReceivableAllowanceForCreditLossesTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffinancingReceivableAllowanceForCreditLossesTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails"}, "lang": {"en-us": {"role": {"label": "Financing Receivable, Allowance for Credit Loss {Table}", "documentation": "Disclosure of information about allowance for credit loss on financing receivable." } } }, "auth_ref": {"r187": {"r988": {"us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureGoodwillAndOtherAssetsTables"}, "lang": {"en-us": {"role": {"terseLabel": "Schedule of Goodwill and Other Assets", "label": "Schedule of Intangible Assets and Goodwill {Table Text Block}", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": {"r61": {"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInventoryTables"}, "lang": {"en-us": {"role": {"label": "Schedule of Inventory, Current {Table Text Block}", "terseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": {"r24": {"r123": {"r124": {"r125": {"us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsTables"}, "lang": {"en-us": {"role": {"terseLabel": "Schedule Of Notional Amounts of Outstanding Derivative Instruments", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions {Table Text Block}", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": {"r86": {"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"}, "lang": {"en-us": {"role": {"label": "Property, Plant and Equipment {Table}", "terseLabel": "Schedule Of Property Plant And Equipment {Table}", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": {"r10": {"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Related Party Transactions, by Related Party {Table}", "terseLabel": "Schedule Of Related Party Transactions By Related Party {Table}", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": {"r106": {"r107": {"r757": {"r758": {"r761": {"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award {Table}", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": {"r446": {"r447": {"r450": {"r451": {"r452": {"r453": {"r454": {"r455": {"r456": {"r457": {"r458": {"r459": {"r460": {"r461": {"r462": {"r463": {"r464": {"r465": {"r466": {"r467": {"r468": {"r469": {"r470": {"r471": {"r472": {"r473": {"r474": {"r475": {"us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}, "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity {Table Text Block}", "terseLabel": "Summary of RSU Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": {"r77": {"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}, "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Option, Activity {Table Text Block}", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": {"r18": {"r19": {"r77": {"us-gaap_ScheduleOfStockByClassTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}, "lang": {"en-us": {"role": {"label": "Schedule of Stock by Class {Table}", "terseLabel": "Schedule Of Stock By Class {Table}", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": {"r63": {"r68": {"r69": {"r70": {"r71": {"r72": {"r73": {"r153": {"r154": {"r155": {"r203": {"r204": {"r205": {"r279": {"r409": {"r410": {"r411": {"r413": {"r416": {"r423": {"r698": {"r699": {"r700": {"r701": {"r826": {"r937": {"r960": {"vitl_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTables"}, "lang": {"en-us": {"role": {"documentation": "Schedule of supplemental balance sheet information table text block", "label": "Schedule Of Supplemental Balance Sheet Information Table {Table Text Block}", "terseLabel": "Summary of Supplemental Balance Sheet Information Related to Leases" } } }, "auth_ref": {"vitl_ScheduleOfSupplementalCashFlowInformationTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ScheduleOfSupplementalCashFlowInformationTableTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesTables"}, "lang": {"en-us": {"role": {"documentation": "Schedule of supplemental cash flow information table text block", "label": "Schedule Of Supplemental Cash Flow Information Table {Table Text Block}", "terseLabel": "Summary of Cash Flow Information related to Leases" } } }, "auth_ref": {"us-gaap_ScheduleOfConcentrationOfRiskByRiskFactorTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureRevenueRecognitionTables"}, "lang": {"en-us": {"role": {"label": "Schedules of Concentration of Risk, by Risk Factor {Table Text Block}", "terseLabel": "Summary of Percentage of Net Revenue and Accounts Receivable, Net Due from Significant Customers", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": {"r53": {"r54": {"r56": {"r57": {"r100": {"r161": {"us-gaap_SecuredOvernightFinancingRateSofOvernightIndexSwapRateMember": {"xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."}}}, "auth_ref": {"r1036"}, "dei_Security12bTitle": {"xbrltype": "SecurityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}, "lang": {"en-us": {"role": {"label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security."}}}, "auth_ref": {"r860"}, "dei_SecurityExchangeName": {"xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}, "lang": {"en-us": {"role": {"label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered."}}}, "auth_ref": {"r862"}, "us-gaap_SellingGeneralAndAdministrativeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited"}, "lang": {"en-us": {"role": {"label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."}}}, "auth_ref": {"r135"}, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRecognizedStockbasedCompensationExpenseDetails"}, "lang": {"en-us": {"role": {"label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."}}}, "auth_ref": {"us-gaap_ShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}, "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement."}}}, "auth_ref": {"r8"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Stock options - vest year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDfnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."}}}, "auth_ref": {"r838"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Share-based compensation award, description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."}}}, "auth_ref": {"r74", "r76"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."}}}, "auth_ref": {"r466"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."}}}, "auth_ref": {"r466"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."}}, "auth_ref": {"r464"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."}}, "auth_ref": {"r464"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Unvested as of December 31, 2023", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."}}}, "auth_ref": {"r461", "r462"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."}}}, "auth_ref": {"r461", "r462"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."}}}, "auth_ref": {"r465"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."}}}, "auth_ref": {"r468"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."}}}, "auth_ref": {"r465"}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfPsaActivityDetails"}, "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain

members defined in one or many axes to the table." } } } , "auth_ref": { "r446", "r447", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of new shares issued", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } } , "auth_ref": { "r446", "r447", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum number of shares issuable", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } } , "auth_ref": { "r840" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } } , "auth_ref": { "r75" } } , "vitl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award options cancelled in period total intrinsic value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Cancelled In Period Total Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Cancelled" } } } , "auth_ref": { "r446", "r447", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Number of Options, Options exercisable as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } } , "auth_ref": { "r455" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Options exercisable as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } } , "auth_ref": { "r455" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } } , "auth_ref": { "r468" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options Cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } } , "auth_ref": { "r1012" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options, Cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } } , "auth_ref": { "r459" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Options, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } } , "auth_ref": { "r457" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "PeriodEndLabel": "Aggregate Intrinsic Value, Ending balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } } , "auth_ref": { "r75" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "PeriodStartLabel": "Number of Options, Beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } , "auth_ref": { "r453", "r454" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Exercise Price, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } } , "auth_ref": { "r453", "r454" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": { "r469" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "TerseLabel": "Number of Options, Options vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": { "r469" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": { "r469" } } , "vitl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfNumberOfSharesEarned": { "xbrltype": "percentItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfNumberOfSharesEarned", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award percentage of number of shares earned", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Percentage of Number of Shares Earned", "terseLabel": "Percentage of number of shares earned" } } } , "auth_ref": { "r446", "r447", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of outstanding common stock", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock" } } } , "auth_ref": { "r446", "r447", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" } } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfPsaActivityDetails",

"http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails",
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsuActivityParenteticalDetails",
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
 "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } },
 "auth_ref": { "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470",
 "r471", "r472", "r473", "r474", "r475" } }, "us-
 gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label":
 "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average
 Exercise Price, Options Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } },
 "auth_ref": { "r458" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype":
 "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label":
 "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average
 Exercise Price, Options Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } },
 "auth_ref": { "r457" } }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement
 Performance Shares, Activity [Table Text Block]", "terseLabel": "Summary of PSU activity", "documentation": "Tabular disclosure of number and weighted-average grant date
 fair value for nonvested performance shares." } } }, "auth_ref": { "r21" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": {
 "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod",
 "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Stock options - date of grant and expire", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
 "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one
 year, five months, and thirteen days." } } }, "auth_ref": { "r839" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Aggregate Intrinsic Value, Options exercisable as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable,
 Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options
 outstanding and currently exercisable." } } }, "auth_ref": { "r75" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Weighted Average Remaining Contractual Life (Years), Options exercisable as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment
 Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options
 outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and
 thirteen days." } } }, "auth_ref": { "r75" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
 "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label":
 "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted
 Average Remaining Contractual Life (Years), Balance", "documentation": "Weighted average remaining contractual term for option awards outstanding, in
 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r156" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
 "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
 "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Weighted Average Remaining Contractual Life (Years), Options vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation
 Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation":
 "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents
 reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are
 expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r469" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based
 Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested", "documentation": "Fair value
 of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": {
 "r468" } }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsuActivityParenteticalDetails",
 "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" }, "lang": { "en-us": { "role": { "label": "Share-
 Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "verboseLabel": "Shares of common stock withheld to cover taxes", "terseLabel": "Shares
 withheld for tax liability on vested restricted stock units, Shares", "negatedLabel": "Shares withheld for tax liability on vested restricted stock units, Shares", "documentation":
 "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": { } },
 "vitl_ShippingAndDistributionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "ShippingAndDistributionExpense", "crdr":
 "debit", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited" }, "lang": { "en-us": { "role": {
 "documentation": "Shipping and distribution expense.", "label": "Shipping And Distribution Expense", "terseLabel": "Shipping and distribution" } } }, "auth_ref": { } }, "us-
 gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" }, "lang": { "en-us": { "role": { "label": "Short-Term Lease
 Cost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref":
 { "r582", "r844" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "SignificantAccountingPoliciesTextBlock", "presentation": { "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
 "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire
 disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r144", "r241" } }, "vitl_SixthAmendmentMember": { "xbrltype":
 "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "SixthAmendmentMember", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Sixth amendment",
 "label": "Sixth Amendment [Member]", "terseLabel": "Sixth Amendment" } } }, "auth_ref": { } }, "vitl_SoybeanMealMember": { "xbrltype": "domainItemType", "nsuri":
 "http://vitalfarms.com/20240630", "localname": "SoybeanMealMember", "presentation": {
 "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeIn

"StatementOfIncomeAndComprehensiveIncomeAbstract": {"lang": {"en-us": {"role": {"label": "Statement of Comprehensive Income [Abstract]"}}}, "auth_ref": []}, "us-gaap_StatementOfStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": {"en-us": {"role": {"label": "Statement of Stockholders' Equity [Abstract]"}}}, "auth_ref": []}, "us-gaap_StatementTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfAccumulatedOtherComprehensiveIncomeDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfComponentOfOtherComprehensiveIncomeDetails", "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."}}}, "auth_ref": [{"r246", "r247", "r248", "r278", "r633", "r697", "r720", "r724", "r725", "r726", "r727", "r728", "r729", "r732", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r746", "r747", "r748", "r749", "r751", "r755", "r756", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r777", "r851"}]}, "ecd_StkPrOrTsrEstimationMethodTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ecd_StkPrOrTsrEstimationMethodTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method"}}, "auth_ref": [{"r869", "r880", "r890", "r915"}]}, "us-gaap_StockAppreciationRightsSARSMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."}}}, "auth_ref": []}, "us-gaap_StockCompensationPlanMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"}], "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Shares Available for Grant", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."}}}, "auth_ref": [{"r969"}]}, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."}}}, "auth_ref": [{"r14", "r116", "r117", "r155"}]}, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Vesting of restricted stock units, Shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."}}}, "auth_ref": [{"r14", "r116", "r117", "r155"}]}, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails", "http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, Shares", "negatedLabel": "Number of Options, Exercised", "documentation": "Number of share options (or share units) exercised during the current period."}}}, "auth_ref": [{"r14", "r116", "r117", "r155", "r458"}]}, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."}}}, "auth_ref": [{"r14", "r116", "r117", "r155"}]}, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Shares withheld for tax liability on vested restricted stock units", "terseLabel": "Vesting of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."}}}, "auth_ref": [{"r14", "r155"}]}, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": [{"r14", "r36", "r155"}]}, "us-gaap_StockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}], "lang": {"en-us": {"role": {"label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' 2019 equity attributable to Vital Farms, Inc. stockholders", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."}}}, "auth_ref": [{"r117", "r120", "r121", "r146", "r734", "r750", "r778", "r779", "r845", "r859", "r962", "r987", "r1039", "r1059"}]}, "us-gaap_StockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"}], "lang": {"en-us": {"role": {"label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' 2019 equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."}}}, "auth_ref": [{"r79", "r80", "r82", "r191", "r192", "r224", "r246", "r247", "r248", "r250", "r258", "r342", "r348", "r424", "r481", "r482", "r483", "r493", "r494", "r520", "r522", "r523", "r524", "r525", "r527", "r538", "r557", "r559", "r563", "r591", "r687", "r688", "r707", "r734", "r750", "r778", "r779", "r801", "r858", "r962", "r987", "r1039", "r1059"}]}, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStock"}], "lang": {"en-us": {"role": {"label": "Equity [Text Block]", "terseLabel": "Common Stock", "documentation": "The entire disclosure for equity."}}}, "auth_ref": [{"r152", "r242", "r408", "r410", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r424", "r529", "r780", "r782", "r802"}]}, "us-gaap_SubsequentEventLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."}}}, "auth_ref": [{"r564", "r600"}]}, "us-gaap_SubsequentEventMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, "auth_ref": [{"r564", "r600"}]}, "us-gaap_SubsequentEventTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."}}}, "auth_ref": [{"r564", "r600"}]}, "us-gaap_SubsequentEventTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, "auth_ref": [{"r564", "r600"}]}, "us-gaap_SubsequentEventTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, "auth_ref": [{"r564", "r600"}]}, "us-gaap_SubsequentEventsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": {"en-us": {"role": {"label": "Subsequent Events [Abstract]"}}}, "auth_ref": []}, "us-gaap_SubsequentEventsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEvents"}], "lang": {"en-us": {"role": {"terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."}}}, "auth_ref": [{"r599", "r601"}]}, "us-gaap_SubsidarySaleOfStockAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidarySaleOfStockAxis", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}], "lang": {"en-us": {"role": {"label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock."}}}, "auth_ref": []}, "vital_SummaryOfSignificantAccountingPoliciesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary of Significant Accounting Policies [Line Items]"}}}, "auth_ref": []}, "vital_SummaryOfSignificantAccountingPoliciesTable": {"xbrltype": "stringItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]"}}}, "auth_ref": []}, "us-gaap_SupplementalCashFlowInformationAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [{"http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}], "lang": {"en-us": {"role": {"label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information."}}}, "auth_ref": []}, "ecd_TableularListTableTextBlock": {"

"xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "tabularListTableTextBlock": "Tabular List Table", "auth_ref": "r909", "us-gaap_TaxesPayableCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "lang": "en-us", "role": "label", "Taxes Payable, Current": "terseLabel": "Income taxes payable", "totalLabel": "Taxes Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": "r28", "vltl_TenthAmendmentMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TenthAmendmentMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Tenth Amendment [Member]: "documentation": "Tenth amendment.", "auth_ref": "vltl_TermLoanAndEquipmentLoanMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TermLoanAndEquipmentLoanMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Term Loan and Equipment Loan": "label": "Term Loan And Equipment Loan [Member]", "terseLabel": "Term Loan And Equipment Loan", "auth_ref": "vltl_TermLoanMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TermLoanMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Term loan": "label": "Term Loan [Member]", "terseLabel": "Term Loan", "auth_ref": "ecd_TotalShareholderRtnAmt": "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Total Shareholder Return Amount": "terseLabel": "Total Shareholder Return Amount", "auth_ref": "r901", "ecd_TotalShareholderRtnVsPeerGroupTextBlock": "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Total Shareholder Return Vs Peer Group [Text Block]: "terseLabel": "Total Shareholder Return Vs Peer Group", "auth_ref": "r908", "us-gaap_TradeAccountsReceivableMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAccountsReceivableMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureAllowanceForCreditLossesScheduleOfChangesInAllowanceForCreditLossesDetails", "lang": "en-us", "role": "label", "Trade Accounts Receivable [Member]: "terseLabel": "Trade Receivable [Member]", "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.", "auth_ref": "ecd_TradingArrAxis": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement [Axis]: "terseLabel": "Trading Arrangement", "auth_ref": "r928", "ecd_TradingArrByIndTable": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangements, by Individual [Table]: "terseLabel": "Trading Arrangements, by Individual", "auth_ref": "r930", "dei_TradingSymbol": "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "Trading Symbol": "documentation": "Trading symbol of an instrument as listed on an exchange.", "auth_ref": "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureDerivativeFinancialInstrumentsScheduleOfNotionalAmountsOfOutstandingDerivativeInstrumentsDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails", "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails", "lang": "en-us", "role": "label", "Financial Instruments [Domain]: "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "auth_ref": "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r406", "r421", "r528", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r673", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r983", "r984", "r985", "r986", "ecd_TrdArrAdoptionDate": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement Adoption Date": "terseLabel": "Adoption Date", "auth_ref": "r931", "ecd_TrdArrDuration": "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement Duration": "terseLabel": "Arrangement Duration", "auth_ref": "r932", "vltl_TrdArrExpirationDate": "xbrltype": "stringItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TrdArrExpirationDate", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trade Arrangement Expiration Date": "label", "Trd Arr Expiration Date": "documentation": "Trade arrangement expiration date.", "auth_ref": "ecd_TrdArrIndName": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement, Individual Name": "terseLabel": "Name", "auth_ref": "r930", "ecd_TrdArrIndTitle": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement, Individual Title": "terseLabel": "Title", "auth_ref": "r930", "ecd_TrdArrSecuritiesAggAvailAmt": "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement, Securities Aggregate Available Amount": "terseLabel": "Aggregate Available", "auth_ref": "r933", "ecd_TrdArrTerminationDate": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "Trading Arrangement Termination Date": "terseLabel": "Termination Date", "auth_ref": "r931", "vltl_TwentyTwentyEmployeeStockPurchasePlanMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Twenty twenty employee stock purchase plan": "label": "Twenty Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan", "auth_ref": "vltl_TwentyTwentyEmployeeStockPurchasePlanMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails", "lang": "en-us", "role": "label", "2020 Employee Stock Purchase Plan (2020 ESPP)": "documentation": "Twenty twenty equity incentive plan and twenty twenty employee stock purchase plan": "label": "Twenty Twenty Equity Incentive Plan And Twenty Twenty Employee Stock Purchase Plan [Member]", "auth_ref": "vltl_TwentyTwentyEmployeeStockPurchasePlanMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Twenty twenty equity incentive plan": "label": "Twenty Twenty Equity Incentive Plan [Member]", "verboseLabel": "2020 Equity Incentive Plan", "auth_ref": "us-gaap_TypeOfAdoptionMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": "en-us", "role": "label", "Accounting Standards Update [Domain]: "terseLabel": "Accounting Standards Update", "documentation": "Amendment to accounting standards.", "auth_ref": "r189", "r190", "r191", "r192", "r193", "r249", "r250", "r251", "r252", "r261", "r301", "r302", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r373", "r401", "r402", "r403", "r491", "r492", "r493", "r494", "r504", "r505", "r506", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r550", "r551", "r553", "r554", "r555", "r556", "r565", "r566", "r571", "r572", "r573", "r574", "r587", "r588", "r589", "r590", "r591", "r634", "r635", "r636", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "us-gaap_TypeOfArrangementAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]: "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "auth_ref": "r507", "vltl_USCorporateBondsAndUSDenominatedForeignBondsMember": "xbrltype": "domainItemType", "nsuri": "http://vitalfarms.com/20240630", "localname": "USCorporateBondsAndUSDenominatedForeignBondsMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails", "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails", "lang": "en-us", "role": "label", "U.S. corporate bonds and U.S. dollar denominated foreign bonds": "documentation": "US corporate bonds and US denominated foreign bonds": "label", "U S Corporate Bonds And U S Denominated Foreign Bonds [Member]: "auth_ref": "us-gaap_USTreasurySecuritiesMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureInvestmentSecuritiesScheduleOfUnrealizedLossAgingForAvailableforsaleSecuritiesDetails", "http://vitalfarms.com/20240630/taxonomy/role/Role_DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesDetails", "lang": "en-us", "role": "label", "U.S. Treasury": "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "auth_ref": "r814", "r834", "r836", "r1051", "ecd_UndrlygSecurityMktPriceChngPct": "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Underlying Security Market Price Change, Percent": "terseLabel": "Underlying Security Market Price Change", "auth_ref": "r927", "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualRiskOrUncertaintyByNatureAxis", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Unusual Risk or Uncertainty, Nature [Axis]: "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of a labor force at a reasonable cost.", "auth_ref": "us-gaap_UnusualRiskOrUncertaintyNatureDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualRiskOrUncertaintyNatureDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Unusual Risk or Uncertainty, Nature [Domain]: "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of a labor force at a reasonable cost.", "auth_ref": "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityunaudited", "lang": "en-us", "role": "label", "Variable Interest Entity, Primary Beneficiary [Member]: "terseLabel": "Variable Interest Entity, Primary Beneficiary", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "auth_ref": "r81", "r509", "r510", "r513", "r514", "us-gaap_VariableLeaseCost": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "lang": "en-us", "role": "label", "Variable Lease Cost": "terseLabel": "Variable Lease Cost", "auth_ref": "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "us-gaap_UnusualRiskOrUncertaintyNatureDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualRiskOrUncertaintyNatureDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Unusual Risk or Uncertainty, Nature [Domain]: "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of a labor force at a reasonable cost.", "auth_ref": "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "lang": "en-us", "role": "label", "Variable Interest Entity, Primary Beneficiary [Member]: "terseLabel": "Variable Interest Entity, Primary Beneficiary", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "auth_ref": "r81", "r509", "r510", "r513", "r514", "us-gaap_VariableLeaseCost": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/Role_StatementCONDENSEDConsolidatedBALANCESHEETS", "lang": "en-us", "role": "label", "Variable Lease Cost": "terseLabel": "Variable Lease Cost", "auth_ref": "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "us-gaap_UnusualRiskOrUncertaintyNatureDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualRiskOrUncertaintyNatureDomain", "presentation": "http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Unusual Risk or Uncertainty, Nature [Domain]: "

```

{"type": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {"lang": {"en-us": {"role": {"label": "Variable Lease Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."}}}, "auth_ref": {"583": {"844": {"us-gaap_VariableRateAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Variable Rate {Axis}", "documentation": "Information by type of variable rate."}}}, "auth_ref": {"us-gaap_VariableRateDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Variable Rate {Domain}", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."}}}, "auth_ref": {"us-gaap_VehiclesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/Role-DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {"lang": {"en-us": {"role": {"label": "Vehicles {Member}", "terseLabel": "Vehicles", "documentation": "Equipment used primarily for road transportation."}}}, "auth_ref": {"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": {"lang": {"en-us": {"role": {"label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted average common shares outstanding lu2014 diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}}, "auth_ref": {"264": {"273": {"us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/DisclosureNetIncomePerShareScheduleOfBasicAndDilutedNetIncomePerShareDetails": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": {"lang": {"en-us": {"role": {"label": "Weighted Average Number of Shares Outstanding, Diluted {Abstract}", "terseLabel": "Weighted average common shares outstanding", "verboseLabel": "Denominator", "auth_ref": {"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {"http://vitalfarms.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeUnaudited": {"lang": {"en-us": {"role": {"label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average common shares outstanding lu2014 basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."}}}, "auth_ref": {"263": {"273": {"std_ref": {"r0": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-1", "r1": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1", "r2": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12", "r4": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r5": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15", "r6": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481071/942-405-45-2", "r7": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r8": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r9": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r10": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r11": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1", "r12": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r13": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r14": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2", "r17": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2", "r18": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r19": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r20": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r21": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r22": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r23": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r24": {"role": {"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1",
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]~~1WB1+!W.~@;6\$<>LH\$*15.,26\$5M>>2F-59XQC92#*ABR22K:B1_9&R M 6_+&1D.5 JI=4IDQ2#Q_5Jv916;20J0_/135 Af_=R<:;#QB=G M165.0CK-6G-1M-DQ/MJ2.N+1-0-~~

[illegible]

Y:ENQNF&+MM-1MOH:P66RKY69-1MHUC+7:PF+-1MO-V8>SDY<:H:5P1\$BDD01UALS1L ME9-8,EN+H%U-1K17/R-/AFTX?<@>@?2,FI)JG<#@12%Q16GH64)H
M18\$+?>NFSM1)1)2D,(\$Z&X3YB+66\$?XUD\$4YF+U>+>#RYJ+>1J3M1BWA-1,86WAYG1:QCG934\$R=U?3-DRE<X?>1D"O28BP1?9#1VE[PW\$+-5\$
7%<C:OX+>A)=4XU1T2\$C9E M1.@#Y\$SEB+<HN8A8,VZ>-RU/H/AEPPAY-2\$ KG:17Z?N-4-7-1/1T-2"XWV+HUL\$?>#T6>3.3&1TJXGR"=4JM3H\$4
GGK<BT0+>A)=Z2<94,SHI&S4,BN<8#<-MN1B1P5D/6F7CXK127KO-EVYF+>1-1WCY+K1=H%>?1,JC"1&I93WA8K-Lf61C3X1&O16EN\$M PYX-1?>10-I0A+5\$2
(H10=U8A"XA"29?<@>18A)29?<K0>+<KG,ZB12+>10%LL1V+>1<QGLT1L M-8NUC73=K0HE+U6AF0BAE=+1#H-?>C&3-?7BK&?>3T3P)B16#4#8RX<M#>PES
?F-56&U1U:-R,OY1PW/31-FOFKBN1R6TMT-E1CEC<CQW1<VOT76-PYQ\$46O@1IT-N?>1YGO7H M1H1D1<91.K1<9S\$<8<1O-N-1(GG-?MV/0?1-3OU-PG-W2=M4Y'E,+2M?<ZK,N2?>-GG-2Q?>2PSLN A5GCHA55M1,GR<1E1CF#>S+>1J&+>1LK=6M+>MY

[illegible]

[illegible]

[illegible]

71PYP8PHJG8D1TV2:4T4A:Q1Y5SD:6M&MEI243CB2JK:0.89/W3_Q_ELO_Q#KJ:AV/3:Q&Q#NS:GJJS=YMTSHZ7N8.R3JOHJ&9N1H=6.G0T%8%<Q\$
L16Q6FJ:0Z22@<MIN9Q&WTP&XSLR43Q:0D:P=H6N9655<Q?>75*Q@<M81&FGR16EJ>6A-SG5Q7W3J@VVUQ>?#1=I(67H4I2=<N<L1%#X%G+Q
M#4#RZAA3Y1SB+L#8C@.6MYP4#4SRPVK7HHK06C:CH3M'WM'QE:1+@U:5L1Z2.8YBN1F7J5Z/LA:(H02PIBEPMA@C/F8XGTS&XRRL>?>96M9@/GSVHAM9Y^>9
QMJ4UL2POXXGEC.SAW#1%#M2I.GTAA+V>Q1T-.0L.SY7K@MZDZL1&LMT+Q1FR21MDG2@<7X0ISOUZM3N+13BZC0+N9P10HK4
H1+OP9016>3WYHX1Z2G6&@PL611LYNH>Q1H1M@I27YFE95JLHWIYEAZHTGMC:Q(Y<1=2.BXH0H0)KCN:Y?PH9:20664&EO4M+RA@KMF*62
*K169U2G7IM1P#AY.MHJW=I2RNI1P?>ON>V@H1K&RDXFMJ&Z3&S>HDK-6S0D&I&UZMKO.7PMLMPH<@W*U1I+D'GZ79L_V%K
9EMQJFP32X15G0K@EZ&N@01)M&CDBT%GFM51K7ZDSZX+&D1F1M05X#B-1NXG0.TIBH01I1Z4#RB2K-K4L4XFF1FPAPAJR_%(65+GC9MLA/0R
H1+P61ZGS@>17XG7JH1R2>4HR.P&Z1NH-IGXYPZP26Y.M-M-9HPY?>1Y7K9L.G%Y0=>NDUURTS*0M@K410X0MUCIHF?>3CT6:6.MCIP>17_)=
(#6UPBR07=>C2EEN1_.#N81<41.75.8>2G&A.Q2C10XSP1LM12DK4K188CQ10KZFV1@'BQ.H1LV&W2P2K#9C1@EP90>4Q7QW)V?>NH)M1J61BHJ3?>NKF4UD8M
1A93#R1595:0?>8MI982L2C6GWXE@GUC&A.YQCMWGRK<@<03-Z0J1SHQ)EOC.C&SW6Y1BVU0ULEO'G<?>6N1690QJ1M7W1M?>TH(8714M#++M&%.#>PP0Y>Z5+1P?T
@EINE#J6D14F1%3XYM.M.Q1N&S?>Z4Y01L'X0T_...S2@DU01261GQ:US6BN2=>KR>IK3.KHRFP81<M0
Y6#KCN2P1&F&#H1&XJFON<?<J&S&SHO1&A/XDH&E1XPU3.KD'FUP.M.LGQ'KX'>K&A463L30@FFV15?>0=5@F.OJND3HCY:CL-BSL>=>#LPP6
MH2#>343A9R10J:R>X-L'>DG'SSFGVY>#>15_>H?>XN>LEMGMA1'Y(W-M2=EBW7B'>W&KZB8/ZJCE1U39H@>3BH(A1-RP'CGMK^>)>151#R4C#P+S*5^G-MX#?>DV-E
XG7JMN174D2.E325M2C26H1'AHGCE143+1+D#E.Z25T1+G62>7-5JRD2D1@>1'6LCVQ0+&R<@>M>F&#WLE1=YQD00Q@EX?>?>0E=O/VQ0QM9
5K9LK4E2&5#1@>S1V>01FD+P+J1M7Y8IC@HSPQOC09N'G@T1%31%U4/RZC&S&C9:(<10B'4'>KJ61U->?2MJ'XCOJF6.8%<@>1%?>TOHPH@M02="R/UMI3<V^Q-
S>PU&8-AF5J0&@>E&F&OW<55G'UZYNNR&@>HPC.BLG.M-3VU>OHUHRH@IRS'>TX3Y1125'LDZ342'>5LA&DN4V20M0%>AQNWW#2S1P.MGL?>
L-27272F#>9)51-D***RPI1Q@2&W:9D9Q.&5F3I>3KYV5X-K8.H.M#E5Y(CR'7D'>2F&SCTZ-HG;D2'502'KBS'>7-ELYD<9&OHP3'>PKXK<SD+01M<?>OJG
*1Y4I&>K7&K150#X13FYL6#B#X:HMN980)3:(P=PU*Q%069H>?>M*(6'F1)7(HK1?>13B'T@PHI>?>S'V3BYA<?>#G%\$M=A:TA7X17X)M:<@>f>?>XV8>46.IXVO/W#>@>?
871+&F'@P1AN#4'M6G14J<LZ.M-X&H'&S<@>7XB7RQI?>F1@>PQ>ND2@>A21SIAZ'>1E<>Y68U?>XUMY7'>C'KK41G1L\$1Y>?>ZYE&51>#>6M1'0HME1=91-
X&PBG81L.MXW<0>IDEU?>Y=D#=>627ZM&6G-AW'>4Z<(XUHU1GX>?>(ZHR)&R0'0MCL1N7H2'>XOY5K5H2'>K&D\$1=>GL-9V1U?>Z6E&1QH2#>0EN1'NOH1X
MOJNFH2NE1+FY50P&K2L'>LZBQ6C@<W31K4R09L\$1S#7AG1@<6K1Q0>=>F4K7M1UC&OPZ'U9X+&@&P&P=>1Y#DH8&S.E0670S>7R5YH74M=0%7\$>6EB
(20W.Y715<?>3J6X3ALR2&L'N&1_#>K57CL6PG.MAES.0D3N#>H&S7FSI0F'9X>=>EAK4EAFW&S&GL9XLS0B.FY<?>HX'HX&M1CX&S#H-MW'/(BS'.9Z#BIS@>P&EWJ08'MMH1
47VD&B4ANDC1Y#<@>JN'Q72&47H"MM-RJW>4QBAAJ6>70A1#1-/O-U18B.L@>ZOZIDGX&7KO(&1H7'YHYVD0M8-M8ZIQ
M1L6RDL1X1U1Y&S5'4F03CKWLK755AZN0Q+1Z+N&W=VSO5'QKH5)U&@>0P1&59VYV5O9ZCF751TFB47%P1_SJ=8W.MP
>0&AY&72>4J50_>1J&15UYJPJ\$>GEU'>1'>DQ>S1'>LPHHG24JBT2L7J-(M(8N6N#Q+<#>FS#51L8Q64195G1MN-XN1+Y+>1DM
R#<=>6&C1L31SACHOS#>P'DI0LO101N=>3RDLMR2'2'=>M1_6X7NXC6&B1B8-2X>VY0X+1>ST6+FN->Y(S(NR7#N'<P+>?>C23TF
M&P'>0Q6B1'>L1_MY=>@93_1Y7GXGN/00LHN-MK'53YX1>=>2*1K27TA&#&4B'MX&X-R3A1@>12-T8@>VF2J1>1NVU3ZJ60R.GGU.MXGCI?>Y<_>A'YXMI@IRV
2.MA1Q0R.1YD.3FXQ'@>X'0UGPS\$>2YBZ8PG.M1'8K%P@IDWFH'E8\$BO+343L9MZESHN)2=WS8N9A/7%PMGXH?>3Y)-1LJ920-VO(VEGB3-MH3MTAG.\$Q9V
15SWX%1%#37XW51CMYR1WG21#W4.1C'>F2%=>0.6WYX1H#>1YSV1U>#1=[N9-01&1\$K'W
M@=>HNQ03R01#1W=92WXXA31YBP46&AC9EKF<@>MPSYV>?>MHHR7FD2J+M1M.COFS1132TEU_HV>HMMWUYG:2=TD36GW5NF(TSA.KI&IK33@)Q0M-AL3Y42I#N%<
<0.46E1FW6C5_L4'>1YSYSJ'>#G6MIWH1TU2-UESVYQ1Y+H/7N1'Y7I)K'>P#SW71MY5HW9>0^4<2ZUUD4
M18.D-1=>S&9FL12_4&L1G&H16.ONLW75=>H&4'>COT2JH1Z12.3CT4FE MZDBC=E272JH1<L4.TD=>4>2W153W1T:(03@>?)@D'AZ.YE'HA4+E3>2
MOOQ013NP?>7U.DZK?I'>QYVW0:=>G00&#>PAI-B=71ZD1'8**B14M#H#HN#T'RS.G<@>HM4DY6N/TE21'U-31&OILL51C\$+@>IES.VL2A**>^N-M.\$>
MQO-613'U/(&QCE24'D0_>QZB#VYW26Y1G'>@>N#R0&015AZN1475>=>S1P'M^X'FHEH?>013'=>NSF(QO)Q1'>F&BDJ18YVC1NPW=Y'>#13'G&M:07?>
5F495GFM7M1EQM41'>UO"Z5CBHT1A84Y12#21#RT37PRU>)>K1=M'Y8GE.CYL.9@102-11UPX1R@OJRDRE1F8N>@>Q3B6TL11H0W2?>#B M6&APA-6'>Z6&JG1?
P'QMDYBP.06E0F'>L1+16Z6IE9Y08B'>FEK7'>BA-MJ8-1+6LH2MNM5TU91+ZC1H4C'BE18F01'61CJ5H12>=>KX+AWXFE/ MO/O&G.67RC=>5&4HFE9+&35#
588H&5TFENBJR'>#94C1#PDT1XUMJYJ-C.D5H1ORF#M1Q#3Y9<6\$>CJN37H4F<@>21BK06J.M1M1A<8B'>NNX+D&A.FB.E2Z

[illegible]

M9-K:9X"DIK08:91<4 G6&5H63P:9AW17L3U3B+U+ISF2(G:S)B)W-M(0-P"NO3"UV15X"U"OZJL&S1"NM-VG19483.DG00-F3<@'GR44BEF4'
M5:X\$7-LPJ\$JG(7H0C4V4E0+Y.U.IMGAKNYA).(OBCG"J"J%A*F=JO(AI MV&S=Z)-6\$XNO<JBA<PUDEVX+Y+P+OW6\$H<+>Y7D<IN<9&EC7(OGP MQ(0L1SCW5?
EQ5/72/QF=F.SPK)UQ4P17 MP72PO:FSB6A'U'Y CB6:3%<@>1HC6MV&S=7R747Q.P.9OB<=>E7&7HRS>P17-C>P>F<KJ<LZD>+GZ A4+QT M'W<W&GWRH'DWRQ?
Y)YSDQ0W+186%UW.Z97LZVZR IM=1JZJ&SPQAK MN3SN MJN+LJHRAGE1%ECMA+T1(J1N0QEA42GNIDHDXVXV6'6)1G1<=POX%G(YV1 MJ U31+95C<NTD=051W'<K
DZ= L8P3Y+18P(0(CMXM21J1) 6V8IH(S M Z1Z<@JAN.1'190(1'1H'OT'Q(0<193C<@RX1U'6JNLA.FWW15H03:M P#D#28#3X)8GES1HK90<=L YCE355B.0L&?<
\$1#H0B(W7.01)H=>0TH14 MU'7&B<U6 J9073LQUF>JLZ<+D 9T23THVL.S.0\$=>Y)N Z6NYZVJL MY MX1D7LDD=>C0.C6)00@5YES4H'<0.0&1P+Z+H.JHC68;IF=KZV7
KY2GRS" MJ.Z201'IP ZIDGH<9"=>G3HQC<BFLZ<+>2F81<9 IKZ3L.W7FE.XF X84 MHG<D1(6I4A.Y0ISQX<+UG1.D0G<5SK'U(01745-L2<=>HHI)>IKZYVZ6<
MOW7C6C@>RIZU7F7#H H.E'8'W+X9T1.EB7A'Y&K<+2F8'T9'7'5=> MV4Y>Q@3.CZNY&C.ZZ2:1U=KRN9ZS:SS8H7ELP=5TV7 F.HQ6D% S.M2M
RL1@H1C<S8:XWO:5L1 M&P+U6 WQHJYK JY(7WKO10)15C@<L6G'<3\$>0>IM'E'&M'&F0P(TW59>Z70'E1AXOQ(0IOWH)ADW0A5 1Q0H8>1QH<7Q'6ZX1U1 M<
Y<D+01(PLK2<CGUMOWKA'7Z5<5 LHQ2YV4BXO(C-W7)H'>H'Y3A' M @2SRT1@ G1'92'EE F11L8ALCH57D<7Z=X> RLZ7 RH63.061<QMK8Z1<+> NV
M+UHV8G3VMP+0J9.8YVW<C PUA BB&G=62:B<12QWZYBI(S7J2'XZ\$Z1 M'0IOBGS1#17-6RYV(3\$K5\$B%7T5DUHR8:#\$=3H&P'YVB>7:01/7@ M2(Z21.A4&(YV16f6
ZEHHMM0 (46+>SD2H<D1X8H'>H<+>3P7K64HX'X' P252:NQ'<M'<MROPG7CHDL M21A'=>P'ZZZ1(K<L'>JH'YJ(CI8C<=F7B8B9>#3M.6H45 B3FE13A8H' M
ISA:W+>S'J.HP<QOF<X'F>@/21<+J7<0 (3#<Wk13T'>WB'<@>1.0ZB ME W1C1J2:1% (P7P'<=>Z7P'<=>J%4GT7Z681J.S5?+U0<L0&2 U=2 M2.FW36'SUAV<^Q4 M+G6<
>7DFXZ<P1T7L D1'>H+>:1=160)AMRBBGR'7M(21<3BYAD0FT MP2'>14Q3%5JC.86CPD11.180DAS1)KD.(9'>8W@00'P.Y+>+>QC6'31 M'1815IUTK'2LX44>7\$ (SLVYE74<+>%V
<@>DWA'>C300N(H1 F0Z2PD'0H M1E'>MZ8181EHY5XU337Z52A(MNV>13C.R05Y5Q&0<+H1H'<@'6IXK5H1C@>AD RW.U9PH& MPA+61<1'>@>7Q'TD7.K3Z2/SLO0'<1'>
<KJY<631.UYB4 H<+>H78>S M'F1/0/BP'>A' D1'<C' E.W1@>C'0P.DYVR<C'>TH'W031@'1#>3>HOXJNYU010K M2.&#N.405X9R/G RLIS1E+AXD7(181+>1
<RBE'>N1AIOX8X\$13.1K5<0 S.O'F6 L1<5-BFG6'<+>G0.M1P AMM'82H2HTU1A.13 ZCU.HJH'6'P'Y'V2Q M6BA14(R.LG<+>L'>6H890.F.HY.K5JR&#(1
I9KN21'>N'ZF<SQ58UR)D1= M'C-8G6-&ZFX0#1\$U%3TY.L#0AH329)@>V7.L6EY@IP0F05Z08(9H7+>M1O105MPTCNU9C1)RZS 9#<K=GNE
MHUA=>UK90'Q2<0'0.K5LIM6K'K84(1'>74R16M.S'8U<+1'>V4'>1@>10X MYN'YU'>@>HHR06H.KT+U'>U020R<PWGK9@PU M<8(RW+>W&18(1ZV6F9
<RJR&S0B00)G1G76.18H1KEE'XN@<#>UUY1 M'>E'>U&A&A2 T 0A@>1H VR30DT L.ZG<8'>1'>V5E3T4=1A1 M'>T'>U'U51F1A1F7Y1SL1(Y1+>1X8HMM51 7)DFPQP'MK@H33?<
T.E86LF0 M6527Q20Z7BPPNS'00Z>2=2M7.DIG0:2U0L56&271M'>91K6L75Q7U09 M00GRS5'<5\$Z2>D'DIZRE DU<+>1H.G6L9L9L6)6X.M0(08BP>91-TB=DT M'>O'>Z9>
NBR813BE.61/61.ARW1X&MYK<K=3<2G.Y0>Z>Z<9.ZW.TK1EWF'<5X8<=>Y3F7HCPK.M1 ME6=>1X0'L229331A.RSNI77TQUB06&3OP'<+>G(AUANOJEGIAUHE40#>+>+>
MELTZXI@1X2ID0A 802ICM)V\$P#Z:Z\$PC5 MWZIJ&I(WWKFB/@.46V73GE 01E'>IUG4(6#L48DHX65 # F-D+1)10>&5AG M<5.0T'G+1 KP=RX(P'<=>011'>VC:08=>*RVY
=>PR.U5C'U'09C'P'02 M=>E'>P'<=>P'<=>BSNQ<@>319YB0BV@D1'>7 TD7@>@>#>3'>VPB@>P'>F'>M'5&E13>RL+>E
Y<M1@>EWT1'ROW&9S@>1=2J+74#ESN&S<@>SDIAD19X.U'04X15U/0P=>M2U)U-R-Q+955MC040BHO10H842<L'>YHQT'>1U:##>NML1'9<7'>1\$ MC=UG#1J5'>
1Z1Z A'>6Z'>BC60C8'>T9712'>1(82.Y4'>7K13N8.6W'>@9%25 L.B'>Y'>EJ230C3AC2'>+>1\$>G766DL<+>
<MX.H#FGH7HJ7>12=>KNG>6THP'>2=>5M.NE'>A\$5%<@>XKV15E1J'>1SRT'>EK M81A.AOQ1(5FZC)13'>#E'>ND1'>2A0 ZU7<
\$>8ZKV/HYFHDPJ>#>UA811\$5.T6CXN3>6W%)UOP^#>LUGZLI=BLGDR%G(L<^>K09'>6ZW#KO:J1X M86B10)53 IYK%3<L2<+>OY:IOFPB M3052BPQ3>V1ZNN?3
<?>N%<O'>+>JMT@>HNLZW'<#>IYV9M6V74 K1.C.WV5B.01 MOS/P0W+1'>6V13U/HJGB1LS'>P'NG60.14CE2UPSRFME4(C+MDK00\$C'<#>T6 M2>=>8&79+7.(E>#>@>)HWC5K?<
VZ&GJ<2AHOH'<#>M'>F'>Y>HCDZGVL'<#>NHS0GN3K MJHR169>8 N<6V2Z'>TJHBN1+0H38BIN2'>YJHC H=(W'>2'>(W<7'>1P3P M.FPZKR&S'>FZS.
9'>7Z8.Z009TID0E'>N<+>1/1XP4 M8 U410U'<+>T'>8C'>M1@>R U'>H'>V'>V'>0'>6X1 M'>A'>C'>M'>+>GP M'>M'>A71(Z'>1GBS>B&M3GZBD(450H6705<+>@>R #RFC2M\$>C1L8R1N
M303Q1(10'>OZO=>N<+>K:TAZA.14H1G1P=F'>U'>H=QDAZ'YU 31L7 M4YLV7'>9H+O85&10B14QH13H'>RZV=<+>#>16U'>1'>23<=<K'>5'>7Q7TW>G MV17.P10DD<TDSMJU
N:K4L(5+>+>ID.&S<=>6\$B'>ZP58F)>D-2:M=>1XVQ84=VL(0F2KH#0E5QJSHX-5GR&JU.BKM<GIPV7J6RRZA\$0OS M8=>Z

0,4T)+VZ,QNCG:GJLSJNKN:ME/ZQU=X*0,0PPF:7XSM:44,3)+>B5<+>+TH:M6,B6V1+>X\$S%G64:6HMA1+>P3+>3DLKQOWE,M,P3%:NS7ZKG(=7UKN*8*G61-
JROHJN3UX@Z\$01B@QC681MDKAB3DPKRG5Y=B1_81M(44:3)+>=:%J1H:W5S(=O6S5D1):K\$W@EB*MSD+4T+>@F@A+>A01TFB):5(1
MU4D9YSYQZC74H+9ELHHT3(=BF:PK6%G%:M1,S5G*BP8Q@/NT65:P,M5:B,H,N+9,E,AN*BYVF6K/HF:>E:57H8>Z<WRPBI1*57193U2:RV7L6M%:2/2H1)4ASA
S1S16<3*NOB@>U2-VMRPTJ(XZAZ1Y0*W*JHJW11T+T3M2JG:3+>?>R1BK1G03EPBAPBV9\$=>+654?Y8\$VSTJTG&MCI59<3BNA21MF>+FHHU4Y@U+L@>4>IZEI+9
VNZ@+G%:7T-VXFXI19VSVDZL1W>=MC40L1/NXH<7Q)P(=1CAE2EL1XKHJH4V88HRK=JK-L(UO4COS@?KAR1R-LD+XFM44Y(PV4+US1-P5CVZG72A5V@+M%K?
EIEHJZ4U441K<>@?2M:T61QSPOP:=6*2FU(HBAJ-IN:6=U/E\$E=XX8U@>DME>@HUG&G*U5>2-MIL\$)&1?>
F515HH7IXC6%UPW/MXGT6*8F678*0F68KW+13J%>AGE01=9MKO?79-WZQ060.OY=>@<6(F19L7V@>H4D+7G6720DX06G:U/AIFC@70TH?>H:U:S72CHU
M.%N%N.KBLYVC=ONXCT1H&2P=A92Q5*1<@&78Z\$1H1L*6*61W5A24>9M6MBVA(R-N3*W\$H2KG,ZN:8HD<4F)*0<W^BCKAABI=JFFU+H4C:\$S:HD<1
MHT04\$=:CWYK@:C1Q470120\$>3019IC8:1+W4+HQZ1+1WH:6&9XFKSNVYQ1M%>V%VD01\$K:2.SYM*TWZK%203R<5.S-IT91532FLB1+1\$3\$%#>W8(01#
MCT#A:C887LOQ+14HFFIT-SDK:=5BX2+K.FE.SPG(2Z?T@>:HR*AT\$P.M7QW:(J9RS*XM:103@:=5Y1%:VRY*JK<1<=<B#BINL+T+061\$-H,M
<2RTF:(BIMQM@BIUHUHQOOL6+(QOZ:OW\$R1H>@QT.XT?>2>7\$5F?AH+1ME14A108W3VH.H\$+>H1*4MA%0&K1H+@>A*O7V.%02OT
60D>T:BGWVAVQ@>@V1EW1\$84C8&K:R*MKP\$3P7ZQO\$MH5>=>?>F+>%(S51H2V@MS/PM.#EJB.FXKISK?ZPGFLH+@>DICE.OX\$%1MHD\$<@>?>
S8.1410L4@HLSX46H601#)F0-S0G@:C1H-3Q31+FG&KMZCPS5AZE\$AWG:TFE1@CW162/N0&K&K&I9HS@%N%&N&J\$-00WVKLCV1
D>?>8GSH*/Q?2P5Z>6D8**AK(H:81\$):%22G<1#1(DZ2<#<1YT:L0M\$%#%>?>BSE@XRXK:1F\$G@<C1?JDK1/E%G%>RZEQO*BP*ZZC<4\$1=MO*250&UTFP
M2C?HBU1*AC9&ISBJ@1QNN#1)2+1F+A17M=>V%G.CN31MIP\$>?>114HDW\$Z:085247P2(C:QW\$5):<4Q:G1VJ9@SAC\$4Y&C21.M+2Y@<1=PX<1\$174?>
3@EM1U74:1\$141EYV4XES(ZWD70#@W#>8=X4*O.M6MPOSSA<QV4AM24UE@>8@1+>W:C9<52D9H1\$1T*Q18Q3A15=8TJ131KZM1H-H0HMOED\$>OH1H777+H8G?
ME2F%>3&PD1HJ6\$1=XBHJ.2R2&D\$1D743(CP,M9#N*OD0AU3:1,22):I21817?>2>A1:0&5RBA1@>+129V8Q08HXHDM7U7@>0+>F+>VEU+1)P2>Q1+H#
<3416V&A(E@P%>F6:S3L2%:7\$N7E-MX?AWRE8CU3^HWW9_ME@Z:K6JV1F.TOX11+3*50<1.G37N<16W+1%=\$.C.M/34(P?VO?>ED&415F+12&6.28MO*OU^10L:
1%>?27M1:AM<00JY#1H160302:DU0\$T.L=KX+4C0&D1T1090+1M1NEVPQ@<=<35C0Q*HKX121-D&\$<M\$>A+L%>D.61HU>2=87L+H818B:JKXQJBP<8CA%+@SY135J1
16S13M%1=520676P1RD+>1E1J>?>86*Q0Z81N(W3R1+15.HVY+7&E=H=<@<33C4N8(SO_2UX+8ZIK*7G+V+U+K9AND>1D+7H10ZUBB%YX1+>5%?
?YCT68#1Z\$243A1D71Z12M=LNK4H91J15213TTP6260U8VHDG.6%#92WA1*AO1R1L+U1S19D.PC6M%MK7+VYVH187JL%>?>@>D:1YCH1DA1:0IH:10L+V.VNT@Z.2P
MIQXBH1@AP01V@1@=A2M17?Q1L5<1*06K&Q0C.MY2Q.GAW+HQF\$TSPB32H2=FSV5DMU4A+UW33M1<=<FS>XW2/DN^
M9N_0GMOE:YXTKC>=L/@@TLC88=LIF.KY2MK.LAM1:H7O#X<>M61*Q+M:Z:0:<215RTD.MOV1Y151HDE&U+:@B+A=S\$AK-C8R3151#1LY%BY7GME78A-
9.9.W21M+M<@<QNC@Q3R1H=<MK1&41Z38N1K@J.NJHU=>@<NLD6\$FCL>=>@>0XIT2.MAVK@<@<N76D66=26:M1F1Z.HDB<+>GDVH4L\$17/EE\$D+V=B62TH(9K1-
DWT.LRZ17ANM4AD.M\$1+7L1SNQV1#P6>6>K\$UQCL@<@<GNSQSMID.M+O4\$&5KM841HWWK71UO.M9Q.VJ917IE<=>?>91OC2M00LX&1&1CM.21YD1@X9J1I=<3
M6RIANQJ#1S-O1K1OKW@<@EY1VQ.S1A30.ENX3Z7E0H3YAL7J.M2ZG6X1.U1M6B93Q1OTLBZ\$>O1KHU(SQ8RBDW3.F7A11>=>V.P%JX&7^Q.MMUMB28LGT
IA&B1H4>5E&Z91%1Y7>DAS3H(UOE=8X?P1BK%U@X\$2F.O.M1L1L.623&KEG&A2R1V.TLC*68C1H1H1W2X*FDS\$P.L=P5<Q0:
M1>W3.LL#W:=007P.U1&BV%1LPTA=4&7S4^FI>=>FO4E+P/3M*MG7&*XXM5X10#>UO1Z+YO=Z\$Q511H1N)*2D6069.M*REXWWR<@HUTHYM<87FYBP>?>
V2=&S.M17616/GCM>75D26P9Q6P+181=KBB.UR8F1H(L1096G8D).ASUFI31P21W91.(ONF1+1.MK?P*F0QX^KTTH73&R&Y4U+10VND5/NACT1H1RVLM7D.F401%1E:6<1
MFA1.QNM16\$E.F-N#92Q1X7WBROA7<>3>=UJH1@32G.WMJ3R7P>?>PR16.LB.M7V3JPQ02>3YV1RG4H.K11^>TH83110L+Y*Y8D.D<5?D=MS1A1016F
MEHWZ+UD>W78:LP19:1%T1Y1V1R(M1810H1@PUZPT25XZ)<1@?>1F1M1K1Y6L16350D+D1^<F\$<C8.M81D64H316M71@1&C1D1#2W1@
B12.B#21K5M21V371B1VQY38DOP.M9Q1H852T1B1UW1K@<S1901H61Y1@J1U6PQ91Z1K1B1L91H31L.M6W+1FYX8R<OPT+H.G15\$R*BC-H1%N8S8X11?
1LRVGRW6%6WV3<19.M&01+1MC61)1P4@YX^T>?>N.ZB/26\$):\$CGZQTO=AWGB36#1TNI\$X1X+ZC.MLBQO\$1XRX\$SCBTWU@>H.E1#S4.B#9YCX111M1H1%1A2)?
1Z28611R1H1H1N1F=>A1N1P15YQM=#N@>M+M=PC61N1Q1T.HZ.P016V1+3EAL+171M*0V\$XU+3E+13@<CQEOFPN31A>TAXKPF=4Y(CX0>12?070.M10K41Y1
1@32H8.E\$%J1H1W1A219=RUH1TSC.4VW@<@>PMQO8051N1^NE26H2.MH64164:2Y&K1#1M04\$9<3GMO1RD1U>8RM+2W3HF.F+>B1P3DQ>053.M5KMD1YH1
07FAU1TP.ZNGY41&C&X42181R1TJR.M1C45#T1R41YPS6216131P2.Y19GD01ZEI?>P.M.WID?>=>8R+1.M1\$C1X1H1B1N1V?
DZ151:Q9%&BC13EG.>1071L(80K1F11)1Q1E=8FA.R.M.CKUAON:43P.O*H831<29=A1H11<7U&7B19.BAZ9T701X.M4F0521VVG72E%Q>?>Y%CA11**T
75K1GGHGFDPNE1FK^C+0.#W=T8=X.M11.WK3#AT1/2=>FFSUVJM1LEJ1P1MEXZH1DW:31PLA1.KUDA1.68M1HR.P.S.Y515R491

[illegible]

C#16IX73H.SR>3\$*0?JK*2^C/VFW7I/004-8KB00V^0 X=XNG0YRK(M-F^*Q)/(SRFSPT080H&I#>1096?E6/L^PWUA^0^0HIV5J4R>=%ZIU^0^IF0^0\$=%ML^PIE5M40^1^OGI&2
(78B\$6 &Y%=-ICWAD:TF6HJ.BTH#Q5#RUXTF@%B4%-M=I^I&T^? @5IEF%NOL^AH80+2.5%<&K-2K20DP^GV\$1 4X3\$<@.QG^K-M9K0Q\$>R/ZJ^*KSIB>X7+1=UN@HB
YB@Q/KL\$E+HCVY+1.PAYS\$Z^I@O.ML10.^20^0^K20^U^VELL15%315AL^OR/CASKA7J 7^YK8Q0^?H5^* @.MID HEY7@18R.H^IBNV71^W7I7\$30SL#J0EN.,US\$0Z0P*
I^N^B#Y02.MGVY.&G3H.8ADPR^*C^XLI/(18NR518X+1=I\$+67H1U0W8IO^QRY/MJN7K^9^S46@&53Q490^A^@7E631+225J^AYX^LUMP414>
ML/@4WDI7&0)\$L.R0X;P1&C&I+1(3@HF0IFB(INE%87IGD-WIR>^3H5.F3.MNU.5BQ^C&.DS2IH979H;"+RY^E&IU^?K#NZ.NX1^&<=>62E!H.N.37X5
M7>7^PL5Y\$G.\$M#DIG^@.W5S0Q1+1FHCU^=-J7<1.2KXD0+&+U+JE@DS1^H>^ MKCGXW1.LEEFOQ(CW.5X1^I^ZE@C88X\$A^I8.SUGVGN^S1L&Y^U+1>26G^IURWN
M7@Q<1.,CL\$H42+>@.EQ<3JWJLHHC.MXO^HJ^KM\$H.HHY^Z.6M.MID^KGB6B1@21^XO?SVNTZ(C^?EQFIOGP>1.MGB^C^+&60.^25%<=QR-FDR+DX@ITZZ+1
1^D+1\$@97B+4=>X0^GG.6G. MHZT^MKK&Q3X3E^?3%T^<@.ALYO.H4(HA^H^UD03@HJ9\$1+S\$2>S0T4^1T1^MWM^Y^%&C^ZL6JA.PTN.9PTFN^Z1.1\$7673Z^7^Z.25PLP.Z6
MFEZ^ISR.U@.V53>=>19JQK)D\$>00QD4P^?J626.1K162^1XW1L^<WK.MPM^..TXA1&E^U0.3<=5NSI3(C7K0)^(\$4^\$K&GM1A7VQ?XL\$7+@5OEH-SW.M6+1="BIBF=+@!
NG=-W%AG^E8M2V0=+HDKR9^4I<.<0DP=-B(MID!608!F.M4IV^A>,,UF=,,^7^#VYV^?=@8T5V2?U.OH3.NHY-1SD;WMPBFX+QF^=-I.M.2!AOC6-4^S^V7+10^N4O.=#17197!
24FN\$P<0^PUOD^QI^A^A^0^M7XVW^XZ^Y.^/16Z.H@K.53!>16SS\$G&Z.D.X^A^THH&8PB^X.N.F+1.YT4L5U1^MN>+7^N7B^&M0^=>10GAH^6YE7Y!
HAYT0TPK>SX/L@15^1^H^CU@#175+ MX.2\$N175+1H9HJ.^8I8UC3.LEEX4!\$0D6P^?J2!>OAH.90CIM?2\$S.X.M.13HW@+1202ASXW.W^P^RRR)G.(S6F25@R!
HJ8L^P^4K1H^HIC^I^U^QHW^M^?P^V\$K@2%.(8#..U.B@.#MNDQ0SC^34E.N\$75LT=9^.#6\$US.GW^XFH^?M\$-0?<
Q09^M8E87W6K5RBA1^FY8I^M^?P^#9DZ.L^1^29A0.VH2>^\$KAC870.MD@6Y1.815^%18\$G^H.C^=@118MCEAP.5^V00L.X0\$=N#1^4.P2^1H^1G
M7V9.V.X^IR4<1^A^=JTS@W.A.#<=>#(1X^OT@SDKM06%RL1\$HDBNUIDZD.MI%(4I0<.(H63@Z?G12R.H-MC?PE)4^JT=2KBU^Q5TWIF)/CX=(*W2^M^I^>
FLBK.WMHPE.GT^?>WAMQ0H7H\$S.(8J6A^1A^+9)4QI.SHDJ(C^E^W.M^I^Q^OHHIG^1HUE5^HHYU^QK1GWB919B3D4MJY^IB^E00KQ^?..0H1YVH96D1H\$Z=EOD.
F0R@1&1\$=0B24BJP^?E0Q60.BEAQW\$S^J.N@1D^4XJROB.MIS..91.YN>?9YQ^/DLG1(C5V.D12@6)1BQ1^=3WXEHY7>AU^D<5+1^0.M02HJ0^307ISROIQCE.RP/ZRCIH@RFR
MEATR<0\$Y&C#K^ZD^?SAC1^1^3W1@18C^FIUHH^51T9WZ3X^0\$S.(5ZIG6.D2^1.M.N^K=&1=GRM^J5MPH.LQ^TG^G^..OE^(*?+I&.\$XDY71^U^Y2^MPN.E^<
3RUK^78P.SCAZE^?7=SO^?7W15C&27BDC&2WE56.7H^EN^DX.M&1P^8^8T1^>G1Y.GC@DGH1H.C^HSY.NH^H>2>10J5P44Q.9\$D7^WGA.M\$3^5BIDB^?^O^&NWP5^?99^QOX?<
CY\$J1809NF>62Z.M=)RA#Z^M1C^&VE.E\$@.1GHU2+&FLY(I1M&DYF1J+AAD0@@L5&2\$1ZBD^MAL%AV1^U36=;/BOH^CP^#^PYS0PG.2^8J<1ID^@S
^2=3AX^&K^R/L^T^B>?>#M@;3\$S./I^?1#Y^T4+1^71<7@&T^<@Q7H1L.N25^A^ZB.M48=VK=A^O^G.X.Y41.YZ>?79.^TNT?^GAY8U^1=VJL&RC6<1<=>
#%GE#�^MNS^D^O<@4Y4E7MM.6.D8P82CT29J^4Q6G.C7T7&4%.(N8Y1+GA)5^?2D.MF.FAI^C&YZN>2XBW.2G<S^2P^WTQX^&BOI0@&Y0@<@#5Z>3N^#LRT1
M4.CH7T2U^U^X1M.M589#>N079C@#1754Q6V\$7N.R^CMFJ^9.968^<XV1.MC^IUA8P+^V4+1^P^7CDH41K^X^W^GGF&DP^O@L1^H(M6E7FN.C2D.M6GM^1^1Q^C>W1
A^%P12\$;U^F33Q^?37Z)WJO.3L.MX3T18-K0K@<D^1+SEWQIG^ON8I^VNS^WYQ.U^..X8+1^YK?G^2^10U.MUV5^KBAXML%170KE^%L1&8^FLN=4J2R.H7P^1VFKFR>
(EPIY1\$#M@%-%.FD1<2B5OYP6X2+O^#B@&Z.7B4.HDK04K^N6IOU^90\$>Y<9L^M@O^MOZ^?OP1^ALEX&1_6.RS><=>RXIO.HC^W^0#NT1^U;U.80.UP@AIT
M1O9V1XQ^3T^H^?X#<+1^V>@K/R15.XZ0?H1^..Y^W^@.1XY@0E^WPT^F<&E^2^2^1.MQ@=0^..@/1=U^D4R^?C.VY30+1Q^GE^U^5.WG5R^WCP1\$Q0>?>?H1^I%GS
M8IHW1NGY^1^?5^9^1^=1Z18N^1^H^6C^GIV@V8^FD1^JL1@>4_9F^MAZ^D^PW1E^CT1N^W7H.XGLR^PIG1^>ZV\$X5IM^Y^K=&8_9?MEZV5YB1^M^#2YX?<
XGT8YW<?7^N7^X1L.GCD.H^C=00K^R17^AV8^H.HQ.HK&H.H^#R9.MC.X91X.^J1R2^SMZL^%HZZ\$XQ3DK.X1&KD^D%=@.1L^1K+SLZB.34_MGROP^CDS.CCMH@EOLN!O!
(P2\$=VR7QG)!MK1^H3LH1P77^>DWJZG&G1^F1J66^M7QX^NCR.Q00Z>EL^CH^GICE<3@Y^M^UB^FC9GH>S^+&80^196R\$1\$?<
QP^#G.#.8G1^@151%#^IM.10R1E.YL5^#=>I6Z1.Y<=>Y^+Q\$_.@HLP07.P.N.S.^?KTHFFB1^4Y\$S@/M9T^CB9F.T7HSD>S23(C>3<IBXJ/H/C.^ELVN.CZ^0^+YU=5\$4#9.OEQ-SKM=1
1_4Z=;M1^GUF2^M^+1JKH107^&E2P.AK^#KU7X.3M8H(28\$<S000)4S#1\$U9^<M9F32UW.O^>N^YX^F>?FFD1^47PRFA^3Y76.LQK^YR>3>?Q?#Y\$S16P^<
MVH1+1^N19A7^17C9E.60%N1+200^Q0\$5D0T&G).AX>?T=FQ.1N^>9^..I^M^U.MJF8D1C1.C2G9^S4E6BF.R=H7EB0H9266)H7Z.S^S2>ENTR>6QJH^MR=6T^P.R^10^IW.
I%6156G1P/GG1P>CZ.Y^=>O18G<6>..SR5HJ24T^P^C8.M3XYTA4Z3T1^>B^T^Q^O=GE^XIEY^<C43(C^2T3^?20ZFLWA_#1_V8.G1Y^MHM.L1^2C^%5^9J@ZA^57V1^TB>
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M^34G162E24\$K.N^F74^1^R=200U.46Y1H41P1F.D.M\$N@1C@959E@R^?<
(C@3110FBB^Q1^O>3XU.R.3<=>#.#.M1E^UGV.3D1Y^%1D^Y^S^<=>@.19J61H1G.6Y1A.^YVY1^U^R3D1^Y^Z1\$X^TZR^H=0^..CT1^?^TBBD1D32>#C.MG9V^68S.H0C^H6E2L2Z?
XR#^<0KD.B.60\$FL)E7T^..1^<V^=S^F^M^&+^RNX\$K89.Q^Z1#..MG.^XOW9V^IOP1^7@&&L1C=2^I>4.Z.MSH^#R=MRIG^X^AC(H.B.H.X=&EQEIP>G^G^MDMLX4=IT)^.#1
<3W^EG1?^MT#A@H^Y2I2.G.M^ZRC.U.5IAT^?3T3W1F>?>@1^D^P1=1Q>1^B^P^I^Q^&NCSML^<+B^U^A^U^F^M.VO.QO.D^?^C^HJ.KB^JN6XIBAV8^<Y^1J&1^N^ED+EUJ
ML^I^WISD1^F91\$S^Y^EN.F@.U^BF1^R^9%+1^Y6HML(ERGZ_5PS0Q0821R1V1^?TGID0B07K^6Z1^&WLOK.M69R^..CEX1^H4\$S^P1^@Z.AA.X^0H1A1^>
<5.EY>PM1^9&G^C15J^G.#M5YB2P>HVMJ^P^M+V.RC^I^W8I2>VIM.MT^Z81^<#W.V1^5M

0JHJLXGN:DRVJ>K.TUZN002*%N.55J0U02=&K&K(4)1M*B)HW.7P7(RLPP&G8?=<01)>U6Sf2HJ236TE;+1HW0G60.S4*BJ/HEZEK.Z.71+)>ROTI5U*P.B21KOB0<
>S)D>LH6+>M*U*F=118;1+>+MPB8IS2=60Y(T=>3.D+XW)PX<VWO'HL3U<1LU36<MVR.HUV9M.M.T.YN71>3.SRD4M*G6.6LX1=HJ33+B%=>6SXKJHSZF?
>@C9C4+>162H.MN?>K.YK6CM6A=B+1+>C77.H80.9077FFJ.943CPW90?>9IZGB+FEK.MSR>WHBH.0L.9PHG#>E6.6.M.GS4+>=>S=Q(1)&16XWJX>V.3.7>18
M9@0GJ8C&UJ4=>>@0G17J.FXJ>J.T+4-MI@XZO@&QW'N822.K0Q7.M.CM9>=>C.>@'15FXD)=SSS5G)Q.WJL.EY8HJ.LYJK(Z)S5+T.5FE.MOL@RRV.
J6WJU>G2>9<>@25J@>K6@GNIBOPRA.1=>1571JD.S.T>>U0I8232KNQ3N.MSZN5J6)FKM@18N(4)H1.MI-QJ1TJMXJGJL>OF>050>VUUJ(ZV.S5+U6550EG0.S)
(P.M.QM00<4VC.G.M.MXN(4).G.UJUPNHX5D&2AU.VA3GZX6@2I=>C7B025H9;@I#=-2)XK2(I-&+>X>X.J.>1111>100517%16I&X6PCP.B3.N(W)H.MMAW53WMT4
W<+>HS'5V5K&M.M.HN<+>+JR(E)=FD14=>U-S-W-KB?&M.M.EE7HQI56.V734P&G'9YCI5S).>1NHV673U=>S.4H+>2.W6&L.V>+1M.N.9N91<
>(88H.L>15&I#&#=>#>CN95<2N'DXW)J262.(S2.X/G<0+>0+>Y=>1.MOTI'G8)00?>1&I9I3U0(6XY.SC@>P>PR.#=>70.08+41UJ#X1\$66R0M+7ET.IVCI>5>B9?
>M1)D>4.V1Z?7>1MK1Z=>(7&WS+>C.29S2J+H1.MYO9I76PHWJ5EW3E+>UJ2.SFXH=GTTP.F7H)QAYC<@O)H.MWG(GT(C21B6<+>4.6)BV'G9C.0+>
MGAB'PUJHJH<9&2AT1H.H2.EI2>+0>=>YGA.M624>CJH.TH.V>=>5UWU>+>N0&A.OUVRHV.HW<@1R<+>M.916H>T+>1&X&X+>I&I6B.98D6TG66F596);NI=>TM'.3?
MOWI<DRIIL>L.P'<C15>K2=>69@.AZ.W.O@CZ8H2I.AFR2&S1PDS5EIVJ.M=>S6S7>3/ANJHBUJQ<0J'WWV>=>X.Z00.000%CE.IYXQROT@EXJX2YS7>U.WZZAXML4@VW?<
XR(N7T)=M<@>(73.97H.MM.PMUBX8T3+2)Z(H4HO7N9X99DE7>IOQVHC0Z2X.HUSBNOVH(HH)B)DOKOPE.M.OUR\$H'Y+XK(0)>12
UX.#841.06T.X'8.C(6Y)QI'HK>7&Z=>SOP)MVMVP21KK+0.7.0.3.1.25U'0I'>M8+8.9D@KMGRA250X.JE.Y'G'EH5>=>T4.MK@GTC2>=>43SQ@SUXM<5>2YFOSI+&
MX4FIQ4D16#R.(M95T2VWAQ&HNO&5K<0WFD.R=>M.J.8&S72V3H9P4J.MA2'M4E3'>+>S.E.LD6FIWQ<6D68@UQP.B=>0H.WJL6QDQD'77896F.M.>V<+>C.>1ZZ?
SDJ90-8.R.QI.LA86<C'PP8.#>M'N2S'Q5I9E4>=>K4.M1.RKRG'RS<GDT7SH.P'>XCAR.P7H.VV.3%>M.FWQ'QSR/LBTR.MA=>I62.M.M&I7E.O)CL2'KB.1=>A'VA<+>LYN
+>E=>3&K.N4/S>U.H.M6#>2.VL%K'>B1E147&U0Q'>17H8=0.M4(QV9)OQ'>#H\$1&MNYG7XEP.T'>A'QYF>B>.>H@DP=>5>YR>7&N6VQ
MGWEI>3&A5K<P'GW0KHG)IDP1.2IP57P6CDVIFKKL5U88V>L<=>S930S'1M.00A.VINIPA/H8.MXW'F\$>1TN<+>=>.&N1K(1LGOA(91<52.81)OH.R'18X.JZ1'>#1.7##ZQ0H1.M<
>@JAZ.T+>KB'P.(G.SOIP2IM3+>+>E.VJAYN1MN9QI.07H.1'>35JL'G.M'>@TUI3HF.RJ.E&T)=IK&A'@OZS1@<C.M'N@K.KI.SWYQ1'<IS'DU2EIE9CDL.NK5R2.29L'ED')
M.A66N03PMQHIJX.#B#3<0>PQ5CVI0'HO1.EGNAVE.>K6+KTH0Q0H20.M9'T5J(3)<C'U@K9CMJ3<0UJH@UQJ>JR=<C167JTF9J.YE25E1'J'Y'VA.M4)1>+>E1&ZF3G4=0I7>=>
Y<=>+1.G)TZZ=IFN'Y>M.U'0002V5F2R2A.C%>YLM<1'>N3WQ9PNVLO6.M(AZ)>S8P'23V8H.66H&63'0BU71TJ1>T9F4J.P34B>=>A1=>OY.5UJ1'J
MNUJ1.WMFOF0D+>0.0.75+>0X&Q'R3<2F3D3FAH'YHK<'1052VW9>JFHI.L<M.QI&K.3=>I)H<29S'>MFM.LFRN.HW\$ARKHR7.Q.MN8V041.9&KB.L5.1>IE'
M<=>C/L.1#>41&W4M14754V+>6A.3.UGGLUYBIL&OG+>X4.PY'OB>IV.XK1.M'0T512=>L<=>9N8'84YU'0768H'CI&G9SGYV'1X&C%)>.UQA3E1'>M.M.IYX1
MH'E&S.50+08H'>OAPOM3'1DC<+>0'JHYMHM.GTSL5E'ID'KP'DR.1'>LX.NX#>MX7X'97#D=>1%15WL5L&4R#>ZHU'16%JHBUH'Y7J.N'>M'0'U'Y9D96F'>MFEU20MM>Y
>X4J>1PTVH6W-IV%K%>2.V6HD4IRZEMOND'P>2.048R5)&H.M0PMKRIE+VJH&DHJ'P'>35N6HJF5'PAA.LHMM'D)DLCGR.MF<C.R&F&H@.MP2ZDFXW4X4
>4NCLMGCG1/>C&A.W9M.HJEDJ5>V>0M.M.181'98STQV.M2X1+<ES>7P>V>WSM<1'D'WDM<G.C.2&A.#E.3.>+>9J@H1K1+>D.M&A1F8PHRRU5>Q>MX'87JHYV5.KI0?
PH.ISEIZST2+>=>#&G@RKH141H'YVW'S.MR'9&H3D>1513HUYDI90N@>S1'YV6.V5&K&N2>M.#XSWB&K16I6J.D.5H67/5>+>7'NO.L2.M2ZMKJHJZHL6H.VETC>6.MCN?>
1\$1FQI7(H'969B9CXY.RU.8'>18LTHXDFN'X+<2%7>15-IA(Z>#5.M20&K.MYV>F=<M.L5S.Y.YA'Y>=>C.M.IC0B)H#<=<S.Y.VDPH<0&K&A'ZGK.K0.G>2.16.VR1'F@=>=>FAI9L'IM
M=>Z<=>PKLD/?>85V2ZXRDR5<=>(6Y:CVYQ-(1K8)1X6'08NG\$%>Z2>M.N.M.>C06N<S'FFV02'EBKN?IM?H.61.NSAV.YRTEOW(1'D'>F@<VP&?>K&T%>M%6I)?>
4Z>YD1@EK/F?>2M2@<DID>=>=<0.63X42A>GH6I9V%TY?>C=>=>S16KZ+1X34LTPHIS1L'DY&UM+60VMN1S
M.TW2D16E.%<XZ.R-2M1DPS&S.DIC>5/K=>3ZCV%72SIF6L6R184EWM.MR41P.6.0+6&U3FQZ'Y=VJ.9PN(4+S.R2>=>1K.IV'>XV50Z>6(2XUF
MDSU7L.W1X3P1Y>DDBYVJX'OC&S'RG'6B.(F81)@<KCDI>=>2>46WJ0H0UW.M.M'G6Z2'K'F'U'U'UZ'W=M@U.SU.D60'8ZUKN5'XAM'4MDMIDF5E'
MTI0D.<K.RUT4Z'P'>+>AS+1L.T.0L7@<I8#>1214VYI49'M.TI+>I.Y.YBZB.O6ZQ>+>P'D.BR'N..B84SL.P#>K'R'14>@.175D'Z3X5%UZZQ'0+AX2&XV4GK<6?>MUMK%?'>?>OU.GGL?
>WJH31C55=>IH.FD7+>TZ>Q.M3#>KTF<279>8.Y'<ALTE.OG/UB'08Q0\$2(KS691'>DL31'>35>17R'N'>#1%79I%>M.0.L#>1B'X3P9\$L%K5P&+4A.C>VM?>
RAD\$H+D5YH87JFMN..H'L=>1XN.MLOM>1C14.1#J.D5&A.(ZYVJ'FIMVY@CRII&SVT'>00K<1+57.<4U004.N.M.5'>0'K'>+

BT9+Q45Z2@#6XYGE@>|F|,XU@ZT|AVHH-OD,1PIO,SW5BGIF,M&NX%S(<Y#7|@*A|,9'51#->|2/@K?2\$X>L2|7_06B9&9\$00@>2QH|_M-0K3|8F6BM24WX|<#*
(=^X^X^KT@>953|8\$D\$X,K:&N|>1>NSGG@C^K>7=U>UAHR&E)8#6 M5EFFP,W+S7BR4CV,7|0_T|&0|F#X4Z|28B7F,E<960N7|F,K\$>=,|ZCG-M/L,GK7X^L^HWWR
U^U^U^U^Y12_63PA551+P'D2H|H02\$>=#00ZSY0H_MCT76Y0|3,T^PA,FN0|8_,W|2^+@<K^LFEM^@<L^R08@>Q^L^B|B13(P&M_M#V@^1HE(FZC=^M^6K7X@/17_MY|,Y^|
L^XWVEL8,KX3RC,296M_033|L^M-2_C2PZT3_8|2J5|P>=#WM@<N^A2V|2>=VM<B^L9U7Q|>:9^<H^W^WM/MXU0|>T7@7OXWZ\$50V^20HGD1^2|>
|C|4@<K^<H^KUQ|H01^4XP,@<H^8^M-7|4K;T^Y@<S^Y^M^T|>2|>Q2|A3FEG|>+>BHE(|H^8P@>Q@<Q^OY?2^Q>Q^M^N_H2U6;P@JOLN|YU/GG4|7?
E\$3I&EN;I3F#N=F#^X|L2RH%BD,\$|^COD-M?W|'X+P+>F|V6&|Z>_2)2T4>,%-@<OW|7B,B=5Q\$1X,ZK=U&CCE;LN2Q)M)4MEUFYB60<|2^D^F9525=/'L8 C-SJ,JP^Y(4#
<<=<,<CTP00|U|Z_MN_Q>3R,%>07^4#<=<D,|P|QV8,KQ>^|^E&A50N&RVLR=0K|LB@+<E_MK^,J^J>5Y#<S\$A&Q&KBQ>@>7|HJ,Y|>1H|H|J^|>M^D^7_Z,^|D^C6|3
M2ZC3P0U=1|C(0%3^<U|H5|N_M-D7<|35|Q0^M^M^920^60&KQ>=^H|9^=MLQ2^|7A,^R^R+7WRK|3^|Z>2_Q^4H_T9M|H|VZ2,M0|>^F|FQ9KRC<0DLR6Y
M^6A^1^0MEK^1^H4D|3_N2599^T7|E7B<A&45L|N,K:L^<R^V|C|U(056_U_MJNMD|6D^Y|>40A9P=SGT^W6G&670W|IR|>NDBR&E:0005^1|NPH|L5^M^Q+>4#
<=<DQY|H96D,B^<^#F|E|=WEGC70PK^'''F|U|H8G_K|BRH^T^BQC^M^U^J^U;U8H0L4>L^1^4J0_M|8=<0K^0P|5^#PS,^5^4V|G|ZR>Z_G>0E,<2W_M2U|H^>AD,TD^*WC?
(Z0S+>|4JH;H\$K6<=<=&X4|@?#BMUFHD5BY#<@M&GIZ|<^O^NT07@VI(|>?L|L083;<G|B|Q^O^MY@#(A:O^0T|^E^CA^P^06A|X^|61=(B&#/\$B_R8G6^D|L;G\$K<
K|<C<2^D|41G\$51^|Y|MO^>SQ|<1^5_DF(|A|&M^Z00,^2J6|Z2|6D|^|A|N8|>P^1^X|H|(|<+<M=I5^K^M^F|E|<0,0|26D^Y^|>M^<G^R|<I29C|P2S^2_H|@>?<H^V|
HE#HQ#<I90,^2|6JAI|HEB6_1MOD#6WM|Q|N9)2^T=026_25^>|C|A|>7^D&G<5CX^|>P^Y8N|H^=0_A|D^W|MBB7^|AF|9H2<XK67>5^>51K\$K^5^<9HW0&T_2PRW(RN|V|)3:0
W<|IGSN<N^0^<0K|H^0_5K(K^<A^U3|>U^A|5|6334>0^N07^|>L>W_3^|<O&NPKPH6_MV2330T^DHTD|Z^L=>JDP&L|>L=>302\$<MG6@5D9>VESB3^<8%5<L<
M>E|H|&8|Q^<9Z&V|Y^9#R0<SLD6R^|>#AXAK^C^2YF3U^P^J6D^45R8@>|?B^M-76GVZC21VU^H^H^95^A#<3R%|<S|J|Q>=1^9N,DB410>|LV=|^J^A|5\$W_M\$>|MRJZA:FL%
(46_E^D#A^2XQ=|X<76EA#<X^Y|Y^A<8D=1^5U|P^2AF0^<Q^M-|F77^>|>^D2A|<#CDE&W#M^Y^L^MU|^M65TS/46_2^J0|5Q<DWR>Q^#S0P
MELG#M%|JP@<=<4V|<=>Y^H|6,K^Q\$H>#M^<KEI^#ZD^G^N:16U2G0C02L^Y^MP,K&N:O@_33^B&L^<N^O^KA,R06|P|PNA|Y|0GM^X^O^F^<2^<I0W_3^|L^H=|R^M^R
@^P^C|^B|Q0|SCOX,P|>1^YU&M^D|5H|I3^E|H8|W0M&G^<H^<EY^N^7^>85_M|HGA4Q|Z|V^|0KM^O|HZER_4^JN^<8^V|^1H|D>3^66\$V2^KC^<#^0^%<V^G^Z^M|H|>=<ZQ,DV,FG43^++>R&^
>4|>=>L^L^>1^5_M^3MU32^2^7A4ZTWS^<6|5>=>0@S^M|VCT@A|0DKX\$<M^<7P9|5A4^X^Y|<L^>R8D,1>28P^>M^G3^ST|OC4|>@#M^M^Y|H|L|32_?
1>|>T|>EEB8|Z_DIF#ASU9#BR^7|K|<=M^DU82<39J^V<_I3^|ZQ@<=<D^Y3^<L^M|8\$<O^Y^<@<DUS7J|567|B^M1<I^Y0_M|3>9C6\$<X9^YB|<629>X^#NZC<
L|H(6H>=>VM<S8G^<V^|735N|B0^<6\$>72^6_M^JAZ^X|S9N30#>15J>9^7^UR2|5,95\$<^<S^<IDEY<J^X|H^0|T^>^J|Z^Y^M^P^F^W^R^A^E|^A|>1^W^<H^K^A^B^K^<^B^|H^>UJ|JRO<3XOMR%>+
<N<#G^<P46|'B-7>7=M-^M^FQ7K<6,4>5U^U^KV3A|4C^<M^F+>M^<N|>@|0^>3^2<^F|<L^4P0|S^M|HGSA^T^A=4G:6+<6F5^9^L^D|QEA|9SEUX<5^B8X^>+<O(|)3%\$<^<L^M^%

[illegible]

[illegible]

ZLS(LW)B>T.V-Y-81GM<36EUS>M1T30I/A28D2DRB:H(O:82P>FB>H42R2R4CU.F.MI@>VXUUVNTS'0_N(FSI;HHAZRL<#>=OY>JCS? M3GHZ'Q1\$0YH1?<0>R
 AGK-1H7C1s>?TVHVH1V'U10GPA+PH3MH3F1#>+O:Q'H:5H-RX77EM227#1)OHM-CL4%LQTORF4E3)LKAR)S1/2R6DE'5;1N7'-E&
 MCLGNO:OK<KA9-TN2Z>M19<325U1V'3#595%MR0KAGT2P#W:0H1LA5G)FOAJ-X:U3A-P'V'U#TS42RDW-G6GH1FV'Z3P=98A0<91X1
 1IBFZO:RPNM2S'G2A1HHFEK>N35ZOY'7H9>=H1--5DKI&SEBRO5Y MONK-N:2<U)ISV3H.R0>#A15R8BRO7&#>DRU2)4H OUB-W.MHH-
 27E>#>SV1'88U>LP.HHKH<DCO>S4N66KDEUI705>ZB7E:04XPS75C.M1<30-C4'AU'UW.E0T=>#X62G<#8&S>TKR1(WB7V.Y8 OGORK1P1RLW>1?>
 @PI.IT@40C'H1KM.U>V1O:BS>(NS)X#K=0VU#M#&5F4V7E.T0SU.MU+Z>U3FE170(Q500(OR\$OI=VB.FUL<+/->I'@.Q30I-K(B3'R7FZO-M.MES\$GSM+Z1%N\$;01OWHV7-
 3Y8&+*V/V1+&15J.OK'1'55>#A(GT.M7.U1'2<R5UYW729H)M7W4QU1H'0C'R7FJPH'6W+TKIOBH'K6-H:KYM7ZE9+13R&=>#A@W7G2.M^ (RASK>Z-E
 144577>WBI'SU1.TF.RT@ABJ'7C2G4A+T7ZS 042U1N1M="E4#M.T5A<1R-1%#55T0E70#2X0383UELCRS.M7F.9F=>692M7YWX<+K9E.
 0X1+1>Z2.EKBPDAE#DYL12#PDEU72T)M.LJ.ME+>=0)SSKK<M3'3R'>="WOA8=V.12ROUG<Z.G&S'6I2E-8V.A5S'F33XPX'>M9.HO..TEIO'1484GW?
 Q2.5JH#H.'Q6APAZW.H.50R(80X'42-T)SO.M9(U+04'6.&XHLR)C1+&5)U1.RET(S%10+1'<@G9'EIUS'>TD<=>#1A'1
 A2>0<26G.HZUY.PVN'W'K<KOKET'R'@0MGN'N7K+>2S.X8J'0XZ10VU(M-C.R0.YYHD)I.O2KJ'9Y>DS.LAIG&MJR>J1V5>>J1FV&N5#&.<#B>7=Z
 3/HTG08V2C71SN7DPPE1O&NS'95G2Y3L)M1.EK+OG@J1S=520=Z<#>MNM16M(HM&OP.P.H71<42<36J4BJ<#>M.B.WB5>.\$D31VH)J1Z9#D<EUPG6TE1
 KEKX(SJWTB)VZ'>C>1GZ(5EDD1Z3L6)M1.V)K&U#*M1+M12N0'8XTF)4H-B.V.E5+6X+VX+HAOFR4'>5.3TH.MN(I'>27X9D>W12CZLK6)>C.M.VKZT>.
 B.C71W4H1J41(QO'YCO:1B\$118B60\$)S'2<S1@+>N'N10Z071.M+3L@Q'S%SM="2L1UV<2+1#5>@1@J.Z.YS'>11.MK172C'R.S&R1.817XN+7K.D)G91=XRMRWT'/ZD1-
 DPKS7GOA1&1#>."O.M#>7.P7TZLU<1'>E'FSA'1'>T1Y1A(M301)F0Z0.'S'.MOJ.R.(9Y.'H4.DOREZ2KV'T&BA05<@/ODXX&(3H'F.DC\$01&XN<5.G3\$M'D8A.CXZ'IM'>
 >AOGX.Z7E'W7E=6W=6RRJNRJFSW\$HGF@1N+JP.ZS.JY.MSU2IQN\$41T#5G1\$ESL.W8\$XRE\$H.N7H21Q.V&S.CNO.T3&+58P'H.M'MB6G\$1@Z1#&#M'69IG.P<21'
 F'D+&L+>@P1K@'F101D<4P.M+&TBA16@>17.R%CU010Z.9=>\$G<5CU1073;K3K3P48'7%W@>1V41Z0.M6H'W'CFU..0+>77BZ0A11'F'M'GEW'9JMTOW?
 U10LGITGZ>P.Y1O.MY\$N8CH'DFSV>TPV6F'2>S.MMDPM=>="K1YCPH1P1M4E4JMWXBBC7.M.T+PNKXSAY68Z'516C'@C:09RWNYIS0C'
 3>05WVW.OPEPEI4TT115FB0(RSG.MYR<3EM4)SVNJJ&1000.F1(1OUV'5%MZ=H4H1F911C.D0+>5>9RU/RJ1=1.MZ1.0EKTB+>6X12X'G19J21'
 1C)A=&62G<12RU(AJ'V'10.WPFIY'YMN'T>=NN0E(VAFH15TG3'H'5>=>=EQ10E6P1'>FEQOMBF.H4UIS0\$1.M2+1H1APPI+GL41#F
 Z2.D.BATWPD>C1B10HT8P1#1@QZ>(2KBN.KV6.M'7060S<1WYVZC1&DAKUH'NC<313R4R'Z>PIPL6CS3ZP121G=6GTF.MJFE2\$C1TBHHH'00'9D'AWE:HRV)
 @RS'6N+B#..0S0PTT51\$>4'00'80&42HF7CC'UH1PTU'7%<+&UP' M18.MCK(1'<#>=NN)OH7%1L9&1C>CHHZ+1G61'U:W.P.Y0G.0J(6LYFX
 @VSENEGW4C<5F4S1R.8Q0F6'6B19#>F6XB6SW49%1'IRIW.'3@>A<M6GPP4.71+Z.T19.LCW2DZ'55U1=>G1M7'U/VX\$<#>YLF.MOJIG3EK1)M)B/3?>
 @FAD1>Z3Q3.P>86J.AB'872SCHY@1U920IGP1G9.U1<K1F1.MMZ..O+H.P.5ZIMV4'P>UQD:S41N.RN1JW3V72(21SCONW4'4K.MH41.21+&=N.Y.E'EOB8>BUH
 21'CPUSPT-T.O.7X19U.ZEF3SH&E+MX1&V.F1C1P+UBOT.M66B.9Z=>1.1ATE0.J19(Q0\$>'FBZ25B8D\$1'>4'2T6'72K'B3'W6FOME0>WG(5S3Z'>Y1Q&4K<+M.C9C
 412<4<7&P\$5G121+9TU'KJN'Y'9K+4>2'2'JF58DM'>1J1EY.<49(990D)CBNEJ+R2F.M(K'HL1>..ORD.X'Q2DU'2>1N'Y.WA0FSV1'<X06Y.12CX'(C1#>1M>T41LO6W.0&H?
 S'YWX9+XCV.T#2H'FJHR90Q'97%>H1X&E1O)U932ZHM1PE+&G31FBJN7FKPZ\$T9'+4=12OK(Y&X+UGIG15T1'7&S'K'KF&K90>P.M.R)U.YRPF1F33'6X
 90>W+Q>+P29124'@BU13P'721P&P.MO10&F810@>#Y'KUR.OYUW1PH.C@.78S>0=>71Q9Y'Q53XZICL1R0'Q.M3'G'GMFF+04R(G1+Q2TN.F'&C<
 LQ74QH'B'00RD4A&S'PP6.1.CAW.M'2<JR.C'6P9BK6'71B1U1U-00%N0%4P'G=C4V1.C7'Y'N1R&A.M9FLA'0.YG\$>A9Z61E'92T&.&8Z
 1247&H7HEZOC.IDZ<61N94T2>..M9BP0U7'OCN.G3'>M'P24B.E543'VW763EUI1VOUGV1.C5J0B010B7P'&M.(9.R.HIT1D3A@>1W4C0&Q.6)R3N.5Y.DY.7A1+1
 2'V'N41M.W1K9B<#>MHXC<61N'PIBXL9H(M1(OZ'7'D8931+1BH13L.KS'>L5+13J.AY@=>9.M.M=5@DV1Z.P19Y=>F+1+>EPP-.8M%'ZOIZI'>1ML7X'N0XRN.N5+&C3N1G
 6.147C2A'G'<C'>POL1.93'8.N1L\$21+>V.T06V9'0'>AQTO&2'D1C3.M'MJ9:9#>0'2B801GZ&0'Q'DZ'RM'D19ZD'6LMR66+1CT1+>S'NW.G1C'U)U3Z=>@>X
 YV.1UPN1X'7QR.F<0.P'51H1#<1>)X139TJ8.9JLBH\$T8V0'1XPS5+MDJ50Z'>DR9&V\$N9CR&LAH'&FJPI9%'SXX.Z2'1'>101D5V16U.MU\$E8B<X
 8H2&21'OCB)@XQH1C3'1%&F&W.D.X1.KI2E9LKE.M.7G.M3'2V1V2Y>+X.8&X'XTF.PAEMS4'&SKVZ\$T6G'X0EBH9.YC.MG/MX3
 112(6080)IQ.C'>IRH9'HC&PMZG.X'W31\$K&2JL'&C'>@GR&S'ME821A.#64D07(UYB.C'>9'4'<#>=HYB5'2V1.&W<G>.BP.1'>HHR<#>Z1D'G'B.T6D.M'1?
 1J3.K<76T4E3G>V>R0'>R\$>Q0L1GK1L'&H5&5<#>S1'>=>DGD'GP<5Y.M9H.61.820YTFBF12V1W'>W'>W'>UD+07A44KW2'>1Y3Y'>#D'6B60.MB=E4H.O.Q3\$'1@>+7C2?
 4&S&U>1J1@>?7MY.IA1#7CA\$YQ18=F=>9'0HQV1(C8K6<

3B-E-F-0QZCZM:137204C5>AU:4P&L2U020 MX2:BN(TT<#<70X.&RMO5<#<+4A.2E6H+MA=8.81%;F"AK&:O.(DHHI.Q.M4>5M.7V(FKSF6M@M^F"EK="ZDSM#D
LKK<#M^M9Y&SJB21?PAXR#17E#HDK#>QHA=>PHK30@HR.6+@JBHST OYPS(C8 MHG<=<+>+6V6>D">+>+0F+M6H04P_74D 8U.VMX^8@AG<+>FUM.YL^95 MR^
KFF)901+>+0\$1<#>+0R#>#3\$1?<ID>+I2F7I13M2G#H&5JKM- ML.GU&8(8)2@IU&4<#<(&#<#<DIN.<VU.9E.IG@CIBNGG9?12VW0K@U.M9.7.S#>#H4R454&#<JH KB)
10P+U172EP..@RJ<2H1 P#P=5U&K>P<M6E\$90C<V7E5 W7^<#<A.3A>B<P<ND\$SD0J M^>P<K<AS&#<S..&DA10F"JOPH1+MEF 25.HDX1=EU.GFY13N.4 J N
JDU@UWG85MG."R 7.7)M\$G<1H1+1J1>MS<#<8D\$<NZ+91KA"IRU4R<K<Y1DX3G<8.3<2T>IGW..>5<S<YB9@O MWA80F>JIC70+1H9;83HOGK80">#SP9Q2V+EA??
@N%>R45&42%31+1(9NP.M)U0\$<N0<#<Y"J1"=X^1+>#0B)PLT^4C.@G^49<1+>280>8>K(D<6C.&GD
M9<=>FK(IU^+H4EJ+<F7\$90C<B01ZG6<3)Q94TUGXIV^5#>TTF#W7D<EL7 M76=>B.GA3BIA&#<TN:G1.4%DA#>7(X.9HR.<#YO@>WET.(I.KO4A11(Z8E1
MLR6R+M^G4D4W1.7 6@JK761P>?>G+U9.S58H7Y^H^T(SWL T+>IJO DISP.MAOWXIZH4&I33^Y01< SD6E^R1OKR2.B6PJ#35WM.AOIB9RCH3JF^NU^7Y.M.+W&K
=>91F&X0X@Y2Y0H1@<XIN.PPTOT N+31L.G1=>11 PB=F15Q^B-MR1.SA14V.6 9VH1Y@<Q1 H51H9QJ2IYX41Q<K3WRK@<XP<6UP^H12 MF>+S7.<@<0^WE.%VM.Q^*F7I2D
+>0P>W>S1H<K<D.72)00U6P5+M&8BDDG16<+U1%2514FN>20 K7 PC6VD1V1<^>8>YGLM0770D6P.7SGSG.HDZ8F4(AZH.2>@>
MTCMV4G7G@<=JYXK3181H+1758^&K&1GX<#<V0.HD#>R18V8A.M+<BJ<H1MHE..<A.IU0VU.<@ZM>(R.>#SRXB6RT>1G1X@NMZ281>L7."W/6D#>JR.<^0XF<@93828LKUEF M"
(Q^P^<V1.KIM4V+V-M6D+<C0T3FMU&WDFRC4S0.JFWR=5R:>O55?FDGSD M+<0#<#L6.5#M%=>T1P L+<C2\$T^!<X.A.KD.1LLF5R8H41NVQCGF&
M&8Q1^H#>#>.&N8P5J51V^M1..1Y@T6X-M9#17^>#6=>1+>=&#<47S^ZKF#W%GASD>E0>OHHB+P(4C29AG7>I@<Q27N0\$>#PIH?W547Y^RAI M+..N7..PNO2^V.
OLC..3V<5XXJ7JW?3V<#<#<#Z1<..IFES.M.2I8^P-M.L2ODBY1<NGK6(TU.ZVEH1238SD<+>T1 VFB&1P4M90 @IH/MJ\$9.90
P%#>6C1<T0 F814D>#<P.UHED>#<@>0.82>4Q318>S^<U\$<U5 MEK(TO.LD&@CVCVD4^LAW>2<92-RLIBD)A10Q0F#F19W3H^<PZDAUDSF M4HW)>C00PX3V0.
B1#Q<NACL3G29T&Q^<A^WPF0T328P\$>H5@<1T7J> MOHW.M1.5.0Q<04DE.H+>041YX<362.A11.MH&A<Q10KWS>7F4EM+>5D\$W<^<31Q.RD&1K<#
(Y=RS5E0 X\$>#04<P2T L M1<C131P.DW<+&C\$5Y& P^D194L=>07SOC1ODE.H+>91Y<0\$9.918&FW M!<A51.2%NL>7A1Y>AAW>OB=IT6H1^F6(1RD)PA
7.5^>V0^<H1W7.8.Q MZYHO>..0U#7LXH5+^B1J58#0M%+>XJ\$2%>MZV8817T(YF.5.1U.>#>..B3?T2016>(IM9^B3*Q@>32%QTF>3(5F6^>T.H=>MHFV7N>.)
(?<Z>Y2D>2GHFN1H1.YKW&#<N4A1MTFDLH5K&4.M.U.C4I.QY<U1M7T.L98BWI M^<S1Z.G^<F1.G.L0R&W&M^EZF5FWQSM0Y9.XZ..B&6.3Y107LDD9_0M.(
MNI.P1>@QB#NS1H1<1H08D)YU BD2 >RL<@GR^0&88L1G2JK<^<E1=>M^3KAX+QM& BW15.(H6S^OC^000 22R.YWGN37Y.DM^W&K&K^A^FU0&
MGU<16G1>U1X3Z6S80Q<5QPD1N<3YKALONF5PDLGOKH16KA^>Y1K0 M&L C1.FE B58HF&W3CT8G=>G02=>L/W.R91WYH.6R@>7^<8+>1.7H5&#<2
MV+J28W&#<U1S&#<0Q<=>LDO9.M37@<#>RWA.K.C.T5T@<R&3?2.P3ANG.N1.M7EOL1<4Z1RV1.L13C4&+>K&6DPD1N_8A2.2
MNI.B1<R^9\$41+W4H&R+>7GJ\$VQZ>7PFI&#<JY98&#<I.B41:MWZJFBPUF3P2 M7W@O6<Q7RH4H1.WAAIBV1S201516AW+5.LK.[8X.3.8D1Y&003D8.L6 M+>#>P2<7L
(T@<P^<Z1+IQY^>P<10444Z9A-KD1C816A->BQ9IK MB4T^AF^HD22H1A(ASK<DV3ZM2590RCOC.)J8>=>28UAXI7#>91EIQPT<Q MB2K2.8WN1F6G)<
IY4INC@HKKQYVZ(FS7AYX.C.Y.22<KK8H1UYHUX^U.M.#>2)>#<7C@H1^<#<+>E=8H6H91NNLRD^CEUBA@<JG1/M%16<2 TFM4.RM^<Q1.Q9E.HFAY1A.OBAL.)@84.
Q^M&B1F2T.GT.D.Y^>F.DM6T1>H.L.E.AC.M0G<ZP^8>K^<#<3>D53Y4BB=>5P14PEH=4ZA0H1YAUP@<516G.28 @<L6 M>X5Y93N38K1<@NV^<K9M96%5J1^<R6.MHLO7.H/
M^8IRMF2^8JO5%5.6\$3A2^1H3R6G0^A1ZT51ADJC AR^@N(4D.8^<M^FVU^>2=U^<TJE3UHOP#>514F5>2F2>?GY5^<91<M^6R M.AUK7V59W>J\$?>
E0CX7.C>=>H1X4FH<@<M^LL>#>25P5T.X21P^HJ.19P^M^R^M^N^/B4@<V(D=>DB^<#>U+TCS&8A^#<C.V(K.<4>#>IHP>=>OAPX<#>7\$!M^?N^EM1=>160S6^..H\$<1^
WQ#>..Y^PQ^K1GAMPD)96TF<#<BZ7N0>M28D.L2>4^5^@<#<1^<N1J\$<V1FJ8H7B02=>PDN&5 NWZ1U4.Q865@<#>7+Q M^W+<C.O.LAS&EDZ 52Q?T1^RFO<#<J.
X1^<P1=>8+<6YUB=>IAHPLH^>N19C14H7DE M^Y.N.<+>5PU0Q0SC<W10X03HOA.R.P130R2T2FB8Q.<#<X&+<SQ#L00^1.MEHC0Z^>A01CQ^KXZBZO/1H^>
(R.OWHNXXM)2^DY#>7FDN&TRM>..RL<10^>MP.<A.Q0&T0>..E^<K(6&+<K^MHRGP01^HSD.G1D<K953G^KM^W&B@>.)>G1C<LFDG^<S^M(02^HVVH\$VE..3HHUOT^%20^5V7GE
E1H0A1WP.D16<#>#<BIUB&#<M^<E1YLCY<T.(N1C1>CHB6V9R331VMX.M.R^81T6.L&#<B91.1>@>1%78.M1XV=>JY^P3P^CH&FA
#HIFB&#<3^J0\$X=>EXB^<FX3(CBB^%X1.U2>Y=>AY13BJOZ^<1_1O7^74^F1 M#83>AAP1F=>7IRV..3^AW%<FN2A)E#8-W.U2J2>VZ3S7RNIZ13R-3P1@<O M6I?
PX.V1+W+8HFE1H8H8D@<E^<W^R5M1>=>M^N1S1^DYK&Q.3QU.<MDM.30CDIZ&X&NR7%<H1

```

L455E5H7P03AWGEC010A1@C0R6:2JKBH+&N%OLLE MFQ03^1D&2>7P/G,+|F+@:232^08-4^%|D5%=&JE:=-A-TP1AHUDS M^5>N-P:V:IA-Q=&KW@P(Q<
<=I#&C(A44:3)M=NM-6^0J/IJ-WXG>9HU-A3S N-MH+9&+2>IUE15^P40^4^7>+>BK:PSR+8#^+9:&+&YVNG:C7I@=+Y/N:G-M-M-L-M+J+M%#>P4>51H?>
9E1S1^Z^7^ACK^187@0HLZK+JWSA7KHU4UM(C)MWM>2>7G^1^BO^1^7^6^7^<=&A#E#^1^NAB&@:021YV>78IMDS5AMJ58D3@>30XA(RMPD^ANGT^ST&K0IGU4>JX<
6^Y4:DP@P1SZU(U-M0Y-D7:59JZ41-671=8DP:CS71NH<(MLRIBFYWKVIM/Q6S M<(E&PQ/NB<-|V|=-+QO>AVYOQX0&KHE76A010X^<
MC+T2N&2>8I@C^JOVSL7^0@&XLB&B>=61=&=&6UK8HDI8P8^FUKNA48E2>2L^0/3G/M^P^7&H^I^Q MS-V3U3LYVRVIA=O&6&#^19^BB
Q180I^1^2B390Q&KX^1M@N^F5^IR8L-G^2^B5Q+2H MK(X2JWDEMF:6Q-&#J>+J3Y10KWNGB+&C^E+E^12(OX^PUPH0&X^X14 M^6R:R4-93:
J4=1LH19E%G>5^0^IG:&ANQ)K1#8H:YH8HU4VY3S MK(X2NH(SRF609L^&32 MU6K-D<6=5)3:U9J4=3P81>D4N1 IAM@D^720Q7ZG203Z1^9L2BQ0RXI3 ME
I^E004^8^M6H^1&B^RGPJ^N0:ZRIFC(XGUNT+M^ MJH5HF43TF I5MAK^N2S&@&Q^S^K^>X%10NX0E$S:G^ULNFK3#@&A A62G7#<7^5G^H&T5 TcCOK@^56 M^DHLQ:1-
5A1>1>:588ZG(Q^3>2^1>=72>1^7EUXYA^0LOR=E^H05X7J^M+&KVS D1 CLML^1:BAU4R1Y^ED102L^P^&2^1^2^U^M3U^1Y6(PF<8EZZG^V1TUDU^>
59BV5I5G&6&8H&F&Z^1K01=^3^1-M68R9P>2>JH(C+&5)H-O^&6-1551^P&6B^02C@&SEFF&S^M0=3VBABIMW,MWJ^Y@=&E^1^2^T^H3:2^2P6U74>=I^W>X?>
%#5A@6Y^K:D9>J^LJ1RH86S:JCYDU6Q^AYXO M^2+T^J^W^544W^41F6&R^F@O^X58IM^4U^B6VYX^M^P^G^NDYF^8:69>66>XQ>G^>
M^&+H^WRBP7^VANA^&QDM4M72E:C8KH1M^&N^HDXL U^17^&3^7MT1B^157413 M915B&4T^GDCFE^PZGR^4D711S:==TAI>G>O^&NHHXYV^O>T^XK7%0^&6+&180#>23IG399U$V>
2(97^LXLS MTIE6:~%J^N)P>&L7JSEG9+&(SGR06H)>+>URJL U^17^&3^&J3%=&Y1)AF:IS?D=O M^+MK7)0<=&#^1+M^MIHH&OYKOVIHKC T@5.14U(=6#Z5H(7K^#H/I6=I
M^&AU^V04>=&M^1A17H4^C^K^OPN1VJH^P1V7^H91<=&SFZH>=NSI/D^C^Q<=&1 M^1WO<H1TA>=&R6P3JBNM9Y1CJ2DY=&C@V^Z28^P^OR^XWL^Z&P^11^OQB^NE8^4^3KT6>
M8L^NCFAN Z608A4VZAN$1@^#65-D&B8922^G^S:N2H1^2632L29R1@>QO MCGJ^1^1NA 19?>@3G^1VS4BWSWA^1J9P&E^QW(MM IZ3^>NNFQI^&L10Q MSC0 2UMWA4 B^N^YI
&B^KWC2^C^VPU>+>YFWKBZ6&8BB4^KH^24^YAD.BL M^81^P^DVUUMAMF&S^M4&QX^+&PRZ616^D1D7B3>3>S0IG1EXN^0&5%=>I>S+>M37^E&K^#16-C&J0B^7>=IWU^1-
M^HXLH^Y@G@&WEMANPX^H+H^M2N5<=&#>2VBWZWZK M^&A^1A55URK^C&K^&+R^S(BH>1A^XG7F1S=3H&K^&454^1BHJH:G19XK&5 MKY766G02-OLUBMT&OE45Q5&C^C^&
(&#>2^P1^602^JTS=83A030.K&#T9) MB^YT+&YMF^L^Y OV^8s9)/0=S:VJP^6-Q N^00&K.B&9(C)+O>^W1H0^SL MF5 O+>=&S^1H$A:1>S1H79$7R/DEM@97F^I5+13^N^2D
9NL^HF:JUZ M^9P29P34A0X8<^SV<Z&C^&X@Y^IHF:EN>20W2D7910THAZCT^PIBGC0^1 MOX20^D^33^&N^6B^JH^X1RLYR4B>+JUN0^OMPJG MWE^&T@9161^WTN
M^+PDDPM^>C&7KS^G^WQ^>2^T101^>M>AU>JQ5EYF^VVR1XZP^1L2^NAMQOK^VPUH6^&6B00^>=4LS@&K&S^WLBH8 M^5K520^1>G7JMK8>=>GIZY^&GXUHN>2>
3>3IFUHL^B^M^M2B^+B0X&C^3X MW^>J^VUM^1B^YJG^1@6H>+>5^FVWD^XH^14=5^:PUPG^O^&CINCK=O0M7ROM^O^Z M^O8O7^P00AS>NP<3^&+&B0F4E@&^L^SM>+2+
14A1247WZU713P2F16H M5&O&K&M4Z7?>+20TA4A^21Z^JH^Q^U55<=&W132=&L6N.8W1^7P=&S^MH3M^FCU3FEIHR>2POCNMOK4UND^INV2N^O.WT8E%HI
EDRO)&8EY4C M^7B>+1+16J^IW^1^R%?2Y^INH8=&^O=V^2NWTEG^MNW^=&Y^C=&^ALM&4B8QI^97@159=&X0^INS0W>IOY8@$HPP^%AO+>=>MH759^&J2:
L^M1@QNWV.VU^X6^&K^M^YU4GCVI^PDP^I^M^AQ^H^HNZWT^M^SQUJ^MSDZM^YCG1^EMX&C50IHG^+ALG^2^V^D17<=&#^MA0N4^2^=5%&+5694Z+WE.%FI?G>
6&G49^AT^7>J^3PY5 GME^UZI=1^IR4-M^&R^H61^K1#&G^Q5.N5M^C0H^@&4Y1X^1@&94E8^Z5:5^SA1>9KGEQ=78U72^ME14&1H4-P^OS
7<+3J^MUWMD16>16H^&DW^GXO^GMG152^XH=&#^MN0C^M^2:SRWE&32P^Y6=&5^B7^KK&Q^1U^M7KU^H^KM2^&3BWFI^V^W^XMM^AIZG^+&Y2I3W^3SLB^U@&+J^XFHFW^17
M1^0Z1^%MCS089.9XTO&C^&O&C16A^20R&GBZ.B8$^54N^H^1H1=&+>V^VIXW5 M^8I^1A^E9^Q10+1KWS^1^WDC^FQ5=&5$DWO:01YNS&WK^H^>X>J^D4 M80^HS^L^HOH^:~%
I&OE^NMONT5XBF9^71?2^MNOMD^N=O=5G-D^Z61$^ZBO:~%#R%&V:IV@&#NE48^6 BL^U^B>D>0^H M11^XH:R^I^091A^>=>#LEVB^&0H$7RD0/ATB^1C^VIC6
M^SVU<+&4&88#&J&C4<+&3AU>+15^#071ZMM^G^1@&1^X^B+IGX^&BE:~%MGS4>2+20U^M^W^YK7^1^1W^&^1M=7^C^M^R^7&D4H^&#&6+&3^RH1&=&S^M^#X<
JEVH1=&@&S1K41$QGR5>=&LHGN^1@TOR+>@815TNL01U=GS^W^JPV1M88PMDK^E=O^%1^79HPI0162#@&M2^R^&G^U^NGI2H$N6#@JL^>T^&88 MR^&C1K0XB:
10H&HS^E1JG@&F1+1Q&S:BL<=&DN$%1=&7K^%1^U@&4^&VIG6^&M^1+M^B6^T^L^E4B&K^P=&C^UFES^J@&C^VULP^7^&#&5DIE^L^SDHJ&@&ZHH3T
M1^0Z1^%MCS089.9XTO&C^&O&C16A^20R&GBZ.B8$^54N^H^1H1=&+>V^VIXW5 M^8I^1A^E9^Q10+1KWS^1^WDC^FQ5=&5$DWO:01YNS&WK^H^>X>J^D4 M80^HS^L^HOH^:~%
I&OE^NMONT5XBF9^71?2^MNOMD^N=O=5G-D^Z61$^ZBO:~%#R%&V:IV@&#NE48^6 BL^U^B>D>0^H M11^XH:R^I^091A^>=>#LEVB^&0H$7RD0/ATB^1C^VIC6
M^SVU<+&4&88#&J&C4<+&3AU>+15^#071ZMM^G^1@&1^X^B+IGX^&BE:~%MGS4>2+20U^M^W^YK7^
```

AS2WK6GR9DAJ1CFTRZEE4ZY43Y6B2HBB22@.J/ /E. MC6OEPPTEG1WP00@("N414E" S>@XW K+2E/Q/06#K#B22=JGSJY MHJ1HFPH1>8D/UT7=>E2S8.IA32H1
1>_PHHJ57VT.PZND>4K5V91.AMO.PJ.NK8NF4FH HQ=>GAY@JFEA.OU4+J/>ZOF2.LJK/>OVW8E7F.LC.T6 MBIAIK.VK4V5S6B.YTTP6.T.T.YAWU5.6G1H7@<1TM>#1?
N0.VDM.M.HS.82\$A9V8H#6ZDE4.L4.*9.N3UNF4IDFF>F5ZKDA.LTRS90.7AU<0.M.CIG6.<R187.G0Z2=>K*W*V.A6.9JH1.C80*W6H9/58H1NOV176JDES
MLU@.72.E8@YEYU10<15.VJE*QB/G<J5H1HJGHS3W@DIT>@.Q.E23P1+>1* MYTDP63@M9>6.6#H1.E1\$XDP3@<@D2H0.P4.U2RQ.0.C.HF8.O57G0E1P5 M45G*%0
ITDQSLVMIHOBQ<0#R7W*U<1>VP6ZWD-1J0YHJF75H@QV.B1+>W&1M*F.4.F7A.WY60(F1EKF1H73=>3=>M@<13N&F<13.MT72HMTV72.5<1ZQ005B1FPE&E=JM#=-.T
>MH9<*>S).M1<XB.M17ZV.PCN.N@KA6YR75HN.WI@1#HFB.*INT72+>S&XKJ=FE6YVUK4.3IQ8.MV1@1/G<1#1B7K@OI+Z+>9/GG(5/0S184.OTUJNO+V62+3.5X*AU**6B-IF3
M#063.3D.C.M"=5.9HR\$0R10>0."%SM42.L.L0.M5.%>N9+>F+>FX-MV.XM26B2.(B2.)1N1.Z/N2P.SN*YKXQCOEN\$43?5.FH.NW7ZP"=J@I.MPT2.C.N6N.X:2>84U
ISF2&KF6P3@<1XJFA9V51+>6C679.MC.RP.MOH.A*=>O+1JG&1;CH6R.76WU.RZUR173J+>JP+1YD/W1<0.M.ST66PV>5IR.TG<14.IGOM\$MWC9.X.D33F1
14BNC>MF.M1.IQOQ1R.M.JZZA4<1#10+1HXJBCX<GO.8.<C.NF9&JM<0#BY.RP>9LO7M<T4&X4*V1=>@Q.M7.P2SP1+1<1@.IO1&H1.S\$RP
FC+6<GJ@.AKXJH1ASH.CPNWGU@6F.M.ZM%CN#6E+192.T72&H.K#<PJS&EQ<13J01>7Z.TG.5<G.FV3.H.M.E.D1.65.JC.G.3.2#N0.P#QITQ\$*1W.
\$Y5K19PE3KVSFVJWW(7=L0).2.M1.8.F.K7F2.E#%1A.U.M(BX)RINS&P2P@<P0.QJ.SZER<1#>8RBD.M.CEBLEKCPD1X1&Z=0@.5"7Z*QRLZ"<9E29M3TPW.1
<8VO.P42.6016U.M.R3..(7>7H1R+<15LOIA@OE\$0U34M..@X#E064G>QMS.S.C3TJ.STUM857=>1.D.C.#JQ?>M8TANR7I=F.E.D.ONIPQI
IOWZ=>D3K1FOU@OZAZLO@>B9TDFY.71>5KS.5\$AGICVPZ80T6M.M.RDYZ.30.MGY.T.Y2.H.2#9EZ.3.O8@DJ1I<9K1RSNC2.RKA#UPWJE+J%9VO->?
M5(BJCH3<SL&H1#<C.#YVY<Z.P18+1PDCN@R8>70ZJH1<1HMW&JH1MPSU1N>C&D5P16#H1=>K#P7RZE(6L1.L#>H196E1C1H.M9V9QZIFXRVRB70?2
313G&X0*UJRIJ53ND4U.N=19C.6L1#P1#>RJOJ8.MS(4U1B35?>JH.253.15)6OZR.Y90KQ31.6*F9ARV+V1@.N1J9043%LH1M2=(0#>D.90X.44KN.V6\$1=>0.
45VJBTFN>HX\$Y1H852L.<Y1H5<73.MEKM@1YQ.2<1N7RENAQBRWB.2JH55H73YV2=>OPD.50Y\$Z10.L41\$S.3.M3X89%3EH14)UC(2.TPFGK.8.Y1Z7.0TZP2?
BFID76HU=7L>#..N5Y1>M1.6.V4V562<=>GLS>Y4<=>C<1R86E(ETXRIA9:CLIM>E2PLZ=3.BBCO?..H7.M2#B5PIDH:HA#=>POAY>98(T.B.BKC@.Z1.WK/2NGYC:\$U4#TC%
1#>U&A1.M&Q1<41J18KTSPT41G.C>1.5X41<C4@<DN.C.T16.HSY.IYX1>EQ.5Y.MJ<2>?DY5:QDZFKXMOV>ZIBCA13D2N#5.BE=R90>R<1(DH1COH0+Y5
M.P.M)X091X%0.0.85&Y4H1FH1H2?>K0&5.648<62QY2HPMF&F7#XMM.M413GK+1+>B+T\$1&5..5VT1F+PLNCT.DU0.N81BGD+V+9=>I2N5FE&.*?
M5/HJX036.G.K1L.ZBSCU6%LH1H1C@X&7E.7.F.A.026."2217R0.L02)X65(1Q1T.H63B4.8.6UJ&HJ41<A(OE?N.3D3C+X4X@.JDH30..MS.MTFL5
5LOIP<..P2GMR\$5B19.5.E&C53Q5LB2J.64K.B4H..0E.K78.A9/HQUWGP.A.M.TOU1=U<1.PW=HS.TC=HC@.L6MC.LG24S<6H1L.N@KEQJH-9#5S@.MIGS.7B-
1K9.ESB51+>A.9HA6YRMEF=P/RNX@R/F@HUUW0V.31B14B.M59P4@KD+E.I@<FG68MW.M2M*YER1.F05\$XCTJL.X7VY#RZ476-26U
MV.VHD4N8.RY71A03NP18C0<1>CP.<1&B.O?D.W.MG@>4Q8Q.IE9T05P208>2Y(1V7=B>)>1W+1QH.#0GV#Y=O.R+DVP<1TWD.MJX=>KWAM3<.(9H6%JXT=&
<#0%<@F@L1AU<D.HYR7B660T2JPM2.MK6%0B03315E1B+1>THZL15U0>5573P22>2GD7F<46G1&ANNY5H1D1.M%<1>.>HT20B32F2.T95G0RG32A1+1%?2-1
H2.LF.E1.M1W0.W0N.NX1.MP.WJ&J301.O.1UNX1O.OYV1#..<1K1P1COHEL.#7ANNP9GLA10B35C.M.U.PD<1.C1C161T1UEBT&GW.OO1E7.C.BTFED(Z95.%VKI24M
MP*GX1<1.H93WZUPV5(YE1=E.CC0AT9W1BD57&K1A2X054QF5)Z5<1T.M1>?4T4GN3EJH>2J10J02.D4W7>N2>7.L.ZZ15D33217HS.M1&D#M&K12<3.1YNO2G5\$O?
VRHO*YMSST0756FO.NAVIX@<D<Y8.32.MYE6216J>U+>N50KTTU?212)OU..N.VE6F5IDK.I4147C1P70.N.<1M71K1C1NP43JH00+1WUH30J012N.DKPI?
7B+1B&D1K&P.8.71A.OB&K&M.8.<H&E1XS(C148WRNYR9K2PLIWIJ1#>1>1M.C1M1K1W1T1F1<4A1BSWAU14<1.BV#BGMV7.OH.H#4)3PVT2#5
M1.M1NLIH1N41C84.Q.0V0>0&OE965N7H(M2751&31U1<Q?HBT6@<BMV.MXG1M5#DA22UP1B1H1F#>AL<@QMXQ1.F@.T1.TP\$W.MV66G>D@<P.90AZ5ZFB17>
MK6V79.U.K<1X.72>2.95DS<44BX1T+16M13H1.4.80C.T.EQ1L=6.MJ/<SH1QW7E9U#<12W716H1H1EVE61Y#B&XLMGSHK6%2%>OGC\$C=4
M517H1Q1@1DOP6<Z1Z29..5>#Y31B.<H3A.2.2.H1H3GN391.M1.3.3JHPI&XES.1L7VIR8"NT"7.7.2R\$>MYNIR21=2.51.16JH2C%G1ZDF>21L1H1B6N3Y1#>E..11=>RC+Z12
M1BGN<1+BC<T.2141H#1810=5MA1.G55WBL194\$A.121+1H1LO.10.M.M@Q&I472.T.2L1%73C*QD1.H18U>25>3F+J9>2)SKK5.M600+11Z<C.P#ZC91<1X=>G.57Q+PH33F
M7>9>..P>2692.GH.ZZML>KMD/GOXO.M.P/2PFO.SN(W1D3PI9M2WP2D1Z.BY.OT1.PCX2L1MWR@GU.N1.XYH14@P.U\$41)>K1F19K+
ME2FY.79CY.TP/B1KFLMMB6M1C71@GL1P59.M1.MG.2BF700961F&1M.5L1P+61KM7V00QHR&K1D1@X4LP1LX59.8.F13AUS.N.HP\$>K6W63M1
M1N1L.B14YV4X87U&..1.(PB01P#..B.>XG%>RWY.P57.G0.P1QVOH\$>MV12U.YJ53.3.231.ZVL.YJDL33PSL05V1)1U5.MPOQM.ZM&G&5.OZDY1@<RO
42Q521H18.M>D8P2.KR\$>IM#BINQ.86.D16.<1U.MER>DS4RH1J3&5=>1%<XKAC8CYD=E1A30Y'N0=8Q?<1>8>WKAK3.U0975.MK6CT1.X#1YKJ@#Z1.
4(H00FS/5XA06F.>Y14V+1(W77FN)M1<1+>OGS&M7U.BGC>F1HJR.C%G046-WZ\$8F1-V=>E1&1Z.O>MHU6LZE>SZR>MJP<4.M1C+8X\$4)HJKPV7H1T8.C@1J1V3ZO#?
P<H1FEW1PZGA.A46<2.SM@<MX15B3E6

[illegible]

+8EX2.HOY(3PY3'UIC'5.V=M1...YH...+UUIVC'7R7B9LC@/4F/1881)...-AMG29'A.G'6C'0^B'6'(*7367GS7QMBZN-M3B&IP6', &1T^6H')UI.W'5>)<NIPS>+IS
OY@/PIJFI/H4B(41PR5..M8&2&2&..H<#&59J>..J8'E5'S..I.W'0*E..MBUHS8E'..H#B#&VXMFN'G\$=YWA#F5'7KG)OIF..HJ.KO'#9.@>+WTFD/7'P^N..ML.ZJ'4'6T13KE14V#V.3S
=T'7H7R.T5Z3Z'1..E=8M'7'<8CN>.O9MPX87V.M'K'1^D.Z4+OE(=D^D)H@PX.&^F.Z4UW.FD.PZ@>3CS5SGF.8K'Q290.M'>00#HPIF5Q?<
Q..W'FX<35'08+121ET^IDSKR248BPHWZ.OUHZ^NBP4K'1#W<@<X&T^MJ'1#..E.GH(RQ51.1+VWF=M'...#FS72%F0%\$RIBV'<2#B1>)<#98=<C.MD^+80M?
BA<+@K%MIKCI=0MM&W.4251+V.H..P\$ 2/R.M6W>#V.8LA.DMAH89.LM8@-KW46.12IN;7COPRL96U2+4.N%N<5HP.1.4;127KC1A^BZ'7.M-7P2(431MKL=103F<@DO*
I&8)YLTW+RTGHS\$Q'U4P>FCW;1.2>.#9<IE2MU.MJL4B4J&R'..543A.Z1YD?72..8P)EL>LG90FT'P.FR/GY=OUP&6HPP#..M\$4E5U3Y2#B0&P0H.U'0JHC/IB'Z'<F*F
ZQ#8QM+MWHH\$&..L'U'VG=2'<#>..J'1'NO1-J6&..1=P2U'2(O4JON(3\$..*..H0\$'V'GYQ48.MH1=ZX#B9M..1..9>>&F1\$>2(055MBTBZ' HCN'112'Q'0712U1CZ
MH4LSY1+0&EY&A1X7RPSV>13U/LG31>>4J<..Z.30UBUY^A9&TDO/B)ITM3.M9KHSC.31N979S7E4U'PIHY1MCW)3IO..@>B'JH'J'>86GTVM'14W'PMI/M5YE0)250.4#2X2
9HC.MR&94+G1BXO2UW>17NUJFX+V'5(F&F'<S'Y'Y..HO'Z'97A'Q'F0B'9'V.M657SR48'G'1WAL'29&(K&PAD^Q21V57MABR@6#7U50.2G7%..@QIOO.80-OUAKAY
MGJ@E1.EH2'IMEY+1.7FV'>..=PSD)'YS1G)QN78\$7SJ&Y'"/UD^R7-Z=Q.M7W1=67J870DI/IZAN')Y1.N)5]'=5#MD6150CDIHHBUK.G^13@)WZ-W'16<
MJ.V8'QC'P'V>12G'10EX+1.@9N74XY-BW9^36F3+H\$18264'0JF'2'@>G&M'Z1'..VMM2.KRH..P.@1R\$<v>+71SP.BQJ4744FJHG>+10<9..65A\$
ML#R@/PM.LIS99U4A'EGW9.J9>2427X'W+6G.MG1>1.N>=2G<@>.D#@>S>..U4'.67G.'GCV7&6.GXJRW/MXA27YA5'&'K'1411'
M=DCH'7R.U7H'.L8A1&L'MF'..6C3P.P.SVP.01TZE3JHU17^VUIE.AUH7\$=70.M7B+O5Q.F0'>H#L'..%09'&V.LH\$N2134XYT^1J31'1'0+T\$>5&S)>)>X'..T.M)-VF.0?JHK?
9.ACL'G'7'NSAMW+1+5%T3.MIPB.P.11\$=5\$S.DSH3'N/N/O'>G7*CVB'@QK@/564T6JZS8.W'1..%M7.N.RC/ZH\$3'YVGAOIA^NS.V\$;P\$*+FNH@CF.M(QVIZ)LW7-
<3RXNOJE<3 %>WGIGCC^1JYLI??COU&Q+P.R>.>NVUGV'!!M%A9T)@SO#Z=W/QS^#HJ.K^ZZU'P.^B0+O/6.11>1^793(Z(X.FIC^IZ.M
^ZD3B'1QIUU'@HJO'1 WK^XBFLK.IDL=^FV<2.C.MIBIG^10%RC1'Y.W'1A.C'G'>0'LO\$Q*SC'RPYKUE+SB8M('X1XD0&^KS')P'>E&85.V.B.#AC^C&IB
MXF'P@/AHI(^(D.N0JK)@5.5>+CM.X&L^4.P.11..M.Y'Y'1Z4.Y.T+51.MN1<9J\$2MJK(=12PK61/KFPIR'>1^2N71+1..P'QI&X&U'@#6>Z2M810'N9.56%..6J.FD9N7F%FJK-0
DJ2S1&5MKT67H6?@MG1V^QCHM'..1'PUOIHV.MMDMOP.MXFFN8A&(21+RT'JY'15'W330.W<..4+3&6D+G'1%7ZHH95E.E5.1.MAC&X'1'D6\$+1.Q'0%9%>B.ZG@<
#8B7.W=5.L1.VHJCI<=210L&I\$=27%<41.M9..1+1+12>26;LISMH9=..DRG5+@QD.M-2<(<T9W6#<4^NXN02217G.M4070PWEQ.E16216/4ZH>..P?P\$T'..^..CJ.HJX'
1>J'P'QZ#<O'P'Q'V.B..MIA06RJK+HJ0-WT#JD>#9W'7?>N<4MDMQL0UIQI.N7P\$UB'B&MI04#JY#J..M6#2E11%)Q^F@.T<1\$?Y8*+>)P'TBS:
=>FX@ZE<+1.MXZ1'0IRTY1^1RT.M1LX.43#KGO-6)H1110LAWP>0H1#N\$3.311=FS.Y'Y'<#>.KS90PP4&5.MC=<1^45E0P'INH#<1S7..1'>)QO6F7CM7'P>5Y^H.H88
O6LK3'P#<#<1-4.M15Y9>MC.RW.EA5'V'Y'JH1.H'1.A%3L^MZRY\$S@<1VQ\$W6>1.Z.4PU'IR.M.NVHC>1.L/5QAU>+D13+U.3.IDU>4RH2YMO>D#0'Q1BC&(FJED)J7^?<
M^0^Z'761(CY^P^5UH%SZHF2.1>V\$O'Q'1B8H'55J2;H(M48%'>#P8'.M'<VNFV\$K4.4>..R*Q.17>A17E.515.FC4Y1I08W\$@M5X1XH)20/QIA#4G.M\$TA71=6RZJ0S493=W5?<
M^9D\$53T3.OH&<^<N9C.1.M1BTAM.N)3Q#V1>152ISN;1>W\$E3HA>..16Q.6V^F8J\$3(1=1P4L.K12UO.MKY6%=>H2\$E'V6=X\$>5\$>..%R+&G.2U&D?
^<A^X'F'PI#Q0.GVZ'Y.<12.C.MLOV..IT@15=">IP3DEZ..=2UF.6^M7%YEC8KT^X(UA^K7FR=+>ZGNZ'^(M.MO>+K2(^BENLYF&2.HWOH5'(^.X)S&A#"T<%C+&A7'P@3-1
(6V.HQ?KZB(SIEH'1=0N..090>8.MP=1%16H7%ZZ27'F'..%>O1.M-9>D4E^M'W8B=8.R'..4YHSE.<Y7F\$>2L.MFS=UHUJ+X+X'ATF<O'>D)H=6'G+U'0'RIG.UWF..5>+<
L.B5XVF.U#<1^1A+Z12448\$1^AHK1@0>..MX\$8\$;C'..1=">343&1'H6.M.#G(7WBW1^1H7HG+5HO..1>RH^5Z=>..>MCKPIR^O4F'W.SV.#)AE.PC\$..MW7'KB4KDY74..0-#F.Q-
MIW1MVSL.HK16.M'7T'R.NCP3.2>8P.PHG.TPMH73V'..@W9QAI.V1.1226'HGN'Z'..1QIF'W.MZ(C'2HW&7H31JN'OR6STVE\$8=2'XK'7>+JH+V.K148\$V.MLDC@H(HB91U;1#?<
Y>Z.1%QVX52.MQYVFK#ZEN4IPK3.PD.1P@<30P.1B4VUD901'1.E'6D7\$1.M21>1.OU4\$59G4\$S.OX.100.VYU5=0\$..V'YH'N.VND.'\$>=6.Z#7#1VZ\$3..M#<0>+<1>F@Q&Q<
<..HL.B-9T^>?H7ZK1'<^PCEZ'U7.W<@LP+2DEX3'Z'0.M7N.H6AI=T.^YVMH@08P80+8^1&NB187%(7.2C14W1^YH28E.1C)EU^1^MJ.FA)P^9F34WZ%=>A'MV\$+1^<
M5U'.D7H0D+1X\$>QB@1=^/5LQ-@<R=6EBR'..N.H1N=<0L1F6BDMWY.51%>30.7.VU>..VZIGTNXAROQ'GUBCFY^TQ&D.ACXSP9+1J5.MD'..Y'YJMXM'1MD'+H.L-AP^&
(MV#P=<DL6VQ1Z2GFI\$S(15\$1.M8I318BDQ\$ULN.&1.6%>@SVDT8'YH^A&EFMWQ\$B.13BD4B3QY69C'.71.2Q*MTK.Z2W8GX3R'..ML^BWM'4IM..1%>#B+<^<N-
4N7G.CY.1JQIRP>#2YF.1P1.MOKZ'>6.A1.SZJN(BZ2QC'LOJHJHGQ'0.L&^U.JSYCN.P3U46'GQUTYD'0.MJFG@.1'<801'301%<261XK'1>^EVH%>Z.YE-JIS'Y?<
X#2Y.0'19WGFU.M2<0QXSY2W.L'JHG'U#96.M52HF@?68B57497F6M3@Z@EU'P\$5\$G=4Y..12<^Y6J1.RX9UO6Q166BDO.M-1O.H659EQ.T
F6(31=JG.P8E#10L.V.FHA.U'Q'0.A4C+UMUBF'>#BRA.MUAT^E+.00>\$>O/E2..R8CDITUWW..P0IM9M@<G-5-JK09177W16N0504>76.M(MS3.R.FH4OVT4.CZ'
10'H1SA1\$..#JE@4(O..M'<21C'>=7U.A.MOC^U@D4P>B1P&Q1%>2^9^1ADE(9?..35XG(VD'.74W1-IBL1NPHU5'Y.MYFO..1%>P.WJF.BU'0^+Y7W&V'
24\$UL4'7.W9224(4<13<..O.BW(TE'.MDI8F20RGZ'..B221'..9K&3'>YVY7RTU'..P6N\$X1A'>U'Q'D43Y.MNYO'W9U5'..M23%9..2%>PWRJF..X=<^Y9KCE1.1^&X(W5#-
&ZIG6CH(C.M.MQ..6.61\$#S233LCT.H..&M'Z0L\$110JF1^EMH1^97K'RV+>#45DH.2-Q1M1RK1A0WCG989?/9W223JUD1HQJ1P/L&6%Q0D10P\$BGC>V41.JH70'..MHG6PFD+
1A1A@P..JAE4>11678^&1PDR^&89A7XRI^C92Y614+083Y9R1X3).0W4AC.I..Y@.0E2'E'..T.M1XVDAIP^&%R&R'J8'>R&=ZOK8R'JX'..#=@@<..R2.9E201F8Y4?BQ1ZU
MGV@D^E&ZP'/1^77AWOF^ZT/1A.IS^H.JH21EOW'FJQ6&1>\$X1+>1^SFU0D=^KGPEP@..UHS#63Z.7&-?>3-M>1^NW4)JLA>*.412^XXQ^1RIE'.MQ.1<#1LX1'
1UXNZG6>N\$1\$5..110J1TFF'1>XBBXU+LGN\$P'..Y-W'1^MBOQY'PBV'1^47'..1^010OC3'F68J030X&1^@1JKN^Z-Q+ROV3)P611=13.M4'1^<^CNUF8Y\$1.R1=6G\$J2+1B7'
EAA@<F^D.WBIFD'..SV^UZF'>@0D.M>Y4@L.B16CFQO6B49PB.U/NZF1KJH1^B91.VGZZ'NM2T1AJ^1Q9X.D9E%3Y1U.59.R=.(27H1&6>5L&HPI.M/995\$C1-1/P/DJ-
Z.TYJY25'1^QAYT^..M.61R\$11.D7N.M<8V7D@52WK>^NES.Z.F+1.FTD1K.A^N1Y157WT&7G\$C9E.ORAU.10TT1SR9Y.MB..
AN6MFYF'GKX'O1&AGD0^G^D1QY.R2A^T4L6G1.Y.TGHHNG^Y^P1^H^M4JH13MWV#<CQ&@J'E'6Q=<=RJJT766.Y.MG.6?<
915%WFC7\$S&YE#=(818+0SD^4M('ZHL^05B5AR'1W\$2.^V.TQ108.MM0P-AP>X14OXSO.SHPM#09F.HR0F'VIZ>P7.983GSM#A>D\$P<20Z<6J8+\$E
M@<1#8Y7/OE1<..V2X<#>Y7JHGIGCBUBJOKDK^P8Y\$353><F7.6TH<1^0L.MG?B@AD184+1<4>1'>U>0>AH3)LO@BPPI+IGW.G1-93^?<FCTFT#1FWZ.
MJG'F7H4IK1+>1\$ISHV1.U.Z22?7#HIEH1.BHV.G.P8B3L.59WBK).MQ<80&F.M\$F.T8HJ1A\$S1>B>9EL7QW10>IQ<=>J1X?MUA.#EKIN.WM0=>6XDI^A#12"?)T62@HM-QK=N-G
M19E.U4P\$N=MX<^1^4TA">+..W.OW'Z1H08.933F1X'B3N.2&Z&3L'6K18.MH.G'F'Q'>42DYH^C'2\$5Y+>1^K^N201Z@H9C19P85XPOAK=M1B3RMY.L6GW7
19UX+1.MBB.2+X3&64^LIB\$&DJ16JIBF0GZCFZCGGN.MKS(7'1'>1=IQASW.G66H0P.61-6JM.R@.L&8T'6Q.C=Y1G6H8V5\$S&D1R
M#<16IN<>P^VA.3#V\$+A'G.F.M'1KE^D'K7')NXOGTZ)MG9X.IP(AV1#;WIF^D0.^1^JWK.4K-360-(@N62G'NBNDW#1+M#E\$%MLB.M1M%<1X'>??U7=<6G/8;0)
1^K7#EA(4\$)8S1TQUPU19TPC91<1>?>W'E'HW'T.MJ474G^@YX^LMOE.RHDT.F5U.A.JRDT^Y8DC\$<^S1^X7.R'FV>HXLOFZ.MG2EINN&07\$RFX.XKN<9X=3DO.ZK9;BK-
BSW=510.Y.WQ\$OLW'>X&XV>?QCL.MC3\$=ODIZBURBNW3KP#>M290Q>6K1X&A.1JFMSU1B=M/T9'P1^&#Q8.D.MX6C'X3110.N>G&+M9>#5XU4#8U.R^82)2.7762JG.PGD
@61KG1'9JLPP'G#1=9E7&@N4+MB8-0'W7.KCK7'4D^GC'U1G^1.CZ4L.B1810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
86M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>AS5.MR.9'P'19'F7W1EUA.E\$G.)01\$1L810Z2@K1@19BURZ1^%BT\$Y1X&1A.PET8BL11\$E3D1BL2+BZZ3&F&Q.D.0AA&M8YRXMI
H8M.L8H1&NHJ01=926&14R1EZF7'LV.S10'F7.BA52ZG7^0Z.MR1D1^1.G^6A11.MEMU1.MUJ'DP'GXU'6K.4L.D2H8L11H7'>5.H\$EFL122'F.M=PRDIUHF\$R8'DY9>#<C#Z?
N=Y1ZL1517C01%#B#9F)>1J3R.PM164Z0.XVK6&X03(A2Y1=N.MM1A^2Y10M%<1^MR7-Y\$C81UGP.OW+FO+V%..8HSO1+..@CKWAO1+G.\$6^OO*^&1?&V5H09.M_9H@1?
AC0#&ZEW'..P7@30FZ17>V\$M@.T30@.1/1+1^455UQ4'Z7RC.L'H(C@<HJ\$1H'V59PK1M&G/5%5W^7ICAZ.114P1.KF1H8IVIC.MB>9W'W=>#Y#ICE?
6USUQW^HS8631OBY11.OV6GAYKT9L.5P<^KS\$Y.E1#M&K\$-Y1C1F'X\$&4\$2<1>=AJZ@+1.OES.516R412'3F9\$H67'YCYBRH1M.X1383'..X#F1N532.
M160#AGB.YLWU'Q>6.(YA18^1'Q+>2221>

[illegible]

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s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

[illegible]

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s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

[illegible]

[illegible]

VI-XQ5 M7!2W%8Z(HV"-?I?Q?JG::VOVIS=-<IG5?M1%O%FBB1MNZN0=2A%T5FIH4M4R09C=C F0&^?TC/Q?>I>NU=IWIIC?/UDWFI5>*I>IT?OEM2/I5=O'M#M
MKT5?/56P2%W=75 V^F3P-X<IBJN^E#=#R#N?2.GX0?0ISQIH7@S(S2=2SMN M5HH0-XMZ5I>2IT+I>M^=5E+>RXUD 560UV^Q^IHU/I>+IHU YHKU&F
M?Z@IP<P>+B+195R13%JOZIR>USOJYE4A 51K)<2YI.OOI+&FOFR M0GRF+1GQ(RI2L1LZL?P?>2A5D0P=&IT72(JMGJ SFIK@=L^CN1=E^M MO>MDH#L1\$TTF:VN6454-4
=ZC502?0.A6V5IE3D+!>D2L.MNUO@Y^LBP06I9B+N244.M9&1@>BCT+M#H9R1AN>^3?I4LJAH6SR2I@J25C6GOMUS/VS^F\$T84FV 90\$1 M5V.M-WI0K92-40+&ZP6.1DS^XR/5+!
"&.(?WE5+!@O"H.Y1#BT">+!T!M1 M'A..ST@:&Y7BX@>3CH 5P@&E\$5PI#E@24AJN^2(C2/I^="2/I^&+F.ZVIFB%)M1+!R&>?)IXJ9I-0@#0PHT:
AP#?7RN ?0^!LABZ@R2PS@A.VA13>?O1P14R0C M@A.(N1:0P15=NQC!G3?I^?HAIQI^IC!>+2@E.%60TF@):06&Q^Q^XZ M#(2!AA+!K 3!5P%:@AV.U/IC\$@L:CCP%:OT@/X
I(M#H)0Q!C5 82.M.810A0!9(I>88F<>37AD:~TX.IX@12(I!GK9X-25QZ>23\$!A5I3<5\$ M7M.M#2~YW<(&5F^?OT+!LPC:40I^&OV/C7+ C^#1Z O.I0I0NU^EE-9Q?7
ME8!PADR:2XL@5H8I9Q (&X&K!&D@I@DN!XC.9)=\$#IB#(G7>=2>D#M! M2C&BXDL15Z\$D5P^K!IB^U@!MXN:2.U3VXO M^+&9%G 0K!+I7ZQJ>296RVYV.Y4IB@<
Z6(R)7C-C.S.UY/K=&K15P=&M3U>I>O.L00P9-1L)Q!5D!DLM1!TC.H#I!MXK9D2P!CQ!I^?%:QGBDHA@&BNTB#14.M3D6^!IOZD(QK\$R!QO:1T<=&4V9=55YV/7.8ERI49XPY
\$10\$*!/=G\$RI-ME^O/LMVI/U@&/\$ W30.GIJ<(&5NY1SK6:26V@ 4^K C.-6B9 N:~Y&I3 MGQ#~I^G%2)=A@P>!XZ&.)U+=NCD&E.I3U\$Q!+)>@Q0D5I59~BC C^ME8GL&~?
>7F6M?4&4MC15.BIKI>?7FW~!W%>Y?4YIP!IKD3JFRB.4P MM%QV^XNP#G!K46+17&A6PT#B.B12L3>?WL#>\$B1-X.OFF+H.GH:3?Q!H#S?X&.&RW5&+&~!I.U.P=BP@N.JI+2B
M7!M#P92~WN6A@V2-MR9D\$M@>I@>HV.S^C^S!A^Q=>1^ 68I65.2N\$U& MHX!X#G8Y68!U@&A^F0#D.&I2038!U@FW-PPD=2^6
>=I9TZ=M!W.UZMB+MA?7.S0H15\$15#3.YCI@I^P^PIE3JH@2%&G M4DP8BU@B0!KWHJK^T4B64+&+&1.OI+E2!2RP07!WWJ^&GNSTR=CU4?CP.\$ M4JH5:39.WN6?
E/0B!H.U7K5..M5L^!Q!H.GDI.HGMY%&XYWAOA099PN!MCO6+1+I!U5IV=>M^!U>X!KIBUFIK739WE.C6 CH.X#&GG=HPYIC4AXK
M):=;Y5&CKO%1!R1C@W_<<+M+=P.E.V.K&NC^84YMTTQ\$@CFMD\$MT=R& MR\$72SU8-7^IE?)RM+4U!V^!+WA?@H0~!M6*#B!936UH#&G.YIWNZDZA(O^G.XY7S(?
HOXO!U+ P04^#.#+PA9IEFD ML^!)IM6 #P-9I&PM97@5.5IR!FA?>Y04.F.C.3 MAR802A0Z.SD(KQITX JAO?>1L>5\$1.9<24I(=C^N^PIE)(\$S\$N!+&?I<+R2
M5FOIMZN5..AB<7^COQ-8D.DCPXU@!M?O/UZM7&YRYI8^?7.I+<3?T MFQOCYRNI8!%?%7\$U.M.D=2J5H8EHS0>3+PR52WUWYGPPWY%Q!0I20<Q
M^<6>PWC@AKI>+?I^!33^/~KM=2T73N>D?E:IM!88VYF@I^C~+MB8 M7.F8H5@70HC8Y.UYX5!HXBML\$50#M4I@112>?>IKH<I^G^&~!W2@/FT.MMY08T-0U:
W2H4(IPVNZ)D.Z#&H1GZ\$3>+?I01Y2Z>D?E:YX8XV>8(1T M4!4&ZCN?>P^2C.DU!8X!H3L3^S.HXO+&GFGZOKFY%&ONGV^2+!M3+!U6^!H+Q2Y!
!VZN.BM^M%>KIVR77WY.JO<~P.MTO.M0HV+O!3)9V3^KD!C 76-D%E6^W7N2:=T!O/O>H_&A^<ID1MEI!KH(FLI3M7 MGS7W60O!LMOW76QFO4.B^8CR^Y66#1
R!HJO7F>~G!7^600.W+EU4!K7 MNGI>G^TA^Y+I5C^B!R@O!H0R0&G^J^A?&=&EQM2A459IM\$W@Z9XUO-T.MC.#M=VOL.UJ.AU@Q:~N3P.D33S?5
4JH8#%RC/ALM@&TV%~CGD%KZ0027M.M.P! 6!80+&HQPNS\$4I&+P!7=88*(HETA L17E^#>#(A62)4AL.#A0.52\$>#(GA2G@&240#>#&1&=&Z.MSD@GIT
@803FHH!BL3TED\$1#(=5\$ U5\$5%>DIP S?7.M.M^!JFLA=^%G+!+8KTIY?9?2?B6C!M2S!0AA^?)1^W&XGIVX5Y1B>? 2075/5(!^~(ZWU=O!G6D0085^H1Z>I^!~MH4X
Y1Q1@>HCE\$9?0!H8A6I6%&S&D%YH434%>#0=A@&~40~&G+I2.M!%O/233D6!245&S M5&4&+!XH=I^#&M.S.P47RCS0M12R..MYM.E!O=PI6
M/IV..13JK...\$9>GCS^&DE\$X=)RY!Q002RO@&\$<!)PF0A3^~4X+K@JC6.SQ.M@>0>IUR0BLRB^C2L!+I2)0.6PL>+!^I0@>H8.VI5%788KIPEQV!LXI?)H.:
I.9(ZL!BNJ5=4^20H0@>PGXN!A4D M(HU9%JL:KUU5+!~I24V@E#3N+!~!H7I9!HJ M@>=O@JL^I7E3%AY@=F!9LTA&BPWE8B^>SVCWIN2RO76GBF2)K!^N+
M7!@&(H9MYI2=X^K^D25YH@>5..15.HEFF^5FV?D?3&K1=ASA2@&3QLK+RE7KAC7 M \$6X)>X=5?PX53&~!OYVCO+?&T!T7~!C.@4SM4P==R.F.I!#=\$>Z!Q
M0R0KDI@="2^RIUB9).#X=^>P%Y^BPN.IX^!~HJKM.KV\$5&7!HA6X56Q!M\$>DUBIYM@&A@MRD15!6%)^OO-Y^PE5YF?ONZT21BDH1?>C.Z&...&~94 MZ-R75
GX->2@H.UE.UJ!^H.G^XBXK^PNFQOS..%>+!4L^~R1BMJR!VUXP M.ELK.ZM6RIHJ.C!HG60.EE!H!K-OP(FL^!>0=<3!O@PIF0.W3>+!MQC#8.8^!>F^ED3Y-
(2^FDY#..=H!YXJAG+MZYB%0?&T+I^!=:#0>YV-ID^ZREO.#!4A!O%MXT!0K7!DVE!H(Q9!JL.MZ#7WQ4D.8H@4W(2=H+!R.G0!BHS!IX+G.O8O-LI>
MAU.J6RT<FD\$HNG8D!PBGNOV>=9D&C!J^G!H.9M0.X M^ON>+!~I4~B3%Q9.1%~&2>=&2>Y^YRPO7!WR M^=M7!FVZ!V+G!H04!H9!6@Q!~9K7V0^>?IK<#I3
MDM#&GW>=2PYIC44X.HBU=DOQ=&~GND!N^T>+!OGD(N!N!Z=O>=825?0M^>DR\$E\$S!YMTM.W^9QIR.GDGZW@/ORSXNP>? 9KA0!4\$!#10<L!%E2!F2 M8 8 \$LH /
=FEET^UE\$>R7\$S.N!1M15KK4HXLX@I^?4>G79@>EY M 4!9287P12.&Z A7^L^4N=>4.EGR03TK^>5XGD(8!^?72D@>H!ZO=U4!~MDM.MT3!F 0^AFA^!>=AIN(I7>~U&M
^I^!18!>@>TD.9.YXKA!H(N.M&G+A DE^~W^B5Z&..EA%(NABH!D)>6L.G6!4N^!ZVL3! MC^H!0DC^I^>6.XGQ!HIT.CF&T^>V7GIN.JD>9&FS%& U^&AO!6153A MK-
O)0^DW!MVL5>H!^&#DM~H>5\$L>~9J^VR>T/!8A.VIX.VUKW^3.7AP7A9H!Z&RVFJ=(KQ^XP\$S\$)0I+^4^Q8SIP@S.M\$&IX#H\$+Z^410!LB3GUK?~!LC(SYB?
^*FXRNI>?B\$10P9MWICA^EY\$IP\$ M T%FE^*K!L9H!Y<FIUWYLES^CQW@8002U/PZ7(S^&RZH0044^G.9!ZMOD M.FCTA@&G.H^28885^C^8^UJ4N>U7>+I93AN5!C6+
M!CC@&D034(I57U@&5#J^=UTNP=DI>..QOWU..+!B=I!P^W=83!VY(I=&M^W!^!O7M\$W5CHP3L!&+86 1^@!2S.=^MMMMIT^#HRC!KG6Y!U>P0Y M^#RUH15^K<76# 8H2Z
RQ09CP^T\$6ME6!B2F4AKK@>G.M\$&N\$X.N0HXCI1?GO>=0 1L@?2^~!L4 M!JLM.M!/@:30.%>2!UR:B7H!W4ZVH0I2V@!JYTB5H!E7%0H!R5R7G M^ZXQ4?
2A5#O>9!H!\$H\$Z\$>2X19\$>M.DP%&R86#XU!8RMS.U0#W=I8^>Q00NB3+!KC#00I%&=&1E5TG!G5T!^2.M^X46.ZA2^4SD>H^C(O^!V!~!RDK7M^Z!
(ZPKVDK^=9KN!JOK 7N~01^~7RC<=&8A+YI 0!X30P(E-MHTS%TA&LBG^4F!5@&@)HADY9:68=Y5&I=I60X^UMCUTX0!7^~BHSBI@S.D M8E!F^4I&=O^FN^I<#<
M0FP<I?I^&G3X!50!GKGNU!H!<I=O+&W4!^#X#ED.QVM!IC#>N!MU@H7^>@AHD?>4908^K7A> LU^OUVO+63Q?@UN?I=KJH8W67!3Z+ZRXA1 MKXM<~J\$W
>6U5I6@L6U56T!94GW5+23SW!J1N>@G^ET!VLSRQMH!X.MQJ0!POTHQ!MG^!6V!80T0!F!&+86 1^@!2S.=^MMMMIT^#HRC!KG6Y!U>P0Y M^#RUH15^K<76# 8H2Z
~29!V+O>382N!Q2N+@IFMWOS N>LB=5SD0AK! M75U6U!%~# W8KH!L^GBHH!TR>OCEW>D FF M^C^E3)Q06J5E3!E3LRVYK3G!FD=GF77M.#1^2!R.B18>U M!P
#5\$9R<O@H 2.271^!BZ<RE77!H!U5@&N!42Q0BQ.DH!\$@~!9!&PM.M.C.R^# V.S.N!~M4\$!A0#%>RSL(650RNL^U5@&~!VY5!S M!F!X^T^!&PM.C.R^# V.S.N!~D4\$!L
A0#%&@RSL(M60(Q FM(&0 NIP+!H!#4\$~9I=&PM97@Q.%!O+&FAT.M.5!+0!4 Q0<L!L!%G^W+E.G.T^!7P/P^!7E.M!IV:7!L+65X.3!2.BYH=&U02P\$~#4^#~+PA9K(F^#4)
~26 M!P#%#<=<FEET^UE>#Q75\$N!~M4\$!A0#%&@RSL(649>=>K^C0.5@<I^H4!~9I=&PM97@S.5!R M+&FAT.5!+0!4 Q0<L!L!%G^W+E.G.T^!7P/P^!7E.M!IV:7!L+65X.3!2.BYH=&U02P\$~#4^#~+PA9K(F^#4)
4>IPIV:7!L+65X.3!2.BYH=&U02P4Q<I^P0!>0 @B4~end XML 106 vitl-20240630.htm.mml:IDEA: XBRL DOCUMENT 0001579733 2022-12-262023-06-25 0001579733
vitl:JpMorganCreditFacilityMember 2024-04-01-012024-06-30 0001579733 vitl:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-04-
012024-06-30 0001579733 us-gaap:PerformanceSharesMember 2024-01-012024-06-30 0001579733 us-gaap:CommonStockMember 2023-03-26 0001579733 2023-03-26
0001579733 vitl:SandpebbleBuildersPreconstructionIncorporationMember 2022-12-262023-06-25 0001579733 us-
gaap:RevolvingCreditFacilityMember vitl:JpMorganChaseBankNAMember 2024-04-09 0001579733 vitl:EggsAndEggRelatedProductsMember 2023-12-31 0001579733 us-
gaap:VehiclesMember 2023-12-31 0001579733 vitl:PackagingMember 2024-06-30 0001579733 vitl:CustomerAMemberus-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-06-30 0001579733 vitl:SoybeanMealMember 2024-06-30 0001579733 us-gaap:AdditionalPaidInCapitalMember
2023-12-31 0001579733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-26 0001579733 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001579733
us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001579733 us-gaap:EmployeeStockOptionMember 2022-12-262023-06-25 0001579733 srt:MaximumMemberus-
gaap:PerformanceSharesMember 2024-01-012024-06-30 0001579733 vitl:ButterAndButterRelatedProductsMember 2023-12-31 0001579733 us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001579733 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001579733 us-
gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001579733 us-gaap:EmployeeStockOptionMember 2023-03-272023-06-25 0001579733 2024-01-012024-03-31
0001579733 vitl:SandpebbleBuildersPreconstructionIncorporationMember 2024-04-012024-06-30 0001579733 us-gaap:TradeAccountsReceivableMember 2024-03-31
0001579733 vitl:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-06-30 0001579733 vitl:ButterAndButterRelatedProductsMember
2024-01-012024-06-30 0001579733 vitl:EggsAndEggRelatedProductsMember 2024-01-012024-06-30 0001579733
vitl:SandpebbleBuildersPreconstructionIncorporationMember 2023-03-272023-06-25 0001579733 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-
262023-06-25 0001579733 us-gaap:CommodityContractMemberus-gaap:NondesignatedMember 2024-04-012024-06-30 0001579733 vitl:KathrynMckeenMember 2024-04-
012024-06-30 0001579733 vitl:TwentyTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2020-07-31 0001579733 us-gaap:AdditionalPaidInCapitalMember
2024-04-012024-06-30 0001579733 vitl:TwentyTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2020-07-31 012020-07-31 0001579733
vitl:CustomerBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2022-12-262023-12-31 0001579733 2022-12-262023-03-26
0001579733 us-gaap:RestrictedStockUnitsRSUMember 2022-12-262023-06-25 0001579733 us-gaap:TradeAccountsReceivableMember 2024-04-012024-06-30 0001579733
2023-06-25 0001579733 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 us-
gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001579733 us-gaap:RevolvingCreditFacilityMember 2023-03-272023-06-25 0001579733
vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30
0001579733 vitl:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0001579733 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-25 0001579733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001579733 us-
gaap:CommonStockMember 2022-12-262023-03-26 0001579733 us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0001579733 us-
gaap:RetainedEarningsMember 2024-06-30 0001579733 vitl:EmployeeStockPurchasePlanMember 2022-12-262023-06-25 0001579733 vitl:CustomerCMemberus-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2022-12-262023-12-31 0001579733 us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-
gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 vitl:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2020-07-
012020-07-31 0001579733 us-gaap:ConstructionInProgressMember 2023-12-31 0001579733 us-gaap:CommonStockMember 2024-06-30 0001579733 us-
gaap:CommodityContractMemberus-gaap:NondesignatedMember 2022-12-262023-06-25 0001579733 us-gaap:PerformanceSharesMember 2024-04-012024-06-30 0001579733
2024-04-012024-06-30 0001579733 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-06-30 0001579733 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001579733 vitl:ButterAndButterRelatedProductsMember 2024-06-30 0001579733 us-
gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001579733 vitl:EggsAndEggRelatedProductsMember 2023-03-272023-06-25 0001579733
vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31
0001579733 2023-03-272023-06-25 0001579733 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733
vitl:CreditFacilityMember vitl:PNCBankNationalAssociationMember 2024-01-012024-06-30 0001579733 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-01-
012024-03-31 0001579733 us-gaap:CommonStockMember 2024-04-012024-06-30 0001579733 us-gaap:LandMember 2023-12-31 0001579733 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 vitl:JpMorganCreditFacilityMember 2024-04-09
0001579733 us-gaap:CostOfSalesMember 2023-03-272023-06-25 0001579733 us-gaap:RevolvingCreditFacilityMember 2024-01-012024-06-30 0001579733 us-
gaap:CommonStockMember 2023-12-31 0001579733 us-gaap:CostOfSalesMember 2022-12-262023-06-25 0001579733
vitl:SandpebbleBuildersPreconstructionIncorporationMember 2024-06-30 0001579733 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-272023-06-
25 0001579733 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001579733 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-06-30
0001579733 us-gaap:RetainedEarningsMember 2024-03-31 0001579733 us-gaap:EmployeeStockOptionMember 2024-06-30 0001579733 srt:MaximumMember 2024-06-30
0001579733 vitl:OtherMember 2023-12-31 0001579733 vitl:CustomerBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-
012024-06-30 0001579733 us-gaap:RetainedEarningsMember 2022-12-262023-03-26 0001579733 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001579733 us-
gaap:PerformanceSharesMember 2022-12-262023-06-25 0001579733 vitl:USCorporateBondsAndUSDenominatedForeignBondsMember 2024-06-30 0001579733 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001579733 vitl:TwentyTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember
2024-01-012024-01-01 0001579733 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0001579733 us-gaap:EmployeeStockOptionMember 2023-12-31
0001579733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-262023-03-26 0001579733 us-gaap:CommodityContractMemberus-
gaap:NondesignatedMember 2024-01-012024-06-30 0001579733 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001579733
vitl:SandpebbleBuildersPreconstructionIncorporationMember 2024-01-012024-06-30 0001579733 vitl:OtherMember 2024-06-30 0001579733 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 vitl:CustomerDMemberus-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-06-30 0001579733 us-gaap:AdditionalPaidInCapitalMember 2022-12-262023-03-26 0001579733 us-
gaap:RetainedEarningsMember 2024-01-012024-03-31 0001579733 2024-04-012024-06-30 0001579733 us-gaap:RestrictedStockUnitsRSUMember 2023-03-272023-06-25
0001579733 us-gaap:LandImprovementsMember 2024-06-30 0001579733 us-gaap:VehiclesMember 2024-06-30 0001579733 us-gaap:CommonStockMember 2023-03-272023-
06-25 0001579733 us-gaap:LandMember 2024-06-30 0001579733 vitl:AfsSecuritiesMember 2024-06-30 0001579733 vitl:PeterPappasMember 2024-06-30 0001579733 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001579733 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-012024-06-30
0001579733 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-012024-06-30 0001579733 vitl:PulletsMember 2024-06-30 0001579733 us-
gaap:PerformanceSharesMember 2024-06-30 0001579733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001579733 us-
gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0001579733 vitl:CustomerBMemberus-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember 2022-12-262023-12-31 0001579733 us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 us-gaap:AdditionalPaidInCapitalMember 2023-06-25
0001579733 vitl:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2022-12-262023-06-25 0001579733
vitl:USCorporateBondsAndUSDenominatedForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 vitl:PeterPappasMember 2024-

04-012024-06-30 0001579733 us-gaap:RetainedEarningsMember 2022-12-25 0001579733 us-gaap:RetainedEarningsMember 2023-06-25 0001579733 us-gaap:RetainedEarningsMember 2023-03-26 0001579733 vti:JpMorganCreditFacilityMember 2024-06-30 0001579733
gaap:RetainedEarningsMember 2023-03-26 0001579733 vti:JpMorganCreditFacilityMember 2024-06-30 0001579733
viti:TwentyTwentyEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2024-01-012024-01-01 0001579733
viti:SandPebbleBuildersPreconstructionIncorporationMember 2023-06-25 0001579733 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733
viti:JpMorganCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2024-04-092024-04-09 0001579733 2024-03-31
0001579733 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 us-gaap:RestrictedStockUnitsRSUMember
2023-03-272023-06-25 0001579733 viti:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-12-262023-12-31
0001579733 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001579733 us-gaap:CommonStockMember 2023-06-25 0001579733 viti:CorrMember 2024-06-30
0001579733 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0001579733 viti:CorrMember 2023-12-31 0001579733 us-
gaap:RevolvingCreditFacilityMember viti:PNCBankNationalAssociationMember viti:SixthAmendmentMember 2024-03-31 0001579733
viti:ButterAndButterRelatedProductsMember 2024-04-012024-06-30 0001579733 us-gaap:PerformanceSharesMember 2024-04-012024-06-30 0001579733 us-
gaap:CommonStockMember 2022-12-25 0001579733 viti:TwentyTwentyEquityIncentivePlanMember us-gaap:CommonStockMember 2024-01-012024-06-30 0001579733 us-
gaap:PerformanceSharesMember 2024-01-012024-06-30 0001579733 viti:ButterAndButterRelatedProductsMember 2023-03-272023-06-25 0001579733 viti:PulleysMember
2023-12-31 0001579733 viti:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-012024-06-30 0001579733
viti:TwentyTwentyEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2020-07-31 0001579733 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
2024-03-31 0001579733 viti:EggsAndEggRelatedProductsMember 2022-12-262023-06-25 0001579733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-
272023-06-25 0001579733 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001579733 us-gaap:RevolvingCreditFacilityMember 2024-04-012024-06-30 0001579733
viti:EggsAndEggRelatedProductsMember 2024-04-012024-06-30 0001579733 viti:EmployeeStockPurchasePlanMember 2024-04-012024-06-30 0001579733 us-
gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 us-
gaap:RevolvingCreditFacilityMember viti:PNCBankNationalAssociationMember viti:TenthAmendmentMember us-
gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2024-01-012024-03-31 0001579733 viti:ButterAndButterRelatedProductsMember 2022-12-
262023-06-25 0001579733 us-gaap:EmployeeStockOptionMember 2023-03-272023-06-25 0001579733 viti:USCorporateBondsAndUSDenominatedForeignBondsMember 2023-
12-31 0001579733 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001579733 us-gaap:RestrictedStockUnitsRSUMember 2022-12-262023-06-25 0001579733
viti:EmployeeStockPurchasePlanMember 2023-03-272023-06-25 0001579733 us-gaap:CommonStockMember 2024-01-012024-03-31 0001579733 us-
gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001579733 us-gaap:TradeAccountsReceivableMember 2023-12-31 0001579733 us-
gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 us-gaap:RetainedEarningsMember 2023-03-272023-06-25
0001579733 us-gaap:StockCompensationPlanMember viti:TwentyTwentyEquityIncentivePlanAndTwentyTwentyEmployeeStockPurchasePlanMember 2024-06-30 0001579733
us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001579733 us-gaap:EmployeeStockOptionMember 2022-12-262023-06-25 0001579733 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-04-012024-06-30 0001579733 us-
gaap:RevolvingCreditFacilityMember viti:PNCBankNationalAssociationMember viti:TenthAmendmentMember viti:AlternateBaseRateMember 2024-01-012024-03-31
0001579733 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001579733 2024-08-05 0001579733 us-gaap:ConstructionInProgressMember 2024-06-30 0001579733 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-03-272023-06-25 0001579733 us-gaap:AdditionalPaidInCapitalMember 2023-03-26 0001579733 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-012024-06-30 0001579733 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001579733
viti:SoybeanMealMember 2023-12-31 0001579733 us-gaap:LandImprovementsMember 2023-12-31 0001579733 us-gaap:TradeAccountsReceivableMember 2024-01-012024-
03-31 0001579733 viti:KathrynMcKeonMember 2024-06-30 0001579733 us-gaap:CommonStockMember 2024-03-31 0001579733 viti:PackagingMember 2023-12-31
0001579733 us-gaap:CommodityContractMember us-gaap:NonDesignatedMember 2023-03-272023-06-25 0001579733 us-gaap:RestrictedStockUnitsRSUMember 2024-01-
012024-06-30 0001579733 us-gaap:AdditionalPaidInCapitalMember 2023-03-272023-06-25 0001579733 us-gaap:RevolvingCreditFacilityMember 2022-12-262023-06-25
0001579733 us-gaap:CostOfSalesMember 2024-04-012024-06-30 0001579733 us-gaap:CostOfSalesMember 2024-01-012024-06-30 0001579733
viti:TwentyTwentyEquityIncentivePlanMember us-gaap:CommonStockMember 2024-06-30 0001579733 us-gaap:PerformanceSharesMember 2023-12-31 0001579733 us-
gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001579733 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2022-12-262023-06-25 0001579733 2023-12-31 0001579733 us-
gaap:StockCompensationPlanMember viti:TwentyTwentyEquityIncentivePlanAndTwentyTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001579733 us-
gaap:RetainedEarningsMember 2023-12-31 0001579733 viti:USCorporateBondsAndUSDenominatedForeignBondsMember us-gaap:FairValueMeasurementsRecurringMember
2024-06-30 0001579733 viti:EmployeeStockPurchasePlanMember 2024-01-012024-06-30 0001579733 us-gaap:MachineryAndEquipmentMember 2024-06-30 0001579733 us-
gaap:TradeAccountsReceivableMember 2024-06-30 0001579733 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001579733 srt:MinimumMember us-
gaap:PerformanceSharesMember 2024-01-012024-06-30 0001579733 2024-06-30 0001579733 2022-12-25 0001579733 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-25 0001579733 viti:EggsAndEggRelatedProductsMember 2024-06-30 0001579733 us-
gaap:AdditionalPaidInCapitalMember 2022-12-25 0001579733 viti:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-03-
272023-06-25 pure viti:Security shares viti:Position utr:ISO4217:USD shares utr:bu iso4217:USDfalse-12-310001579733P366DQ2726D10-0true2024-06-302024false001-
39411Vital Farms, Inc.DE27-04969853601 South Congress AvenueSuite C100AustinTX78704877455-3063Common Stock, par value \$0.0001 per
shareVITLNASDAQYesYesAccelerated
Fillerfalsefalsefalse430989461331730008414900019533000326670005140005500042863000396990003144800032895000117000227000453000061140002663000023421
168000
37700023842100019267700032048900027517800014738800010644500029531600022561600089710000686450001787420001451490005767800037800000116574000804671
87000-441000-364000-1866000972000-1270001528000-
13510001811100079120004283600017584000177200012290007474000375100016339000668300035362000138330000.380.160.840.340.360.150.790.3242500355409483654
9500001000.
129000192000223000277000774000134000223000277000774000330006100068000019100010100016200020900058300016440000684500035571000144160004168464940001
3770001926770001800682440008240002017026278113100001310001982000198200010800010800019023000190230004200365640001640210004748000-
269000021330400091160556240005624000413161432410004100016843178000178000291600029160001010001010001633900001633900042971988400017349800065087000-
1680002384210004074699040001557160004159000-154700015833200012759535535162700016270004210004210007150000715000040839050400015734300011309000-
11260001675300003075001100001100007903032463600063600011011135000135000206000206000162000162000668300066830004132667400015901200017992000-
9640001760440003536200013833000464700034530003510000158800076000230000190000489800036870000767000-346000-847000-
1320005244000864400061080004008200018911006691400042920006690006620001907001335000184530001000105400005200057300017012000075000006448000114
116400049024000347590008414900012914000133173000476730005120002680001134400010700001500001266000<p style="font-size:10pt;margin-top:18pt;font-
family:Times New Roman;margin-bottom:0;text-align:left;">Note 1. Nature of the Business and Basis of Presentation</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-
family:Times New Roman;margin-bottom:0;text-align:left;">Vital Farms, Inc. (the "Company") was incorporated in Delaware onJune 6, 2013and is headquartered in Austin, Texas. The Company
packages, markets and distributes shell eggs, butter and other products. These products are principally sold under the name Vital Farms in addition to other trade names,
primarily to retail and foodservice channels in the United States.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;">The
accompanying unaudited condensed consolidated financial statements as of June 30, 2024 and for the 13-week and 26-week periods ended June 30, 2024 and June 25, 2023
have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP" or "GAAP" and pursuant to the rules and
regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. Certain information and note disclosures normally included in financial
statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial
statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto in the Company's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 (the "Annual Report").</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;">In the
opinion of management, the included disclosures are adequate, and the accompanying unaudited condensed consolidated financial statements contain all adjustments
necessary for a fair statement of the Company's consolidated financial position as of June 30, 2024, consolidated results of operations for the 13-week and 26-week periods
ended June 30, 2024 and June 25, 2023, and consolidated cash flows for the 26-week periods ended June 30, 2024 and June 25, 2023. Such adjustments are of a normal and
recurring nature and certain reclassifications of previously reported amounts have been made to conform to the current year presentation. The condensed consolidated
balance sheet as of December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the audited annual
financial statements. The condensed consolidated results of operations for the 13-week and 26-week periods ended June 30, 2024 are not necessarily indicative of the
consolidated results of operations that may be expected for the fiscal year ending December 29, 2024.</p><p style="text-indent:4.533%;font-size:10pt;margin-
top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal Year:<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-
content;">The Company's fiscal year ends on the last Sunday in December and contains either 52 or 53 weeks. In a 52-week fiscal year, each of the Company's fiscal quarters
consist of 13 weeks. The additional week in a 53-week fiscal year is added to the fourth quarter, making such quarter consist of 14 weeks. Therefore, the financial results of
certain 53-week fiscal years, and the associated 14-week quarters, will not be exactly comparable to the prior and subsequent 52-week fiscal years and the associated 13-week
quarters. The fiscal quarters ended June 30, 2024 and June 25, 2023both contain operating results for 13 weeks. The fiscal year ended December 31, 2023 consisted of 53 weeks.</p>2013-06-06<p
style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-
weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</p><p style="text-
indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies and estimates used in preparation of the unaudited condensed
consolidated financial statements are described in the Company's audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the
notes thereto, which are included in the Company's Annual Report. Other than the adoption of the new accounting pronouncements and standards as further described below,
there have been no material changes to the Company's significant accounting policies during the 26-week period ended June 30, 2024.</p><div style="font-
size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recently Adopted Accounting
Pronouncements</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The new accounting pronouncements recently adopted by
the Company are described in the Company's audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which
are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 26-week period ended June 30, 2024.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;">Recently
Issued Accounting Pronouncements Not Yet Adopted</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;">In November 2023, the
Financial Accounting Standards Board (the "FASB") issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures ("ASU 2023-
07") in order to improve stockholders' understanding of an entity's business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

U.S. corporate bonds and **U.S. dollar-denominated foreign bonds**

The following table summarizes the Company's net revenue by primary product for the periods presented:

Product	Revenue (\$)	% of Total Revenue
Total assets measured at fair value	\$394.498	64.4%
Derivative financial instruments	\$33.061	5.3%
26-Weeks Ended	\$33.061	5.3%
13-Weeks Ended	\$33.061	5.3%

Note 6. Revenue Recognition

The following table summarizes the Company's net revenue by primary product for the periods presented:

Product	Revenue (\$)	% of Total Revenue
Total assets measured at fair value	\$394.498	64.4%
Derivative financial instruments	\$33.061	5.3%
26-Weeks Ended	\$33.061	5.3%
13-Weeks Ended	\$33.061	5.3%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

italics,min-width:fit-content;">PNC Credit Facility</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In October 2017, the Company entered into a credit facility agreement with PNC Bank, National Association (the "PNC Credit Facility"), which was modified at various times between fiscal 2018 and fiscal 2023. Such amendments included (i) amendments to various definitions and covenants, (ii) waiver of a technical default in May 2020, (iii) increased borrowing capacity, (iv) elimination of a term loan and equipment loan, and (v) extension of the maturity date.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The maximum borrowing capacity under the revolving line of credit was \$20.0 million, prior to its termination in April 2024 when the Company entered into a syndicated credit agreement with JPMorgan Chase Bank, N.A. and the other lenders party thereto (the "JPMorgan Credit Facility"). Interest on borrowings under the PNC Credit Facility's revolving line of credit, as well as loan advances thereunder, accrued at a rate, at the Company's election at the time of borrowing, equal to (i) the secured overnight financing rate as administered by the Federal Reserve Bank of New York plus 2.00% or (ii) 1.00% plus the alternate base rate, as defined in the PNC Credit Facility.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The PNC Credit Facility was secured by all of the Company's assets (other than real property and certain other property excluded pursuant to the terms of the PNC Credit Facility) and required the Company to maintain three financial covenants: a fixed charge coverage ratio, a leverage ratio and a minimum tangible net worth requirement. The PNC Credit Facility also contained various covenants relating to limitations on indebtedness, acquisitions, mergers, consolidations and the sale of properties and liens.The PNC Credit Facility also contained other customary covenants, representations and events of default.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On April 9, 2024, the Company entered into the JPMorgan Credit Facility60.0 million revolving credit facility.The JPMorgan Credit Facility includes a 5.0 million letter of credit sub-limit and an accordion option that would allow the Company to increase the aggregate revolving commitments or add incremental term loans in an aggregate amount not to exceed the greater of (i) 35.0 million and (ii) an amount equal to 100 % of consolidated adjusted EBITDA.Any borrowings under the JPMorgan Credit Facility bear interest, at the Company'ss election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10% or (ii) 1.00% plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company'ss revolving exposure. Additionally, the Company is required to pay a participation fee on the account of each lender for each outstanding letter of credit at a rate equal to the applicable rate used to determine the interest rate applicable to term benchmark revolving loans.The JPMorgan Credit Facility is secured by liens on substantially all of the Company'ss assets, including certain intellectual property assets and investment securities. It requires the Company to maintain (i) a net leverage ratio of no greater than 3.25 and (ii) an alternative base rate plus a margin of either 1.75%, 2.00% or 2.25% depending on the Company's net leverage ratio. The Company is required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on the Company'ss revolving exposure. As a result of the limitations contained in the JPMorgan Credit Facility, certain of the net assets on the Company's consolidated balance sheet as of June 30, 2024 are restricted in use. The Company's wholly owned subsidiaries are non-operating and have no restricted net assets within the meaning of Rule 4-08(e)(3) or Rule 12-04 of Regulation S-X. As of June 30, 2024, the Company was in compliance with all covenants under the JPMorgan Credit Facility.As of June 30, 2024there were nooutstanding amounts under the JPMorgan Credit Facility. During the 13-week periods ended June 30, 2024 and June 25, 2023the Company recognized 0 interest expense related to draws on our revolving lines of creditDuring the 26-week periods ended June 30, 2024 and June 25, 2023, the Company recognized interest expense related to draws on our revolving lines of credit of 0.001003250040<span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:

[illegible]

[illegible]

[illegible]

[illegible]

Options exercisable as of June 30, 2024

The following table summarizes the Company's RSU activity since December 31, 2023:

	Number of Shares	Weighted Average Grant Date Fair Value
Granted	1,796	\$1.46
Vested	(71,781)	\$1.78
Unvested at December 31, 2023	73,577	\$1.76

The fair value of stock options vested during the 26-week periods ended June 30, 2024 and June 25, 2023 was \$97.955 million and \$1.796 million, respectively. The fair value of stock options vested during the 26-week periods ended June 30, 2024 and June 25, 2023 was \$97.955 million and \$1.796 million, respectively.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

white-space:pre-wrap;
" style="vertical-align:top;">
  |  |  ||  |  |  |  |

```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```


Weeks Ended
June 30, 2024
Before Tax
After Tax



| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">Weeks Ended</span> | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">June 30, 2024</span> | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">Before Tax</span> | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">After Tax</span> |
|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">1</span>           | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">2</span>             | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">3</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">4</span>         |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">5</span>           | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">6</span>             | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">7</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">8</span>         |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">9</span>           | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">10</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">11</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">12</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">13</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">14</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">15</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">16</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">17</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">18</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">19</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">20</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">21</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">22</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">23</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">24</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">25</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">26</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">27</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">28</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">29</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">30</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">31</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">32</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">33</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">34</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">35</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">36</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">37</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">38</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">39</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">40</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">41</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">42</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">43</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">44</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">45</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">46</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">47</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">48</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">49</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">50</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">51</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">52</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">53</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">54</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">55</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">56</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">57</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">58</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">59</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">60</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">61</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">62</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">63</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">64</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">65</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">66</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">67</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">68</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">69</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">70</span>            | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">71</span>         | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">72</span>        |
| <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">73</span>          | <span style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">7</span>             |                                                                                                                                     |                                                                                                                                    |


```

[illegible]

[illegible]

0;text-align:left;"><p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.5pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">583</td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.5pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td></tr><table>134000330001010002230006100016200027800068000210000645000159000486000100001000-129000-32000-9700027700068000209000774000191000583000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 20. Commitments and Contingencies<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Supplier ContractsThe Company purchases its egg inventories under long-term supply contracts with farms. Purchase commitments contained in these arrangements are variable and dependent on the quantity of eggs produced by the farms. Accordingly, there are no estimable future purchase commitments associated with these supplier contracts and there are no minimum payments associated with these long-term supply contracts. The Company records the total cost of eggs into inventory and they are expensed to cost of goods sold when the associated eggs are sold to customers and are also reported as part of the Company's variable lease cost.<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company has entered into agreements with certain qualifying suppliers to provide a one-time payment of up to 200,000, for the purpose of funding costs associated with farm start up. As ofJune 30, 2024, the Company has executed 31 such agreements, 2 of which were in fiscal year 2023. The payment of these incremental costs is contingent upon the achievement of certain milestones and is to be made no later than 90 days prior to the pullet placement date specified in each supplier agreement. Upon the achievement of such milestones, the Company recognizes an operating ROU asset and lease liability as a cost of obtaining the embedded lease within the supplier contract, which is included in "Leases" in Note 11. As of June 30, 2024,4.3 million has been paid out and1.3 million remains to be paid.<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Indemnification AgreementsIn the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and its executive officers that will<p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2024, the Company has not incurred any material costs as a result of such indemnification agreements.<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Litigation:The Company is subject to various claims and contingencies that are in the scope of ordinary and routine litigation incidental to its business, including those related to regulation, litigation, business transactions, employee-related matters and taxes, among others. When the Company becomes aware of a claim or potential claim, the likelihood of any loss or exposure is assessed. Based on these assessments and estimates, the Company may establish reserves, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may differ materially from the Company's assessments and estimates.<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On May 20, 2021, the Company and certain of its current and former officers were named as defendants in a class action complaint captionedNicholas A. Usler et al. v. Vital Farms, Inc. et al.in the United States District Court for the Western District of Texas (the "District Court"). The plaintiffs alleged false advertising claims on behalf of themselves and a putative class of alleged consumers of the Company's eggs. The named officers of the Company were subsequently dismissed as defendants in this matter. On July 9, 2024, a U.S. Magistrate Judge issued both an order and report and recommendation, for review and adoption by the District Court. Collectively, the order and the report and recommendation (i) denied the plaintiffs' motion for class certification, (ii) excluded the testimony and report of the plaintiffs' damages expert and (iii) granted summary judgment for the Company with respect to two plaintiffs and three of the plaintiffs' state claims. The plaintiffs have filed objections to the order and report and recommendation, and the matter is ongoing. The Company believes the claims are without merit and is vigorously defending itself in this matter. Given the uncertainty of the litigation, the stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company is unable to reasonably estimate the possible loss or range of loss, if any, that may result from the claim.<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Although the Company maintains insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions and caps on amounts recoverable. Even if the Company believes a claim is covered by insurance, insurers may dispute the Company's entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of the Company's recovery. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company records a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the claim if the likelihood of a potential loss is reasonably possible.<p>20000000043000001300000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 21. Related Party Transactions<p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sandpebble Builders Preconstruction, Inc.The Company utilizes Sandpebble Builders Preconstruction, Inc. and Sandpebble South, Inc. (collectively "Sandpebble") for project management and related services associated with the construction and expansion of the Company's egg processing facilities, including site selection, project management and related services for the Company's planned egg packing facility in Seymour, Indiana. The Company's contract with Sandpebble for services related to the Company's planned egg packing facility in Seymour, Indiana was awarded after a competitive bidding process. Victor Ganseco, the owner and principal of Sandpebble, is the father of Russell Diez-Ganseco, the Company's President and Chief Executive Officer and a member of the Company's Board of Directors. In connection with the services described above, the Company paid Sandpebble292 and139 during the 13-week periods ended June 30, 2024 and June 25, 2023, respectively, and540 and168 and<span style="color:#000000,white-space:

"border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;">white-space:pre-wrap;text-align:left;"><td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Name and Position</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Action</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Adoption/Termination Date</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rule 10b5-1</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Non-Rule 10b5-1</p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total Shares of Common Stock to be Sold</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total Shares of Common Stock to be Purchased</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Expiration Date</p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Kathryn McKeon</p></td><td style="color:#000000:white-space:pre-wrap,min-width:fit-content,"></td><td style="color:#000000:white-space:pre-wrap,min-width:fit-content;">Chief Marketing Officer</td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Adoption</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">May 28, 2024</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">X</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap,vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,164</p></td><td style="white-space:nowrap,vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">February 28, 2025</p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Adoption</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 14, 2024</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">X</p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">99,526</p></td><td style="white-space:nowrap,vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 15, 2025</p></td></tr></table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">* Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">** Non-Rule 10b5-1 trading arrangement"></p><p style="text-indent:40%(c) of Regulation S-K under the Exchange Act"></p></p><p style="text-indent:40%Kathryn McKeonChief Marketing OfficertrueMay 28, 202447164February 28, 2025Peter PappasChief Sales OfficertrueJune 14, 202499526June 15, 2025 includes 64,213 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant to the 2020 Equity Incentive Plan.